0001398344-23-014977.txt : 20230815 0001398344-23-014977.hdr.sgml : 20230815 20230815172954 ACCESSION NUMBER: 0001398344-23-014977 CONFORMED SUBMISSION TYPE: 10-Q/A PUBLIC DOCUMENT COUNT: 63 CONFORMED PERIOD OF REPORT: 20230630 FILED AS OF DATE: 20230815 DATE AS OF CHANGE: 20230815 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Firsthand Technology Value Fund, Inc. CENTRAL INDEX KEY: 0001495584 IRS NUMBER: 273008946 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q/A SEC ACT: 1934 Act SEC FILE NUMBER: 814-00830 FILM NUMBER: 231175904 BUSINESS ADDRESS: STREET 1: 150 ALMADEN BLVD. STREET 2: SUITE 1250 CITY: SAN JOSE STATE: CA ZIP: 95113 BUSINESS PHONE: 408-886-7096 MAIL ADDRESS: STREET 1: 150 ALMADEN BLVD. STREET 2: SUITE 1250 CITY: SAN JOSE STATE: CA ZIP: 95113 10-Q/A 1 fp0084654-3_10qaixbrl.htm
0001495584 false --12-31 2023 Q2 10-Q/A false 0001495584 2023-01-01 2023-06-30 0001495584 2023-06-30 0001495584 2022-12-31 0001495584 2023-04-01 2023-06-30 0001495584 2022-04-01 2022-06-30 0001495584 2022-01-01 2022-06-30 0001495584 2023-03-31 0001495584 2022-03-31 0001495584 2021-12-31 0001495584 2022-06-30 0001495584 2020-12-31 0001495584 2019-12-31 0001495584 2018-12-31 0001495584 2017-12-31 0001495584 2022-01-01 2022-12-31 0001495584 2021-01-01 2021-12-31 0001495584 2020-01-01 2020-12-31 0001495584 2019-01-01 2019-12-31 0001495584 2018-01-01 2018-12-31 0001495584 SVVC:EqxCapitalIncMember 2023-01-01 2023-06-30 0001495584 SVVC:EqxCapitalIncMember 2023-06-30 0001495584 SVVC:EquipmentLeasingMember 2023-01-01 2023-06-30 0001495584 SVVC:EquipmentLeasingMember 2023-06-30 0001495584 SVVC:EqxCapitalInc1Member 2023-06-30 0001495584 SVVC:HeraSystemsIncMember 2023-01-01 2023-06-30 0001495584 SVVC:HeraSystemsIncMember 2023-06-30 0001495584 SVVC:HeraSystemsInc1Member 2023-01-01 2023-06-30 0001495584 SVVC:HeraSystemsInc1Member 2023-06-30 0001495584 SVVC:HeraSystemsInc2Member 2023-01-01 2023-06-30 0001495584 SVVC:HeraSystemsInc2Member 2023-06-30 0001495584 SVVC:HeraSystemsInc3Member 2023-01-01 2023-06-30 0001495584 SVVC:HeraSystemsInc3Member 2023-06-30 0001495584 SVVC:HeraSystemsInc4Member 2023-01-01 2023-06-30 0001495584 SVVC:HeraSystemsInc4Member 2023-06-30 0001495584 SVVC:HeraSystemsInc5Member 2023-01-01 2023-06-30 0001495584 SVVC:HeraSystemsInc5Member 2023-06-30 0001495584 SVVC:HeraSystemsInc6Member 2023-01-01 2023-06-30 0001495584 SVVC:HeraSystemsInc6Member 2023-06-30 0001495584 SVVC:HeraSystemsInc7Member 2023-01-01 2023-06-30 0001495584 SVVC:HeraSystemsInc7Member 2023-06-30 0001495584 SVVC:HeraSystemsInc8Member 2023-01-01 2023-06-30 0001495584 SVVC:HeraSystemsInc8Member 2023-06-30 0001495584 SVVC:HeraSystemsInc9Member 2023-06-30 0001495584 SVVC:IntraopMedicalCorpMember 2023-01-01 2023-06-30 0001495584 SVVC:IntraopMedicalCorpMember 2023-06-30 0001495584 SVVC:IntraopMedicalCorp1Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraopMedicalCorp1Member 2023-06-30 0001495584 SVVC:IntraopMedicalCorp2Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraopMedicalCorp2Member 2023-06-30 0001495584 SVVC:IntraopMedicalCorp3Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraopMedicalCorp3Member 2023-06-30 0001495584 SVVC:IntraopMedicalCorp4Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraopMedicalCorp4Member 2023-06-30 0001495584 SVVC:IntraopMedicalCorp5Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraopMedicalCorp5Member 2023-06-30 0001495584 SVVC:IntraopMedicalCorp6Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraopMedicalCorp6Member 2023-06-30 0001495584 SVVC:IntraopMedicalCorp7Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraopMedicalCorp7Member 2023-06-30 0001495584 SVVC:IntraopMedicalCorp8Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraopMedicalCorp8Member 2023-06-30 0001495584 SVVC:IntraopMedicalCorp9Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraopMedicalCorp9Member 2023-06-30 0001495584 SVVC:IntraopMedicalCorp10Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraopMedicalCorp10Member 2023-06-30 0001495584 SVVC:IntraopMedicalCorp11Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraopMedicalCorp11Member 2023-06-30 0001495584 SVVC:IntraopMedicalCorp12Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraopMedicalCorp12Member 2023-06-30 0001495584 SVVC:IntraopMedicalCorp13Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraopMedicalCorp13Member 2023-06-30 0001495584 SVVC:IntraopMedicalCorp14Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraopMedicalCorp14Member 2023-06-30 0001495584 SVVC:IntraopMedicalCorp15Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraopMedicalCorp15Member 2023-06-30 0001495584 SVVC:IntraopMedicalCorp16Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraopMedicalCorp16Member 2023-06-30 0001495584 SVVC:IntraopMedicalCorp17Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraopMedicalCorp17Member 2023-06-30 0001495584 SVVC:IntraopMedicalCorp18Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraopMedicalCorp18Member 2023-06-30 0001495584 SVVC:IntraopMedicalCorp19Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraopMedicalCorp19Member 2023-06-30 0001495584 SVVC:IntraopMedicalCorp20Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraopMedicalCorp20Member 2023-06-30 0001495584 SVVC:IntraopMedicalCorp21Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraopMedicalCorp21Member 2023-06-30 0001495584 SVVC:IntraopMedicalCorp22Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraopMedicalCorp22Member 2023-06-30 0001495584 SVVC:IntraopMedicalCorp23Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraopMedicalCorp23Member 2023-06-30 0001495584 SVVC:IntraopMedicalCorp24Member 2023-06-30 0001495584 SVVC:KymaIncMember 2023-01-01 2023-06-30 0001495584 SVVC:KymaIncMember 2023-06-30 0001495584 SVVC:LynceanTechnologiesIncMember 2023-01-01 2023-06-30 0001495584 SVVC:LynceanTechnologiesIncMember 2023-06-30 0001495584 SVVC:RevasumIncMember 2023-01-01 2023-06-30 0001495584 SVVC:RevasumIncMember 2023-06-30 0001495584 SVVC:UctCoatingsIncMember 2023-01-01 2023-06-30 0001495584 SVVC:UctCoatingsIncMember 2023-06-30 0001495584 SVVC:WrightSpeedIncMember 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedIncMember 2023-06-30 0001495584 SVVC:WrightSpeedInc1Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedInc1Member 2023-06-30 0001495584 SVVC:WrightSpeedInc2Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedInc2Member 2023-06-30 0001495584 SVVC:WrightSpeedInc3Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedInc3Member 2023-06-30 0001495584 SVVC:WrightSpeedInc4Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedInc4Member 2023-06-30 0001495584 SVVC:WrightSpeedInc5Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedInc5Member 2023-06-30 0001495584 SVVC:WrightSpeedInc6Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedInc6Member 2023-06-30 0001495584 SVVC:WrightSpeedInc7Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedInc7Member 2023-06-30 0001495584 SVVC:WrightSpeedInc8Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedInc8Member 2023-06-30 0001495584 SVVC:WrightSpeedInc9Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedInc9Member 2023-06-30 0001495584 SVVC:WrightSpeedInc10Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedInc10Member 2023-06-30 0001495584 SVVC:WrightSpeedInc11Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedInc11Member 2023-06-30 0001495584 SVVC:WrightSpeedInc12Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedInc12Member 2023-06-30 0001495584 SVVC:WrightSpeedInc13Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedInc13Member 2023-06-30 0001495584 SVVC:WrightSpeedInc14Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedInc14Member 2023-06-30 0001495584 SVVC:WrightSpeedInc15Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedInc15Member 2023-06-30 0001495584 SVVC:WrightSpeedInc16Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedInc16Member 2023-06-30 0001495584 SVVC:WrightSpeedInc17Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedInc17Member 2023-06-30 0001495584 SVVC:WrightSpeedInc18Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedInc18Member 2023-06-30 0001495584 SVVC:WrightSpeedInc19Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedInc19Member 2023-06-30 0001495584 SVVC:WrightSpeedInc20Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedInc20Member 2023-06-30 0001495584 SVVC:WrightSpeedInc21Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedInc21Member 2023-06-30 0001495584 SVVC:WrightSpeedInc22Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedInc22Member 2023-06-30 0001495584 SVVC:WrightSpeedInc23Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedInc23Member 2023-06-30 0001495584 SVVC:WrightSpeedInc24Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedInc24Member 2023-06-30 0001495584 SVVC:WrightSpeedInc25Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedInc25Member 2023-06-30 0001495584 SVVC:WrightSpeedInc26Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedInc26Member 2023-06-30 0001495584 SVVC:WrightSpeedInc27Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedInc27Member 2023-06-30 0001495584 SVVC:WrightSpeedInc28Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedInc28Member 2023-06-30 0001495584 SVVC:WrightSpeedInc29Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedInc29Member 2023-06-30 0001495584 SVVC:WrightSpeedInc30Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedInc30Member 2023-06-30 0001495584 SVVC:WrightSpeedInc31Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedInc31Member 2023-06-30 0001495584 SVVC:WrightSpeedInc32Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedInc32Member 2023-06-30 0001495584 SVVC:WrightSpeedInc33Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedInc33Member 2023-06-30 0001495584 SVVC:WrightSpeedInc34Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedInc34Member 2023-06-30 0001495584 SVVC:WrightSpeedInc36Member 2023-06-30 0001495584 SVVC:InvestmentCompanyMember 2023-01-01 2023-06-30 0001495584 SVVC:InvestmentCompanyMember 2023-06-30 0001495584 SVVC:EqxCapitalIncMember 2022-01-01 2022-12-31 0001495584 SVVC:EqxCapitalIncMember 2022-12-31 0001495584 SVVC:EquipmentLeasingMember 2022-01-01 2022-12-31 0001495584 SVVC:EquipmentLeasingMember 2022-12-31 0001495584 SVVC:EqxCapitalInc1Member 2022-12-31 0001495584 SVVC:HeraSystemsIncMember 2022-01-01 2022-12-31 0001495584 SVVC:HeraSystemsIncMember 2022-12-31 0001495584 SVVC:HeraSystemsInc1Member 2022-01-01 2022-12-31 0001495584 SVVC:HeraSystemsInc1Member 2022-12-31 0001495584 SVVC:HeraSystemsInc2Member 2022-01-01 2022-12-31 0001495584 SVVC:HeraSystemsInc2Member 2022-12-31 0001495584 SVVC:HeraSystemsInc3Member 2022-01-01 2022-12-31 0001495584 SVVC:HeraSystemsInc3Member 2022-12-31 0001495584 SVVC:HeraSystemsInc4Member 2022-01-01 2022-12-31 0001495584 SVVC:HeraSystemsInc4Member 2022-12-31 0001495584 SVVC:HeraSystemsInc5Member 2022-01-01 2022-12-31 0001495584 SVVC:HeraSystemsInc5Member 2022-12-31 0001495584 SVVC:HeraSystemsInc6Member 2022-01-01 2022-12-31 0001495584 SVVC:HeraSystemsInc6Member 2022-12-31 0001495584 SVVC:HeraSystemsInc7Member 2022-01-01 2022-12-31 0001495584 SVVC:HeraSystemsInc7Member 2022-12-31 0001495584 SVVC:HeraSystemsInc8Member 2022-01-01 2022-12-31 0001495584 SVVC:HeraSystemsInc8Member 2022-12-31 0001495584 SVVC:HeraSystemsInc9Member 2022-12-31 0001495584 SVVC:IntraopMedicalCorpMember 2022-01-01 2022-12-31 0001495584 SVVC:IntraopMedicalCorpMember 2022-12-31 0001495584 SVVC:IntraopMedicalCorp1Member 2022-01-01 2022-12-31 0001495584 SVVC:IntraopMedicalCorp1Member 2022-12-31 0001495584 SVVC:IntraopMedicalCorp2Member 2022-01-01 2022-12-31 0001495584 SVVC:IntraopMedicalCorp2Member 2022-12-31 0001495584 SVVC:IntraopMedicalCorp3Member 2022-01-01 2022-12-31 0001495584 SVVC:IntraopMedicalCorp3Member 2022-12-31 0001495584 SVVC:IntraopMedicalCorp4Member 2022-01-01 2022-12-31 0001495584 SVVC:IntraopMedicalCorp4Member 2022-12-31 0001495584 SVVC:IntraopMedicalCorp5Member 2022-01-01 2022-12-31 0001495584 SVVC:IntraopMedicalCorp5Member 2022-12-31 0001495584 SVVC:IntraopMedicalCorp6Member 2022-01-01 2022-12-31 0001495584 SVVC:IntraopMedicalCorp6Member 2022-12-31 0001495584 SVVC:IntraopMedicalCorp7Member 2022-01-01 2022-12-31 0001495584 SVVC:IntraopMedicalCorp7Member 2022-12-31 0001495584 SVVC:IntraopMedicalCorp8Member 2022-01-01 2022-12-31 0001495584 SVVC:IntraopMedicalCorp8Member 2022-12-31 0001495584 SVVC:IntraopMedicalCorp9Member 2022-01-01 2022-12-31 0001495584 SVVC:IntraopMedicalCorp9Member 2022-12-31 0001495584 SVVC:IntraopMedicalCorp10Member 2022-01-01 2022-12-31 0001495584 SVVC:IntraopMedicalCorp10Member 2022-12-31 0001495584 SVVC:IntraopMedicalCorp11Member 2022-01-01 2022-12-31 0001495584 SVVC:IntraopMedicalCorp11Member 2022-12-31 0001495584 SVVC:IntraopMedicalCorp12Member 2022-01-01 2022-12-31 0001495584 SVVC:IntraopMedicalCorp12Member 2022-12-31 0001495584 SVVC:IntraopMedicalCorp13Member 2022-01-01 2022-12-31 0001495584 SVVC:IntraopMedicalCorp13Member 2022-12-31 0001495584 SVVC:IntraopMedicalCorp14Member 2022-01-01 2022-12-31 0001495584 SVVC:IntraopMedicalCorp14Member 2022-12-31 0001495584 SVVC:IntraopMedicalCorp15Member 2022-01-01 2022-12-31 0001495584 SVVC:IntraopMedicalCorp15Member 2022-12-31 0001495584 SVVC:IntraopMedicalCorp16Member 2022-01-01 2022-12-31 0001495584 SVVC:IntraopMedicalCorp16Member 2022-12-31 0001495584 SVVC:IntraopMedicalCorp17Member 2022-01-01 2022-12-31 0001495584 SVVC:IntraopMedicalCorp17Member 2022-12-31 0001495584 SVVC:IntraopMedicalCorp18Member 2022-01-01 2022-12-31 0001495584 SVVC:IntraopMedicalCorp18Member 2022-12-31 0001495584 SVVC:IntraopMedicalCorp19Member 2022-01-01 2022-12-31 0001495584 SVVC:IntraopMedicalCorp19Member 2022-12-31 0001495584 SVVC:IntraopMedicalCorp20Member 2022-01-01 2022-12-31 0001495584 SVVC:IntraopMedicalCorp20Member 2022-12-31 0001495584 SVVC:IntraopMedicalCorp21Member 2022-01-01 2022-12-31 0001495584 SVVC:IntraopMedicalCorp21Member 2022-12-31 0001495584 SVVC:IntraopMedicalCorp22Member 2022-01-01 2022-12-31 0001495584 SVVC:IntraopMedicalCorp22Member 2022-12-31 0001495584 SVVC:IntraopMedicalCorp23Member 2022-01-01 2022-12-31 0001495584 SVVC:IntraopMedicalCorp23Member 2022-12-31 0001495584 SVVC:IntraopMedicalCorp24Member 2022-12-31 0001495584 SVVC:KymaIncMember 2022-01-01 2022-12-31 0001495584 SVVC:KymaIncMember 2022-12-31 0001495584 SVVC:LynceanTechnologiesIncMember 2022-01-01 2022-12-31 0001495584 SVVC:LynceanTechnologiesIncMember 2022-12-31 0001495584 SVVC:RevasumIncMember 2022-01-01 2022-12-31 0001495584 SVVC:RevasumIncMember 2022-12-31 0001495584 SVVC:SiliconGenesisCorpMember 2022-01-01 2022-12-31 0001495584 SVVC:SiliconGenesisCorpMember 2022-12-31 0001495584 SVVC:SiliconGenesisCorp1Member 2022-01-01 2022-12-31 0001495584 SVVC:SiliconGenesisCorp1Member 2022-12-31 0001495584 SVVC:SiliconGenesisCorp2Member 2022-01-01 2022-12-31 0001495584 SVVC:SiliconGenesisCorp2Member 2022-12-31 0001495584 SVVC:SiliconGenesisCorp3Member 2022-01-01 2022-12-31 0001495584 SVVC:SiliconGenesisCorp3Member 2022-12-31 0001495584 SVVC:SiliconGenesisCorp4Member 2022-01-01 2022-12-31 0001495584 SVVC:SiliconGenesisCorp4Member 2022-12-31 0001495584 SVVC:SiliconGenesisCorp5Member 2022-01-01 2022-12-31 0001495584 SVVC:SiliconGenesisCorp5Member 2022-12-31 0001495584 SVVC:SiliconGenesisCorp6Member 2022-01-01 2022-12-31 0001495584 SVVC:SiliconGenesisCorp6Member 2022-12-31 0001495584 SVVC:SiliconGenesisCorp7Member 2022-01-01 2022-12-31 0001495584 SVVC:SiliconGenesisCorp7Member 2022-12-31 0001495584 SVVC:SiliconGenesisCorp8Member 2022-12-31 0001495584 SVVC:UctCoatingsIncMember 2022-01-01 2022-12-31 0001495584 SVVC:UctCoatingsIncMember 2022-12-31 0001495584 SVVC:WrightSpeedIncMember 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedIncMember 2022-12-31 0001495584 SVVC:WrightSpeedInc1Member 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedInc1Member 2022-12-31 0001495584 SVVC:WrightSpeedInc2Member 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedInc2Member 2022-12-31 0001495584 SVVC:WrightSpeedInc3Member 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedInc3Member 2022-12-31 0001495584 SVVC:WrightSpeedInc4Member 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedInc4Member 2022-12-31 0001495584 SVVC:WrightSpeedInc5Member 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedInc5Member 2022-12-31 0001495584 SVVC:WrightSpeedInc6Member 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedInc6Member 2022-12-31 0001495584 SVVC:WrightSpeedInc7Member 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedInc7Member 2022-12-31 0001495584 SVVC:WrightSpeedInc8Member 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedInc8Member 2022-12-31 0001495584 SVVC:WrightSpeedInc9Member 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedInc9Member 2022-12-31 0001495584 SVVC:WrightSpeedInc10Member 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedInc10Member 2022-12-31 0001495584 SVVC:WrightSpeedInc11Member 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedInc11Member 2022-12-31 0001495584 SVVC:WrightSpeedInc12Member 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedInc12Member 2022-12-31 0001495584 SVVC:WrightSpeedInc13Member 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedInc13Member 2022-12-31 0001495584 SVVC:WrightSpeedInc14Member 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedInc14Member 2022-12-31 0001495584 SVVC:WrightSpeedInc15Member 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedInc15Member 2022-12-31 0001495584 SVVC:WrightSpeedInc16Member 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedInc16Member 2022-12-31 0001495584 SVVC:WrightSpeedInc17Member 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedInc17Member 2022-12-31 0001495584 SVVC:WrightSpeedInc18Member 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedInc18Member 2022-12-31 0001495584 SVVC:WrightSpeedInc19Member 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedInc19Member 2022-12-31 0001495584 SVVC:WrightSpeedInc20Member 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedInc20Member 2022-12-31 0001495584 SVVC:WrightSpeedInc21Member 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedInc21Member 2022-12-31 0001495584 SVVC:WrightSpeedInc22Member 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedInc22Member 2022-12-31 0001495584 SVVC:WrightSpeedInc23Member 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedInc23Member 2022-12-31 0001495584 SVVC:WrightSpeedInc24Member 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedInc24Member 2022-12-31 0001495584 SVVC:WrightSpeedInc25Member 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedInc25Member 2022-12-31 0001495584 SVVC:WrightSpeedInc26Member 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedInc26Member 2022-12-31 0001495584 SVVC:WrightSpeedInc27Member 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedInc27Member 2022-12-31 0001495584 SVVC:WrightSpeedInc28Member 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedInc28Member 2022-12-31 0001495584 SVVC:WrightSpeedInc29Member 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedInc29Member 2022-12-31 0001495584 SVVC:WrightSpeedInc30Member 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedInc30Member 2022-12-31 0001495584 SVVC:WrightSpeedInc31Member 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedInc31Member 2022-12-31 0001495584 SVVC:WrightSpeedInc32Member 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedInc32Member 2022-12-31 0001495584 SVVC:WrightSpeedInc33Member 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedInc33Member 2022-12-31 0001495584 SVVC:WrightSpeedInc34Member 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedInc34Member 2022-12-31 0001495584 SVVC:WrightSpeedInc36Member 2022-12-31 0001495584 SVVC:InvestmentCompanyMember 2022-01-01 2022-12-31 0001495584 SVVC:InvestmentCompanyMember 2022-12-31 0001495584 us-gaap:FairValueInputsLevel1Member SVVC:AdvancedMaterialsMember us-gaap:CommonStockMember 2023-06-30 0001495584 us-gaap:FairValueInputsLevel2Member SVVC:AdvancedMaterialsMember us-gaap:CommonStockMember 2023-06-30 0001495584 us-gaap:FairValueInputsLevel3Member SVVC:AdvancedMaterialsMember us-gaap:CommonStockMember 2023-06-30 0001495584 us-gaap:FairValueInputsLevel1Member SVVC:AutomotiveMember us-gaap:CommonStockMember 2023-06-30 0001495584 us-gaap:FairValueInputsLevel2Member SVVC:AutomotiveMember us-gaap:CommonStockMember 2023-06-30 0001495584 us-gaap:FairValueInputsLevel3Member SVVC:AutomotiveMember us-gaap:CommonStockMember 2023-06-30 0001495584 us-gaap:FairValueInputsLevel1Member SVVC:EquipmentLeasingMember us-gaap:CommonStockMember 2023-06-30 0001495584 us-gaap:FairValueInputsLevel2Member SVVC:EquipmentLeasingMember us-gaap:CommonStockMember 2023-06-30 0001495584 us-gaap:FairValueInputsLevel3Member SVVC:EquipmentLeasingMember us-gaap:CommonStockMember 2023-06-30 0001495584 us-gaap:FairValueInputsLevel1Member SVVC:SemiconductorEquipmentMember us-gaap:CommonStockMember 2023-06-30 0001495584 us-gaap:FairValueInputsLevel2Member SVVC:SemiconductorEquipmentMember us-gaap:CommonStockMember 2023-06-30 0001495584 us-gaap:FairValueInputsLevel3Member SVVC:SemiconductorEquipmentMember us-gaap:CommonStockMember 2023-06-30 0001495584 us-gaap:FairValueInputsLevel1Member us-gaap:CommonStockMember 2023-06-30 0001495584 us-gaap:FairValueInputsLevel2Member us-gaap:CommonStockMember 2023-06-30 0001495584 us-gaap:FairValueInputsLevel3Member us-gaap:CommonStockMember 2023-06-30 0001495584 us-gaap:FairValueInputsLevel1Member SVVC:AerospaceMember us-gaap:PreferredStockMember 2023-06-30 0001495584 us-gaap:FairValueInputsLevel2Member SVVC:AerospaceMember us-gaap:PreferredStockMember 2023-06-30 0001495584 us-gaap:FairValueInputsLevel3Member SVVC:AerospaceMember us-gaap:PreferredStockMember 2023-06-30 0001495584 us-gaap:FairValueInputsLevel1Member SVVC:AutomotiveMember us-gaap:PreferredStockMember 2023-06-30 0001495584 us-gaap:FairValueInputsLevel2Member SVVC:AutomotiveMember us-gaap:PreferredStockMember 2023-06-30 0001495584 us-gaap:FairValueInputsLevel3Member SVVC:AutomotiveMember us-gaap:PreferredStockMember 2023-06-30 0001495584 us-gaap:FairValueInputsLevel1Member SVVC:EquipmentLeasingMember us-gaap:PreferredStockMember 2023-06-30 0001495584 us-gaap:FairValueInputsLevel2Member SVVC:EquipmentLeasingMember us-gaap:PreferredStockMember 2023-06-30 0001495584 us-gaap:FairValueInputsLevel3Member SVVC:EquipmentLeasingMember us-gaap:PreferredStockMember 2023-06-30 0001495584 us-gaap:FairValueInputsLevel1Member us-gaap:PreferredStockMember 2023-06-30 0001495584 us-gaap:FairValueInputsLevel2Member us-gaap:PreferredStockMember 2023-06-30 0001495584 us-gaap:FairValueInputsLevel3Member us-gaap:PreferredStockMember 2023-06-30 0001495584 SVVC:EquityContractsMember us-gaap:FairValueInputsLevel1Member us-gaap:PreferredStockMember 2023-06-30 0001495584 SVVC:EquityContractsMember us-gaap:FairValueInputsLevel2Member us-gaap:PreferredStockMember 2023-06-30 0001495584 SVVC:EquityContractsMember us-gaap:FairValueInputsLevel3Member us-gaap:PreferredStockMember 2023-06-30 0001495584 SVVC:AssetDerivativesMember us-gaap:FairValueInputsLevel1Member us-gaap:PreferredStockMember 2023-06-30 0001495584 SVVC:AssetDerivativesMember us-gaap:FairValueInputsLevel2Member us-gaap:PreferredStockMember 2023-06-30 0001495584 SVVC:AssetDerivativesMember us-gaap:FairValueInputsLevel3Member us-gaap:PreferredStockMember 2023-06-30 0001495584 SVVC:ConvertibleNotesMember us-gaap:FairValueInputsLevel1Member SVVC:AdvancedMaterialsMember 2023-06-30 0001495584 SVVC:ConvertibleNotesMember us-gaap:FairValueInputsLevel2Member SVVC:AdvancedMaterialsMember 2023-06-30 0001495584 SVVC:ConvertibleNotesMember us-gaap:FairValueInputsLevel3Member SVVC:AdvancedMaterialsMember 2023-06-30 0001495584 SVVC:ConvertibleNotesMember us-gaap:FairValueInputsLevel1Member SVVC:AerospaceMember 2023-06-30 0001495584 SVVC:ConvertibleNotesMember us-gaap:FairValueInputsLevel2Member SVVC:AerospaceMember 2023-06-30 0001495584 SVVC:ConvertibleNotesMember us-gaap:FairValueInputsLevel3Member SVVC:AerospaceMember 2023-06-30 0001495584 SVVC:ConvertibleNotesMember us-gaap:FairValueInputsLevel1Member SVVC:AutomotiveMember 2023-06-30 0001495584 SVVC:ConvertibleNotesMember us-gaap:FairValueInputsLevel2Member SVVC:AutomotiveMember 2023-06-30 0001495584 SVVC:ConvertibleNotesMember us-gaap:FairValueInputsLevel3Member SVVC:AutomotiveMember 2023-06-30 0001495584 SVVC:ConvertibleNotesMember us-gaap:FairValueInputsLevel1Member SVVC:MedicalDevicesMember 2023-06-30 0001495584 SVVC:ConvertibleNotesMember us-gaap:FairValueInputsLevel2Member SVVC:MedicalDevicesMember 2023-06-30 0001495584 SVVC:ConvertibleNotesMember us-gaap:FairValueInputsLevel3Member SVVC:MedicalDevicesMember 2023-06-30 0001495584 SVVC:ConvertibleNotesMember us-gaap:FairValueInputsLevel1Member 2023-06-30 0001495584 SVVC:ConvertibleNotesMember us-gaap:FairValueInputsLevel2Member 2023-06-30 0001495584 SVVC:ConvertibleNotesMember us-gaap:FairValueInputsLevel3Member 2023-06-30 0001495584 SVVC:MutualFundsMember us-gaap:FairValueInputsLevel1Member 2023-06-30 0001495584 SVVC:MutualFundsMember us-gaap:FairValueInputsLevel2Member 2023-06-30 0001495584 SVVC:MutualFundsMember us-gaap:FairValueInputsLevel3Member 2023-06-30 0001495584 us-gaap:FairValueInputsLevel1Member 2023-06-30 0001495584 us-gaap:FairValueInputsLevel2Member 2023-06-30 0001495584 us-gaap:FairValueInputsLevel3Member 2023-06-30 0001495584 SVVC:AdvancedMaterialsMember us-gaap:CommonStockMember 2022-12-31 0001495584 SVVC:AdvancedMaterialsMember us-gaap:CommonStockMember 2023-01-01 2023-06-30 0001495584 SVVC:AdvancedMaterialsMember us-gaap:CommonStockMember 2023-06-30 0001495584 SVVC:AutomotiveMember us-gaap:CommonStockMember 2022-12-31 0001495584 SVVC:AutomotiveMember us-gaap:CommonStockMember 2023-01-01 2023-06-30 0001495584 SVVC:AutomotiveMember us-gaap:CommonStockMember 2023-06-30 0001495584 SVVC:EquipmentLeasingMember us-gaap:CommonStockMember 2022-12-31 0001495584 SVVC:EquipmentLeasingMember us-gaap:CommonStockMember 2023-01-01 2023-06-30 0001495584 SVVC:EquipmentLeasingMember us-gaap:CommonStockMember 2023-06-30 0001495584 us-gaap:IntellectualPropertyMember us-gaap:CommonStockMember 2022-12-31 0001495584 us-gaap:IntellectualPropertyMember us-gaap:CommonStockMember 2023-01-01 2023-06-30 0001495584 us-gaap:IntellectualPropertyMember us-gaap:CommonStockMember 2023-06-30 0001495584 us-gaap:CommonStockMember 2022-12-31 0001495584 us-gaap:CommonStockMember 2023-01-01 2023-06-30 0001495584 us-gaap:CommonStockMember 2023-06-30 0001495584 SVVC:AerospaceMember us-gaap:PreferredStockMember 2022-12-31 0001495584 SVVC:AerospaceMember us-gaap:PreferredStockMember 2023-01-01 2023-06-30 0001495584 SVVC:AerospaceMember us-gaap:PreferredStockMember 2023-06-30 0001495584 SVVC:AutomotiveMember us-gaap:PreferredStockMember 2022-12-31 0001495584 SVVC:AutomotiveMember us-gaap:PreferredStockMember 2023-01-01 2023-06-30 0001495584 SVVC:AutomotiveMember us-gaap:PreferredStockMember 2023-06-30 0001495584 SVVC:EquipmentLeasingMember us-gaap:PreferredStockMember 2022-12-31 0001495584 SVVC:EquipmentLeasingMember us-gaap:PreferredStockMember 2023-01-01 2023-06-30 0001495584 SVVC:EquipmentLeasingMember us-gaap:PreferredStockMember 2023-06-30 0001495584 us-gaap:IntellectualPropertyMember us-gaap:PreferredStockMember 2022-12-31 0001495584 us-gaap:IntellectualPropertyMember us-gaap:PreferredStockMember 2023-01-01 2023-06-30 0001495584 us-gaap:IntellectualPropertyMember us-gaap:PreferredStockMember 2023-06-30 0001495584 us-gaap:PreferredStockMember 2022-12-31 0001495584 us-gaap:PreferredStockMember 2023-01-01 2023-06-30 0001495584 us-gaap:PreferredStockMember 2023-06-30 0001495584 SVVC:EquityContractsMember us-gaap:PreferredStockMember 2022-12-31 0001495584 SVVC:EquityContractsMember us-gaap:PreferredStockMember 2023-01-01 2023-06-30 0001495584 SVVC:EquityContractsMember us-gaap:PreferredStockMember 2023-06-30 0001495584 SVVC:AssetDerivativesMember us-gaap:PreferredStockMember 2022-12-31 0001495584 SVVC:AssetDerivativesMember us-gaap:PreferredStockMember 2023-01-01 2023-06-30 0001495584 SVVC:AssetDerivativesMember us-gaap:PreferredStockMember 2023-06-30 0001495584 SVVC:ConvertibleNotesMember SVVC:AdvancedMaterialsMember 2022-12-31 0001495584 SVVC:ConvertibleNotesMember SVVC:AdvancedMaterialsMember 2023-01-01 2023-06-30 0001495584 SVVC:ConvertibleNotesMember SVVC:AdvancedMaterialsMember 2023-06-30 0001495584 SVVC:ConvertibleNotesMember SVVC:AerospaceMember 2022-12-31 0001495584 SVVC:ConvertibleNotesMember SVVC:AerospaceMember 2023-01-01 2023-06-30 0001495584 SVVC:ConvertibleNotesMember SVVC:AerospaceMember 2023-06-30 0001495584 SVVC:ConvertibleNotesMember SVVC:AutomotiveMember 2022-12-31 0001495584 SVVC:ConvertibleNotesMember SVVC:AutomotiveMember 2023-01-01 2023-06-30 0001495584 SVVC:ConvertibleNotesMember SVVC:AutomotiveMember 2023-06-30 0001495584 SVVC:ConvertibleNotesMember SVVC:MedicalDevicesMember 2022-12-31 0001495584 SVVC:ConvertibleNotesMember SVVC:MedicalDevicesMember 2023-01-01 2023-06-30 0001495584 SVVC:ConvertibleNotesMember SVVC:MedicalDevicesMember 2023-06-30 0001495584 SVVC:ConvertibleNotesMember 2022-12-31 0001495584 SVVC:ConvertibleNotesMember 2023-01-01 2023-06-30 0001495584 SVVC:ConvertibleNotesMember 2023-06-30 0001495584 SVVC:AdvancedMaterialsMember 2023-06-30 0001495584 SVVC:AerospaceMember 2023-06-30 0001495584 SVVC:AutomotiveMember 2023-06-30 0001495584 SVVC:EquipmentLeasingMember 2023-06-30 0001495584 SVVC:MedicalDevicesMember 2023-06-30 0001495584 SVVC:CapitalLossCarryforward1Member 2023-01-01 2023-06-30 0001495584 SVVC:CapitalLossCarryforward1Member 2023-06-30 0001495584 SVVC:CapitalLossCarryforward2Member 2023-01-01 2023-06-30 0001495584 SVVC:CapitalLossCarryforward2Member 2023-06-30 0001495584 SVVC:CapitalLossCarryforward3Member 2023-01-01 2023-06-30 0001495584 SVVC:CapitalLossCarryforward3Member 2023-06-30 0001495584 SVVC:CapitalLossCarryforwardsMember 2023-06-30 0001495584 us-gaap:CommonStockMember 2016-04-26 0001495584 2016-04-01 2016-04-26 0001495584 2017-11-10 0001495584 2017-11-01 2017-11-10 0001495584 SVVC:SVVCStockMember 2018-08-30 2018-08-31 0001495584 2018-08-30 2018-08-31 0001495584 2014-12-01 2014-12-22 0001495584 2014-12-31 0001495584 us-gaap:CommonStockMember 2019-12-15 2019-12-16 0001495584 srt:MinimumMember us-gaap:CommonStockMember 2019-12-16 0001495584 srt:MaximumMember us-gaap:CommonStockMember 2019-12-16 0001495584 us-gaap:CommonStockMember 2019-12-16 0001495584 2020-03-31 0001495584 SVVC:EQXCapitalIncCommonStockMember 2022-12-31 0001495584 SVVC:EQXCapitalIncCommonStockMember 2023-01-01 2023-06-30 0001495584 SVVC:EQXCapitalIncCommonStockMember 2023-06-30 0001495584 SVVC:EQXCapitalIncSeriesAPreferredStockMember 2022-12-31 0001495584 SVVC:EQXCapitalIncSeriesAPreferredStockMember 2023-01-01 2023-06-30 0001495584 SVVC:EQXCapitalIncSeriesAPreferredStockMember 2023-06-30 0001495584 SVVC:EquipmentLeasingMember 2022-12-31 0001495584 SVVC:EquipmentLeasingMember 2023-01-01 2023-06-30 0001495584 SVVC:HeraSystemsIncConvertibleNoteMember 2022-12-31 0001495584 SVVC:HeraSystemsIncConvertibleNoteMember 2023-01-01 2023-06-30 0001495584 SVVC:HeraSystemsIncConvertibleNoteMember 2023-06-30 0001495584 SVVC:HeraSystemsIncConvertibleNote1Member 2022-12-31 0001495584 SVVC:HeraSystemsIncConvertibleNote1Member 2023-01-01 2023-06-30 0001495584 SVVC:HeraSystemsIncConvertibleNote1Member 2023-06-30 0001495584 SVVC:HeraSystemsIncSeriesAPreferredMember 2022-12-31 0001495584 SVVC:HeraSystemsIncSeriesAPreferredMember 2023-01-01 2023-06-30 0001495584 SVVC:HeraSystemsIncSeriesAPreferredMember 2023-06-30 0001495584 SVVC:HeraSystemsIncSeriesBPreferredMember 2022-12-31 0001495584 SVVC:HeraSystemsIncSeriesBPreferredMember 2023-01-01 2023-06-30 0001495584 SVVC:HeraSystemsIncSeriesBPreferredMember 2023-06-30 0001495584 SVVC:HeraSystemsIncSeriesBWarrantsMember 2022-12-31 0001495584 SVVC:HeraSystemsIncSeriesBWarrantsMember 2023-01-01 2023-06-30 0001495584 SVVC:HeraSystemsIncSeriesBWarrantsMember 2023-06-30 0001495584 SVVC:HeraSystemsIncSeriesBWarrants1Member 2022-12-31 0001495584 SVVC:HeraSystemsIncSeriesBWarrants1Member 2023-01-01 2023-06-30 0001495584 SVVC:HeraSystemsIncSeriesBWarrants1Member 2023-06-30 0001495584 SVVC:HeraSystemsIncSeriesBWarrants2Member 2022-12-31 0001495584 SVVC:HeraSystemsIncSeriesBWarrants2Member 2023-01-01 2023-06-30 0001495584 SVVC:HeraSystemsIncSeriesBWarrants2Member 2023-06-30 0001495584 SVVC:HeraSystemsIncSeriesBWarrants3Member 2022-12-31 0001495584 SVVC:HeraSystemsIncSeriesBWarrants3Member 2023-01-01 2023-06-30 0001495584 SVVC:HeraSystemsIncSeriesBWarrants3Member 2023-06-30 0001495584 SVVC:HeraSystemsIncSeriesCPreferredMember 2022-12-31 0001495584 SVVC:HeraSystemsIncSeriesCPreferredMember 2023-01-01 2023-06-30 0001495584 SVVC:HeraSystemsIncSeriesCPreferredMember 2023-06-30 0001495584 SVVC:AerospaceMember 2022-12-31 0001495584 SVVC:AerospaceMember 2023-01-01 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNoteMember 2022-12-31 0001495584 SVVC:IntraOpMedicalCorpConvertibleNoteMember 2023-01-01 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNoteMember 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote1Member 2022-12-31 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote1Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote1Member 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote2Member 2022-12-31 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote2Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote2Member 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote3Member 2022-12-31 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote3Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote3Member 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote4Member 2022-12-31 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote4Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote4Member 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote5Member 2022-12-31 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote5Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote5Member 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote6Member 2022-12-31 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote6Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote6Member 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote7Member 2022-12-31 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote7Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote7Member 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote8Member 2022-12-31 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote8Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote8Member 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote9Member 2022-12-31 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote9Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote9Member 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote10Member 2022-12-31 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote10Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote10Member 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote11Member 2022-12-31 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote11Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote11Member 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote12Member 2022-12-31 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote12Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote12Member 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote13Member 2022-12-31 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote13Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote13Member 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote14Member 2022-12-31 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote14Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote14Member 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote15Member 2022-12-31 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote15Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote15Member 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote16Member 2022-12-31 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote16Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote16Member 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote17Member 2022-12-31 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote17Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote17Member 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote18Member 2022-12-31 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote18Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote18Member 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote19Member 2022-12-31 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote19Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote19Member 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote20Member 2022-12-31 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote20Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote20Member 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote21Member 2022-12-31 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote21Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote21Member 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpSeriesCPreferredMember 2022-12-31 0001495584 SVVC:IntraOpMedicalCorpSeriesCPreferredMember 2023-01-01 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpSeriesCPreferredMember 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpTermNoteMember 2022-12-31 0001495584 SVVC:IntraOpMedicalCorpTermNoteMember 2023-01-01 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpTermNoteMember 2023-06-30 0001495584 SVVC:MedicalDevicesMember 2022-12-31 0001495584 SVVC:MedicalDevicesMember 2023-01-01 2023-06-30 0001495584 SVVC:RevasumIncCDIMember 2022-12-31 0001495584 SVVC:RevasumIncCDIMember 2023-01-01 2023-06-30 0001495584 SVVC:RevasumIncCDIMember 2023-06-30 0001495584 SVVC:SemiconductorEquipmentMember 2022-12-31 0001495584 SVVC:SemiconductorEquipmentMember 2023-01-01 2023-06-30 0001495584 SVVC:SemiconductorEquipmentMember 2023-06-30 0001495584 SVVC:SiliconGenesisCorpCommonStockMember 2022-12-31 0001495584 SVVC:SiliconGenesisCorpCommonStockMember 2023-01-01 2023-06-30 0001495584 SVVC:SiliconGenesisCorpCommonStockMember 2023-06-30 0001495584 SVVC:SiliconGenesisCorpCommonWarrantsMember 2022-12-31 0001495584 SVVC:SiliconGenesisCorpCommonWarrantsMember 2023-01-01 2023-06-30 0001495584 SVVC:SiliconGenesisCorpCommonWarrantsMember 2023-06-30 0001495584 SVVC:SiliconGenesisCorpSeries1GPreferredMember 2022-12-31 0001495584 SVVC:SiliconGenesisCorpSeries1GPreferredMember 2023-01-01 2023-06-30 0001495584 SVVC:SiliconGenesisCorpSeries1GPreferredMember 2023-06-30 0001495584 SVVC:SiliconGenesisCorpSeries1HPreferredMember 2022-12-31 0001495584 SVVC:SiliconGenesisCorpSeries1HPreferredMember 2023-01-01 2023-06-30 0001495584 SVVC:SiliconGenesisCorpSeries1HPreferredMember 2023-06-30 0001495584 SVVC:SiliconGenesisCorpSeries1DPreferredMember 2022-12-31 0001495584 SVVC:SiliconGenesisCorpSeries1DPreferredMember 2023-01-01 2023-06-30 0001495584 SVVC:SiliconGenesisCorpSeries1DPreferredMember 2023-06-30 0001495584 SVVC:SiliconGenesisCorpSeries1EPreferredMember 2022-12-31 0001495584 SVVC:SiliconGenesisCorpSeries1EPreferredMember 2023-01-01 2023-06-30 0001495584 SVVC:SiliconGenesisCorpSeries1EPreferredMember 2023-06-30 0001495584 SVVC:SiliconGenesisCorpSeries1FPreferredMember 2022-12-31 0001495584 SVVC:SiliconGenesisCorpSeries1FPreferredMember 2023-01-01 2023-06-30 0001495584 SVVC:SiliconGenesisCorpSeries1FPreferredMember 2023-06-30 0001495584 SVVC:SiliconGenesisCorpSeries1CPreferredStockMember 2022-12-31 0001495584 SVVC:SiliconGenesisCorpSeries1CPreferredStockMember 2023-01-01 2023-06-30 0001495584 SVVC:SiliconGenesisCorpSeries1CPreferredStockMember 2023-06-30 0001495584 SVVC:IntellectualsPropertyMember 2022-12-31 0001495584 SVVC:IntellectualsPropertyMember 2023-01-01 2023-06-30 0001495584 SVVC:IntellectualsPropertyMember 2023-06-30 0001495584 SVVC:UCTCoatingsIncCommonStockMember SVVC:AdvancedMaterialsMember 2022-12-31 0001495584 SVVC:UCTCoatingsIncCommonStockMember SVVC:AdvancedMaterialsMember 2023-01-01 2023-06-30 0001495584 SVVC:UCTCoatingsIncCommonStockMember SVVC:AdvancedMaterialsMember 2023-06-30 0001495584 SVVC:AdvancedMaterialsMember 2022-12-31 0001495584 SVVC:AdvancedMaterialsMember 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncCommonStockMember 2022-12-31 0001495584 SVVC:WrightspeedIncCommonStockMember 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncCommonStockMember 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNoteMember 2022-12-31 0001495584 SVVC:WrightspeedIncConvertibleNoteMember 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNoteMember 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote1Member 2022-12-31 0001495584 SVVC:WrightspeedIncConvertibleNote1Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote1Member 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote2Member 2022-12-31 0001495584 SVVC:WrightspeedIncConvertibleNote2Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote2Member 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote3Member 2022-12-31 0001495584 SVVC:WrightspeedIncConvertibleNote3Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote3Member 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote4Member 2022-12-31 0001495584 SVVC:WrightspeedIncConvertibleNote4Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote4Member 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote5Member 2022-12-31 0001495584 SVVC:WrightspeedIncConvertibleNote5Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote5Member 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote6Member 2022-12-31 0001495584 SVVC:WrightspeedIncConvertibleNote6Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote6Member 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote7Member 2022-12-31 0001495584 SVVC:WrightspeedIncConvertibleNote7Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote7Member 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote8Member 2022-12-31 0001495584 SVVC:WrightspeedIncConvertibleNote8Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote8Member 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote9Member 2022-12-31 0001495584 SVVC:WrightspeedIncConvertibleNote9Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote9Member 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote10Member 2022-12-31 0001495584 SVVC:WrightspeedIncConvertibleNote10Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote10Member 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote11Member 2022-12-31 0001495584 SVVC:WrightspeedIncConvertibleNote11Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote11Member 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote12Member 2022-12-31 0001495584 SVVC:WrightspeedIncConvertibleNote12Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote12Member 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote13Member 2022-12-31 0001495584 SVVC:WrightspeedIncConvertibleNote13Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote13Member 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote14Member 2022-12-31 0001495584 SVVC:WrightspeedIncConvertibleNote14Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote14Member 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote15Member 2022-12-31 0001495584 SVVC:WrightspeedIncConvertibleNote15Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote15Member 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote16Member 2022-12-31 0001495584 SVVC:WrightspeedIncConvertibleNote16Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote16Member 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote17Member 2022-12-31 0001495584 SVVC:WrightspeedIncConvertibleNote17Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote17Member 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote18Member 2022-12-31 0001495584 SVVC:WrightspeedIncConvertibleNote18Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote18Member 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote19Member 2022-12-31 0001495584 SVVC:WrightspeedIncConvertibleNote19Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote19Member 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote20Member 2022-12-31 0001495584 SVVC:WrightspeedIncConvertibleNote20Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote20Member 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote21Member 2022-12-31 0001495584 SVVC:WrightspeedIncConvertibleNote21Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote21Member 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote22Member 2022-12-31 0001495584 SVVC:WrightspeedIncConvertibleNote22Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote22Member 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote23Member 2022-12-31 0001495584 SVVC:WrightspeedIncConvertibleNote23Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote23Member 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote24Member 2022-12-31 0001495584 SVVC:WrightspeedIncConvertibleNote24Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote24Member 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote25Member 2022-12-31 0001495584 SVVC:WrightspeedIncConvertibleNote25Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote25Member 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote26Member 2022-12-31 0001495584 SVVC:WrightspeedIncConvertibleNote26Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote26Member 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote27Member 2022-12-31 0001495584 SVVC:WrightspeedIncConvertibleNote27Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote27Member 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote28Member 2022-12-31 0001495584 SVVC:WrightspeedIncConvertibleNote28Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote28Member 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote29Member 2022-12-31 0001495584 SVVC:WrightspeedIncConvertibleNote29Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote29Member 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote30Member 2022-12-31 0001495584 SVVC:WrightspeedIncConvertibleNote30Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote30Member 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote31Member 2022-12-31 0001495584 SVVC:WrightspeedIncConvertibleNote31Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote31Member 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote32Member 2022-12-31 0001495584 SVVC:WrightspeedIncConvertibleNote32Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote32Member 2023-06-30 0001495584 SVVC:WrightspeedIncSeriesAAPreferredMember 2022-12-31 0001495584 SVVC:WrightspeedIncSeriesAAPreferredMember 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncSeriesAAPreferredMember 2023-06-30 0001495584 SVVC:WrightspeedIncSeriesAAWarrantsMember 2022-12-31 0001495584 SVVC:WrightspeedIncSeriesAAWarrantsMember 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncSeriesAAWarrantsMember 2023-06-30 0001495584 SVVC:AutomotiveMember 2022-12-31 0001495584 SVVC:AutomotiveMember 2023-01-01 2023-06-30 0001495584 SVVC:TotalAffiliatesAndControlledInvestmentsMember 2022-12-31 0001495584 SVVC:TotalAffiliatesAndControlledInvestmentsMember 2023-01-01 2023-06-30 0001495584 SVVC:TotalAffiliatesAndControlledInvestmentsMember 2023-06-30 0001495584 SVVC:AffiliatesMember 2022-12-31 0001495584 SVVC:AffiliatesMember 2023-01-01 2023-06-30 0001495584 SVVC:AffiliatesMember 2023-06-30 0001495584 SVVC:ControlledInvestmentsMember 2022-12-31 0001495584 SVVC:ControlledInvestmentsMember 2023-01-01 2023-06-30 0001495584 SVVC:ControlledInvestmentsMember 2023-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

 

 

 

U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 10-Q/A

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period of June 30, 2023

 

or

 

TRANSITION QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Commission File Number 333-168195

 

FIRSTHAND TECHNOLOGY VALUE FUND, INC.

(Exact Name of Registrant as Specified in Charter)

 

maryland
(State or Other Jurisdiction of
Incorporation or Organization)

27-3008946
(I.R.S. Employer
Identification No)

   

150 Almaden Boulevard, Suite 1250
San Jose, California
(Address of Principal Executive Offices)

95113
(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (408) 886-7096

 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    ☑ Yes     ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

☐ Large Accelerated Filer

 

Non-accelerated Filer
(Do not check if smaller reporting company)

☐ Accelerated Filer

 

Smaller Reporting Company

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
☐Yes         ☑ No

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

 

Class

Outstanding at June 30, 2023

Common Stock, $0.001 par value per share

6,893,056

 

 

 

 Filed solely to include iXBRL tagging.

 

 

TABLE OF CONTENTS

 

PART I. FINANCIAL INFORMATION

2

Item 1. Financial Statements

2

Consolidated Statements of Assets and Liabilities as of June 30, 2023 (Unaudited) and December 31, 2022

3

Consolidated Statements of Operations (Unaudited) for the Three Months Ended June 30, 2023, and June 30, 2022, and for the Six Months Ended June 30, 2023, and June 30, 2022

4

Consolidated Statements of Cash Flows (Unaudited) for the Three Months Ended June 30, 2023, and June 30, 2022, and for the Six Months Ended June 30, 2023, and June 30, 2022

5

Consolidated Statements of Changes in Net Assets (Unaudited) for the Three Months Ended June 30, 2023, and June 30, 2022, and for the Six Months Ended June 30, 2023, and June 30, 2022

6

Selected Per Share Data and Ratios for the Six Months Ended June 30, 2023 (Unaudited) (Consolidated), for the Year Ended December 31, 2022 (Consolidated), for the Year Ended December 31, 2021 (Consolidated), for the Year Ended December 31, 2020 (Consolidated), for the Year Ended December 31, 2019 (Consolidated), and for the Year Ended December 31, 2018 (Consolidated)

7

Consolidated Schedule of Investments as of June 30, 2023 (Unaudited) and for the Year Ended December 31, 2022

9

Notes to Consolidated Financial Statements (Unaudited)

24

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

44

Item 3. Quantitative and Qualitative Disclosures About Market Risk

52

Item 4. Controls and Procedures

54

PART II. OTHER INFORMATION

55

Item 1. Legal Proceedings

56

Item 1A. Risk Factors

56

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

56

Item 3. Defaults Upon Senior Securities

56

Item 4. Mine Safety Disclosures

56

Item 5. Other Information

56

Item 6. Exhibits

56

SIGNATURES

57

 

1

 

 

PART I. FINANCIAL INFORMATION

 

Item 1.    Financial Statements

 

 

See accompanying notes to financial statements

2

 

 

Firsthand Technology Value Fund, Inc.

 

Consolidated Statements of Assets and Liabilities

 

                 
   

AS OF
JUNE 30, 2023
(UNAUDITED)

   

AS OF
DECEMBER 31,
2022

 

ASSETS

               

Investment securities:

               

Unaffiliated investments at acquisition cost

  $ 1,667,150 *   $ 1,772,422 *

Affiliated investments at acquisition cost

    662,235       662,235  

Controlled investments at acquisition cost

    132,091,932       140,355,353  

Total acquisition cost

  $ 134,421,317     $ 142,790,010  

Unaffiliated investments at market value

  $ 667,150 *

 

 

$ 772,422 *

Affiliated investments at market value

    266,091       337,500  

Controlled investments at market value

    19,679,716       39,012,002  

Total Market value** (Note 6)

    20,612,957       40,121,924  

Foreign currency at value (cost $2,629 and $3,235)

    2,703       3,404  

Receivable from dividends and interest

    279,358       14,463  

Other assets

    47,203       64,066  

Total Assets

    20,942,221       40,203,857  

LIABILITIES

               

Payable to affiliates (Note 4)

    9,586,630       9,188,187  

Trustees’ fees payable

    34,586       50,000  

Consulting fee payable

    46,000       46,000  

Accrued expenses and other payables

    175,949       310,079  

Total Liabilities

    9,843,165       9,594,266  

NET ASSETS

  $ 11,099,056     $ 30,609,591  
                 

Net Assets consist of:

               

Common Stock, par value $0.001 per share 100,000,000 shares authorized

  $ 6,893     $ 6,893  

Paid-in-capital

    176,770,722       176,770,722  

Total distributable earnings (loss)

    (165,678,559 )     (146,168,024 )

NET ASSETS

  $ 11,099,056     $ 30,609,591  
                 

Shares of Common Stock outstanding

    7,016,432       7,016,432  

Shares of Treasury Stock outstanding

    (123,376 )     (123,376 )

Total Shares of Common Stock outstanding

    6,893,056       6,893,056  

Net asset value per share (Note 2)

  $ 1.61     $ 4.44  

 

*

Includes Fidelity Investment Money Market Treasury Portfolio - Class I, which invests primarily in U.S. Treasury securities. The yields as of 06/30/23 and 12/31/22 were 4.98% and 4.13%, respectively. Please see https://fundresearch.fidelity.com/mutual-funds/summary/316175504 for additional information.

 

**

Includes warrants whose primary risk exposure is equity contracts.

 

 

See accompanying notes to financial statements

3

 

 

Firsthand Technology Value Fund, Inc.

 

Consolidated Statements of Operations (Unaudited)

 

                                 
   

FOR THE THREE MONTHS ENDED

   

FOR THE SIX MONTHS ENDED

 
   

JUNE 30, 2023

   

JUNE 30, 2022

   

JUNE 30, 2023

   

JUNE 30, 2022

 

INVESTMENT INCOME

                               

Unaffiliated interest

  $ (18,808 )   $ (45,718 )   $ 23,471     $ (10,480 )

Affiliated/controlled interest

    150,484       (3,767,193 )     299,467       (1,866,141 )

TOTAL INVESTMENT INCOME

    131,676       (3,812,911 )     322,938       (1,876,621 )
                                 

EXPENSES

                               

Investment advisory fees (Note 4)

    146,723       386,024       339,543       875,796  

Administration fees

    29,001       28,348       57,504       57,927  

Custody fees

    4,440       8,308       6,600       14,115  

Transfer agent fees

    12,633       2,420       20,511       12,397  

Registration and filing fees

    8,801       8,427       17,505       16,761  

Professional fees

    96,540       116,483       162,309       185,705  

Printing fees

    85,923       26,203       100,471       44,943  

Trustees fees

    3,336       50,000       22,086       100,000  

Compliance fees

    29,612       29,613       58,900       58,900  

Miscellaneous fees

    21,770       24,320       42,701       46,467  

TOTAL GROSS EXPENSES

    438,779       680,146       828,130       1,413,011  

NET INVESTMENT INCOME/(LOSS)

    (307,103 )     (4,493,057 )     (505,192 )     (3,289,632 )

Net Realized and Unrealized Gain (Loss) on Investments:

                               

Net realized gains (losses) from security transactions on:

                               

Affiliated/controlled

          (5,113,635 )     (7,864,997 )     (4,929,722 )

Foreign currency

    16       (714 )     16       1,946  

Net realized gains (losses)

    16       (5,114,349 )     (7,864,981 )     (4,927,776 )

Net change in unrealized appreciation (depreciation) on:

                               

Non-affiliated investments

          (87,762 )           104,114  

Affiliated/controlled investments and foreign currency

    (13,505,591 )     (27,284,454 )     (10,948,320 )     (36,322,228 )

Affiliated/controlled warrants investments (1)

    (955,633 )     (628,865 )     (192,042 )     (522,907 )

Net change in unrealized (depreciation)

    (14,461,224 )     (28,001,081 )     (11,140,362 )     (36,741,021 )

Net Realized and Unrealized (Loss) on Investments

    (14,461,208 )     (33,115,430 )     (19,005,343 )     (41,668,797 )

Net Decrease In Net Assets Resulting From Operations

  $ (14,768,311 )   $ (37,608,487 )   $ (19,510,535 )   $ (44,958,429 )

Net Decrease In Net Assets Per Share Resulting From Operations (2)

  $ (2.14 )   $ (5.45 )   $ (2.83 )   $ (6.52 )

 

(1)

Primary exposure is equity risk.

 

(2)

Per share results are calculated based on weighted average shares outstanding for each period.

 

 See accompanying notes to financial statements

4

 

 

Firsthand Technology Value Fund, Inc.

 

Consolidated Statements of Cash Flows (Unaudited)

 

                                 
   

FOR THE THREE
MONTHS ENDED
JUNE 30, 2023

   

FOR THE THREE
MONTHS ENDED
JUNE 30, 2022

   

FOR THE SIX
MONTHS ENDED
JUNE 30, 2023

   

FOR THE SIX
MONTHS ENDED
JUNE 30, 2022

 

CASH FLOWS FROM OPERATING ACTIVITIES

                               

Net increase (decrease) in Net Assets resulting from operations

  $ (14,768,311 )   $ (37,608,487 )   $ (19,510,535 )   $ (44,958,429 )

Adjustments to reconcile net increase (decrease) in Net Assets derived from operations to net cash provided by (used in) operating activities

                               

Purchases of investments

    (100,000 )           (100,000 )      

Proceeds from disposition of investments

          2,693,092       498,425       3,502,047  

Net purchases/sales from short-term investments

    387,743       (2,955,459 )     105,273       (3,382,103 )

Increase (decrease) in dividends, interest, and reclaims receivable

    (96,581 )     3,827,456       (264,896 )     2,003,270  

Increase (decrease) in due to Custodian

    (10,000 )     (13,589 )           (13,589 )

Increase (decrease) in receivable in investment sold

          339,624              

Increase (decrease) in payable to affiliates

    176,336       415,637       398,443       934,697  

Increase (decrease) in other assets

    25,426       25,852       16,863       17,619  

Increase (decrease) in accrued expenses and other payables

    (76,387 )     96,303       (149,544 )     227,691  

Net realized gain (loss) from investments

          5,114,349       7,864,995       4,927,776  

Net unrealized appreciation (depreciation) from investments, other assets, and warrants transactions

    14,461,135       28,001,081       11,140,275       36,741,021  

Net cash (used in) operating activities

    (639 )     (64,141 )     (701 )      
                                 

CASH FLOWS FROM FINANCING ACTIVITIES

                               

Net cash provided by financing activities

                       
                                 

Net increase (decrease) in cash

    (639 )     64,141       (701 )      

Cash and foreign currency - beginning of period

    3,342       (64,141 )     3,404        

Cash and foreign currency - end of period

  $ 2,703     $     $ 2,703     $  

 

 

See accompanying notes to financial statements

5

 

 

Firsthand Technology Value Fund, Inc.

 

Consolidated Statements of Changes in Net Assets (Unaudited)

 

                                 
   

FOR THE THREE
MONTHS ENDED
JUNE 30, 2023

   

FOR THE THREE
MONTHS ENDED
JUNE 30, 2022

   

FOR THE SIX
MONTHS ENDED
JUNE 30, 2023

   

FOR THE SIX
MONTHS ENDED
JUNE 30, 2022

 

FROM OPERATIONS:

                               

Net investment income (loss)

  $ (307,103 )     (4,493,057 )     (505,192 )     (3,289,632 )

Net realized gain (loss) from security transactions and foreign currency

    16       (5,114,349 )     (7,864,981 )     (4,927,776 )

Net change in unrealized (depreciation) on investments, other assets, and warrants transactions

    (14,461,224 )     (28,001,081 )     (11,140,362 )     (36,741,021 )

Net decrease in net assets from operations

    (14,768,311 )     (37,608,487 )     (19,510,535 )     (44,958,429 )
                                 

TOTAL DECREASE IN NET ASSETS

    (14,768,311 )     (37,608,487 )     (19,510,535 )     (44,958,429 )
                                 

NET ASSETS:

                               

Beginning of period

    25,867,367       87,404,682       30,609,591       94,754,624  

End of period

  $ 11,099,056     $ 49,796,195     $ 11,099,056     $ 49,796,195  
                                 

COMMON STOCK ACTIVITY:

                               

Shares outstanding, beginning of period

    6,893,056       6,893,056       6,893,056       6,893,056  

Shares outstanding, end of period

    6,893,056       6,893,056       6,893,056       6,893,056  

 

See accompanying notes to financial statements

6

 

 

Firsthand Technology Value Fund, Inc.

 

Consolidated Financial Highlights
Selected per share data and ratios for a share outstanding throughout each period

 

                                                 
   

FOR THE
SIX MONTHS
ENDED
JUNE 30, 2023
(Unaudited)

   

FOR THE
YEAR ENDED
DECEMBER 31,
2022

   

FOR THE
YEAR ENDED
DECEMBER 31,
2021

   

FOR THE
YEAR ENDED
DECEMBER 31,
2020

   

FOR THE
YEAR ENDED
DECEMBER 31,
2019

   

FOR THE
YEAR ENDED
DECEMBER 31,
2018

 

Net asset value at beginning of period

  $ 4.44     $ 13.75     $ 14.82     $ 17.70     $ 26.69     $ 23.83  

Income from investment operations:

                                               

Net investment income (loss), before deferred taxes

    (0.07 )     (1.81 )     0.44 (1)      0.09 (1)      0.90 (1)      (1.29 )(1)

Deferred tax benefit

                            (0.08 )     0.07  

Net investment gain (losses)

    (0.07 )     (1.81 )     0.44       0.09       0.82       (1.22 )

Net realized and unrealized gains (losses) on investments, before deferred taxes

    (2.76 )     (7.50 )     (1.51 )     (2.30 )     (12.15 )     5.13  

Deferred tax expense

                      (1.13 )     2.34       (1.23 )

Net realized and unrealized gains (losses) on investments, after deferred taxes

    (2.76 )     (7.50 )     (1.51 )     (3.43 )     (9.81 )     3.90  

Total from investment operations

    (2.83 )     (9.31 )     (1.07 )     (3.34 )     (8.99 )     2.68  
                                                 

Distributions from:

                                               

Realized capital gains

                                  (0.03 )

Anti-dilutive effect from capital share transactions

                      0.46             0.21  

Net asset value at end of period

  $ 1.61     $ 4.44     $ 13.75     $ 14.82     $ 17.70     $ 26.69  
                                                 

Market value at end of period

  $ 0.63     $ 0.95     $ 4.01     $ 4.47     $ 6.43     $ 11.20  
                                                 

Total Return

                                               

Based on Net Asset Value

    (63.74 )%(A)     (67.71 )%     (7.22 )%     (16.27 )%     (33.68 )%     12.39 %

Based on Market Value

    (33.68 )%(A)     (76.31 )%     (10.29 )%     (30.48 )%     (42.59 )%     25.43 %

Net assets at end of period (millions)

  $ 11.1     $ 30.6     $ 94.8     $ 102.1     $ 127.1     $ 191.6  

 

See accompanying notes to financial statements

7

 

 

Firsthand Technology Value Fund, Inc.

 

Consolidated Financial Highlights - continued
Selected per share data and ratios for a share outstanding throughout each period

 

   

FOR THE
SIX MONTHS
ENDED
JUNE 30, 2023
(Unaudited)

   

FOR THE
YEAR ENDED
DECEMBER 31,
2022

   

FOR THE
YEAR ENDED
DECEMBER 31,
2021

   

FOR THE
YEAR ENDED
DECEMBER 31,
2020

   

FOR THE
YEAR ENDED
DECEMBER 31,
2019

   

FOR THE
YEAR ENDED
DECEMBER 31,
2018

 

Ratio of total expenses to average net assets:

                                               

Before tax (benefit)/expense

    7.16 %(B)     4.11 %     3.12 %     3.10 %     (2.84 )%(2)     6.75 %(2)

Deferred tax (benefit)/expense(3)(4)

                      8.02 %(5)     (9.91 )%     4.43 %

Total expenses

    7.16 %(B)     4.11 %     3.12 %     11.12 %     (12.75 )%(2)     11.18 %(2)

Total expenses, excluding incentive fees and deferred tax expense

    7.16 %(B)     4.11 %     3.12 %     3.10 %     2.80 %     2.77 %

Ratio of net investment income (loss) to average net assets:

                                               

Before tax benefit

    (4.37 )%(B)     (20.96 )%     2.94 %     0.64 %     3.93 %(2)     (4.93 )%(2)

Deferred tax benefit (4)(6)

                            (0.33 )%     0.28 %

Net investment income (loss)

    (4.37 )%(B)     (20.96 )%     2.94 %     0.64 %     3.60 %     (4.65 )%

Portfolio turnover rate

    0 %(A)(C)     15 %     16 %     13 %     18 %     44 %

 

(1)

Calculated using average shares outstanding.

 

(2)

Amount includes the incentive fee. For the years ended December 31, 2019 and December 31, 2018, the ratio of the incentive fee to average net assets was (5.64)% and 3.98%, respectively.

 

(3)

Deferred tax expense estimate is derived from net investment income (loss), and realized and unrealized gains (losses).

 

(4)

The deferred tax expense and tax benefit are based on average net assets.

 

(5)

As restated to reflect the removal of parenthetical notation to appropriately present ratio as deferred tax expense.

 

(6)

Deferred tax benefit estimate for the ratio calculation is derived from net investment income (loss) only.

 

(A)

Not Annualized.

 

(B)

Annualized.

 

(C)

Less than 1%

 

 See accompanying notes to financial statements

8

 

 

Firsthand Technology Value Fund, Inc.

 

Consolidated Schedule of Investments

 

JUNE 30, 2023 (UNAUDITED)

                           

PORTFOLIO
COMPANY
(% OF NET
ASSETS)
AND INDUSTRY

TYPE OF INVESTMENT

 

ACQUISITION DATE

   

SHARES/PAR
VALUE ($)

 

COST BASIS

 

VALUE

 

EQX CAPITAL, INC.

Common Stock *(1)(2)(4)

  6/10/2016     100,000   $ 20,000   $ 1,880  

(3.5%) Equipment Leasing

Preferred Stock - Series A *(1)(2)(4)

  6/10/16-11/7/16     1,950,000     1,950,000     383,756  
                        385,636  
                           

HERA SYSTEMS, INC. (68.7%) Aerospace

Convertible Note Matures December 2024 Interest Rate 10% (1)(2)(4)

  12/29/2022     5,359,791     5,359,791     5,359,791  
 

Convertible Note Matures December 2024 Interest Rate 5% (1)(2)(4)

  12/29/2022     1,200,000     1,200,000     1,200,000  
 

Preferred Stock - Series B *(1)(2)(4)

  8/7/17-2/1/19     7,039,203     6,587,102     219,233  
 

Preferred Stock - Series C *(1)(2)(4)

  8/7/19-2/12/20     2,650,000     2,650,000     82,533  
 

Preferred Stock - Series A *(1)(2)(4)

  9/18/2015     3,642,324     2,000,000     2,566  
 

Preferred Stock Warrants - Series B *(1)(2)(4)

  2/1/2019     5,250,000     0     163,082  
 

Preferred Stock Warrants - Series B *(1)(2)(4)

  7/9/18-9/4/18     12,250,000     0     380,524  
 

Preferred Stock Warrants - Series B *(1)(2)(4)

  8/7/2017     6,214,922     0     193,055  
 

Preferred Stock Warrants - Series B *(1)(2)(4)

  9/28/2017     700,000     0     21,744  
                        7,622,528  
                           

INTRAOP MEDICAL CORP. (45.4%) Medical Devices

Convertible Note Matures December 2023 Interest Rate 15% (1)(2)(4)(6)

  10/11/2019     500,000     500,000     90,539  
 

Convertible Note Matures December 2023 Interest Rate 15% (1)(2)(4)(6)

  10/22/2021     1,000,000     1,000,000     181,078  
 

Convertible Note Matures December 2023 Interest Rate 15% (1)(2)(4)(6)

  10/29/2019     500,000     500,000     90,539  

 

See accompanying notes to financial statements

9

 

 

Firsthand Technology Value Fund, Inc.

 

Consolidated Schedule of Investments - continued

 

JUNE 30, 2023 (UNAUDITED)

 

PORTFOLIO
COMPANY
(% OF NET
ASSETS)
AND INDUSTRY

TYPE OF INVESTMENT

 

ACQUISITION DATE

 

SHARES/PAR
VALUE ($)

 

COST BASIS

 

VALUE

 

INTRAOP MEDICAL CORP. (continued)

Convertible Note Matures December 2023 Interest Rate 15% (1)(2)(4)(6)

  10/6/2021   500,000   $ 500,000   $ 90,539  
 

Convertible Note Matures December 2023 Interest Rate 15% (1)(2)(4)(6)

  11/12/2021   500,000     500,000     90,539  
 

Convertible Note Matures December 2023 Interest Rate 15% (1)(2)(4)(6)

  11/29/2021   500,000     500,000     90,539  
 

Convertible Note Matures December 2023 Interest Rate 15% (1)(2)(4)(6)

  12/31/2018   10,961,129     10,961,129     1,984,819  
 

Convertible Note Matures December 2023 Interest Rate 15% (1)(2)(4)(6)

  2/27/2020   1,000,000     1,000,000     181,078  
 

Convertible Note Matures December 2023 Interest Rate 15% (1)(2)(4)(6)

  2/28/2022   200,000     200,000     36,216  
 

Convertible Note Matures December 2023 Interest Rate 15% (1)(2)(4)(6)

  3/25/2020   500,000     500,000     90,539  
 

Convertible Note Matures December 2023 Interest Rate 15% (1)(2)(4)(6)

  3/30/2022   150,000     150,000     27,162  
 

Convertible Note Matures December 2023 Interest Rate 15% (1)(2)(4)(6)

  4/20/2021   1,000,000     1,000,000     181,078  
 

Convertible Note Matures December 2023 Interest Rate 15% (1)(2)(4)(6)

  4/6/2022   350,000     350,000     63,377  
 

Convertible Note Matures December 2023 Interest Rate 15% (1)(2)(4)(6)

  5/8/2020   400,000     400,000     72,431  
 

Convertible Note Matures December 2023 Interest Rate 15% (1)(2)(4)(6)

  6/10/2021   500,000     500,000     90,539  

 

See accompanying notes to financial statements

10

 

 

Firsthand Technology Value Fund, Inc.

 

Consolidated Schedule of Investments - continued

 

JUNE 30, 2023 (UNAUDITED)

 

PORTFOLIO
COMPANY
(% OF NET
ASSETS)
AND INDUSTRY

TYPE OF INVESTMENT

 

ACQUISITION DATE

   

SHARES/PAR
VALUE ($)

   

COST BASIS

   

VALUE

INTRAOP MEDICAL CORP. (continued)

Convertible Note Matures December 2023 Interest Rate 15% (1)(2)(4)

  6/10/2022     700,000   $ 700,000   $ 126,755  
 

Convertible Note Matures December 2023 Interest Rate 15% (1)(2)(4)(6)

  7/12/2019     1,300,000     1,300,000     235,401  
 

Convertible Note Matures December 2023 Interest Rate 15% (1)(2)(4)(6)

  7/16/2021     500,000     500,000     90,539  
 

Convertible Note Matures December 2023 Interest Rate 15% (1)(2)(4)(6)

  7/31/2020     500,000     500,000     90,539  
 

Convertible Note Matures December 2023 Interest Rate 15% (1)(2)(4)(6)

  8/28/2020     750,000     750,000     135,809  
 

Convertible Note Matures December 2023 Interest Rate 15% (1)(2)(4)(6)

  9/22/2021     500,000     500,000     90,539  
 

Preferred Stock - Series C *(1)(2)(4)

  7/12/2013     26,856,187     26,299,939     0  
 

Term Note Matures December 2023 Interest Rate 8% (1)(2)(4)

  2/10/2017     2,000,000     2,000,000     362,156  
 

Term Note Matures December 2023 Interest Rate 8% (1)(2)(4)

  2/28/2014     3,000,000     3,000,000     543,234  
                        5,035,984  
                           

KYMA, INC. (0.9%) Advanced Materials

Convertible Note Matures March 2024 Interest Rate 10% (1)(4)

  3/11/2019     100,000     100,000     100,000  
                           

LYNCEAN TECHNOLOGIES, INC. (0.0%)

Preferred Stock - Series B *(1)(4)

  7/3/2018     869,792     1,000,000     0  

Semiconductor Equipment

                         

 

See accompanying notes to financial statements

11

 

 

Firsthand Technology Value Fund, Inc.

 

Consolidated Schedule of Investments - continued

 

JUNE 30, 2023 (UNAUDITED)

 

PORTFOLIO
COMPANY
(% OF NET
ASSETS)
AND INDUSTRY

TYPE OF INVESTMENT

 

ACQUISITION DATE

   

SHARES/PAR
VALUE ($)

   

COST BASIS

   

VALUE

 

REVASUM, INC. (33.4%)

CDIs *(2)

  11/14/16-10/3/22     39,774,889   $ 9,268,218   $ 3,709,446  

Semiconductor Equipment

                         
                           
                           

UCT COATINGS, INC. (2.4%)

Common Stock *(1)(3)(4)

  4/18/2011     1,500,000     662,235     266,091  

Advanced Materials

                         
                           

WRIGHTSPEED, INC. (26.3%)

Common Stock *(1)(2)(4)

  6/7/2019     69,102     7,460,851     311  

Automotive

Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6)

  1/10/2023     100,000     100,000     9,750  
 

Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6)

  10/13/2020     1,050,000     1,050,000     102,375  
 

Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6)

  10/20/2021     1,000,000     1,000,000     97,500  
 

Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6)

  10/21/2022     135,000     135,000     13,162  
 

Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6)

  10/5/2021     700,000     700,000     68,250  
 

Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6)

  11/11/2020     400,000     400,000     39,000  
 

Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6)

  11/14/2022     165,000     165,000     16,088  
 

Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6)

  11/23/2021     1,000,000     1,000,000     97,500  
 

Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6)

  11/24/2020     375,000     375,000     36,562  

 

See accompanying notes to financial statements

12

 

 

Firsthand Technology Value Fund, Inc.

 

Consolidated Schedule of Investments - continued

 

JUNE 30, 2023 (UNAUDITED)

 

PORTFOLIO
COMPANY
(% OF NET
ASSETS)
AND INDUSTRY

TYPE OF INVESTMENT

 

ACQUISITION DATE

   

SHARES/PAR
VALUE ($)

   

COST BASIS

   

VALUE

 

WRIGHTSPEED, INC.(continued)

Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6)

  12/11/2020     400,000   $ 400,000   $ 39,000  
 

Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6)

  12/23/2020     2,000,000     2,000,000     195,000  
 

Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6)

  12/28/2021     1,000,000     1,000,000     97,500  
 

Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6)

  12/9/2022     125,000     125,000     12,188  
 

Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6)

  2/23/2021     1,400,000     1,400,000     136,500  
 

Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6)

  2/23/2022     200,000     200,000     19,500  
 

Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6)

  3/11/2022     185,000     185,000     18,037  
 

Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6)

  4/12/2021     1,200,000     1,200,000     117,000  
 

Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6)

  4/14/2022     65,000     65,000     6,337  
 

Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6)

  5/10/2022     250,000     250,000     24,375  
 

Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6)

  5/18/2021     1,000,000     1,000,000     97,500  
 

Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6)

  5/26/2022     250,000     250,000     24,375  

 

See accompanying notes to financial statements

13

 

 

Firsthand Technology Value Fund, Inc.

 

Consolidated Schedule of Investments - continued

 

JUNE 30, 2023 (UNAUDITED)

 

PORTFOLIO
COMPANY
(% OF NET
ASSETS)
AND INDUSTRY

TYPE OF INVESTMENT

 

ACQUISITION DATE

   

SHARES/PAR
VALUE ($)

   

COST BASIS

   

VALUE

 

WRIGHTSPEED, INC.(continued)

Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6)

  6/10/2022     250,000   $ 250,000   $ 24,375  
 

Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6)

  6/22/2021     1,000,000     1,000,000     97,500  
 

Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6)

  6/28/2022     250,000     250,000     24,375  
 

Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6)

  6/7/2019     4,929,015     4,929,015     480,579  
 

Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6)

  7/13/2022     250,000     250,000     24,375  
 

Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6)

  7/26/2021     1,000,000     1,000,000     97,500  
 

Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6)

  7/28/2022     250,000     250,000     24,375  
 

Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6)

  8/12/2020     750,000     750,000     73,125  
 

Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6)

  8/12/2022     250,000     250,000     24,375  
 

Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6)

  8/19/2021     1,000,000     1,000,000     97,500  
 

Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6)

  9/10/2020     900,000     900,000     87,750  
 

Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6)

  9/22/2021     300,000     300,000     29,250  

 

See accompanying notes to financial statements

14

 

 

Firsthand Technology Value Fund, Inc.

 

Consolidated Schedule of Investments - continued

 

JUNE 30, 2023 (UNAUDITED)

 

PORTFOLIO
COMPANY
(% OF NET
ASSETS)
AND INDUSTRY

TYPE OF INVESTMENT

 

ACQUISITION DATE

   

SHARES/PAR
VALUE ($)

   

COST BASIS

   

VALUE

 

WRIGHTSPEED, INC.(continued)

Preferred Stock - Series AA *(1)(2)(4)

  6/7/19-7/20/20     60,733,693   $ 17,355,887   $ 573,233    
                        2,926,122    
                             

INVESTMENT COMPANY (5.1%)

Fidelity Investments Money Market Treasury Portfolio - Class I (5)

  Various     567,150     567,150     567,150    
                             

TOTAL INVESTMENTS (Cost $134,421,317) — 185.7%

                    $ 20,612,957    
                             

LIABILITIES IN EXCESS OF OTHER ASSETS — (85.7)%

                      (9,513,901 )  
                             

NET ASSETS — 100.0%

                    $ 11,099,056    

 

All investments except the Fidelity Investments Money Market Portfolio are considered qualifying investments.

CDI CHESS Depositary Interests

*

Non-income producing security.

(1)

Restricted security. Fair Value is determined by or under the direction of the Company's Board of Directors (see Note 3). At June 30, 2023, we held $16,336,361 (or 147.2% of net assets) in restricted securities (see Note 2).

(2)

Controlled investments.

(3)

Affiliated issuer.

(4)

Fair Value Level 3 security (147.2% of net assets).

(5)

The Fidelity Investments Money Market Treasury Portfolio invests primarily in U.S. Treasury securities.

(6)

Security whose interest accrues until maturity however, based on June 30, 2023 valuation no such interest accrued during period ended June 30, 2023.

 

See accompanying notes to financial statements

15

 

 

Firsthand Technology Value Fund, Inc.

 

Consolidated Schedule of Investments - continued

 

DECEMBER 31, 2022

 

PORTFOLIO
COMPANY
(% OF NET
ASSETS)
AND INDUSTRY

TYPE OF INVESTMENT

 

ACQUISITION DATE

   

SHARES/PAR
VALUE ($)

   

COST BASIS

   

VALUE

 

EQX CAPITAL, INC.

(2.9%)

Common Stock *(1)(2)(4)

    6/10/2016       100,000     $ 20,000     $ 11,130  

Equipment Leasing

Preferred Stock - Series A *(1)(2)(4)

    6/10/16-11/7/16       1,950,000       1,950,000       865,995  
                                877,125  
                                   

HERA SYSTEMS, INC.

(25.8%)

Aerospace

Convertible Note Matures December 2024 Interest Rate 5% (1)(2)(4)

    12/29/2022       1,200,000       1,200,000       1,200,000  
 

Convertible Note Matures December 2022 Interest Rate 10% (1)(2)(4)

    12/29/2022       5,359,791       5,359,791       5,359,791  
 

Preferred Stock - Series A *(1)(2)(4)

    9/18/2015       3,642,324       2,000,000       4,735  
 

Preferred Stock - Series B *(1)(2)(4)

    8/7/17 - 2/1/19       7,039,203       6,587,102       275,585  
 

Preferred Stock - Series C *(1)(2)(4)

    8/7/19-2/12/20       2,650,000       2,650,000       103,748  
 

Preferred Stock Warrants - Series B *(1)(2)(4)

    7/9/18 - 9/4/18       12,250,000       0       478,608  
 

Preferred Stock Warrants - Series B *(1)(2)(4)

    2/1/2019       5,250,000       0       205,117  
 

Preferred Stock Warrants - Series B *(1)(2)(4)

    8/7/2017       6,214,922       0       242,817  
 

Preferred Stock Warrants - Series B *(1)(2)(4)

    9/28/2017       700,000       0       27,349  
                                7,897,750  
                                   

INTRAOP MEDICAL CORP.

(55.9%)

Medical Devices

Convertible Note Matures December 2022 Interest Rate 15% (1)(2)(4)(6)

    12/31/2018       10,961,129       10,961,129       6,746,169  
 

Convertible Note Matures December 2022 Interest Rate 15% (1)(2)(4)(6)

    7/12/2019       1,300,000       1,300,000       800,102  
 

`Convertible Note Matures December 2022 Interest Rate 15% (1)(2)(4)(6)

    10/11/2019       500,000       500,000       307,731  

 

See accompanying notes to financial statements

16

 

 

Firsthand Technology Value Fund, Inc.

 

Consolidated Schedule of Investments - continued

 

DECEMBER 31, 2022

 

PORTFOLIO
COMPANY
(% OF NET
ASSETS)
AND INDUSTRY

TYPE OF INVESTMENT

 

ACQUISITION DATE

   

SHARES/PAR
VALUE ($)

   

COST BASIS

   

VALUE

 

INTRAOP MEDICAL CORP.

(continued)

Convertible Note Matures December 2022 Interest Rate 15% (1)(2)(4)(6)

    10/29/2019       500,000     $ 500,000     $ 307,732  
 

Convertible Note Matures December 2022 Interest Rate 15% (1)(2)(4)(6)

    2/27/2020       1,000,000       1,000,000       615,463  
 

Convertible Note Matures December 2022 Interest Rate 15% (1)(2)(4)(6)

    3/25/2020       500,000       500,000       307,732  
 

Convertible Note Matures December 2022 Interest Rate 15% (1)(2)(4)(6)

    5/8/2020       400,000       400,000       246,185  
 

Convertible Note Matures December 2022 Interest Rate 15% (1)(2)(4)(6)

    7/31/2020       500,000       500,000       307,731  
 

Convertible Note Matures December 2022 Interest Rate 15% (1)(2)(4)(6)

    8/28/2020       750,000       750,000       461,597  
 

Convertible Note Matures December 2022 Interest Rate 15% (1)(2)(4)(6)

    4/20/2021       1,000,000       1,000,000       615,463  
 

Convertible Note Matures December 2022 Interest Rate 15% (1)(2)(4)(6)

    6/10/2021       500,000       500,000       307,732  
 

Convertible Note Matures December 2022 Interest Rate 15% (1)(2)(4)(6)

    7/16/2021       500,000       500,000       307,732  
 

Convertible Note Matures December 2022 Interest Rate 15% (1)(2)(4)(6)

    9/22/2021       500,000       500,000       307,731  
 

Convertible Note Matures December 2022 Interest Rate 15% (1)(2)(4)(6)

    10/6/2021       500,000       500,000       307,731  
 

Convertible Note Matures December 2022 Interest Rate 15% (1)(2)(4)(6)

    10/22/2021       1,000,000       1,000,000       615,463  

 

See accompanying notes to financial statements

17

 

 

Firsthand Technology Value Fund, Inc.

 

Consolidated Schedule of Investments - continued

 

DECEMBER 31, 2022

 

PORTFOLIO
COMPANY
(% OF NET
ASSETS)
AND INDUSTRY

TYPE OF INVESTMENT

 

ACQUISITION DATE

   

SHARES/PAR
VALUE ($)

   

COST BASIS

   

VALUE

 

INTRAOP MEDICAL CORP.

(continued)

Convertible Note Matures December 2022 Interest Rate 15% (1)(2)(4)(6)

    11/12/2021       500,000     $ 500,000     $ 307,732  
 

Convertible Note Matures December 2022 Interest Rate 15% (1)(2)(4)(6)

    11/29/2021       500,000       500,000       307,732  
 

Convertible Note Matures December 2022 Interest Rate 15% (1)(2)(4)(6)

    2/28/2022       200,000       200,000       123,093  
 

Convertible Note Matures December 2022 Interest Rate 15% (1)(2)(4)(6)

    3/30/2022       150,000       150,000       92,319  
 

Convertible Note Matures December 2022 Interest Rate 15% (1)(2)(4)(6)

    4/6/2022       350,000       350,000       215,412  
 

Convertible Note Matures December 2022 Interest Rate 15% (1)(2)(4)(6)

    6/10/2022       700,000       700,000       430,824  
 

Preferred Stock - Series C *(1)(2)(4)

    7/12/2013       26,856,187       26,299,938       0  
 

Term Note Matures December 2022 Interest Rate 8% (1)(2)(4)(6)

    2/28/2014       3,000,000       3,000,000       1,846,389  
 

Term Note Matures December 2022 Interest Rate 8% (1)(2)(4)(6)

    2/10/2017       2,000,000       2,000,000       1,230,926  
                                17,116,721  
                                   

KYMA, INC.

(0.3%)

Advanced Materials

Convertible Note Matures March 2023 Interest Rate 10% (1)(4)

    3/11/2019       100,000       100,000       100,000  
                                   

LYNCEAN TECHNOLOGIES, INC.

(0.0%)

Preferred Stock - Series B *(1)(4)

    7/3/2018       869,792       1,000,000       0  

Semiconductor Equipment

                                 
                                   

 

See accompanying notes to financial statements

18

 

 

Firsthand Technology Value Fund, Inc.

 

Consolidated Schedule of Investments - continued

 

DECEMBER 31, 2022

 

PORTFOLIO
COMPANY
(% OF NET
ASSETS)
AND INDUSTRY

TYPE OF INVESTMENT

 

ACQUISITION DATE

   

SHARES/PAR
VALUE ($)

   

COST BASIS

   

VALUE

 

REVASUM, INC.

(11.5%)

CDIs *(2)

    11/14/16 - 10/3/22       39,774,889     $ 9,268,219     $ 3,520,496  

Semiconductor Equipment

                                 
                                   

SILICON GENESIS CORP.

(2.4%)

Preferred Stock - Series 1-E *(1)(2)(4)

    4/18/2011       5,704,480       2,372,403       320,592  

Intellectual Property

Preferred Stock - Series 1-C *(1)(2)(4)

    4/18/2011       82,914       109,518       962  
 

Preferred Stock - Series 1-D *(1)(2)(4)

    4/18/2011       850,830       431,901       2,552  
 

Common Stock *(1)(2)(4)

    4/18/2011       921,892       169,045       111  
 

Common Stock Warrants *(1)(2)(4)

    4/18/2011       37,982       6,678       1  
 

Preferred Stock - Series 1-F *(1)(2)(4)

    4/18/2011       912,453       456,389       70,806  
 

Preferred Stock - Series 1-G *(1)(2)(4)

    3/10/2016       48,370,793       3,880,592       306,671  
 

Preferred Stock - Series 1-H *(1)(2)(4)

    3/10/2016       837,942       936,895       35,529  
                                737,224  
                                   

UCT COATINGS, INC.

(1.1%)

Common Stock *(1)(3)(4)

    4/18/2011       1,500,000       662,235       337,500  

Advanced Materials

                                 
                                   

WRIGHTSPEED, INC.

(29.0%)

Common Stock *(1)(2)(4)

    4/11/2013 - 5/6/2019       69,102       7,460,851       546  

Automotive

Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6)

    6/7/2019       4,929,015       4,929,015       1,601,930  
 

Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6)

    8/12/2020       750,000       750,000       243,750  
 

Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6)

    9/10/2020       900,000       900,000       292,500  

 

See accompanying notes to financial statements

19

 

 

Firsthand Technology Value Fund, Inc.

 

Consolidated Schedule of Investments - continued

 

DECEMBER 31, 2022

 

PORTFOLIO
COMPANY
(% OF NET
ASSETS)
AND INDUSTRY

TYPE OF INVESTMENT

 

ACQUISITION DATE

   

SHARES/PAR
VALUE ($)

   

COST BASIS

   

VALUE

 

WRIGHTSPEED, INC.

(continued)

Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6)

    10/13/2020       1,050,000     $ 1,050,000     $ 341,250  
 

Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6)

    11/11/2020       400,000       400,000       130,000  
 

Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6)

    11/24/2020       375,000       375,000       121,875  
 

Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6)

    12/11/2020       400,000       400,000       130,000  
 

Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6)

    12/23/2020       2,000,000       2,000,000       650,000  
 

Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6)

    2/23/2021       1,400,000       1,400,000       455,000  
 

Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6)

    4/12/2021       1,200,000       1,200,000       390,000  
 

Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6)

    5/18/2021       1,000,000       1,000,000       325,000  
 

Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6)

    6/22/2021       1,000,000       1,000,000       325,000  
 

Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6)

    7/26/2021       1,000,000       1,000,000       325,000  
 

Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6)

    8/19/2021       1,000,000       1,000,000       325,000  
 

Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6)

    9/22/2021       300,000       300,000       97,500  

 

See accompanying notes to financial statements

20

 

 

Firsthand Technology Value Fund, Inc.

 

Consolidated Schedule of Investments - continued

 

DECEMBER 31, 2022

 

PORTFOLIO
COMPANY
(% OF NET
ASSETS)
AND INDUSTRY

TYPE OF INVESTMENT

 

ACQUISITION DATE

   

SHARES/PAR
VALUE ($)

   

COST BASIS

   

VALUE

 

WRIGHTSPEED, INC.

(continued)

Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6)

    10/5/2021       700,000     $ 700,000     $ 227,500  
 

Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6)

    10/20/2021       1,000,000       1,000,000       325,000  
 

Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6)

    11/23/2021       1,000,000       1,000,000       325,000  
 

Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6)

    12/28/2021       1,000,000       1,000,000       325,000  
 

Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6)

    2/23/2022       200,000       200,000       65,000  
 

Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6)

    3/11/2022       185,000       185,000       60,125  
 

Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6)

    4/14/2022       65,000       65,000       21,125  
 

Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6)

    5/10/2022       250,000       250,000       81,250  
 

Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6)

    5/26/2022       250,000       250,000       81,250  
 

Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6)

    6/10/2022       250,000       250,000       81,250  
 

Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6)

    6/28/2022       250,000       250,000       81,250  
 

Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6)

    7/13/2022       250,000       250,000       81,250  

 

See accompanying notes to financial statements

21

 

 

Firsthand Technology Value Fund, Inc.

 

Consolidated Schedule of Investments - continued

 

DECEMBER 31, 2022

 

PORTFOLIO
COMPANY
(% OF NET
ASSETS)
AND INDUSTRY

TYPE OF INVESTMENT

 

ACQUISITION DATE

   

SHARES/PAR
VALUE ($)

   

COST BASIS

   

VALUE

 

WRIGHTSPEED, INC.

(continued)

Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6)

    7/28/2022       250,000     $ 250,000     $ 81,250  
 

Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6)

    8/12/2022       250,000       250,000       81,250  
 

Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6)

    10/21/2022       135,000       135,000       43,875  
 

Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6)

    11/14/2022       165,000       165,000       53,625  
 

Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6)

    12/9/2022       125,000       125,000       40,625  
 

Preferred Stock - Series AA *(1)(2)(4)

    6/7/19 - 7/20/20       60,733,693       17,355,887       1,049,478  
 

Preferred Stock Warrants - Series AA *(1)(2)(4)

    6/7/2019       609,756       0       3,232  
                                8,862,686  
                                   

 

See accompanying notes to financial statements

22

 

 

Firsthand Technology Value Fund, Inc.

 

Consolidated Schedule of Investments - continued

 

DECEMBER 31, 2022

 

PORTFOLIO
COMPANY
(% OF NET
ASSETS)
AND INDUSTRY

TYPE OF INVESTMENT

 

ACQUISITION DATE

   

SHARES/PAR
VALUE ($)

   

COST BASIS

   

VALUE

 

INVESTMENT COMPANY

(2.2%)

Fidelity Investments Money Market Treasury Portfolio - Class I (5)

    Various       672,422     $ 672,422     $ 672,422  
                                   

TOTAL INVESTMENTS (Cost $142,790,010) — 131.1%

                            $ 40,121,924  
                                   

LIABILITIES IN EXCESS OF OTHER ASSETS — (31.1)%

                              (9,512,333 )
                                   

NET ASSETS — 100.0%

                            $ 30,609,591  

 

All investments except the Fidelity Investments Money Market Portfolio are considered qualifying investments.

CDI: CHESS Depositary Interest.

*

Non-income producing security.

(1)

Restricted security. Fair Value is determined by or under the direction of the Company's Board of Directors (See note 3). At December 31, 2022, we held $35,929,006 (or 117.3% of net assets) in restricted securities (see Note 2).

(2)

Controlled investments.

(3)

Affiliated issuer.

(4)

Fair Value Level 3 security.

(5)

The Fidelity Investments Money Market Treasury Portfolio invests primarily in U.S. Treasury securities.

(6)

Security whose interest accrues over the life of the Note and is not payable until maturity. An interest adjustment was made during the year ending December 31, 2022 of approximately $21,400,000.

 

See accompanying notes to financial statements

23

 

 

Firsthand Technology Value Fund, Inc.

 

Notes to Consolidated Financial Statements

 

JUNE 30, 2023 (UNAUDITED)

 

NOTE 1. THE COMPANY

 

Firsthand Technology Value Fund, Inc. (the “Company,” the “Fund,” “us,” “our,” and “we”), is a Maryland corporation and an externally managed, non-diversified, closed-end management investment company that has elected to be treated as a business development company (“BDC”) under the Investment Company Act of 1940, as amended (the “1940 Act”). The Company acquired its initial portfolio of securities through the reorganization of Firsthand Technology Value Fund, a series of Firsthand Funds, into the Company. The reorganization was completed on April 15, 2011. The Company commenced operations on April 18th, 2011. Under normal circumstances, the Company will invest at least 80% of its assets for investment purposes in technology companies, which are considered to be those companies that derive at least 50% of their revenues from products and/ or services within the information technology sector or the “cleantech” sector. Information technology companies include, but are not limited to, those focused on computer hardware, software, telecommunications, networking, Internet, and consumer electronics. While there is no standard definition of cleantech, it is generally regarded as including goods and services designed to harness renewable energy and materials, eliminate emissions and waste, and reduce the use of natural resources. In addition, under normal circumstances we will invest at least 70% of our assets in privately held companies and in public companies with market capitalizations less than $250 million. Our portfolio is primarily composed of equity and equity derivative securities of technology and cleantech companies (as defined above). These investments generally range between $1 million and $10 million each, although the investment size will vary proportionately with the size of the Company’s capital base. The Company’s shares are listed on the NASDAQ Global Market under the symbol “SVVC.” Firsthand Capital Management, Inc., which was previously known as SiVest Group, Inc. (“FCM” or the “Advisor”), serves as the investment adviser to the Company.

 

The Company is an investment company and follows accounting and reporting guidance in the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification Topic 946.

 

CONSOLIDATION OF SUBSIDIARIES. On May 8, 2015, the Board of Directors of the Company approved the formation of a fully owned and controlled subsidiary (as defined by the 1940 Act) of the Company named Firsthand Venture Investors (“FVI”), a California general partnership formed on March 30, 2015. After the close of business on June 30, 2015, the Company contributed substantially all of its assets to FVI in return for a controlling general partner ownership interest in FVI. The transaction was completed on July 1, 2015. Under this structure, we have all or substantially all of our investment activities conducted through our fully owned subsidiary, FVI.

 

During the fiscal years ended December 31, 2016 and 2017, with the approval of its Board of Directors, the Company organized three separate fully owned and controlled subsidiaries (as defined by the 1940 Act). Each subsidiary was a Cayman Islands corporation and the financial statements of each subsidiary were reported on a consolidated basis with the Company. Each subsidiary was formed for the purpose of holding one or more investments made by the Company, and was treated as a controlled foreign corporation under the Internal Revenue Code not separately subject to U.S. federal income tax. FVI was treated as the sole U.S. shareholder of each subsidiary.

 

The Board of Directors of the Company approved the liquidation of those three Cayman subsidiaries on November 2, 2018. That liquidation was completed on December 27, 2018.

 

24

 

 

Firsthand Technology Value Fund, Inc.

 

Notes to Consolidated Financial Statements - continued

 

JUNE 30, 2023 (UNAUDITED)

 

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

The following is a summary of significant accounting policies followed in the preparation of the Company’s financial statements included in this report:

 

BASIS OF PRESENTATION. The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) pursuant to the requirements on Form 10-K. ASC 946, Financial Services—Investment Companies (“ASC 946”), and Articles 6, 10 and 12 of Regulation S-X. In the opinion of management, all adjustments, which are of a normal recurring nature, considered necessary for the fair presentation of the financial statements for the periods presented, have been included.

 

Under the 1940 Act, ASC 946, and the regulations pursuant to Article 6 of Regulation S-X, we are precluded from consolidating any entity other than another investment company or an operating company which provides substantially all of its services to benefit us. Consequentially, as of December 31, 2018, the Company consolidated some special purpose entities. These special purpose entities only hold investments of the Company and have no other significant asset and liabilities. All significant intercompany transactions and balances have been eliminated in consolidation.

 

USE OF ESTIMATES. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ from those estimates.

 

PORTFOLIO INVESTMENT VALUATIONS. Investments are stated at “value” as defined in the 1940 Act and in the applicable regulations of the Securities and Exchange Commission and in accordance with GAAP. Value, as defined in Section 2(a)(41) of the 1940 Act, is (i) the market value of those securities for which a market quotation is readily available and (ii) the fair value as determined in good faith by the Advisor as the valuation designee appointed by the Board of Directors, and subject to oversight by the Board of Directors. On June 30, 2023, our financial statements include venture capital investments valued at approximately 16.3 million. The fair values of our venture capital investments were also determined by the Advisor as the valuation designee. Upon sale of these investments, the values that are ultimately realized may be different from what is presently estimated. The difference could be material. Also see note 6 regarding the fair value of the company’s investments.

 

CASH AND CASH EQUIVALENTS. The Company considers liquid assets deposited with a bank, investments in money market funds, and certain short-term debt instruments with maturities of three months or less to be cash equivalents. These investments represent amounts held with financial institutions that are readily accessible to pay our expenses or purchase investments. Cash and cash equivalents are valued at cost plus accrued interest, which approximates market value.

 

RESTRICTED SECURITIES. At June 30, 2023, we held $16,336,361 in restricted securities. At December 31, 2022, we held $35,929,006. in restricted securities.

 

INCOME RECOGNITION. Dividend income is recorded on the ex-dividend date. Interest income is accrued as earned. Discounts and premiums on securities purchased are amortized over the lives of the respective securities. Other non-cash dividends are recognized as investment income at the fair value of the property received. When debt securities are determined to be non-income producing, the Company ceases accruing interest and writes off any previously accrued interest. These write-offs are recorded as an adjustment to interest income.

 

25

 

 

Firsthand Technology Value Fund, Inc.

 

Notes to Consolidated Financial Statements - continued

 

JUNE 30, 2023 (UNAUDITED)

 

SHARE VALUATION. The net asset value (“NAV”) per share of the Fund is calculated by dividing the sum of the value of the securities held by the Fund, plus cash or other assets, minus all liabilities (including estimated accrued expenses) by the total number of shares outstanding of the Fund, rounded to the nearest cent.

 

REALIZED GAIN OR LOSS AND UNREALIZED APPRECIATION OR DEPRECIATION OF PORTFOLIO INVESTMENTS. A realized gain or loss is recognized when an investment is disposed of and is computed as the difference between the Company’s cost basis in the investment at the disposition date and the net proceeds received from such disposition. Realized gains and losses are calculated on a specific identification basis. Unrealized appreciation or depreciation is computed as the difference between the fair value of the investment and the cost basis of such investment.

 

INCOME TAXES. The Company provides for state and federal corporate income tax, as appropriate, because it is regarded as a corporation under Subchapter C of the Code. The Company recognizes interest and penalties in income tax expense.

 

FOREIGN CURRENCY TRANSLATION. The accounting records of the Company are maintained in U.S. dollars. All assets and liabilities denominated in foreign currencies are translated into U.S. dollars based on the foreign exchange rate on the date of valuation. The Company does not isolate that portion of the results of operation resulting from changes in foreign exchange rates on investments from the fluctuations arising from changes in market prices of securities held. The Company’s investments in foreign securities may involve certain risks, including without limitation: foreign exchange restrictions, expropriation, taxation or other political, social, or economic risks, all of which could affect the market and/or credit risk of the investment. In addition, changes in the relationship of foreign currencies to the U.S. dollar can significantly affect the value of these investments and therefore the earnings of the Company.

 

SECURITIES TRANSACTIONS. Securities transactions are accounted for on the date the transaction for the purchase or sale of the securities is entered into by the Company (i.e., trade date).

 

CONCENTRATION OF CREDIT RISK. The Company places its cash and cash equivalents with financial institutions and, at times, cash held in checking accounts may exceed the Federal Deposit Insurance Corporation insured limit.

 

OPTIONS. The Company is subject to equity price risk in the normal course of pursuing its investment objectives and may enter into options written to hedge against changes in the value of equities. The Company may purchase put and call options to attempt to provide protection against adverse price effects from anticipated changes in prevailing prices of securities or stock indices. The Company may also write put and call options. When the Company writes an option, an amount equal to the premium received by the Company is recorded as a liability and is subsequently adjusted to the current fair value of the option written.

 

Premiums received from writing options that expire unexercised are treated by the Company on the expiration date as realized gains from investments. The difference between the premium and the amount paid on effecting a closing purchase transaction, including brokerage commissions, is also treated as a realized gain, or, if the premium is less than the amount paid for the closing purchase transaction, as a realized loss. If a call option is exercised, the premium is added to the proceeds from the sale of the underlying security or currency in determining whether the Company has realized a gain or loss. The Company as writer of an option bears the market risk of an unfavorable change in the price of the security underlying the written option.

 

26

 

 

Firsthand Technology Value Fund, Inc.

 

Notes to Consolidated Financial Statements - continued

 

JUNE 30, 2023 (UNAUDITED)

 

The average monthly volume of the Company’s derivatives during the six months ended June 30, 2023 is as follows:

 

     
 

PURCHASED OPTIONS
(CONTRACTS)

WARRANTS (NOTIONAL
VALUE)

WRITTEN OPTIONS
(CONTRACTS)

Firsthand Technology Value Fund, Inc.

1,252,639

 

NOTE 3. BUSINESS RISKS AND UNCERTAINTIES

 

We invest a substantial portion of our assets in privately-held companies, the securities of which are inherently illiquid. We also seek to invest in small publicly-traded companies that we believe have exceptional growth potential and to make opportunistic investments in publicly-traded companies, both large and small. In the case of investments in small publicly-traded companies, although these companies are publicly traded, their stock may not trade at high volumes, and prices can be volatile, which may restrict our ability to sell our positions. We may also be subject to contractual restrictions or securities law limits on our ability to sell portfolio holdings because of, for example, our affiliation with a portfolio company or the relative size of our holding in a company. These privately held and publicly traded businesses tend to lack management depth, have limited or no history of operations and typically have not attained profitability. Because of the speculative nature of our investments and the lack of public markets for privately held investments, there is greater risk of loss than is the case with traditional investment securities.

 

We do not choose investments based on a strategy of diversification. We also do not rebalance the portfolio should one of our portfolio companies increase in value substantially relative to the rest of the portfolio. Therefore, the value of our portfolio may be more vulnerable to events affecting a single sector, industry or portfolio company and, therefore, may be subject to greater volatility than a company that follows a diversification strategy.

 

Because there is typically no public or readily-ascertainable market for our interests in the small privately-held companies in which we invest, the valuation of those securities is determined in good faith by the Valuation Committee, comprised of all members of the Board who are not “interested persons” of the Company, as such term is defined in Section 2(a)(19) of the 1940 Act, in accordance with our Valuation Procedures and is subject to significant estimates and judgments. The determined value of the securities in our portfolio may differ significantly from the values that would be placed on these securities if a ready market for the securities existed. Any changes in valuation are recorded in our Statement of Operations as “Net increase (decrease) in unrealized appreciation on investments.” Changes in valuation of any of our investments in privately-held companies from one period to another may be volatile.

 

The Board has engaged an independent valuation firm to provide it with valuation assistance with respect to certain of our portfolio investments. The Company intends to continue to engage an independent valuation firm to provide us with assistance regarding our determination of the fair value of select portfolio investments each quarter unless directed by the Board to cancel such valuation services. The scope of the services rendered by an independent valuation firm is at the discretion of the Board. The Board is ultimately and solely responsible for determining the fair value of the Company’s investments in good faith.

 

27

 

 

Firsthand Technology Value Fund, Inc.

 

Notes to Consolidated Financial Statements - continued

 

JUNE 30, 2023 (UNAUDITED)

 

With respect to investments for which market quotations are not readily available or when such market quotations are deemed not to represent fair value, the Board has approved a multi-step valuation process to be followed each quarter, as described below:

 

 

(1)

each quarter the valuation process begins with each portfolio company or investment being initially valued by the Advisor’s Valuation Committee or the independent valuation firm;

 

 

(2)

the Valuation Committee of the Board on a quarterly basis reviews the preliminary valuation of the Advisor’s Valuation Committee and that of the independent valuation firms and makes the fair value determination, in good faith, based on the valuation recommendations of the Advisor’s Valuation Committee and the independent valuation firms; and

 

 

(3)

at each quarterly Board meeting, the Board considers the valuations recommended by the Advisor’s Valuation Committee and the independent valuation firms that were previously submitted to the Valuation Committee of the Board and ratifies the fair value determinations made by the Valuation Committee of the Board.

 

NOTE 4. INVESTMENT MANAGEMENT FEE

 

The Company has entered into an investment management agreement (the “Investment Management Agreement”) with FCM pursuant to which the Company will pay FCM a fee for providing investment management services consisting of two components—a base management fee and an incentive fee.

 

The base management fee will be calculated at an annual rate of 2.00% of our gross assets. For services rendered under the Investment Management Agreement, the base management fee will be payable quarterly in arrears. The base management fee will be calculated based on the average of (1) the value of our gross assets at the end of the current calendar quarter and (2) the value of the Company’s gross assets at the end of the preceding calendar quarter; and will be appropriately adjusted for any share issuances or repurchases during the current calendar quarter. Base management fees for any partial month or quarter will be pro-rated.

 

The incentive fee is determined and payable in arrears as of the end of each calendar year (or upon termination of the Investment Management Agreement, as of the termination date), commencing on April 15, 2011, and equals 20% of the Company’s realized capital gains, if any, on a cumulative basis from inception through the end of each calendar year, computed net of all realized capital losses and unrealized capital depreciation on a cumulative basis, less the aggregate amount of any previously paid incentive fees, provided that the incentive fee determined as of December 31, 2022, will be calculated for a period of shorter than twelve calendar months to take into account any realized gains computed net of all realized capital losses and unrealized capital depreciation from inception. For the six months ended June 30, 2023, there were no incentive fee adjustments.

 

NOTE 5. DEBT

 

The Company currently has no plan to use leverage and does not have any significant outstanding debt obligations (other than normal operating expense accruals).

 

28

 

 

Firsthand Technology Value Fund, Inc.

 

Notes to Consolidated Financial Statements - continued

 

JUNE 30, 2023 (UNAUDITED)

 

NOTE 6. FAIR VALUE

 

Securities traded on stock exchanges, or quoted by NASDAQ, are valued according to the NASDAQ Stock Market, Inc. (“NASDAQ”) official closing price, if applicable, or at their last reported sale price as of the close of trading on the New York Stock Exchange (“NYSE”) (normally 4:00 P.M. Eastern Time). If a security is not traded that day, the security will be valued at its most recent bid price.

 

Securities traded in the over-the-counter market, but not quoted by NASDAQ, are valued at the last sale price (or, if the last sale price is not readily available, at the most recent closing bid price as quoted by brokers that make markets in the securities) at the close of trading on the NYSE.

 

Securities traded both in the over-the-counter market and on a stock exchange are valued according to the broadest and most representative market.

 

Securities and other assets that do not have market quotations readily available are valued at their fair value as determined by FCM, as the Board’s valuation designee under SEC rule 2a-5. Those valuations are determined in accordance with the Valuation Procedures used by FCM, subject to oversight by the Board.

 

In pricing illiquid, privately placed securities, FCM, as the valuation designee, is responsible for (1) determining overall valuation guidelines and (2) ensuring that the investments of the Company are valued within the prescribed guidelines.

 

FCM and the Board receive information and recommendations from an independent valuation firm.

 

The values assigned to these investments are based on available information and do not necessarily represent amounts that might ultimately be realized when that investment is sold, as such amounts depend on future circumstances and cannot reasonably be determined until the individual investments are actually liquidated or become readily marketable.

 

APPROACHES TO DETERMINING FAIR VALUE. GAAP. defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). In effect, GAAP applies fair value terminology to all valuations whereas the 1940 Act applies market value terminology to readily marketable assets and fair value terminology to other assets.

 

The main approaches to measuring fair value utilized are the market approach, the income approach, and the asset-based approach. The choice of which approach to use in a particular situation depends on the specific facts and circumstances associated with the company, as well as the purpose for which the valuation analysis is being conducted. Firsthand and the independent valuation firm rely primarily on the market approach. We also considered the income and asset-based approaches in our analysis because certain of the portfolio companies do not have substantial operating earnings relative to the value of their underlying assets.

 

 

-

Market Approach (M): The market approach uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities. For example, the market approach often uses market multiples derived from a set of comparables. Multiples might lie in ranges with a different multiple for each comparable. The selection of where within the range each appropriate multiple falls requires the use of judgment in considering factors specific to the measurement (qualitative and quantitative).

 

 

-

Income Approach (I): The income approach uses valuation techniques to convert future amounts (for example, cash flows or earnings) to a single present value amount (discounted). The measurement is based on the value indicated by current market expectations about those future amounts. Those

 

29

 

 

Firsthand Technology Value Fund, Inc.

 

Notes to Consolidated Financial Statements - continued

 

JUNE 30, 2023 (UNAUDITED)

 

valuation techniques include present value techniques; option-pricing models, such as the Black-Scholes-Merton formula (a closed-form model) and a binomial model (a lattice model), which incorporate present value techniques; and the multi-period excess earnings method, which is used to measure the fair value of certain assets.

 

 

-

Asset-Based Approach (A): The asset-based approach examines the value of a company’s assets net of its liabilities to derive a value for the equity holders.

 

FAIR VALUE MEASUREMENT. In accordance with the guidance from the Financial Accounting Standards Board on fair value measurements and disclosures under GAAP, the Company discloses the fair value of its investments in a hierarchy that prioritizes the inputs to valuation techniques used to measure the fair value. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements).

 

The guidance establishes three levels of the fair value hierarchy as follows:

 

 

Level 1 -

Unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the date of measurement.

 

 

Level 2 -

Observable inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These inputs may include quoted prices for the identical instrument in an inactive market, prices for similar instruments in an active or inactive market, interest rates, prepayment speeds, credit risks, yield curves, default rates, and similar data.

 

 

Level 3 -

Unobservable inputs for the asset or liability, to the extent relevant observable inputs are not available, representing the Company’s own assumptions about the assumptions a market participant would use in valuing the asset or liability based on the best information available.

 

The availability of observable inputs can vary from security to security and is affected by a wide variety of factors, including, for example, the type of security, whether the security is new and not yet established in the marketplace, the liquidity of markets, and other characteristics particular to the security. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised in determining fair value is greatest for instruments categorized in Level 3.

 

The inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement falls in its entirety, is determined based on the lowest level input that is significant to the fair value measurement in its entirety.

 

30

 

 

Firsthand Technology Value Fund, Inc.

 

Notes to Consolidated Financial Statements - continued

 

JUNE 30, 2023 (UNAUDITED)

 

The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities. The following is a summary of the inputs used to value the Company’s net assets as of June 30, 2023:

 

                       

ASSETS

 

LEVEL 1
QUOTED PRICES

   

LEVEL 2 OTHER
SIGNIFICANT
OBSERVABLE INPUTS

   

LEVEL 3 SIGNIFICANT
UNOBSERVABLE INPUTS

 

Common Stocks

                       

Advanced Materials

  $     $     $ 266,091  

Automotive

                311  

Equipment Leasing

                1,880  

Semiconductor Equipment

    3,709,446              

Total Common Stocks

    3,709,446             268,282  

Preferred Stocks

                       

Aerospace

                304,332  

Automotive

                573,233  

Equipment Leasing

                383,756  

Total Preferred Stocks

                1,261,321  

Asset Derivatives *

                       

Equity Contracts

                758,405  

Total Asset Derivatives

                758,405  

Convertible Notes

                       

Advanced Materials

                100,000  

Aerospace

                6,559,791  

Automotive

                2,352,578  

Medical Devices

                5,035,984  

Total Convertible Notes

                14,048,353  

Mutual Funds

    567,150              

Total

  $ 4,276,596     $     $ 16,336,361  

 

*

Asset derivatives include warrants.

 

At the end of each calendar quarter, management evaluates the Level 2 and Level 3 assets and liabilities for changes in liquidity, including but not limited to: whether a broker is willing to execute at the quoted price, the depth and consistency of prices from third party services, and the existence of contemporaneous, observable trades in the market. Additionally, management evaluates the Level 1 and Level 2 assets and liabilities on a quarterly basis for changes in listings or delistings on national exchanges.

 

31

 

 

Firsthand Technology Value Fund, Inc.

 

Notes to Consolidated Financial Statements - continued

 

JUNE 30, 2023 (UNAUDITED)

 

Following is a reconciliation of Level 3 assets (at either the beginning or the ending of the period) for which significant unobservable inputs were used to determine fair value.

 

                                                       

INVESTMENTS AT FAIR
VALUE USING SIGNIFICANT
UNOBSERVABLE INPUTS
(LEVEL 3)

 

BALANCE
AS OF
12/31/22

   

NET
PURCHASES/
CONVERSIONS

   

NET SALES/
CONVERSIONS

   

NET REALIZED
GAINS/
(LOSSES)

   

NET UNREALIZED
APPRECIATION
(DEPRECIATION)
(1)

   

TRANSFERS
IN (OUT) OF
LEVEL 3

   

BALANCE
AS OF
06/30/23

 

Common Stocks

                                                       

Advanced Materials

  $ 337,500     $     $     $     $ (71,409 )   $     $ 266,091  

Automotive

    546                         (235 )           311  

Equipment Leasing

    11,130                         (9,250 )           1,880  

Intellectual Property

    111             (7,966 )     (161,079 )     168,934              

Total Common Stocks

    349,287             (7,966 )     (161,079 )     88,040             268,282  

Preferred Stocks

                                                       

Aerospace

    384,067                         (79,735 )           304,332  

Automotive

    1,049,478                         (476,245 )           573,233  

Equipment Leasing

    865,995                         (482,239 )           383,756  

Intellectual Property

    737,112             (490,459 )     (7,697,238 )     7,450,585              

Total Preferred Stocks

    3,036,652             (490,459 )     (7,697,238 )     6,412,366             1,261,321  

Asset Derivatives

                                                       

Equity Contracts

    957,125                   (6,678 )     (192,042 )           758,405  

Total Asset Derivatives

    957,125                   (6,678 )     (192,042 )           758,405  

Convertible Notes

                                                       

Advanced Materials

    100,000                                     100,000  

Aerospace

    6,559,791                                     6,559,791  

Automotive

    7,809,430       100,000                   (5,556,852 )           2,352,578  

Medical Devices

    17,116,721                         (12,080,737 )           5,035,984  

Total Convertible Notes

    31,585,942       100,000                   (17,637,589 )           14,048,353  

Total

  $ 35,929,006     $ 100,000     $ (498,425 )   $ (7,864,995 )   $ (11,329,225 )   $     $ 16,336,361  

 

(1)

The net change in unrealized appreciation (depreciation) from Level 3 instruments held as of June 30, 2023 was $ (18,952,188).

 

 

32

 

 

Firsthand Technology Value Fund, Inc.

 

Notes to Consolidated Financial Statements - continued

 

JUNE 30, 2023 (UNAUDITED)

 

The table below represents quantitative disclosure about significant unobservable inputs for Level 3 fair value measurements at June 30, 2023:

 

       

 

FAIR VALUE
AT 6/30/23

VALUATION TECHNIQUES(1)

UNOBSERVABLE INPUTS

RANGE
(WEIGHTED AVG.)
(1)

Direct venture capital investments: Advanced Materials

$0.4M

Market Comparable Companies

Option Pricing Model

Revenue Multiple(2)

Years to Maturity(2)

Volatility(2)

Risk-Free Rate(2)

Discount for Lack of

Marketability(3)

0.7x – 1.0x (0.9x)

5 years (5 years)

50.0% (50.0%)

4.13% (4.13%)

22.7% (22.7%)

Direct venture capital investments: Aerospace

$7.6M

Market Comparable Companies

Option Pricing Model

EBITDA Multiple(2)

Years to Maturity(2)

Volatility(2)

Risk-Free Rate(2)

2.1x (2.1x)

5 years (5 years)

60.0% (60.0%)

4.13% (4.13%)

Direct venture capital investments: Automotive

$2.9M

Prior Transaction Analysis

Option Pricing Model

Probability-Weighted Expected Return Method

Years to Maturity(2)

Volatility(2)

Risk-Free Rate(2)

Discount for Lack of

Marketability(3)

Going Concern Probability(2)

5 years (5 years)

50.0% (50.0%)

4.13% (4.13%)

0.0% - 22.7% (0.0%)

 

5% (5%)

Direct venture capital investments: Equipment Leasing

$0.4M

Market Comparable Companies

Liquidation Value

Option Pricing Model

EBITDA Multiple(2)

Years to Maturity(2)

Volatility(2)

Risk-Free Rate(2)

3.0x – 5.1x (4.0x)

5 years (5 years)

50.0% (50.0%)

4.13% (4.13%)

Direct venture capital investments: Medical Devices

$5.0M

Market Comparable Companies

Revenue Multiple(2)

2.0x – 2.3x (2.1x)

 

(1)

Weighted average is calculated by weighting the significant unobservable input by the relative fair value of each investment in the category

(2)

An increase in the input would result in an increase in the security’s valuation; a decrease in the input would result in a decrease in the security’s valuation.

(3)

An increase in the input would result in a decrease in the security’s valuation; a decrease in the input would result in an increase in the security’s valuation.

 

Changes in any of our unobservable inputs, individually, may change the fair value of certain of the Company’s investments.

 

Due to the inherent uncertainty of determining the fair value of investments that do not have a readily available market value, the fair value of the Company’s investments may fluctuate from period to period. Additionally, the fair value of the Company’s investments may differ significantly from the values that would have been used had a ready market existed for such investments and may differ materially from the values that the Company may ultimately realize. Further, such

 

33

 

 

Firsthand Technology Value Fund, Inc.

 

Notes to Consolidated Financial Statements - continued

 

JUNE 30, 2023 (UNAUDITED)

 

investments are generally subject to legal and other restrictions on resale or otherwise are less liquid than publicly traded securities. If the Company was required to liquidate a portfolio investment in a forced or liquidation sale, it could realize significantly less than the value at which the Company has recorded it.

 

In addition, changes in the market environment and other events that may occur over the life of the investments may cause the gains or losses ultimately realized on these investments to be different than the unrealized gains or losses reflected in the valuations currently assigned.

 

NOTE 7. FEDERAL INCOME TAXES

 

Beginning in 2018, we were no longer able to qualify as a RIC under Subchapter M of the Code. The increase in value that resulted from the initial public offerings (IPOs) of Pivotal Systems and Revasum meant that we were no longer able to satisfy the diversification requirements for qualification as a RIC. As a result of this change, we were taxed as a corporation for our fiscal year ended December 31, 2018, and will continue to be taxed in that manner for future fiscal years, paying federal and applicable state corporate taxes on our taxable income, unless and until we are able to once again qualify as a RIC, based on changes in the composition of our portfolio. Consequently, at the close of each fiscal quarter beginning with the quarter ended June 30, 2018, we will record a deferred tax liability for any net realized gains and net ordinary income for the year-to-date period plus net unrealized gains as of the end of the quarter.

 

The reorganization described in Note 1 (the formation of FVI as a fully owned subsidiary for investment activities) was structured to avoid any adverse tax consequences for the Company and its shareholders. For the fiscal years which the Company operates as a RIC, we believe Company’s engaging in investment activities through FVI did not, in our view, jeopardize the Company’s ability to continue to qualify as a RIC under the Code at that time when the Company was eligible to be treated as a RIC.

 

The following information is based upon the U.S. federal income tax cost of portfolio investments as of June 30, 2023.

 

       
   

FEDERAL INCOME
TAX COST:

 

Gross unrealized appreciation

  $ 758,405  

Gross unrealized depreciation

    (114,566,765 )

Net unrealized (depreciation)

  $ (113,808,360 )

Federal income tax cost, Investments

  $ 134,421,317  

 

The Company did not qualify as a regulated investment company pursuant to Subchapter M of the Internal Revenue Code, therefore it is taxed as a corporation. As a corporation, the Company is obligated to pay federal and state income tax on taxable income. The Company’s net deferred tax asset balance has a full valuation allowance based on management’s estimate of future realization of such assets. The Company is currently using an estimated tax rate of 21% for Federal and 6.98% for state taxes.

 

The Company’s income tax provision consists of the following as of December 31, 2022:

 

       

Deferred tax (expense)/benefit

       

Federal

  $  

State

     

Total deferred tax (expense)/benefit

  $  

 

34

 

 

Firsthand Technology Value Fund, Inc.

 

Notes to Consolidated Financial Statements - continued

 

JUNE 30, 2023 (UNAUDITED)

 

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Such temporary differences are principally: (i) taxes on unrealized gains/(losses), which are attributable to the temporary difference between fair market value and tax basis, and (ii) the net tax benefit of accumulated net operating losses and capital loss carryforwards. Deferred tax assets and liabilities are measured using effective tax rates expected to apply to taxable income in the years such temporary differences are realized or otherwise settled.

 

Components of the Company’s deferred tax assets and liabilities as of December 31, 2022 are as follows:

 

       
   

AMOUNT

 

Deferred tax assets:

       

Net operating loss carryforward

  $ 4,616,720  

Capital loss carryforward

    6,960,412  

Net unrealized losses (gains) on investment securities

    28,726,530  

Total deferred tax assets, net

    40,303,662  

Valuation allowance

    (40,303,662 )

Net

  $  

 

For the year ended December 31, 2022, the Company had an effective tax rate of 0% and a statutory tax rate of 21% (27.98% with state income tax) with the difference being attributable to changes in the components of the deferred tax assets and the valuation allowance account.

 

The effective tax rate and statutory federal income tax rate for the three- and six-month periods ended June 30, 2023 and 2022 were as follows:

 

       

 

THREE MONTHS ENDED
JUNE 30, 2023

THREE MONTHS ENDED
JUNE 30, 2022

SIX MONTHS ENDED
JUNE 30, 2023

SIX MONTHS ENDED
JUNE, 2023

Effective tax rate

0%

0%

0%

0%

Statutory federal income tax rate

21%

21%

21%

21%

 

The variance in the effective tax rate and statutory federal income tax rate for the three-month period ending June 30, 2023, is the result of changes to the deferred tax assets and related valuation allowance account. At June 30, 2023, the Company has established a full valuation allowance on its net deferred tax assets.

 

To the extent the Company has a deferred tax asset or if a portion of the deferred tax liability is offset by a tax asset resulting from net operating losses, consideration is given to whether or not a valuation allowance is required against the deferred tax asset amount. A valuation allowance is required if, based on the evaluation criterion provided by Accounting Standard Codification (“ASC”) 740, Income Taxes (ASC 740), it is more-likely-than-not that some portion or all of the deferred tax asset will not be realized. Among the factors considered in assessing the Company’s valuation allowance are: the nature, frequency and severity of current and cumulative losses, forecasts of future profitability, the duration of the statutory carryforward periods, and the associated risks that operating and capital loss carryforwards may expire unused. Based on the Company’s assessment, it has determined that in the future it is more likely than not that the Company will not generate the necessary appropriate character of income within the carryforward periods to realize its deferred tax assets, and as such, has placed a full allowance on the deferred tax assets.

 

35

 

 

Firsthand Technology Value Fund, Inc.

 

Notes to Consolidated Financial Statements - continued

 

JUNE 30, 2023 (UNAUDITED)

 

From time to time, and as new information becomes available, the Company will modify its forecasts, estimates or assumptions regarding its deferred tax liability or asset.

 

Modifications of the Company’s estimates or assumptions regarding its deferred tax liability and/or asset balances and any applicable valuation allowance, changes in generally accepted accounting principles or related guidance or interpretations thereof, limitations imposed on net operating losses (if any), and changes in applicable tax law could result in increases or decreases in the Company’s NAV, which could be material. Such changes could have a material impact on the Company’s NAV and results of operations with respect to the Company’s shareholders in the period it is recorded, even though the shareholders at such time might not have held shares in the Company at the time the deferred tax asset or liability had been established.

 

The Company’s policy is to classify interest and penalties associated with underpayment of federal and state income taxes, if any, as income tax expense on its Statement of Operations. As of December 31, 2022, the Company did not have any interest or penalties associated with the underpayment of any income taxes.

 

The Company files income tax returns in the U.S. federal jurisdiction and California. The Company has reviewed all major jurisdictions and concluded that there is no significant impact on the Company’s net assets and no tax liability resulting from unrecognized tax benefits relating to uncertain tax positions expected to be taken on its tax returns. Furthermore, management of the Company is not aware of any tax positions for which it is reasonably possible that the total amounts of unrecognized tax benefits will significantly change in the next 12 months.

 

As of December 31, 2022, the Company had net operating loss carryforwards for federal and state of income tax purposes of $16,500,072, which may be carried forward indefinitely.

 

As of December 31, 2022, the Company had net capital loss carryforwards for federal and state income tax purposes, which may be carried forward for 5 years, as follows:

 

       

EXPIRATION DATE

 

AMOUNT

 

12/31/24

  $ 14,230,073  

12/31/25

    7,516,642  

12/31/27

    3,129,665  

Total

  $ 24,876,380  

 

NOTE 8. INVESTMENT TRANSACTIONS

 

Investment transactions (excluding short-term investments) were as follows for the quarter ended June 30, 2023.

       
PURCHASES AND SALES        
Purchases of investment securities   $ 100,000  
Proceeds from sales and maturities of investment securities   $ 498,425  

 

36

 

 

Firsthand Technology Value Fund, Inc.

 

Notes to Consolidated Financial Statements - continued

 

JUNE 30, 2023 (UNAUDITED)

 

NOTE 9. SHARE BUYBACKS

 

SHARE BUYBACKS. On April 26, 2016, the Board of Directors of the Fund approved a discretionary share repurchase plan (the “Plan”). Pursuant to the Plan, the Fund was authorized to purchase in the open market up to $2 million worth of its common stock. The Plan allowed the Fund to acquire its own shares at certain thresholds below its NAV per share, in accordance with the guidelines specified in Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The intent of the Plan was to increase NAV per share and thereby enhance shareholder value. The Fund completed the repurchase plan in September 2016, having repurchased and retired a total of 272,008 shares of stock, at a total cost of approximately $2 million.

 

On November 10, 2017, the Board of Directors of the Fund approved a discretionary share purchase plan (the “Plan”). Pursuant to the Plan, the Fund was authorized to purchase in the open market up to $2 million worth of its common stock. The Plan allowed the Fund to acquire its own shares in accordance with the guidelines specified in Rule 10b-18 of the Exchange Act. The intent of the Plan was to increase NAV per share and thereby enhance shareholder value. As of December 31, 2017, the Fund had repurchased and retired 128,551 shares of stock at a total cost of approximately $1.1 million. The Fund had 7,302,146 shares outstanding as of December 31, 2017.

 

On August 31, 2018, the Fund announced a plan to repurchase up to $2 million worth of SVVC stock in the open market by March 31, 2019. The Fund completed this open market repurchase plan on October 24, 2018. Through that date, the Fund repurchased 123,376 shares at an average price of $16.21 per share, for total consideration of $2.0 million. As of December 31, 2018, the Fund had 7,178,770 shares outstanding.

 

TENDER OFFERS. On December 22, 2014, pursuant to our agreement with a shareholder, the Fund commenced a tender offer to purchase up to $20 million of its issued and outstanding common shares for cash at a price per share equal to 95% of the Company’s NAV per share determined as of the close of ordinary trading on the NASDAQ Global Market on December 31, 2014 ($23.2702 per share). The tender offer, which expired on January 22, 2015 at 12:00 midnight, New York City time, was oversubscribed. Because the number of shares tendered exceeded the maximum amount of its offer, the Fund purchased shares from tendering shareholders on a pro-rata basis based on the number of shares properly tendered. Of the 5,044,728 shares properly tendered, the Fund purchased 859,468 shares of common stock pursuant to the tender offer.

 

On December 16, 2019, the Fund announced the commencement of a “modified Dutch auction” tender offer to purchase up to $2 million of its common stock at a price per share not less than $6.00 and not greater than $8.00, in $0.10 increments. The tender offer expired on February 14, 2020, and resulted in the purchase by the Fund of 285,714 shares of common stock at a price of $7.00 per share. As of March 31, 2020, the Fund had 6,893,056 shares outstanding.

 

37

 

 

Firsthand Technology Value Fund, Inc.

 

Notes to Consolidated Financial Statements - continued

 

JUNE 30, 2023 (UNAUDITED)

 

NOTE 10. INVESTMENTS IN AFFILIATES AND CONTROLLED INVESTMENTS

 

Under the 1940 Act, the Company is required to identify investments where it owns greater than 5% (but less than 25%) of the portfolio company’s outstanding voting shares as an affiliate of the Company. Also, under the 1940 Act, the Company is required to identify investments where it owns greater than 25% of the portfolio company’s outstanding voting shares as a controlled investment of the Company. A summary of the Company’s investments in affiliates and controlled investments for the period from December 31, 2022, through June 30, 2023, is noted below:

 

                                                               

AFFILIATE/
CONTROLLED
INVESTMENTS*

 

VALUE AT
12/31/22

   

PURCHASE/
MERGER

   

INTEREST

   

SALES/
MATURITY/
EXPIRATION

   

REALIZED
GAIN (LOSS)

   

CHANGE IN
APPRECIATION/
DEPRECIATION

   

VALUE
6/30/23

   

SHARES HELD
AT 6/30/23

 

Equipment Leasing

                                                               

EQX Capital, Inc. Common Stock*

  $ 11,130     $     $     $     $     $ (9,250 )   $ 1,880       100,000  

EQX Capital, Inc. Series A Preferred Stock*

    865,995                               (482,239 )     383,756       1,950,000  

Total Equipment Leasing

  $ 877,125             $             $     $ (491,489 )   $ 385,636          

Aerospace

                                                               

Hera Systems, Inc. Convertible Note*

    5,359,791             269,478                         5,359,791       5,359,791  

Hera Systems, Inc. Convertible Note*

    1,200,000             29,989                         1,200,000       1,200,000  

Hera Systems, Inc. Series A Preferred*

    4,735                               (2,169 )     2,566       3,642,324  

Hera Systems, Inc. Series B Preferred*

    275,585                               (56,352 )     219,233       7,039,203  

Hera Systems, Inc. Series B Warrants*

    478,608                               (98,084 )     380,524       12,250,000  

Hera Systems, Inc. Series B Warrants*

    242,817                               (49,762 )     193,055       6,214,922  

Hera Systems, Inc. Series B Warrants*

    205,118                               (42,036 )     163,082       5,250,000  

Hera Systems, Inc. Series B Warrants*

    27,349                               (5,605 )     21,744       700,000  

Hera Systems, Inc. Series C Preferred*

    103,747                               (21,214 )     82,533       2,650,000  

Total Aerospace

  $ 7,897,750             $ 299,467             $     $ (275,222 )   $ 7,622,528          

Medical Devices

                                                               

IntraOp Medical Corp. Convertible Note*

    6,746,169                               (4,761,350 )     1,984,819       10,961,129  

IntraOp Medical Corp. Convertible Note*

    800,102                               (564,701 )     235,401       1,300,000  

 

38

 

 

Firsthand Technology Value Fund, Inc.

 

Notes to Consolidated Financial Statements - continued

 

JUNE 30, 2023 (UNAUDITED)

 

AFFILIATE/
CONTROLLED
INVESTMENTS*

 

VALUE AT
12/31/22

   

PURCHASE/
MERGER

   

INTEREST

   

SALES/
MATURITY/
EXPIRATION

   

REALIZED
GAIN (LOSS)

   

CHANGE IN
APPRECIATION/
DEPRECIATION

   

VALUE
6/30/23

   

SHARES HELD
AT 6/30/23

 

IntraOp Medical Corp. Convertible Note*

  $ 307,731     $     $     $     $     $ (217,192 )   $ 90,539       500,000  

IntraOp Medical Corp. Convertible Note*

    307,731                               (217,192 )     90,539       500,000  

IntraOp Medical Corp. Convertible Note*

    1,846,389                               (1,303,155 )     543,234       3,000,000  

IntraOp Medical Corp. Convertible Note*

    615,463                               (434,385 )     181,078       1,000,000  

IntraOp Medical Corp. Convertible Note*

    246,185                               (173,754 )     72,431       400,000  

IntraOp Medical Corp. Convertible Note*

    307,731                               (217,192 )     90,539       500,000  

IntraOp Medical Corp. Convertible Note*

    461,597                               (325,788 )     135,809       750,000  

IntraOp Medical Corp. Convertible Note*

    307,731                               (217,192 )     90,539       500,000  

IntraOp Medical Corp. Convertible Note*

    307,732                               (217,193 )     90,539       500,000  

IntraOp Medical Corp. Convertible Note*

    307,732                               (217,193 )     90,539       500,000  

IntraOp Medical Corp. Convertible Note*

    615,463                               (434,385 )     181,078       1,000,000  

IntraOp Medical Corp. Convertible Note*

    307,732                               (217,193 )     90,539       500,000  

IntraOp Medical Corp. Convertible Note*

    615,463                               (434,385 )     181,078       1,000,000  

IntraOp Medical Corp. Convertible Note*

    307,732                               (217,193 )     90,539       500,000  

IntraOp Medical Corp. Convertible Note*

    307,732                               (217,193 )     90,539       500,000  

 

39

 

 

Firsthand Technology Value Fund, Inc.

 

Notes to Consolidated Financial Statements - continued

 

JUNE 30, 2023 (UNAUDITED)

 

AFFILIATE/
CONTROLLED
INVESTMENTS*

 

VALUE AT
12/31/22

   

PURCHASE/
MERGER

   

INTEREST

   

SALES/
MATURITY/
EXPIRATION

   

REALIZED
GAIN (LOSS)

   

CHANGE IN
APPRECIATION/
DEPRECIATION

   

VALUE
6/30/23

   

SHARES HELD
AT 6/30/23

 

IntraOp Medical Corp. Convertible Note*

  $ 307,732     $     $     $     $     $ (217,193 )   $ 90,539       500,000  

IntraOp Medical Corp. Convertible Note*

    123,093                               (86,877 )     36,216       200,000  

IntraOp Medical Corp. Convertible Note*

    430,824                               (304,069 )     126,755       700,000  

IntraOp Medical Corp. Convertible Note*

    92,319                               (65,157 )     27,162       150,000  

IntraOp Medical Corp. Convertible Note*

    215,412                               (152,035 )     63,377       350,000  

IntraOp Medical Corp. Series C Preferred*

                                              26,856,187  

IntraOp Medical Corp. Term Note*

    1,230,926                               (868,770 )     362,156       2,000,000  

Total Medical Devices

  $ 17,116,721             $             $     $ (12,080,737 )   $ 5,035,984          

Semiconductor Equipment

                                                               

Revasum, Inc. CDI*(1)

    3,520,496                               188,950       3,709,446       39,774,889  

Total Semiconductor Equipment

  $ 3,520,496             $             $     $ 188,950     $ 3,709,446          

Intellectual Property

                                                               

Silicon Genesis Corp. Common Stock*

    111                   (7,966 )     (161,080 )     168,935              

Silicon Genesis Corp. Common Warrants*

    1                   (1 )     (6,677 )     6,677              

Silicon Genesis Corp. Series 1-G Preferred*

    306,671       88             (417,972 )     (3,462,620 )     3,573,833              

Silicon Genesis Corp. Series 1-H Preferred*

    35,529                   (7,241 )     (929,654 )     901,366              

Silicon Genesis Corp. Series 1-D Preferred*

    2,552                   (7,351 )     (424,549 )     429,348              

 

40

 

 

Firsthand Technology Value Fund, Inc.

 

Notes to Consolidated Financial Statements - continued

 

JUNE 30, 2023 (UNAUDITED)

 

AFFILIATE/
CONTROLLED
INVESTMENTS*

 

VALUE AT
12/31/22

   

PURCHASE/
MERGER

   

INTEREST

   

SALES/
MATURITY/
EXPIRATION

   

REALIZED
GAIN (LOSS)

   

CHANGE IN
APPRECIATION/
DEPRECIATION

   

VALUE
6/30/23

   

SHARES HELD
AT 6/30/23

 

Silicon Genesis Corp. Series 1-E Preferred*

  $ 320,592     $     $     $ (49,292 )   $ (2,323,111 )   $ 2,051,811     $        

Silicon Genesis Corp. Series 1-F Preferred*

    70,806                   (7,885 )     (448,504 )     385,583              

Silicon Genesis Corp. Series 1-C Preferred Stock*

    962                   (716 )     (108,802 )     108,556              

Total Intellectual Property

  $ 737,224             $             $ (7,864,997 )   $ 7,626,109     $          

Advanced Materials

                                                               

UCT Coatings, Inc. Common Stock

    337,500                               (71,409 )     266,091       1,500,000  

Total Advanced Materials

  $ 337,500             $             $     $ (71,409 )   $ 266,091          

Automotive

                                                               

Wrightspeed, Inc. Common Stock*

    546                               (235 )     311       69,102  

Wrightspeed, Inc. Convertible Note*

    65,000                               (45,500 )     19,500       200,000  

Wrightspeed, Inc. Convertible Note*

    60,125                               (42,088 )     18,037       185,000  

Wrightspeed, Inc. Convertible Note*

    21,125                               (14,788 )     6,337       65,000  

Wrightspeed, Inc. Convertible Note*

    81,250                               (56,875 )     24,375       250,000  

Wrightspeed, Inc. Convertible Note*

    81,250                               (56,875 )     24,375       250,000  

Wrightspeed, Inc. Convertible Note*

    81,250                               (56,875 )     24,375       250,000  

Wrightspeed, Inc. Convertible Note*

    227,500                               (159,250 )     68,250       700,000  

Wrightspeed, Inc. Convertible Note*

    81,250                               (56,875 )     24,375       250,000  

Wrightspeed, Inc. Convertible Note*

    81,250                               (56,875 )     24,375       250,000  

Wrightspeed, Inc. Convertible Note*

    81,250                               (56,875 )     24,375       250,000  

Wrightspeed, Inc. Convertible Note*

    43,875                               (30,713 )     13,162       135,000  

Wrightspeed, Inc. Convertible Note*

    53,625                               (37,537 )     16,088       165,000  

 

41

 

 

Firsthand Technology Value Fund, Inc.

 

Notes to Consolidated Financial Statements - continued

 

JUNE 30, 2023 (UNAUDITED)

 

AFFILIATE/
CONTROLLED
INVESTMENTS*

 

VALUE AT
12/31/22

   

PURCHASE/
MERGER

   

INTEREST

   

SALES/
MATURITY/
EXPIRATION

   

REALIZED
GAIN (LOSS)

   

CHANGE IN
APPRECIATION/
DEPRECIATION

   

VALUE
6/30/23

   

SHARES HELD
AT 6/30/23

 

Wrightspeed, Inc. Convertible Note*

  $ 40,625     $     $     $     $     $ (28,437 )   $ 12,188       125,000  

Wrightspeed, Inc. Convertible Note*

          100,000                         (90,250 )     9,750       100,000  

Wrightspeed, Inc. Convertible Note*

    81,250                               (56,875 )     24,375       250,000  

Wrightspeed, Inc. Convertible Note*

    325,000                               (227,500 )     97,500       1,000,000  

Wrightspeed, Inc. Convertible Note*

    325,000                               (227,500 )     97,500       1,000,000  

Wrightspeed, Inc. Convertible Note*

    325,000                               (227,500 )     97,500       1,000,000  

Wrightspeed, Inc. Convertible Note*

    1,601,930                               (1,121,351 )     480,579       4,929,015  

Wrightspeed, Inc. Convertible Note*

    243,750                               (170,625 )     73,125       750,000  

Wrightspeed, Inc. Convertible Note*

    292,500                               (204,750 )     87,750       900,000  

Wrightspeed, Inc. Convertible Note*

    121,875                               (85,313 )     36,562       375,000  

Wrightspeed, Inc. Convertible Note*

    130,000                               (91,000 )     39,000       400,000  

Wrightspeed, Inc. Convertible Note*

    341,250                               (238,875 )     102,375       1,050,000  

Wrightspeed, Inc. Convertible Note*

    325,000                               (227,500 )     97,500       1,000,000  

Wrightspeed, Inc. Convertible Note*

    325,000                               (227,500 )     97,500       1,000,000  

Wrightspeed, Inc. Convertible Note*

    325,000                               (227,500 )     97,500       1,000,000  

Wrightspeed, Inc. Convertible Note*

    390,000                               (273,000 )     117,000       1,200,000  

Wrightspeed, Inc. Convertible Note*

    455,000                               (318,500 )     136,500       1,400,000  

Wrightspeed, Inc. Convertible Note*

    650,000                               (455,000 )     195,000       2,000,000  

Wrightspeed, Inc. Convertible Note*

    130,000                               (91,000 )     39,000       400,000  

Wrightspeed, Inc. Convertible Note*

    97,500                               (68,250 )     29,250       300,000  

Wrightspeed, Inc. Convertible Note*

    325,000                               (227,500 )     97,500       1,000,000  

 

42

 

 

Firsthand Technology Value Fund, Inc.

 

Notes to Consolidated Financial Statements - continued

 

JUNE 30, 2023 (UNAUDITED)

 

AFFILIATE/
CONTROLLED
INVESTMENTS*

 

VALUE AT
12/31/22

   

PURCHASE/
MERGER

   

INTEREST

   

SALES/
MATURITY/
EXPIRATION

   

REALIZED
GAIN (LOSS)

   

CHANGE IN
APPRECIATION/
DEPRECIATION

   

VALUE
6/30/23

   

SHARES HELD
AT 6/30/23

 

Wrightspeed, Inc. Series AA Preferred*

  $ 1,049,478     $     $     $     $     $ (476,245 )   $ 573,233       60,733,693  

Wrightspeed, Inc. Series AA Warrants*

    3,232                               (3,232 )            

Total Automotive

  $ 8,862,686             $             $     $ (6,036,564 )   $ 2,926,122          

Total Affiliates and Controlled Investments

  $ 39,349,502             $ 299,467             $ (7,864,997 )   $ (11,140,362 )   $ 19,945,807          

Total Affiliates

    337,500                                   (71,409 )     266,091          

Total Controlled Investments

  $ 39,012,002             $ 299,467             $ (7,864,997 )   $ (11,068,953 )   $ 19,679,716          

 

*

Controlled Investments.

(1)

CDI: CHESS Depositary Interest

 

As of June 30, 2023, Kevin Landis, the Company’s Chairman, President and Chief Executive Officer, represented the Company and sat on the boards of directors of Hera Systems, Inc.; IntraOp Medical Corp.; Revasum, Inc.; and Wrightspeed, Inc. As of June 30,2023, Mr. Landis served as interim CEO at IntraOp Medical Corp. and Wrightspeed, Inc. Serving as a director or officer of portfolio companies may cause conflicts of interest. The Advisor has adopted various procedures to ensure that the Company will not be unfavorably affected by these potential conflicts.

 

NOTE 11. MARKET DISRUPTION AND GEOPOLITICAL RISKS

 

Certain local, regional or global events such as war, acts of terrorism, the spread of infectious illness or other public health issues, or other events could have a significant impact on a security or instrument. Since 2020, the novel strain of coronavirus (COVID-19) has negatively affected the worldwide economy, as well as the economies of individual countries, the financial health of individual companies and the market in general in significant and unforeseen ways. Following Russia’s large-scale invasion of Ukraine, the President of the United States signed an Executive Order in February 2022 prohibiting U.S. persons from entering transactions with the Central Bank of Russia and Executive Orders in March 2022 prohibiting U.S. persons from importing oil and gas from Russia as well as other popular Russian exports, such as diamonds, seafood and vodka. The duration of the coronavirus outbreak and the Russian-Ukraine conflict could adversely affect the Company’s performance. The ultimate impact of COVID-19 and Russia invasion on the financial performance of the Company’s investments is not reasonably estimable at this time.

 

NOTE 12. SUBSEQUENT EVENTS

 

Management has evaluated the impact of all subsequent events on the Company through the date the financial statements were issued and has determined that there were no subsequent events requiring recognition or disclosure in the financial statements.

 

43

 

 

Item 2.    Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

 

FORWARD-LOOKING STATEMENTS

 

The matters discussed in this report, as well as in future oral and written statements by management of the Company, include forward-looking statements based on current management expectations that involve substantial risks and uncertainties which could cause actual results to differ materially from the results expressed in, or implied by, these forward-looking statements. Forward-looking statements related to future events or our future financial performance. We generally identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” or “continue” or the negative of these terms or other similar words. Important assumptions include our ability to originate new investments and to achieve certain margins and levels of profitability and the availability of additional capital. In light of these and other uncertainties, the inclusion of a projection or forward-looking statement in this report should not be regarded as a representation by us that our plans or objectives will be achieved. The forward-looking statements contained in this report include, without limitations, statements as to:

 

our future operating results;

our business prospects and the prospects of our prospective portfolio companies;

the impact of investments that we expect to make;

the impact of a protracted decline in the liquidity of the credit markets on our business;

our informal relationships with third parties;

the expected market for venture capital investments and our addressable market;

the dependence of our future success on the general economy and its impact on the industries in which we invest;

our ability to access the equity market;

the ability of our portfolio companies to achieve their objectives;

our expected financings and investments;

our regulatory structure and tax status;

our ability to operate as a business development company and a regulated investment company;

the adequacy of our cash resources and working capital;

the timing of cash flows, if any, from the operation of our portfolio companies;

the timing, form, and amount of any dividend distributions;

impact of fluctuation of interest rates on our business;

valuation of any investments in portfolio companies particularly those having no liquid trading market; and

our ability to recover unrealized losses.

 

You should not place undue reliance on these forward-looking statements. The forward-looking statements made in this report relate only to events as of the date on which the statements are made. We undertake no obligation to update any forward-looking statement to reflect events or circumstances occurring after the date of this report.

 

The following discussion should be read in conjunction with our consolidated financial statements and related notes and other financial information appearing elsewhere in this prospectus. In addition to historical information, the following discussion and other parts of this prospectus contain forward-looking information that involves risks and uncertainties. Our actual results could differ materially from those anticipated by such forward-looking information due to the factors discussed under “Risk Factors” and “Forward-Looking Statements” appearing elsewhere herein.

 

OVERVIEW

 

We are an externally managed, closed-end, non-diversified management investment company organized as a Maryland corporation that has elected to be treated as a BDC under the 1940 Act. As such, we are required to comply with certain regulatory requirements. For instance, we generally have to invest at least 70% of our total assets in “qualifying assets,”

 

44

 

 

including securities of private or micro-cap public U.S. companies, cash, cash equivalents, U.S. government securities and high-quality debt investments that mature in one year or less. In addition, for tax purposes we are treated as a corporation and are subject to federal and state taxes on our income. FCM serves as our investment adviser and manages the investment process on a daily basis.

 

Our investment objective is to seek long-term growth of capital, principally by seeking capital gains on our equity and equity-related investments. There can be no assurance that we will achieve our investment objective. Under normal circumstances, we invest at least 80% of our net assets for investment purposes in technology companies. We consider technology companies to be those companies that derive at least 50% of their revenues from products and/or services within the information technology sector or in the “cleantech” sector. Information technology companies include, but are not limited to, those focused on computer hardware, software, telecommunications, networking, Internet, and consumer electronics. While there is no standard definition of cleantech, it is generally regarded as including goods and services designed to harness renewable energy and materials, eliminate emissions and waste, and reduce the use of natural resources. In addition, under normal circumstances we invest at least 70% of our total assets in privately held companies and public companies with market capitalizations of less than $250 million. Our portfolio is primarily composed of equity and equity derivative securities of technology and cleantech companies (as defined above). These investments generally range between $1 million and $10 million each, although the investment size will vary proportionately with the size of our capital base. We acquire our investments through direct investments in private companies, negotiations with selling shareholders, and in organized secondary marketplaces for private securities.

 

While our primary focus is to invest in illiquid private technology and cleantech companies, we also may invest in micro-cap publicly traded companies. In addition, we may invest up to 30 percent of the portfolio in opportunistic investments that do not constitute the private companies and micro-cap public companies described above. These other investments may include investments in securities of public companies that are actively traded or in actively traded derivative securities such as options on securities or security indices. These other investments may also include investments in high-yield bonds, distressed debt, or securities of public companies that are actively traded and securities of companies located outside of the United States. Our investment activities are managed by FCM.

 

PORTFOLIO COMPOSITION

 

We make investments in securities of both public and private companies. Our portfolio investments consist principally of equity and equity-like securities, including common and preferred stock, warrants for the purchase of common and preferred stock, and convertible and term notes. The fair value of our investment portfolio was approximately $20.6 million as of June 30, 2023, as compared to approximately $40.2 million as of December 31, 2022.

 

The following table summarizes the fair value of our investment portfolio by industry sector as of June 30, 2023, and December 31, 2022.

 

 

June 30, 2023

December 31, 2022

Aerospace

68.7%

25.8%

Medical Devices

45.4%

55.9%

Semiconductor Equipment

33.4%

11.5%

Automotive

26.3%

29.0%

Exchange-Traded/Money Market Funds

5.1%

2.2%

Equipment Leasing

3.5%

2.9%

Advanced Materials

3.3%

1.4%

Intellectual Property

2.4%

Other Assets in Excess of Liabilities

(85.7%)

(31.1%)

Net Assets

100.0%

100.0%

 

45

 

 

MATURITY OF PRIVATE COMPANIES IN THE CURRENT PORTFOLIO

 

The Fund invests in private companies at various stages of maturity. As our portfolio companies mature, they move from the “early (development) stage” to the “middle (revenue) stage” and then to the “late stage.” We expect that this continuous progression may create a pipeline of potential exit opportunities through initial public offerings (IPOs) or acquisitions. Of course, some companies do not progress.

 

The illustration below describes typical characteristics of companies at each stage of maturity and where we believe our current portfolio companies fit within these categories. We expect some of our portfolio companies to transition between stages of maturity over time. The transition may be forward if the company is maturing and is successfully executing its business plan or may be backward if the company is not successfully executing its business plan or decides to change its business plan substantially from its original plan.

 

EARLY STAGE

MIDDLE STAGE

LATE STAGE

Developing product or service for market, high level of research and development, little or no revenue.

Established product, customers, business model; limited revenues.

Appreciable revenue; may be break-even or profitable; IPO or acquisition candidate.

 

 

RESULTS OF OPERATIONS

 

Comparison of the three months ended June 30, 2023, to the three months ended June 30, 2022.

 

INVESTMENT INCOME

 

For the three months ended June 30, 2023, we had investment income of $131,676 primarily attributable to interest accrued on convertible/term note investments with Hera Systems.

 

For the three months ended June 30, 2022, we had investment income of $(3,812,911) primarily attributable to an adjustment to interest accrued on convertible/term note investments with IntraOp Medical, Hera Systems and Wrightspeed.

 

The higher level of investment income in the three months ended June 30, 2023, compared to the three months ended June 30, 2022, was due to an adjustment to interest income during the three months ended June 30, 2022

 

OPERATING EXPENSES

 

Net operating expenses totaled approximately $438,779 during the three months ended June 30, 2023, and $680,146 during the three months ended June 30, 2022.

 

46

 

 

Significant components of net operating expenses for the three months ended June 30, 2023, were management fee expense of $146,723, professional fees (audit, legal, and consulting) of $96,540, and printing fees of $85,923. Significant components of net operating expenses for the three months ended June 30, 2022, were management fee expense of $386,024, and professional fees (audit, legal, and consulting) of $116,483.

 

The lower level of net operating expenses for the three months ended June 30, 2023, compared to the three months ended June 30, 2022, is primarily attributable to a decrease in our total assets, on which the investment advisory fees are based.

 

NET INVESTMENT INCOME/(LOSS)

 

The net investment income/(loss) before taxes was $(307,103) for the three months ended June 30, 2023, and $(4,493,057) for the three months ended June 30, 2022.

 

The higher net investment income in the three months ended June 30, 2023, compared to the three months ended June 30, 2022, is primarily attributable to an increase in interest income due to an adjustment for the three months ended June 30, 2022.

 

NET INVESTMENT REALIZED GAINS AND LOSSES AND UNREALIZED APPRECIATION AND DEPRECIATION

 

A summary of the net realized and unrealized gains and losses on investments for the three-month periods ended June 30, 2023, and June 30, 2022, is shown below.

 

   

Three Months Ended
June 30, 2023

 

Realized losses

  $ 16  

Net change in unrealized depreciation on investments

    (14,461,224 )

Net realized and unrealized losses on investments

  $ (14,461,208 )

 

   

As of
June 30, 2023

 

Gross unrealized appreciation on portfolio investments

  $ 758,405  

Gross unrealized depreciation on portfolio investments

    (114,566,765 )

Net unrealized depreciation on portfolio investments

  $ (113,808,360 )

 

   

Three Months Ended
June 30, 2022

 

Realized losses

  $ (5,114,349 )

Net change in unrealized depreciation on investments

    (28,001,081 )

Net realized and unrealized losses on investments

  $ (33,115,430 )

 

   

As of
June 30, 2022

 

Gross unrealized appreciation on portfolio investments

  $ 2,024,675  

Gross unrealized depreciation on portfolio investments

    (92,865,713 )

Net unrealized depreciation on portfolio investments

  $ (90,841,038 )

 

During the three months ended June 30, 2023, we recognized net realized gains of $16.

 

47

 

 

During the three months ended June 30, 2023, net unrealized depreciation on total investments increased by $14,461,224. The change in net unrealized appreciation and depreciation of our private investments is based on portfolio asset valuations determined in good faith by our Board of Directors. This change in net unrealized depreciation was primarily composed of a decrease in the valuations of our Wrightspeed, IntraOp Medical, and Revasum holdings.

 

During the three months ended June 30, 2022, we recognized net realized loss of $(5,114,349).

 

During the three months ended June 30, 2022, net unrealized depreciation on total investments increased by $28,001,081. The change in net unrealized appreciation and depreciation of our private investments is based on portfolio asset valuations determined in good faith by our Board of Directors. This change in net unrealized depreciation was primarily composed of a decrease in the valuations of our Wrightspeed, Pivotal Systems IntraOp Medical, Hera Systems and Revasum holdings.

 

NET INCREASE/(DECREASE) IN ASSETS RESULTING FROM OPERATIONS AND CHANGE IN NET ASSETS PER SHARE

 

For the three months ended June 30, 2023, the net decrease in net assets resulting from operations (net of deferred taxes) totaled $(14,768,311), and basic and fully diluted net change in net assets per share for the three months ended June 30, 2022, was $(2.14).

 

For the three months ended June 30, 2022, the net decrease in net assets resulting from operations (net of deferred taxes) totaled $(37,608,487), and basic and fully diluted net change in net assets per share for the three months ended June 30, 2022, was $(5.45).

 

The greater decrease in net assets resulting from operations for the three months ended June 30, 2023, as compared to the three months ended June 30, 2022, is due primarily to a decrease in the valuation of certain of our investments, primarily our Wrightspeed, Pivotal Systems, IntraOp Medical, Hera Systems and Revasum holdings.

 

The following information is a comparison for the six months ended June 30, 2023, and the six months ended June 30, 2022.

 

INVESTMENT INCOME

 

For the six months ended June 30, 2023, we had investment income of $322,938 primarily attributable to interest accrued on convertible/term note investments with Hera Systems.

 

For the six months ended June 30, 2022, we had investment income of $(1,876,621) primarily attributable to interest accrued/adjustments on convertible/term note investments with IntraOp Medical, Hera Systems and Wrightspeed.

 

The higher level of investment income in the six months ended June 30, 2023, compared to the six months ended June 30, 2022, is primarily attributable to a decrease in interest income due to an interest adjustment for the six months ended June 30, 2022.

 

OPERATING EXPENSES

 

Net operating expenses totaled approximately $828,130 during the six months ended June 30, 2023, and $1,413,011 during the six months ended June 30, 2022.

 

Significant components of net operating expenses for the six months ended June 30, 2023, were management fee expense of $339,543, and professional fees (audit, legal, and consulting) of $162,309. Significant components of operating expenses for the six months ended June 30, 2022, were management fee expense of $875,796 and professional fees (audit, legal, and consulting) of $185,705.

 

The lower level of net operating expenses for the six months ended June 30, 2023, compared to the six months ended June 30, 2022, is primarily attributable to a decrease in our total assets, on which the investment advisory fees are based.

 

48

 

 

NET INVESTMENT INCOME

 

The net investment income/(loss) was $(505,192) for the six months ended June 30, 2023, and $(3,289,632) for the six months ended June 30, 2022.

 

The lower net investment income/(loss) in the six months ended June 30, 2023, compared to the six months ended June 30, 2022, is primarily attributable to a decrease in interest income due to an interest adjustment for the six months ended June 30, 2022.

 

NET INVESTMENT REALIZED GAINS AND LOSSES AND UNREALIZED APPRECIATION AND DEPRECIATION

 

A summary of the net realized and unrealized gains and loss on investments for the six-month periods ended June 30, 2023, and June 30, 2022, is shown below.

 

   

Six Months Ended
June 30, 2023

 

Realized losses

  $ (7,864,981 )

Net change in unrealized depreciation on investments

    (11,140,362 )

Net realized and unrealized losses on investments

  $ (19,005,343 )

 

   

As of
June 30, 2023

 

Gross unrealized appreciation on portfolio investments

  $ 758,405  

Gross unrealized depreciation on portfolio investments

    (114,566,765 )

Net unrealized depreciation on portfolio investments

  $ (113,808,360 )

 

   

Six Months Ended
June 30, 2022

 

Realized losses

  $ (4,927,776 )

Net change in unrealized depreciation on investments

    (36,741,021 )

Net realized and unrealized losses on investments

  $ (41,668,797 )

 

   

As of
June 30, 2022

 

Gross unrealized appreciation on portfolio investments

  $ 2,024,675  

Gross unrealized depreciation on portfolio investments

    (92,865,713 )

Net unrealized depreciation on portfolio investments

  $ (90,841,038 )

 

During the six months ended June 30, 2023, we recognized net realized losses of $(7,864,981) from the sale of investments.

 

During the six months ended June 30, 2023, net unrealized depreciation on total investments increased by $11,140,362. The change in net unrealized appreciation and depreciation of our private investments is based on portfolio asset valuations determined in good faith by our Board of Directors. This change in net unrealized depreciation was primarily caused by a decrease in the valuations of our Wrightspeed, Hera Systems, IntraOp Medical and Revasum holdings.

 

During the six months ended June 30, 2022, we recognized net realized losses of $(4,927,776) from the sale of investments.

 

49

 

 

During the six months ended June 30, 2022, net unrealized depreciation on total investments increased by $36,741,021. The change in net unrealized appreciation and depreciation of our private investments is based on portfolio asset valuations determined in good faith by our Board of Directors. This change in net unrealized depreciation was primarily caused by a decrease in the valuations of our Wrightspeed, Hera Systems, Pivotal Systems, IntraOp Medical and Revasum holdings.

 

NET INCREASE/(DECREASE) IN ASSETS RESULTING FROM OPERATIONS AND CHANGE IN NET ASSETS PER SHARE

 

For the six months ended June 30, 2023, the net decrease in net assets resulting from operations (net of deferred taxes) totaled $(19,510,535) and basic and the fully diluted net change in net assets per share for the six months ended June 30, 2023 was $(2.83).

 

For the six months ended June 30, 2022, the net decrease in net assets resulting from operations (net of deferred taxes) totaled $(44,958,429) and basic and the fully diluted net change in net assets per share for the six months ended June 30, 2022 was $(6.52).

 

The smaller decrease in net assets resulting from operations for the six months ended June 30, 2023, as compared to the six months ended June 30, 2022, is due primarily to unrealized losses on our investments, primarily Revasum, Wrightspeed, Hera Systems and IntraOp Medical, during the period.

 

DISTRIBUTION POLICY

 

During the years that the Company qualifies as a RIC our board of directors will determine the timing and amount, if any, of our distributions. We intend to pay distributions on an annual basis out of assets legally available therefore. In order to qualify as a RIC and to avoid corporate-level tax on our income, we must distribute to our stockholders at least 90% of our ordinary income and realized net short-term capital gains in excess of realized net long-term capital losses, if any, on an annual basis. In addition, we also intend to distribute any realized net capital gains (i.e., realized net long-term capital gains in excess of realized net short-term capital losses) at least annually.

 

CONTRACTUAL OBLIGATIONS

 

The Fund does not have any Contractual Obligations that meet the requirements for disclosure under Item 303 of Regulation S-K.

 

OFF-BALANCE SHEET ARRANGEMENTS

 

The Fund does not have any Off-Balance Sheet Arrangements.

 

CRITICAL ACCOUNTING POLICIES

 

This discussion of our financial condition and results of operations is based upon our financial statements, which are prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP. The preparation of these financial statements will require management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, and expenses. Changes in the economic environment, financial markets, and any other parameters used in determining such estimates could cause actual results to differ. In addition to the discussion below, we will describe our critical accounting policies in the notes to our future financial statements.

 

Valuation of Portfolio Investments

 

As a business development company, we generally invest in illiquid equity and equity derivatives of securities of venture capital stage technology companies. Under written procedures established by our board of directors, securities traded on stock exchanges, or quoted by NASDAQ, are valued according to the NASDAQ Stock Market, Inc. (“NASDAQ”) official closing price, if applicable, or at their last reported sale price as of the close of trading on the New York Stock Exchange (“NYSE”) (normally 4:00 P.M. Eastern Time). If a security is not traded that day, the security will be valued at its most recent bid price. Securities traded in the over-the-counter market, but not quoted by NASDAQ, are valued at the last sale price (or, if the last sale price is not readily available, at the most recent closing bid price as quoted by brokers that make markets in the securities) at the close of trading on the NYSE. Securities traded both in the over-the-counter market and on a stock exchange are valued according to the broadest and most representative market. We obtain these market values from

 

50

 

 

an independent pricing service or at the mean between the bid and ask prices obtained from at least two brokers or dealers (if available, otherwise by a principal market maker or a primary market dealer). In addition, a large percentage of our portfolio investments are in the form of securities that are not publicly traded. The fair value of securities and other investments that are not publicly traded may not be readily determinable. We value these securities quarterly at fair value as determined in good faith by our board of directors. Our board of directors may use the services of a nationally recognized independent valuation firm to aid it in determining the fair value of these securities. The methods for valuing these securities may include: fundamental analysis (sales, income, or earnings multiples, etc.), discounts from market prices of similar securities, purchase price of securities, subsequent private transactions in the security or related securities, or discounts applied to the nature and duration of restrictions on the disposition of the securities, as well as a combination of these and other factors. Because such valuations, and particularly valuations of private securities and private companies, are inherently uncertain, may fluctuate over short periods of time, and may be based on estimates, our determinations of fair value may differ materially from the values that would have been used if a ready market for these securities existed. Our net asset value could be adversely affected if our determinations regarding the fair value of our investments were materially higher than the values that we ultimately realize upon the disposal of such securities.

 

Revenue Recognition

 

We record interest or dividend income on an accrual basis to the extent that we expect to collect such amounts. We do not accrue as a receivable interest on loans and debt securities if we have reason to doubt our ability to collect such interest. Loan origination fees, original issue discount, and market discount are capitalized, and we amortize any such amounts as interest income. Upon the prepayment of a loan or debt security, any unamortized loan origination is recorded as interest income. We will record prepayment premiums on loans and debt securities as interest income when we receive such amounts.

 

Net Realized Gains or Losses and Net Change in Unrealized Appreciation or Depreciation

 

We measure realized gains or losses by the difference between the net proceeds from the repayment or sale and the cost basis of the investment, without regard to unrealized appreciation or depreciation previously recognized. Net change in unrealized appreciation or depreciation reflects the change in portfolio investment values during the reporting period, including any reversal of previously recorded unrealized appreciation or depreciation, when gains or losses are realized.

 

Recently Issued Accounting Standards

 

From time to time, new accounting pronouncements are issued by the FASB or other standards setting bodies that are adopted by us as of the specified effective date. We believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial statements upon effectiveness.

 

Inflation

 

Inflation has not had a significant effect on our results of operations in any of the reporting periods presented herein. However, our portfolio companies have experienced, and may in the future experience, the impacts of inflation on their operating results.

 

SUBSEQUENT EVENTS

 

Subsequent to the close of the fiscal quarter on June 30, 2023, and through the date of the issuance of the financial statements included herein, a number of material events related to our portfolio of investments occurred, consisting primarily of the purchase and sale of public and private securities. Since that date, we have purchased private securities with an aggregate cost of approximately $100 thousand and sold public securities with an aggregate value of approximately $0.5 million.

 

51

 

 

Item 3.    Quantitative and Qualitative Disclosures About Market Risk.

 

 

The Company’s business activities contain elements of risk. We consider the principal types of market risk to be valuation risk and small company investment risk.

 

VALUATION RISK

 

Value, as defined in Section 2(a)(41) of the 1940 Act, is (i) the market price for those securities for which market quotations are readily available and (ii) fair value as determined in good faith by, or under the direction of, the Board of Directors for all other assets.

 

Because there is typically no public market for our interests in the small privately-held companies in which we invest, the valuation of the securities in that portion of our portfolio is determined in good faith by our Board of Directors with the assistance of our Valuation Committee, comprised of the independent members of our Board of Directors, in accordance with our Valuation Procedures. In addition, the Board of Directors may use the services of a nationally recognized independent valuation firm to aid it in determining the fair value of some of these securities. In the absence of a readily ascertainable market value, the determined value of our portfolio of securities may differ significantly from the values that would be placed on the portfolio if a ready market for such securities existed. Determining fair value requires that judgment be applied to the specific facts and circumstances of each portfolio investment, although our valuation policy is intended to provide a consistent basis for determining fair value of the portfolio investments. The methods for valuing these securities may include: fundamental analysis (sales, income, or earnings multiples, etc.), discounts from market prices of similar securities, purchase price of securities, subsequent private transactions in the security or related securities, or discounts applied to the nature and duration of restrictions on the disposition of the securities, as well as a combination of these and other factors. Because such valuations, and particularly valuations of private securities and private companies, are inherently uncertain, may fluctuate over short periods of time, and may be based on estimates, our determinations of fair value may differ materially from the values that would have been used if a ready market for these securities existed.

 

Furthermore, changes in valuation of any of our investments in privately-held companies from one period to another may be volatile.

 

Investments in privately held, immature companies are inherently more volatile than investments in more mature businesses. Such immature businesses are inherently fragile and easily affected by both internal and external forces.

 

Our portfolio companies can lose much or all of their value suddenly in response to an internal or external adverse event. Conversely, these immature businesses can gain suddenly in value in response to an internal or external positive development.

 

The values assigned to our assets are based on available information and do not necessarily represent amounts that might ultimately be realized, as these amounts depend on future circumstances and cannot be reasonably determined until the individual investments are actually liquidated or become readily marketable. Upon sale of investments, the values that are ultimately realized may be different from what is presently estimated. This difference could be material.

 

PRIVATELY PLACED SMALL COMPANIES RISK

 

The Company invests in small companies, and its investments in these companies are considered speculative in nature. The Company’s investments often include securities that are subject to legal or contractual restrictions on resale that adversely affect the liquidity and marketability of such securities. As a result, the Company is subject to risk of loss which may prevent our shareholders from achieving price appreciation, dividend distributions and return of capital.

 

52

 

 

WE CURRENTLY HOLD A PORTION OF OUR ASSETS IN CASH

 

As of June 30, 2023, a portion of the Company’s assets was invested in cash and/or cash equivalents, which are expected to earn low yields. Given the current low interest rate environment, to the extent the management fee and other operating expenses exceed interest income on the cash holdings of the Company, the Company may experience losses. Furthermore, the investment advisory fee payable by us will not be reduced while our assets are invested in cash-equivalent securities.

 

In some cases, particularly for primary transactions, it is to our advantage to hold sufficient cash reserve so that we can make additional subsequent investments in these companies in order to (a) avoid having our earlier investments become diluted in future dilutive financings, (b) invest additional capital into existing portfolio companies in case additional investments are necessary, and/or (c) exercise warrants, options, or convertible securities that were acquired as part of the earlier transactions. For this reason, in the case of primary transactions (as opposed to secondary transactions where we do not buy the securities from the issuing companies but instead from existing stockholders), we typically reserve cash in an amount at least equal to our initial investment for such follow-on opportunities. Cash reserves held with respect to a particular investment should, therefore, decline as it is held longer, and will typically not be needed once that portfolio company becomes public or we determine it is no longer in our best interest to make investments in such portfolio company.

 

We may from time to time liquidate various investments. We are required to distribute substantially all of our net realized gains to stockholders on an annual basis and, therefore, will generally hold the proceeds of liquidated investments in cash pending its distribution.

 

53

 

 

Item 4.    Controls and Procedures.

 

 

(a) Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this Quarterly Report on Form 10-Q, our management, with the participation of our Chief Executive Officer and Chief Financial Officer, conducted an evaluation of the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)). Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective and provided reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.

 

(b) Changes in Internal Control Over Financial Reporting

There have been no changes in our internal control over financial reporting, as defined in Rule 13a-15(f) under the Exchange Act, that occurred during the fiscal quarter ended June 30, 2023, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

 

54

 

 

PART II. OTHER INFORMATION

 

 

55

 

 

Item 1.    Legal Proceedings.

 

 

We are not a party to any material pending legal proceeding, and no such proceedings are known to be contemplated.

 

Item 1A.    Risk Factors.

 

 

There have been no material changes from risk factors as previously disclosed in our Form 10-K for the period ended December 31, 2022, in response to Item 1A of Part 1 of Form 10-K.

 

Item 2.    Unregistered Sales of Equity Securities and Use of Proceeds.

 

 

None.

 

Item 3.    Defaults Upon Senior Securities.

 

 

None.

 

Item 4.    Mine Safety Disclosures.

 

 

None.

 

Item 5.    Other Information.

 

 

None.

 

Item 6.    Exhibits.

 

 

EXHIBIT NUMBER

DESCRIPTION

31.1 Chief Executive Officer Certification Pursuant to Rule 13a-14 of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
   
31.2

Chief Financial Officer Certification Pursuant to Rule 13a-14 of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

   
32. Chief Executive Officer and Chief Financial Officer Certification Pursuant to Section 1350, Chapter 63 of Title 18, United States Code, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

 

SIGNATURES

 

 

Pursuant to the requirements of the Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

   

FIRSTHAND TECHNOLOGY VALUE FUND, INC.

(Registrant)

Dated: August 15, 2023

 

   

Kevin Landis

Chief Executive Officer and Chief Financial Officer

 

EXHIBIT INDEX

 

EXHIBIT NUMBER

Description

31.1

Chief Executive Officer Certification Pursuant to Rule 13a-14 of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

   
31.2 Chief Financial Officer Certification Pursuant to Rule 13a-14 of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
   
32.

Chief Executive Officer and Chief Financial Officer Certification Pursuant to Section 1350, Chapter 63 of Title 18, United States Code, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

EX-31.1 2 fp0084654-3_ex311.htm

 Certification of Chief Executive Officer

 

Pursuant to Exchange Act Rule 13a-14(a) or 15d-14(a)

 

I, Kevin Landis, certify that:

 

1.

I have reviewed the Quarterly Report on Form 10-Q of Firsthand Technology Value Fund, Inc.;

 

2.

Based on my knowledge, this report does not contain any untrue statement or a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

 

(a)

Designed such disclosure controls and procedures, or caused such disclosure control and procedures to be designed under our supervision, to ensure material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

 

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

 

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

 

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.

 

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

 

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

 

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

 

Name: Kevin Landis

Title: Chief Executive Officer

Dated: August 15, 2023

 
EX-31.2 3 fp0084654-3_ex312.htm

 Certification of Chief Financial Officer

 

Pursuant to Exchange Act Rule 13a-14(a) or 15d-14(a)

 

I, Omar Billawala, certify that:

 

1.

I have reviewed the Quarterly Report on Form 10-Q of Firsthand Technology Value Fund, Inc.;

 

2.

Based on my knowledge, this report does not contain any untrue statement or a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

 

(a)

Designed such disclosure controls and procedures, or caused such disclosure control and procedures to be designed under our supervision, to ensure material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

 

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

 

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

 

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.

 

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

 

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

 

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

 

Name: Omar Billawala

Title: Chief Financial Officer

Dated: August 15, 2023

 
EX-32 4 fp0084654-3_ex32.htm

 Certification of CEO and CFO Pursuant to
18 U.S.C. Section 1350,

 

As Adopted Pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002

 

In connection with the Quarterly Report on Form 10-Q of Firsthand Technology Value Fund, Inc. (the “Company”) for the quarter ended June 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Kevin Landis and Omar Billawala, as Chief Executive Officer and Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge:

 

(1)

The report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 134; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

Name: Kevin Landis

Title: Chief Executive Officer

Dated: August 15, 2023

 

 

Name: Omar Billawala

Title: Chief Financial Officer

Dated: August 15, 2023

 
EX-101.SCH 5 svvc-20230630.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Statements of Assets and Liabilities (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Statements of Assets and Liabilities (UNAUDITED) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Consolidated Statements of Changes in Net Assets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - Consolidated Financial Highlights link:presentationLink link:calculationLink link:definitionLink 00000008 - Statement - Consolidated Schedule of Investments link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - THE COMPANY link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - BUSINESS RISKS AND UNCERTAINTIES link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - INVESTMENT MANAGEMENT FEE link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - DEBT link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - FAIR VALUE link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - FEDERAL INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - INVESTMENT TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - SHARE BUYBACKS link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - INVESTMENTS IN AFFILIATES AND CONTROLLED INVESTMENTS link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - MARKET DISRUPTION AND GEOPOLITICAL RISKS link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - FAIR VALUE (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - FEDERAL INCOME TAXES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - INVESTMENT TRANSACTIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - INVESTMENTS IN AFFILIATES AND CONTROLLED INVESTMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - INVESTMENT MANAGEMENT FEE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - FAIR VALUE (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - FAIR VALUE (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - FAIR VALUE (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - FEDERAL INCOME TAXES (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - FEDERAL INCOME TAXES (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - FEDERAL INCOME TAXES (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - FEDERAL INCOME TAXES (Details 3) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - FEDERAL INCOME TAXES (Details 4) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - FEDERAL INCOME TAXES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - INVESTMENT TRANSACTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - SHARE BUYBACKS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - INVESTMENTS IN AFFILIATES AND CONTROLLED INVESTMENTS (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 svvc-20230630_cal.xml XBRL CALCULATION FILE EX-101.DEF 7 svvc-20230630_def.xml XBRL DEFINITION FILE EX-101.LAB 8 svvc-20230630_lab.xml XBRL LABEL FILE Investment Type [Axis] Eqx Capital Inc [Member] Equipment Leasing [Member] Eqx Capital Inc 1 [Member] Hera Systems Inc [Member] Hera Systems Inc 1 [Member] Hera Systems Inc 2 [Member] Hera Systems Inc 3 [Member] Hera Systems Inc 4 [Member] Hera Systems Inc 5 [Member] Hera Systems Inc 6 [Member] Hera Systems Inc 7 [Member] Hera Systems Inc 8 [Member] Hera Systems Inc 9 [Member] Intraop Medical Corp [Member] Intraop Medical Corp 1 [Member] Intraop Medical Corp 2 [Member] Intraop Medical Corp 3 [Member] Intraop Medical Corp 4 [Member] Intraop Medical Corp 5 [Member] Intraop Medical Corp 6 [Member] Intraop Medical Corp 7 [Member] Intraop Medical Corp 8 [Member] Intraop Medical Corp 9 [Member] Intraop Medical Corp 10 [Member] Intraop Medical Corp 11 [Member] Intraop Medical Corp 12 [Member] Intraop Medical Corp 13 [Member] Intraop Medical Corp 14 [Member] Intraop Medical Corp 15 [Member] Intraop Medical Corp 16 [Member] Intraop Medical Corp 17 [Member] Intraop Medical Corp 18 [Member] Intraop Medical Corp 19 [Member] Intraop Medical Corp 20 [Member] Intraop Medical Corp 21 [Member] Intraop Medical Corp 22 [Member] Intraop Medical Corp 23 [Member] Intraop Medical Corp 24 [Member] Kyma Inc [Member] Lyncean Technologies Inc [Member] Revasum Inc [Member] Uct Coatings Inc [Member] Wright Speed Inc [Member] Wright Speed Inc 1 [Member] Wright Speed Inc 2 [Member] Wright Speed Inc 3 [Member] Wright Speed Inc 4 [Member] Wright Speed Inc 5 [Member] Wright Speed Inc 6 [Member] Wright Speed Inc 7 [Member] Wright Speed Inc 8 [Member] Wright Speed Inc 9 [Member] Wright Speed Inc 10 [Member] Wright Speed Inc 11 [Member] Wright Speed Inc 12 [Member] Wright Speed Inc 13 [Member] Wright Speed Inc 14 [Member] Wright Speed Inc 15 [Member] Wright Speed Inc 16 [Member] Wright Speed Inc 17 [Member] Wright Speed Inc 18 [Member] Wright Speed Inc 19 [Member] Wright Speed Inc 20 [Member] Wright Speed Inc 21 [Member] Wright Speed Inc 22 [Member] Wright Speed Inc 23 [Member] Wright Speed Inc 24 [Member] Wright Speed Inc 25 [Member] Wright Speed Inc 26 [Member] Wright Speed Inc 27 [Member] Wright Speed Inc 28 [Member] Wright Speed Inc 29 [Member] Wright Speed Inc 30 [Member] Wright Speed Inc 31 [Member] Wright Speed Inc 32 [Member] Wright Speed Inc 33 [Member] Wright Speed Inc 34 [Member] Wright Speed Inc 36 [Member] Investment Company [Member] Silicon Genesis Corp [Member] Silicon Genesis Corp 1 [Member] Silicon Genesis Corp 2 [Member] Silicon Genesis Corp 3 [Member] Silicon Genesis Corp 4 [Member] Silicon Genesis Corp 5 [Member] Silicon Genesis Corp 6 [Member] Silicon Genesis Corp 7 [Member] Silicon Genesis Corp 8 [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 1 [Member] Long-Lived Tangible Asset [Axis] Advanced Materials [Member] Equity Components [Axis] Common Stock [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Automotive [Member] Semiconductor Equipment [Member] Aerospace [Member] Preferred Stock [Member] Derivative Instrument [Axis] Equity Contracts [Member] Asset Derivatives [Member] Debt Instrument [Axis] Convertible Notes [Member] Medical Devices [Member] Mutual Funds [Member] Finite-Lived Intangible Assets by Major Class [Axis] Intellectual Property [Member] Tax Credit Carryforward [Axis] Capital Loss Carryforward 1 [Member] Capital Loss Carryforward 2 [Member] Capital Loss Carryforward 3 [Member] Capital Loss Carryforwards [Member] S V V C Stock [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] E Q X Capital Inc Common Stock [Member] E Q X Capital Inc Series A Preferred Stock [Member] Hera Systems Inc Convertible Note [Member] Hera Systems Inc Convertible Note 1 [Member] Hera Systems Inc Series A Preferred [Member] Hera Systems Inc Series B Preferred [Member] Hera Systems Inc Series B Warrants [Member] Hera Systems Inc Series B Warrants 1 [Member] Hera Systems Inc Series B Warrants 2 [Member] Hera Systems Inc Series B Warrants 3 [Member] Hera Systems Inc Series C Preferred [Member] Intra Op Medical Corp Convertible Note [Member] Intra Op Medical Corp Convertible Note 1 [Member] Intra Op Medical Corp Convertible Note 2 [Member] Intra Op Medical Corp Convertible Note 3 [Member] Intra Op Medical Corp Convertible Note 4 [Member] Intra Op Medical Corp Convertible Note 5 [Member] Intra Op Medical Corp Convertible Note 6 [Member] Intra Op Medical Corp Convertible Note 7 [Member] Intra Op Medical Corp Convertible Note 8 [Member] Intra Op Medical Corp Convertible Note 9 [Member] Intra Op Medical Corp Convertible Note 10 [Member] Intra Op Medical Corp Convertible Note 11 [Member] Intra Op Medical Corp Convertible Note 12 [Member] Intra Op Medical Corp Convertible Note 13 [Member] Intra Op Medical Corp Convertible Note 14 [Member] Intra Op Medical Corp Convertible Note 15 [Member] Intra Op Medical Corp Convertible Note 16 [Member] Intra Op Medical Corp Convertible Note 17 [Member] Intra Op Medical Corp Convertible Note 18 [Member] Intra Op Medical Corp Convertible Note 19 [Member] Intra Op Medical Corp Convertible Note 20 [Member] Intra Op Medical Corp Convertible Note 21 [Member] Intra Op Medical Corp Series C Preferred [Member] Intra Op Medical Corp Term Note [Member] Revasum Inc C D I [Member] Silicon Genesis Corp Common Stock [Member] Silicon Genesis Corp Common Warrants [Member] Silicon Genesis Corp Series 1 G Preferred [Member] Silicon Genesis Corp Series 1 H Preferred [Member] Silicon Genesis Corp Series 1 D Preferred [Member] Silicon Genesis Corp Series 1 E Preferred [Member] Silicon Genesis Corp Series 1 F Preferred [Member] Silicon Genesis Corp Series 1 C Preferred Stock [Member] Intellectuals Property [Member] U C T Coatings Inc Common Stock [Member] Wrightspeed Inc Common Stock [Member] Wrightspeed Inc Convertible Note [Member] Wrightspeed Inc Convertible Note 1 [Member] Wrightspeed Inc Convertible Note 2 [Member] Wrightspeed Inc Convertible Note 3 [Member] Wrightspeed Inc Convertible Note 4 [Member] Wrightspeed Inc Convertible Note 5 [Member] Wrightspeed Inc Convertible Note 6 [Member] Wrightspeed Inc Convertible Note 7 [Member] Wrightspeed Inc Convertible Note 8 [Member] Wrightspeed Inc Convertible Note 9 [Member] Wrightspeed Inc Convertible Note 10 [Member] Wrightspeed Inc Convertible Note 11 [Member] Wrightspeed Inc Convertible Note 12 [Member] Wrightspeed Inc Convertible Note 13 [Member] Wrightspeed Inc Convertible Note 14 [Member] Wrightspeed Inc Convertible Note 15 [Member] Wrightspeed Inc Convertible Note 16 [Member] Wrightspeed Inc Convertible Note 17 [Member] Wrightspeed Inc Convertible Note 18 [Member] Wrightspeed Inc Convertible Note 19 [Member] Wrightspeed Inc Convertible Note 20 [Member] Wrightspeed Inc Convertible Note 21 [Member] Wrightspeed Inc Convertible Note 22 [Member] Wrightspeed Inc Convertible Note 23 [Member] Wrightspeed Inc Convertible Note 24 [Member] Wrightspeed Inc Convertible Note 25 [Member] Wrightspeed Inc Convertible Note 26 [Member] Wrightspeed Inc Convertible Note 27 [Member] Wrightspeed Inc Convertible Note 28 [Member] Wrightspeed Inc Convertible Note 29 [Member] Wrightspeed Inc Convertible Note 30 [Member] Wrightspeed Inc Convertible Note 31 [Member] Wrightspeed Inc Convertible Note 32 [Member] Wrightspeed Inc Series A A Preferred [Member] Wrightspeed Inc Series A A Warrants [Member] Total Affiliates And Controlled Investments [Member] Affiliates [Member] Controlled Investments [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] ASSETS Investment securities: Unaffiliated investments at acquisition cost Affiliated investments at acquisition cost Controlled investments at acquisition cost Total acquisition cost Unaffiliated investments at market value Affiliated investments at market value Controlled investments at market value Total Market value (Note 6) Foreign currency at value (cost $2,629 and $3,235) Receivable from dividends and interest Other assets Total Assets LIABILITIES Payable to affiliates (Note 4) Trustees’ fees payable Consulting fee payable Accrued expenses and other payables Total Liabilities NET ASSETS Net Assets consist of: Common Stock, par value $0.001 per share 100,000,000 shares authorized Paid-in-capital Total distributable earnings (loss) Shares of Common Stock outstanding Shares of Treasury Stock outstanding Total Shares of Common Stock outstanding Net asset value per share (Note 2) Consolidated Statements Of Assets And Liabilities Unaudited Foreign currency cost Common stock, par value Common stock, shares authorized Income Statement [Abstract] INVESTMENT INCOME Unaffiliated interest Affiliated/controlled interest TOTAL INVESTMENT INCOME EXPENSES Investment advisory fees (Note 4) Administration fees Custody fees Transfer agent fees Registration and filing fees Professional fees Printing fees Trustees fees Compliance fees Miscellaneous fees TOTAL GROSS EXPENSES NET INVESTMENT INCOME/(LOSS) Net Realized and Unrealized Gain (Loss) on Investments: Net realized gains (losses) from security transactions on: Affiliated/controlled Foreign currency Net realized gains (losses) Net change in unrealized appreciation (depreciation) on: Non-affiliated investments Affiliated/controlled investments and foreign currency Affiliated/controlled warrants investments Net change in unrealized (depreciation) Net Realized and Unrealized (Loss) on Investments Net Decrease In Net Assets Resulting From Operations Net Decrease In Net Assets Per Share Resulting From Operations Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Net increase (decrease) in Net Assets resulting from operations Adjustments to reconcile net increase (decrease) in Net Assets derived from operations to net cash provided by (used in) operating activities Purchases of investments Proceeds from disposition of investments Net purchases/sales from short-term investments Increase (decrease) in dividends, interest, and reclaims receivable Increase (decrease) in due to Custodian Increase (decrease) in receivable in investment sold Increase (decrease) in payable to affiliates Increase (decrease) in other assets Increase (decrease) in accrued expenses and other payables Net realized gain (loss) from investments Net unrealized appreciation (depreciation) from investments, other assets, and warrants transactions Net cash (used in) operating activities CASH FLOWS FROM FINANCING ACTIVITIES Net cash provided by financing activities Net increase (decrease) in cash Cash and foreign currency - beginning of period Cash and foreign currency - end of period Consolidated Statements Of Changes In Net Assets FROM OPERATIONS: Net investment income (loss) Net realized gain (loss) from security transactions and foreign currency Net change in unrealized (depreciation) on investments, other assets, and warrants transactions Net decrease in net assets from operations TOTAL DECREASE IN NET ASSETS NET ASSETS: Beginning of period End of period COMMON STOCK ACTIVITY: Shares outstanding, beginning of period Shares outstanding, end of period Fair Value Disclosures [Abstract] Net asset value at beginning of period Income from investment operations: Net investment income (loss), before deferred taxes Deferred tax benefit Net investment gain (losses) Net realized and unrealized gains (losses) on investments, before deferred taxes Deferred tax expense Net realized and unrealized gains (losses) on investments, after deferred taxes Total from investment operations Realized capital gains Anti-dilutive effect from capital share transactions Net asset value at end of period Market value at end of period Based on Net Asset Value Based on Market Value Net assets at end of period (millions) Ratio of total expenses to average net assets: Before tax (benefit)/expense Deferred tax (benefit)/expense Total expenses Total expenses, excluding incentive fees and deferred tax expense Ratio of net investment income (loss) to average net assets: Before tax benefit Deferred tax benefit Net investment income (loss) Portfolio turnover rate Schedule of Investments [Table] Schedule of Investments [Line Items] TYPE OF INVESTMENT ACQUISITION DATE SHARES/PAR VALUE COST BASIS VALUE TOTAL INVESTMENTS LIABILITIES IN EXCESS OF OTHER ASSETS Net assets Investment Company [Abstract] THE COMPANY Accounting Policies [Abstract] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Business Risks And Uncertainties BUSINESS RISKS AND UNCERTAINTIES Investment Management Fee INVESTMENT MANAGEMENT FEE Debt Disclosure [Abstract] DEBT FAIR VALUE Income Tax Disclosure [Abstract] FEDERAL INCOME TAXES Investments, All Other Investments [Abstract] INVESTMENT TRANSACTIONS Equity [Abstract] SHARE BUYBACKS Investments in and Advances to Affiliates [Abstract] INVESTMENTS IN AFFILIATES AND CONTROLLED INVESTMENTS Market Disruption And Geopolitical Risks MARKET DISRUPTION AND GEOPOLITICAL RISKS Subsequent Events [Abstract] SUBSEQUENT EVENTS BASIS OF PRESENTATION USE OF ESTIMATES PORTFOLIO INVESTMENT VALUATIONS CASH AND CASH EQUIVALENTS RESTRICTED SECURITIES INCOME RECOGNITION SHARE VALUATION REALIZED GAIN OR LOSS AND UNREALIZED APPRECIATION OR DEPRECIATION OF PORTFOLIO INVESTMENTS INCOME TAXES FOREIGN CURRENCY TRANSLATION SECURITIES TRANSACTIONS CONCENTRATION OF CREDIT RISK OPTIONS Schedule of derivatives Schedule of fair value of net asset Schedule of unobservable inputs of fair value Schedule of unobservable inputs fair value measurements Schedule of federal income tax cost of portfolio investments Schedule of income tax provision Schedule of deferred tax assets and liabilities Schedule of effective tax rate and statutory federal income tax rate Schedule of net capital loss carryforwards Schedule of investment transactions Schedule of investments in affiliates and controlled investments PURCHASED OPTIONS (CONTRACTS) WARRANTS (NOTIONAL VALUE) WRITTEN OPTIONS (CONTRACTS) Venture capital investments Restricted securities Annual rate Incentive fee adjustments Fair Value, Recurring and Nonrecurring [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Assets Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] BEGINNING BALANCE NET PURCHASES/CONVERSIONS NET SALES/CONVERSIONS NET REALIZED GAINS/(LOSSES) NET UNREALIZED APPRECIATION (DEPRECIATION) TRANSFERS IN (OUT) OF LEVEL 3 ENDING BALANCE Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] FAIR VALUE Gross unrealized appreciation Gross unrealized depreciation Net unrealized (depreciation) Federal income tax cost, Investments Federal State Total deferred tax (expense)/benefit Net operating loss carryforward Capital loss carryforward Net unrealized losses (gains) on investment securities Total deferred tax assets Valuation allowance Net Effective tax rate Statutory federal income tax rate Tax Credit Carryforward [Table] Tax Credit Carryforward [Line Items] EXPIRATION DATE Capital loss carryforwards Statutory tax rate State tax rate Effective tax rate State income tax Net operating loss carryforwards Net capital loss carryforwards Purchases of investment securities Proceeds from sales and maturities of investment securities Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Line Items] Common stock value Repurchased of shares value Repurchased of shares value Authorized to purchase Repurchased and retired shares Repurchased and retired shares value Shares outstanding Average price Total consideration amount Common shares for cash Trading price Tender offer description Tender offer Price per share Increment of per share Tender offer expired Purchase of shares Common stock price Investments in and Advances to Affiliates [Line Items] PURCHASE/MERGER INTEREST SALES/MATURITY/EXPIRATION REALIZED GAIN (LOSS) CHANGE IN APPRECIATION/(DEPRECIATION) SHARES HELD Business Acquisition, Transaction Costs Equity Method Investment, Quoted Market Value Liabilities Treasury Stock, Common, Shares Common Stock, Other Shares, Outstanding Investment Company, Gain (Loss) on in-kind Redemption Operating Expenses Debt Securities, Realized Gain (Loss) NetChangeInUnrealizedDepreciation NetRealizedAndUnrealizedLossOnInvestments PurchasesOfInvestments Interest Income, Short-Term Investment, Increase (Decrease) Increase (Decrease) in Interest and Dividends Receivable Increase (Decrease) in Other Current Assets Equity Securities, FV-NI, Realized Gain (Loss) Net Cash Provided by (Used in) Operating Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Shares, Outstanding Auction Market Preferred Securities, Stock Series, Par Value Per Share BasedOnMarketValue DeferredTaxBenefits NetInvestmentIncomeLoss Fair Value Hedge Assets Investment, Tax Basis, Unrealized Loss Deferred Tax Assets, Valuation Allowance Effective Income Tax Rate Reconciliation, Percent Stock Repurchased During Period, Value EX-101.PRE 9 svvc-20230630_pre.xml XBRL PRESENTATION FILE GRAPHIC 10 fp0084654-2_46.jpg GRAPHIC begin 644 fp0084654-2_46.jpg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end GRAPHIC 11 fp0084654-2_57.jpg GRAPHIC begin 644 fp0084654-2_57.jpg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end GRAPHIC 12 fp0084654-2_60.jpg GRAPHIC begin 644 fp0084654-2_60.jpg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end GRAPHIC 13 fp0084654-2_60a.jpg GRAPHIC begin 644 fp0084654-2_60a.jpg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end GRAPHIC 14 fp0084654-2_58.jpg GRAPHIC begin 644 fp0084654-2_58.jpg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end GRAPHIC 15 fp0084654-2_59.jpg GRAPHIC begin 644 fp0084654-2_59.jpg M_]C_X 02D9)1@ ! @$ > !X #_[0 L4&AO=&]S:&]P(#,N, X0DE- ^T M ! > $ 0!X 0 !_^X $T%D;V)E &0 04 DE$_]L MA " @(" @(" @(" P(" @,$ P,# P0%! 0$! 0%!04%!04%!04%!P@(" <% M"0H*"@H)# P,# P,# P,# P,# P, 0," @,# P<%!0<-"PD+#0\-#0T-#P\, M# P,# \/# P,# P,#PP.#@X.#@P1$1$1$1$1$1$1$1$1$1$1$1$1$1'_P 1 M" !Q :0# 1$ A$! Q$!_\0!H@ $S%F+P)'*"\25# M-%.2HK)C<\(U1">3H[,V%U1D=,/2X@@F@PD*&!F$E$5&I+16TU4H&O+C\\34 MY/1E=865I;7%U>7U9G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_(B8J+C( MV.CX*3E)66EYB9FINGM\?7Y_(B8J+C( MV.CX.4E9:7F)F:FYR=GI^2HZ2EIJ>HJ:JKK*VNKZ_]H # ,! (1 Q$ /P#[ M^8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[% M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[% M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[% M7DOYE?G9Y#_*R_\ +.A^8+N[U#S;YUN#;:!Y;T>V>^U;460J)&AMH^D:VE[;JCLDD:R2"A M60%6#$$=,5>BXJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%6'7W MY@>3]-\[Z'^6][KD-OYV\RZ==ZMIFELK^K<6=BR+<2JP4H AD&Q(/ATQ5F.* MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V* MNQ5V*NQ5V*NQ5V*L1\_>=]!_+?R7YF\^>9[H6>@^5-/FU&\D[E(EJ$7Q9VHJ MCN2!BKYQ_P"<:?R[UO4KC6O^?O,,6C/YKU6VT72;<*TUQ=7=U*D2".&,,Y56D7F].*@[G%7E/Y^_F/YN?S M%Y._(3\H=2AT[\TOS'$EW?ZNT?K#RUY9MS2]U4J1Q]9C^ZME;8R&O[.*I[_S MBMK&M:W^2N@7.N>:+_SKI:WIL&O:J0;[4+2PU6\M;:XN2 O[QHH5Y;8J^ MB<5=BJUF5%9W8(B LS,: ;DDG%7YR_\XU>:YOSM_P"7"%Y!8$N)9Y)HF/3UFC=R1U# '8#%7Z.8J[%78J[%78J[%78J[%7 M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J^)_ MSSE@_.+\]_RG_P"<=X;R-M \M,OYE>?;5I> NK+3Y FDZ<4!4R"6Z/J2+N B M#D/B&*OMC%7SA_SC3://Y?\ S$\Y2VKVW_*P_P PO,6MV_J#XFLTN18VS18885+R2.0JHJBK,Q- -SBKYBU/_ M )RN\C75U-_:2/#-)Y)TQKO3(9%!VDU2=H+0CD.),U%?;%43>_RMUN.-PTMM>:3J5FL@WJADBGG8 M#W&^*H:Y_,7_ )R^\K2H-;_YQ^\L?F#9Q0F2XNO)WF=;0U )(CM]5A25B /L M@&IZ'%6=_EO_ ,Y%^3?/9\Q:3K>FZM^67GCR7IK:QYA\K^:[HJ;Y6 M^*.:V\)48]N04FF*OA.[M+7\Z_.'D7\[/S(,-M#Y^\V?7?(]G>4IHOY<>2A- MJ]YJ0C-?COY(8S(Q6H21 /M8J][_ ".?4'_+K\Y_^LQ_;+*3OBKZ$_YQN\MW?E/\AORFT34;?ZMJL/E MJQN-12H)^NW<8N;IF()W:69B=^IQ5[;BKL5?-_\ SE)YRU/R[^61\J>5Y%'G MS\WM2M?(GEM*KR6YU@F.XN>)925MK42S,1N M<5>9_\ .$WY?6'D;1OSB&DA MSHY\^7>@:7.P'&[L?+=O!ID=VK@D/ZKQ274S;+'# C22.?8*I.*OAG_G$KR'IOYB:EYH_P"< MN?.&C>KYW_-'6;RX\K270)DT?RW &L;.*W)H1Z\,?)SN&7C3;%7UC^;7F[_ M7Y8>?_.:NJ3>6] O[ZW+_9-Q' Y@4_.3B,54_P H/+3>3ORL_+WRS+'Z5SI& M@6$-TO(O2Y,"-+_\Y">0=2_-#\HO./D?1M6&DZKK M5JOU8/.UM!>-!(DQL;F1*.(+@)Z4I7?BQQ5BOY-_G1^4UQ^7FEV?K>7_ ,HK MORGZFAZMY.O+RRL3H=]8DQSVJH)$1HJCG'(E5D1@X.YQ5-M3_P"5R=^@&*L)'_.;/_./LQN%TW7M?UMK= M/4/Z-\L:[<(W@%D73^!)_P!;%5"'_G+[0=3]<^6OR5_-[S0D4/K*]AY4F57! M^R!Z\T)W]QBKSW\U?^XD*,"Q0"E!\1 Q5F<&N_P#.<^IV.G6\'D+\KO+-V(8TO+O6 M-7OKQVD4 22+%8P\!S.X6I Z5Q5&S?E+_P Y/^<8Y4\Z_P#.2-OY*M))UD6S M_+[08()4C7J@U#43<2;U/^Z_ XJ\0_-/\AO*WE+4_)WY3>5=2\P>8_S _P"< MDK]M#\Y>;O,&H3ZIK(\E:8%O=9AAE<\+>.4F./C&J+\5>H!Q5CG_ #D7;6/G M'S^WY4>4)%LI[M/+_P"3FA6MI( MG87S)J_FJ:$A@\?I:7!;V[,#^V%.],5? M6_\ SD?!%IGY-6?Y=Z'";4>>-5T#R'I\,*%O3MK^[@@F4*M/A6TCDKV &*OI M&W@AM8(;6WC6&WMHUBBC445$0!54#P &*JN*NQ5\4S:N_G[\^/S"_,>\BBN_ MR_\ ^<6M$O\ 2]#$A#0R^;+BU%QJUT0"QY6UKQMP: J7DIUQ5ZA_SBAI5UI7 M_./7Y7M?R--?ZYI;>8+F1_MM+K<\VI$M\*[_ .E4H1MTQ5]#8J[%78J[%78J M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J M[%7R1_SFKYGU72?R4N/)WER:2'S-^<.MZ9Y!TYX"1+'^FYU@N94 !KP@YEO: MM=L5?37E?R]IOE'RUY?\JZ/ MMI7EO3K73+.)10)!:1+%&-J?LH,5>%_\Y+R MP:OY>\B?EDX>5OS8\ZZ/HDT2+RY:?:3?I2_YCKP]"Q96([-X8J^D H"J ! M0 = ,5?EU^9/YJ_\Y8?EW^9'F&V_,CSW'^6WY67.HO\ H/S-H'D0^:=,BL9" MYA%Y<+=QSPRJH',-"PK4CX=\5>J?EGHVN_F]#)JVE?\ .=-_Y[B532#R79Z+ MIHB8TJ9X&BO95('[)XT/7PQ5G\G_ #B=9:M,)O./YY_FUYM8'=)/,KZ;&0I) MC'#3(;.G'D>A%:_%7%76/_.$_P"0D-P;G5]+\R><)"7/_.R>9]:U-07Z\1/? M,!]&*L_\O?\ .,G_ #CWY5A>'1?R<\J0K(2SO<:;#=R,32I:6Y69R=NYQ5Z- MI?Y?^0]$C$6C>2M!TF-1Q"V>G6L IX?NXEQ5E4444*+'#&L4:BBH@"J![ 4Q M54Q5\4?F) GYG_\ .8OY-^38_3O=%_([0K_SYK25#+%J6H%;+2D=>TB\3*G^ M3RQ5]KXJ[%7Q?Y-\QVNN_GY_SD3^3?R5T:+R)ILI4!%^J1_I;790S M$ LLO!*UZ#B>F*O&_P#G&[RY=^=?SXTGSYJD;1W'EGR=<>==2AEDY2P:[^8] MS)=01-$PY1\-+MHU()V*[;'%7UGYKGMO-7Y__EMY0W=?R^T;4//-ZK*3&9KH M-I&GKR&W,&:=P#_*#BKZ!Q5V*O"O^W\O>7]"T"TY"TT/3[7 M3X>;%F].VB2)>3'"]T7 M\H?*NK>?KX,#S@U+4F.DZ;)4;;*)Z _/%7V7BKYFU& ^=?\ G*CR\DM:"TNBZG&'IR*7>G/;2 F@ M[XJ\X;_G&W\W?*,K7'Y2?\Y2>;=+@1V,&C^=K:V\TZ=&C"G -*+:Z^1:9CWZ MXJU-^9O_ #EM^7K7!\\_D5HWYJZ+;,$75/RZU0Q7K( *R-I>H@2,QW^%&H#W MIBK,]+_YRU_)>6XCT[SAK%_^4NN2,$_1GGZQET&8.: ();@?5F:II192<5?1 M.FZGINL6<.HZ1J%MJFGW*AHKFTE2:&13O59(RRGZ#BJ.Q5:[I$CR2.L<<:EF M=B JJ!4DD[ #%7QY_P XG1_XSO?SI_/^X0/R^\Z^=KZ9+>V\JZ)?:HSR?9!MH7D0 M&OBP IBKX-L/*>IZ!_SA_P#E1^4.MV\\/GS_ )R/UBRLO,428R^9KM]5\ MP23,26"QV?JH37X1Q [8J]=_YQ %EKLGY^_F-:213V_FS\R-0TK3FB2GIZ1Y M;AATRP@Y=2(Q&X'SQ5GGY$O#YQ\P_FW^<(M@(O-_F%]!T2XH3ZVB>6N5C#+& MQZI-0;=^^V*OH_%78J^.O)TB?G]^?-]^9J3?7ORH_(Y[KR]Y1'VK;4_-$ ME8M5U:.H972VC/U:%P?M&1E.*LE_YRBO9;G2/RG\C6LZI<_F'^9?EO3W@:/U M#/9V%S^E;M!784CL:DU&P.*OJ#%78J[%78J[%78J[%78J[%78J[%78J[%78J M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7QO_SCFT/G;\X?^0])N%D+@6/EFVCCF5.@XR3RF2M#N: [8J^PYYHK:&:XN)%A@@ M1I))'-%5%!+,2>@ &*OFC_G%]#YB\N>=OS@N/WEU^<_FO4--O:A@:='Q5].8J[%78J[%78JD^M^7M!\S63:9YCT2PU_3G/)K74;:* MZA)H17TY5=:T)WIBKY5U+_G#/R'I-U>ZU^2OFSS/^0'F&[Y'GY1OW_1)9V5I M#)HUR9K1N7'3O+M_9 MZGI/EO0+*QCN["19;:9XXAZLD;JS@AI"QZXJ]:Q5\B_\YH3SW_Y8>5_(%I<1 M0W'YK>?/+7E9EE (EMI;Y+NZC%>A:&T<5\,5=YDU>'6?S\\P7=G:>O9_\XU? MEY=7T,; I$FN>8HB\04;AN-C8D5I5?4([XJ\:_*KS5>^4?\ G!#\MI_*UD@\ M^?G'$-/T:"V%'?7/.%_V*OOKR9Y6TWR1Y2\M>3](3A MIGEC3;;3+8=S';1+&&-2=VXU/N<59+BKYD_YR%\V>8M3?0/R&_+:_?3_ ,QO MS8CF6YU2)0_^'?+4/P:GJ[UV#\6]&W!^U*XI]DXJ]S\E>3O+_P"7WE/R]Y)\ MJ6"Z9Y=\L6,5A8VZ_LQ1"G)C^T[&K,QW9B2=SBKY>_YR(#ZA^?O_ #AIHHB9 MHX/.6MZV[KO_ +Q:'=Q*"!T%;FI/L,5?9.*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V* MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5+M7U*#1M)U36 M+I@EKI5I/>3,QH!'!&TC$GL*+BKY7_YP>T>ZL?\ G'GRYKNH1+'J?G_5-8\U MW14U]0ZG?SM#(34CXH$C.*LM_P"1-$*+S M876O2BUDEH-Z16[2R$]N.*O:/)WE;2O(_E3RWY-T.,Q:/Y7TVUTNS5J6*-G5F3D;=>177O)WYXZ7:.3_B+3[2>VUI;<;#U](6X1'DIU,)8'_,; M\]/-OY'&7\X/(FESZ%K6K^9V^IZ!?FY\JWNAZ7-<2/J^G:A<0.Z+%(ZHP(!; MXE)IBKVG\F?RK_YRC\[_ )::K^8MI^=/EORU=?GU'/YAU6QU'R:+BZECO+<6 MUFC3G486B1K9$*Q^F?2Y'[1K55Y)_P XI>3_ /G)/SSY9\A:]Y8\P^5+#R]_ MSCZ-3\H>6+#S#I]YZ#78_P!%OY6-O(#-)$L?I+,0./)^(^U55[/^:'_.2G_. M3/Y,7&F1>9G_ "9\WZEKETEGIWEKR[=:W/KMU(: F*U2*2@Y,%Y,:5([G%4@ M\U?\YP_G;Y!_-"S\K^;?R6M[[2=*$>F:S9^59Y]5N)-:U:V6YTJU2X])5B[@TFR ML(V<6.F:;?HD\*6=LA^U(Z%Y"SMVHJ_0S1=?T+S)I]OJ_EW6;'7=*NT$D-YI M]Q'\TFDAU3YD( M3]&*OK?%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%5K-Q5FH6X@FB MBI-/ 8J\PT'\Z_RH\Q:=!J5C^8&A0I,61[>]OK>UNH)4/&2&:":1'1T:JLI& MQ%,59Q!YC\O748EM=>TZYB/1XKJ%U-=^JN1BJ+BU/39RP@U"VF*4+>G*C4KT MK0G%42D\,A*QS)(P%:*P)I]!Q55Q5V*NQ5V*NQ5V*NQ5V*O /^0_TF(V]:$CIZM<59;^1^@VOE?\FORI\NV:.EMHWE M+1[6,2_;I'9P@E]A\1/7WQ5XOJ$D/YL_\Y7:;HS1&?RS_P XU:/^F9VW,4OF MGS%$8;125(%;6Q65J&OQ2@T!7%7K/YW?G/Y=_(_R7+YJUJTN=K4!9C2BJ"3BKYOT__G.KRWK_ )T_*KRSY7\BZEK6F>=C MIMKYCU9+B,1>6M1U=7:VL)_A*RS(L;/* PX1_%[8JJZ1_P Y;ZMYU_YR,\F_ ME[Y$\O65_P#E#K":];3>:+J;A+J4^B16D+2$4=V/$@+NJ^TO M+WF3R_YMT>R\P^5]:LO,.A:DI>UU#3YTN+:958H3'+&64T92#0]<53AW2)'D MD=8XXU+,S$!54"I))Z 8JE^DZSH^O6:ZCH>JV>LZ>[,BW5C/'<0ED/%E$D3, MM010BN*IEBKL5=BK%/,WD?RGYRN/+%WYGT2WUBX\F:Q#K^BO/RK9ZE;I(D5S M'Q8?$HD:E:C%65XJ^'?-?_.5*:'_ ,Y.Z#^7TFM:-H_Y/:7IFLVGFK7M2F@M MHH?,%C;Q7?H?69I%"K#'+&KCN[E>JXJ^+O\ G+W\R?R+_-[SCY'U;\L_+&M> M8=8T^^IYK\\:+ILB:;=^4("!K,3R%4>ZCCCDY/,HXHE:2,#0*OO7\P_S33ST MND_D9_SCKK]IJ/F'S+911ZMYGT26.[LO)WEV2-5:]::-S']:DB8+:13_SFU'RO_P XQ7U_'K&H^5[82KYC:Y^!KBS@UM)$ MD6VGEC$CUJ_)FZUKBKY=\_?\X>_GSY MOS'G_+/R_P"7)?)-AYRA\Z:-::&\ M\GFO5;:VN+HH_^ M5F?F#J-SYL\W.H3X-3U$\OJRE*KQMX@D*A33X33KBKW"_P!.T_5;2;3]4L;? M4K"Y7C-;74230R*>SQN&4CYC%7R=YA_YP\\D66J7GG'\D=;U3\A/S EEDNEO M?+4K'2+B>0EG%]HLKFTEC?+?5[G\S/+!>+1I-/U"TN=+F&HV+!I;21!>NZ)Y MFTJQUWR[J]GKNBZG$)K2^L)DN+>:-NC1RQLRL/D<537%78J[%78J[%78J[%7 M8J[%78J[%78J[%78J[%78J[%7GOF;\I?RO\ .DHN/-WY>>7/,ET"2)]1TRUG MFW-3^\>(MN34[XJ\OO?^9M:LY2II4%XKY6IMTKBJ[_H3K\L4!2U\V_F991EBY2#SUKX M%3M^U?,:;>.*HP?\XI>58+:6VT_\T/S7T[F#P>/SKJDK(W\P$\LH/R((Q5CS M_P#.(LQG#I_SD?\ G''!Z97T?\1*?C/1^9MN6WA6F*H=/^<3?-5K%Z>F_P#. M67YQV#_,PD-_T.7^;U14==!IO[?H>F*JZ M_P#.-OYMVR!++_G,;\RVJ27-_::%DN"!T#T10??88JC+K\D?\ G)BB&Q_YRVO.53S%SY6TXJ13 M:GIR(1OBKQW\^/R/_P"_YR)M_/FBKY;O9[W0V\KV=C)?P6R_ M6)(EO%N>41*Q&C $]J;XJNM(O^L?)6F>3K37%&H> M2[:XB2R^IQRPPB5;^%WD-516)J6/2NV*O*ORBT;_ )S MO,=EY6TC\VO*_EC MSI^:&EW?YK>;[;4/+45Y*VLX[N47*@_6.!"1(!Z2QN*[;JO-_.\W_. M1.N>5/S+_P"7-6T?\FXM9\H^4+I?+QA@U=+QAI]_J&CQ_6O]'E>1 MS''V:'3]0MH]1U.XTV&621HW(=(YYF)Y.U%^(8J]5_YQJ\P?F;^2 M_P"67YJ:U/\ F1Y!_*:R\O>:VTO7]%\Y6]]=WUG?6MO!#;V]M!;S@D2Q4*JB M,\C M2I)Q5[;%Y7_ .?EQ'=>M#HLL.I:9+YPLZ\X M+C4(X93=06S;$0%DYC=Q3%7M'D[\I?\ G*K\OTUVV\F:W^4'EO3=?O8M0?3- M/T?4;>PMIH[>.WYJJRNX\L?\YM7\'U8?FG^6/E]Y)% M!O+70+Z]DCC&[%89[F-&)Z4)'SQ5 VWY<_\ .;3%OKG_ #DMY(A4-1?0\B>H M67N3RU2.A^_%4<_Y3_\ .6;\Q_T-7IJ\Z_9\D6((KX?Z7M[8JEB?\X^?\Y&W MIC?6/^C^YJ/;%7D?YU_D=YK\A>3#>3?\Y.? MFQYW\X^:M3M/+/E#2+_7;72[:ZUS59!%:K*]C:6K>G'1IG"LIXH0",52_P \ M?\XL?E5^0]K^5?YD7/D"X_,[3_+6IRK^9FH:BMSKUY<6E_:2)/JK6DIG9EAN MB)66-"0#6AH<5>Z_D-H?_*Q_//F_\^;_ ,JS>6/)UYI,7DG\NM"U&Q%DZ^6H M&%QFW$S7,MMI M-I%:1/*_5V6%$!/:I[;8JRG%78J[%78J[%6"?F?Y"TK\T?R]\X_E[K:@Z;YN MTJXTZ1F'+TVE0^E*!M4QR!7 \1BK\T_RI?S-^2.D^8=?\D1'3_-7Y/,EI^>' MY4M(PLM2M(8P5\V>7A(56&2>W7ZP?3I%+\:,%=02J_5;1]6L=>TC2]?EW_G&+\[M0M/*'Y'?F)YET*\_P"<;ORXUK], M6D^GR3?IWS!:VETUSIFD:C$T2Q1V\+,!)P)YJBI[XJQ;\YO-U_Y0_//_ )R" MT70[A(_S/_-3REY+\D^0+-Z\I%U6:]M[BX15(I':EI968=".F*OIKS=_SC'I MNO\ Y8?D[^3VF>8WTOR)^6NL:+?:O92VR3?I^TT<^J;:X(9 OK3@.] 0:FJ] M,5>O1_E1Y-C_ #4E_.3ZG,_GB3R\GE=9WF8P1:>DYN"L4'V5=G/Q-U( &*OF M[S+_ ,X*_E7YC_//2OSPFU+5A?+K+:_K.C3R+<66H7L?IM:\>:\H8XY(^3(* MA]AMW5?0&H_D/^3.K>>XOS.U3\L_+VH>?H0 NMW%C%)=54 *Q+ @L !1B.0H M-]L5>LXJ[%78J[%78J[%4NO](TK56L'U33+74GTJZ2^LC=0I,;>ZC#!)X2ZM MPD4,:,*$5Q5,<5=BKL5=BKL5=BKL5=BKL5>+_FC^0/Y:_F_>:;J/F_3+M-3T MZ%[)KW2;VXTRYN].E8-+IU[+:O&T]J["K0N2M:TI4U5>P6EI:V%K;6-E;QVE ME91)!;P0J$CBBC4*B(HH J@ #%41BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL58IJ7D;R=K'F;0?.>J M^6=-U#S9Y8CFBTG5I[='N[-+@$2K#*064,">GB?'%65XJ[%78J[%78J[%78J M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J ;[%78J[%78J[%78J[%78J[%78J[%78J[%7__9 end XML 16 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover
6 Months Ended
Jun. 30, 2023
shares
Cover [Abstract]  
Document Type 10-Q/A
Amendment Flag false
Document Quarterly Report true
Document Transition Report false
Document Period End Date Jun. 30, 2023
Document Fiscal Period Focus Q2
Document Fiscal Year Focus 2023
Current Fiscal Year End Date --12-31
Entity File Number 333-168195
Entity Registrant Name FIRSTHAND TECHNOLOGY VALUE FUND, INC.
Entity Central Index Key 0001495584
Entity Tax Identification Number 27-3008946
Entity Incorporation, State or Country Code MD
Entity Address, Address Line One 150 Almaden Boulevard
Entity Address, Address Line Two Suite 1250
Entity Address, City or Town San Jose
Entity Address, State or Province CA
Entity Address, Postal Zip Code 95113
City Area Code (408)
Local Phone Number 886-7096
Entity Current Reporting Status Yes
Entity Interactive Data Current Yes
Entity Filer Category Non-accelerated Filer
Entity Small Business false
Entity Emerging Growth Company false
Entity Shell Company false
Entity Common Stock, Shares Outstanding 6,893,056
XML 17 R2.htm IDEA: XBRL DOCUMENT v3.23.2
Consolidated Statements of Assets and Liabilities (UNAUDITED) - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Investment securities:    
Unaffiliated investments at acquisition cost [1] $ 1,667,150 $ 1,772,422
Affiliated investments at acquisition cost 662,235 662,235
Controlled investments at acquisition cost 132,091,932 140,355,353
Total acquisition cost 134,421,317 142,790,010
Unaffiliated investments at market value [1] 667,150 772,422
Affiliated investments at market value 266,091 337,500
Controlled investments at market value 19,679,716 39,012,002
Total Market value (Note 6) [2] 20,612,957 40,121,924
Foreign currency at value (cost $2,629 and $3,235) 2,703 3,404
Receivable from dividends and interest 279,358 14,463
Other assets 47,203 64,066
Total Assets 20,942,221 40,203,857
LIABILITIES    
Payable to affiliates (Note 4) 9,586,630 9,188,187
Trustees’ fees payable 34,586 50,000
Consulting fee payable 46,000 46,000
Accrued expenses and other payables 175,949 310,079
Total Liabilities 9,843,165 9,594,266
NET ASSETS 11,099,056 30,609,591
Net Assets consist of:    
Common Stock, par value $0.001 per share 100,000,000 shares authorized 6,893 6,893
Paid-in-capital 176,770,722 176,770,722
Total distributable earnings (loss) (165,678,559) (146,168,024)
Shares of Common Stock outstanding $ 7,016,432 $ 7,016,432
Shares of Treasury Stock outstanding (123,376) (123,376)
Total Shares of Common Stock outstanding 6,893,056 6,893,056
Net asset value per share (Note 2) $ 1.61 $ 4.44
[1] Includes Fidelity Investment Money Market Treasury Portfolio - Class I, which invests primarily in U.S. Treasury securities. The yields as of 06/30/23 and 12/31/22 were 4.98% and 4.13%, respectively. Please see https://fundresearch.fidelity.com/mutual-funds/summary/316175504 for additional information.
[2] Includes warrants whose primary risk exposure is equity contracts.
XML 18 R3.htm IDEA: XBRL DOCUMENT v3.23.2
Consolidated Statements of Assets and Liabilities (UNAUDITED) (Parenthetical) - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Consolidated Statements Of Assets And Liabilities Unaudited    
Foreign currency cost $ 2,629 $ 3,235
Common stock, par value $ 0.001 $ 0.001
Common stock, shares authorized 100,000,000 100,000,000
XML 19 R4.htm IDEA: XBRL DOCUMENT v3.23.2
Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
INVESTMENT INCOME        
Unaffiliated interest $ (18,808) $ (45,718) $ 23,471 $ (10,480)
Affiliated/controlled interest 150,484 (3,767,193) 299,467 (1,866,141)
TOTAL INVESTMENT INCOME 131,676 (3,812,911) 322,938 (1,876,621)
EXPENSES        
Investment advisory fees (Note 4) 146,723 386,024 339,543 875,796
Administration fees 29,001 28,348 57,504 57,927
Custody fees 4,440 8,308 6,600 14,115
Transfer agent fees 12,633 2,420 20,511 12,397
Registration and filing fees 8,801 8,427 17,505 16,761
Professional fees 96,540 116,483 162,309 185,705
Printing fees 85,923 26,203 100,471 44,943
Trustees fees 3,336 50,000 22,086 100,000
Compliance fees 29,612 29,613 58,900 58,900
Miscellaneous fees 21,770 24,320 42,701 46,467
TOTAL GROSS EXPENSES 438,779 680,146 828,130 1,413,011
NET INVESTMENT INCOME/(LOSS) (307,103) (4,493,057) (505,192) (3,289,632)
Net realized gains (losses) from security transactions on:        
Affiliated/controlled 0 (5,113,635) (7,864,997) (4,929,722)
Foreign currency 16 (714) 16 1,946
Net realized gains (losses) 16 (5,114,349) (7,864,981) (4,927,776)
Net change in unrealized appreciation (depreciation) on:        
Non-affiliated investments 0 (87,762) 0 104,114
Affiliated/controlled investments and foreign currency (13,505,591) (27,284,454) (10,948,320) (36,322,228)
Affiliated/controlled warrants investments [1] (955,633) (628,865) (192,042) (522,907)
Net change in unrealized (depreciation) (14,461,224) (28,001,081) (11,140,362) (36,741,021)
Net Realized and Unrealized (Loss) on Investments (14,461,208) (33,115,430) (19,005,343) (41,668,797)
Net Decrease In Net Assets Resulting From Operations $ (14,768,311) $ (37,608,487) $ (19,510,535) $ (44,958,429)
Net Decrease In Net Assets Per Share Resulting From Operations [2] $ (2.14) $ (5.45) $ (2.83) $ (6.52)
[1] Primary exposure is equity risk.
[2] Per share results are calculated based on weighted average shares outstanding for each period.
XML 20 R5.htm IDEA: XBRL DOCUMENT v3.23.2
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
CASH FLOWS FROM OPERATING ACTIVITIES        
Net increase (decrease) in Net Assets resulting from operations $ (14,768,311) $ (37,608,487) $ (19,510,535) $ (44,958,429)
Adjustments to reconcile net increase (decrease) in Net Assets derived from operations to net cash provided by (used in) operating activities        
Purchases of investments (100,000) 0 (100,000) 0
Proceeds from disposition of investments 0 2,693,092 498,425 3,502,047
Net purchases/sales from short-term investments 387,743 (2,955,459) 105,273 (3,382,103)
Increase (decrease) in dividends, interest, and reclaims receivable (96,581) 3,827,456 (264,896) 2,003,270
Increase (decrease) in due to Custodian (10,000) (13,589) 0 (13,589)
Increase (decrease) in receivable in investment sold 0 339,624 0 0
Increase (decrease) in payable to affiliates 176,336 415,637 398,443 934,697
Increase (decrease) in other assets 25,426 25,852 16,863 17,619
Increase (decrease) in accrued expenses and other payables (76,387) 96,303 (149,544) 227,691
Net realized gain (loss) from investments 0 5,114,349 7,864,995 4,927,776
Net unrealized appreciation (depreciation) from investments, other assets, and warrants transactions 14,461,135 28,001,081 11,140,275 36,741,021
Net cash (used in) operating activities (639) (64,141) (701) 0
CASH FLOWS FROM FINANCING ACTIVITIES        
Net cash provided by financing activities 0 0 0 0
Net increase (decrease) in cash (639) 64,141 (701) 0
Cash and foreign currency - beginning of period 3,342 (64,141) 3,404 0
Cash and foreign currency - end of period $ 2,703 $ 0 $ 2,703 $ 0
XML 21 R6.htm IDEA: XBRL DOCUMENT v3.23.2
Consolidated Statements of Changes in Net Assets (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
FROM OPERATIONS:        
Net investment income (loss) $ (307,103) $ (4,493,057) $ (505,192) $ (3,289,632)
Net realized gain (loss) from security transactions and foreign currency 16 (5,114,349) (7,864,981) (4,927,776)
Net change in unrealized (depreciation) on investments, other assets, and warrants transactions (14,461,224) (28,001,081) (11,140,362) (36,741,021)
Net decrease in net assets from operations (14,768,311) (37,608,487) (19,510,535) (44,958,429)
TOTAL DECREASE IN NET ASSETS (14,768,311) (37,608,487) (19,510,535) (44,958,429)
NET ASSETS:        
Beginning of period 25,867,367 87,404,682 30,609,591 94,754,624
End of period $ 11,099,056 $ 49,796,195 $ 11,099,056 $ 49,796,195
COMMON STOCK ACTIVITY:        
Shares outstanding, beginning of period 6,893,056 6,893,056 6,893,056 6,893,056
Shares outstanding, end of period 6,893,056 6,893,056 6,893,056 6,893,056
XML 22 R7.htm IDEA: XBRL DOCUMENT v3.23.2
Consolidated Financial Highlights - USD ($)
$ in Millions
6 Months Ended 12 Months Ended
Jun. 30, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Fair Value Disclosures [Abstract]            
Net asset value at beginning of period $ 4.44 $ 13.75 $ 14.82 $ 17.70 $ 26.69 $ 23.83
Income from investment operations:            
Net investment income (loss), before deferred taxes (0.07) (1.81) 0.44 [1] 0.09 [1] 0.90 [1] (1.29) [1]
Deferred tax benefit (0.08) 0.07
Net investment gain (losses) (0.07) (1.81) 0.44 0.09 0.82 (1.22)
Net realized and unrealized gains (losses) on investments, before deferred taxes (2.76) (7.50) (1.51) (2.30) (12.15) 5.13
Deferred tax expense (1.13) 2.34 (1.23)
Net realized and unrealized gains (losses) on investments, after deferred taxes (2.76) (7.50) (1.51) (3.43) (9.81) 3.90
Total from investment operations (2.83) (9.31) (1.07) (3.34) (8.99) 2.68
Realized capital gains (0.03)
Anti-dilutive effect from capital share transactions 0.46 0.21
Net asset value at end of period 1.61 4.44 13.75 14.82 17.70 26.69
Market value at end of period $ 0.63 $ 0.95 $ 4.01 $ 4.47 $ 6.43 $ 11.20
Based on Net Asset Value (63.74%) [2] (67.71%) (7.22%) (16.27%) (33.68%) 12.39%
Based on Market Value (33.68%) [2] (76.31%) (10.29%) (30.48%) (42.59%) 25.43%
Net assets at end of period (millions) $ 11.1 $ 30.6 $ 94.8 $ 102.1 $ 127.1 $ 191.6
Ratio of total expenses to average net assets:            
Before tax (benefit)/expense 7.16% [3] 4.11% 3.12% 3.10% (2.84%) [4] 6.75% [4]
Deferred tax (benefit)/expense [5],[6] 8.02% [7] (9.91%) 4.43%
Total expenses 7.16% [3] 4.11% 3.12% 11.12% (12.75%) [4] 11.18% [4]
Total expenses, excluding incentive fees and deferred tax expense 7.16% [3] 4.11% 3.12% 3.10% 2.80% 2.77%
Before tax benefit (4.37%) [3] (20.96%) 2.94% 0.64% 3.93% [4] (4.93%) [4]
Deferred tax benefit [6],[8] (0.33%) 0.28%
Net investment income (loss) (4.37%) [3] (20.96%) 2.94% 0.64% 3.60% (4.65%)
Portfolio turnover rate 0.00% [2],[9] 15.00% 16.00% 13.00% 18.00% 44.00%
[1] Calculated using average shares outstanding.
[2] Not Annualized.
[3] Annualized.
[4] Amount includes the incentive fee. For the years ended December 31, 2019 and December 31, 2018, the ratio of the incentive fee to average net assets was (5.64)% and 3.98%, respectively.
[5] Deferred tax expense estimate is derived from net investment income (loss), and realized and unrealized gains (losses).
[6] The deferred tax expense and tax benefit are based on average net assets.
[7] As restated to reflect the removal of parenthetical notation to appropriately present ratio as deferred tax expense.
[8] Deferred tax benefit estimate for the ratio calculation is derived from net investment income (loss) only.
[9] Less than 1%
XML 23 R8.htm IDEA: XBRL DOCUMENT v3.23.2
Consolidated Schedule of Investments - USD ($)
6 Months Ended 12 Months Ended
Jun. 30, 2023
Dec. 31, 2022
Schedule of Investments [Line Items]    
VALUE $ 16,336,361 $ 35,929,006
TOTAL INVESTMENTS 20,612,957 40,121,924
LIABILITIES IN EXCESS OF OTHER ASSETS (9,513,901) (9,512,333)
Net assets $ 11,099,056 $ 30,609,591
Eqx Capital Inc [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Common Stock *(1)(2)(4) [1],[2],[3] Common Stock *(1)(2)(4) [4],[5],[6],[7]
ACQUISITION DATE 6/10/2016 6/10/2016
SHARES/PAR VALUE 100,000 100,000
COST BASIS $ 20,000 $ 20,000
VALUE $ 1,880 $ 11,130
Equipment Leasing [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Preferred Stock - Series A *(1)(2)(4) [1],[2],[3] Preferred Stock - Series A *(1)(2)(4) [4],[5],[6],[7]
ACQUISITION DATE 6/10/16-11/7/16 6/10/16-11/7/16
SHARES/PAR VALUE 1,950,000 1,950,000
COST BASIS $ 1,950,000 $ 1,950,000
VALUE 383,756 865,995
Eqx Capital Inc 1 [Member]    
Schedule of Investments [Line Items]    
VALUE $ 385,636 $ 877,125
Hera Systems Inc [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Convertible Note Matures December 2024 Interest Rate 10% (1)(2)(4) [1],[2],[3] Convertible Note Matures December 2024 Interest Rate 5% (1)(2)(4) [4],[5],[7]
ACQUISITION DATE 12/29/2022 12/29/2022
SHARES/PAR VALUE 5,359,791 1,200,000
COST BASIS $ 5,359,791 $ 1,200,000
VALUE $ 5,359,791 $ 1,200,000
Hera Systems Inc 1 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Convertible Note Matures December 2024 Interest Rate 5% (1)(2)(4) [1],[2],[3] Convertible Note Matures December 2022 Interest Rate 10% (1)(2)(4) [4],[5],[7]
ACQUISITION DATE 12/29/2022 12/29/2022
SHARES/PAR VALUE 1,200,000 5,359,791
COST BASIS $ 1,200,000 $ 5,359,791
VALUE $ 1,200,000 $ 5,359,791
Hera Systems Inc 2 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Preferred Stock - Series B *(1)(2)(4) [1],[2],[3] Preferred Stock - Series A *(1)(2)(4) [4],[5],[6],[7]
ACQUISITION DATE 8/7/17-2/1/19 9/18/2015
SHARES/PAR VALUE 7,039,203 3,642,324
COST BASIS $ 6,587,102 $ 2,000,000
VALUE $ 219,233 $ 4,735
Hera Systems Inc 3 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Preferred Stock - Series C *(1)(2)(4) [1],[2],[3] Preferred Stock - Series B *(1)(2)(4) [4],[5],[6],[7]
ACQUISITION DATE 8/7/19-2/12/20 8/7/17 - 2/1/19
SHARES/PAR VALUE 2,650,000 7,039,203
COST BASIS $ 2,650,000 $ 6,587,102
VALUE $ 82,533 $ 275,585
Hera Systems Inc 4 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Preferred Stock - Series A *(1)(2)(4) [1],[2],[3] Preferred Stock - Series C *(1)(2)(4) [4],[5],[6],[7]
ACQUISITION DATE 9/18/2015 8/7/19-2/12/20
SHARES/PAR VALUE 3,642,324 2,650,000
COST BASIS $ 2,000,000 $ 2,650,000
VALUE $ 2,566 $ 103,748
Hera Systems Inc 5 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Preferred Stock Warrants - Series B *(1)(2)(4) [1],[2],[3] Preferred Stock Warrants - Series B *(1)(2)(4) [4],[5],[6],[7]
ACQUISITION DATE 2/1/2019 7/9/18 - 9/4/18
SHARES/PAR VALUE 5,250,000 12,250,000
COST BASIS $ 0 $ 0
VALUE $ 163,082 $ 478,608
Hera Systems Inc 6 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Preferred Stock Warrants - Series B *(1)(2)(4) [1],[2],[3] Preferred Stock Warrants - Series B *(1)(2)(4) [4],[5],[6],[7]
ACQUISITION DATE 7/9/18-9/4/18 2/1/2019
SHARES/PAR VALUE 12,250,000 5,250,000
COST BASIS $ 0 $ 0
VALUE $ 380,524 $ 205,117
Hera Systems Inc 7 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Preferred Stock Warrants - Series B *(1)(2)(4) [1],[2],[3] Preferred Stock Warrants - Series B *(1)(2)(4) [4],[5],[6],[7]
ACQUISITION DATE 8/7/2017 8/7/2017
SHARES/PAR VALUE 6,214,922 6,214,922
COST BASIS $ 0 $ 0
VALUE $ 193,055 $ 242,817
Hera Systems Inc 8 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Preferred Stock Warrants - Series B *(1)(2)(4) [1],[2],[3] Preferred Stock Warrants - Series B *(1)(2)(4) [4],[5],[6],[7]
ACQUISITION DATE 9/28/2017 9/28/2017
SHARES/PAR VALUE 700,000 700,000
COST BASIS $ 0 $ 0
VALUE 21,744 27,349
Hera Systems Inc 9 [Member]    
Schedule of Investments [Line Items]    
VALUE $ 7,622,528 $ 7,897,750
Intraop Medical Corp [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Convertible Note Matures December 2023 Interest Rate 15% (1)(2)(4)(6) [1],[2],[3],[8] Convertible Note Matures December 2022 Interest Rate 15% (1)(2)(4)(6) [4],[5],[7],[9]
ACQUISITION DATE 10/11/2019 12/31/2018
SHARES/PAR VALUE 500,000 10,961,129
COST BASIS $ 500,000 $ 10,961,129
VALUE $ 90,539 $ 6,746,169
Intraop Medical Corp 1 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Convertible Note Matures December 2023 Interest Rate 15% (1)(2)(4)(6) [1],[2],[3],[8] Convertible Note Matures December 2022 Interest Rate 15% (1)(2)(4)(6) [4],[5],[7],[9]
ACQUISITION DATE 10/22/2021 7/12/2019
SHARES/PAR VALUE 1,000,000 1,300,000
COST BASIS $ 1,000,000 $ 1,300,000
VALUE $ 181,078 $ 800,102
Intraop Medical Corp 2 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Convertible Note Matures December 2023 Interest Rate 15% (1)(2)(4)(6) [1],[2],[3],[8] `Convertible Note Matures December 2022 Interest Rate 15% (1)(2)(4)(6) [4],[5],[7],[9]
ACQUISITION DATE 10/29/2019 10/11/2019
SHARES/PAR VALUE 500,000 500,000
COST BASIS $ 500,000 $ 500,000
VALUE $ 90,539 $ 307,731
Intraop Medical Corp 3 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Convertible Note Matures December 2023 Interest Rate 15% (1)(2)(4)(6) [1],[2],[3],[8] Convertible Note Matures December 2022 Interest Rate 15% (1)(2)(4)(6) [4],[5],[7],[9]
ACQUISITION DATE 10/6/2021 10/29/2019
SHARES/PAR VALUE 500,000 500,000
COST BASIS $ 500,000 $ 500,000
VALUE $ 90,539 $ 307,732
Intraop Medical Corp 4 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Convertible Note Matures December 2023 Interest Rate 15% (1)(2)(4)(6) [1],[2],[3],[8] Convertible Note Matures December 2022 Interest Rate 15% (1)(2)(4)(6) [4],[5],[7],[9]
ACQUISITION DATE 11/12/2021 2/27/2020
SHARES/PAR VALUE 500,000 1,000,000
COST BASIS $ 500,000 $ 1,000,000
VALUE $ 90,539 $ 615,463
Intraop Medical Corp 5 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Convertible Note Matures December 2023 Interest Rate 15% (1)(2)(4)(6) [1],[2],[3],[8] Convertible Note Matures December 2022 Interest Rate 15% (1)(2)(4)(6) [4],[5],[7],[9]
ACQUISITION DATE 11/29/2021 3/25/2020
SHARES/PAR VALUE 500,000 500,000
COST BASIS $ 500,000 $ 500,000
VALUE $ 90,539 $ 307,732
Intraop Medical Corp 6 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Convertible Note Matures December 2023 Interest Rate 15% (1)(2)(4)(6) [1],[2],[3],[8] Convertible Note Matures December 2022 Interest Rate 15% (1)(2)(4)(6) [4],[5],[7],[9]
ACQUISITION DATE 12/31/2018 5/8/2020
SHARES/PAR VALUE 10,961,129 400,000
COST BASIS $ 10,961,129 $ 400,000
VALUE $ 1,984,819 $ 246,185
Intraop Medical Corp 7 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Convertible Note Matures December 2023 Interest Rate 15% (1)(2)(4)(6) [1],[2],[3],[8] Convertible Note Matures December 2022 Interest Rate 15% (1)(2)(4)(6) [4],[5],[7],[9]
ACQUISITION DATE 2/27/2020 7/31/2020
SHARES/PAR VALUE 1,000,000 500,000
COST BASIS $ 1,000,000 $ 500,000
VALUE $ 181,078 $ 307,731
Intraop Medical Corp 8 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Convertible Note Matures December 2023 Interest Rate 15% (1)(2)(4)(6) [1],[2],[3],[8] Convertible Note Matures December 2022 Interest Rate 15% (1)(2)(4)(6) [4],[5],[7],[9]
ACQUISITION DATE 2/28/2022 8/28/2020
SHARES/PAR VALUE 200,000 750,000
COST BASIS $ 200,000 $ 750,000
VALUE $ 36,216 $ 461,597
Intraop Medical Corp 9 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Convertible Note Matures December 2023 Interest Rate 15% (1)(2)(4)(6) [1],[2],[3],[8] Convertible Note Matures December 2022 Interest Rate 15% (1)(2)(4)(6) [4],[5],[7],[9]
ACQUISITION DATE 3/25/2020 4/20/2021
SHARES/PAR VALUE 500,000 1,000,000
COST BASIS $ 500,000 $ 1,000,000
VALUE $ 90,539 $ 615,463
Intraop Medical Corp 10 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Convertible Note Matures December 2023 Interest Rate 15% (1)(2)(4)(6) [1],[2],[3],[8] Convertible Note Matures December 2022 Interest Rate 15% (1)(2)(4)(6) [4],[5],[7],[9]
ACQUISITION DATE 3/30/2022 6/10/2021
SHARES/PAR VALUE 150,000 500,000
COST BASIS $ 150,000 $ 500,000
VALUE $ 27,162 $ 307,732
Intraop Medical Corp 11 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Convertible Note Matures December 2023 Interest Rate 15% (1)(2)(4)(6) [1],[2],[3],[8] Convertible Note Matures December 2022 Interest Rate 15% (1)(2)(4)(6) [4],[5],[7],[9]
ACQUISITION DATE 4/20/2021 7/16/2021
SHARES/PAR VALUE 1,000,000 500,000
COST BASIS $ 1,000,000 $ 500,000
VALUE $ 181,078 $ 307,732
Intraop Medical Corp 12 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Convertible Note Matures December 2023 Interest Rate 15% (1)(2)(4)(6) [1],[2],[3],[8] Convertible Note Matures December 2022 Interest Rate 15% (1)(2)(4)(6) [4],[5],[7],[9]
ACQUISITION DATE 4/6/2022 9/22/2021
SHARES/PAR VALUE 350,000 500,000
COST BASIS $ 350,000 $ 500,000
VALUE $ 63,377 $ 307,731
Intraop Medical Corp 13 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Convertible Note Matures December 2023 Interest Rate 15% (1)(2)(4)(6) [1],[2],[3],[8] Convertible Note Matures December 2022 Interest Rate 15% (1)(2)(4)(6) [4],[5],[7],[9]
ACQUISITION DATE 5/8/2020 10/6/2021
SHARES/PAR VALUE 400,000 500,000
COST BASIS $ 400,000 $ 500,000
VALUE $ 72,431 $ 307,731
Intraop Medical Corp 14 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Convertible Note Matures December 2023 Interest Rate 15% (1)(2)(4)(6) [1],[2],[3],[8] Convertible Note Matures December 2022 Interest Rate 15% (1)(2)(4)(6) [4],[5],[7],[9]
ACQUISITION DATE 6/10/2021 10/22/2021
SHARES/PAR VALUE 500,000 1,000,000
COST BASIS $ 500,000 $ 1,000,000
VALUE $ 90,539 $ 615,463
Intraop Medical Corp 15 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Convertible Note Matures December 2023 Interest Rate 15% (1)(2)(4) [1],[2],[3] Convertible Note Matures December 2022 Interest Rate 15% (1)(2)(4)(6) [4],[5],[7],[9]
ACQUISITION DATE 6/10/2022 11/12/2021
SHARES/PAR VALUE 700,000 500,000
COST BASIS $ 700,000 $ 500,000
VALUE $ 126,755 $ 307,732
Intraop Medical Corp 16 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Convertible Note Matures December 2023 Interest Rate 15% (1)(2)(4)(6) [1],[2],[3],[8] Convertible Note Matures December 2022 Interest Rate 15% (1)(2)(4)(6) [4],[5],[7],[9]
ACQUISITION DATE 7/12/2019 11/29/2021
SHARES/PAR VALUE 1,300,000 500,000
COST BASIS $ 1,300,000 $ 500,000
VALUE $ 235,401 $ 307,732
Intraop Medical Corp 17 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Convertible Note Matures December 2023 Interest Rate 15% (1)(2)(4)(6) [1],[2],[3],[8] Convertible Note Matures December 2022 Interest Rate 15% (1)(2)(4)(6) [4],[5],[7],[9]
ACQUISITION DATE 7/16/2021 2/28/2022
SHARES/PAR VALUE 500,000 200,000
COST BASIS $ 500,000 $ 200,000
VALUE $ 90,539 $ 123,093
Intraop Medical Corp 18 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Convertible Note Matures December 2023 Interest Rate 15% (1)(2)(4)(6) [1],[2],[3],[8] Convertible Note Matures December 2022 Interest Rate 15% (1)(2)(4)(6) [4],[5],[7],[9]
ACQUISITION DATE 7/31/2020 3/30/2022
SHARES/PAR VALUE 500,000 150,000
COST BASIS $ 500,000 $ 150,000
VALUE $ 90,539 $ 92,319
Intraop Medical Corp 19 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Convertible Note Matures December 2023 Interest Rate 15% (1)(2)(4)(6) [1],[2],[3],[8] Convertible Note Matures December 2022 Interest Rate 15% (1)(2)(4)(6) [4],[5],[7],[9]
ACQUISITION DATE 8/28/2020 4/6/2022
SHARES/PAR VALUE 750,000 350,000
COST BASIS $ 750,000 $ 350,000
VALUE $ 135,809 $ 215,412
Intraop Medical Corp 20 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Convertible Note Matures December 2023 Interest Rate 15% (1)(2)(4)(6) [1],[2],[3],[8] Convertible Note Matures December 2022 Interest Rate 15% (1)(2)(4)(6) [4],[5],[7],[9]
ACQUISITION DATE 9/22/2021 6/10/2022
SHARES/PAR VALUE 500,000 700,000
COST BASIS $ 500,000 $ 700,000
VALUE $ 90,539 $ 430,824
Intraop Medical Corp 21 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Preferred Stock - Series C *(1)(2)(4) [1],[2],[3] Preferred Stock - Series C *(1)(2)(4) [4],[5],[6],[7]
ACQUISITION DATE 7/12/2013 7/12/2013
SHARES/PAR VALUE 26,856,187 26,856,187
COST BASIS $ 26,299,939 $ 26,299,938
VALUE $ 0 $ 0
Intraop Medical Corp 22 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Term Note Matures December 2023 Interest Rate 8% (1)(2)(4) [1],[2],[3] Term Note Matures December 2022 Interest Rate 8% (1)(2)(4)(6) [4],[5],[7],[9]
ACQUISITION DATE 2/10/2017 2/28/2014
SHARES/PAR VALUE 2,000,000 3,000,000
COST BASIS $ 2,000,000 $ 3,000,000
VALUE $ 362,156 $ 1,846,389
Intraop Medical Corp 23 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Term Note Matures December 2023 Interest Rate 8% (1)(2)(4) [1],[2],[3] Term Note Matures December 2022 Interest Rate 8% (1)(2)(4)(6) [4],[5],[7],[9]
ACQUISITION DATE 2/28/2014 2/10/2017
SHARES/PAR VALUE 3,000,000 2,000,000
COST BASIS $ 3,000,000 $ 2,000,000
VALUE 543,234 1,230,926
Intraop Medical Corp 24 [Member]    
Schedule of Investments [Line Items]    
VALUE $ 5,035,984 $ 17,116,721
Kyma Inc [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Convertible Note Matures March 2024 Interest Rate 10% (1)(4) [2],[3] Convertible Note Matures March 2023 Interest Rate 10% (1)(4) [5],[7]
ACQUISITION DATE 3/11/2019 3/11/2019
SHARES/PAR VALUE 100,000 100,000
COST BASIS $ 100,000 $ 100,000
VALUE $ 100,000 $ 100,000
Lyncean Technologies Inc [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Preferred Stock - Series B *(1)(4) [2],[3] Preferred Stock - Series B *(1)(4) [5],[6],[7]
ACQUISITION DATE 7/3/2018 7/3/2018
SHARES/PAR VALUE 869,792 869,792
COST BASIS $ 1,000,000 $ 1,000,000
VALUE $ 0 $ 0
Revasum Inc [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT CDIs *(2) [1] CDIs *(2) [4],[6]
ACQUISITION DATE 11/14/16-10/3/22 11/14/16 - 10/3/22
SHARES/PAR VALUE 39,774,889 39,774,889
COST BASIS $ 9,268,218 $ 9,268,219
VALUE $ 3,709,446 $ 3,520,496
Uct Coatings Inc [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Common Stock *(1)(3)(4) [2],[3],[10] Common Stock *(1)(3)(4) [5],[6],[7],[11]
ACQUISITION DATE 4/18/2011 4/18/2011
SHARES/PAR VALUE 1,500,000 1,500,000
COST BASIS $ 662,235 $ 662,235
VALUE $ 266,091 $ 337,500
Wright Speed Inc [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Common Stock *(1)(2)(4) [1],[2],[3] Common Stock *(1)(2)(4) [4],[5],[6],[7]
ACQUISITION DATE 6/7/2019 4/11/2013 - 5/6/2019
SHARES/PAR VALUE 69,102 69,102
COST BASIS $ 7,460,851 $ 7,460,851
VALUE $ 311 $ 546
Wright Speed Inc 1 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6) [1],[2],[3],[8] Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6) [4],[5],[7],[9]
ACQUISITION DATE 1/10/2023 6/7/2019
SHARES/PAR VALUE 100,000 4,929,015
COST BASIS $ 100,000 $ 4,929,015
VALUE $ 9,750 $ 1,601,930
Wright Speed Inc 2 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6) [1],[2],[3],[8] Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6) [4],[5],[7],[9]
ACQUISITION DATE 10/13/2020 8/12/2020
SHARES/PAR VALUE 1,050,000 750,000
COST BASIS $ 1,050,000 $ 750,000
VALUE $ 102,375 $ 243,750
Wright Speed Inc 3 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6) [1],[2],[3],[8] Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6) [4],[5],[7],[9]
ACQUISITION DATE 10/20/2021 9/10/2020
SHARES/PAR VALUE 1,000,000 900,000
COST BASIS $ 1,000,000 $ 900,000
VALUE $ 97,500 $ 292,500
Wright Speed Inc 4 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6) [1],[2],[3],[8] Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6) [4],[5],[7],[9]
ACQUISITION DATE 10/21/2022 10/13/2020
SHARES/PAR VALUE 135,000 1,050,000
COST BASIS $ 135,000 $ 1,050,000
VALUE $ 13,162 $ 341,250
Wright Speed Inc 5 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6) [1],[2],[3],[8] Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6) [4],[5],[7],[9]
ACQUISITION DATE 10/5/2021 11/11/2020
SHARES/PAR VALUE 700,000 400,000
COST BASIS $ 700,000 $ 400,000
VALUE $ 68,250 $ 130,000
Wright Speed Inc 6 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6) [1],[2],[3],[8] Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6) [4],[5],[7],[9]
ACQUISITION DATE 11/11/2020 11/24/2020
SHARES/PAR VALUE 400,000 375,000
COST BASIS $ 400,000 $ 375,000
VALUE $ 39,000 $ 121,875
Wright Speed Inc 7 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6) [1],[2],[3],[8] Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6) [4],[5],[7],[9]
ACQUISITION DATE 11/14/2022 12/11/2020
SHARES/PAR VALUE 165,000 400,000
COST BASIS $ 165,000 $ 400,000
VALUE $ 16,088 $ 130,000
Wright Speed Inc 8 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6) [1],[2],[3],[8] Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6) [4],[5],[7],[9]
ACQUISITION DATE 11/23/2021 12/23/2020
SHARES/PAR VALUE 1,000,000 2,000,000
COST BASIS $ 1,000,000 $ 2,000,000
VALUE $ 97,500 $ 650,000
Wright Speed Inc 9 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6) [1],[2],[3],[8] Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6) [4],[5],[7],[9]
ACQUISITION DATE 11/24/2020 2/23/2021
SHARES/PAR VALUE 375,000 1,400,000
COST BASIS $ 375,000 $ 1,400,000
VALUE $ 36,562 $ 455,000
Wright Speed Inc 10 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6) [1],[2],[3],[8] Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6) [4],[5],[7],[9]
ACQUISITION DATE 12/11/2020 4/12/2021
SHARES/PAR VALUE 400,000 1,200,000
COST BASIS $ 400,000 $ 1,200,000
VALUE $ 39,000 $ 390,000
Wright Speed Inc 11 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6) [1],[2],[3],[8] Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6) [4],[5],[7],[9]
ACQUISITION DATE 12/23/2020 5/18/2021
SHARES/PAR VALUE 2,000,000 1,000,000
COST BASIS $ 2,000,000 $ 1,000,000
VALUE $ 195,000 $ 325,000
Wright Speed Inc 12 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6) [1],[2],[3],[8] Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6) [4],[5],[7],[9]
ACQUISITION DATE 12/28/2021 6/22/2021
SHARES/PAR VALUE 1,000,000 1,000,000
COST BASIS $ 1,000,000 $ 1,000,000
VALUE $ 97,500 $ 325,000
Wright Speed Inc 13 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6) [1],[2],[3],[8] Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6) [4],[5],[7],[9]
ACQUISITION DATE 12/9/2022 7/26/2021
SHARES/PAR VALUE 125,000 1,000,000
COST BASIS $ 125,000 $ 1,000,000
VALUE $ 12,188 $ 325,000
Wright Speed Inc 14 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6) [1],[2],[3],[8] Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6) [4],[5],[7],[9]
ACQUISITION DATE 2/23/2021 8/19/2021
SHARES/PAR VALUE 1,400,000 1,000,000
COST BASIS $ 1,400,000 $ 1,000,000
VALUE $ 136,500 $ 325,000
Wright Speed Inc 15 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6) [1],[2],[3],[8] Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6) [4],[5],[7],[9]
ACQUISITION DATE 2/23/2022 9/22/2021
SHARES/PAR VALUE 200,000 300,000
COST BASIS $ 200,000 $ 300,000
VALUE $ 19,500 $ 97,500
Wright Speed Inc 16 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6) [1],[2],[3],[8] Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6) [4],[5],[7],[9]
ACQUISITION DATE 3/11/2022 10/5/2021
SHARES/PAR VALUE 185,000 700,000
COST BASIS $ 185,000 $ 700,000
VALUE $ 18,037 $ 227,500
Wright Speed Inc 17 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6) [1],[2],[3],[8] Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6) [4],[5],[7],[9]
ACQUISITION DATE 4/12/2021 10/20/2021
SHARES/PAR VALUE 1,200,000 1,000,000
COST BASIS $ 1,200,000 $ 1,000,000
VALUE $ 117,000 $ 325,000
Wright Speed Inc 18 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6) [1],[2],[3],[8] Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6) [4],[5],[7],[9]
ACQUISITION DATE 4/14/2022 11/23/2021
SHARES/PAR VALUE 65,000 1,000,000
COST BASIS $ 65,000 $ 1,000,000
VALUE $ 6,337 $ 325,000
Wright Speed Inc 19 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6) [1],[2],[3],[8] Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6) [4],[5],[7],[9]
ACQUISITION DATE 5/10/2022 12/28/2021
SHARES/PAR VALUE 250,000 1,000,000
COST BASIS $ 250,000 $ 1,000,000
VALUE $ 24,375 $ 325,000
Wright Speed Inc 20 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6) [1],[2],[3],[8] Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6) [4],[5],[7],[9]
ACQUISITION DATE 5/18/2021 2/23/2022
SHARES/PAR VALUE 1,000,000 200,000
COST BASIS $ 1,000,000 $ 200,000
VALUE $ 97,500 $ 65,000
Wright Speed Inc 21 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6) [1],[2],[3],[8] Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6) [4],[5],[7],[9]
ACQUISITION DATE 5/26/2022 3/11/2022
SHARES/PAR VALUE 250,000 185,000
COST BASIS $ 250,000 $ 185,000
VALUE $ 24,375 $ 60,125
Wright Speed Inc 22 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6) [1],[2],[3],[8] Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6) [4],[5],[7],[9]
ACQUISITION DATE 6/10/2022 4/14/2022
SHARES/PAR VALUE 250,000 65,000
COST BASIS $ 250,000 $ 65,000
VALUE $ 24,375 $ 21,125
Wright Speed Inc 23 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6) [1],[2],[3],[8] Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6) [4],[5],[7],[9]
ACQUISITION DATE 6/22/2021 5/10/2022
SHARES/PAR VALUE 1,000,000 250,000
COST BASIS $ 1,000,000 $ 250,000
VALUE $ 97,500 $ 81,250
Wright Speed Inc 24 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6) [1],[2],[3],[8] Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6) [4],[5],[7],[9]
ACQUISITION DATE 6/28/2022 5/26/2022
SHARES/PAR VALUE 250,000 250,000
COST BASIS $ 250,000 $ 250,000
VALUE $ 24,375 $ 81,250
Wright Speed Inc 25 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6) [1],[2],[3],[8] Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6) [4],[5],[7],[9]
ACQUISITION DATE 6/7/2019 6/10/2022
SHARES/PAR VALUE 4,929,015 250,000
COST BASIS $ 4,929,015 $ 250,000
VALUE $ 480,579 $ 81,250
Wright Speed Inc 26 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6) [1],[2],[3],[8] Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6) [4],[5],[7],[9]
ACQUISITION DATE 7/13/2022 6/28/2022
SHARES/PAR VALUE 250,000 250,000
COST BASIS $ 250,000 $ 250,000
VALUE $ 24,375 $ 81,250
Wright Speed Inc 27 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6) [1],[2],[3],[8] Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6) [4],[5],[7],[9]
ACQUISITION DATE 7/26/2021 7/13/2022
SHARES/PAR VALUE 1,000,000 250,000
COST BASIS $ 1,000,000 $ 250,000
VALUE $ 97,500 $ 81,250
Wright Speed Inc 28 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6) [1],[2],[3],[8] Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6) [4],[5],[7],[9]
ACQUISITION DATE 7/28/2022 7/28/2022
SHARES/PAR VALUE 250,000 250,000
COST BASIS $ 250,000 $ 250,000
VALUE $ 24,375 $ 81,250
Wright Speed Inc 29 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6) [1],[2],[3],[8] Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6) [4],[5],[7],[9]
ACQUISITION DATE 8/12/2020 8/12/2022
SHARES/PAR VALUE 750,000 250,000
COST BASIS $ 750,000 $ 250,000
VALUE $ 73,125 $ 81,250
Wright Speed Inc 30 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6) [1],[2],[3],[8] Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6) [4],[5],[7],[9]
ACQUISITION DATE 8/12/2022 10/21/2022
SHARES/PAR VALUE 250,000 135,000
COST BASIS $ 250,000 $ 135,000
VALUE $ 24,375 $ 43,875
Wright Speed Inc 31 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6) [1],[2],[3],[8] Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6) [4],[5],[7],[9]
ACQUISITION DATE 8/19/2021 11/14/2022
SHARES/PAR VALUE 1,000,000 165,000
COST BASIS $ 1,000,000 $ 165,000
VALUE $ 97,500 $ 53,625
Wright Speed Inc 32 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6) [1],[2],[3],[8] Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6) [4],[5],[7],[9]
ACQUISITION DATE 9/10/2020 12/9/2022
SHARES/PAR VALUE 900,000 125,000
COST BASIS $ 900,000 $ 125,000
VALUE $ 87,750 $ 40,625
Wright Speed Inc 33 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6) [1],[2],[3],[8] Preferred Stock - Series AA *(1)(2)(4) [4],[5],[6],[7]
ACQUISITION DATE 9/22/2021 6/7/19 - 7/20/20
SHARES/PAR VALUE 300,000 60,733,693
COST BASIS $ 300,000 $ 17,355,887
VALUE $ 29,250 $ 1,049,478
Wright Speed Inc 34 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Preferred Stock - Series AA *(1)(2)(4) [1],[2],[3] Preferred Stock Warrants - Series AA *(1)(2)(4) [4],[5],[6],[7]
ACQUISITION DATE 6/7/19-7/20/20 6/7/2019
SHARES/PAR VALUE 60,733,693 609,756
COST BASIS $ 17,355,887 $ 0
VALUE 573,233 3,232
Wright Speed Inc 36 [Member]    
Schedule of Investments [Line Items]    
VALUE $ 2,926,122 $ 8,862,686
Investment Company [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT Fidelity Investments Money Market Treasury Portfolio - Class I (5) [12] Fidelity Investments Money Market Treasury Portfolio - Class I (5) [13]
ACQUISITION DATE Various Various
SHARES/PAR VALUE 567,150 672,422
COST BASIS $ 567,150 $ 672,422
VALUE $ 567,150 $ 672,422
Silicon Genesis Corp [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT [4],[5],[6],[7]   Preferred Stock - Series 1-E *(1)(2)(4)
ACQUISITION DATE   4/18/2011
SHARES/PAR VALUE   5,704,480
COST BASIS   $ 2,372,403
VALUE   $ 320,592
Silicon Genesis Corp 1 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT [4],[5],[6],[7]   Preferred Stock - Series 1-C *(1)(2)(4)
ACQUISITION DATE   4/18/2011
SHARES/PAR VALUE   82,914
COST BASIS   $ 109,518
VALUE   $ 962
Silicon Genesis Corp 2 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT [4],[5],[6],[7]   Preferred Stock - Series 1-D *(1)(2)(4)
ACQUISITION DATE   4/18/2011
SHARES/PAR VALUE   850,830
COST BASIS   $ 431,901
VALUE   $ 2,552
Silicon Genesis Corp 3 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT [4],[5],[6],[7]   Common Stock *(1)(2)(4)
ACQUISITION DATE   4/18/2011
SHARES/PAR VALUE   921,892
COST BASIS   $ 169,045
VALUE   $ 111
Silicon Genesis Corp 4 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT [4],[5],[6],[7]   Common Stock Warrants *(1)(2)(4)
ACQUISITION DATE   4/18/2011
SHARES/PAR VALUE   37,982
COST BASIS   $ 6,678
VALUE   $ 1
Silicon Genesis Corp 5 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT [4],[5],[6],[7]   Preferred Stock - Series 1-F *(1)(2)(4)
ACQUISITION DATE   4/18/2011
SHARES/PAR VALUE   912,453
COST BASIS   $ 456,389
VALUE   $ 70,806
Silicon Genesis Corp 6 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT [4],[5],[6],[7]   Preferred Stock - Series 1-G *(1)(2)(4)
ACQUISITION DATE   3/10/2016
SHARES/PAR VALUE   48,370,793
COST BASIS   $ 3,880,592
VALUE   $ 306,671
Silicon Genesis Corp 7 [Member]    
Schedule of Investments [Line Items]    
TYPE OF INVESTMENT [4],[5],[6],[7]   Preferred Stock - Series 1-H *(1)(2)(4)
ACQUISITION DATE   3/10/2016
SHARES/PAR VALUE   837,942
COST BASIS   $ 936,895
VALUE   35,529
Silicon Genesis Corp 8 [Member]    
Schedule of Investments [Line Items]    
VALUE   $ 737,224
[1] Controlled investments.
[2] Fair Value Level 3 security (147.2% of net assets).
[3]

Restricted security. Fair Value is determined by or under the direction of the Company's Board of Directors (see Note 3). At June 30, 2023, we held $16,336,361 (or 147.2% of net assets) in restricted securities (see Note 2).

[4] Controlled investments.
[5] Fair Value Level 3 security.
[6] Non-income producing security.
[7] Restricted security. Fair Value is determined by or under the direction of the Company's Board of Directors (See note 3). At December 31, 2022, we held $35,929,006 (or 117.3% of net assets) in restricted securities (see Note 2).
[8] Security whose interest accrues until maturity however, based on June 30, 2023 valuation no such interest accrued during period ended June 30, 2023.
[9] Security whose interest accrues over the life of the Note and is not payable until maturity. An interest adjustment was made during the year ending December 31, 2022 of approximately $21,400,000.
[10] Affiliated issuer.
[11] Affiliated issuer.
[12] The Fidelity Investments Money Market Treasury Portfolio invests primarily in U.S. Treasury securities.
[13] The Fidelity Investments Money Market Treasury Portfolio invests primarily in U.S. Treasury securities.
XML 24 R9.htm IDEA: XBRL DOCUMENT v3.23.2
THE COMPANY
6 Months Ended
Jun. 30, 2023
Investment Company [Abstract]  
THE COMPANY

NOTE 1. THE COMPANY

 

Firsthand Technology Value Fund, Inc. (the “Company,” the “Fund,” “us,” “our,” and “we”), is a Maryland corporation and an externally managed, non-diversified, closed-end management investment company that has elected to be treated as a business development company (“BDC”) under the Investment Company Act of 1940, as amended (the “1940 Act”). The Company acquired its initial portfolio of securities through the reorganization of Firsthand Technology Value Fund, a series of Firsthand Funds, into the Company. The reorganization was completed on April 15, 2011. The Company commenced operations on April 18th, 2011. Under normal circumstances, the Company will invest at least 80% of its assets for investment purposes in technology companies, which are considered to be those companies that derive at least 50% of their revenues from products and/ or services within the information technology sector or the “cleantech” sector. Information technology companies include, but are not limited to, those focused on computer hardware, software, telecommunications, networking, Internet, and consumer electronics. While there is no standard definition of cleantech, it is generally regarded as including goods and services designed to harness renewable energy and materials, eliminate emissions and waste, and reduce the use of natural resources. In addition, under normal circumstances we will invest at least 70% of our assets in privately held companies and in public companies with market capitalizations less than $250 million. Our portfolio is primarily composed of equity and equity derivative securities of technology and cleantech companies (as defined above). These investments generally range between $1 million and $10 million each, although the investment size will vary proportionately with the size of the Company’s capital base. The Company’s shares are listed on the NASDAQ Global Market under the symbol “SVVC.” Firsthand Capital Management, Inc., which was previously known as SiVest Group, Inc. (“FCM” or the “Advisor”), serves as the investment adviser to the Company.

 

The Company is an investment company and follows accounting and reporting guidance in the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification Topic 946.

 

CONSOLIDATION OF SUBSIDIARIES. On May 8, 2015, the Board of Directors of the Company approved the formation of a fully owned and controlled subsidiary (as defined by the 1940 Act) of the Company named Firsthand Venture Investors (“FVI”), a California general partnership formed on March 30, 2015. After the close of business on June 30, 2015, the Company contributed substantially all of its assets to FVI in return for a controlling general partner ownership interest in FVI. The transaction was completed on July 1, 2015. Under this structure, we have all or substantially all of our investment activities conducted through our fully owned subsidiary, FVI.

 

During the fiscal years ended December 31, 2016 and 2017, with the approval of its Board of Directors, the Company organized three separate fully owned and controlled subsidiaries (as defined by the 1940 Act). Each subsidiary was a Cayman Islands corporation and the financial statements of each subsidiary were reported on a consolidated basis with the Company. Each subsidiary was formed for the purpose of holding one or more investments made by the Company, and was treated as a controlled foreign corporation under the Internal Revenue Code not separately subject to U.S. federal income tax. FVI was treated as the sole U.S. shareholder of each subsidiary.

 

The Board of Directors of the Company approved the liquidation of those three Cayman subsidiaries on November 2, 2018. That liquidation was completed on December 27, 2018.

 

XML 25 R10.htm IDEA: XBRL DOCUMENT v3.23.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
6 Months Ended
Jun. 30, 2023
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

The following is a summary of significant accounting policies followed in the preparation of the Company’s financial statements included in this report:

 

BASIS OF PRESENTATION. The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) pursuant to the requirements on Form 10-K. ASC 946, Financial Services—Investment Companies (“ASC 946”), and Articles 6, 10 and 12 of Regulation S-X. In the opinion of management, all adjustments, which are of a normal recurring nature, considered necessary for the fair presentation of the financial statements for the periods presented, have been included.

 

Under the 1940 Act, ASC 946, and the regulations pursuant to Article 6 of Regulation S-X, we are precluded from consolidating any entity other than another investment company or an operating company which provides substantially all of its services to benefit us. Consequentially, as of December 31, 2018, the Company consolidated some special purpose entities. These special purpose entities only hold investments of the Company and have no other significant asset and liabilities. All significant intercompany transactions and balances have been eliminated in consolidation.

 

USE OF ESTIMATES. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ from those estimates.

 

PORTFOLIO INVESTMENT VALUATIONS. Investments are stated at “value” as defined in the 1940 Act and in the applicable regulations of the Securities and Exchange Commission and in accordance with GAAP. Value, as defined in Section 2(a)(41) of the 1940 Act, is (i) the market value of those securities for which a market quotation is readily available and (ii) the fair value as determined in good faith by the Advisor as the valuation designee appointed by the Board of Directors, and subject to oversight by the Board of Directors. On June 30, 2023, our financial statements include venture capital investments valued at approximately 16.3 million. The fair values of our venture capital investments were also determined by the Advisor as the valuation designee. Upon sale of these investments, the values that are ultimately realized may be different from what is presently estimated. The difference could be material. Also see note 6 regarding the fair value of the company’s investments.

 

CASH AND CASH EQUIVALENTS. The Company considers liquid assets deposited with a bank, investments in money market funds, and certain short-term debt instruments with maturities of three months or less to be cash equivalents. These investments represent amounts held with financial institutions that are readily accessible to pay our expenses or purchase investments. Cash and cash equivalents are valued at cost plus accrued interest, which approximates market value.

 

RESTRICTED SECURITIES. At June 30, 2023, we held $16,336,361 in restricted securities. At December 31, 2022, we held $35,929,006. in restricted securities.

 

INCOME RECOGNITION. Dividend income is recorded on the ex-dividend date. Interest income is accrued as earned. Discounts and premiums on securities purchased are amortized over the lives of the respective securities. Other non-cash dividends are recognized as investment income at the fair value of the property received. When debt securities are determined to be non-income producing, the Company ceases accruing interest and writes off any previously accrued interest. These write-offs are recorded as an adjustment to interest income.

 

SHARE VALUATION. The net asset value (“NAV”) per share of the Fund is calculated by dividing the sum of the value of the securities held by the Fund, plus cash or other assets, minus all liabilities (including estimated accrued expenses) by the total number of shares outstanding of the Fund, rounded to the nearest cent.

 

REALIZED GAIN OR LOSS AND UNREALIZED APPRECIATION OR DEPRECIATION OF PORTFOLIO INVESTMENTS. A realized gain or loss is recognized when an investment is disposed of and is computed as the difference between the Company’s cost basis in the investment at the disposition date and the net proceeds received from such disposition. Realized gains and losses are calculated on a specific identification basis. Unrealized appreciation or depreciation is computed as the difference between the fair value of the investment and the cost basis of such investment.

 

INCOME TAXES. The Company provides for state and federal corporate income tax, as appropriate, because it is regarded as a corporation under Subchapter C of the Code. The Company recognizes interest and penalties in income tax expense.

 

FOREIGN CURRENCY TRANSLATION. The accounting records of the Company are maintained in U.S. dollars. All assets and liabilities denominated in foreign currencies are translated into U.S. dollars based on the foreign exchange rate on the date of valuation. The Company does not isolate that portion of the results of operation resulting from changes in foreign exchange rates on investments from the fluctuations arising from changes in market prices of securities held. The Company’s investments in foreign securities may involve certain risks, including without limitation: foreign exchange restrictions, expropriation, taxation or other political, social, or economic risks, all of which could affect the market and/or credit risk of the investment. In addition, changes in the relationship of foreign currencies to the U.S. dollar can significantly affect the value of these investments and therefore the earnings of the Company.

 

SECURITIES TRANSACTIONS. Securities transactions are accounted for on the date the transaction for the purchase or sale of the securities is entered into by the Company (i.e., trade date).

 

CONCENTRATION OF CREDIT RISK. The Company places its cash and cash equivalents with financial institutions and, at times, cash held in checking accounts may exceed the Federal Deposit Insurance Corporation insured limit.

 

OPTIONS. The Company is subject to equity price risk in the normal course of pursuing its investment objectives and may enter into options written to hedge against changes in the value of equities. The Company may purchase put and call options to attempt to provide protection against adverse price effects from anticipated changes in prevailing prices of securities or stock indices. The Company may also write put and call options. When the Company writes an option, an amount equal to the premium received by the Company is recorded as a liability and is subsequently adjusted to the current fair value of the option written.

 

Premiums received from writing options that expire unexercised are treated by the Company on the expiration date as realized gains from investments. The difference between the premium and the amount paid on effecting a closing purchase transaction, including brokerage commissions, is also treated as a realized gain, or, if the premium is less than the amount paid for the closing purchase transaction, as a realized loss. If a call option is exercised, the premium is added to the proceeds from the sale of the underlying security or currency in determining whether the Company has realized a gain or loss. The Company as writer of an option bears the market risk of an unfavorable change in the price of the security underlying the written option.

 

The average monthly volume of the Company’s derivatives during the six months ended June 30, 2023 is as follows:

 

     
 

PURCHASED OPTIONS
(CONTRACTS)

WARRANTS (NOTIONAL
VALUE)

WRITTEN OPTIONS
(CONTRACTS)

Firsthand Technology Value Fund, Inc.

1,252,639

 

XML 26 R11.htm IDEA: XBRL DOCUMENT v3.23.2
BUSINESS RISKS AND UNCERTAINTIES
6 Months Ended
Jun. 30, 2023
Business Risks And Uncertainties  
BUSINESS RISKS AND UNCERTAINTIES

NOTE 3. BUSINESS RISKS AND UNCERTAINTIES

 

We invest a substantial portion of our assets in privately-held companies, the securities of which are inherently illiquid. We also seek to invest in small publicly-traded companies that we believe have exceptional growth potential and to make opportunistic investments in publicly-traded companies, both large and small. In the case of investments in small publicly-traded companies, although these companies are publicly traded, their stock may not trade at high volumes, and prices can be volatile, which may restrict our ability to sell our positions. We may also be subject to contractual restrictions or securities law limits on our ability to sell portfolio holdings because of, for example, our affiliation with a portfolio company or the relative size of our holding in a company. These privately held and publicly traded businesses tend to lack management depth, have limited or no history of operations and typically have not attained profitability. Because of the speculative nature of our investments and the lack of public markets for privately held investments, there is greater risk of loss than is the case with traditional investment securities.

 

We do not choose investments based on a strategy of diversification. We also do not rebalance the portfolio should one of our portfolio companies increase in value substantially relative to the rest of the portfolio. Therefore, the value of our portfolio may be more vulnerable to events affecting a single sector, industry or portfolio company and, therefore, may be subject to greater volatility than a company that follows a diversification strategy.

 

Because there is typically no public or readily-ascertainable market for our interests in the small privately-held companies in which we invest, the valuation of those securities is determined in good faith by the Valuation Committee, comprised of all members of the Board who are not “interested persons” of the Company, as such term is defined in Section 2(a)(19) of the 1940 Act, in accordance with our Valuation Procedures and is subject to significant estimates and judgments. The determined value of the securities in our portfolio may differ significantly from the values that would be placed on these securities if a ready market for the securities existed. Any changes in valuation are recorded in our Statement of Operations as “Net increase (decrease) in unrealized appreciation on investments.” Changes in valuation of any of our investments in privately-held companies from one period to another may be volatile.

 

The Board has engaged an independent valuation firm to provide it with valuation assistance with respect to certain of our portfolio investments. The Company intends to continue to engage an independent valuation firm to provide us with assistance regarding our determination of the fair value of select portfolio investments each quarter unless directed by the Board to cancel such valuation services. The scope of the services rendered by an independent valuation firm is at the discretion of the Board. The Board is ultimately and solely responsible for determining the fair value of the Company’s investments in good faith.

 

With respect to investments for which market quotations are not readily available or when such market quotations are deemed not to represent fair value, the Board has approved a multi-step valuation process to be followed each quarter, as described below:

 

 

(1)

each quarter the valuation process begins with each portfolio company or investment being initially valued by the Advisor’s Valuation Committee or the independent valuation firm;

 

 

(2)

the Valuation Committee of the Board on a quarterly basis reviews the preliminary valuation of the Advisor’s Valuation Committee and that of the independent valuation firms and makes the fair value determination, in good faith, based on the valuation recommendations of the Advisor’s Valuation Committee and the independent valuation firms; and

 

 

(3)

at each quarterly Board meeting, the Board considers the valuations recommended by the Advisor’s Valuation Committee and the independent valuation firms that were previously submitted to the Valuation Committee of the Board and ratifies the fair value determinations made by the Valuation Committee of the Board.

 

XML 27 R12.htm IDEA: XBRL DOCUMENT v3.23.2
INVESTMENT MANAGEMENT FEE
6 Months Ended
Jun. 30, 2023
Investment Management Fee  
INVESTMENT MANAGEMENT FEE

NOTE 4. INVESTMENT MANAGEMENT FEE

 

The Company has entered into an investment management agreement (the “Investment Management Agreement”) with FCM pursuant to which the Company will pay FCM a fee for providing investment management services consisting of two components—a base management fee and an incentive fee.

 

The base management fee will be calculated at an annual rate of 2.00% of our gross assets. For services rendered under the Investment Management Agreement, the base management fee will be payable quarterly in arrears. The base management fee will be calculated based on the average of (1) the value of our gross assets at the end of the current calendar quarter and (2) the value of the Company’s gross assets at the end of the preceding calendar quarter; and will be appropriately adjusted for any share issuances or repurchases during the current calendar quarter. Base management fees for any partial month or quarter will be pro-rated.

 

The incentive fee is determined and payable in arrears as of the end of each calendar year (or upon termination of the Investment Management Agreement, as of the termination date), commencing on April 15, 2011, and equals 20% of the Company’s realized capital gains, if any, on a cumulative basis from inception through the end of each calendar year, computed net of all realized capital losses and unrealized capital depreciation on a cumulative basis, less the aggregate amount of any previously paid incentive fees, provided that the incentive fee determined as of December 31, 2022, will be calculated for a period of shorter than twelve calendar months to take into account any realized gains computed net of all realized capital losses and unrealized capital depreciation from inception. For the six months ended June 30, 2023, there were no incentive fee adjustments.

 

XML 28 R13.htm IDEA: XBRL DOCUMENT v3.23.2
DEBT
6 Months Ended
Jun. 30, 2023
Debt Disclosure [Abstract]  
DEBT

NOTE 5. DEBT

 

The Company currently has no plan to use leverage and does not have any significant outstanding debt obligations (other than normal operating expense accruals).

 

XML 29 R14.htm IDEA: XBRL DOCUMENT v3.23.2
FAIR VALUE
6 Months Ended
Jun. 30, 2023
Fair Value Disclosures [Abstract]  
FAIR VALUE

NOTE 6. FAIR VALUE

 

Securities traded on stock exchanges, or quoted by NASDAQ, are valued according to the NASDAQ Stock Market, Inc. (“NASDAQ”) official closing price, if applicable, or at their last reported sale price as of the close of trading on the New York Stock Exchange (“NYSE”) (normally 4:00 P.M. Eastern Time). If a security is not traded that day, the security will be valued at its most recent bid price.

 

Securities traded in the over-the-counter market, but not quoted by NASDAQ, are valued at the last sale price (or, if the last sale price is not readily available, at the most recent closing bid price as quoted by brokers that make markets in the securities) at the close of trading on the NYSE.

 

Securities traded both in the over-the-counter market and on a stock exchange are valued according to the broadest and most representative market.

 

Securities and other assets that do not have market quotations readily available are valued at their fair value as determined by FCM, as the Board’s valuation designee under SEC rule 2a-5. Those valuations are determined in accordance with the Valuation Procedures used by FCM, subject to oversight by the Board.

 

In pricing illiquid, privately placed securities, FCM, as the valuation designee, is responsible for (1) determining overall valuation guidelines and (2) ensuring that the investments of the Company are valued within the prescribed guidelines.

 

FCM and the Board receive information and recommendations from an independent valuation firm.

 

The values assigned to these investments are based on available information and do not necessarily represent amounts that might ultimately be realized when that investment is sold, as such amounts depend on future circumstances and cannot reasonably be determined until the individual investments are actually liquidated or become readily marketable.

 

APPROACHES TO DETERMINING FAIR VALUE. GAAP. defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). In effect, GAAP applies fair value terminology to all valuations whereas the 1940 Act applies market value terminology to readily marketable assets and fair value terminology to other assets.

 

The main approaches to measuring fair value utilized are the market approach, the income approach, and the asset-based approach. The choice of which approach to use in a particular situation depends on the specific facts and circumstances associated with the company, as well as the purpose for which the valuation analysis is being conducted. Firsthand and the independent valuation firm rely primarily on the market approach. We also considered the income and asset-based approaches in our analysis because certain of the portfolio companies do not have substantial operating earnings relative to the value of their underlying assets.

 

 

-

Market Approach (M): The market approach uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities. For example, the market approach often uses market multiples derived from a set of comparables. Multiples might lie in ranges with a different multiple for each comparable. The selection of where within the range each appropriate multiple falls requires the use of judgment in considering factors specific to the measurement (qualitative and quantitative).

 

 

-

Income Approach (I): The income approach uses valuation techniques to convert future amounts (for example, cash flows or earnings) to a single present value amount (discounted). The measurement is based on the value indicated by current market expectations about those future amounts. Those

 

valuation techniques include present value techniques; option-pricing models, such as the Black-Scholes-Merton formula (a closed-form model) and a binomial model (a lattice model), which incorporate present value techniques; and the multi-period excess earnings method, which is used to measure the fair value of certain assets.

 

 

-

Asset-Based Approach (A): The asset-based approach examines the value of a company’s assets net of its liabilities to derive a value for the equity holders.

 

FAIR VALUE MEASUREMENT. In accordance with the guidance from the Financial Accounting Standards Board on fair value measurements and disclosures under GAAP, the Company discloses the fair value of its investments in a hierarchy that prioritizes the inputs to valuation techniques used to measure the fair value. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements).

 

The guidance establishes three levels of the fair value hierarchy as follows:

 

 

Level 1 -

Unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the date of measurement.

 

 

Level 2 -

Observable inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These inputs may include quoted prices for the identical instrument in an inactive market, prices for similar instruments in an active or inactive market, interest rates, prepayment speeds, credit risks, yield curves, default rates, and similar data.

 

 

Level 3 -

Unobservable inputs for the asset or liability, to the extent relevant observable inputs are not available, representing the Company’s own assumptions about the assumptions a market participant would use in valuing the asset or liability based on the best information available.

 

The availability of observable inputs can vary from security to security and is affected by a wide variety of factors, including, for example, the type of security, whether the security is new and not yet established in the marketplace, the liquidity of markets, and other characteristics particular to the security. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised in determining fair value is greatest for instruments categorized in Level 3.

 

The inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement falls in its entirety, is determined based on the lowest level input that is significant to the fair value measurement in its entirety.

 

The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities. The following is a summary of the inputs used to value the Company’s net assets as of June 30, 2023:

 

                       

ASSETS

 

LEVEL 1
QUOTED PRICES

   

LEVEL 2 OTHER
SIGNIFICANT
OBSERVABLE INPUTS

   

LEVEL 3 SIGNIFICANT
UNOBSERVABLE INPUTS

 

Common Stocks

                       

Advanced Materials

  $     $     $ 266,091  

Automotive

                311  

Equipment Leasing

                1,880  

Semiconductor Equipment

    3,709,446              

Total Common Stocks

    3,709,446             268,282  

Preferred Stocks

                       

Aerospace

                304,332  

Automotive

                573,233  

Equipment Leasing

                383,756  

Total Preferred Stocks

                1,261,321  

Asset Derivatives *

                       

Equity Contracts

                758,405  

Total Asset Derivatives

                758,405  

Convertible Notes

                       

Advanced Materials

                100,000  

Aerospace

                6,559,791  

Automotive

                2,352,578  

Medical Devices

                5,035,984  

Total Convertible Notes

                14,048,353  

Mutual Funds

    567,150              

Total

  $ 4,276,596     $     $ 16,336,361  

 

*

Asset derivatives include warrants.

 

At the end of each calendar quarter, management evaluates the Level 2 and Level 3 assets and liabilities for changes in liquidity, including but not limited to: whether a broker is willing to execute at the quoted price, the depth and consistency of prices from third party services, and the existence of contemporaneous, observable trades in the market. Additionally, management evaluates the Level 1 and Level 2 assets and liabilities on a quarterly basis for changes in listings or delistings on national exchanges.

 

Following is a reconciliation of Level 3 assets (at either the beginning or the ending of the period) for which significant unobservable inputs were used to determine fair value.

 

                                                       

INVESTMENTS AT FAIR
VALUE USING SIGNIFICANT
UNOBSERVABLE INPUTS
(LEVEL 3)

 

BALANCE
AS OF
12/31/22

   

NET
PURCHASES/
CONVERSIONS

   

NET SALES/
CONVERSIONS

   

NET REALIZED
GAINS/
(LOSSES)

   

NET UNREALIZED
APPRECIATION
(DEPRECIATION)
(1)

   

TRANSFERS
IN (OUT) OF
LEVEL 3

   

BALANCE
AS OF
06/30/23

 

Common Stocks

                                                       

Advanced Materials

  $ 337,500     $     $     $     $ (71,409 )   $     $ 266,091  

Automotive

    546                         (235 )           311  

Equipment Leasing

    11,130                         (9,250 )           1,880  

Intellectual Property

    111             (7,966 )     (161,079 )     168,934              

Total Common Stocks

    349,287             (7,966 )     (161,079 )     88,040             268,282  

Preferred Stocks

                                                       

Aerospace

    384,067                         (79,735 )           304,332  

Automotive

    1,049,478                         (476,245 )           573,233  

Equipment Leasing

    865,995                         (482,239 )           383,756  

Intellectual Property

    737,112             (490,459 )     (7,697,238 )     7,450,585              

Total Preferred Stocks

    3,036,652             (490,459 )     (7,697,238 )     6,412,366             1,261,321  

Asset Derivatives

                                                       

Equity Contracts

    957,125                   (6,678 )     (192,042 )           758,405  

Total Asset Derivatives

    957,125                   (6,678 )     (192,042 )           758,405  

Convertible Notes

                                                       

Advanced Materials

    100,000                                     100,000  

Aerospace

    6,559,791                                     6,559,791  

Automotive

    7,809,430       100,000                   (5,556,852 )           2,352,578  

Medical Devices

    17,116,721                         (12,080,737 )           5,035,984  

Total Convertible Notes

    31,585,942       100,000                   (17,637,589 )           14,048,353  

Total

  $ 35,929,006     $ 100,000     $ (498,425 )   $ (7,864,995 )   $ (11,329,225 )   $     $ 16,336,361  

 

(1)

The net change in unrealized appreciation (depreciation) from Level 3 instruments held as of June 30, 2023 was $ (18,952,188).

 

 

The table below represents quantitative disclosure about significant unobservable inputs for Level 3 fair value measurements at June 30, 2023:

 

       

 

FAIR VALUE
AT 6/30/23

VALUATION TECHNIQUES(1)

UNOBSERVABLE INPUTS

RANGE
(WEIGHTED AVG.)
(1)

Direct venture capital investments: Advanced Materials

$0.4M

Market Comparable Companies

Option Pricing Model

Revenue Multiple(2)

Years to Maturity(2)

Volatility(2)

Risk-Free Rate(2)

Discount for Lack of

Marketability(3)

0.7x – 1.0x (0.9x)

5 years (5 years)

50.0% (50.0%)

4.13% (4.13%)

22.7% (22.7%)

Direct venture capital investments: Aerospace

$7.6M

Market Comparable Companies

Option Pricing Model

EBITDA Multiple(2)

Years to Maturity(2)

Volatility(2)

Risk-Free Rate(2)

2.1x (2.1x)

5 years (5 years)

60.0% (60.0%)

4.13% (4.13%)

Direct venture capital investments: Automotive

$2.9M

Prior Transaction Analysis

Option Pricing Model

Probability-Weighted Expected Return Method

Years to Maturity(2)

Volatility(2)

Risk-Free Rate(2)

Discount for Lack of

Marketability(3)

Going Concern Probability(2)

5 years (5 years)

50.0% (50.0%)

4.13% (4.13%)

0.0% - 22.7% (0.0%)

 

5% (5%)

Direct venture capital investments: Equipment Leasing

$0.4M

Market Comparable Companies

Liquidation Value

Option Pricing Model

EBITDA Multiple(2)

Years to Maturity(2)

Volatility(2)

Risk-Free Rate(2)

3.0x – 5.1x (4.0x)

5 years (5 years)

50.0% (50.0%)

4.13% (4.13%)

Direct venture capital investments: Medical Devices

$5.0M

Market Comparable Companies

Revenue Multiple(2)

2.0x – 2.3x (2.1x)

 

(1)

Weighted average is calculated by weighting the significant unobservable input by the relative fair value of each investment in the category

(2)

An increase in the input would result in an increase in the security’s valuation; a decrease in the input would result in a decrease in the security’s valuation.

(3)

An increase in the input would result in a decrease in the security’s valuation; a decrease in the input would result in an increase in the security’s valuation.

 

Changes in any of our unobservable inputs, individually, may change the fair value of certain of the Company’s investments.

 

Due to the inherent uncertainty of determining the fair value of investments that do not have a readily available market value, the fair value of the Company’s investments may fluctuate from period to period. Additionally, the fair value of the Company’s investments may differ significantly from the values that would have been used had a ready market existed for such investments and may differ materially from the values that the Company may ultimately realize. Further, such

 

investments are generally subject to legal and other restrictions on resale or otherwise are less liquid than publicly traded securities. If the Company was required to liquidate a portfolio investment in a forced or liquidation sale, it could realize significantly less than the value at which the Company has recorded it.

 

In addition, changes in the market environment and other events that may occur over the life of the investments may cause the gains or losses ultimately realized on these investments to be different than the unrealized gains or losses reflected in the valuations currently assigned.

 

XML 30 R15.htm IDEA: XBRL DOCUMENT v3.23.2
FEDERAL INCOME TAXES
6 Months Ended
Jun. 30, 2023
Income Tax Disclosure [Abstract]  
FEDERAL INCOME TAXES

NOTE 7. FEDERAL INCOME TAXES

 

Beginning in 2018, we were no longer able to qualify as a RIC under Subchapter M of the Code. The increase in value that resulted from the initial public offerings (IPOs) of Pivotal Systems and Revasum meant that we were no longer able to satisfy the diversification requirements for qualification as a RIC. As a result of this change, we were taxed as a corporation for our fiscal year ended December 31, 2018, and will continue to be taxed in that manner for future fiscal years, paying federal and applicable state corporate taxes on our taxable income, unless and until we are able to once again qualify as a RIC, based on changes in the composition of our portfolio. Consequently, at the close of each fiscal quarter beginning with the quarter ended June 30, 2018, we will record a deferred tax liability for any net realized gains and net ordinary income for the year-to-date period plus net unrealized gains as of the end of the quarter.

 

The reorganization described in Note 1 (the formation of FVI as a fully owned subsidiary for investment activities) was structured to avoid any adverse tax consequences for the Company and its shareholders. For the fiscal years which the Company operates as a RIC, we believe Company’s engaging in investment activities through FVI did not, in our view, jeopardize the Company’s ability to continue to qualify as a RIC under the Code at that time when the Company was eligible to be treated as a RIC.

 

The following information is based upon the U.S. federal income tax cost of portfolio investments as of June 30, 2023.

 

       
   

FEDERAL INCOME
TAX COST:

 

Gross unrealized appreciation

  $ 758,405  

Gross unrealized depreciation

    (114,566,765 )

Net unrealized (depreciation)

  $ (113,808,360 )

Federal income tax cost, Investments

  $ 134,421,317  

 

The Company did not qualify as a regulated investment company pursuant to Subchapter M of the Internal Revenue Code, therefore it is taxed as a corporation. As a corporation, the Company is obligated to pay federal and state income tax on taxable income. The Company’s net deferred tax asset balance has a full valuation allowance based on management’s estimate of future realization of such assets. The Company is currently using an estimated tax rate of 21% for Federal and 6.98% for state taxes.

 

The Company’s income tax provision consists of the following as of December 31, 2022:

 

       

Deferred tax (expense)/benefit

       

Federal

  $  

State

     

Total deferred tax (expense)/benefit

  $  

 

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Such temporary differences are principally: (i) taxes on unrealized gains/(losses), which are attributable to the temporary difference between fair market value and tax basis, and (ii) the net tax benefit of accumulated net operating losses and capital loss carryforwards. Deferred tax assets and liabilities are measured using effective tax rates expected to apply to taxable income in the years such temporary differences are realized or otherwise settled.

 

Components of the Company’s deferred tax assets and liabilities as of December 31, 2022 are as follows:

 

       
   

AMOUNT

 

Deferred tax assets:

       

Net operating loss carryforward

  $ 4,616,720  

Capital loss carryforward

    6,960,412  

Net unrealized losses (gains) on investment securities

    28,726,530  

Total deferred tax assets, net

    40,303,662  

Valuation allowance

    (40,303,662 )

Net

  $  

 

For the year ended December 31, 2022, the Company had an effective tax rate of 0% and a statutory tax rate of 21% (27.98% with state income tax) with the difference being attributable to changes in the components of the deferred tax assets and the valuation allowance account.

 

The effective tax rate and statutory federal income tax rate for the three- and six-month periods ended June 30, 2023 and 2022 were as follows:

 

       

 

THREE MONTHS ENDED
JUNE 30, 2023

THREE MONTHS ENDED
JUNE 30, 2022

SIX MONTHS ENDED
JUNE 30, 2023

SIX MONTHS ENDED
JUNE, 2023

Effective tax rate

0%

0%

0%

0%

Statutory federal income tax rate

21%

21%

21%

21%

 

The variance in the effective tax rate and statutory federal income tax rate for the three-month period ending June 30, 2023, is the result of changes to the deferred tax assets and related valuation allowance account. At June 30, 2023, the Company has established a full valuation allowance on its net deferred tax assets.

 

To the extent the Company has a deferred tax asset or if a portion of the deferred tax liability is offset by a tax asset resulting from net operating losses, consideration is given to whether or not a valuation allowance is required against the deferred tax asset amount. A valuation allowance is required if, based on the evaluation criterion provided by Accounting Standard Codification (“ASC”) 740, Income Taxes (ASC 740), it is more-likely-than-not that some portion or all of the deferred tax asset will not be realized. Among the factors considered in assessing the Company’s valuation allowance are: the nature, frequency and severity of current and cumulative losses, forecasts of future profitability, the duration of the statutory carryforward periods, and the associated risks that operating and capital loss carryforwards may expire unused. Based on the Company’s assessment, it has determined that in the future it is more likely than not that the Company will not generate the necessary appropriate character of income within the carryforward periods to realize its deferred tax assets, and as such, has placed a full allowance on the deferred tax assets.

 

From time to time, and as new information becomes available, the Company will modify its forecasts, estimates or assumptions regarding its deferred tax liability or asset.

 

Modifications of the Company’s estimates or assumptions regarding its deferred tax liability and/or asset balances and any applicable valuation allowance, changes in generally accepted accounting principles or related guidance or interpretations thereof, limitations imposed on net operating losses (if any), and changes in applicable tax law could result in increases or decreases in the Company’s NAV, which could be material. Such changes could have a material impact on the Company’s NAV and results of operations with respect to the Company’s shareholders in the period it is recorded, even though the shareholders at such time might not have held shares in the Company at the time the deferred tax asset or liability had been established.

 

The Company’s policy is to classify interest and penalties associated with underpayment of federal and state income taxes, if any, as income tax expense on its Statement of Operations. As of December 31, 2022, the Company did not have any interest or penalties associated with the underpayment of any income taxes.

 

The Company files income tax returns in the U.S. federal jurisdiction and California. The Company has reviewed all major jurisdictions and concluded that there is no significant impact on the Company’s net assets and no tax liability resulting from unrecognized tax benefits relating to uncertain tax positions expected to be taken on its tax returns. Furthermore, management of the Company is not aware of any tax positions for which it is reasonably possible that the total amounts of unrecognized tax benefits will significantly change in the next 12 months.

 

As of December 31, 2022, the Company had net operating loss carryforwards for federal and state of income tax purposes of $16,500,072, which may be carried forward indefinitely.

 

As of December 31, 2022, the Company had net capital loss carryforwards for federal and state income tax purposes, which may be carried forward for 5 years, as follows:

 

       

EXPIRATION DATE

 

AMOUNT

 

12/31/24

  $ 14,230,073  

12/31/25

    7,516,642  

12/31/27

    3,129,665  

Total

  $ 24,876,380  

 

XML 31 R16.htm IDEA: XBRL DOCUMENT v3.23.2
INVESTMENT TRANSACTIONS
6 Months Ended
Jun. 30, 2023
Investments, All Other Investments [Abstract]  
INVESTMENT TRANSACTIONS

NOTE 8. INVESTMENT TRANSACTIONS

 

Investment transactions (excluding short-term investments) were as follows for the quarter ended June 30, 2023.

       
PURCHASES AND SALES        
Purchases of investment securities   $ 100,000  
Proceeds from sales and maturities of investment securities   $ 498,425  

 

XML 32 R17.htm IDEA: XBRL DOCUMENT v3.23.2
SHARE BUYBACKS
6 Months Ended
Jun. 30, 2023
Equity [Abstract]  
SHARE BUYBACKS

NOTE 9. SHARE BUYBACKS

 

SHARE BUYBACKS. On April 26, 2016, the Board of Directors of the Fund approved a discretionary share repurchase plan (the “Plan”). Pursuant to the Plan, the Fund was authorized to purchase in the open market up to $2 million worth of its common stock. The Plan allowed the Fund to acquire its own shares at certain thresholds below its NAV per share, in accordance with the guidelines specified in Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The intent of the Plan was to increase NAV per share and thereby enhance shareholder value. The Fund completed the repurchase plan in September 2016, having repurchased and retired a total of 272,008 shares of stock, at a total cost of approximately $2 million.

 

On November 10, 2017, the Board of Directors of the Fund approved a discretionary share purchase plan (the “Plan”). Pursuant to the Plan, the Fund was authorized to purchase in the open market up to $2 million worth of its common stock. The Plan allowed the Fund to acquire its own shares in accordance with the guidelines specified in Rule 10b-18 of the Exchange Act. The intent of the Plan was to increase NAV per share and thereby enhance shareholder value. As of December 31, 2017, the Fund had repurchased and retired 128,551 shares of stock at a total cost of approximately $1.1 million. The Fund had 7,302,146 shares outstanding as of December 31, 2017.

 

On August 31, 2018, the Fund announced a plan to repurchase up to $2 million worth of SVVC stock in the open market by March 31, 2019. The Fund completed this open market repurchase plan on October 24, 2018. Through that date, the Fund repurchased 123,376 shares at an average price of $16.21 per share, for total consideration of $2.0 million. As of December 31, 2018, the Fund had 7,178,770 shares outstanding.

 

TENDER OFFERS. On December 22, 2014, pursuant to our agreement with a shareholder, the Fund commenced a tender offer to purchase up to $20 million of its issued and outstanding common shares for cash at a price per share equal to 95% of the Company’s NAV per share determined as of the close of ordinary trading on the NASDAQ Global Market on December 31, 2014 ($23.2702 per share). The tender offer, which expired on January 22, 2015 at 12:00 midnight, New York City time, was oversubscribed. Because the number of shares tendered exceeded the maximum amount of its offer, the Fund purchased shares from tendering shareholders on a pro-rata basis based on the number of shares properly tendered. Of the 5,044,728 shares properly tendered, the Fund purchased 859,468 shares of common stock pursuant to the tender offer.

 

On December 16, 2019, the Fund announced the commencement of a “modified Dutch auction” tender offer to purchase up to $2 million of its common stock at a price per share not less than $6.00 and not greater than $8.00, in $0.10 increments. The tender offer expired on February 14, 2020, and resulted in the purchase by the Fund of 285,714 shares of common stock at a price of $7.00 per share. As of March 31, 2020, the Fund had 6,893,056 shares outstanding.

 

XML 33 R18.htm IDEA: XBRL DOCUMENT v3.23.2
INVESTMENTS IN AFFILIATES AND CONTROLLED INVESTMENTS
6 Months Ended
Jun. 30, 2023
Investments in and Advances to Affiliates [Abstract]  
INVESTMENTS IN AFFILIATES AND CONTROLLED INVESTMENTS

NOTE 10. INVESTMENTS IN AFFILIATES AND CONTROLLED INVESTMENTS

 

Under the 1940 Act, the Company is required to identify investments where it owns greater than 5% (but less than 25%) of the portfolio company’s outstanding voting shares as an affiliate of the Company. Also, under the 1940 Act, the Company is required to identify investments where it owns greater than 25% of the portfolio company’s outstanding voting shares as a controlled investment of the Company. A summary of the Company’s investments in affiliates and controlled investments for the period from December 31, 2022, through June 30, 2023, is noted below:

 

                                                               

AFFILIATE/
CONTROLLED
INVESTMENTS*

 

VALUE AT
12/31/22

   

PURCHASE/
MERGER

   

INTEREST

   

SALES/
MATURITY/
EXPIRATION

   

REALIZED
GAIN (LOSS)

   

CHANGE IN
APPRECIATION/
DEPRECIATION

   

VALUE
6/30/23

   

SHARES HELD
AT 6/30/23

 

Equipment Leasing

                                                               

EQX Capital, Inc. Common Stock*

  $ 11,130     $     $     $     $     $ (9,250 )   $ 1,880       100,000  

EQX Capital, Inc. Series A Preferred Stock*

    865,995                               (482,239 )     383,756       1,950,000  

Total Equipment Leasing

  $ 877,125             $             $     $ (491,489 )   $ 385,636          

Aerospace

                                                               

Hera Systems, Inc. Convertible Note*

    5,359,791             269,478                         5,359,791       5,359,791  

Hera Systems, Inc. Convertible Note*

    1,200,000             29,989                         1,200,000       1,200,000  

Hera Systems, Inc. Series A Preferred*

    4,735                               (2,169 )     2,566       3,642,324  

Hera Systems, Inc. Series B Preferred*

    275,585                               (56,352 )     219,233       7,039,203  

Hera Systems, Inc. Series B Warrants*

    478,608                               (98,084 )     380,524       12,250,000  

Hera Systems, Inc. Series B Warrants*

    242,817                               (49,762 )     193,055       6,214,922  

Hera Systems, Inc. Series B Warrants*

    205,118                               (42,036 )     163,082       5,250,000  

Hera Systems, Inc. Series B Warrants*

    27,349                               (5,605 )     21,744       700,000  

Hera Systems, Inc. Series C Preferred*

    103,747                               (21,214 )     82,533       2,650,000  

Total Aerospace

  $ 7,897,750             $ 299,467             $     $ (275,222 )   $ 7,622,528          

Medical Devices

                                                               

IntraOp Medical Corp. Convertible Note*

    6,746,169                               (4,761,350 )     1,984,819       10,961,129  

IntraOp Medical Corp. Convertible Note*

    800,102                               (564,701 )     235,401       1,300,000  

 

Firsthand Technology Value Fund, Inc.

AFFILIATE/
CONTROLLED
INVESTMENTS*

 

VALUE AT
12/31/22

   

PURCHASE/
MERGER

   

INTEREST

   

SALES/
MATURITY/
EXPIRATION

   

REALIZED
GAIN (LOSS)

   

CHANGE IN
APPRECIATION/
DEPRECIATION

   

VALUE
6/30/23

   

SHARES HELD
AT 6/30/23

 

IntraOp Medical Corp. Convertible Note*

  $ 307,731     $     $     $     $     $ (217,192 )   $ 90,539       500,000  

IntraOp Medical Corp. Convertible Note*

    307,731                               (217,192 )     90,539       500,000  

IntraOp Medical Corp. Convertible Note*

    1,846,389                               (1,303,155 )     543,234       3,000,000  

IntraOp Medical Corp. Convertible Note*

    615,463                               (434,385 )     181,078       1,000,000  

IntraOp Medical Corp. Convertible Note*

    246,185                               (173,754 )     72,431       400,000  

IntraOp Medical Corp. Convertible Note*

    307,731                               (217,192 )     90,539       500,000  

IntraOp Medical Corp. Convertible Note*

    461,597                               (325,788 )     135,809       750,000  

IntraOp Medical Corp. Convertible Note*

    307,731                               (217,192 )     90,539       500,000  

IntraOp Medical Corp. Convertible Note*

    307,732                               (217,193 )     90,539       500,000  

IntraOp Medical Corp. Convertible Note*

    307,732                               (217,193 )     90,539       500,000  

IntraOp Medical Corp. Convertible Note*

    615,463                               (434,385 )     181,078       1,000,000  

IntraOp Medical Corp. Convertible Note*

    307,732                               (217,193 )     90,539       500,000  

IntraOp Medical Corp. Convertible Note*

    615,463                               (434,385 )     181,078       1,000,000  

IntraOp Medical Corp. Convertible Note*

    307,732                               (217,193 )     90,539       500,000  

IntraOp Medical Corp. Convertible Note*

    307,732                               (217,193 )     90,539       500,000  

 

Firsthand Technology Value Fund, Inc.

 

AFFILIATE/
CONTROLLED
INVESTMENTS*

 

VALUE AT
12/31/22

   

PURCHASE/
MERGER

   

INTEREST

   

SALES/
MATURITY/
EXPIRATION

   

REALIZED
GAIN (LOSS)

   

CHANGE IN
APPRECIATION/
DEPRECIATION

   

VALUE
6/30/23

   

SHARES HELD
AT 6/30/23

 

IntraOp Medical Corp. Convertible Note*

  $ 307,732     $     $     $     $     $ (217,193 )   $ 90,539       500,000  

IntraOp Medical Corp. Convertible Note*

    123,093                               (86,877 )     36,216       200,000  

IntraOp Medical Corp. Convertible Note*

    430,824                               (304,069 )     126,755       700,000  

IntraOp Medical Corp. Convertible Note*

    92,319                               (65,157 )     27,162       150,000  

IntraOp Medical Corp. Convertible Note*

    215,412                               (152,035 )     63,377       350,000  

IntraOp Medical Corp. Series C Preferred*

                                              26,856,187  

IntraOp Medical Corp. Term Note*

    1,230,926                               (868,770 )     362,156       2,000,000  

Total Medical Devices

  $ 17,116,721             $             $     $ (12,080,737 )   $ 5,035,984          

Semiconductor Equipment

                                                               

Revasum, Inc. CDI*(1)

    3,520,496                               188,950       3,709,446       39,774,889  

Total Semiconductor Equipment

  $ 3,520,496             $             $     $ 188,950     $ 3,709,446          

Intellectual Property

                                                               

Silicon Genesis Corp. Common Stock*

    111                   (7,966 )     (161,080 )     168,935              

Silicon Genesis Corp. Common Warrants*

    1                   (1 )     (6,677 )     6,677              

Silicon Genesis Corp. Series 1-G Preferred*

    306,671       88             (417,972 )     (3,462,620 )     3,573,833              

Silicon Genesis Corp. Series 1-H Preferred*

    35,529                   (7,241 )     (929,654 )     901,366              

Silicon Genesis Corp. Series 1-D Preferred*

    2,552                   (7,351 )     (424,549 )     429,348              

 

AFFILIATE/
CONTROLLED
INVESTMENTS*

 

VALUE AT
12/31/22

   

PURCHASE/
MERGER

   

INTEREST

   

SALES/
MATURITY/
EXPIRATION

   

REALIZED
GAIN (LOSS)

   

CHANGE IN
APPRECIATION/
DEPRECIATION

   

VALUE
6/30/23

   

SHARES HELD
AT 6/30/23

 

Silicon Genesis Corp. Series 1-E Preferred*

  $ 320,592     $     $     $ (49,292 )   $ (2,323,111 )   $ 2,051,811     $        

Silicon Genesis Corp. Series 1-F Preferred*

    70,806                   (7,885 )     (448,504 )     385,583              

Silicon Genesis Corp. Series 1-C Preferred Stock*

    962                   (716 )     (108,802 )     108,556              

Total Intellectual Property

  $ 737,224             $             $ (7,864,997 )   $ 7,626,109     $          

Advanced Materials

                                                               

UCT Coatings, Inc. Common Stock

    337,500                               (71,409 )     266,091       1,500,000  

Total Advanced Materials

  $ 337,500             $             $     $ (71,409 )   $ 266,091          

Automotive

                                                               

Wrightspeed, Inc. Common Stock*

    546                               (235 )     311       69,102  

Wrightspeed, Inc. Convertible Note*

    65,000                               (45,500 )     19,500       200,000  

Wrightspeed, Inc. Convertible Note*

    60,125                               (42,088 )     18,037       185,000  

Wrightspeed, Inc. Convertible Note*

    21,125                               (14,788 )     6,337       65,000  

Wrightspeed, Inc. Convertible Note*

    81,250                               (56,875 )     24,375       250,000  

Wrightspeed, Inc. Convertible Note*

    81,250                               (56,875 )     24,375       250,000  

Wrightspeed, Inc. Convertible Note*

    81,250                               (56,875 )     24,375       250,000  

Wrightspeed, Inc. Convertible Note*

    227,500                               (159,250 )     68,250       700,000  

Wrightspeed, Inc. Convertible Note*

    81,250                               (56,875 )     24,375       250,000  

Wrightspeed, Inc. Convertible Note*

    81,250                               (56,875 )     24,375       250,000  

Wrightspeed, Inc. Convertible Note*

    81,250                               (56,875 )     24,375       250,000  

Wrightspeed, Inc. Convertible Note*

    43,875                               (30,713 )     13,162       135,000  

Wrightspeed, Inc. Convertible Note*

    53,625                               (37,537 )     16,088       165,000  

 

AFFILIATE/
CONTROLLED
INVESTMENTS*

 

VALUE AT
12/31/22

   

PURCHASE/
MERGER

   

INTEREST

   

SALES/
MATURITY/
EXPIRATION

   

REALIZED
GAIN (LOSS)

   

CHANGE IN
APPRECIATION/
DEPRECIATION

   

VALUE
6/30/23

   

SHARES HELD
AT 6/30/23

 

Wrightspeed, Inc. Convertible Note*

  $ 40,625     $     $     $     $     $ (28,437 )   $ 12,188       125,000  

Wrightspeed, Inc. Convertible Note*

          100,000                         (90,250 )     9,750       100,000  

Wrightspeed, Inc. Convertible Note*

    81,250                               (56,875 )     24,375       250,000  

Wrightspeed, Inc. Convertible Note*

    325,000                               (227,500 )     97,500       1,000,000  

Wrightspeed, Inc. Convertible Note*

    325,000                               (227,500 )     97,500       1,000,000  

Wrightspeed, Inc. Convertible Note*

    325,000                               (227,500 )     97,500       1,000,000  

Wrightspeed, Inc. Convertible Note*

    1,601,930                               (1,121,351 )     480,579       4,929,015  

Wrightspeed, Inc. Convertible Note*

    243,750                               (170,625 )     73,125       750,000  

Wrightspeed, Inc. Convertible Note*

    292,500                               (204,750 )     87,750       900,000  

Wrightspeed, Inc. Convertible Note*

    121,875                               (85,313 )     36,562       375,000  

Wrightspeed, Inc. Convertible Note*

    130,000                               (91,000 )     39,000       400,000  

Wrightspeed, Inc. Convertible Note*

    341,250                               (238,875 )     102,375       1,050,000  

Wrightspeed, Inc. Convertible Note*

    325,000                               (227,500 )     97,500       1,000,000  

Wrightspeed, Inc. Convertible Note*

    325,000                               (227,500 )     97,500       1,000,000  

Wrightspeed, Inc. Convertible Note*

    325,000                               (227,500 )     97,500       1,000,000  

Wrightspeed, Inc. Convertible Note*

    390,000                               (273,000 )     117,000       1,200,000  

Wrightspeed, Inc. Convertible Note*

    455,000                               (318,500 )     136,500       1,400,000  

Wrightspeed, Inc. Convertible Note*

    650,000                               (455,000 )     195,000       2,000,000  

Wrightspeed, Inc. Convertible Note*

    130,000                               (91,000 )     39,000       400,000  

Wrightspeed, Inc. Convertible Note*

    97,500                               (68,250 )     29,250       300,000  

Wrightspeed, Inc. Convertible Note*

    325,000                               (227,500 )     97,500       1,000,000  

 

AFFILIATE/
CONTROLLED
INVESTMENTS*

 

VALUE AT
12/31/22

   

PURCHASE/
MERGER

   

INTEREST

   

SALES/
MATURITY/
EXPIRATION

   

REALIZED
GAIN (LOSS)

   

CHANGE IN
APPRECIATION/
DEPRECIATION

   

VALUE
6/30/23

   

SHARES HELD
AT 6/30/23

 

Wrightspeed, Inc. Series AA Preferred*

  $ 1,049,478     $     $     $     $     $ (476,245 )   $ 573,233       60,733,693  

Wrightspeed, Inc. Series AA Warrants*

    3,232                               (3,232 )            

Total Automotive

  $ 8,862,686             $             $     $ (6,036,564 )   $ 2,926,122          

Total Affiliates and Controlled Investments

  $ 39,349,502             $ 299,467             $ (7,864,997 )   $ (11,140,362 )   $ 19,945,807          

Total Affiliates

    337,500                                   (71,409 )     266,091          

Total Controlled Investments

  $ 39,012,002             $ 299,467             $ (7,864,997 )   $ (11,068,953 )   $ 19,679,716          

 

*

Controlled Investments.

(1)

CDI: CHESS Depositary Interest

 

As of June 30, 2023, Kevin Landis, the Company’s Chairman, President and Chief Executive Officer, represented the Company and sat on the boards of directors of Hera Systems, Inc.; IntraOp Medical Corp.; Revasum, Inc.; and Wrightspeed, Inc. As of June 30,2023, Mr. Landis served as interim CEO at IntraOp Medical Corp. and Wrightspeed, Inc. Serving as a director or officer of portfolio companies may cause conflicts of interest. The Advisor has adopted various procedures to ensure that the Company will not be unfavorably affected by these potential conflicts.

 

XML 34 R19.htm IDEA: XBRL DOCUMENT v3.23.2
MARKET DISRUPTION AND GEOPOLITICAL RISKS
6 Months Ended
Jun. 30, 2023
Market Disruption And Geopolitical Risks  
MARKET DISRUPTION AND GEOPOLITICAL RISKS

NOTE 11. MARKET DISRUPTION AND GEOPOLITICAL RISKS

 

Certain local, regional or global events such as war, acts of terrorism, the spread of infectious illness or other public health issues, or other events could have a significant impact on a security or instrument. Since 2020, the novel strain of coronavirus (COVID-19) has negatively affected the worldwide economy, as well as the economies of individual countries, the financial health of individual companies and the market in general in significant and unforeseen ways. Following Russia’s large-scale invasion of Ukraine, the President of the United States signed an Executive Order in February 2022 prohibiting U.S. persons from entering transactions with the Central Bank of Russia and Executive Orders in March 2022 prohibiting U.S. persons from importing oil and gas from Russia as well as other popular Russian exports, such as diamonds, seafood and vodka. The duration of the coronavirus outbreak and the Russian-Ukraine conflict could adversely affect the Company’s performance. The ultimate impact of COVID-19 and Russia invasion on the financial performance of the Company’s investments is not reasonably estimable at this time.

 

XML 35 R20.htm IDEA: XBRL DOCUMENT v3.23.2
SUBSEQUENT EVENTS
6 Months Ended
Jun. 30, 2023
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS

NOTE 12. SUBSEQUENT EVENTS

 

Management has evaluated the impact of all subsequent events on the Company through the date the financial statements were issued and has determined that there were no subsequent events requiring recognition or disclosure in the financial statements.

XML 36 R21.htm IDEA: XBRL DOCUMENT v3.23.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
6 Months Ended
Jun. 30, 2023
Accounting Policies [Abstract]  
BASIS OF PRESENTATION

BASIS OF PRESENTATION. The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) pursuant to the requirements on Form 10-K. ASC 946, Financial Services—Investment Companies (“ASC 946”), and Articles 6, 10 and 12 of Regulation S-X. In the opinion of management, all adjustments, which are of a normal recurring nature, considered necessary for the fair presentation of the financial statements for the periods presented, have been included.

 

Under the 1940 Act, ASC 946, and the regulations pursuant to Article 6 of Regulation S-X, we are precluded from consolidating any entity other than another investment company or an operating company which provides substantially all of its services to benefit us. Consequentially, as of December 31, 2018, the Company consolidated some special purpose entities. These special purpose entities only hold investments of the Company and have no other significant asset and liabilities. All significant intercompany transactions and balances have been eliminated in consolidation.

 

USE OF ESTIMATES

USE OF ESTIMATES. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ from those estimates.

 

PORTFOLIO INVESTMENT VALUATIONS

PORTFOLIO INVESTMENT VALUATIONS. Investments are stated at “value” as defined in the 1940 Act and in the applicable regulations of the Securities and Exchange Commission and in accordance with GAAP. Value, as defined in Section 2(a)(41) of the 1940 Act, is (i) the market value of those securities for which a market quotation is readily available and (ii) the fair value as determined in good faith by the Advisor as the valuation designee appointed by the Board of Directors, and subject to oversight by the Board of Directors. On June 30, 2023, our financial statements include venture capital investments valued at approximately 16.3 million. The fair values of our venture capital investments were also determined by the Advisor as the valuation designee. Upon sale of these investments, the values that are ultimately realized may be different from what is presently estimated. The difference could be material. Also see note 6 regarding the fair value of the company’s investments.

 

CASH AND CASH EQUIVALENTS

CASH AND CASH EQUIVALENTS. The Company considers liquid assets deposited with a bank, investments in money market funds, and certain short-term debt instruments with maturities of three months or less to be cash equivalents. These investments represent amounts held with financial institutions that are readily accessible to pay our expenses or purchase investments. Cash and cash equivalents are valued at cost plus accrued interest, which approximates market value.

 

RESTRICTED SECURITIES

RESTRICTED SECURITIES. At June 30, 2023, we held $16,336,361 in restricted securities. At December 31, 2022, we held $35,929,006. in restricted securities.

 

INCOME RECOGNITION

INCOME RECOGNITION. Dividend income is recorded on the ex-dividend date. Interest income is accrued as earned. Discounts and premiums on securities purchased are amortized over the lives of the respective securities. Other non-cash dividends are recognized as investment income at the fair value of the property received. When debt securities are determined to be non-income producing, the Company ceases accruing interest and writes off any previously accrued interest. These write-offs are recorded as an adjustment to interest income.

 

SHARE VALUATION

SHARE VALUATION. The net asset value (“NAV”) per share of the Fund is calculated by dividing the sum of the value of the securities held by the Fund, plus cash or other assets, minus all liabilities (including estimated accrued expenses) by the total number of shares outstanding of the Fund, rounded to the nearest cent.

 

REALIZED GAIN OR LOSS AND UNREALIZED APPRECIATION OR DEPRECIATION OF PORTFOLIO INVESTMENTS

REALIZED GAIN OR LOSS AND UNREALIZED APPRECIATION OR DEPRECIATION OF PORTFOLIO INVESTMENTS. A realized gain or loss is recognized when an investment is disposed of and is computed as the difference between the Company’s cost basis in the investment at the disposition date and the net proceeds received from such disposition. Realized gains and losses are calculated on a specific identification basis. Unrealized appreciation or depreciation is computed as the difference between the fair value of the investment and the cost basis of such investment.

 

INCOME TAXES

INCOME TAXES. The Company provides for state and federal corporate income tax, as appropriate, because it is regarded as a corporation under Subchapter C of the Code. The Company recognizes interest and penalties in income tax expense.

 

FOREIGN CURRENCY TRANSLATION

FOREIGN CURRENCY TRANSLATION. The accounting records of the Company are maintained in U.S. dollars. All assets and liabilities denominated in foreign currencies are translated into U.S. dollars based on the foreign exchange rate on the date of valuation. The Company does not isolate that portion of the results of operation resulting from changes in foreign exchange rates on investments from the fluctuations arising from changes in market prices of securities held. The Company’s investments in foreign securities may involve certain risks, including without limitation: foreign exchange restrictions, expropriation, taxation or other political, social, or economic risks, all of which could affect the market and/or credit risk of the investment. In addition, changes in the relationship of foreign currencies to the U.S. dollar can significantly affect the value of these investments and therefore the earnings of the Company.

 

SECURITIES TRANSACTIONS

SECURITIES TRANSACTIONS. Securities transactions are accounted for on the date the transaction for the purchase or sale of the securities is entered into by the Company (i.e., trade date).

 

CONCENTRATION OF CREDIT RISK

CONCENTRATION OF CREDIT RISK. The Company places its cash and cash equivalents with financial institutions and, at times, cash held in checking accounts may exceed the Federal Deposit Insurance Corporation insured limit.

 

OPTIONS

OPTIONS. The Company is subject to equity price risk in the normal course of pursuing its investment objectives and may enter into options written to hedge against changes in the value of equities. The Company may purchase put and call options to attempt to provide protection against adverse price effects from anticipated changes in prevailing prices of securities or stock indices. The Company may also write put and call options. When the Company writes an option, an amount equal to the premium received by the Company is recorded as a liability and is subsequently adjusted to the current fair value of the option written.

 

Premiums received from writing options that expire unexercised are treated by the Company on the expiration date as realized gains from investments. The difference between the premium and the amount paid on effecting a closing purchase transaction, including brokerage commissions, is also treated as a realized gain, or, if the premium is less than the amount paid for the closing purchase transaction, as a realized loss. If a call option is exercised, the premium is added to the proceeds from the sale of the underlying security or currency in determining whether the Company has realized a gain or loss. The Company as writer of an option bears the market risk of an unfavorable change in the price of the security underlying the written option.

 

The average monthly volume of the Company’s derivatives during the six months ended June 30, 2023 is as follows:

 

     
 

PURCHASED OPTIONS
(CONTRACTS)

WARRANTS (NOTIONAL
VALUE)

WRITTEN OPTIONS
(CONTRACTS)

Firsthand Technology Value Fund, Inc.

1,252,639

 

XML 37 R22.htm IDEA: XBRL DOCUMENT v3.23.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
6 Months Ended
Jun. 30, 2023
Accounting Policies [Abstract]  
Schedule of derivatives
     
 

PURCHASED OPTIONS
(CONTRACTS)

WARRANTS (NOTIONAL
VALUE)

WRITTEN OPTIONS
(CONTRACTS)

Firsthand Technology Value Fund, Inc.

1,252,639

XML 38 R23.htm IDEA: XBRL DOCUMENT v3.23.2
FAIR VALUE (Tables)
6 Months Ended
Jun. 30, 2023
Fair Value Disclosures [Abstract]  
Schedule of fair value of net asset
                       

ASSETS

 

LEVEL 1
QUOTED PRICES

   

LEVEL 2 OTHER
SIGNIFICANT
OBSERVABLE INPUTS

   

LEVEL 3 SIGNIFICANT
UNOBSERVABLE INPUTS

 

Common Stocks

                       

Advanced Materials

  $     $     $ 266,091  

Automotive

                311  

Equipment Leasing

                1,880  

Semiconductor Equipment

    3,709,446              

Total Common Stocks

    3,709,446             268,282  

Preferred Stocks

                       

Aerospace

                304,332  

Automotive

                573,233  

Equipment Leasing

                383,756  

Total Preferred Stocks

                1,261,321  

Asset Derivatives *

                       

Equity Contracts

                758,405  

Total Asset Derivatives

                758,405  

Convertible Notes

                       

Advanced Materials

                100,000  

Aerospace

                6,559,791  

Automotive

                2,352,578  

Medical Devices

                5,035,984  

Total Convertible Notes

                14,048,353  

Mutual Funds

    567,150              

Total

  $ 4,276,596     $     $ 16,336,361  

 

*

Asset derivatives include warrants.

Schedule of unobservable inputs of fair value
                                                       

INVESTMENTS AT FAIR
VALUE USING SIGNIFICANT
UNOBSERVABLE INPUTS
(LEVEL 3)

 

BALANCE
AS OF
12/31/22

   

NET
PURCHASES/
CONVERSIONS

   

NET SALES/
CONVERSIONS

   

NET REALIZED
GAINS/
(LOSSES)

   

NET UNREALIZED
APPRECIATION
(DEPRECIATION)
(1)

   

TRANSFERS
IN (OUT) OF
LEVEL 3

   

BALANCE
AS OF
06/30/23

 

Common Stocks

                                                       

Advanced Materials

  $ 337,500     $     $     $     $ (71,409 )   $     $ 266,091  

Automotive

    546                         (235 )           311  

Equipment Leasing

    11,130                         (9,250 )           1,880  

Intellectual Property

    111             (7,966 )     (161,079 )     168,934              

Total Common Stocks

    349,287             (7,966 )     (161,079 )     88,040             268,282  

Preferred Stocks

                                                       

Aerospace

    384,067                         (79,735 )           304,332  

Automotive

    1,049,478                         (476,245 )           573,233  

Equipment Leasing

    865,995                         (482,239 )           383,756  

Intellectual Property

    737,112             (490,459 )     (7,697,238 )     7,450,585              

Total Preferred Stocks

    3,036,652             (490,459 )     (7,697,238 )     6,412,366             1,261,321  

Asset Derivatives

                                                       

Equity Contracts

    957,125                   (6,678 )     (192,042 )           758,405  

Total Asset Derivatives

    957,125                   (6,678 )     (192,042 )           758,405  

Convertible Notes

                                                       

Advanced Materials

    100,000                                     100,000  

Aerospace

    6,559,791                                     6,559,791  

Automotive

    7,809,430       100,000                   (5,556,852 )           2,352,578  

Medical Devices

    17,116,721                         (12,080,737 )           5,035,984  

Total Convertible Notes

    31,585,942       100,000                   (17,637,589 )           14,048,353  

Total

  $ 35,929,006     $ 100,000     $ (498,425 )   $ (7,864,995 )   $ (11,329,225 )   $     $ 16,336,361  

 

(1)

The net change in unrealized appreciation (depreciation) from Level 3 instruments held as of June 30, 2023 was $ (18,952,188).

Schedule of unobservable inputs fair value measurements
       

 

FAIR VALUE
AT 6/30/23

VALUATION TECHNIQUES(1)

UNOBSERVABLE INPUTS

RANGE
(WEIGHTED AVG.)
(1)

Direct venture capital investments: Advanced Materials

$0.4M

Market Comparable Companies

Option Pricing Model

Revenue Multiple(2)

Years to Maturity(2)

Volatility(2)

Risk-Free Rate(2)

Discount for Lack of

Marketability(3)

0.7x – 1.0x (0.9x)

5 years (5 years)

50.0% (50.0%)

4.13% (4.13%)

22.7% (22.7%)

Direct venture capital investments: Aerospace

$7.6M

Market Comparable Companies

Option Pricing Model

EBITDA Multiple(2)

Years to Maturity(2)

Volatility(2)

Risk-Free Rate(2)

2.1x (2.1x)

5 years (5 years)

60.0% (60.0%)

4.13% (4.13%)

Direct venture capital investments: Automotive

$2.9M

Prior Transaction Analysis

Option Pricing Model

Probability-Weighted Expected Return Method

Years to Maturity(2)

Volatility(2)

Risk-Free Rate(2)

Discount for Lack of

Marketability(3)

Going Concern Probability(2)

5 years (5 years)

50.0% (50.0%)

4.13% (4.13%)

0.0% - 22.7% (0.0%)

 

5% (5%)

Direct venture capital investments: Equipment Leasing

$0.4M

Market Comparable Companies

Liquidation Value

Option Pricing Model

EBITDA Multiple(2)

Years to Maturity(2)

Volatility(2)

Risk-Free Rate(2)

3.0x – 5.1x (4.0x)

5 years (5 years)

50.0% (50.0%)

4.13% (4.13%)

Direct venture capital investments: Medical Devices

$5.0M

Market Comparable Companies

Revenue Multiple(2)

2.0x – 2.3x (2.1x)

 

(1)

Weighted average is calculated by weighting the significant unobservable input by the relative fair value of each investment in the category

(2)

An increase in the input would result in an increase in the security’s valuation; a decrease in the input would result in a decrease in the security’s valuation.

(3)

An increase in the input would result in a decrease in the security’s valuation; a decrease in the input would result in an increase in the security’s valuation.

XML 39 R24.htm IDEA: XBRL DOCUMENT v3.23.2
FEDERAL INCOME TAXES (Tables)
6 Months Ended
Jun. 30, 2023
Income Tax Disclosure [Abstract]  
Schedule of federal income tax cost of portfolio investments
       
   

FEDERAL INCOME
TAX COST:

 

Gross unrealized appreciation

  $ 758,405  

Gross unrealized depreciation

    (114,566,765 )

Net unrealized (depreciation)

  $ (113,808,360 )

Federal income tax cost, Investments

  $ 134,421,317  
Schedule of income tax provision
       

Deferred tax (expense)/benefit

       

Federal

  $  

State

     

Total deferred tax (expense)/benefit

  $  
Schedule of deferred tax assets and liabilities
       
   

AMOUNT

 

Deferred tax assets:

       

Net operating loss carryforward

  $ 4,616,720  

Capital loss carryforward

    6,960,412  

Net unrealized losses (gains) on investment securities

    28,726,530  

Total deferred tax assets, net

    40,303,662  

Valuation allowance

    (40,303,662 )

Net

  $  
Schedule of effective tax rate and statutory federal income tax rate
       

 

THREE MONTHS ENDED
JUNE 30, 2023

THREE MONTHS ENDED
JUNE 30, 2022

SIX MONTHS ENDED
JUNE 30, 2023

SIX MONTHS ENDED
JUNE, 2023

Effective tax rate

0%

0%

0%

0%

Statutory federal income tax rate

21%

21%

21%

21%

Schedule of net capital loss carryforwards
       

EXPIRATION DATE

 

AMOUNT

 

12/31/24

  $ 14,230,073  

12/31/25

    7,516,642  

12/31/27

    3,129,665  

Total

  $ 24,876,380  
XML 40 R25.htm IDEA: XBRL DOCUMENT v3.23.2
INVESTMENT TRANSACTIONS (Tables)
6 Months Ended
Jun. 30, 2023
Investments, All Other Investments [Abstract]  
Schedule of investment transactions
       
PURCHASES AND SALES        
Purchases of investment securities   $ 100,000  
Proceeds from sales and maturities of investment securities   $ 498,425  
XML 41 R26.htm IDEA: XBRL DOCUMENT v3.23.2
INVESTMENTS IN AFFILIATES AND CONTROLLED INVESTMENTS (Tables)
6 Months Ended
Jun. 30, 2023
Investments in and Advances to Affiliates [Abstract]  
Schedule of investments in affiliates and controlled investments
                                                               

AFFILIATE/
CONTROLLED
INVESTMENTS*

 

VALUE AT
12/31/22

   

PURCHASE/
MERGER

   

INTEREST

   

SALES/
MATURITY/
EXPIRATION

   

REALIZED
GAIN (LOSS)

   

CHANGE IN
APPRECIATION/
DEPRECIATION

   

VALUE
6/30/23

   

SHARES HELD
AT 6/30/23

 

Equipment Leasing

                                                               

EQX Capital, Inc. Common Stock*

  $ 11,130     $     $     $     $     $ (9,250 )   $ 1,880       100,000  

EQX Capital, Inc. Series A Preferred Stock*

    865,995                               (482,239 )     383,756       1,950,000  

Total Equipment Leasing

  $ 877,125             $             $     $ (491,489 )   $ 385,636          

Aerospace

                                                               

Hera Systems, Inc. Convertible Note*

    5,359,791             269,478                         5,359,791       5,359,791  

Hera Systems, Inc. Convertible Note*

    1,200,000             29,989                         1,200,000       1,200,000  

Hera Systems, Inc. Series A Preferred*

    4,735                               (2,169 )     2,566       3,642,324  

Hera Systems, Inc. Series B Preferred*

    275,585                               (56,352 )     219,233       7,039,203  

Hera Systems, Inc. Series B Warrants*

    478,608                               (98,084 )     380,524       12,250,000  

Hera Systems, Inc. Series B Warrants*

    242,817                               (49,762 )     193,055       6,214,922  

Hera Systems, Inc. Series B Warrants*

    205,118                               (42,036 )     163,082       5,250,000  

Hera Systems, Inc. Series B Warrants*

    27,349                               (5,605 )     21,744       700,000  

Hera Systems, Inc. Series C Preferred*

    103,747                               (21,214 )     82,533       2,650,000  

Total Aerospace

  $ 7,897,750             $ 299,467             $     $ (275,222 )   $ 7,622,528          

Medical Devices

                                                               

IntraOp Medical Corp. Convertible Note*

    6,746,169                               (4,761,350 )     1,984,819       10,961,129  

IntraOp Medical Corp. Convertible Note*

    800,102                               (564,701 )     235,401       1,300,000  

 

Firsthand Technology Value Fund, Inc.

AFFILIATE/
CONTROLLED
INVESTMENTS*

 

VALUE AT
12/31/22

   

PURCHASE/
MERGER

   

INTEREST

   

SALES/
MATURITY/
EXPIRATION

   

REALIZED
GAIN (LOSS)

   

CHANGE IN
APPRECIATION/
DEPRECIATION

   

VALUE
6/30/23

   

SHARES HELD
AT 6/30/23

 

IntraOp Medical Corp. Convertible Note*

  $ 307,731     $     $     $     $     $ (217,192 )   $ 90,539       500,000  

IntraOp Medical Corp. Convertible Note*

    307,731                               (217,192 )     90,539       500,000  

IntraOp Medical Corp. Convertible Note*

    1,846,389                               (1,303,155 )     543,234       3,000,000  

IntraOp Medical Corp. Convertible Note*

    615,463                               (434,385 )     181,078       1,000,000  

IntraOp Medical Corp. Convertible Note*

    246,185                               (173,754 )     72,431       400,000  

IntraOp Medical Corp. Convertible Note*

    307,731                               (217,192 )     90,539       500,000  

IntraOp Medical Corp. Convertible Note*

    461,597                               (325,788 )     135,809       750,000  

IntraOp Medical Corp. Convertible Note*

    307,731                               (217,192 )     90,539       500,000  

IntraOp Medical Corp. Convertible Note*

    307,732                               (217,193 )     90,539       500,000  

IntraOp Medical Corp. Convertible Note*

    307,732                               (217,193 )     90,539       500,000  

IntraOp Medical Corp. Convertible Note*

    615,463                               (434,385 )     181,078       1,000,000  

IntraOp Medical Corp. Convertible Note*

    307,732                               (217,193 )     90,539       500,000  

IntraOp Medical Corp. Convertible Note*

    615,463                               (434,385 )     181,078       1,000,000  

IntraOp Medical Corp. Convertible Note*

    307,732                               (217,193 )     90,539       500,000  

IntraOp Medical Corp. Convertible Note*

    307,732                               (217,193 )     90,539       500,000  

 

Firsthand Technology Value Fund, Inc.

 

AFFILIATE/
CONTROLLED
INVESTMENTS*

 

VALUE AT
12/31/22

   

PURCHASE/
MERGER

   

INTEREST

   

SALES/
MATURITY/
EXPIRATION

   

REALIZED
GAIN (LOSS)

   

CHANGE IN
APPRECIATION/
DEPRECIATION

   

VALUE
6/30/23

   

SHARES HELD
AT 6/30/23

 

IntraOp Medical Corp. Convertible Note*

  $ 307,732     $     $     $     $     $ (217,193 )   $ 90,539       500,000  

IntraOp Medical Corp. Convertible Note*

    123,093                               (86,877 )     36,216       200,000  

IntraOp Medical Corp. Convertible Note*

    430,824                               (304,069 )     126,755       700,000  

IntraOp Medical Corp. Convertible Note*

    92,319                               (65,157 )     27,162       150,000  

IntraOp Medical Corp. Convertible Note*

    215,412                               (152,035 )     63,377       350,000  

IntraOp Medical Corp. Series C Preferred*

                                              26,856,187  

IntraOp Medical Corp. Term Note*

    1,230,926                               (868,770 )     362,156       2,000,000  

Total Medical Devices

  $ 17,116,721             $             $     $ (12,080,737 )   $ 5,035,984          

Semiconductor Equipment

                                                               

Revasum, Inc. CDI*(1)

    3,520,496                               188,950       3,709,446       39,774,889  

Total Semiconductor Equipment

  $ 3,520,496             $             $     $ 188,950     $ 3,709,446          

Intellectual Property

                                                               

Silicon Genesis Corp. Common Stock*

    111                   (7,966 )     (161,080 )     168,935              

Silicon Genesis Corp. Common Warrants*

    1                   (1 )     (6,677 )     6,677              

Silicon Genesis Corp. Series 1-G Preferred*

    306,671       88             (417,972 )     (3,462,620 )     3,573,833              

Silicon Genesis Corp. Series 1-H Preferred*

    35,529                   (7,241 )     (929,654 )     901,366              

Silicon Genesis Corp. Series 1-D Preferred*

    2,552                   (7,351 )     (424,549 )     429,348              

 

AFFILIATE/
CONTROLLED
INVESTMENTS*

 

VALUE AT
12/31/22

   

PURCHASE/
MERGER

   

INTEREST

   

SALES/
MATURITY/
EXPIRATION

   

REALIZED
GAIN (LOSS)

   

CHANGE IN
APPRECIATION/
DEPRECIATION

   

VALUE
6/30/23

   

SHARES HELD
AT 6/30/23

 

Silicon Genesis Corp. Series 1-E Preferred*

  $ 320,592     $     $     $ (49,292 )   $ (2,323,111 )   $ 2,051,811     $        

Silicon Genesis Corp. Series 1-F Preferred*

    70,806                   (7,885 )     (448,504 )     385,583              

Silicon Genesis Corp. Series 1-C Preferred Stock*

    962                   (716 )     (108,802 )     108,556              

Total Intellectual Property

  $ 737,224             $             $ (7,864,997 )   $ 7,626,109     $          

Advanced Materials

                                                               

UCT Coatings, Inc. Common Stock

    337,500                               (71,409 )     266,091       1,500,000  

Total Advanced Materials

  $ 337,500             $             $     $ (71,409 )   $ 266,091          

Automotive

                                                               

Wrightspeed, Inc. Common Stock*

    546                               (235 )     311       69,102  

Wrightspeed, Inc. Convertible Note*

    65,000                               (45,500 )     19,500       200,000  

Wrightspeed, Inc. Convertible Note*

    60,125                               (42,088 )     18,037       185,000  

Wrightspeed, Inc. Convertible Note*

    21,125                               (14,788 )     6,337       65,000  

Wrightspeed, Inc. Convertible Note*

    81,250                               (56,875 )     24,375       250,000  

Wrightspeed, Inc. Convertible Note*

    81,250                               (56,875 )     24,375       250,000  

Wrightspeed, Inc. Convertible Note*

    81,250                               (56,875 )     24,375       250,000  

Wrightspeed, Inc. Convertible Note*

    227,500                               (159,250 )     68,250       700,000  

Wrightspeed, Inc. Convertible Note*

    81,250                               (56,875 )     24,375       250,000  

Wrightspeed, Inc. Convertible Note*

    81,250                               (56,875 )     24,375       250,000  

Wrightspeed, Inc. Convertible Note*

    81,250                               (56,875 )     24,375       250,000  

Wrightspeed, Inc. Convertible Note*

    43,875                               (30,713 )     13,162       135,000  

Wrightspeed, Inc. Convertible Note*

    53,625                               (37,537 )     16,088       165,000  

 

AFFILIATE/
CONTROLLED
INVESTMENTS*

 

VALUE AT
12/31/22

   

PURCHASE/
MERGER

   

INTEREST

   

SALES/
MATURITY/
EXPIRATION

   

REALIZED
GAIN (LOSS)

   

CHANGE IN
APPRECIATION/
DEPRECIATION

   

VALUE
6/30/23

   

SHARES HELD
AT 6/30/23

 

Wrightspeed, Inc. Convertible Note*

  $ 40,625     $     $     $     $     $ (28,437 )   $ 12,188       125,000  

Wrightspeed, Inc. Convertible Note*

          100,000                         (90,250 )     9,750       100,000  

Wrightspeed, Inc. Convertible Note*

    81,250                               (56,875 )     24,375       250,000  

Wrightspeed, Inc. Convertible Note*

    325,000                               (227,500 )     97,500       1,000,000  

Wrightspeed, Inc. Convertible Note*

    325,000                               (227,500 )     97,500       1,000,000  

Wrightspeed, Inc. Convertible Note*

    325,000                               (227,500 )     97,500       1,000,000  

Wrightspeed, Inc. Convertible Note*

    1,601,930                               (1,121,351 )     480,579       4,929,015  

Wrightspeed, Inc. Convertible Note*

    243,750                               (170,625 )     73,125       750,000  

Wrightspeed, Inc. Convertible Note*

    292,500                               (204,750 )     87,750       900,000  

Wrightspeed, Inc. Convertible Note*

    121,875                               (85,313 )     36,562       375,000  

Wrightspeed, Inc. Convertible Note*

    130,000                               (91,000 )     39,000       400,000  

Wrightspeed, Inc. Convertible Note*

    341,250                               (238,875 )     102,375       1,050,000  

Wrightspeed, Inc. Convertible Note*

    325,000                               (227,500 )     97,500       1,000,000  

Wrightspeed, Inc. Convertible Note*

    325,000                               (227,500 )     97,500       1,000,000  

Wrightspeed, Inc. Convertible Note*

    325,000                               (227,500 )     97,500       1,000,000  

Wrightspeed, Inc. Convertible Note*

    390,000                               (273,000 )     117,000       1,200,000  

Wrightspeed, Inc. Convertible Note*

    455,000                               (318,500 )     136,500       1,400,000  

Wrightspeed, Inc. Convertible Note*

    650,000                               (455,000 )     195,000       2,000,000  

Wrightspeed, Inc. Convertible Note*

    130,000                               (91,000 )     39,000       400,000  

Wrightspeed, Inc. Convertible Note*

    97,500                               (68,250 )     29,250       300,000  

Wrightspeed, Inc. Convertible Note*

    325,000                               (227,500 )     97,500       1,000,000  

 

AFFILIATE/
CONTROLLED
INVESTMENTS*

 

VALUE AT
12/31/22

   

PURCHASE/
MERGER

   

INTEREST

   

SALES/
MATURITY/
EXPIRATION

   

REALIZED
GAIN (LOSS)

   

CHANGE IN
APPRECIATION/
DEPRECIATION

   

VALUE
6/30/23

   

SHARES HELD
AT 6/30/23

 

Wrightspeed, Inc. Series AA Preferred*

  $ 1,049,478     $     $     $     $     $ (476,245 )   $ 573,233       60,733,693  

Wrightspeed, Inc. Series AA Warrants*

    3,232                               (3,232 )            

Total Automotive

  $ 8,862,686             $             $     $ (6,036,564 )   $ 2,926,122          

Total Affiliates and Controlled Investments

  $ 39,349,502             $ 299,467             $ (7,864,997 )   $ (11,140,362 )   $ 19,945,807          

Total Affiliates

    337,500                                   (71,409 )     266,091          

Total Controlled Investments

  $ 39,012,002             $ 299,467             $ (7,864,997 )   $ (11,068,953 )   $ 19,679,716          

 

*

Controlled Investments.

(1)

CDI: CHESS Depositary Interest

XML 42 R27.htm IDEA: XBRL DOCUMENT v3.23.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)
6 Months Ended
Jun. 30, 2023
USD ($)
Accounting Policies [Abstract]  
PURCHASED OPTIONS (CONTRACTS) $ 0
WARRANTS (NOTIONAL VALUE) 1,252,639
WRITTEN OPTIONS (CONTRACTS) $ 0
XML 43 R28.htm IDEA: XBRL DOCUMENT v3.23.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
6 Months Ended
Jun. 30, 2023
Dec. 31, 2022
Accounting Policies [Abstract]    
Venture capital investments $ 16,300,000  
Restricted securities $ 16,336,361 $ 35,929,006
XML 44 R29.htm IDEA: XBRL DOCUMENT v3.23.2
INVESTMENT MANAGEMENT FEE (Details Narrative)
6 Months Ended
Jun. 30, 2023
USD ($)
Investment Management Fee  
Annual rate 2.00%
Incentive fee adjustments $ 0
XML 45 R30.htm IDEA: XBRL DOCUMENT v3.23.2
FAIR VALUE (Details) - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets $ 20,942,221 $ 40,203,857
Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets 4,276,596  
Fair Value, Inputs, Level 1 [Member] | Convertible Notes [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets 0  
Fair Value, Inputs, Level 1 [Member] | Mutual Funds [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets 567,150  
Fair Value, Inputs, Level 1 [Member] | Common Stock [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets 3,709,446  
Fair Value, Inputs, Level 1 [Member] | Preferred Stock [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets 0  
Fair Value, Inputs, Level 1 [Member] | Preferred Stock [Member] | Equity Contracts [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets [1] 0  
Fair Value, Inputs, Level 1 [Member] | Preferred Stock [Member] | Asset Derivatives [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets [1] 0  
Fair Value, Inputs, Level 1 [Member] | Advanced Materials [Member] | Convertible Notes [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets 0  
Fair Value, Inputs, Level 1 [Member] | Advanced Materials [Member] | Common Stock [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets 0  
Fair Value, Inputs, Level 1 [Member] | Automotive [Member] | Convertible Notes [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets 0  
Fair Value, Inputs, Level 1 [Member] | Automotive [Member] | Common Stock [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets 0  
Fair Value, Inputs, Level 1 [Member] | Automotive [Member] | Preferred Stock [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets 0  
Fair Value, Inputs, Level 1 [Member] | Equipment Leasing [Member] | Common Stock [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets 0  
Fair Value, Inputs, Level 1 [Member] | Equipment Leasing [Member] | Preferred Stock [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets 0  
Fair Value, Inputs, Level 1 [Member] | Semiconductor Equipment [Member] | Common Stock [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets 3,709,446  
Fair Value, Inputs, Level 1 [Member] | Aerospace [Member] | Convertible Notes [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets 0  
Fair Value, Inputs, Level 1 [Member] | Aerospace [Member] | Preferred Stock [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets 0  
Fair Value, Inputs, Level 1 [Member] | Medical Devices [Member] | Convertible Notes [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets 0  
Fair Value, Inputs, Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets 0  
Fair Value, Inputs, Level 2 [Member] | Convertible Notes [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets 0  
Fair Value, Inputs, Level 2 [Member] | Mutual Funds [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets 0  
Fair Value, Inputs, Level 2 [Member] | Common Stock [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets 0  
Fair Value, Inputs, Level 2 [Member] | Preferred Stock [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets 0  
Fair Value, Inputs, Level 2 [Member] | Preferred Stock [Member] | Equity Contracts [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets [1] 0  
Fair Value, Inputs, Level 2 [Member] | Preferred Stock [Member] | Asset Derivatives [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets [1] 0  
Fair Value, Inputs, Level 2 [Member] | Advanced Materials [Member] | Convertible Notes [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets 0  
Fair Value, Inputs, Level 2 [Member] | Advanced Materials [Member] | Common Stock [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets 0  
Fair Value, Inputs, Level 2 [Member] | Automotive [Member] | Convertible Notes [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets 0  
Fair Value, Inputs, Level 2 [Member] | Automotive [Member] | Common Stock [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets 0  
Fair Value, Inputs, Level 2 [Member] | Automotive [Member] | Preferred Stock [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets 0  
Fair Value, Inputs, Level 2 [Member] | Equipment Leasing [Member] | Common Stock [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets 0  
Fair Value, Inputs, Level 2 [Member] | Equipment Leasing [Member] | Preferred Stock [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets 0  
Fair Value, Inputs, Level 2 [Member] | Semiconductor Equipment [Member] | Common Stock [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets 0  
Fair Value, Inputs, Level 2 [Member] | Aerospace [Member] | Convertible Notes [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets 0  
Fair Value, Inputs, Level 2 [Member] | Aerospace [Member] | Preferred Stock [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets 0  
Fair Value, Inputs, Level 2 [Member] | Medical Devices [Member] | Convertible Notes [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets 0  
Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets 16,336,361  
Fair Value, Inputs, Level 3 [Member] | Convertible Notes [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets 14,048,353  
Fair Value, Inputs, Level 3 [Member] | Mutual Funds [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets 0  
Fair Value, Inputs, Level 3 [Member] | Common Stock [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets 268,282  
Fair Value, Inputs, Level 3 [Member] | Preferred Stock [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets 1,261,321  
Fair Value, Inputs, Level 3 [Member] | Preferred Stock [Member] | Equity Contracts [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets [1] 758,405  
Fair Value, Inputs, Level 3 [Member] | Preferred Stock [Member] | Asset Derivatives [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets [1] 758,405  
Fair Value, Inputs, Level 3 [Member] | Advanced Materials [Member] | Convertible Notes [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets 100,000  
Fair Value, Inputs, Level 3 [Member] | Advanced Materials [Member] | Common Stock [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets 266,091  
Fair Value, Inputs, Level 3 [Member] | Automotive [Member] | Convertible Notes [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets 2,352,578  
Fair Value, Inputs, Level 3 [Member] | Automotive [Member] | Common Stock [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets 311  
Fair Value, Inputs, Level 3 [Member] | Automotive [Member] | Preferred Stock [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets 573,233  
Fair Value, Inputs, Level 3 [Member] | Equipment Leasing [Member] | Common Stock [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets 1,880  
Fair Value, Inputs, Level 3 [Member] | Equipment Leasing [Member] | Preferred Stock [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets 383,756  
Fair Value, Inputs, Level 3 [Member] | Semiconductor Equipment [Member] | Common Stock [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets 0  
Fair Value, Inputs, Level 3 [Member] | Aerospace [Member] | Convertible Notes [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets 6,559,791  
Fair Value, Inputs, Level 3 [Member] | Aerospace [Member] | Preferred Stock [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets 304,332  
Fair Value, Inputs, Level 3 [Member] | Medical Devices [Member] | Convertible Notes [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets $ 5,035,984  
[1] Asset derivatives include warrants.
XML 46 R31.htm IDEA: XBRL DOCUMENT v3.23.2
FAIR VALUE (Details 1)
6 Months Ended
Jun. 30, 2023
USD ($)
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]  
BEGINNING BALANCE $ 35,929,006
NET PURCHASES/CONVERSIONS 100,000
NET SALES/CONVERSIONS (498,425)
NET REALIZED GAINS/(LOSSES) (7,864,995)
NET UNREALIZED APPRECIATION (DEPRECIATION) (11,329,225) [1]
TRANSFERS IN (OUT) OF LEVEL 3 0
ENDING BALANCE 16,336,361
Convertible Notes [Member]  
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]  
BEGINNING BALANCE 31,585,942
NET PURCHASES/CONVERSIONS 100,000
NET SALES/CONVERSIONS 0
NET REALIZED GAINS/(LOSSES) 0
NET UNREALIZED APPRECIATION (DEPRECIATION) (17,637,589) [1]
TRANSFERS IN (OUT) OF LEVEL 3 0
ENDING BALANCE 14,048,353
Common Stock [Member]  
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]  
BEGINNING BALANCE 349,287
NET PURCHASES/CONVERSIONS 0
NET SALES/CONVERSIONS (7,966)
NET REALIZED GAINS/(LOSSES) (161,079)
NET UNREALIZED APPRECIATION (DEPRECIATION) 88,040 [1]
TRANSFERS IN (OUT) OF LEVEL 3 0
ENDING BALANCE 268,282
Common Stock [Member] | Intellectual Property [Member]  
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]  
BEGINNING BALANCE 111
NET PURCHASES/CONVERSIONS 0
NET SALES/CONVERSIONS (7,966)
NET REALIZED GAINS/(LOSSES) (161,079)
NET UNREALIZED APPRECIATION (DEPRECIATION) 168,934 [1]
TRANSFERS IN (OUT) OF LEVEL 3 0
ENDING BALANCE 0
Preferred Stock [Member]  
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]  
BEGINNING BALANCE 3,036,652
NET PURCHASES/CONVERSIONS 0
NET SALES/CONVERSIONS (490,459)
NET REALIZED GAINS/(LOSSES) (7,697,238)
NET UNREALIZED APPRECIATION (DEPRECIATION) 6,412,366 [1]
TRANSFERS IN (OUT) OF LEVEL 3 0
ENDING BALANCE 1,261,321
Preferred Stock [Member] | Equity Contracts [Member]  
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]  
BEGINNING BALANCE 957,125
NET PURCHASES/CONVERSIONS 0
NET SALES/CONVERSIONS 0
NET REALIZED GAINS/(LOSSES) (6,678)
NET UNREALIZED APPRECIATION (DEPRECIATION) (192,042) [1]
TRANSFERS IN (OUT) OF LEVEL 3 0
ENDING BALANCE 758,405
Preferred Stock [Member] | Asset Derivatives [Member]  
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]  
BEGINNING BALANCE 957,125
NET PURCHASES/CONVERSIONS 0
NET SALES/CONVERSIONS 0
NET REALIZED GAINS/(LOSSES) (6,678)
NET UNREALIZED APPRECIATION (DEPRECIATION) (192,042) [1]
TRANSFERS IN (OUT) OF LEVEL 3 0
ENDING BALANCE 758,405
Preferred Stock [Member] | Intellectual Property [Member]  
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]  
BEGINNING BALANCE 737,112
NET PURCHASES/CONVERSIONS 0
NET SALES/CONVERSIONS (490,459)
NET REALIZED GAINS/(LOSSES) (7,697,238)
NET UNREALIZED APPRECIATION (DEPRECIATION) 7,450,585 [1]
TRANSFERS IN (OUT) OF LEVEL 3 0
ENDING BALANCE 0
Advanced Materials [Member]  
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]  
BEGINNING BALANCE 337,500
ENDING BALANCE 266,091
Advanced Materials [Member] | Convertible Notes [Member]  
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]  
BEGINNING BALANCE 100,000
NET PURCHASES/CONVERSIONS 0
NET SALES/CONVERSIONS 0
NET REALIZED GAINS/(LOSSES) 0
NET UNREALIZED APPRECIATION (DEPRECIATION) 0 [1]
TRANSFERS IN (OUT) OF LEVEL 3 0
ENDING BALANCE 100,000
Advanced Materials [Member] | Common Stock [Member]  
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]  
BEGINNING BALANCE 337,500
NET PURCHASES/CONVERSIONS 0
NET SALES/CONVERSIONS 0
NET REALIZED GAINS/(LOSSES) 0
NET UNREALIZED APPRECIATION (DEPRECIATION) (71,409) [1]
TRANSFERS IN (OUT) OF LEVEL 3 0
ENDING BALANCE 266,091
Automotive [Member]  
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]  
BEGINNING BALANCE 8,862,686
ENDING BALANCE 2,926,122
Automotive [Member] | Convertible Notes [Member]  
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]  
BEGINNING BALANCE 7,809,430
NET PURCHASES/CONVERSIONS 100,000
NET SALES/CONVERSIONS 0
NET REALIZED GAINS/(LOSSES) 0
NET UNREALIZED APPRECIATION (DEPRECIATION) (5,556,852) [1]
TRANSFERS IN (OUT) OF LEVEL 3 0
ENDING BALANCE 2,352,578
Automotive [Member] | Common Stock [Member]  
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]  
BEGINNING BALANCE 546
NET PURCHASES/CONVERSIONS 0
NET SALES/CONVERSIONS 0
NET REALIZED GAINS/(LOSSES) 0
NET UNREALIZED APPRECIATION (DEPRECIATION) (235) [1]
TRANSFERS IN (OUT) OF LEVEL 3 0
ENDING BALANCE 311
Automotive [Member] | Preferred Stock [Member]  
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]  
BEGINNING BALANCE 1,049,478
NET PURCHASES/CONVERSIONS 0
NET SALES/CONVERSIONS 0
NET REALIZED GAINS/(LOSSES) 0
NET UNREALIZED APPRECIATION (DEPRECIATION) (476,245) [1]
TRANSFERS IN (OUT) OF LEVEL 3 0
ENDING BALANCE 573,233
Equipment Leasing [Member]  
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]  
BEGINNING BALANCE 877,125
ENDING BALANCE 385,636
Equipment Leasing [Member] | Common Stock [Member]  
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]  
BEGINNING BALANCE 11,130
NET PURCHASES/CONVERSIONS 0
NET SALES/CONVERSIONS 0
NET REALIZED GAINS/(LOSSES) 0
NET UNREALIZED APPRECIATION (DEPRECIATION) (9,250) [1]
TRANSFERS IN (OUT) OF LEVEL 3 0
ENDING BALANCE 1,880
Equipment Leasing [Member] | Preferred Stock [Member]  
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]  
BEGINNING BALANCE 865,995
NET PURCHASES/CONVERSIONS 0
NET SALES/CONVERSIONS 0
NET REALIZED GAINS/(LOSSES) 0
NET UNREALIZED APPRECIATION (DEPRECIATION) (482,239) [1]
TRANSFERS IN (OUT) OF LEVEL 3 0
ENDING BALANCE 383,756
Aerospace [Member]  
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]  
BEGINNING BALANCE 7,897,750
ENDING BALANCE 7,622,528
Aerospace [Member] | Convertible Notes [Member]  
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]  
BEGINNING BALANCE 6,559,791
NET PURCHASES/CONVERSIONS 0
NET SALES/CONVERSIONS 0
NET REALIZED GAINS/(LOSSES) 0
NET UNREALIZED APPRECIATION (DEPRECIATION) 0 [1]
TRANSFERS IN (OUT) OF LEVEL 3 0
ENDING BALANCE 6,559,791
Aerospace [Member] | Preferred Stock [Member]  
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]  
BEGINNING BALANCE 384,067
NET PURCHASES/CONVERSIONS 0
NET SALES/CONVERSIONS 0
NET REALIZED GAINS/(LOSSES) 0
NET UNREALIZED APPRECIATION (DEPRECIATION) (79,735) [1]
TRANSFERS IN (OUT) OF LEVEL 3 0
ENDING BALANCE 304,332
Medical Devices [Member]  
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]  
BEGINNING BALANCE 17,116,721
ENDING BALANCE 5,035,984
Medical Devices [Member] | Convertible Notes [Member]  
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]  
BEGINNING BALANCE 17,116,721
NET PURCHASES/CONVERSIONS 0
NET SALES/CONVERSIONS 0
NET REALIZED GAINS/(LOSSES) 0
NET UNREALIZED APPRECIATION (DEPRECIATION) (12,080,737) [1]
TRANSFERS IN (OUT) OF LEVEL 3 0
ENDING BALANCE $ 5,035,984
[1] The net change in unrealized appreciation (depreciation) from Level 3 instruments held as of June 30, 2023 was $ (18,952,188).
XML 47 R32.htm IDEA: XBRL DOCUMENT v3.23.2
FAIR VALUE (Details 2)
$ in Millions
Jun. 30, 2023
USD ($)
Advanced Materials [Member]  
Property, Plant and Equipment [Line Items]  
FAIR VALUE $ 0.4
Aerospace [Member]  
Property, Plant and Equipment [Line Items]  
FAIR VALUE 7.6
Automotive [Member]  
Property, Plant and Equipment [Line Items]  
FAIR VALUE 2.9
Equipment Leasing [Member]  
Property, Plant and Equipment [Line Items]  
FAIR VALUE 0.4
Medical Devices [Member]  
Property, Plant and Equipment [Line Items]  
FAIR VALUE $ 5.0
XML 48 R33.htm IDEA: XBRL DOCUMENT v3.23.2
FEDERAL INCOME TAXES (Details)
Jun. 30, 2023
USD ($)
Income Tax Disclosure [Abstract]  
Gross unrealized appreciation $ 758,405
Gross unrealized depreciation (114,566,765)
Net unrealized (depreciation) (113,808,360)
Federal income tax cost, Investments $ 134,421,317
XML 49 R34.htm IDEA: XBRL DOCUMENT v3.23.2
FEDERAL INCOME TAXES (Details 1)
6 Months Ended
Jun. 30, 2023
USD ($)
Income Tax Disclosure [Abstract]  
Federal $ 0
State 0
Total deferred tax (expense)/benefit $ 0
XML 50 R35.htm IDEA: XBRL DOCUMENT v3.23.2
FEDERAL INCOME TAXES (Details 2)
Jun. 30, 2023
USD ($)
Income Tax Disclosure [Abstract]  
Net operating loss carryforward $ 4,616,720
Capital loss carryforward 6,960,412
Net unrealized losses (gains) on investment securities 28,726,530
Total deferred tax assets 40,303,662
Valuation allowance (40,303,662)
Net $ 0
XML 51 R36.htm IDEA: XBRL DOCUMENT v3.23.2
FEDERAL INCOME TAXES (Details 3)
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Income Tax Disclosure [Abstract]        
Effective tax rate 0.00% 0.00% 0.00% 0.00%
Statutory federal income tax rate 21.00% 21.00% 21.00% 21.00%
XML 52 R37.htm IDEA: XBRL DOCUMENT v3.23.2
FEDERAL INCOME TAXES (Details 4)
6 Months Ended
Jun. 30, 2023
USD ($)
Tax Credit Carryforward [Line Items]  
Capital loss carryforwards $ 6,960,412
Capital Loss Carryforward 1 [Member]  
Tax Credit Carryforward [Line Items]  
EXPIRATION DATE 12/31/24
Capital loss carryforwards $ 14,230,073
Capital Loss Carryforward 2 [Member]  
Tax Credit Carryforward [Line Items]  
EXPIRATION DATE 12/31/25
Capital loss carryforwards $ 7,516,642
Capital Loss Carryforward 3 [Member]  
Tax Credit Carryforward [Line Items]  
EXPIRATION DATE 12/31/27
Capital loss carryforwards $ 3,129,665
Capital Loss Carryforwards [Member]  
Tax Credit Carryforward [Line Items]  
Capital loss carryforwards $ 24,876,380
XML 53 R38.htm IDEA: XBRL DOCUMENT v3.23.2
FEDERAL INCOME TAXES (Details Narrative) - USD ($)
6 Months Ended 12 Months Ended
Jun. 30, 2023
Dec. 31, 2022
Income Tax Disclosure [Abstract]    
Statutory tax rate 21.00%  
State tax rate 6.98%  
Effective tax rate   0.00%
State income tax 21.00% 27.98%
Net operating loss carryforwards   $ 16,500,072
Net capital loss carryforwards   5 years
XML 54 R39.htm IDEA: XBRL DOCUMENT v3.23.2
INVESTMENT TRANSACTIONS (Details)
3 Months Ended
Jun. 30, 2023
USD ($)
Investments, All Other Investments [Abstract]  
Purchases of investment securities $ 100,000
Proceeds from sales and maturities of investment securities $ 498,425
XML 55 R40.htm IDEA: XBRL DOCUMENT v3.23.2
SHARE BUYBACKS (Details Narrative) - USD ($)
$ / shares in Units, $ in Millions
1 Months Ended
Dec. 16, 2019
Aug. 31, 2018
Nov. 10, 2017
Apr. 26, 2016
Dec. 22, 2014
Mar. 31, 2020
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2014
Accumulated Other Comprehensive Income (Loss) [Line Items]                  
Repurchased of shares value   123,376   272,008          
Repurchased of shares value       $ 2.0          
Authorized to purchase     $ 2.0            
Repurchased and retired shares     128,551            
Repurchased and retired shares value     $ 1.1            
Shares outstanding           6,893,056 7,178,770 7,302,146  
Average price   $ 16.21              
Common shares for cash         $ 20.0        
Trading price                 $ 23.2702
Tender offer description         Of the 5,044,728 shares properly tendered, the Fund purchased 859,468 shares of common stock pursuant to the tender offer        
Common Stock [Member]                  
Accumulated Other Comprehensive Income (Loss) [Line Items]                  
Common stock value       2,000,000          
Tender offer $ 2.0                
Increment of per share $ 0.10                
Tender offer expired Feb. 14, 2020                
Purchase of shares 285,714                
Common stock price $ 7.00                
Common Stock [Member] | Minimum [Member]                  
Accumulated Other Comprehensive Income (Loss) [Line Items]                  
Price per share 6.00                
Common Stock [Member] | Maximum [Member]                  
Accumulated Other Comprehensive Income (Loss) [Line Items]                  
Price per share $ 8.00                
S V V C Stock [Member]                  
Accumulated Other Comprehensive Income (Loss) [Line Items]                  
Repurchased of shares value   $ 2.0              
Total consideration amount   $ 2.0              
XML 56 R41.htm IDEA: XBRL DOCUMENT v3.23.2
INVESTMENTS IN AFFILIATES AND CONTROLLED INVESTMENTS (Details)
6 Months Ended
Jun. 30, 2023
USD ($)
shares
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 35,929,006
ENDING BALANCE 16,336,361
Equipment Leasing [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE 877,125
INTEREST 0
REALIZED GAIN (LOSS) 0
CHANGE IN APPRECIATION/(DEPRECIATION) (491,489)
ENDING BALANCE 385,636
Aerospace [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE 7,897,750
INTEREST 299,467
REALIZED GAIN (LOSS) 0
CHANGE IN APPRECIATION/(DEPRECIATION) (275,222)
ENDING BALANCE 7,622,528
Medical Devices [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE 17,116,721
INTEREST 0
REALIZED GAIN (LOSS) 0
CHANGE IN APPRECIATION/(DEPRECIATION) (12,080,737)
ENDING BALANCE 5,035,984
Semiconductor Equipment [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE 3,520,496
INTEREST 0
REALIZED GAIN (LOSS) 0
CHANGE IN APPRECIATION/(DEPRECIATION) 188,950
ENDING BALANCE 3,709,446
Intellectuals Property [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE 737,224
INTEREST 0
REALIZED GAIN (LOSS) (7,864,997)
CHANGE IN APPRECIATION/(DEPRECIATION) 7,626,109
ENDING BALANCE 0
Advanced Materials [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE 337,500
INTEREST 0
REALIZED GAIN (LOSS) 0
CHANGE IN APPRECIATION/(DEPRECIATION) (71,409)
ENDING BALANCE 266,091
Automotive [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE 8,862,686
INTEREST 0
REALIZED GAIN (LOSS) 0
CHANGE IN APPRECIATION/(DEPRECIATION) (6,036,564)
ENDING BALANCE 2,926,122
E Q X Capital Inc Common Stock [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE 11,130 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) (9,250) [1]
ENDING BALANCE $ 1,880 [1]
SHARES HELD | shares 100,000 [1]
E Q X Capital Inc Series A Preferred Stock [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 865,995 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) (482,239) [1]
ENDING BALANCE $ 383,756 [1]
SHARES HELD | shares 1,950,000 [1]
Hera Systems Inc Convertible Note [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 5,359,791 [1]
PURCHASE/MERGER 0 [1]
INTEREST 269,478 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) 0 [1]
ENDING BALANCE $ 5,359,791 [1]
SHARES HELD | shares 5,359,791 [1]
Hera Systems Inc Convertible Note 1 [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 1,200,000 [1]
PURCHASE/MERGER 0 [1]
INTEREST 29,989 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) 0 [1]
ENDING BALANCE $ 1,200,000 [1]
SHARES HELD | shares 1,200,000 [1]
Hera Systems Inc Series A Preferred [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 4,735 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) (2,169) [1]
ENDING BALANCE $ 2,566 [1]
SHARES HELD | shares 3,642,324 [1]
Hera Systems Inc Series B Preferred [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 275,585 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) (56,352) [1]
ENDING BALANCE $ 219,233 [1]
SHARES HELD | shares 7,039,203
Hera Systems Inc Series B Warrants [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 478,608
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) (98,084) [1]
ENDING BALANCE $ 380,524 [1]
SHARES HELD | shares 12,250,000 [1]
Hera Systems Inc Series B Warrants 1 [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 242,817 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) (49,762) [1]
ENDING BALANCE $ 193,055 [1]
SHARES HELD | shares 6,214,922 [1]
Hera Systems Inc Series B Warrants 2 [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 205,118 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) (42,036) [1]
ENDING BALANCE $ 163,082 [1]
SHARES HELD | shares 5,250,000 [1]
Hera Systems Inc Series B Warrants 3 [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 27,349 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) (5,605) [1]
ENDING BALANCE $ 21,744 [1]
SHARES HELD | shares 700,000 [1]
Hera Systems Inc Series C Preferred [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 103,747 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) (21,214) [1]
ENDING BALANCE $ 82,533 [1]
SHARES HELD | shares 2,650,000 [1]
Intra Op Medical Corp Convertible Note [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 6,746,169 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) (4,761,350) [1]
ENDING BALANCE $ 1,984,819 [1]
SHARES HELD | shares 10,961,129 [1]
Intra Op Medical Corp Convertible Note 1 [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 800,102 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) (564,701) [1]
ENDING BALANCE $ 235,401 [1]
SHARES HELD | shares 1,300,000 [1]
Intra Op Medical Corp Convertible Note 2 [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 307,731 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) (217,192) [1]
ENDING BALANCE $ 90,539 [1]
SHARES HELD | shares 500,000 [1]
Intra Op Medical Corp Convertible Note 3 [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 307,731 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) (217,192) [1]
ENDING BALANCE $ 90,539 [1]
SHARES HELD | shares 500,000 [1]
Intra Op Medical Corp Convertible Note 4 [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 1,846,389 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) (1,303,155) [1]
ENDING BALANCE $ 543,234 [1]
SHARES HELD | shares 3,000,000 [1]
Intra Op Medical Corp Convertible Note 5 [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 615,463 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) (434,385) [1]
ENDING BALANCE $ 181,078 [1]
SHARES HELD | shares 1,000,000 [1]
Intra Op Medical Corp Convertible Note 6 [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 246,185 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) (173,754) [1]
ENDING BALANCE $ 72,431 [1]
SHARES HELD | shares 400,000 [1]
Intra Op Medical Corp Convertible Note 7 [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 307,731 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) (217,192) [1]
ENDING BALANCE $ 90,539 [1]
SHARES HELD | shares 500,000 [1]
Intra Op Medical Corp Convertible Note 8 [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 461,597 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) (325,788) [1]
ENDING BALANCE $ 135,809 [1]
SHARES HELD | shares 750,000 [1]
Intra Op Medical Corp Convertible Note 9 [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 307,731 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) (217,192) [1]
ENDING BALANCE $ 90,539 [1]
SHARES HELD | shares 500,000 [1]
Intra Op Medical Corp Convertible Note 10 [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 307,732 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) (217,193) [1]
ENDING BALANCE $ 90,539 [1]
SHARES HELD | shares 500,000 [1]
Intra Op Medical Corp Convertible Note 11 [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 307,732 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) (217,193) [1]
ENDING BALANCE $ 90,539 [1]
SHARES HELD | shares 500,000 [1]
Intra Op Medical Corp Convertible Note 12 [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 615,463 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) (434,385) [1]
ENDING BALANCE $ 181,078 [1]
SHARES HELD | shares 1,000,000 [1]
Intra Op Medical Corp Convertible Note 13 [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 307,732 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) (217,193) [1]
ENDING BALANCE $ 90,539 [1]
SHARES HELD | shares 500,000 [1]
Intra Op Medical Corp Convertible Note 14 [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 615,463 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) (434,385) [1]
ENDING BALANCE $ 181,078 [1]
SHARES HELD | shares 1,000,000 [1]
Intra Op Medical Corp Convertible Note 15 [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 307,732 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) (217,193) [1]
ENDING BALANCE $ 90,539 [1]
SHARES HELD | shares 500,000 [1]
Intra Op Medical Corp Convertible Note 16 [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 307,732 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) (217,193) [1]
ENDING BALANCE $ 90,539 [1]
SHARES HELD | shares 500,000 [1]
Intra Op Medical Corp Convertible Note 17 [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 307,732 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) (217,193) [1]
ENDING BALANCE $ 90,539 [1]
SHARES HELD | shares 500,000 [1]
Intra Op Medical Corp Convertible Note 18 [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 123,093 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) (86,877) [1]
ENDING BALANCE $ 36,216 [1]
SHARES HELD | shares 200,000 [1]
Intra Op Medical Corp Convertible Note 19 [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 430,824 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) (304,069) [1]
ENDING BALANCE $ 126,755 [1]
SHARES HELD | shares 700,000 [1]
Intra Op Medical Corp Convertible Note 20 [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 92,319 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) (65,157) [1]
ENDING BALANCE $ 27,162 [1]
SHARES HELD | shares 150,000 [1]
Intra Op Medical Corp Convertible Note 21 [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 215,412 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) (152,035) [1]
ENDING BALANCE $ 63,377 [1]
SHARES HELD | shares 350,000 [1]
Intra Op Medical Corp Series C Preferred [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 0 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) 0 [1]
ENDING BALANCE $ 0 [1]
SHARES HELD | shares 26,856,187 [1]
Intra Op Medical Corp Term Note [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 1,230,926 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) (868,770) [1]
ENDING BALANCE $ 362,156 [1]
SHARES HELD | shares 2,000,000 [1]
Revasum Inc C D I [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 3,520,496 [1],[2]
PURCHASE/MERGER 0 [1],[2]
INTEREST 0 [1],[2]
SALES/MATURITY/EXPIRATION 0 [1],[2]
REALIZED GAIN (LOSS) 0 [1],[2]
CHANGE IN APPRECIATION/(DEPRECIATION) 188,950 [1],[2]
ENDING BALANCE $ 3,709,446 [1],[2]
SHARES HELD | shares 39,774,889 [1],[2]
Silicon Genesis Corp Common Stock [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 111 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION (7,966) [1]
REALIZED GAIN (LOSS) (161,080) [1]
CHANGE IN APPRECIATION/(DEPRECIATION) 168,935 [1]
ENDING BALANCE $ 0 [1]
SHARES HELD | shares 0 [1]
Silicon Genesis Corp Common Warrants [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 1 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION (1) [1]
REALIZED GAIN (LOSS) (6,677) [1]
CHANGE IN APPRECIATION/(DEPRECIATION) 6,677 [1]
ENDING BALANCE $ 0 [1]
SHARES HELD | shares 0 [1]
Silicon Genesis Corp Series 1 G Preferred [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 306,671 [1]
PURCHASE/MERGER 88 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION (417,972) [1]
REALIZED GAIN (LOSS) (3,462,620) [1]
CHANGE IN APPRECIATION/(DEPRECIATION) 3,573,833 [1]
ENDING BALANCE $ 0 [1]
SHARES HELD | shares 0 [1]
Silicon Genesis Corp Series 1 H Preferred [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 35,529 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION (7,241) [1]
REALIZED GAIN (LOSS) (929,654) [1]
CHANGE IN APPRECIATION/(DEPRECIATION) 901,366 [1]
ENDING BALANCE $ 0 [1]
SHARES HELD | shares 0 [1]
Silicon Genesis Corp Series 1 D Preferred [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 2,552 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION (7,351) [1]
REALIZED GAIN (LOSS) (424,549) [1]
CHANGE IN APPRECIATION/(DEPRECIATION) 429,348 [1]
ENDING BALANCE $ 0 [1]
SHARES HELD | shares 0 [1]
Silicon Genesis Corp Series 1 E Preferred [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 320,592 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION (49,292) [1]
REALIZED GAIN (LOSS) (2,323,111) [1]
CHANGE IN APPRECIATION/(DEPRECIATION) 2,051,811 [1]
ENDING BALANCE $ 0 [1]
SHARES HELD | shares 0 [1]
Silicon Genesis Corp Series 1 F Preferred [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 70,806 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION (7,885) [1]
REALIZED GAIN (LOSS) (448,504) [1]
CHANGE IN APPRECIATION/(DEPRECIATION) 385,583 [1]
ENDING BALANCE $ 0 [1]
SHARES HELD | shares 0 [1]
Silicon Genesis Corp Series 1 C Preferred Stock [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 962 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION (716) [1]
REALIZED GAIN (LOSS) (108,802) [1]
CHANGE IN APPRECIATION/(DEPRECIATION) 108,556 [1]
ENDING BALANCE $ 0 [1]
SHARES HELD | shares 0 [1]
U C T Coatings Inc Common Stock [Member] | Advanced Materials [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 337,500
PURCHASE/MERGER 0
INTEREST 0
SALES/MATURITY/EXPIRATION 0
REALIZED GAIN (LOSS) 0
CHANGE IN APPRECIATION/(DEPRECIATION) (71,409)
ENDING BALANCE $ 266,091
SHARES HELD | shares 1,500,000
Wrightspeed Inc Common Stock [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 546 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) (235) [1]
ENDING BALANCE $ 311 [1]
SHARES HELD | shares 69,102 [1]
Wrightspeed Inc Convertible Note [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 65,000 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) (45,500) [1]
ENDING BALANCE $ 19,500 [1]
SHARES HELD | shares 200,000 [1]
Wrightspeed Inc Convertible Note 1 [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 60,125 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) (42,088) [1]
ENDING BALANCE $ 18,037 [1]
SHARES HELD | shares 185,000 [1]
Wrightspeed Inc Convertible Note 2 [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 21,125 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) (14,788) [1]
ENDING BALANCE $ 6,337 [1]
SHARES HELD | shares 65,000 [1]
Wrightspeed Inc Convertible Note 3 [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 81,250 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) (56,875) [1]
ENDING BALANCE $ 24,375 [1]
SHARES HELD | shares 250,000 [1]
Wrightspeed Inc Convertible Note 4 [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 81,250 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) (56,875) [1]
ENDING BALANCE $ 24,375 [1]
SHARES HELD | shares 250,000 [1]
Wrightspeed Inc Convertible Note 5 [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 81,250 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) (56,875) [1]
ENDING BALANCE $ 24,375 [1]
SHARES HELD | shares 250,000 [1]
Wrightspeed Inc Convertible Note 6 [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 227,500 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) (159,250) [1]
ENDING BALANCE $ 68,250 [1]
SHARES HELD | shares 700,000 [1]
Wrightspeed Inc Convertible Note 7 [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 81,250 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) (56,875) [1]
ENDING BALANCE $ 24,375 [1]
SHARES HELD | shares 250,000 [1]
Wrightspeed Inc Convertible Note 8 [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 81,250 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) (56,875) [1]
ENDING BALANCE $ 24,375 [1]
SHARES HELD | shares 250,000 [1]
Wrightspeed Inc Convertible Note 9 [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 81,250 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) (56,875) [1]
ENDING BALANCE $ 24,375 [1]
SHARES HELD | shares 250,000 [1]
Wrightspeed Inc Convertible Note 10 [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 43,875 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) (30,713) [1]
ENDING BALANCE $ 13,162 [1]
SHARES HELD | shares 135,000 [1]
Wrightspeed Inc Convertible Note 11 [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 53,625 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) (37,537) [1]
ENDING BALANCE $ 16,088 [1]
SHARES HELD | shares 165,000 [1]
Wrightspeed Inc Convertible Note 12 [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 40,625 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) (28,437) [1]
ENDING BALANCE $ 12,188 [1]
SHARES HELD | shares 125,000 [1]
Wrightspeed Inc Convertible Note 13 [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 0 [1]
PURCHASE/MERGER 100,000 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) (90,250) [1]
ENDING BALANCE $ 9,750 [1]
SHARES HELD | shares 100,000 [1]
Wrightspeed Inc Convertible Note 14 [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 81,250 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) (56,875) [1]
ENDING BALANCE $ 24,375 [1]
SHARES HELD | shares 250,000 [1]
Wrightspeed Inc Convertible Note 15 [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 325,000 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) (227,500) [1]
ENDING BALANCE $ 97,500 [1]
SHARES HELD | shares 1,000,000 [1]
Wrightspeed Inc Convertible Note 16 [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 325,000 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) (227,500) [1]
ENDING BALANCE $ 97,500 [1]
SHARES HELD | shares 1,000,000 [1]
Wrightspeed Inc Convertible Note 17 [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 325,000 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) (227,500) [1]
ENDING BALANCE $ 97,500 [1]
SHARES HELD | shares 1,000,000 [1]
Wrightspeed Inc Convertible Note 18 [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 1,601,930 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) (1,121,351) [1]
ENDING BALANCE $ 480,579 [1]
SHARES HELD | shares 4,929,015 [1]
Wrightspeed Inc Convertible Note 19 [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 243,750 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) (170,625) [1]
ENDING BALANCE $ 73,125 [1]
SHARES HELD | shares 750,000 [1]
Wrightspeed Inc Convertible Note 20 [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 292,500 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) (204,750) [1]
ENDING BALANCE $ 87,750 [1]
SHARES HELD | shares 900,000 [1]
Wrightspeed Inc Convertible Note 21 [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 121,875 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) (85,313) [1]
ENDING BALANCE $ 36,562 [1]
SHARES HELD | shares 375,000 [1]
Wrightspeed Inc Convertible Note 22 [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 130,000 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) (91,000) [1]
ENDING BALANCE $ 39,000 [1]
SHARES HELD | shares 400,000 [1]
Wrightspeed Inc Convertible Note 23 [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 341,250 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) (238,875) [1]
ENDING BALANCE $ 102,375 [1]
SHARES HELD | shares 1,050,000 [1]
Wrightspeed Inc Convertible Note 24 [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 325,000 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) (227,500) [1]
ENDING BALANCE $ 97,500 [1]
SHARES HELD | shares 1,000,000 [1]
Wrightspeed Inc Convertible Note 25 [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 325,000 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) (227,500) [1]
ENDING BALANCE $ 97,500 [1]
SHARES HELD | shares 1,000,000 [1]
Wrightspeed Inc Convertible Note 26 [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 325,000 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) (227,500) [1]
ENDING BALANCE $ 97,500 [1]
SHARES HELD | shares 1,000,000 [1]
Wrightspeed Inc Convertible Note 27 [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 390,000 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) (273,000) [1]
ENDING BALANCE $ 117,000 [1]
SHARES HELD | shares 1,200,000 [1]
Wrightspeed Inc Convertible Note 28 [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 455,000 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) (318,500) [1]
ENDING BALANCE $ 136,500 [1]
SHARES HELD | shares 1,400,000 [1]
Wrightspeed Inc Convertible Note 29 [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 650,000 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) (455,000) [1]
ENDING BALANCE $ 195,000 [1]
SHARES HELD | shares 2,000,000 [1]
Wrightspeed Inc Convertible Note 30 [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 130,000 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) (91,000) [1]
ENDING BALANCE $ 39,000 [1]
SHARES HELD | shares 400,000 [1]
Wrightspeed Inc Convertible Note 31 [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 97,500 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) (68,250) [1]
ENDING BALANCE $ 29,250 [1]
SHARES HELD | shares 300,000 [1]
Wrightspeed Inc Convertible Note 32 [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 325,000 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) (227,500) [1]
ENDING BALANCE $ 97,500 [1]
SHARES HELD | shares 1,000,000 [1]
Wrightspeed Inc Series A A Preferred [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 1,049,478 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) (476,245) [1]
ENDING BALANCE $ 573,233 [1]
SHARES HELD | shares 60,733,693 [1]
Wrightspeed Inc Series A A Warrants [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 3,232 [1]
PURCHASE/MERGER 0 [1]
INTEREST 0 [1]
SALES/MATURITY/EXPIRATION 0 [1]
REALIZED GAIN (LOSS) 0 [1]
CHANGE IN APPRECIATION/(DEPRECIATION) (3,232) [1]
ENDING BALANCE $ 0 [1]
SHARES HELD | shares 0 [1]
Total Affiliates And Controlled Investments [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE $ 39,349,502
INTEREST 299,467
REALIZED GAIN (LOSS) (7,864,997)
CHANGE IN APPRECIATION/(DEPRECIATION) (11,140,362)
ENDING BALANCE 19,945,807
Affiliates [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE 337,500
INTEREST 0
REALIZED GAIN (LOSS) 0
CHANGE IN APPRECIATION/(DEPRECIATION) (71,409)
ENDING BALANCE 266,091
Controlled Investments [Member]  
Investments in and Advances to Affiliates [Line Items]  
BEGINNING BALANCE 39,012,002
INTEREST 299,467
REALIZED GAIN (LOSS) (7,864,997)
CHANGE IN APPRECIATION/(DEPRECIATION) (11,068,953)
ENDING BALANCE $ 19,679,716
[1] Controlled Investments.
[2] CDI: CHESS Depositary Interest
XML 57 fp0084654-3_10qaixbrl_htm.xml IDEA: XBRL DOCUMENT 0001495584 2023-01-01 2023-06-30 0001495584 2023-06-30 0001495584 2022-12-31 0001495584 2023-04-01 2023-06-30 0001495584 2022-04-01 2022-06-30 0001495584 2022-01-01 2022-06-30 0001495584 2023-03-31 0001495584 2022-03-31 0001495584 2021-12-31 0001495584 2022-06-30 0001495584 2020-12-31 0001495584 2019-12-31 0001495584 2018-12-31 0001495584 2017-12-31 0001495584 2022-01-01 2022-12-31 0001495584 2021-01-01 2021-12-31 0001495584 2020-01-01 2020-12-31 0001495584 2019-01-01 2019-12-31 0001495584 2018-01-01 2018-12-31 0001495584 SVVC:EqxCapitalIncMember 2023-01-01 2023-06-30 0001495584 SVVC:EqxCapitalIncMember 2023-06-30 0001495584 SVVC:EquipmentLeasingMember 2023-01-01 2023-06-30 0001495584 SVVC:EquipmentLeasingMember 2023-06-30 0001495584 SVVC:EqxCapitalInc1Member 2023-06-30 0001495584 SVVC:HeraSystemsIncMember 2023-01-01 2023-06-30 0001495584 SVVC:HeraSystemsIncMember 2023-06-30 0001495584 SVVC:HeraSystemsInc1Member 2023-01-01 2023-06-30 0001495584 SVVC:HeraSystemsInc1Member 2023-06-30 0001495584 SVVC:HeraSystemsInc2Member 2023-01-01 2023-06-30 0001495584 SVVC:HeraSystemsInc2Member 2023-06-30 0001495584 SVVC:HeraSystemsInc3Member 2023-01-01 2023-06-30 0001495584 SVVC:HeraSystemsInc3Member 2023-06-30 0001495584 SVVC:HeraSystemsInc4Member 2023-01-01 2023-06-30 0001495584 SVVC:HeraSystemsInc4Member 2023-06-30 0001495584 SVVC:HeraSystemsInc5Member 2023-01-01 2023-06-30 0001495584 SVVC:HeraSystemsInc5Member 2023-06-30 0001495584 SVVC:HeraSystemsInc6Member 2023-01-01 2023-06-30 0001495584 SVVC:HeraSystemsInc6Member 2023-06-30 0001495584 SVVC:HeraSystemsInc7Member 2023-01-01 2023-06-30 0001495584 SVVC:HeraSystemsInc7Member 2023-06-30 0001495584 SVVC:HeraSystemsInc8Member 2023-01-01 2023-06-30 0001495584 SVVC:HeraSystemsInc8Member 2023-06-30 0001495584 SVVC:HeraSystemsInc9Member 2023-06-30 0001495584 SVVC:IntraopMedicalCorpMember 2023-01-01 2023-06-30 0001495584 SVVC:IntraopMedicalCorpMember 2023-06-30 0001495584 SVVC:IntraopMedicalCorp1Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraopMedicalCorp1Member 2023-06-30 0001495584 SVVC:IntraopMedicalCorp2Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraopMedicalCorp2Member 2023-06-30 0001495584 SVVC:IntraopMedicalCorp3Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraopMedicalCorp3Member 2023-06-30 0001495584 SVVC:IntraopMedicalCorp4Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraopMedicalCorp4Member 2023-06-30 0001495584 SVVC:IntraopMedicalCorp5Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraopMedicalCorp5Member 2023-06-30 0001495584 SVVC:IntraopMedicalCorp6Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraopMedicalCorp6Member 2023-06-30 0001495584 SVVC:IntraopMedicalCorp7Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraopMedicalCorp7Member 2023-06-30 0001495584 SVVC:IntraopMedicalCorp8Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraopMedicalCorp8Member 2023-06-30 0001495584 SVVC:IntraopMedicalCorp9Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraopMedicalCorp9Member 2023-06-30 0001495584 SVVC:IntraopMedicalCorp10Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraopMedicalCorp10Member 2023-06-30 0001495584 SVVC:IntraopMedicalCorp11Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraopMedicalCorp11Member 2023-06-30 0001495584 SVVC:IntraopMedicalCorp12Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraopMedicalCorp12Member 2023-06-30 0001495584 SVVC:IntraopMedicalCorp13Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraopMedicalCorp13Member 2023-06-30 0001495584 SVVC:IntraopMedicalCorp14Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraopMedicalCorp14Member 2023-06-30 0001495584 SVVC:IntraopMedicalCorp15Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraopMedicalCorp15Member 2023-06-30 0001495584 SVVC:IntraopMedicalCorp16Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraopMedicalCorp16Member 2023-06-30 0001495584 SVVC:IntraopMedicalCorp17Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraopMedicalCorp17Member 2023-06-30 0001495584 SVVC:IntraopMedicalCorp18Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraopMedicalCorp18Member 2023-06-30 0001495584 SVVC:IntraopMedicalCorp19Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraopMedicalCorp19Member 2023-06-30 0001495584 SVVC:IntraopMedicalCorp20Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraopMedicalCorp20Member 2023-06-30 0001495584 SVVC:IntraopMedicalCorp21Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraopMedicalCorp21Member 2023-06-30 0001495584 SVVC:IntraopMedicalCorp22Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraopMedicalCorp22Member 2023-06-30 0001495584 SVVC:IntraopMedicalCorp23Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraopMedicalCorp23Member 2023-06-30 0001495584 SVVC:IntraopMedicalCorp24Member 2023-06-30 0001495584 SVVC:KymaIncMember 2023-01-01 2023-06-30 0001495584 SVVC:KymaIncMember 2023-06-30 0001495584 SVVC:LynceanTechnologiesIncMember 2023-01-01 2023-06-30 0001495584 SVVC:LynceanTechnologiesIncMember 2023-06-30 0001495584 SVVC:RevasumIncMember 2023-01-01 2023-06-30 0001495584 SVVC:RevasumIncMember 2023-06-30 0001495584 SVVC:UctCoatingsIncMember 2023-01-01 2023-06-30 0001495584 SVVC:UctCoatingsIncMember 2023-06-30 0001495584 SVVC:WrightSpeedIncMember 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedIncMember 2023-06-30 0001495584 SVVC:WrightSpeedInc1Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedInc1Member 2023-06-30 0001495584 SVVC:WrightSpeedInc2Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedInc2Member 2023-06-30 0001495584 SVVC:WrightSpeedInc3Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedInc3Member 2023-06-30 0001495584 SVVC:WrightSpeedInc4Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedInc4Member 2023-06-30 0001495584 SVVC:WrightSpeedInc5Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedInc5Member 2023-06-30 0001495584 SVVC:WrightSpeedInc6Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedInc6Member 2023-06-30 0001495584 SVVC:WrightSpeedInc7Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedInc7Member 2023-06-30 0001495584 SVVC:WrightSpeedInc8Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedInc8Member 2023-06-30 0001495584 SVVC:WrightSpeedInc9Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedInc9Member 2023-06-30 0001495584 SVVC:WrightSpeedInc10Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedInc10Member 2023-06-30 0001495584 SVVC:WrightSpeedInc11Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedInc11Member 2023-06-30 0001495584 SVVC:WrightSpeedInc12Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedInc12Member 2023-06-30 0001495584 SVVC:WrightSpeedInc13Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedInc13Member 2023-06-30 0001495584 SVVC:WrightSpeedInc14Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedInc14Member 2023-06-30 0001495584 SVVC:WrightSpeedInc15Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedInc15Member 2023-06-30 0001495584 SVVC:WrightSpeedInc16Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedInc16Member 2023-06-30 0001495584 SVVC:WrightSpeedInc17Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedInc17Member 2023-06-30 0001495584 SVVC:WrightSpeedInc18Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedInc18Member 2023-06-30 0001495584 SVVC:WrightSpeedInc19Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedInc19Member 2023-06-30 0001495584 SVVC:WrightSpeedInc20Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedInc20Member 2023-06-30 0001495584 SVVC:WrightSpeedInc21Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedInc21Member 2023-06-30 0001495584 SVVC:WrightSpeedInc22Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedInc22Member 2023-06-30 0001495584 SVVC:WrightSpeedInc23Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedInc23Member 2023-06-30 0001495584 SVVC:WrightSpeedInc24Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedInc24Member 2023-06-30 0001495584 SVVC:WrightSpeedInc25Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedInc25Member 2023-06-30 0001495584 SVVC:WrightSpeedInc26Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedInc26Member 2023-06-30 0001495584 SVVC:WrightSpeedInc27Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedInc27Member 2023-06-30 0001495584 SVVC:WrightSpeedInc28Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedInc28Member 2023-06-30 0001495584 SVVC:WrightSpeedInc29Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedInc29Member 2023-06-30 0001495584 SVVC:WrightSpeedInc30Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedInc30Member 2023-06-30 0001495584 SVVC:WrightSpeedInc31Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedInc31Member 2023-06-30 0001495584 SVVC:WrightSpeedInc32Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedInc32Member 2023-06-30 0001495584 SVVC:WrightSpeedInc33Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedInc33Member 2023-06-30 0001495584 SVVC:WrightSpeedInc34Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightSpeedInc34Member 2023-06-30 0001495584 SVVC:WrightSpeedInc36Member 2023-06-30 0001495584 SVVC:InvestmentCompanyMember 2023-01-01 2023-06-30 0001495584 SVVC:InvestmentCompanyMember 2023-06-30 0001495584 SVVC:EqxCapitalIncMember 2022-01-01 2022-12-31 0001495584 SVVC:EqxCapitalIncMember 2022-12-31 0001495584 SVVC:EquipmentLeasingMember 2022-01-01 2022-12-31 0001495584 SVVC:EquipmentLeasingMember 2022-12-31 0001495584 SVVC:EqxCapitalInc1Member 2022-12-31 0001495584 SVVC:HeraSystemsIncMember 2022-01-01 2022-12-31 0001495584 SVVC:HeraSystemsIncMember 2022-12-31 0001495584 SVVC:HeraSystemsInc1Member 2022-01-01 2022-12-31 0001495584 SVVC:HeraSystemsInc1Member 2022-12-31 0001495584 SVVC:HeraSystemsInc2Member 2022-01-01 2022-12-31 0001495584 SVVC:HeraSystemsInc2Member 2022-12-31 0001495584 SVVC:HeraSystemsInc3Member 2022-01-01 2022-12-31 0001495584 SVVC:HeraSystemsInc3Member 2022-12-31 0001495584 SVVC:HeraSystemsInc4Member 2022-01-01 2022-12-31 0001495584 SVVC:HeraSystemsInc4Member 2022-12-31 0001495584 SVVC:HeraSystemsInc5Member 2022-01-01 2022-12-31 0001495584 SVVC:HeraSystemsInc5Member 2022-12-31 0001495584 SVVC:HeraSystemsInc6Member 2022-01-01 2022-12-31 0001495584 SVVC:HeraSystemsInc6Member 2022-12-31 0001495584 SVVC:HeraSystemsInc7Member 2022-01-01 2022-12-31 0001495584 SVVC:HeraSystemsInc7Member 2022-12-31 0001495584 SVVC:HeraSystemsInc8Member 2022-01-01 2022-12-31 0001495584 SVVC:HeraSystemsInc8Member 2022-12-31 0001495584 SVVC:HeraSystemsInc9Member 2022-12-31 0001495584 SVVC:IntraopMedicalCorpMember 2022-01-01 2022-12-31 0001495584 SVVC:IntraopMedicalCorpMember 2022-12-31 0001495584 SVVC:IntraopMedicalCorp1Member 2022-01-01 2022-12-31 0001495584 SVVC:IntraopMedicalCorp1Member 2022-12-31 0001495584 SVVC:IntraopMedicalCorp2Member 2022-01-01 2022-12-31 0001495584 SVVC:IntraopMedicalCorp2Member 2022-12-31 0001495584 SVVC:IntraopMedicalCorp3Member 2022-01-01 2022-12-31 0001495584 SVVC:IntraopMedicalCorp3Member 2022-12-31 0001495584 SVVC:IntraopMedicalCorp4Member 2022-01-01 2022-12-31 0001495584 SVVC:IntraopMedicalCorp4Member 2022-12-31 0001495584 SVVC:IntraopMedicalCorp5Member 2022-01-01 2022-12-31 0001495584 SVVC:IntraopMedicalCorp5Member 2022-12-31 0001495584 SVVC:IntraopMedicalCorp6Member 2022-01-01 2022-12-31 0001495584 SVVC:IntraopMedicalCorp6Member 2022-12-31 0001495584 SVVC:IntraopMedicalCorp7Member 2022-01-01 2022-12-31 0001495584 SVVC:IntraopMedicalCorp7Member 2022-12-31 0001495584 SVVC:IntraopMedicalCorp8Member 2022-01-01 2022-12-31 0001495584 SVVC:IntraopMedicalCorp8Member 2022-12-31 0001495584 SVVC:IntraopMedicalCorp9Member 2022-01-01 2022-12-31 0001495584 SVVC:IntraopMedicalCorp9Member 2022-12-31 0001495584 SVVC:IntraopMedicalCorp10Member 2022-01-01 2022-12-31 0001495584 SVVC:IntraopMedicalCorp10Member 2022-12-31 0001495584 SVVC:IntraopMedicalCorp11Member 2022-01-01 2022-12-31 0001495584 SVVC:IntraopMedicalCorp11Member 2022-12-31 0001495584 SVVC:IntraopMedicalCorp12Member 2022-01-01 2022-12-31 0001495584 SVVC:IntraopMedicalCorp12Member 2022-12-31 0001495584 SVVC:IntraopMedicalCorp13Member 2022-01-01 2022-12-31 0001495584 SVVC:IntraopMedicalCorp13Member 2022-12-31 0001495584 SVVC:IntraopMedicalCorp14Member 2022-01-01 2022-12-31 0001495584 SVVC:IntraopMedicalCorp14Member 2022-12-31 0001495584 SVVC:IntraopMedicalCorp15Member 2022-01-01 2022-12-31 0001495584 SVVC:IntraopMedicalCorp15Member 2022-12-31 0001495584 SVVC:IntraopMedicalCorp16Member 2022-01-01 2022-12-31 0001495584 SVVC:IntraopMedicalCorp16Member 2022-12-31 0001495584 SVVC:IntraopMedicalCorp17Member 2022-01-01 2022-12-31 0001495584 SVVC:IntraopMedicalCorp17Member 2022-12-31 0001495584 SVVC:IntraopMedicalCorp18Member 2022-01-01 2022-12-31 0001495584 SVVC:IntraopMedicalCorp18Member 2022-12-31 0001495584 SVVC:IntraopMedicalCorp19Member 2022-01-01 2022-12-31 0001495584 SVVC:IntraopMedicalCorp19Member 2022-12-31 0001495584 SVVC:IntraopMedicalCorp20Member 2022-01-01 2022-12-31 0001495584 SVVC:IntraopMedicalCorp20Member 2022-12-31 0001495584 SVVC:IntraopMedicalCorp21Member 2022-01-01 2022-12-31 0001495584 SVVC:IntraopMedicalCorp21Member 2022-12-31 0001495584 SVVC:IntraopMedicalCorp22Member 2022-01-01 2022-12-31 0001495584 SVVC:IntraopMedicalCorp22Member 2022-12-31 0001495584 SVVC:IntraopMedicalCorp23Member 2022-01-01 2022-12-31 0001495584 SVVC:IntraopMedicalCorp23Member 2022-12-31 0001495584 SVVC:IntraopMedicalCorp24Member 2022-12-31 0001495584 SVVC:KymaIncMember 2022-01-01 2022-12-31 0001495584 SVVC:KymaIncMember 2022-12-31 0001495584 SVVC:LynceanTechnologiesIncMember 2022-01-01 2022-12-31 0001495584 SVVC:LynceanTechnologiesIncMember 2022-12-31 0001495584 SVVC:RevasumIncMember 2022-01-01 2022-12-31 0001495584 SVVC:RevasumIncMember 2022-12-31 0001495584 SVVC:SiliconGenesisCorpMember 2022-01-01 2022-12-31 0001495584 SVVC:SiliconGenesisCorpMember 2022-12-31 0001495584 SVVC:SiliconGenesisCorp1Member 2022-01-01 2022-12-31 0001495584 SVVC:SiliconGenesisCorp1Member 2022-12-31 0001495584 SVVC:SiliconGenesisCorp2Member 2022-01-01 2022-12-31 0001495584 SVVC:SiliconGenesisCorp2Member 2022-12-31 0001495584 SVVC:SiliconGenesisCorp3Member 2022-01-01 2022-12-31 0001495584 SVVC:SiliconGenesisCorp3Member 2022-12-31 0001495584 SVVC:SiliconGenesisCorp4Member 2022-01-01 2022-12-31 0001495584 SVVC:SiliconGenesisCorp4Member 2022-12-31 0001495584 SVVC:SiliconGenesisCorp5Member 2022-01-01 2022-12-31 0001495584 SVVC:SiliconGenesisCorp5Member 2022-12-31 0001495584 SVVC:SiliconGenesisCorp6Member 2022-01-01 2022-12-31 0001495584 SVVC:SiliconGenesisCorp6Member 2022-12-31 0001495584 SVVC:SiliconGenesisCorp7Member 2022-01-01 2022-12-31 0001495584 SVVC:SiliconGenesisCorp7Member 2022-12-31 0001495584 SVVC:SiliconGenesisCorp8Member 2022-12-31 0001495584 SVVC:UctCoatingsIncMember 2022-01-01 2022-12-31 0001495584 SVVC:UctCoatingsIncMember 2022-12-31 0001495584 SVVC:WrightSpeedIncMember 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedIncMember 2022-12-31 0001495584 SVVC:WrightSpeedInc1Member 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedInc1Member 2022-12-31 0001495584 SVVC:WrightSpeedInc2Member 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedInc2Member 2022-12-31 0001495584 SVVC:WrightSpeedInc3Member 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedInc3Member 2022-12-31 0001495584 SVVC:WrightSpeedInc4Member 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedInc4Member 2022-12-31 0001495584 SVVC:WrightSpeedInc5Member 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedInc5Member 2022-12-31 0001495584 SVVC:WrightSpeedInc6Member 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedInc6Member 2022-12-31 0001495584 SVVC:WrightSpeedInc7Member 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedInc7Member 2022-12-31 0001495584 SVVC:WrightSpeedInc8Member 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedInc8Member 2022-12-31 0001495584 SVVC:WrightSpeedInc9Member 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedInc9Member 2022-12-31 0001495584 SVVC:WrightSpeedInc10Member 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedInc10Member 2022-12-31 0001495584 SVVC:WrightSpeedInc11Member 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedInc11Member 2022-12-31 0001495584 SVVC:WrightSpeedInc12Member 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedInc12Member 2022-12-31 0001495584 SVVC:WrightSpeedInc13Member 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedInc13Member 2022-12-31 0001495584 SVVC:WrightSpeedInc14Member 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedInc14Member 2022-12-31 0001495584 SVVC:WrightSpeedInc15Member 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedInc15Member 2022-12-31 0001495584 SVVC:WrightSpeedInc16Member 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedInc16Member 2022-12-31 0001495584 SVVC:WrightSpeedInc17Member 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedInc17Member 2022-12-31 0001495584 SVVC:WrightSpeedInc18Member 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedInc18Member 2022-12-31 0001495584 SVVC:WrightSpeedInc19Member 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedInc19Member 2022-12-31 0001495584 SVVC:WrightSpeedInc20Member 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedInc20Member 2022-12-31 0001495584 SVVC:WrightSpeedInc21Member 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedInc21Member 2022-12-31 0001495584 SVVC:WrightSpeedInc22Member 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedInc22Member 2022-12-31 0001495584 SVVC:WrightSpeedInc23Member 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedInc23Member 2022-12-31 0001495584 SVVC:WrightSpeedInc24Member 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedInc24Member 2022-12-31 0001495584 SVVC:WrightSpeedInc25Member 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedInc25Member 2022-12-31 0001495584 SVVC:WrightSpeedInc26Member 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedInc26Member 2022-12-31 0001495584 SVVC:WrightSpeedInc27Member 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedInc27Member 2022-12-31 0001495584 SVVC:WrightSpeedInc28Member 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedInc28Member 2022-12-31 0001495584 SVVC:WrightSpeedInc29Member 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedInc29Member 2022-12-31 0001495584 SVVC:WrightSpeedInc30Member 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedInc30Member 2022-12-31 0001495584 SVVC:WrightSpeedInc31Member 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedInc31Member 2022-12-31 0001495584 SVVC:WrightSpeedInc32Member 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedInc32Member 2022-12-31 0001495584 SVVC:WrightSpeedInc33Member 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedInc33Member 2022-12-31 0001495584 SVVC:WrightSpeedInc34Member 2022-01-01 2022-12-31 0001495584 SVVC:WrightSpeedInc34Member 2022-12-31 0001495584 SVVC:WrightSpeedInc36Member 2022-12-31 0001495584 SVVC:InvestmentCompanyMember 2022-01-01 2022-12-31 0001495584 SVVC:InvestmentCompanyMember 2022-12-31 0001495584 us-gaap:FairValueInputsLevel1Member SVVC:AdvancedMaterialsMember us-gaap:CommonStockMember 2023-06-30 0001495584 us-gaap:FairValueInputsLevel2Member SVVC:AdvancedMaterialsMember us-gaap:CommonStockMember 2023-06-30 0001495584 us-gaap:FairValueInputsLevel3Member SVVC:AdvancedMaterialsMember us-gaap:CommonStockMember 2023-06-30 0001495584 us-gaap:FairValueInputsLevel1Member SVVC:AutomotiveMember us-gaap:CommonStockMember 2023-06-30 0001495584 us-gaap:FairValueInputsLevel2Member SVVC:AutomotiveMember us-gaap:CommonStockMember 2023-06-30 0001495584 us-gaap:FairValueInputsLevel3Member SVVC:AutomotiveMember us-gaap:CommonStockMember 2023-06-30 0001495584 us-gaap:FairValueInputsLevel1Member SVVC:EquipmentLeasingMember us-gaap:CommonStockMember 2023-06-30 0001495584 us-gaap:FairValueInputsLevel2Member SVVC:EquipmentLeasingMember us-gaap:CommonStockMember 2023-06-30 0001495584 us-gaap:FairValueInputsLevel3Member SVVC:EquipmentLeasingMember us-gaap:CommonStockMember 2023-06-30 0001495584 us-gaap:FairValueInputsLevel1Member SVVC:SemiconductorEquipmentMember us-gaap:CommonStockMember 2023-06-30 0001495584 us-gaap:FairValueInputsLevel2Member SVVC:SemiconductorEquipmentMember us-gaap:CommonStockMember 2023-06-30 0001495584 us-gaap:FairValueInputsLevel3Member SVVC:SemiconductorEquipmentMember us-gaap:CommonStockMember 2023-06-30 0001495584 us-gaap:FairValueInputsLevel1Member us-gaap:CommonStockMember 2023-06-30 0001495584 us-gaap:FairValueInputsLevel2Member us-gaap:CommonStockMember 2023-06-30 0001495584 us-gaap:FairValueInputsLevel3Member us-gaap:CommonStockMember 2023-06-30 0001495584 us-gaap:FairValueInputsLevel1Member SVVC:AerospaceMember us-gaap:PreferredStockMember 2023-06-30 0001495584 us-gaap:FairValueInputsLevel2Member SVVC:AerospaceMember us-gaap:PreferredStockMember 2023-06-30 0001495584 us-gaap:FairValueInputsLevel3Member SVVC:AerospaceMember us-gaap:PreferredStockMember 2023-06-30 0001495584 us-gaap:FairValueInputsLevel1Member SVVC:AutomotiveMember us-gaap:PreferredStockMember 2023-06-30 0001495584 us-gaap:FairValueInputsLevel2Member SVVC:AutomotiveMember us-gaap:PreferredStockMember 2023-06-30 0001495584 us-gaap:FairValueInputsLevel3Member SVVC:AutomotiveMember us-gaap:PreferredStockMember 2023-06-30 0001495584 us-gaap:FairValueInputsLevel1Member SVVC:EquipmentLeasingMember us-gaap:PreferredStockMember 2023-06-30 0001495584 us-gaap:FairValueInputsLevel2Member SVVC:EquipmentLeasingMember us-gaap:PreferredStockMember 2023-06-30 0001495584 us-gaap:FairValueInputsLevel3Member SVVC:EquipmentLeasingMember us-gaap:PreferredStockMember 2023-06-30 0001495584 us-gaap:FairValueInputsLevel1Member us-gaap:PreferredStockMember 2023-06-30 0001495584 us-gaap:FairValueInputsLevel2Member us-gaap:PreferredStockMember 2023-06-30 0001495584 us-gaap:FairValueInputsLevel3Member us-gaap:PreferredStockMember 2023-06-30 0001495584 SVVC:EquityContractsMember us-gaap:FairValueInputsLevel1Member us-gaap:PreferredStockMember 2023-06-30 0001495584 SVVC:EquityContractsMember us-gaap:FairValueInputsLevel2Member us-gaap:PreferredStockMember 2023-06-30 0001495584 SVVC:EquityContractsMember us-gaap:FairValueInputsLevel3Member us-gaap:PreferredStockMember 2023-06-30 0001495584 SVVC:AssetDerivativesMember us-gaap:FairValueInputsLevel1Member us-gaap:PreferredStockMember 2023-06-30 0001495584 SVVC:AssetDerivativesMember us-gaap:FairValueInputsLevel2Member us-gaap:PreferredStockMember 2023-06-30 0001495584 SVVC:AssetDerivativesMember us-gaap:FairValueInputsLevel3Member us-gaap:PreferredStockMember 2023-06-30 0001495584 SVVC:ConvertibleNotesMember us-gaap:FairValueInputsLevel1Member SVVC:AdvancedMaterialsMember 2023-06-30 0001495584 SVVC:ConvertibleNotesMember us-gaap:FairValueInputsLevel2Member SVVC:AdvancedMaterialsMember 2023-06-30 0001495584 SVVC:ConvertibleNotesMember us-gaap:FairValueInputsLevel3Member SVVC:AdvancedMaterialsMember 2023-06-30 0001495584 SVVC:ConvertibleNotesMember us-gaap:FairValueInputsLevel1Member SVVC:AerospaceMember 2023-06-30 0001495584 SVVC:ConvertibleNotesMember us-gaap:FairValueInputsLevel2Member SVVC:AerospaceMember 2023-06-30 0001495584 SVVC:ConvertibleNotesMember us-gaap:FairValueInputsLevel3Member SVVC:AerospaceMember 2023-06-30 0001495584 SVVC:ConvertibleNotesMember us-gaap:FairValueInputsLevel1Member SVVC:AutomotiveMember 2023-06-30 0001495584 SVVC:ConvertibleNotesMember us-gaap:FairValueInputsLevel2Member SVVC:AutomotiveMember 2023-06-30 0001495584 SVVC:ConvertibleNotesMember us-gaap:FairValueInputsLevel3Member SVVC:AutomotiveMember 2023-06-30 0001495584 SVVC:ConvertibleNotesMember us-gaap:FairValueInputsLevel1Member SVVC:MedicalDevicesMember 2023-06-30 0001495584 SVVC:ConvertibleNotesMember us-gaap:FairValueInputsLevel2Member SVVC:MedicalDevicesMember 2023-06-30 0001495584 SVVC:ConvertibleNotesMember us-gaap:FairValueInputsLevel3Member SVVC:MedicalDevicesMember 2023-06-30 0001495584 SVVC:ConvertibleNotesMember us-gaap:FairValueInputsLevel1Member 2023-06-30 0001495584 SVVC:ConvertibleNotesMember us-gaap:FairValueInputsLevel2Member 2023-06-30 0001495584 SVVC:ConvertibleNotesMember us-gaap:FairValueInputsLevel3Member 2023-06-30 0001495584 SVVC:MutualFundsMember us-gaap:FairValueInputsLevel1Member 2023-06-30 0001495584 SVVC:MutualFundsMember us-gaap:FairValueInputsLevel2Member 2023-06-30 0001495584 SVVC:MutualFundsMember us-gaap:FairValueInputsLevel3Member 2023-06-30 0001495584 us-gaap:FairValueInputsLevel1Member 2023-06-30 0001495584 us-gaap:FairValueInputsLevel2Member 2023-06-30 0001495584 us-gaap:FairValueInputsLevel3Member 2023-06-30 0001495584 SVVC:AdvancedMaterialsMember us-gaap:CommonStockMember 2022-12-31 0001495584 SVVC:AdvancedMaterialsMember us-gaap:CommonStockMember 2023-01-01 2023-06-30 0001495584 SVVC:AdvancedMaterialsMember us-gaap:CommonStockMember 2023-06-30 0001495584 SVVC:AutomotiveMember us-gaap:CommonStockMember 2022-12-31 0001495584 SVVC:AutomotiveMember us-gaap:CommonStockMember 2023-01-01 2023-06-30 0001495584 SVVC:AutomotiveMember us-gaap:CommonStockMember 2023-06-30 0001495584 SVVC:EquipmentLeasingMember us-gaap:CommonStockMember 2022-12-31 0001495584 SVVC:EquipmentLeasingMember us-gaap:CommonStockMember 2023-01-01 2023-06-30 0001495584 SVVC:EquipmentLeasingMember us-gaap:CommonStockMember 2023-06-30 0001495584 us-gaap:IntellectualPropertyMember us-gaap:CommonStockMember 2022-12-31 0001495584 us-gaap:IntellectualPropertyMember us-gaap:CommonStockMember 2023-01-01 2023-06-30 0001495584 us-gaap:IntellectualPropertyMember us-gaap:CommonStockMember 2023-06-30 0001495584 us-gaap:CommonStockMember 2022-12-31 0001495584 us-gaap:CommonStockMember 2023-01-01 2023-06-30 0001495584 us-gaap:CommonStockMember 2023-06-30 0001495584 SVVC:AerospaceMember us-gaap:PreferredStockMember 2022-12-31 0001495584 SVVC:AerospaceMember us-gaap:PreferredStockMember 2023-01-01 2023-06-30 0001495584 SVVC:AerospaceMember us-gaap:PreferredStockMember 2023-06-30 0001495584 SVVC:AutomotiveMember us-gaap:PreferredStockMember 2022-12-31 0001495584 SVVC:AutomotiveMember us-gaap:PreferredStockMember 2023-01-01 2023-06-30 0001495584 SVVC:AutomotiveMember us-gaap:PreferredStockMember 2023-06-30 0001495584 SVVC:EquipmentLeasingMember us-gaap:PreferredStockMember 2022-12-31 0001495584 SVVC:EquipmentLeasingMember us-gaap:PreferredStockMember 2023-01-01 2023-06-30 0001495584 SVVC:EquipmentLeasingMember us-gaap:PreferredStockMember 2023-06-30 0001495584 us-gaap:IntellectualPropertyMember us-gaap:PreferredStockMember 2022-12-31 0001495584 us-gaap:IntellectualPropertyMember us-gaap:PreferredStockMember 2023-01-01 2023-06-30 0001495584 us-gaap:IntellectualPropertyMember us-gaap:PreferredStockMember 2023-06-30 0001495584 us-gaap:PreferredStockMember 2022-12-31 0001495584 us-gaap:PreferredStockMember 2023-01-01 2023-06-30 0001495584 us-gaap:PreferredStockMember 2023-06-30 0001495584 SVVC:EquityContractsMember us-gaap:PreferredStockMember 2022-12-31 0001495584 SVVC:EquityContractsMember us-gaap:PreferredStockMember 2023-01-01 2023-06-30 0001495584 SVVC:EquityContractsMember us-gaap:PreferredStockMember 2023-06-30 0001495584 SVVC:AssetDerivativesMember us-gaap:PreferredStockMember 2022-12-31 0001495584 SVVC:AssetDerivativesMember us-gaap:PreferredStockMember 2023-01-01 2023-06-30 0001495584 SVVC:AssetDerivativesMember us-gaap:PreferredStockMember 2023-06-30 0001495584 SVVC:ConvertibleNotesMember SVVC:AdvancedMaterialsMember 2022-12-31 0001495584 SVVC:ConvertibleNotesMember SVVC:AdvancedMaterialsMember 2023-01-01 2023-06-30 0001495584 SVVC:ConvertibleNotesMember SVVC:AdvancedMaterialsMember 2023-06-30 0001495584 SVVC:ConvertibleNotesMember SVVC:AerospaceMember 2022-12-31 0001495584 SVVC:ConvertibleNotesMember SVVC:AerospaceMember 2023-01-01 2023-06-30 0001495584 SVVC:ConvertibleNotesMember SVVC:AerospaceMember 2023-06-30 0001495584 SVVC:ConvertibleNotesMember SVVC:AutomotiveMember 2022-12-31 0001495584 SVVC:ConvertibleNotesMember SVVC:AutomotiveMember 2023-01-01 2023-06-30 0001495584 SVVC:ConvertibleNotesMember SVVC:AutomotiveMember 2023-06-30 0001495584 SVVC:ConvertibleNotesMember SVVC:MedicalDevicesMember 2022-12-31 0001495584 SVVC:ConvertibleNotesMember SVVC:MedicalDevicesMember 2023-01-01 2023-06-30 0001495584 SVVC:ConvertibleNotesMember SVVC:MedicalDevicesMember 2023-06-30 0001495584 SVVC:ConvertibleNotesMember 2022-12-31 0001495584 SVVC:ConvertibleNotesMember 2023-01-01 2023-06-30 0001495584 SVVC:ConvertibleNotesMember 2023-06-30 0001495584 SVVC:AdvancedMaterialsMember 2023-06-30 0001495584 SVVC:AerospaceMember 2023-06-30 0001495584 SVVC:AutomotiveMember 2023-06-30 0001495584 SVVC:EquipmentLeasingMember 2023-06-30 0001495584 SVVC:MedicalDevicesMember 2023-06-30 0001495584 SVVC:CapitalLossCarryforward1Member 2023-01-01 2023-06-30 0001495584 SVVC:CapitalLossCarryforward1Member 2023-06-30 0001495584 SVVC:CapitalLossCarryforward2Member 2023-01-01 2023-06-30 0001495584 SVVC:CapitalLossCarryforward2Member 2023-06-30 0001495584 SVVC:CapitalLossCarryforward3Member 2023-01-01 2023-06-30 0001495584 SVVC:CapitalLossCarryforward3Member 2023-06-30 0001495584 SVVC:CapitalLossCarryforwardsMember 2023-06-30 0001495584 us-gaap:CommonStockMember 2016-04-26 0001495584 2016-04-01 2016-04-26 0001495584 2017-11-10 0001495584 2017-11-01 2017-11-10 0001495584 SVVC:SVVCStockMember 2018-08-30 2018-08-31 0001495584 2018-08-30 2018-08-31 0001495584 2014-12-01 2014-12-22 0001495584 2014-12-31 0001495584 us-gaap:CommonStockMember 2019-12-15 2019-12-16 0001495584 srt:MinimumMember us-gaap:CommonStockMember 2019-12-16 0001495584 srt:MaximumMember us-gaap:CommonStockMember 2019-12-16 0001495584 us-gaap:CommonStockMember 2019-12-16 0001495584 2020-03-31 0001495584 SVVC:EQXCapitalIncCommonStockMember 2022-12-31 0001495584 SVVC:EQXCapitalIncCommonStockMember 2023-01-01 2023-06-30 0001495584 SVVC:EQXCapitalIncCommonStockMember 2023-06-30 0001495584 SVVC:EQXCapitalIncSeriesAPreferredStockMember 2022-12-31 0001495584 SVVC:EQXCapitalIncSeriesAPreferredStockMember 2023-01-01 2023-06-30 0001495584 SVVC:EQXCapitalIncSeriesAPreferredStockMember 2023-06-30 0001495584 SVVC:EquipmentLeasingMember 2022-12-31 0001495584 SVVC:EquipmentLeasingMember 2023-01-01 2023-06-30 0001495584 SVVC:HeraSystemsIncConvertibleNoteMember 2022-12-31 0001495584 SVVC:HeraSystemsIncConvertibleNoteMember 2023-01-01 2023-06-30 0001495584 SVVC:HeraSystemsIncConvertibleNoteMember 2023-06-30 0001495584 SVVC:HeraSystemsIncConvertibleNote1Member 2022-12-31 0001495584 SVVC:HeraSystemsIncConvertibleNote1Member 2023-01-01 2023-06-30 0001495584 SVVC:HeraSystemsIncConvertibleNote1Member 2023-06-30 0001495584 SVVC:HeraSystemsIncSeriesAPreferredMember 2022-12-31 0001495584 SVVC:HeraSystemsIncSeriesAPreferredMember 2023-01-01 2023-06-30 0001495584 SVVC:HeraSystemsIncSeriesAPreferredMember 2023-06-30 0001495584 SVVC:HeraSystemsIncSeriesBPreferredMember 2022-12-31 0001495584 SVVC:HeraSystemsIncSeriesBPreferredMember 2023-01-01 2023-06-30 0001495584 SVVC:HeraSystemsIncSeriesBPreferredMember 2023-06-30 0001495584 SVVC:HeraSystemsIncSeriesBWarrantsMember 2022-12-31 0001495584 SVVC:HeraSystemsIncSeriesBWarrantsMember 2023-01-01 2023-06-30 0001495584 SVVC:HeraSystemsIncSeriesBWarrantsMember 2023-06-30 0001495584 SVVC:HeraSystemsIncSeriesBWarrants1Member 2022-12-31 0001495584 SVVC:HeraSystemsIncSeriesBWarrants1Member 2023-01-01 2023-06-30 0001495584 SVVC:HeraSystemsIncSeriesBWarrants1Member 2023-06-30 0001495584 SVVC:HeraSystemsIncSeriesBWarrants2Member 2022-12-31 0001495584 SVVC:HeraSystemsIncSeriesBWarrants2Member 2023-01-01 2023-06-30 0001495584 SVVC:HeraSystemsIncSeriesBWarrants2Member 2023-06-30 0001495584 SVVC:HeraSystemsIncSeriesBWarrants3Member 2022-12-31 0001495584 SVVC:HeraSystemsIncSeriesBWarrants3Member 2023-01-01 2023-06-30 0001495584 SVVC:HeraSystemsIncSeriesBWarrants3Member 2023-06-30 0001495584 SVVC:HeraSystemsIncSeriesCPreferredMember 2022-12-31 0001495584 SVVC:HeraSystemsIncSeriesCPreferredMember 2023-01-01 2023-06-30 0001495584 SVVC:HeraSystemsIncSeriesCPreferredMember 2023-06-30 0001495584 SVVC:AerospaceMember 2022-12-31 0001495584 SVVC:AerospaceMember 2023-01-01 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNoteMember 2022-12-31 0001495584 SVVC:IntraOpMedicalCorpConvertibleNoteMember 2023-01-01 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNoteMember 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote1Member 2022-12-31 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote1Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote1Member 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote2Member 2022-12-31 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote2Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote2Member 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote3Member 2022-12-31 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote3Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote3Member 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote4Member 2022-12-31 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote4Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote4Member 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote5Member 2022-12-31 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote5Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote5Member 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote6Member 2022-12-31 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote6Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote6Member 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote7Member 2022-12-31 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote7Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote7Member 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote8Member 2022-12-31 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote8Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote8Member 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote9Member 2022-12-31 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote9Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote9Member 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote10Member 2022-12-31 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote10Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote10Member 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote11Member 2022-12-31 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote11Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote11Member 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote12Member 2022-12-31 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote12Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote12Member 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote13Member 2022-12-31 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote13Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote13Member 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote14Member 2022-12-31 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote14Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote14Member 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote15Member 2022-12-31 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote15Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote15Member 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote16Member 2022-12-31 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote16Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote16Member 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote17Member 2022-12-31 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote17Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote17Member 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote18Member 2022-12-31 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote18Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote18Member 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote19Member 2022-12-31 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote19Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote19Member 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote20Member 2022-12-31 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote20Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote20Member 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote21Member 2022-12-31 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote21Member 2023-01-01 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpConvertibleNote21Member 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpSeriesCPreferredMember 2022-12-31 0001495584 SVVC:IntraOpMedicalCorpSeriesCPreferredMember 2023-01-01 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpSeriesCPreferredMember 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpTermNoteMember 2022-12-31 0001495584 SVVC:IntraOpMedicalCorpTermNoteMember 2023-01-01 2023-06-30 0001495584 SVVC:IntraOpMedicalCorpTermNoteMember 2023-06-30 0001495584 SVVC:MedicalDevicesMember 2022-12-31 0001495584 SVVC:MedicalDevicesMember 2023-01-01 2023-06-30 0001495584 SVVC:RevasumIncCDIMember 2022-12-31 0001495584 SVVC:RevasumIncCDIMember 2023-01-01 2023-06-30 0001495584 SVVC:RevasumIncCDIMember 2023-06-30 0001495584 SVVC:SemiconductorEquipmentMember 2022-12-31 0001495584 SVVC:SemiconductorEquipmentMember 2023-01-01 2023-06-30 0001495584 SVVC:SemiconductorEquipmentMember 2023-06-30 0001495584 SVVC:SiliconGenesisCorpCommonStockMember 2022-12-31 0001495584 SVVC:SiliconGenesisCorpCommonStockMember 2023-01-01 2023-06-30 0001495584 SVVC:SiliconGenesisCorpCommonStockMember 2023-06-30 0001495584 SVVC:SiliconGenesisCorpCommonWarrantsMember 2022-12-31 0001495584 SVVC:SiliconGenesisCorpCommonWarrantsMember 2023-01-01 2023-06-30 0001495584 SVVC:SiliconGenesisCorpCommonWarrantsMember 2023-06-30 0001495584 SVVC:SiliconGenesisCorpSeries1GPreferredMember 2022-12-31 0001495584 SVVC:SiliconGenesisCorpSeries1GPreferredMember 2023-01-01 2023-06-30 0001495584 SVVC:SiliconGenesisCorpSeries1GPreferredMember 2023-06-30 0001495584 SVVC:SiliconGenesisCorpSeries1HPreferredMember 2022-12-31 0001495584 SVVC:SiliconGenesisCorpSeries1HPreferredMember 2023-01-01 2023-06-30 0001495584 SVVC:SiliconGenesisCorpSeries1HPreferredMember 2023-06-30 0001495584 SVVC:SiliconGenesisCorpSeries1DPreferredMember 2022-12-31 0001495584 SVVC:SiliconGenesisCorpSeries1DPreferredMember 2023-01-01 2023-06-30 0001495584 SVVC:SiliconGenesisCorpSeries1DPreferredMember 2023-06-30 0001495584 SVVC:SiliconGenesisCorpSeries1EPreferredMember 2022-12-31 0001495584 SVVC:SiliconGenesisCorpSeries1EPreferredMember 2023-01-01 2023-06-30 0001495584 SVVC:SiliconGenesisCorpSeries1EPreferredMember 2023-06-30 0001495584 SVVC:SiliconGenesisCorpSeries1FPreferredMember 2022-12-31 0001495584 SVVC:SiliconGenesisCorpSeries1FPreferredMember 2023-01-01 2023-06-30 0001495584 SVVC:SiliconGenesisCorpSeries1FPreferredMember 2023-06-30 0001495584 SVVC:SiliconGenesisCorpSeries1CPreferredStockMember 2022-12-31 0001495584 SVVC:SiliconGenesisCorpSeries1CPreferredStockMember 2023-01-01 2023-06-30 0001495584 SVVC:SiliconGenesisCorpSeries1CPreferredStockMember 2023-06-30 0001495584 SVVC:IntellectualsPropertyMember 2022-12-31 0001495584 SVVC:IntellectualsPropertyMember 2023-01-01 2023-06-30 0001495584 SVVC:IntellectualsPropertyMember 2023-06-30 0001495584 SVVC:UCTCoatingsIncCommonStockMember SVVC:AdvancedMaterialsMember 2022-12-31 0001495584 SVVC:UCTCoatingsIncCommonStockMember SVVC:AdvancedMaterialsMember 2023-01-01 2023-06-30 0001495584 SVVC:UCTCoatingsIncCommonStockMember SVVC:AdvancedMaterialsMember 2023-06-30 0001495584 SVVC:AdvancedMaterialsMember 2022-12-31 0001495584 SVVC:AdvancedMaterialsMember 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncCommonStockMember 2022-12-31 0001495584 SVVC:WrightspeedIncCommonStockMember 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncCommonStockMember 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNoteMember 2022-12-31 0001495584 SVVC:WrightspeedIncConvertibleNoteMember 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNoteMember 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote1Member 2022-12-31 0001495584 SVVC:WrightspeedIncConvertibleNote1Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote1Member 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote2Member 2022-12-31 0001495584 SVVC:WrightspeedIncConvertibleNote2Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote2Member 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote3Member 2022-12-31 0001495584 SVVC:WrightspeedIncConvertibleNote3Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote3Member 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote4Member 2022-12-31 0001495584 SVVC:WrightspeedIncConvertibleNote4Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote4Member 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote5Member 2022-12-31 0001495584 SVVC:WrightspeedIncConvertibleNote5Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote5Member 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote6Member 2022-12-31 0001495584 SVVC:WrightspeedIncConvertibleNote6Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote6Member 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote7Member 2022-12-31 0001495584 SVVC:WrightspeedIncConvertibleNote7Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote7Member 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote8Member 2022-12-31 0001495584 SVVC:WrightspeedIncConvertibleNote8Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote8Member 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote9Member 2022-12-31 0001495584 SVVC:WrightspeedIncConvertibleNote9Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote9Member 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote10Member 2022-12-31 0001495584 SVVC:WrightspeedIncConvertibleNote10Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote10Member 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote11Member 2022-12-31 0001495584 SVVC:WrightspeedIncConvertibleNote11Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote11Member 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote12Member 2022-12-31 0001495584 SVVC:WrightspeedIncConvertibleNote12Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote12Member 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote13Member 2022-12-31 0001495584 SVVC:WrightspeedIncConvertibleNote13Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote13Member 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote14Member 2022-12-31 0001495584 SVVC:WrightspeedIncConvertibleNote14Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote14Member 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote15Member 2022-12-31 0001495584 SVVC:WrightspeedIncConvertibleNote15Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote15Member 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote16Member 2022-12-31 0001495584 SVVC:WrightspeedIncConvertibleNote16Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote16Member 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote17Member 2022-12-31 0001495584 SVVC:WrightspeedIncConvertibleNote17Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote17Member 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote18Member 2022-12-31 0001495584 SVVC:WrightspeedIncConvertibleNote18Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote18Member 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote19Member 2022-12-31 0001495584 SVVC:WrightspeedIncConvertibleNote19Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote19Member 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote20Member 2022-12-31 0001495584 SVVC:WrightspeedIncConvertibleNote20Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote20Member 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote21Member 2022-12-31 0001495584 SVVC:WrightspeedIncConvertibleNote21Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote21Member 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote22Member 2022-12-31 0001495584 SVVC:WrightspeedIncConvertibleNote22Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote22Member 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote23Member 2022-12-31 0001495584 SVVC:WrightspeedIncConvertibleNote23Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote23Member 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote24Member 2022-12-31 0001495584 SVVC:WrightspeedIncConvertibleNote24Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote24Member 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote25Member 2022-12-31 0001495584 SVVC:WrightspeedIncConvertibleNote25Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote25Member 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote26Member 2022-12-31 0001495584 SVVC:WrightspeedIncConvertibleNote26Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote26Member 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote27Member 2022-12-31 0001495584 SVVC:WrightspeedIncConvertibleNote27Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote27Member 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote28Member 2022-12-31 0001495584 SVVC:WrightspeedIncConvertibleNote28Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote28Member 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote29Member 2022-12-31 0001495584 SVVC:WrightspeedIncConvertibleNote29Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote29Member 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote30Member 2022-12-31 0001495584 SVVC:WrightspeedIncConvertibleNote30Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote30Member 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote31Member 2022-12-31 0001495584 SVVC:WrightspeedIncConvertibleNote31Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote31Member 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote32Member 2022-12-31 0001495584 SVVC:WrightspeedIncConvertibleNote32Member 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncConvertibleNote32Member 2023-06-30 0001495584 SVVC:WrightspeedIncSeriesAAPreferredMember 2022-12-31 0001495584 SVVC:WrightspeedIncSeriesAAPreferredMember 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncSeriesAAPreferredMember 2023-06-30 0001495584 SVVC:WrightspeedIncSeriesAAWarrantsMember 2022-12-31 0001495584 SVVC:WrightspeedIncSeriesAAWarrantsMember 2023-01-01 2023-06-30 0001495584 SVVC:WrightspeedIncSeriesAAWarrantsMember 2023-06-30 0001495584 SVVC:AutomotiveMember 2022-12-31 0001495584 SVVC:AutomotiveMember 2023-01-01 2023-06-30 0001495584 SVVC:TotalAffiliatesAndControlledInvestmentsMember 2022-12-31 0001495584 SVVC:TotalAffiliatesAndControlledInvestmentsMember 2023-01-01 2023-06-30 0001495584 SVVC:TotalAffiliatesAndControlledInvestmentsMember 2023-06-30 0001495584 SVVC:AffiliatesMember 2022-12-31 0001495584 SVVC:AffiliatesMember 2023-01-01 2023-06-30 0001495584 SVVC:AffiliatesMember 2023-06-30 0001495584 SVVC:ControlledInvestmentsMember 2022-12-31 0001495584 SVVC:ControlledInvestmentsMember 2023-01-01 2023-06-30 0001495584 SVVC:ControlledInvestmentsMember 2023-06-30 iso4217:USD shares iso4217:USD shares pure 0001495584 false --12-31 2023 Q2 10-Q/A false true 2023-06-30 false 333-168195 FIRSTHAND TECHNOLOGY VALUE FUND, INC. MD 27-3008946 150 Almaden Boulevard Suite 1250 San Jose CA 95113 (408) 886-7096 Yes Yes Non-accelerated Filer false false 6893056 1667150 1772422 662235 662235 132091932 140355353 134421317 142790010 667150 772422 266091 337500 19679716 39012002 20612957 40121924 2629 3235 2703 3404 279358 14463 47203 64066 20942221 40203857 9586630 9188187 34586 50000 46000 46000 175949 310079 9843165 9594266 11099056 30609591 0.001 0.001 100000000 100000000 6893 6893 176770722 176770722 -165678559 -146168024 11099056 30609591 7016432 7016432 123376 123376 6893056 6893056 1.61 4.44 -18808 -45718 23471 -10480 150484 -3767193 299467 -1866141 131676 -3812911 322938 -1876621 146723 386024 339543 875796 29001 28348 57504 57927 4440 8308 6600 14115 12633 2420 20511 12397 8801 8427 17505 16761 96540 116483 162309 185705 85923 26203 100471 44943 3336 50000 22086 100000 29612 29613 58900 58900 21770 24320 42701 46467 438779 680146 828130 1413011 -307103 -4493057 -505192 -3289632 0 -5113635 -7864997 -4929722 16 -714 16 1946 16 -5114349 -7864981 -4927776 0 -87762 0 104114 -13505591 -27284454 -10948320 -36322228 -955633 -628865 -192042 -522907 -14461224 -28001081 -11140362 -36741021 -14461208 -33115430 -19005343 -41668797 -14768311 -37608487 -19510535 -44958429 -2.14 -5.45 -2.83 -6.52 -14768311 -37608487 -19510535 -44958429 100000 -0 100000 -0 0 2693092 498425 3502047 -387743 2955459 -105273 3382103 96581 -3827456 264896 -2003270 -10000 -13589 0 -13589 0 339624 0 0 176336 415637 398443 934697 -25426 -25852 -16863 -17619 -76387 96303 -149544 227691 -0 -5114349 -7864995 -4927776 14461135 28001081 11140275 36741021 -639 -64141 -701 0 0 0 0 0 -639 64141 -701 0 3342 -64141 3404 0 2703 0 2703 0 -307103 -4493057 -505192 -3289632 16 -5114349 -7864981 -4927776 -14461224 -28001081 -11140362 -36741021 -14768311 -37608487 -19510535 -44958429 -14768311 -37608487 -19510535 -44958429 25867367 87404682 30609591 94754624 11099056 49796195 11099056 49796195 6893056 6893056 6893056 6893056 6893056 6893056 6893056 6893056 4.44 13.75 14.82 17.70 26.69 23.83 -0.07 -1.81 0.44 0.09 0.90 -1.29 -0.08 0.07 -0.07 -1.81 0.44 0.09 0.82 -1.22 -2.76 -7.50 -1.51 -2.30 -12.15 5.13 -1.13 2.34 -1.23 -2.76 -7.50 -1.51 -3.43 -9.81 3.90 -2.83 -9.31 -1.07 -3.34 -8.99 2.68 -0.03 0.46 0.21 1.61 4.44 13.75 14.82 17.70 26.69 0.63 0.95 4.01 4.47 6.43 11.20 -0.6374 -0.6771 -0.0722 -0.1627 -0.3368 0.1239 0.3368 0.7631 0.1029 0.3048 0.4259 -0.2543 11100000 30600000 94800000 102100000 127100000 191600000 0.0716 0.0411 0.0312 0.0310 -0.0284 0.0675 0.0802 -0.0991 0.0443 0.0716 0.0411 0.0312 0.1112 -0.1275 0.1118 0.0716 0.0411 0.0312 0.0310 0.0280 0.0277 -0.0437 -0.2096 0.0294 0.0064 0.0393 -0.0493 -0.0033 0.0028 -0.0437 -0.2096 0.0294 0.0064 0.0360 -0.0465 0 0.15 0.16 0.13 0.18 0.44 Common Stock *(1)(2)(4) 6/10/2016 100000 20000 1880 Preferred Stock - Series A *(1)(2)(4) 6/10/16-11/7/16 1950000 1950000 383756 385636 Convertible Note Matures December 2024 Interest Rate 10% (1)(2)(4) 12/29/2022 5359791 5359791 5359791 Convertible Note Matures December 2024 Interest Rate 5% (1)(2)(4) 12/29/2022 1200000 1200000 1200000 Preferred Stock - Series B *(1)(2)(4) 8/7/17-2/1/19 7039203 6587102 219233 Preferred Stock - Series C *(1)(2)(4) 8/7/19-2/12/20 2650000 2650000 82533 Preferred Stock - Series A *(1)(2)(4) 9/18/2015 3642324 2000000 2566 Preferred Stock Warrants - Series B *(1)(2)(4) 2/1/2019 5250000 0 163082 Preferred Stock Warrants - Series B *(1)(2)(4) 7/9/18-9/4/18 12250000 0 380524 Preferred Stock Warrants - Series B *(1)(2)(4) 8/7/2017 6214922 0 193055 Preferred Stock Warrants - Series B *(1)(2)(4) 9/28/2017 700000 0 21744 7622528 Convertible Note Matures December 2023 Interest Rate 15% (1)(2)(4)(6) 10/11/2019 500000 500000 90539 Convertible Note Matures December 2023 Interest Rate 15% (1)(2)(4)(6) 10/22/2021 1000000 1000000 181078 Convertible Note Matures December 2023 Interest Rate 15% (1)(2)(4)(6) 10/29/2019 500000 500000 90539 Convertible Note Matures December 2023 Interest Rate 15% (1)(2)(4)(6) 10/6/2021 500000 500000 90539 Convertible Note Matures December 2023 Interest Rate 15% (1)(2)(4)(6) 11/12/2021 500000 500000 90539 Convertible Note Matures December 2023 Interest Rate 15% (1)(2)(4)(6) 11/29/2021 500000 500000 90539 Convertible Note Matures December 2023 Interest Rate 15% (1)(2)(4)(6) 12/31/2018 10961129 10961129 1984819 Convertible Note Matures December 2023 Interest Rate 15% (1)(2)(4)(6) 2/27/2020 1000000 1000000 181078 Convertible Note Matures December 2023 Interest Rate 15% (1)(2)(4)(6) 2/28/2022 200000 200000 36216 Convertible Note Matures December 2023 Interest Rate 15% (1)(2)(4)(6) 3/25/2020 500000 500000 90539 Convertible Note Matures December 2023 Interest Rate 15% (1)(2)(4)(6) 3/30/2022 150000 150000 27162 Convertible Note Matures December 2023 Interest Rate 15% (1)(2)(4)(6) 4/20/2021 1000000 1000000 181078 Convertible Note Matures December 2023 Interest Rate 15% (1)(2)(4)(6) 4/6/2022 350000 350000 63377 Convertible Note Matures December 2023 Interest Rate 15% (1)(2)(4)(6) 5/8/2020 400000 400000 72431 Convertible Note Matures December 2023 Interest Rate 15% (1)(2)(4)(6) 6/10/2021 500000 500000 90539 Convertible Note Matures December 2023 Interest Rate 15% (1)(2)(4) 6/10/2022 700000 700000 126755 Convertible Note Matures December 2023 Interest Rate 15% (1)(2)(4)(6) 7/12/2019 1300000 1300000 235401 Convertible Note Matures December 2023 Interest Rate 15% (1)(2)(4)(6) 7/16/2021 500000 500000 90539 Convertible Note Matures December 2023 Interest Rate 15% (1)(2)(4)(6) 7/31/2020 500000 500000 90539 Convertible Note Matures December 2023 Interest Rate 15% (1)(2)(4)(6) 8/28/2020 750000 750000 135809 Convertible Note Matures December 2023 Interest Rate 15% (1)(2)(4)(6) 9/22/2021 500000 500000 90539 Preferred Stock - Series C *(1)(2)(4) 7/12/2013 26856187 26299939 0 Term Note Matures December 2023 Interest Rate 8% (1)(2)(4) 2/10/2017 2000000 2000000 362156 Term Note Matures December 2023 Interest Rate 8% (1)(2)(4) 2/28/2014 3000000 3000000 543234 5035984 Convertible Note Matures March 2024 Interest Rate 10% (1)(4) 3/11/2019 100000 100000 100000 Preferred Stock - Series B *(1)(4) 7/3/2018 869792 1000000 0 CDIs *(2) 11/14/16-10/3/22 39774889 9268218 3709446 Common Stock *(1)(3)(4) 4/18/2011 1500000 662235 266091 Common Stock *(1)(2)(4) 6/7/2019 69102 7460851 311 Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6) 1/10/2023 100000 100000 9750 Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6) 10/13/2020 1050000 1050000 102375 Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6) 10/20/2021 1000000 1000000 97500 Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6) 10/21/2022 135000 135000 13162 Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6) 10/5/2021 700000 700000 68250 Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6) 11/11/2020 400000 400000 39000 Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6) 11/14/2022 165000 165000 16088 Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6) 11/23/2021 1000000 1000000 97500 Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6) 11/24/2020 375000 375000 36562 Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6) 12/11/2020 400000 400000 39000 Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6) 12/23/2020 2000000 2000000 195000 Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6) 12/28/2021 1000000 1000000 97500 Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6) 12/9/2022 125000 125000 12188 Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6) 2/23/2021 1400000 1400000 136500 Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6) 2/23/2022 200000 200000 19500 Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6) 3/11/2022 185000 185000 18037 Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6) 4/12/2021 1200000 1200000 117000 Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6) 4/14/2022 65000 65000 6337 Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6) 5/10/2022 250000 250000 24375 Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6) 5/18/2021 1000000 1000000 97500 Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6) 5/26/2022 250000 250000 24375 Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6) 6/10/2022 250000 250000 24375 Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6) 6/22/2021 1000000 1000000 97500 Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6) 6/28/2022 250000 250000 24375 Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6) 6/7/2019 4929015 4929015 480579 Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6) 7/13/2022 250000 250000 24375 Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6) 7/26/2021 1000000 1000000 97500 Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6) 7/28/2022 250000 250000 24375 Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6) 8/12/2020 750000 750000 73125 Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6) 8/12/2022 250000 250000 24375 Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6) 8/19/2021 1000000 1000000 97500 Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6) 9/10/2020 900000 900000 87750 Convertible Note Matures June 2024 Interest Rate 12% (1)(2)(4)(6) 9/22/2021 300000 300000 29250 Preferred Stock - Series AA *(1)(2)(4) 6/7/19-7/20/20 60733693 17355887 573233 2926122 Fidelity Investments Money Market Treasury Portfolio - Class I (5) Various 567150 567150 567150 20612957 -9513901 11099056 Common Stock *(1)(2)(4) 6/10/2016 100000 20000 11130 Preferred Stock - Series A *(1)(2)(4) 6/10/16-11/7/16 1950000 1950000 865995 877125 Convertible Note Matures December 2024 Interest Rate 5% (1)(2)(4) 12/29/2022 1200000 1200000 1200000 Convertible Note Matures December 2022 Interest Rate 10% (1)(2)(4) 12/29/2022 5359791 5359791 5359791 Preferred Stock - Series A *(1)(2)(4) 9/18/2015 3642324 2000000 4735 Preferred Stock - Series B *(1)(2)(4) 8/7/17 - 2/1/19 7039203 6587102 275585 Preferred Stock - Series C *(1)(2)(4) 8/7/19-2/12/20 2650000 2650000 103748 Preferred Stock Warrants - Series B *(1)(2)(4) 7/9/18 - 9/4/18 12250000 0 478608 Preferred Stock Warrants - Series B *(1)(2)(4) 2/1/2019 5250000 0 205117 Preferred Stock Warrants - Series B *(1)(2)(4) 8/7/2017 6214922 0 242817 Preferred Stock Warrants - Series B *(1)(2)(4) 9/28/2017 700000 0 27349 7897750 Convertible Note Matures December 2022 Interest Rate 15% (1)(2)(4)(6) 12/31/2018 10961129 10961129 6746169 Convertible Note Matures December 2022 Interest Rate 15% (1)(2)(4)(6) 7/12/2019 1300000 1300000 800102 `Convertible Note Matures December 2022 Interest Rate 15% (1)(2)(4)(6) 10/11/2019 500000 500000 307731 Convertible Note Matures December 2022 Interest Rate 15% (1)(2)(4)(6) 10/29/2019 500000 500000 307732 Convertible Note Matures December 2022 Interest Rate 15% (1)(2)(4)(6) 2/27/2020 1000000 1000000 615463 Convertible Note Matures December 2022 Interest Rate 15% (1)(2)(4)(6) 3/25/2020 500000 500000 307732 Convertible Note Matures December 2022 Interest Rate 15% (1)(2)(4)(6) 5/8/2020 400000 400000 246185 Convertible Note Matures December 2022 Interest Rate 15% (1)(2)(4)(6) 7/31/2020 500000 500000 307731 Convertible Note Matures December 2022 Interest Rate 15% (1)(2)(4)(6) 8/28/2020 750000 750000 461597 Convertible Note Matures December 2022 Interest Rate 15% (1)(2)(4)(6) 4/20/2021 1000000 1000000 615463 Convertible Note Matures December 2022 Interest Rate 15% (1)(2)(4)(6) 6/10/2021 500000 500000 307732 Convertible Note Matures December 2022 Interest Rate 15% (1)(2)(4)(6) 7/16/2021 500000 500000 307732 Convertible Note Matures December 2022 Interest Rate 15% (1)(2)(4)(6) 9/22/2021 500000 500000 307731 Convertible Note Matures December 2022 Interest Rate 15% (1)(2)(4)(6) 10/6/2021 500000 500000 307731 Convertible Note Matures December 2022 Interest Rate 15% (1)(2)(4)(6) 10/22/2021 1000000 1000000 615463 Convertible Note Matures December 2022 Interest Rate 15% (1)(2)(4)(6) 11/12/2021 500000 500000 307732 Convertible Note Matures December 2022 Interest Rate 15% (1)(2)(4)(6) 11/29/2021 500000 500000 307732 Convertible Note Matures December 2022 Interest Rate 15% (1)(2)(4)(6) 2/28/2022 200000 200000 123093 Convertible Note Matures December 2022 Interest Rate 15% (1)(2)(4)(6) 3/30/2022 150000 150000 92319 Convertible Note Matures December 2022 Interest Rate 15% (1)(2)(4)(6) 4/6/2022 350000 350000 215412 Convertible Note Matures December 2022 Interest Rate 15% (1)(2)(4)(6) 6/10/2022 700000 700000 430824 Preferred Stock - Series C *(1)(2)(4) 7/12/2013 26856187 26299938 0 Term Note Matures December 2022 Interest Rate 8% (1)(2)(4)(6) 2/28/2014 3000000 3000000 1846389 Term Note Matures December 2022 Interest Rate 8% (1)(2)(4)(6) 2/10/2017 2000000 2000000 1230926 17116721 Convertible Note Matures March 2023 Interest Rate 10% (1)(4) 3/11/2019 100000 100000 100000 Preferred Stock - Series B *(1)(4) 7/3/2018 869792 1000000 0 CDIs *(2) 11/14/16 - 10/3/22 39774889 9268219 3520496 Preferred Stock - Series 1-E *(1)(2)(4) 4/18/2011 5704480 2372403 320592 Preferred Stock - Series 1-C *(1)(2)(4) 4/18/2011 82914 109518 962 Preferred Stock - Series 1-D *(1)(2)(4) 4/18/2011 850830 431901 2552 Common Stock *(1)(2)(4) 4/18/2011 921892 169045 111 Common Stock Warrants *(1)(2)(4) 4/18/2011 37982 6678 1 Preferred Stock - Series 1-F *(1)(2)(4) 4/18/2011 912453 456389 70806 Preferred Stock - Series 1-G *(1)(2)(4) 3/10/2016 48370793 3880592 306671 Preferred Stock - Series 1-H *(1)(2)(4) 3/10/2016 837942 936895 35529 737224 Common Stock *(1)(3)(4) 4/18/2011 1500000 662235 337500 Common Stock *(1)(2)(4) 4/11/2013 - 5/6/2019 69102 7460851 546 Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6) 6/7/2019 4929015 4929015 1601930 Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6) 8/12/2020 750000 750000 243750 Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6) 9/10/2020 900000 900000 292500 Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6) 10/13/2020 1050000 1050000 341250 Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6) 11/11/2020 400000 400000 130000 Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6) 11/24/2020 375000 375000 121875 Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6) 12/11/2020 400000 400000 130000 Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6) 12/23/2020 2000000 2000000 650000 Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6) 2/23/2021 1400000 1400000 455000 Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6) 4/12/2021 1200000 1200000 390000 Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6) 5/18/2021 1000000 1000000 325000 Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6) 6/22/2021 1000000 1000000 325000 Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6) 7/26/2021 1000000 1000000 325000 Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6) 8/19/2021 1000000 1000000 325000 Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6) 9/22/2021 300000 300000 97500 Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6) 10/5/2021 700000 700000 227500 Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6) 10/20/2021 1000000 1000000 325000 Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6) 11/23/2021 1000000 1000000 325000 Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6) 12/28/2021 1000000 1000000 325000 Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6) 2/23/2022 200000 200000 65000 Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6) 3/11/2022 185000 185000 60125 Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6) 4/14/2022 65000 65000 21125 Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6) 5/10/2022 250000 250000 81250 Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6) 5/26/2022 250000 250000 81250 Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6) 6/10/2022 250000 250000 81250 Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6) 6/28/2022 250000 250000 81250 Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6) 7/13/2022 250000 250000 81250 Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6) 7/28/2022 250000 250000 81250 Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6) 8/12/2022 250000 250000 81250 Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6) 10/21/2022 135000 135000 43875 Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6) 11/14/2022 165000 165000 53625 Convertible Note Matures June 2023 Interest Rate 12% (1)(2)(4)(6) 12/9/2022 125000 125000 40625 Preferred Stock - Series AA *(1)(2)(4) 6/7/19 - 7/20/20 60733693 17355887 1049478 Preferred Stock Warrants - Series AA *(1)(2)(4) 6/7/2019 609756 0 3232 8862686 Fidelity Investments Money Market Treasury Portfolio - Class I (5) Various 672422 672422 672422 40121924 -9512333 30609591 <p id="xdx_800_eus-gaap--InvestmentCompanyFinancialHighlightsTextBlock_zOrXp5AFa3Q5" style="font: 14pt Times New Roman, Times, Serif; text-align: left; margin-left: 18pt; text-indent: -18pt; margin-bottom: 0pt; margin-top: 0pt"><b>NOTE 1. <span id="xdx_82B_zK1aG6MvPWhl">THE COMPANY</span> </b></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">Firsthand Technology Value Fund, Inc. (the “Company,” the “Fund,” “us,” “our,” and “we”), is a Maryland corporation and an externally managed, non-diversified, closed-end management investment company that has elected to be treated as a business development company (“BDC”) under the Investment Company Act of 1940, as amended (the “1940 Act”). The Company acquired its initial portfolio of securities through the reorganization of Firsthand Technology Value Fund, a series of Firsthand Funds, into the Company. The reorganization was completed on April 15, 2011. The Company commenced operations on April 18th, 2011. Under normal circumstances, the Company will invest at least 80% of its assets for investment purposes in technology companies, which are considered to be those companies that derive at least 50% of their revenues from products and/ or services within the information technology sector or the “cleantech” sector. Information technology companies include, but are not limited to, those focused on computer hardware, software, telecommunications, networking, Internet, and consumer electronics. While there is no standard definition of cleantech, it is generally regarded as including goods and services designed to harness renewable energy and materials, eliminate emissions and waste, and reduce the use of natural resources. In addition, under normal circumstances we will invest at least 70% of our assets in privately held companies and in public companies with market capitalizations less than $250 million. Our portfolio is primarily composed of equity and equity derivative securities of technology and cleantech companies (as defined above). These investments generally range between $1 million and $10 million each, although the investment size will vary proportionately with the size of the Company’s capital base. The Company’s shares are listed on the NASDAQ Global Market under the symbol “SVVC.” Firsthand Capital Management, Inc., which was previously known as SiVest Group, Inc. (“FCM” or the “Advisor”), serves as the investment adviser to the Company. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">The Company is an investment company and follows accounting and reporting guidance in the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification Topic 946. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>CONSOLIDATION OF SUBSIDIARIES. </b>On May 8, 2015, the Board of Directors of the Company approved the formation of a fully owned and controlled subsidiary (as defined by the 1940 Act) of the Company named Firsthand Venture Investors (“FVI”), a California general partnership formed on March 30, 2015. After the close of business on June 30, 2015, the Company contributed substantially all of its assets to FVI in return for a controlling general partner ownership interest in FVI. The transaction was completed on July 1, 2015. Under this structure, we have all or substantially all of our investment activities conducted through our fully owned subsidiary, FVI. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">During the fiscal years ended December 31, 2016 and 2017, with the approval of its Board of Directors, the Company organized three separate fully owned and controlled subsidiaries (as defined by the 1940 Act). Each subsidiary was a Cayman Islands corporation and the financial statements of each subsidiary were reported on a consolidated basis with the Company. Each subsidiary was formed for the purpose of holding one or more investments made by the Company, and was treated as a controlled foreign corporation under the Internal Revenue Code not separately subject to U.S. federal income tax. FVI was treated as the sole U.S. shareholder of each subsidiary. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">The Board of Directors of the Company approved the liquidation of those three Cayman subsidiaries on November 2, 2018. That liquidation was completed on December 27, 2018. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p id="xdx_806_eus-gaap--SignificantAccountingPoliciesTextBlock_zyJsXz83kAXa" style="font: 14pt Times New Roman, Times, Serif; text-align: left; margin-left: 18pt; text-indent: -18pt; margin-bottom: 0pt; margin-top: 0pt"><b>NOTE 2. <span id="xdx_823_z8cfSAd1lws2">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span> </b></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: justify; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">The following is a summary of significant accounting policies followed in the preparation of the Company’s financial statements included in this report: </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p id="xdx_842_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zsVjclSpqEn4" style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b><span id="xdx_863_zJ4TIFIM6M5f">BASIS OF PRESENTATION</span>.</b> The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) pursuant to the requirements on Form 10-K. ASC 946, <i>Financial Services—Investment Companies</i> (“ASC 946”), and Articles 6, 10 and 12 of Regulation S-X. In the opinion of management, all adjustments, which are of a normal recurring nature, considered necessary for the fair presentation of the financial statements for the periods presented, have been included. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">Under the 1940 Act, ASC 946, and the regulations pursuant to Article 6 of Regulation S-X, we are precluded from consolidating any entity other than another investment company or an operating company which provides substantially all of its services to benefit us. Consequentially, as of December 31, 2018, the Company consolidated some special purpose entities. These special purpose entities only hold investments of the Company and have no other significant asset and liabilities. All significant intercompany transactions and balances have been eliminated in consolidation. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p id="xdx_841_eus-gaap--UseOfEstimates_zGI8sWIuCuI1" style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b><span id="xdx_86E_zlhDuHC9vT5c">USE OF ESTIMATES</span>.</b> The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ from those estimates. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p id="xdx_84C_eus-gaap--InvestmentPolicyTextBlock_zZMY5GhKlqU8" style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b><span id="xdx_86F_zxoDcoCXZfl2">PORTFOLIO INVESTMENT VALUATIONS</span>.</b> Investments are stated at “value” as defined in the 1940 Act and in the applicable regulations of the Securities and Exchange Commission and in accordance with GAAP. Value, as defined in Section 2(a)(41) of the 1940 Act, is (i) the market value of those securities for which a market quotation is readily available and (ii) the fair value as determined in good faith by the Advisor as the valuation designee appointed by the Board of Directors, and subject to oversight by the Board of Directors. On June 30, 2023, our financial statements include venture capital investments valued at approximately <span id="xdx_90A_eus-gaap--VentureCapitalGainsLossesNet_pn5n6_c20230101__20230630_zQvtniMge2yc" title="Venture capital investments">16.3</span> million. The fair values of our venture capital investments were also determined by the Advisor as the valuation designee. Upon sale of these investments, the values that are ultimately realized may be different from what is presently estimated. The difference could be material. Also see note 6 regarding the fair value of the company’s investments. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zZQFbgy5ezai" style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b><span id="xdx_865_z8OBSiWvZgT4">CASH AND CASH EQUIVALENTS</span>.</b> The Company considers liquid assets deposited with a bank, investments in money market funds, and certain short-term debt instruments with maturities of three months or less to be cash equivalents. These investments represent amounts held with financial institutions that are readily accessible to pay our expenses or purchase investments. Cash and cash equivalents are valued at cost plus accrued interest, which approximates market value. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p id="xdx_845_ecustom--RestrictedSecuritiesPolicyTextBlock_zTny3IRXW367" style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b><span id="xdx_863_ztrSqP8hPRv8">RESTRICTED SECURITIES</span>.</b> At June 30, 2023, we held $<span id="xdx_903_eus-gaap--DebtSecuritiesTradingRestricted_iI_c20230630_zpw1TQCLyJJj" title="Restricted securities">16,336,361</span> in restricted securities. At December 31, 2022, we held $<span id="xdx_903_eus-gaap--DebtSecuritiesTradingRestricted_iI_c20221231_z3YmsIPB2W7j" title="Restricted securities">35,929,006</span>. in restricted securities. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p id="xdx_84B_eus-gaap--RevenueRecognitionPolicyTextBlock_zt9ruHnLjjIi" style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b><span id="xdx_86F_zsTC19s4er55">INCOME RECOGNITION</span>.</b> Dividend income is recorded on the ex-dividend date. Interest income is accrued as earned. Discounts and premiums on securities purchased are amortized over the lives of the respective securities. Other non-cash dividends are recognized as investment income at the fair value of the property received. When debt securities are determined to be non-income producing, the Company ceases accruing interest and writes off any previously accrued interest. These write-offs are recorded as an adjustment to interest income. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p id="xdx_849_ecustom--ShareValuationPolicyTextBlock_zGg2zQFdT28b" style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b><span id="xdx_869_zrSEmpER1wee">SHARE VALUATION</span>. </b>The net asset value (“NAV”) per share of the Fund is calculated by dividing the sum of the value of the securities held by the Fund, plus cash or other assets, minus all liabilities (including estimated accrued expenses) by the total number of shares outstanding of the Fund, rounded to the nearest cent. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p id="xdx_844_ecustom--RealizedGainLossUnrealizedAppreciationDepreciationPortfolioInvestmentsPolicyTextBlock_zdpc7ydRNK8h" style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b><span id="xdx_86A_zY7ulRurNIS2">REALIZED GAIN OR LOSS AND UNREALIZED APPRECIATION OR DEPRECIATION OF PORTFOLIO INVESTMENTS</span>. </b>A realized gain or loss is recognized when an investment is disposed of and is computed as the difference between the Company’s cost basis in the investment at the disposition date and the net proceeds received from such disposition. Realized gains and losses are calculated on a specific identification basis. Unrealized appreciation or depreciation is computed as the difference between the fair value of the investment and the cost basis of such investment. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p id="xdx_84D_eus-gaap--IncomeTaxPolicyTextBlock_zCvSI6AgIKVe" style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b><span id="xdx_869_z1c3HHxohlhi">INCOME TAXES</span>.</b> The Company provides for state and federal corporate income tax, as appropriate, because it is regarded as a corporation under Subchapter C of the Code. The Company recognizes interest and penalties in income tax expense. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p id="xdx_844_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zRSwwN4HaBVk" style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b><span id="xdx_862_zYYnjNuiId24">FOREIGN CURRENCY TRANSLATION</span>. </b>The accounting records of the Company are maintained in U.S. dollars. All assets and liabilities denominated in foreign currencies are translated into U.S. dollars based on the foreign exchange rate on the date of valuation. The Company does not isolate that portion of the results of operation resulting from changes in foreign exchange rates on investments from the fluctuations arising from changes in market prices of securities held. The Company’s investments in foreign securities may involve certain risks, including without limitation: foreign exchange restrictions, expropriation, taxation or other political, social, or economic risks, all of which could affect the market and/or credit risk of the investment. In addition, changes in the relationship of foreign currencies to the U.S. dollar can significantly affect the value of these investments and therefore the earnings of the Company. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p id="xdx_84A_eus-gaap--SecuritiesBorrowedAndLoanedPolicy_zrtI8BiU3KGj" style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b><span id="xdx_86B_z1yJzV5fUSl2">SECURITIES TRANSACTIONS</span>. </b>Securities transactions are accounted for on the date the transaction for the purchase or sale of the securities is entered into by the Company (i.e., trade date). </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p id="xdx_84A_eus-gaap--ConcentrationRiskCreditRisk_zqqOQ6MX5SQf" style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b><span id="xdx_864_z70OmEdKNsIj">CONCENTRATION OF CREDIT RISK</span>. </b>The Company places its cash and cash equivalents with financial institutions and, at times, cash held in checking accounts may exceed the Federal Deposit Insurance Corporation insured limit. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p id="xdx_84D_eus-gaap--AvailableForSaleSecuritiesPurchasedOptionsPricePolicy_zC5DDQtWQEA9" style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b><span id="xdx_86A_z4BuP6x5dIqh">OPTIONS</span>.</b> The Company is subject to equity price risk in the normal course of pursuing its investment objectives and may enter into options written to hedge against changes in the value of equities. The Company may purchase put and call options to attempt to provide protection against adverse price effects from anticipated changes in prevailing prices of securities or stock indices. The Company may also write put and call options. When the Company writes an option, an amount equal to the premium received by the Company is recorded as a liability and is subsequently adjusted to the current fair value of the option written. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">Premiums received from writing options that expire unexercised are treated by the Company on the expiration date as realized gains from investments. The difference between the premium and the amount paid on effecting a closing purchase transaction, including brokerage commissions, is also treated as a realized gain, or, if the premium is less than the amount paid for the closing purchase transaction, as a realized loss. If a call option is exercised, the premium is added to the proceeds from the sale of the underlying security or currency in determining whether the Company has realized a gain or loss. The Company as writer of an option bears the market risk of an unfavorable change in the price of the security underlying the written option. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: justify; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">The average monthly volume of the Company’s derivatives during the six months ended June 30, 2023 is as follows: </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <table cellpadding="2" cellspacing="0" id="xdx_88C_eus-gaap--ScheduleOfDerivativeInstrumentsTextBlock_zIFLuEKllGql" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)"> <tr> <td id="xdx_8B0_z1RIRHQ9NMF9" style="display: none; vertical-align: top">Schedule of derivatives</td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"> </td></tr> <tr> <td style="vertical-align: top; width: 43%"> </td> <td style="border-bottom: #000000 1pt solid; vertical-align: top; width: 19%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>PURCHASED OPTIONS <br/> (CONTRACTS)</b></p></td> <td style="border-bottom: #000000 1pt solid; vertical-align: top; width: 19%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>WARRANTS (NOTIONAL <br/> VALUE)</b></p></td> <td style="border-bottom: #000000 1pt solid; vertical-align: top; width: 19%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>WRITTEN OPTIONS <br/> (CONTRACTS)</b></p></td> </tr> <tr style="background-color: Gainsboro"> <td style="vertical-align: top; width: 43%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Firsthand Technology Value Fund, Inc.</p></td> <td style="vertical-align: bottom; width: 19%"><p id="xdx_98A_ecustom--PurchasedOptionsContracts_pp0p0_d0_c20230101__20230630_z57DmjPQENCg" style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt" title="PURCHASED OPTIONS (CONTRACTS)">—</p></td> <td style="vertical-align: top; width: 19%"><p id="xdx_985_eus-gaap--PaymentsForRepurchaseOfWarrants_c20230101__20230630_pp0p0" style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt" title="WARRANTS (NOTIONAL VALUE)">1,252,639</p></td> <td style="vertical-align: bottom; width: 19%"><p id="xdx_98F_ecustom--WrittenOptionsContracts_pp0p0_d0_c20230101__20230630_z14WhbBhVHod" style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt" title="WRITTEN OPTIONS (CONTRACTS)">—</p></td> </tr> </table> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_842_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zsVjclSpqEn4" style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b><span id="xdx_863_zJ4TIFIM6M5f">BASIS OF PRESENTATION</span>.</b> The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) pursuant to the requirements on Form 10-K. ASC 946, <i>Financial Services—Investment Companies</i> (“ASC 946”), and Articles 6, 10 and 12 of Regulation S-X. In the opinion of management, all adjustments, which are of a normal recurring nature, considered necessary for the fair presentation of the financial statements for the periods presented, have been included. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">Under the 1940 Act, ASC 946, and the regulations pursuant to Article 6 of Regulation S-X, we are precluded from consolidating any entity other than another investment company or an operating company which provides substantially all of its services to benefit us. Consequentially, as of December 31, 2018, the Company consolidated some special purpose entities. These special purpose entities only hold investments of the Company and have no other significant asset and liabilities. All significant intercompany transactions and balances have been eliminated in consolidation. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p id="xdx_841_eus-gaap--UseOfEstimates_zGI8sWIuCuI1" style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b><span id="xdx_86E_zlhDuHC9vT5c">USE OF ESTIMATES</span>.</b> The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ from those estimates. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p id="xdx_84C_eus-gaap--InvestmentPolicyTextBlock_zZMY5GhKlqU8" style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b><span id="xdx_86F_zxoDcoCXZfl2">PORTFOLIO INVESTMENT VALUATIONS</span>.</b> Investments are stated at “value” as defined in the 1940 Act and in the applicable regulations of the Securities and Exchange Commission and in accordance with GAAP. Value, as defined in Section 2(a)(41) of the 1940 Act, is (i) the market value of those securities for which a market quotation is readily available and (ii) the fair value as determined in good faith by the Advisor as the valuation designee appointed by the Board of Directors, and subject to oversight by the Board of Directors. On June 30, 2023, our financial statements include venture capital investments valued at approximately <span id="xdx_90A_eus-gaap--VentureCapitalGainsLossesNet_pn5n6_c20230101__20230630_zQvtniMge2yc" title="Venture capital investments">16.3</span> million. The fair values of our venture capital investments were also determined by the Advisor as the valuation designee. Upon sale of these investments, the values that are ultimately realized may be different from what is presently estimated. The difference could be material. Also see note 6 regarding the fair value of the company’s investments. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> 16300000 <p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zZQFbgy5ezai" style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b><span id="xdx_865_z8OBSiWvZgT4">CASH AND CASH EQUIVALENTS</span>.</b> The Company considers liquid assets deposited with a bank, investments in money market funds, and certain short-term debt instruments with maturities of three months or less to be cash equivalents. These investments represent amounts held with financial institutions that are readily accessible to pay our expenses or purchase investments. Cash and cash equivalents are valued at cost plus accrued interest, which approximates market value. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p id="xdx_845_ecustom--RestrictedSecuritiesPolicyTextBlock_zTny3IRXW367" style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b><span id="xdx_863_ztrSqP8hPRv8">RESTRICTED SECURITIES</span>.</b> At June 30, 2023, we held $<span id="xdx_903_eus-gaap--DebtSecuritiesTradingRestricted_iI_c20230630_zpw1TQCLyJJj" title="Restricted securities">16,336,361</span> in restricted securities. At December 31, 2022, we held $<span id="xdx_903_eus-gaap--DebtSecuritiesTradingRestricted_iI_c20221231_z3YmsIPB2W7j" title="Restricted securities">35,929,006</span>. in restricted securities. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> 16336361 35929006 <p id="xdx_84B_eus-gaap--RevenueRecognitionPolicyTextBlock_zt9ruHnLjjIi" style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b><span id="xdx_86F_zsTC19s4er55">INCOME RECOGNITION</span>.</b> Dividend income is recorded on the ex-dividend date. Interest income is accrued as earned. Discounts and premiums on securities purchased are amortized over the lives of the respective securities. Other non-cash dividends are recognized as investment income at the fair value of the property received. When debt securities are determined to be non-income producing, the Company ceases accruing interest and writes off any previously accrued interest. These write-offs are recorded as an adjustment to interest income. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p id="xdx_849_ecustom--ShareValuationPolicyTextBlock_zGg2zQFdT28b" style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b><span id="xdx_869_zrSEmpER1wee">SHARE VALUATION</span>. </b>The net asset value (“NAV”) per share of the Fund is calculated by dividing the sum of the value of the securities held by the Fund, plus cash or other assets, minus all liabilities (including estimated accrued expenses) by the total number of shares outstanding of the Fund, rounded to the nearest cent. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p id="xdx_844_ecustom--RealizedGainLossUnrealizedAppreciationDepreciationPortfolioInvestmentsPolicyTextBlock_zdpc7ydRNK8h" style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b><span id="xdx_86A_zY7ulRurNIS2">REALIZED GAIN OR LOSS AND UNREALIZED APPRECIATION OR DEPRECIATION OF PORTFOLIO INVESTMENTS</span>. </b>A realized gain or loss is recognized when an investment is disposed of and is computed as the difference between the Company’s cost basis in the investment at the disposition date and the net proceeds received from such disposition. Realized gains and losses are calculated on a specific identification basis. Unrealized appreciation or depreciation is computed as the difference between the fair value of the investment and the cost basis of such investment. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p id="xdx_84D_eus-gaap--IncomeTaxPolicyTextBlock_zCvSI6AgIKVe" style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b><span id="xdx_869_z1c3HHxohlhi">INCOME TAXES</span>.</b> The Company provides for state and federal corporate income tax, as appropriate, because it is regarded as a corporation under Subchapter C of the Code. The Company recognizes interest and penalties in income tax expense. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p id="xdx_844_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zRSwwN4HaBVk" style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b><span id="xdx_862_zYYnjNuiId24">FOREIGN CURRENCY TRANSLATION</span>. </b>The accounting records of the Company are maintained in U.S. dollars. All assets and liabilities denominated in foreign currencies are translated into U.S. dollars based on the foreign exchange rate on the date of valuation. The Company does not isolate that portion of the results of operation resulting from changes in foreign exchange rates on investments from the fluctuations arising from changes in market prices of securities held. The Company’s investments in foreign securities may involve certain risks, including without limitation: foreign exchange restrictions, expropriation, taxation or other political, social, or economic risks, all of which could affect the market and/or credit risk of the investment. In addition, changes in the relationship of foreign currencies to the U.S. dollar can significantly affect the value of these investments and therefore the earnings of the Company. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p id="xdx_84A_eus-gaap--SecuritiesBorrowedAndLoanedPolicy_zrtI8BiU3KGj" style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b><span id="xdx_86B_z1yJzV5fUSl2">SECURITIES TRANSACTIONS</span>. </b>Securities transactions are accounted for on the date the transaction for the purchase or sale of the securities is entered into by the Company (i.e., trade date). </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p id="xdx_84A_eus-gaap--ConcentrationRiskCreditRisk_zqqOQ6MX5SQf" style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b><span id="xdx_864_z70OmEdKNsIj">CONCENTRATION OF CREDIT RISK</span>. </b>The Company places its cash and cash equivalents with financial institutions and, at times, cash held in checking accounts may exceed the Federal Deposit Insurance Corporation insured limit. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p id="xdx_84D_eus-gaap--AvailableForSaleSecuritiesPurchasedOptionsPricePolicy_zC5DDQtWQEA9" style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b><span id="xdx_86A_z4BuP6x5dIqh">OPTIONS</span>.</b> The Company is subject to equity price risk in the normal course of pursuing its investment objectives and may enter into options written to hedge against changes in the value of equities. The Company may purchase put and call options to attempt to provide protection against adverse price effects from anticipated changes in prevailing prices of securities or stock indices. The Company may also write put and call options. When the Company writes an option, an amount equal to the premium received by the Company is recorded as a liability and is subsequently adjusted to the current fair value of the option written. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">Premiums received from writing options that expire unexercised are treated by the Company on the expiration date as realized gains from investments. The difference between the premium and the amount paid on effecting a closing purchase transaction, including brokerage commissions, is also treated as a realized gain, or, if the premium is less than the amount paid for the closing purchase transaction, as a realized loss. If a call option is exercised, the premium is added to the proceeds from the sale of the underlying security or currency in determining whether the Company has realized a gain or loss. The Company as writer of an option bears the market risk of an unfavorable change in the price of the security underlying the written option. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: justify; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">The average monthly volume of the Company’s derivatives during the six months ended June 30, 2023 is as follows: </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <table cellpadding="2" cellspacing="0" id="xdx_88C_eus-gaap--ScheduleOfDerivativeInstrumentsTextBlock_zIFLuEKllGql" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)"> <tr> <td id="xdx_8B0_z1RIRHQ9NMF9" style="display: none; vertical-align: top">Schedule of derivatives</td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"> </td></tr> <tr> <td style="vertical-align: top; width: 43%"> </td> <td style="border-bottom: #000000 1pt solid; vertical-align: top; width: 19%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>PURCHASED OPTIONS <br/> (CONTRACTS)</b></p></td> <td style="border-bottom: #000000 1pt solid; vertical-align: top; width: 19%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>WARRANTS (NOTIONAL <br/> VALUE)</b></p></td> <td style="border-bottom: #000000 1pt solid; vertical-align: top; width: 19%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>WRITTEN OPTIONS <br/> (CONTRACTS)</b></p></td> </tr> <tr style="background-color: Gainsboro"> <td style="vertical-align: top; width: 43%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Firsthand Technology Value Fund, Inc.</p></td> <td style="vertical-align: bottom; width: 19%"><p id="xdx_98A_ecustom--PurchasedOptionsContracts_pp0p0_d0_c20230101__20230630_z57DmjPQENCg" style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt" title="PURCHASED OPTIONS (CONTRACTS)">—</p></td> <td style="vertical-align: top; width: 19%"><p id="xdx_985_eus-gaap--PaymentsForRepurchaseOfWarrants_c20230101__20230630_pp0p0" style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt" title="WARRANTS (NOTIONAL VALUE)">1,252,639</p></td> <td style="vertical-align: bottom; width: 19%"><p id="xdx_98F_ecustom--WrittenOptionsContracts_pp0p0_d0_c20230101__20230630_z14WhbBhVHod" style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt" title="WRITTEN OPTIONS (CONTRACTS)">—</p></td> </tr> </table> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="2" cellspacing="0" id="xdx_88C_eus-gaap--ScheduleOfDerivativeInstrumentsTextBlock_zIFLuEKllGql" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)"> <tr> <td id="xdx_8B0_z1RIRHQ9NMF9" style="display: none; vertical-align: top">Schedule of derivatives</td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"> </td></tr> <tr> <td style="vertical-align: top; width: 43%"> </td> <td style="border-bottom: #000000 1pt solid; vertical-align: top; width: 19%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>PURCHASED OPTIONS <br/> (CONTRACTS)</b></p></td> <td style="border-bottom: #000000 1pt solid; vertical-align: top; width: 19%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>WARRANTS (NOTIONAL <br/> VALUE)</b></p></td> <td style="border-bottom: #000000 1pt solid; vertical-align: top; width: 19%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>WRITTEN OPTIONS <br/> (CONTRACTS)</b></p></td> </tr> <tr style="background-color: Gainsboro"> <td style="vertical-align: top; width: 43%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Firsthand Technology Value Fund, Inc.</p></td> <td style="vertical-align: bottom; width: 19%"><p id="xdx_98A_ecustom--PurchasedOptionsContracts_pp0p0_d0_c20230101__20230630_z57DmjPQENCg" style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt" title="PURCHASED OPTIONS (CONTRACTS)">—</p></td> <td style="vertical-align: top; width: 19%"><p id="xdx_985_eus-gaap--PaymentsForRepurchaseOfWarrants_c20230101__20230630_pp0p0" style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt" title="WARRANTS (NOTIONAL VALUE)">1,252,639</p></td> <td style="vertical-align: bottom; width: 19%"><p id="xdx_98F_ecustom--WrittenOptionsContracts_pp0p0_d0_c20230101__20230630_z14WhbBhVHod" style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt" title="WRITTEN OPTIONS (CONTRACTS)">—</p></td> </tr> </table> 0 1252639 0 <p id="xdx_803_ecustom--BusinessRisksAndUncertaintiesTextBlock_zMwymF1x5JZ4" style="font: 14pt Times New Roman, Times, Serif; text-align: left; margin-left: 18pt; text-indent: -18pt; margin-bottom: 0pt; margin-top: 0pt"><b>NOTE 3. <span id="xdx_82F_zUzc5oOw1N52">BUSINESS RISKS AND UNCERTAINTIES</span> </b></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">We invest a substantial portion of our assets in privately-held companies, the securities of which are inherently illiquid. We also seek to invest in small publicly-traded companies that we believe have exceptional growth potential and to make opportunistic investments in publicly-traded companies, both large and small. In the case of investments in small publicly-traded companies, although these companies are publicly traded, their stock may not trade at high volumes, and prices can be volatile, which may restrict our ability to sell our positions. We may also be subject to contractual restrictions or securities law limits on our ability to sell portfolio holdings because of, for example, our affiliation with a portfolio company or the relative size of our holding in a company. These privately held and publicly traded businesses tend to lack management depth, have limited or no history of operations and typically have not attained profitability. Because of the speculative nature of our investments and the lack of public markets for privately held investments, there is greater risk of loss than is the case with traditional investment securities. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">We do not choose investments based on a strategy of diversification. We also do not rebalance the portfolio should one of our portfolio companies increase in value substantially relative to the rest of the portfolio. Therefore, the value of our portfolio may be more vulnerable to events affecting a single sector, industry or portfolio company and, therefore, may be subject to greater volatility than a company that follows a diversification strategy. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">Because there is typically no public or readily-ascertainable market for our interests in the small privately-held companies in which we invest, the valuation of those securities is determined in good faith by the Valuation Committee, comprised of all members of the Board who are not “interested persons” of the Company, as such term is defined in Section 2(a)(19) of the 1940 Act, in accordance with our Valuation Procedures and is subject to significant estimates and judgments. The determined value of the securities in our portfolio may differ significantly from the values that would be placed on these securities if a ready market for the securities existed. Any changes in valuation are recorded in our Statement of Operations as “Net increase (decrease) in unrealized appreciation on investments.” Changes in valuation of any of our investments in privately-held companies from one period to another may be volatile. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">The Board has engaged an independent valuation firm to provide it with valuation assistance with respect to certain of our portfolio investments. The Company intends to continue to engage an independent valuation firm to provide us with assistance regarding our determination of the fair value of select portfolio investments each quarter unless directed by the Board to cancel such valuation services. The scope of the services rendered by an independent valuation firm is at the discretion of the Board. The Board is ultimately and solely responsible for determining the fair value of the Company’s investments in good faith. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">With respect to investments for which market quotations are not readily available or when such market quotations are deemed not to represent fair value, the Board has approved a multi-step valuation process to be followed each quarter, as described below: </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="width: 36pt"> </td> <td style="width: 36pt; vertical-align: top; text-align: right"> <p style="font: 11pt Times New Roman; text-align: left; margin-top: 0pt; margin-bottom: 0pt"> (1) </p> </td> <td style="vertical-align: top; text-align: left"> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">each quarter the valuation process begins with each portfolio company or investment being initially valued by the Advisor’s Valuation Committee or the independent valuation firm; </p> </td> </tr> </table> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="width: 36pt"> </td> <td style="width: 36pt; vertical-align: top; text-align: right"> <p style="font: 11pt Times New Roman; text-align: left; margin-top: 0pt; margin-bottom: 0pt"> (2) </p> </td> <td style="vertical-align: top; text-align: left"> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">the Valuation Committee of the Board on a quarterly basis reviews the preliminary valuation of the Advisor’s Valuation Committee and that of the independent valuation firms and makes the fair value determination, in good faith, based on the valuation recommendations of the Advisor’s Valuation Committee and the independent valuation firms; and </p> </td> </tr> </table> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="width: 36pt"> </td> <td style="width: 36pt; vertical-align: top; text-align: right"> <p style="font: 11pt Times New Roman; text-align: left; margin-top: 0pt; margin-bottom: 0pt"> (3) </p> </td> <td style="vertical-align: top; text-align: left"> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">at each quarterly Board meeting, the Board considers the valuations recommended by the Advisor’s Valuation Committee and the independent valuation firms that were previously submitted to the Valuation Committee of the Board and ratifies the fair value determinations made by the Valuation Committee of the Board. </p> </td> </tr> </table> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p id="xdx_80B_ecustom--InvestmentManagementFeeTextBlock_zQhObaM6gx03" style="font: 14pt Times New Roman, Times, Serif; text-align: left; margin-left: 18pt; text-indent: -18pt; margin-bottom: 0pt; margin-top: 0pt"><b>NOTE 4. <span id="xdx_825_zURPGlgjG4yc">INVESTMENT MANAGEMENT FEE</span> </b></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">The Company has entered into an investment management agreement (the “Investment Management Agreement”) with FCM pursuant to which the Company will pay FCM a fee for providing investment management services consisting of two components—a base management fee and an incentive fee. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">The base management fee will be calculated at an annual rate of <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_dp_c20230630_zEWzG9OLjhCe" title="Annual rate">2.00</span>% of our gross assets. For services rendered under the Investment Management Agreement, the base management fee will be payable quarterly in arrears. The base management fee will be calculated based on the average of (1) the value of our gross assets at the end of the current calendar quarter and (2) the value of the Company’s gross assets at the end of the preceding calendar quarter; and will be appropriately adjusted for any share issuances or repurchases during the current calendar quarter. Base management fees for any partial month or quarter will be pro-rated. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">The incentive fee is determined and payable in arrears as of the end of each calendar year (or upon termination of the Investment Management Agreement, as of the termination date), commencing on April 15, 2011, and equals 20% of the Company’s realized capital gains, if any, on a cumulative basis from inception through the end of each calendar year, computed net of all realized capital losses and unrealized capital depreciation on a cumulative basis, less the aggregate amount of any previously paid incentive fees, provided that the incentive fee determined as of December 31, 2022, will be calculated for a period of shorter than twelve calendar months to take into account any realized gains computed net of all realized capital losses and unrealized capital depreciation from inception. For the six months ended June 30, 2023, there were <span id="xdx_905_eus-gaap--PaymentForIncentiveFee_pp0p0_do_c20230101__20230630_zmzkN2gvqsZj" title="Incentive fee adjustments">no</span> incentive fee adjustments. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> 0.0200 0 <p id="xdx_809_eus-gaap--DebtDisclosureTextBlock_zO9spjcX5gab" style="font: 14pt Times New Roman, Times, Serif; text-align: left; margin-left: 18pt; text-indent: -18pt; margin-bottom: 0pt; margin-top: 0pt"><b>NOTE 5. <span id="xdx_824_z517t7uiYSS5">DEBT</span> </b></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">The Company currently has no plan to use leverage and does not have any significant outstanding debt obligations (other than normal operating expense accruals). </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p id="xdx_80A_eus-gaap--FairValueDisclosuresTextBlock_zEHdmjyuvrye" style="font: 14pt Times New Roman, Times, Serif; text-align: left; margin-left: 18pt; text-indent: -18pt; margin-bottom: 0pt; margin-top: 0pt"><b>NOTE 6. <span id="xdx_823_zEEwnnYzk1Od">FAIR VALUE</span> </b></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">Securities traded on stock exchanges, or quoted by NASDAQ, are valued according to the NASDAQ Stock Market, Inc. (“NASDAQ”) official closing price, if applicable, or at their last reported sale price as of the close of trading on the New York Stock Exchange (“NYSE”) (normally 4:00 P.M. Eastern Time). If a security is not traded that day, the security will be valued at its most recent bid price. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">Securities traded in the over-the-counter market, but not quoted by NASDAQ, are valued at the last sale price (or, if the last sale price is not readily available, at the most recent closing bid price as quoted by brokers that make markets in the securities) at the close of trading on the NYSE. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">Securities traded both in the over-the-counter market and on a stock exchange are valued according to the broadest and most representative market. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">Securities and other assets that do not have market quotations readily available are valued at their fair value as determined by FCM, as the Board’s valuation designee under SEC rule 2a-5. Those valuations are determined in accordance with the Valuation Procedures used by FCM, subject to oversight by the Board. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">In pricing illiquid, privately placed securities, FCM, as the valuation designee, is responsible for (1) determining overall valuation guidelines and (2) ensuring that the investments of the Company are valued within the prescribed guidelines. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">FCM and the Board receive information and recommendations from an independent valuation firm. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">The values assigned to these investments are based on available information and do not necessarily represent amounts that might ultimately be realized when that investment is sold, as such amounts depend on future circumstances and cannot reasonably be determined until the individual investments are actually liquidated or become readily marketable. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>APPROACHES TO DETERMINING FAIR VALUE. GAAP. </b>defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). In effect, GAAP applies fair value terminology to all valuations whereas the 1940 Act applies market value terminology to readily marketable assets and fair value terminology to other assets. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">The main approaches to measuring fair value utilized are the market approach, the income approach, and the asset-based approach. The choice of which approach to use in a particular situation depends on the specific facts and circumstances associated with the company, as well as the purpose for which the valuation analysis is being conducted. Firsthand and the independent valuation firm rely primarily on the market approach. We also considered the income and asset-based approaches in our analysis because certain of the portfolio companies do not have substantial operating earnings relative to the value of their underlying assets. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="width: 36pt"> </td> <td style="width: 36pt; vertical-align: top; text-align: right"> <p style="font: 11pt Times New Roman; text-align: left; margin-top: 0pt; margin-bottom: 0pt">- </p> </td> <td style="vertical-align: top; text-align: left"> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Market Approach (M): The market approach uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities. For example, the market approach often uses market multiples derived from a set of comparables. Multiples might lie in ranges with a different multiple for each comparable. The selection of where within the range each appropriate multiple falls requires the use of judgment in considering factors specific to the measurement (qualitative and quantitative). </p> </td> </tr> </table> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="width: 36pt"> </td> <td style="width: 36pt; vertical-align: top; text-align: right"> <p style="font: 11pt Times New Roman; text-align: left; margin-top: 0pt; margin-bottom: 0pt">- </p> </td> <td style="vertical-align: top; text-align: left"> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Income Approach (I): The income approach uses valuation techniques to convert future amounts (for example, cash flows or earnings) to a single present value amount (discounted). The measurement is based on the value indicated by current market expectations about those future amounts. Those </p> </td> </tr> </table> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 72pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">valuation techniques include present value techniques; option-pricing models, such as the Black-Scholes-Merton formula (a closed-form model) and a binomial model (a lattice model), which incorporate present value techniques; and the multi-period excess earnings method, which is used to measure the fair value of certain assets. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="width: 36pt"> </td> <td style="width: 36pt; vertical-align: top; text-align: right"> <p style="font: 11pt Times New Roman; text-align: left; margin-top: 0pt; margin-bottom: 0pt">- </p> </td> <td style="vertical-align: top; text-align: left"> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Asset-Based Approach (A): The asset-based approach examines the value of a company’s assets net of its liabilities to derive a value for the equity holders. </p> </td> </tr> </table> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>FAIR VALUE MEASUREMENT. </b>In accordance with the guidance from the Financial Accounting Standards Board on fair value measurements and disclosures under GAAP, the Company discloses the fair value of its investments in a hierarchy that prioritizes the inputs to valuation techniques used to measure the fair value. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements). </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">The guidance establishes three levels of the fair value hierarchy as follows: </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="width: 22.5pt"> </td> <td style="width: 58.5pt; vertical-align: top; text-align: right"> <p style="font: 11pt Times New Roman; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>Level 1 -</b></p> </td> <td style="vertical-align: top; text-align: left"> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-weight: normal; font-style: normal">Unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the date of measurement. </span></p> </td> </tr> </table> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="width: 22.5pt"> </td> <td style="width: 58.5pt; vertical-align: top; text-align: right"> <p style="font: 11pt Times New Roman; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>Level 2 -</b></p> </td> <td style="vertical-align: top; text-align: left"> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-weight: normal; font-style: normal">Observable inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These inputs may include quoted prices for the identical instrument in an inactive market, prices for similar instruments in an active or inactive market, interest rates, prepayment speeds, credit risks, yield curves, default rates, and similar data. </span></p> </td> </tr> </table> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="width: 22.5pt"> </td> <td style="width: 58.5pt; vertical-align: top; text-align: right"> <p style="font: 11pt Times New Roman; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>Level 3 -</b></p> </td> <td style="vertical-align: top; text-align: left"> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-weight: normal; font-style: normal">Unobservable inputs for the asset or liability, to the extent relevant observable inputs are not available, representing the Company’s own assumptions about the assumptions a market participant would use in valuing the asset or liability based on the best information available. </span></p> </td> </tr> </table> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">The availability of observable inputs can vary from security to security and is affected by a wide variety of factors, including, for example, the type of security, whether the security is new and not yet established in the marketplace, the liquidity of markets, and other characteristics particular to the security. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised in determining fair value is greatest for instruments categorized in Level 3. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">The inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement falls in its entirety, is determined based on the lowest level input that is significant to the fair value measurement in its entirety. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: justify; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities. The following is a summary of the inputs used to value the Company’s net assets as of June 30, 2023: </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zh3cH1EOTrkk" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top"><span id="xdx_8B1_zCRqQldTDgLj" style="display: none">Schedule of fair value of net asset</span></td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right" title="Assets"> </td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right" title="Assets"> </td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right" title="Assets"> </td> <td style="white-space: nowrap; text-align: left"> </td></tr> <tr> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>ASSETS</b></p></td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: #000000 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>LEVEL 1 <br/> QUOTED PRICES</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: #000000 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>LEVEL 2 OTHER <br/> SIGNIFICANT <br/> OBSERVABLE INPUTS</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: #000000 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>LEVEL 3 SIGNIFICANT <br/> UNOBSERVABLE INPUTS</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Common Stocks </p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 12%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 12%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 12%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 22.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Advanced Materials</p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_98A_eus-gaap--Assets_iI_pp0p0_d0_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancedMaterialsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWtmCd4RMGIj" style="width: 12%; text-align: right" title="Assets">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_98B_eus-gaap--Assets_iI_pp0p0_d0_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancedMaterialsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgClGJf7zbF" style="width: 12%; text-align: right" title="Assets">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_987_eus-gaap--Assets_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancedMaterialsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pp0p0" style="width: 12%; text-align: right" title="Assets">266,091</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 22.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Automotive</p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--Assets_iI_pp0p0_d0_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zlY7TnjzlmK9" style="width: 12%; text-align: right" title="Assets">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--Assets_iI_pp0p0_d0_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXo082pJH3c3" style="width: 12%; text-align: right" title="Assets">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--Assets_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pp0p0" style="width: 12%; text-align: right" title="Assets">311</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 22.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Equipment Leasing</p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--Assets_iI_pp0p0_d0_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentLeasingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPLzHU7sSmmc" style="width: 12%; text-align: right" title="Assets">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_988_eus-gaap--Assets_iI_pp0p0_d0_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentLeasingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLDIkafxvlrb" style="width: 12%; text-align: right" title="Assets">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--Assets_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentLeasingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pp0p0" style="width: 12%; text-align: right" title="Assets">1,880</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 22.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Semiconductor Equipment</p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--Assets_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--SemiconductorEquipmentMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pp0p0" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Assets">3,709,446</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--Assets_iI_pp0p0_d0_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--SemiconductorEquipmentMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjZnCdLwDkmk" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Assets">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--Assets_iI_pp0p0_d0_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--SemiconductorEquipmentMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLR10gevXRw2" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Assets">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 31.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Total Common Stocks</p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_eus-gaap--Assets_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pp0p0" style="width: 12%; text-align: right" title="Assets">3,709,446</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--Assets_iI_pp0p0_d0_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyqE1sR4oNm4" style="width: 12%; text-align: right" title="Assets">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_981_eus-gaap--Assets_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pp0p0" style="width: 12%; text-align: right" title="Assets">268,282</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Preferred Stocks </p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 12%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 12%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 12%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 22.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Aerospace</p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--Assets_iI_pp0p0_d0_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AerospaceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zt1FJBBG6KD5" style="width: 12%; text-align: right" title="Assets">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--Assets_iI_pp0p0_d0_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AerospaceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zC7zZBn4hund" style="width: 12%; text-align: right" title="Assets">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--Assets_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AerospaceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_pp0p0" style="width: 12%; text-align: right" title="Assets">304,332</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 22.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Automotive</p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_988_eus-gaap--Assets_iI_pp0p0_d0_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zu0S6s4b4VFb" style="width: 12%; text-align: right" title="Assets">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--Assets_iI_pp0p0_d0_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zp5Y1dNXz8ki" style="width: 12%; text-align: right" title="Assets">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--Assets_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_pp0p0" style="width: 12%; text-align: right" title="Assets">573,233</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 22.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Equipment Leasing</p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--Assets_iI_pp0p0_d0_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentLeasingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zEWYHpQCSKZg" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Assets">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_981_eus-gaap--Assets_iI_pp0p0_d0_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentLeasingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zJw2bLVNK2h9" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Assets">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--Assets_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentLeasingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_pp0p0" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Assets">383,756</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 31.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Total Preferred Stocks</p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--Assets_iI_pp0p0_d0_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zg5GfatrhBe2" style="width: 12%; text-align: right" title="Assets">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--Assets_iI_pp0p0_d0_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zb7KkTWdT2Qd" style="width: 12%; text-align: right" title="Assets">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--Assets_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_pp0p0" style="width: 12%; text-align: right" title="Assets">1,261,321</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Asset Derivatives <span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 12%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 12%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 12%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 22.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Equity Contracts</p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--Assets_iI_pp0p0_d0_c20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--EquityContractsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_fKCop_zr8V3yLzbNKc" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Assets">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--Assets_iI_pp0p0_d0_c20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--EquityContractsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_fKCop_zw9tM1jK5sCc" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Assets">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--Assets_iI_pp0p0_c20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--EquityContractsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_fKCop_zpsZ57QF7xSc" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Assets">758,405</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 31.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Total Asset Derivatives</p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--Assets_iI_pp0p0_d0_c20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--AssetDerivativesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_fKCop_zMt1DQrSFb91" style="width: 12%; text-align: right" title="Assets">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--Assets_iI_pp0p0_d0_c20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--AssetDerivativesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_fKCop_zMbLqgknJnY6" style="width: 12%; text-align: right" title="Assets">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--Assets_iI_pp0p0_c20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--AssetDerivativesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_fKCop_ztg7kNwe2MN7" style="width: 12%; text-align: right" title="Assets">758,405</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Convertible Notes </p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 12%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 12%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 12%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 22.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Advanced Materials</p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--Assets_iI_pp0p0_d0_c20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancedMaterialsMember_zIImNnwDIWBb" style="width: 12%; text-align: right" title="Assets">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--Assets_iI_pp0p0_d0_c20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancedMaterialsMember_z3VqRYXguBh6" style="width: 12%; text-align: right" title="Assets">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--Assets_c20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancedMaterialsMember_pp0p0" style="width: 12%; text-align: right" title="Assets">100,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 22.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Aerospace</p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--Assets_iI_pp0p0_d0_c20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AerospaceMember_zSFSonNANVff" style="width: 12%; text-align: right" title="Assets">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--Assets_iI_pp0p0_d0_c20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AerospaceMember_zmPg3Tk8V16f" style="width: 12%; text-align: right" title="Assets">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--Assets_c20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AerospaceMember_pp0p0" style="width: 12%; text-align: right" title="Assets">6,559,791</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 22.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Automotive</p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--Assets_iI_pp0p0_d0_c20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember_zX6KzSN7aXSa" style="width: 12%; text-align: right" title="Assets">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--Assets_iI_pp0p0_d0_c20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember_z3fOoeHlm6Bf" style="width: 12%; text-align: right" title="Assets">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_eus-gaap--Assets_c20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember_pp0p0" style="width: 12%; text-align: right" title="Assets">2,352,578</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 22.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Medical Devices</p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--Assets_iI_pp0p0_d0_c20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalDevicesMember_zx6YpxlQigEk" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Assets">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--Assets_iI_pp0p0_d0_c20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalDevicesMember_zcgWf5Iw7Cmg" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Assets">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_981_eus-gaap--Assets_c20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalDevicesMember_pp0p0" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Assets">5,035,984</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 31.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Total Convertible Notes</p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--Assets_iI_pp0p0_d0_c20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zp1hsj15zKD5" style="width: 12%; text-align: right" title="Assets">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--Assets_iI_pp0p0_d0_c20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zN4Gk7uzlBMa" style="width: 12%; text-align: right" title="Assets">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--Assets_c20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="width: 12%; text-align: right" title="Assets">14,048,353</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Mutual Funds</p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--Assets_c20230630__us-gaap--DebtInstrumentAxis__custom--MutualFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Assets">567,150</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--Assets_iI_pp0p0_d0_c20230630__us-gaap--DebtInstrumentAxis__custom--MutualFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z6R0Dk6OjMUb" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Assets">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--Assets_iI_pp0p0_d0_c20230630__us-gaap--DebtInstrumentAxis__custom--MutualFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zFMjEX8flGOl" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Assets">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 22.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Total</p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td> <td id="xdx_989_eus-gaap--Assets_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Assets">4,276,596</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td> <td id="xdx_988_eus-gaap--Assets_iI_pp0p0_d0_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zCwBVGZOEnz1" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Assets">—</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td> <td id="xdx_987_eus-gaap--Assets_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Assets">16,336,361</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; text-align: left"> </td> </tr> </table><p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="width: 18pt; vertical-align: top; text-align: right"> <p style="font: 11pt Times New Roman; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><i><span id="xdx_F01_zuMYJpzXQ474" style="font-size: 11pt; vertical-align: bottom">*</span></i> </p> </td> <td style="vertical-align: top; text-align: left"> <p id="xdx_F1A_zb45V42eSxxl" style="font: 11pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><i>Asset derivatives include warrants. </i></p> </td> </tr> </table> <p style="font: 11pt Times New Roman, Times, Serif; text-align: justify; margin-left: 18pt; text-indent: -18pt; margin-bottom: 0pt; margin-top: 0pt"><i> </i></p> <p id="xdx_8AA_zKDILuhgqd" style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">At the end of each calendar quarter, management evaluates the Level 2 and Level 3 assets and liabilities for changes in liquidity, including but not limited to: whether a broker is willing to execute at the quoted price, the depth and consistency of prices from third party services, and the existence of contemporaneous, observable trades in the market. Additionally, management evaluates the Level 1 and Level 2 assets and liabilities on a quarterly basis for changes in listings or delistings on national exchanges. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: justify; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">Following is a reconciliation of Level 3 assets (at either the beginning or the ending of the period) for which significant unobservable inputs were used to determine fair value. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock_zKTgQLu0OCT7" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE (Details 1)"> <tr style="vertical-align: bottom"> <td style="vertical-align: top"><span id="xdx_8B5_z0ndyAgdZCB6" style="display: none">Schedule of unobservable inputs of fair value</span></td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right" title="BEGINNING BALANCE"> </td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right" title="NET PURCHASES/CONVERSIONS"> </td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right" title="NET SALES/CONVERSIONS"> </td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right" title="NET REALIZED GAINS/(LOSSES)"> </td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right" title="NET UNREALIZED APPRECIATION (DEPRECIATION)"> </td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right" title="TRANSFERS IN (OUT) OF LEVEL 3"> </td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right" title="ENDING BALANCE"> </td> <td style="white-space: nowrap; text-align: left"> </td></tr> <tr> <td style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>INVESTMENTS AT FAIR <br/> VALUE USING SIGNIFICANT <br/> UNOBSERVABLE INPUTS <br/> (LEVEL 3)</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>BALANCE <br/> AS OF <br/> 12/31/22</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>NET <br/> PURCHASES/<br/> CONVERSIONS</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>NET SALES/<br/> CONVERSIONS</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>NET REALIZED <br/> GAINS/<br/> (LOSSES)</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>NET UNREALIZED <br/> APPRECIATION <br/> (DEPRECIATION)</b><sup><b>(1)</b></sup></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>TRANSFERS <br/> IN (OUT) OF <br/> LEVEL 3</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>BALANCE <br/> AS OF <br/> 06/30/23</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt"><b>Common Stocks</b></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 22.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Advanced Materials</p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_982_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancedMaterialsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zMKWbXjLQfzi" style="width: 8%; text-align: right" title="BEGINNING BALANCE">337,500</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_985_ecustom--NetPurchasesconversions_pp0p0_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancedMaterialsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPQo9XYKPCZ3" style="width: 8%; text-align: right" title="NET PURCHASES/CONVERSIONS">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_981_ecustom--NetSalesconversions_pp0p0_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancedMaterialsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z0ZADVSGeJ65" style="width: 8%; text-align: right" title="NET SALES/CONVERSIONS">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_98B_eus-gaap--DebtAndEquitySecuritiesRealizedGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancedMaterialsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zpK3XcQ7kZeh" style="width: 8%; text-align: right" title="NET REALIZED GAINS/(LOSSES)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_98A_ecustom--NetUnrealizedAppreciationDepreciation_pp0p0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancedMaterialsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKDEp_zvNq538W6srk" style="width: 8%; text-align: right" title="NET UNREALIZED APPRECIATION (DEPRECIATION)">(71,409</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_988_ecustom--TransfersInOutOfLevel3_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancedMaterialsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrYfIJMTQtvi" style="width: 8%; text-align: right" title="TRANSFERS IN (OUT) OF LEVEL 3">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_98F_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancedMaterialsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8XpJF2x5jfa" style="width: 8%; text-align: right" title="ENDING BALANCE">266,091</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 22.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Automotive</p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFhW1bztESh9" style="width: 8%; text-align: right" title="BEGINNING BALANCE">546</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_ecustom--NetPurchasesconversions_pdp0_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zq2KdW3Ckom8" style="width: 8%; text-align: right" title="NET PURCHASES/CONVERSIONS">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_ecustom--NetSalesconversions_pdp0_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zim27JrTXCE" style="width: 8%; text-align: right" title="NET SALES/CONVERSIONS">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--DebtAndEquitySecuritiesRealizedGainLoss_pdp0_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7v5EhF0Jsff" style="width: 8%; text-align: right" title="NET REALIZED GAINS/(LOSSES)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_ecustom--NetUnrealizedAppreciationDepreciation_pp0p0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKDEp_zF7QgBfv5eGf" style="width: 8%; text-align: right" title="NET UNREALIZED APPRECIATION (DEPRECIATION)">(235</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_ecustom--TransfersInOutOfLevel3_pdp0_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zanqleJRhZXi" style="width: 8%; text-align: right" title="TRANSFERS IN (OUT) OF LEVEL 3">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXfXy5pYctVh" style="width: 8%; text-align: right" title="ENDING BALANCE">311</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 22.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Equipment Leasing</p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentLeasingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z891K1Azcloh" style="width: 8%; text-align: right" title="BEGINNING BALANCE">11,130</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98C_ecustom--NetPurchasesconversions_pdp0_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentLeasingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCr0C1zIlzaa" style="width: 8%; text-align: right" title="NET PURCHASES/CONVERSIONS">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_ecustom--NetSalesconversions_pdp0_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentLeasingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZ7qS7toc0Fd" style="width: 8%; text-align: right" title="NET SALES/CONVERSIONS">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--DebtAndEquitySecuritiesRealizedGainLoss_pdp0_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentLeasingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zYnXxTIq4sSb" style="width: 8%; text-align: right" title="NET REALIZED GAINS/(LOSSES)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_ecustom--NetUnrealizedAppreciationDepreciation_pp0p0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentLeasingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKDEp_zIlIAx6NUhyj" style="width: 8%; text-align: right" title="NET UNREALIZED APPRECIATION (DEPRECIATION)">(9,250</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_ecustom--TransfersInOutOfLevel3_pdp0_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentLeasingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zi2Fgt5W79Ng" style="width: 8%; text-align: right" title="TRANSFERS IN (OUT) OF LEVEL 3">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentLeasingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIYMeeoV8U0i" style="width: 8%; text-align: right" title="ENDING BALANCE">1,880</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 22.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Intellectual Property</p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_983_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQWWPtAjWHTa" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="BEGINNING BALANCE">111</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98B_ecustom--NetPurchasesconversions_pdp0_d0_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zedHxZD5m5Wi" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="NET PURCHASES/CONVERSIONS">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_980_ecustom--NetSalesconversions_pdp0_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxkSb9EABqG8" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="NET SALES/CONVERSIONS">(7,966</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left">)</td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--DebtAndEquitySecuritiesRealizedGainLoss_pdp0_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjx6fxduC3ga" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="NET REALIZED GAINS/(LOSSES)">(161,079</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left">)</td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98C_ecustom--NetUnrealizedAppreciationDepreciation_pp0p0_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKDEp_zPVz2cHapGBk" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="NET UNREALIZED APPRECIATION (DEPRECIATION)">168,934</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_989_ecustom--TransfersInOutOfLevel3_pdp0_d0_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ziDrM7Lq9t1l" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="TRANSFERS IN (OUT) OF LEVEL 3">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--Investments_iE_pp0p0_d0_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zl9YK1bsQBNg" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="ENDING BALANCE">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt"><b>Total Common Stocks</b></p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbA59z7UG5Ug" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="BEGINNING BALANCE">349,287</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98C_ecustom--NetPurchasesconversions_pdp0_d0_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwTVb1ACRT4b" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="NET PURCHASES/CONVERSIONS">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_987_ecustom--NetSalesconversions_pdp0_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zGoxGOYGr2z4" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="NET SALES/CONVERSIONS">(7,966</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left">)</td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_983_eus-gaap--DebtAndEquitySecuritiesRealizedGainLoss_pdp0_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9VUg7UISPke" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="NET REALIZED GAINS/(LOSSES)">(161,079</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left">)</td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98B_ecustom--NetUnrealizedAppreciationDepreciation_pp0p0_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKDEp_z2P1sKmFNkGb" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="NET UNREALIZED APPRECIATION (DEPRECIATION)">88,040</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_984_ecustom--TransfersInOutOfLevel3_pdp0_d0_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZ2GXEOATGAb" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="TRANSFERS IN (OUT) OF LEVEL 3">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKx3bEEb7kH4" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="ENDING BALANCE">268,282</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt"><b>Preferred Stocks</b></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 22.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Aerospace</p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AerospaceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zLA6cAo0QRBj" style="width: 8%; text-align: right" title="BEGINNING BALANCE">384,067</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_ecustom--NetPurchasesconversions_pdp0_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AerospaceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z4keU8moGuj8" style="width: 8%; text-align: right" title="NET PURCHASES/CONVERSIONS">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_988_ecustom--NetSalesconversions_pdp0_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AerospaceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zxia8TeC5ujg" style="width: 8%; text-align: right" title="NET SALES/CONVERSIONS">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--DebtAndEquitySecuritiesRealizedGainLoss_pdp0_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AerospaceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z7GhNu8Zhyv4" style="width: 8%; text-align: right" title="NET REALIZED GAINS/(LOSSES)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_ecustom--NetUnrealizedAppreciationDepreciation_pp0p0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AerospaceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_fKDEp_zreQ6PK3lrb2" style="width: 8%; text-align: right" title="NET UNREALIZED APPRECIATION (DEPRECIATION)">(79,735</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_ecustom--TransfersInOutOfLevel3_pdp0_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AerospaceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zj8jNrmNBKob" style="width: 8%; text-align: right" title="TRANSFERS IN (OUT) OF LEVEL 3">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AerospaceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zSPjdDy8SShe" style="width: 8%; text-align: right" title="ENDING BALANCE">304,332</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 22.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Automotive</p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zagXmZ4948Lb" style="width: 8%; text-align: right" title="BEGINNING BALANCE">1,049,478</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_ecustom--NetPurchasesconversions_pdp0_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zDqvx03IzXka" style="width: 8%; text-align: right" title="NET PURCHASES/CONVERSIONS">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_ecustom--NetSalesconversions_pdp0_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zXaxbIidq9Ka" style="width: 8%; text-align: right" title="NET SALES/CONVERSIONS">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--DebtAndEquitySecuritiesRealizedGainLoss_pdp0_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z4s3RQeXFqU4" style="width: 8%; text-align: right" title="NET REALIZED GAINS/(LOSSES)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_ecustom--NetUnrealizedAppreciationDepreciation_pp0p0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_fKDEp_zu2MhesEo4Y6" style="width: 8%; text-align: right" title="NET UNREALIZED APPRECIATION (DEPRECIATION)">(476,245</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_ecustom--TransfersInOutOfLevel3_pdp0_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z5nRWHtAuebd" style="width: 8%; text-align: right" title="TRANSFERS IN (OUT) OF LEVEL 3">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zyutY8W8SvPg" style="width: 8%; text-align: right" title="ENDING BALANCE">573,233</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 22.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Equipment Leasing</p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentLeasingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z6NIXBbJfiol" style="width: 8%; text-align: right" title="BEGINNING BALANCE">865,995</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_ecustom--NetPurchasesconversions_pdp0_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentLeasingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zGMzy4p9O1j8" style="width: 8%; text-align: right" title="NET PURCHASES/CONVERSIONS">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_ecustom--NetSalesconversions_pp0p0_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentLeasingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zvsw7uiQX8lk" style="width: 8%; text-align: right" title="NET SALES/CONVERSIONS">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--DebtAndEquitySecuritiesRealizedGainLoss_pdp0_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentLeasingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zrjjZXKn0Ns9" style="width: 8%; text-align: right" title="NET REALIZED GAINS/(LOSSES)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_ecustom--NetUnrealizedAppreciationDepreciation_pp0p0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentLeasingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_fKDEp_z2N6VxGE4PTh" style="width: 8%; text-align: right" title="NET UNREALIZED APPRECIATION (DEPRECIATION)">(482,239</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_ecustom--TransfersInOutOfLevel3_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentLeasingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zyrRsgVCxtpb" style="width: 8%; text-align: right" title="TRANSFERS IN (OUT) OF LEVEL 3">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_981_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentLeasingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zx7InaW60ZBd" style="width: 8%; text-align: right" title="ENDING BALANCE">383,756</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 22.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Intellectual Property</p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_983_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zEp5hzfaq1b8" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="BEGINNING BALANCE">737,112</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_988_ecustom--NetPurchasesconversions_pdp0_d0_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zaLEDmmYHWL4" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="NET PURCHASES/CONVERSIONS">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_986_ecustom--NetSalesconversions_pdp0_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z713hhJv7U6e" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="NET SALES/CONVERSIONS">(490,459</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left">)</td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_983_eus-gaap--DebtAndEquitySecuritiesRealizedGainLoss_pdp0_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zNGsAW3Zwpz6" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="NET REALIZED GAINS/(LOSSES)">(7,697,238</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left">)</td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_984_ecustom--NetUnrealizedAppreciationDepreciation_pp0p0_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_fKDEp_zsLU3ayEYJlc" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="NET UNREALIZED APPRECIATION (DEPRECIATION)">7,450,585</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_984_ecustom--TransfersInOutOfLevel3_pdp0_d0_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zdi6RhxGt46b" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="TRANSFERS IN (OUT) OF LEVEL 3">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--Investments_iE_pp0p0_d0_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zZi215VOo0rd" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="ENDING BALANCE">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt"><b>Total Preferred Stocks</b></p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zUx7wEMJAw7" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="BEGINNING BALANCE">3,036,652</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_980_ecustom--NetPurchasesconversions_pdp0_d0_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zSb1x5Em2rTj" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="NET PURCHASES/CONVERSIONS">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98D_ecustom--NetSalesconversions_pp0p0_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zvZkmEx6njZe" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="NET SALES/CONVERSIONS">(490,459</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left">)</td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--DebtAndEquitySecuritiesRealizedGainLoss_pp0p0_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zlxHldv7Pzqf" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="NET REALIZED GAINS/(LOSSES)">(7,697,238</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left">)</td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_985_ecustom--NetUnrealizedAppreciationDepreciation_pp0p0_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_fKDEp_z86KX2qhbnD3" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="NET UNREALIZED APPRECIATION (DEPRECIATION)">6,412,366</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_982_ecustom--TransfersInOutOfLevel3_pdp0_d0_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zrxi2BIwSUuh" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="TRANSFERS IN (OUT) OF LEVEL 3">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_988_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zVYEi4uNO3d3" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="ENDING BALANCE">1,261,321</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt"><b>Asset Derivatives</b></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 22.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Equity Contracts</p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_983_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--EquityContractsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zr59FtZvaom8" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="BEGINNING BALANCE">957,125</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98B_ecustom--NetPurchasesconversions_pdp0_d0_c20230101__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--EquityContractsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zKuiEWsxyii8" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="NET PURCHASES/CONVERSIONS">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98A_ecustom--NetSalesconversions_pdp0_d0_c20230101__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--EquityContractsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zHdJrbS30yj" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="NET SALES/CONVERSIONS">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--DebtAndEquitySecuritiesRealizedGainLoss_pdp0_c20230101__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--EquityContractsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zF12uLvJgigl" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="NET REALIZED GAINS/(LOSSES)">(6,678</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left">)</td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98F_ecustom--NetUnrealizedAppreciationDepreciation_pp0p0_c20230101__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--EquityContractsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_fKDEp_zaJnGJ72UxCi" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="NET UNREALIZED APPRECIATION (DEPRECIATION)">(192,042</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left">)</td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98D_ecustom--TransfersInOutOfLevel3_pdp0_d0_c20230101__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--EquityContractsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zvA5c5RTxjhd" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="TRANSFERS IN (OUT) OF LEVEL 3">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--EquityContractsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zwqiCV79FRx4" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="ENDING BALANCE">758,405</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt"><b>Total Asset Derivatives</b></p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--AssetDerivativesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zOZ4MA2P2s86" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="BEGINNING BALANCE">957,125</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98E_ecustom--NetPurchasesconversions_pdp0_d0_c20230101__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--AssetDerivativesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zefu27H9Zo17" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="NET PURCHASES/CONVERSIONS">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_985_ecustom--NetSalesconversions_pdp0_d0_c20230101__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--AssetDerivativesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zDVM0NGW2f57" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="NET SALES/CONVERSIONS">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_983_eus-gaap--DebtAndEquitySecuritiesRealizedGainLoss_pdp0_c20230101__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--AssetDerivativesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zpdewH5Fjke" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="NET REALIZED GAINS/(LOSSES)">(6,678</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left">)</td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_987_ecustom--NetUnrealizedAppreciationDepreciation_pp0p0_c20230101__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--AssetDerivativesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_fKDEp_ztzwstPn3Bob" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="NET UNREALIZED APPRECIATION (DEPRECIATION)">(192,042</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left">)</td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_988_ecustom--TransfersInOutOfLevel3_pdp0_d0_c20230101__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--AssetDerivativesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zwfnN9F2Zeuj" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="TRANSFERS IN (OUT) OF LEVEL 3">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--AssetDerivativesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zwRv80ksiVu3" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="ENDING BALANCE">758,405</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt"><b>Convertible Notes</b></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 22.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Advanced Materials</p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancedMaterialsMember_zpjEG7w70wkb" style="width: 8%; text-align: right" title="BEGINNING BALANCE">100,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_ecustom--NetPurchasesconversions_pdp0_d0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancedMaterialsMember_zUigi44dKDT1" style="width: 8%; text-align: right" title="NET PURCHASES/CONVERSIONS">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_ecustom--NetSalesconversions_pdp0_d0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancedMaterialsMember_zl9HR6FOqobg" style="width: 8%; text-align: right" title="NET SALES/CONVERSIONS">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--DebtAndEquitySecuritiesRealizedGainLoss_pdp0_d0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancedMaterialsMember_zuoKdyy877y6" style="width: 8%; text-align: right" title="NET REALIZED GAINS/(LOSSES)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_ecustom--NetUnrealizedAppreciationDepreciation_pp0p0_d0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancedMaterialsMember_fKDEp_zmIoqE22Ut9i" style="width: 8%; text-align: right" title="NET UNREALIZED APPRECIATION (DEPRECIATION)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_ecustom--TransfersInOutOfLevel3_pdp0_d0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancedMaterialsMember_zdQUyjxaLDAh" style="width: 8%; text-align: right" title="TRANSFERS IN (OUT) OF LEVEL 3">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancedMaterialsMember_zLeieeOluArf" style="width: 8%; text-align: right" title="ENDING BALANCE">100,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 22.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Aerospace</p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AerospaceMember_zpWVvWHs28Fa" style="width: 8%; text-align: right" title="BEGINNING BALANCE">6,559,791</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_ecustom--NetPurchasesconversions_pp0p0_d0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AerospaceMember_z0D9WMjSSDZe" style="width: 8%; text-align: right" title="NET PURCHASES/CONVERSIONS">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_ecustom--NetSalesconversions_pdp0_d0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AerospaceMember_zshTRZ2TtHa6" style="width: 8%; text-align: right" title="NET SALES/CONVERSIONS">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_981_eus-gaap--DebtAndEquitySecuritiesRealizedGainLoss_pdp0_d0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AerospaceMember_z7JaM9hYGoEg" style="width: 8%; text-align: right" title="NET REALIZED GAINS/(LOSSES)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_ecustom--NetUnrealizedAppreciationDepreciation_pp0p0_d0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AerospaceMember_fKDEp_zMTS3h6qSgo9" style="width: 8%; text-align: right" title="NET UNREALIZED APPRECIATION (DEPRECIATION)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_ecustom--TransfersInOutOfLevel3_pdp0_d0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AerospaceMember_zsg2D5GISSO9" style="width: 8%; text-align: right" title="TRANSFERS IN (OUT) OF LEVEL 3">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AerospaceMember_z3jlBJVaN3f6" style="width: 8%; text-align: right" title="ENDING BALANCE">6,559,791</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 22.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Automotive</p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember_zxiE7QwAdkT3" style="width: 8%; text-align: right" title="BEGINNING BALANCE">7,809,430</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_ecustom--NetPurchasesconversions_pp0p0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember_zbURio0KBMK5" style="width: 8%; text-align: right" title="NET PURCHASES/CONVERSIONS">100,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_ecustom--NetSalesconversions_pdp0_d0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember_zMDaxmuRuNR3" style="width: 8%; text-align: right" title="NET SALES/CONVERSIONS">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--DebtAndEquitySecuritiesRealizedGainLoss_pdp0_d0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember_z5F62KmKpbyk" style="width: 8%; text-align: right" title="NET REALIZED GAINS/(LOSSES)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_ecustom--NetUnrealizedAppreciationDepreciation_pp0p0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember_fKDEp_zVWTGCEaB8e6" style="width: 8%; text-align: right" title="NET UNREALIZED APPRECIATION (DEPRECIATION)">(5,556,852</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_ecustom--TransfersInOutOfLevel3_pdp0_d0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember_zHdFUESFtZKd" style="width: 8%; text-align: right" title="TRANSFERS IN (OUT) OF LEVEL 3">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember_zgXT2y7D9y5" style="width: 8%; text-align: right" title="ENDING BALANCE">2,352,578</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 22.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Medical Devices</p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_988_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalDevicesMember_z8f15X9cBsLf" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="BEGINNING BALANCE">17,116,721</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_981_ecustom--NetPurchasesconversions_pp0p0_d0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalDevicesMember_zxFHokipk428" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="NET PURCHASES/CONVERSIONS">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_988_ecustom--NetSalesconversions_pdp0_d0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalDevicesMember_zjwtW2mDCvnb" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="NET SALES/CONVERSIONS">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--DebtAndEquitySecuritiesRealizedGainLoss_pdp0_d0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalDevicesMember_zo8nzbWmHGRl" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="NET REALIZED GAINS/(LOSSES)">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_987_ecustom--NetUnrealizedAppreciationDepreciation_pp0p0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalDevicesMember_fKDEp_z49AU2OgSEf5" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="NET UNREALIZED APPRECIATION (DEPRECIATION)">(12,080,737</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left">)</td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_988_ecustom--TransfersInOutOfLevel3_pdp0_d0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalDevicesMember_z9BkCGlUSgVl" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="TRANSFERS IN (OUT) OF LEVEL 3">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalDevicesMember_zhf134wKg8i8" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="ENDING BALANCE">5,035,984</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt"><b>Total Convertible Notes</b></p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember_zb23F0vnQc86" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="BEGINNING BALANCE">31,585,942</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_988_ecustom--NetPurchasesconversions_pp0p0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember_zauYXn2TpmK6" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="NET PURCHASES/CONVERSIONS">100,000</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_980_ecustom--NetSalesconversions_pdp0_d0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember_zYWoIBPXDXih" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="NET SALES/CONVERSIONS">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--DebtAndEquitySecuritiesRealizedGainLoss_pdp0_d0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember_zzE3zZaTmVti" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="NET REALIZED GAINS/(LOSSES)">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_986_ecustom--NetUnrealizedAppreciationDepreciation_pp0p0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember_fKDEp_zlapj2bYqloj" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="NET UNREALIZED APPRECIATION (DEPRECIATION)">(17,637,589</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left">)</td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_988_ecustom--TransfersInOutOfLevel3_pdp0_d0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember_zafLdgEFOYM1" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="TRANSFERS IN (OUT) OF LEVEL 3">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember_zQAYI29z4Ifb" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="ENDING BALANCE">14,048,353</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Total </p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td> <td id="xdx_982_eus-gaap--Investments_iS_pp0p0_c20230101__20230630_zCgBPYI2fbwi" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right" title="BEGINNING BALANCE">35,929,006</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td> <td id="xdx_98A_ecustom--NetPurchasesconversions_pp0p0_c20230101__20230630_zhTBLSPATbqc" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right" title="NET PURCHASES/CONVERSIONS">100,000</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td> <td id="xdx_983_ecustom--NetSalesconversions_pp0p0_c20230101__20230630_zdG7N6kbRPzj" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right" title="NET SALES/CONVERSIONS">(498,425</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; text-align: left">)</td> <td style="border-bottom: Black 2.5pt double; width: 1%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td> <td id="xdx_98B_eus-gaap--DebtAndEquitySecuritiesRealizedGainLoss_pp0p0_c20230101__20230630_z4WDgP6lcP3g" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right" title="NET REALIZED GAINS/(LOSSES)">(7,864,995</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; text-align: left">)</td> <td style="border-bottom: Black 2.5pt double; width: 1%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td> <td id="xdx_98D_ecustom--NetUnrealizedAppreciationDepreciation_pp0p0_c20230101__20230630_fKDEp_zwnQu1m4G8Jj" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right" title="NET UNREALIZED APPRECIATION (DEPRECIATION)">(11,329,225</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; text-align: left">)</td> <td style="border-bottom: Black 2.5pt double; width: 1%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td> <td id="xdx_982_ecustom--TransfersInOutOfLevel3_pdp0_d0_c20230101__20230630_zL0ZQ5Z9akE3" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right" title="TRANSFERS IN (OUT) OF LEVEL 3">—</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td> <td id="xdx_986_eus-gaap--Investments_iE_pp0p0_c20230101__20230630_z1QFjqXlAive" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right" title="ENDING BALANCE">16,336,361</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; text-align: left"> </td> </tr> </table><p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="width: 18pt; vertical-align: top; text-align: right"> <p style="font: 11pt Times New Roman; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><i id="xdx_F0E_zjvxGOLs8fO3">(1)</i></p> </td> <td style="vertical-align: top; text-align: left"> <p style="font: 11pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"> <i id="xdx_F11_zKkhWfjrZxtj"> The net change in unrealized appreciation (depreciation) from Level 3 instruments held as of June 30, 2023 was $ (18,952,188). </i></p> </td> </tr> </table> <p id="xdx_8A8_ztl4tOsDoqnd" style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: justify; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">The table below represents quantitative disclosure about significant unobservable inputs for Level 3 fair value measurements at June 30, 2023:<i> </i></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <table cellpadding="4" cellspacing="0" id="xdx_893_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_za6glIaXte4" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - FAIR VALUE (Details 2)"> <tr> <td style="vertical-align: top"><span id="xdx_8B7_zOkquNH2MPrk" style="display: none">Schedule of unobservable inputs fair value measurements</span></td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"> </td></tr> <tr> <td style="border-bottom: #000000 1pt solid; vertical-align: bottom; width: 20%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"> </p></td> <td style="border-bottom: #000000 1pt solid; vertical-align: bottom; width: 9%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>FAIR VALUE <br/> AT 6/30/23</b></p></td> <td style="border-bottom: #000000 1pt solid; vertical-align: bottom; width: 20%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>VALUATION TECHNIQUES</b><sup><b>(1)</b></sup></p></td> <td style="border-bottom: #000000 1pt solid; vertical-align: bottom; width: 30%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>UNOBSERVABLE INPUTS</b></p></td> <td style="border-bottom: #000000 1pt solid; vertical-align: bottom; width: 21%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>RANGE <br/> (WEIGHTED AVG.)</b><sup><b>(1)</b></sup></p></td> </tr> <tr style="background-color: Gainsboro"> <td style="vertical-align: top; width: 20%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">Direct venture capital investments: Advanced Materials</p></td> <td style="vertical-align: top; width: 9%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">$<span id="xdx_907_eus-gaap--FairValueHedgeAssetsAtFairValue_iI_pn5n6_c20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancedMaterialsMember_z8dykTXZ0duf" title="FAIR VALUE">0.4</span>M</p></td> <td style="vertical-align: top; width: 20%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Market Comparable Companies </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Option Pricing Model</p></td> <td style="vertical-align: top; width: 30%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">Revenue Multiple<sup>(2)</sup> </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">Years to Maturity<sup>(2)</sup> </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">Volatility<sup>(2)</sup> </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">Risk-Free Rate<sup>(2)</sup> </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">Discount for Lack of </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 4.5pt; margin-bottom: 0pt; margin-top: 0pt">Marketability<sup>(3)</sup></p></td> <td style="vertical-align: top; width: 21%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: right; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">0.7x – 1.0x (0.9x) </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: right; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">5 years (5 years) </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: right; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">50.0% (50.0%) </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: right; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">4.13% (4.13%) </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: right; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">22.7% (22.7%)</p></td> </tr> <tr style="background-color: White"> <td style="vertical-align: top; width: 20%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">Direct venture capital investments: Aerospace</p></td> <td style="vertical-align: top; width: 9%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">$<span id="xdx_90B_eus-gaap--FairValueHedgeAssetsAtFairValue_iI_pn5n6_c20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AerospaceMember_zpyQ4RrWkgyc" title="FAIR VALUE">7.6</span>M</p></td> <td style="vertical-align: top; width: 20%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Market Comparable Companies </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Option Pricing Model</p></td> <td style="vertical-align: top; width: 30%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">EBITDA Multiple<sup>(2)</sup> </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">Years to Maturity<sup>(2)</sup> </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">Volatility<sup>(2)</sup> </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">Risk-Free Rate<sup>(2)</sup></p></td> <td style="vertical-align: top; width: 21%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: right; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">2.1x (2.1x) </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: right; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">5 years (5 years) </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: right; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">60.0% (60.0%) </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: right; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">4.13% (4.13%)</p></td> </tr> <tr style="background-color: Gainsboro"> <td style="vertical-align: top; width: 20%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">Direct venture capital investments: Automotive</p></td> <td style="vertical-align: top; width: 9%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">$<span id="xdx_90A_eus-gaap--FairValueHedgeAssetsAtFairValue_iI_pn5n6_c20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember_zIalS71YFqd5" title="FAIR VALUE">2.9</span>M</p></td> <td style="vertical-align: top; width: 20%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Prior Transaction Analysis </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Option Pricing Model </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Probability-Weighted Expected Return Method</p></td> <td style="vertical-align: top; width: 30%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">Years to Maturity<sup>(2)</sup> </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">Volatility<sup>(2)</sup> </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">Risk-Free Rate<sup>(2)</sup> </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">Discount for Lack of </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 4.5pt; margin-bottom: 0pt; margin-top: 0pt">Marketability<sup>(3)</sup> </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">Going Concern Probability<sup>(2)</sup></p></td> <td style="vertical-align: top; width: 21%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: right; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">5 years (5 years) </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: right; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">50.0% (50.0%) </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: right; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">4.13% (4.13%) </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: right; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">0.0% - 22.7% (0.0%) </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: right; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"> </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: right; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">5% (5%)</p></td> </tr> <tr style="background-color: White"> <td style="vertical-align: top; width: 20%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">Direct venture capital investments: Equipment Leasing</p></td> <td style="vertical-align: top; width: 9%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">$<span id="xdx_90F_eus-gaap--FairValueHedgeAssetsAtFairValue_iI_pn5n6_c20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentLeasingMember_zIY9qSi2y024" title="FAIR VALUE">0.4</span>M</p></td> <td style="vertical-align: top; width: 20%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Market Comparable Companies </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Liquidation Value </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Option Pricing Model</p></td> <td style="vertical-align: top; width: 30%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">EBITDA Multiple<sup>(2)</sup> </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">Years to Maturity<sup>(2)</sup> </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">Volatility<sup>(2)</sup> </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">Risk-Free Rate<sup>(2)</sup></p></td> <td style="vertical-align: top; width: 21%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: right; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">3.0x – 5.1x (4.0x) </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: right; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">5 years (5 years) </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: right; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">50.0% (50.0%) </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: right; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">4.13% (4.13%)</p></td> </tr> <tr style="background-color: Gainsboro"> <td style="vertical-align: top; width: 20%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">Direct venture capital investments: Medical Devices</p></td> <td style="vertical-align: top; width: 9%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">$<span id="xdx_901_eus-gaap--FairValueHedgeAssetsAtFairValue_iI_pn5n6_c20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalDevicesMember_zTFqjLxOoWN9" title="FAIR VALUE">5.0</span>M</p></td> <td style="vertical-align: top; width: 20%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Market Comparable Companies</p></td> <td style="vertical-align: top; width: 30%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">Revenue Multiple<sup>(2)</sup></p></td> <td style="vertical-align: top; width: 21%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: right; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">2.0x – 2.3x (2.1x)</p></td> </tr> </table> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="width: 18pt; vertical-align: top; text-align: right"> <p style="font: 11pt Times New Roman; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><i>(1)</i></p> </td> <td style="vertical-align: top; text-align: left"> <p style="font: 11pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"> <i>Weighted average is calculated by weighting the significant unobservable input by the relative fair value of each investment in the category </i></p> </td> </tr> </table> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="width: 18pt; vertical-align: top; text-align: right"> <p style="font: 11pt Times New Roman; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><i>(2)</i></p> </td> <td style="vertical-align: top; text-align: left"> <p style="font: 11pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"> <i>An increase in the input would result in an increase in the security’s valuation; a decrease in the input would result in a decrease in the security’s valuation. </i></p> </td> </tr> </table> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="width: 18pt; vertical-align: top; text-align: right"> <p style="font: 11pt Times New Roman; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><i>(3)</i></p> </td> <td style="vertical-align: top; text-align: left"> <p style="font: 11pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"> <i>An increase in the input would result in a decrease in the security’s valuation; a decrease in the input would result in an increase in the security’s valuation. </i></p> </td> </tr> </table> <p style="font: 11pt Times New Roman, Times, Serif; text-align: justify; margin-left: 18pt; text-indent: -18pt; margin-bottom: 0pt; margin-top: 0pt"><i> </i></p> <p id="xdx_8A9_zrjQ4wkO5qw6" style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">Changes in any of our unobservable inputs, individually, may change the fair value of certain of the Company’s investments. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">Due to the inherent uncertainty of determining the fair value of investments that do not have a readily available market value, the fair value of the Company’s investments may fluctuate from period to period. Additionally, the fair value of the Company’s investments may differ significantly from the values that would have been used had a ready market existed for such investments and may differ materially from the values that the Company may ultimately realize. Further, such </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">investments are generally subject to legal and other restrictions on resale or otherwise are less liquid than publicly traded securities. If the Company was required to liquidate a portfolio investment in a forced or liquidation sale, it could realize significantly less than the value at which the Company has recorded it. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">In addition, changes in the market environment and other events that may occur over the life of the investments may cause the gains or losses ultimately realized on these investments to be different than the unrealized gains or losses reflected in the valuations currently assigned. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zh3cH1EOTrkk" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top"><span id="xdx_8B1_zCRqQldTDgLj" style="display: none">Schedule of fair value of net asset</span></td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right" title="Assets"> </td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right" title="Assets"> </td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right" title="Assets"> </td> <td style="white-space: nowrap; text-align: left"> </td></tr> <tr> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>ASSETS</b></p></td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: #000000 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>LEVEL 1 <br/> QUOTED PRICES</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: #000000 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>LEVEL 2 OTHER <br/> SIGNIFICANT <br/> OBSERVABLE INPUTS</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: #000000 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>LEVEL 3 SIGNIFICANT <br/> UNOBSERVABLE INPUTS</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Common Stocks </p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 12%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 12%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 12%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 22.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Advanced Materials</p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_98A_eus-gaap--Assets_iI_pp0p0_d0_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancedMaterialsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWtmCd4RMGIj" style="width: 12%; text-align: right" title="Assets">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_98B_eus-gaap--Assets_iI_pp0p0_d0_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancedMaterialsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgClGJf7zbF" style="width: 12%; text-align: right" title="Assets">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_987_eus-gaap--Assets_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancedMaterialsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pp0p0" style="width: 12%; text-align: right" title="Assets">266,091</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 22.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Automotive</p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--Assets_iI_pp0p0_d0_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zlY7TnjzlmK9" style="width: 12%; text-align: right" title="Assets">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--Assets_iI_pp0p0_d0_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXo082pJH3c3" style="width: 12%; text-align: right" title="Assets">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--Assets_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pp0p0" style="width: 12%; text-align: right" title="Assets">311</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 22.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Equipment Leasing</p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--Assets_iI_pp0p0_d0_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentLeasingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPLzHU7sSmmc" style="width: 12%; text-align: right" title="Assets">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_988_eus-gaap--Assets_iI_pp0p0_d0_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentLeasingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLDIkafxvlrb" style="width: 12%; text-align: right" title="Assets">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--Assets_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentLeasingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pp0p0" style="width: 12%; text-align: right" title="Assets">1,880</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 22.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Semiconductor Equipment</p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--Assets_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--SemiconductorEquipmentMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pp0p0" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Assets">3,709,446</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--Assets_iI_pp0p0_d0_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--SemiconductorEquipmentMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjZnCdLwDkmk" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Assets">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--Assets_iI_pp0p0_d0_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--SemiconductorEquipmentMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLR10gevXRw2" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Assets">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 31.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Total Common Stocks</p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_eus-gaap--Assets_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pp0p0" style="width: 12%; text-align: right" title="Assets">3,709,446</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--Assets_iI_pp0p0_d0_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyqE1sR4oNm4" style="width: 12%; text-align: right" title="Assets">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_981_eus-gaap--Assets_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pp0p0" style="width: 12%; text-align: right" title="Assets">268,282</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Preferred Stocks </p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 12%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 12%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 12%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 22.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Aerospace</p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--Assets_iI_pp0p0_d0_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AerospaceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zt1FJBBG6KD5" style="width: 12%; text-align: right" title="Assets">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--Assets_iI_pp0p0_d0_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AerospaceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zC7zZBn4hund" style="width: 12%; text-align: right" title="Assets">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--Assets_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AerospaceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_pp0p0" style="width: 12%; text-align: right" title="Assets">304,332</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 22.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Automotive</p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_988_eus-gaap--Assets_iI_pp0p0_d0_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zu0S6s4b4VFb" style="width: 12%; text-align: right" title="Assets">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--Assets_iI_pp0p0_d0_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zp5Y1dNXz8ki" style="width: 12%; text-align: right" title="Assets">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--Assets_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_pp0p0" style="width: 12%; text-align: right" title="Assets">573,233</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 22.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Equipment Leasing</p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--Assets_iI_pp0p0_d0_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentLeasingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zEWYHpQCSKZg" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Assets">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_981_eus-gaap--Assets_iI_pp0p0_d0_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentLeasingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zJw2bLVNK2h9" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Assets">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--Assets_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentLeasingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_pp0p0" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Assets">383,756</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 31.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Total Preferred Stocks</p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--Assets_iI_pp0p0_d0_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zg5GfatrhBe2" style="width: 12%; text-align: right" title="Assets">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--Assets_iI_pp0p0_d0_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zb7KkTWdT2Qd" style="width: 12%; text-align: right" title="Assets">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--Assets_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_pp0p0" style="width: 12%; text-align: right" title="Assets">1,261,321</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Asset Derivatives <span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 12%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 12%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 12%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 22.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Equity Contracts</p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--Assets_iI_pp0p0_d0_c20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--EquityContractsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_fKCop_zr8V3yLzbNKc" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Assets">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--Assets_iI_pp0p0_d0_c20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--EquityContractsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_fKCop_zw9tM1jK5sCc" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Assets">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--Assets_iI_pp0p0_c20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--EquityContractsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_fKCop_zpsZ57QF7xSc" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Assets">758,405</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 31.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Total Asset Derivatives</p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--Assets_iI_pp0p0_d0_c20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--AssetDerivativesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_fKCop_zMt1DQrSFb91" style="width: 12%; text-align: right" title="Assets">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--Assets_iI_pp0p0_d0_c20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--AssetDerivativesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_fKCop_zMbLqgknJnY6" style="width: 12%; text-align: right" title="Assets">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--Assets_iI_pp0p0_c20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--AssetDerivativesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_fKCop_ztg7kNwe2MN7" style="width: 12%; text-align: right" title="Assets">758,405</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Convertible Notes </p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 12%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 12%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 12%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 22.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Advanced Materials</p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--Assets_iI_pp0p0_d0_c20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancedMaterialsMember_zIImNnwDIWBb" style="width: 12%; text-align: right" title="Assets">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--Assets_iI_pp0p0_d0_c20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancedMaterialsMember_z3VqRYXguBh6" style="width: 12%; text-align: right" title="Assets">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--Assets_c20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancedMaterialsMember_pp0p0" style="width: 12%; text-align: right" title="Assets">100,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 22.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Aerospace</p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--Assets_iI_pp0p0_d0_c20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AerospaceMember_zSFSonNANVff" style="width: 12%; text-align: right" title="Assets">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--Assets_iI_pp0p0_d0_c20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AerospaceMember_zmPg3Tk8V16f" style="width: 12%; text-align: right" title="Assets">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--Assets_c20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AerospaceMember_pp0p0" style="width: 12%; text-align: right" title="Assets">6,559,791</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 22.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Automotive</p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--Assets_iI_pp0p0_d0_c20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember_zX6KzSN7aXSa" style="width: 12%; text-align: right" title="Assets">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--Assets_iI_pp0p0_d0_c20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember_z3fOoeHlm6Bf" style="width: 12%; text-align: right" title="Assets">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_eus-gaap--Assets_c20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember_pp0p0" style="width: 12%; text-align: right" title="Assets">2,352,578</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 22.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Medical Devices</p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--Assets_iI_pp0p0_d0_c20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalDevicesMember_zx6YpxlQigEk" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Assets">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--Assets_iI_pp0p0_d0_c20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalDevicesMember_zcgWf5Iw7Cmg" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Assets">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_981_eus-gaap--Assets_c20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalDevicesMember_pp0p0" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Assets">5,035,984</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 31.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Total Convertible Notes</p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--Assets_iI_pp0p0_d0_c20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zp1hsj15zKD5" style="width: 12%; text-align: right" title="Assets">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--Assets_iI_pp0p0_d0_c20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zN4Gk7uzlBMa" style="width: 12%; text-align: right" title="Assets">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--Assets_c20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="width: 12%; text-align: right" title="Assets">14,048,353</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Mutual Funds</p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--Assets_c20230630__us-gaap--DebtInstrumentAxis__custom--MutualFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Assets">567,150</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--Assets_iI_pp0p0_d0_c20230630__us-gaap--DebtInstrumentAxis__custom--MutualFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z6R0Dk6OjMUb" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Assets">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--Assets_iI_pp0p0_d0_c20230630__us-gaap--DebtInstrumentAxis__custom--MutualFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zFMjEX8flGOl" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Assets">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 22.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Total</p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td> <td id="xdx_989_eus-gaap--Assets_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Assets">4,276,596</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td> <td id="xdx_988_eus-gaap--Assets_iI_pp0p0_d0_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zCwBVGZOEnz1" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Assets">—</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td> <td id="xdx_987_eus-gaap--Assets_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Assets">16,336,361</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; text-align: left"> </td> </tr> </table><p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="width: 18pt; vertical-align: top; text-align: right"> <p style="font: 11pt Times New Roman; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><i><span id="xdx_F01_zuMYJpzXQ474" style="font-size: 11pt; vertical-align: bottom">*</span></i> </p> </td> <td style="vertical-align: top; text-align: left"> <p id="xdx_F1A_zb45V42eSxxl" style="font: 11pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><i>Asset derivatives include warrants. </i></p> </td> </tr> </table> <p style="font: 11pt Times New Roman, Times, Serif; text-align: justify; margin-left: 18pt; text-indent: -18pt; margin-bottom: 0pt; margin-top: 0pt"><i> </i></p> 0 0 266091 0 0 311 0 0 1880 3709446 0 0 3709446 0 268282 0 0 304332 0 0 573233 0 0 383756 0 0 1261321 0 0 758405 0 0 758405 0 0 100000 0 0 6559791 0 0 2352578 0 0 5035984 0 0 14048353 567150 0 0 4276596 0 16336361 <table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock_zKTgQLu0OCT7" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE (Details 1)"> <tr style="vertical-align: bottom"> <td style="vertical-align: top"><span id="xdx_8B5_z0ndyAgdZCB6" style="display: none">Schedule of unobservable inputs of fair value</span></td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right" title="BEGINNING BALANCE"> </td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right" title="NET PURCHASES/CONVERSIONS"> </td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right" title="NET SALES/CONVERSIONS"> </td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right" title="NET REALIZED GAINS/(LOSSES)"> </td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right" title="NET UNREALIZED APPRECIATION (DEPRECIATION)"> </td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right" title="TRANSFERS IN (OUT) OF LEVEL 3"> </td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right" title="ENDING BALANCE"> </td> <td style="white-space: nowrap; text-align: left"> </td></tr> <tr> <td style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>INVESTMENTS AT FAIR <br/> VALUE USING SIGNIFICANT <br/> UNOBSERVABLE INPUTS <br/> (LEVEL 3)</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>BALANCE <br/> AS OF <br/> 12/31/22</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>NET <br/> PURCHASES/<br/> CONVERSIONS</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>NET SALES/<br/> CONVERSIONS</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>NET REALIZED <br/> GAINS/<br/> (LOSSES)</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>NET UNREALIZED <br/> APPRECIATION <br/> (DEPRECIATION)</b><sup><b>(1)</b></sup></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>TRANSFERS <br/> IN (OUT) OF <br/> LEVEL 3</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>BALANCE <br/> AS OF <br/> 06/30/23</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt"><b>Common Stocks</b></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 22.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Advanced Materials</p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_982_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancedMaterialsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zMKWbXjLQfzi" style="width: 8%; text-align: right" title="BEGINNING BALANCE">337,500</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_985_ecustom--NetPurchasesconversions_pp0p0_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancedMaterialsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPQo9XYKPCZ3" style="width: 8%; text-align: right" title="NET PURCHASES/CONVERSIONS">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_981_ecustom--NetSalesconversions_pp0p0_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancedMaterialsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z0ZADVSGeJ65" style="width: 8%; text-align: right" title="NET SALES/CONVERSIONS">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_98B_eus-gaap--DebtAndEquitySecuritiesRealizedGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancedMaterialsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zpK3XcQ7kZeh" style="width: 8%; text-align: right" title="NET REALIZED GAINS/(LOSSES)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_98A_ecustom--NetUnrealizedAppreciationDepreciation_pp0p0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancedMaterialsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKDEp_zvNq538W6srk" style="width: 8%; text-align: right" title="NET UNREALIZED APPRECIATION (DEPRECIATION)">(71,409</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_988_ecustom--TransfersInOutOfLevel3_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancedMaterialsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrYfIJMTQtvi" style="width: 8%; text-align: right" title="TRANSFERS IN (OUT) OF LEVEL 3">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_98F_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancedMaterialsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8XpJF2x5jfa" style="width: 8%; text-align: right" title="ENDING BALANCE">266,091</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 22.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Automotive</p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFhW1bztESh9" style="width: 8%; text-align: right" title="BEGINNING BALANCE">546</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_ecustom--NetPurchasesconversions_pdp0_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zq2KdW3Ckom8" style="width: 8%; text-align: right" title="NET PURCHASES/CONVERSIONS">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_ecustom--NetSalesconversions_pdp0_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zim27JrTXCE" style="width: 8%; text-align: right" title="NET SALES/CONVERSIONS">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--DebtAndEquitySecuritiesRealizedGainLoss_pdp0_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7v5EhF0Jsff" style="width: 8%; text-align: right" title="NET REALIZED GAINS/(LOSSES)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_ecustom--NetUnrealizedAppreciationDepreciation_pp0p0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKDEp_zF7QgBfv5eGf" style="width: 8%; text-align: right" title="NET UNREALIZED APPRECIATION (DEPRECIATION)">(235</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_ecustom--TransfersInOutOfLevel3_pdp0_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zanqleJRhZXi" style="width: 8%; text-align: right" title="TRANSFERS IN (OUT) OF LEVEL 3">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXfXy5pYctVh" style="width: 8%; text-align: right" title="ENDING BALANCE">311</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 22.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Equipment Leasing</p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentLeasingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z891K1Azcloh" style="width: 8%; text-align: right" title="BEGINNING BALANCE">11,130</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98C_ecustom--NetPurchasesconversions_pdp0_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentLeasingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCr0C1zIlzaa" style="width: 8%; text-align: right" title="NET PURCHASES/CONVERSIONS">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_ecustom--NetSalesconversions_pdp0_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentLeasingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZ7qS7toc0Fd" style="width: 8%; text-align: right" title="NET SALES/CONVERSIONS">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--DebtAndEquitySecuritiesRealizedGainLoss_pdp0_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentLeasingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zYnXxTIq4sSb" style="width: 8%; text-align: right" title="NET REALIZED GAINS/(LOSSES)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_ecustom--NetUnrealizedAppreciationDepreciation_pp0p0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentLeasingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKDEp_zIlIAx6NUhyj" style="width: 8%; text-align: right" title="NET UNREALIZED APPRECIATION (DEPRECIATION)">(9,250</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_ecustom--TransfersInOutOfLevel3_pdp0_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentLeasingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zi2Fgt5W79Ng" style="width: 8%; text-align: right" title="TRANSFERS IN (OUT) OF LEVEL 3">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentLeasingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIYMeeoV8U0i" style="width: 8%; text-align: right" title="ENDING BALANCE">1,880</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 22.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Intellectual Property</p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_983_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQWWPtAjWHTa" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="BEGINNING BALANCE">111</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98B_ecustom--NetPurchasesconversions_pdp0_d0_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zedHxZD5m5Wi" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="NET PURCHASES/CONVERSIONS">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_980_ecustom--NetSalesconversions_pdp0_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxkSb9EABqG8" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="NET SALES/CONVERSIONS">(7,966</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left">)</td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--DebtAndEquitySecuritiesRealizedGainLoss_pdp0_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjx6fxduC3ga" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="NET REALIZED GAINS/(LOSSES)">(161,079</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left">)</td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98C_ecustom--NetUnrealizedAppreciationDepreciation_pp0p0_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKDEp_zPVz2cHapGBk" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="NET UNREALIZED APPRECIATION (DEPRECIATION)">168,934</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_989_ecustom--TransfersInOutOfLevel3_pdp0_d0_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ziDrM7Lq9t1l" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="TRANSFERS IN (OUT) OF LEVEL 3">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--Investments_iE_pp0p0_d0_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zl9YK1bsQBNg" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="ENDING BALANCE">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt"><b>Total Common Stocks</b></p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbA59z7UG5Ug" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="BEGINNING BALANCE">349,287</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98C_ecustom--NetPurchasesconversions_pdp0_d0_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwTVb1ACRT4b" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="NET PURCHASES/CONVERSIONS">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_987_ecustom--NetSalesconversions_pdp0_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zGoxGOYGr2z4" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="NET SALES/CONVERSIONS">(7,966</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left">)</td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_983_eus-gaap--DebtAndEquitySecuritiesRealizedGainLoss_pdp0_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9VUg7UISPke" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="NET REALIZED GAINS/(LOSSES)">(161,079</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left">)</td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98B_ecustom--NetUnrealizedAppreciationDepreciation_pp0p0_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKDEp_z2P1sKmFNkGb" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="NET UNREALIZED APPRECIATION (DEPRECIATION)">88,040</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_984_ecustom--TransfersInOutOfLevel3_pdp0_d0_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZ2GXEOATGAb" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="TRANSFERS IN (OUT) OF LEVEL 3">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKx3bEEb7kH4" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="ENDING BALANCE">268,282</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt"><b>Preferred Stocks</b></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 22.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Aerospace</p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AerospaceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zLA6cAo0QRBj" style="width: 8%; text-align: right" title="BEGINNING BALANCE">384,067</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_ecustom--NetPurchasesconversions_pdp0_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AerospaceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z4keU8moGuj8" style="width: 8%; text-align: right" title="NET PURCHASES/CONVERSIONS">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_988_ecustom--NetSalesconversions_pdp0_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AerospaceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zxia8TeC5ujg" style="width: 8%; text-align: right" title="NET SALES/CONVERSIONS">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--DebtAndEquitySecuritiesRealizedGainLoss_pdp0_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AerospaceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z7GhNu8Zhyv4" style="width: 8%; text-align: right" title="NET REALIZED GAINS/(LOSSES)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_ecustom--NetUnrealizedAppreciationDepreciation_pp0p0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AerospaceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_fKDEp_zreQ6PK3lrb2" style="width: 8%; text-align: right" title="NET UNREALIZED APPRECIATION (DEPRECIATION)">(79,735</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_ecustom--TransfersInOutOfLevel3_pdp0_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AerospaceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zj8jNrmNBKob" style="width: 8%; text-align: right" title="TRANSFERS IN (OUT) OF LEVEL 3">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AerospaceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zSPjdDy8SShe" style="width: 8%; text-align: right" title="ENDING BALANCE">304,332</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 22.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Automotive</p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zagXmZ4948Lb" style="width: 8%; text-align: right" title="BEGINNING BALANCE">1,049,478</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_ecustom--NetPurchasesconversions_pdp0_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zDqvx03IzXka" style="width: 8%; text-align: right" title="NET PURCHASES/CONVERSIONS">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_ecustom--NetSalesconversions_pdp0_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zXaxbIidq9Ka" style="width: 8%; text-align: right" title="NET SALES/CONVERSIONS">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--DebtAndEquitySecuritiesRealizedGainLoss_pdp0_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z4s3RQeXFqU4" style="width: 8%; text-align: right" title="NET REALIZED GAINS/(LOSSES)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_ecustom--NetUnrealizedAppreciationDepreciation_pp0p0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_fKDEp_zu2MhesEo4Y6" style="width: 8%; text-align: right" title="NET UNREALIZED APPRECIATION (DEPRECIATION)">(476,245</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_ecustom--TransfersInOutOfLevel3_pdp0_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z5nRWHtAuebd" style="width: 8%; text-align: right" title="TRANSFERS IN (OUT) OF LEVEL 3">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zyutY8W8SvPg" style="width: 8%; text-align: right" title="ENDING BALANCE">573,233</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 22.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Equipment Leasing</p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentLeasingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z6NIXBbJfiol" style="width: 8%; text-align: right" title="BEGINNING BALANCE">865,995</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_ecustom--NetPurchasesconversions_pdp0_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentLeasingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zGMzy4p9O1j8" style="width: 8%; text-align: right" title="NET PURCHASES/CONVERSIONS">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_ecustom--NetSalesconversions_pp0p0_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentLeasingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zvsw7uiQX8lk" style="width: 8%; text-align: right" title="NET SALES/CONVERSIONS">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--DebtAndEquitySecuritiesRealizedGainLoss_pdp0_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentLeasingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zrjjZXKn0Ns9" style="width: 8%; text-align: right" title="NET REALIZED GAINS/(LOSSES)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_ecustom--NetUnrealizedAppreciationDepreciation_pp0p0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentLeasingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_fKDEp_z2N6VxGE4PTh" style="width: 8%; text-align: right" title="NET UNREALIZED APPRECIATION (DEPRECIATION)">(482,239</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_ecustom--TransfersInOutOfLevel3_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentLeasingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zyrRsgVCxtpb" style="width: 8%; text-align: right" title="TRANSFERS IN (OUT) OF LEVEL 3">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_981_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentLeasingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zx7InaW60ZBd" style="width: 8%; text-align: right" title="ENDING BALANCE">383,756</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 22.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Intellectual Property</p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_983_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zEp5hzfaq1b8" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="BEGINNING BALANCE">737,112</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_988_ecustom--NetPurchasesconversions_pdp0_d0_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zaLEDmmYHWL4" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="NET PURCHASES/CONVERSIONS">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_986_ecustom--NetSalesconversions_pdp0_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z713hhJv7U6e" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="NET SALES/CONVERSIONS">(490,459</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left">)</td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_983_eus-gaap--DebtAndEquitySecuritiesRealizedGainLoss_pdp0_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zNGsAW3Zwpz6" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="NET REALIZED GAINS/(LOSSES)">(7,697,238</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left">)</td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_984_ecustom--NetUnrealizedAppreciationDepreciation_pp0p0_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_fKDEp_zsLU3ayEYJlc" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="NET UNREALIZED APPRECIATION (DEPRECIATION)">7,450,585</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_984_ecustom--TransfersInOutOfLevel3_pdp0_d0_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zdi6RhxGt46b" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="TRANSFERS IN (OUT) OF LEVEL 3">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--Investments_iE_pp0p0_d0_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zZi215VOo0rd" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="ENDING BALANCE">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt"><b>Total Preferred Stocks</b></p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zUx7wEMJAw7" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="BEGINNING BALANCE">3,036,652</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_980_ecustom--NetPurchasesconversions_pdp0_d0_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zSb1x5Em2rTj" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="NET PURCHASES/CONVERSIONS">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98D_ecustom--NetSalesconversions_pp0p0_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zvZkmEx6njZe" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="NET SALES/CONVERSIONS">(490,459</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left">)</td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--DebtAndEquitySecuritiesRealizedGainLoss_pp0p0_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zlxHldv7Pzqf" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="NET REALIZED GAINS/(LOSSES)">(7,697,238</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left">)</td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_985_ecustom--NetUnrealizedAppreciationDepreciation_pp0p0_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_fKDEp_z86KX2qhbnD3" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="NET UNREALIZED APPRECIATION (DEPRECIATION)">6,412,366</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_982_ecustom--TransfersInOutOfLevel3_pdp0_d0_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zrxi2BIwSUuh" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="TRANSFERS IN (OUT) OF LEVEL 3">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_988_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zVYEi4uNO3d3" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="ENDING BALANCE">1,261,321</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt"><b>Asset Derivatives</b></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 22.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Equity Contracts</p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_983_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--EquityContractsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zr59FtZvaom8" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="BEGINNING BALANCE">957,125</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98B_ecustom--NetPurchasesconversions_pdp0_d0_c20230101__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--EquityContractsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zKuiEWsxyii8" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="NET PURCHASES/CONVERSIONS">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98A_ecustom--NetSalesconversions_pdp0_d0_c20230101__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--EquityContractsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zHdJrbS30yj" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="NET SALES/CONVERSIONS">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--DebtAndEquitySecuritiesRealizedGainLoss_pdp0_c20230101__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--EquityContractsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zF12uLvJgigl" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="NET REALIZED GAINS/(LOSSES)">(6,678</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left">)</td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98F_ecustom--NetUnrealizedAppreciationDepreciation_pp0p0_c20230101__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--EquityContractsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_fKDEp_zaJnGJ72UxCi" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="NET UNREALIZED APPRECIATION (DEPRECIATION)">(192,042</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left">)</td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98D_ecustom--TransfersInOutOfLevel3_pdp0_d0_c20230101__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--EquityContractsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zvA5c5RTxjhd" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="TRANSFERS IN (OUT) OF LEVEL 3">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--EquityContractsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zwqiCV79FRx4" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="ENDING BALANCE">758,405</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt"><b>Total Asset Derivatives</b></p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--AssetDerivativesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zOZ4MA2P2s86" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="BEGINNING BALANCE">957,125</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98E_ecustom--NetPurchasesconversions_pdp0_d0_c20230101__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--AssetDerivativesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zefu27H9Zo17" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="NET PURCHASES/CONVERSIONS">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_985_ecustom--NetSalesconversions_pdp0_d0_c20230101__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--AssetDerivativesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zDVM0NGW2f57" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="NET SALES/CONVERSIONS">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_983_eus-gaap--DebtAndEquitySecuritiesRealizedGainLoss_pdp0_c20230101__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--AssetDerivativesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zpdewH5Fjke" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="NET REALIZED GAINS/(LOSSES)">(6,678</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left">)</td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_987_ecustom--NetUnrealizedAppreciationDepreciation_pp0p0_c20230101__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--AssetDerivativesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_fKDEp_ztzwstPn3Bob" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="NET UNREALIZED APPRECIATION (DEPRECIATION)">(192,042</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left">)</td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_988_ecustom--TransfersInOutOfLevel3_pdp0_d0_c20230101__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--AssetDerivativesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zwfnN9F2Zeuj" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="TRANSFERS IN (OUT) OF LEVEL 3">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--AssetDerivativesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zwRv80ksiVu3" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="ENDING BALANCE">758,405</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt"><b>Convertible Notes</b></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 22.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Advanced Materials</p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancedMaterialsMember_zpjEG7w70wkb" style="width: 8%; text-align: right" title="BEGINNING BALANCE">100,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_ecustom--NetPurchasesconversions_pdp0_d0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancedMaterialsMember_zUigi44dKDT1" style="width: 8%; text-align: right" title="NET PURCHASES/CONVERSIONS">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_ecustom--NetSalesconversions_pdp0_d0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancedMaterialsMember_zl9HR6FOqobg" style="width: 8%; text-align: right" title="NET SALES/CONVERSIONS">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--DebtAndEquitySecuritiesRealizedGainLoss_pdp0_d0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancedMaterialsMember_zuoKdyy877y6" style="width: 8%; text-align: right" title="NET REALIZED GAINS/(LOSSES)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_ecustom--NetUnrealizedAppreciationDepreciation_pp0p0_d0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancedMaterialsMember_fKDEp_zmIoqE22Ut9i" style="width: 8%; text-align: right" title="NET UNREALIZED APPRECIATION (DEPRECIATION)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_ecustom--TransfersInOutOfLevel3_pdp0_d0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancedMaterialsMember_zdQUyjxaLDAh" style="width: 8%; text-align: right" title="TRANSFERS IN (OUT) OF LEVEL 3">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancedMaterialsMember_zLeieeOluArf" style="width: 8%; text-align: right" title="ENDING BALANCE">100,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 22.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Aerospace</p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AerospaceMember_zpWVvWHs28Fa" style="width: 8%; text-align: right" title="BEGINNING BALANCE">6,559,791</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_ecustom--NetPurchasesconversions_pp0p0_d0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AerospaceMember_z0D9WMjSSDZe" style="width: 8%; text-align: right" title="NET PURCHASES/CONVERSIONS">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_ecustom--NetSalesconversions_pdp0_d0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AerospaceMember_zshTRZ2TtHa6" style="width: 8%; text-align: right" title="NET SALES/CONVERSIONS">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_981_eus-gaap--DebtAndEquitySecuritiesRealizedGainLoss_pdp0_d0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AerospaceMember_z7JaM9hYGoEg" style="width: 8%; text-align: right" title="NET REALIZED GAINS/(LOSSES)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_ecustom--NetUnrealizedAppreciationDepreciation_pp0p0_d0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AerospaceMember_fKDEp_zMTS3h6qSgo9" style="width: 8%; text-align: right" title="NET UNREALIZED APPRECIATION (DEPRECIATION)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_ecustom--TransfersInOutOfLevel3_pdp0_d0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AerospaceMember_zsg2D5GISSO9" style="width: 8%; text-align: right" title="TRANSFERS IN (OUT) OF LEVEL 3">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AerospaceMember_z3jlBJVaN3f6" style="width: 8%; text-align: right" title="ENDING BALANCE">6,559,791</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 22.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Automotive</p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember_zxiE7QwAdkT3" style="width: 8%; text-align: right" title="BEGINNING BALANCE">7,809,430</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_ecustom--NetPurchasesconversions_pp0p0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember_zbURio0KBMK5" style="width: 8%; text-align: right" title="NET PURCHASES/CONVERSIONS">100,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_ecustom--NetSalesconversions_pdp0_d0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember_zMDaxmuRuNR3" style="width: 8%; text-align: right" title="NET SALES/CONVERSIONS">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--DebtAndEquitySecuritiesRealizedGainLoss_pdp0_d0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember_z5F62KmKpbyk" style="width: 8%; text-align: right" title="NET REALIZED GAINS/(LOSSES)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_ecustom--NetUnrealizedAppreciationDepreciation_pp0p0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember_fKDEp_zVWTGCEaB8e6" style="width: 8%; text-align: right" title="NET UNREALIZED APPRECIATION (DEPRECIATION)">(5,556,852</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_ecustom--TransfersInOutOfLevel3_pdp0_d0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember_zHdFUESFtZKd" style="width: 8%; text-align: right" title="TRANSFERS IN (OUT) OF LEVEL 3">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember_zgXT2y7D9y5" style="width: 8%; text-align: right" title="ENDING BALANCE">2,352,578</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 22.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Medical Devices</p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_988_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalDevicesMember_z8f15X9cBsLf" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="BEGINNING BALANCE">17,116,721</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_981_ecustom--NetPurchasesconversions_pp0p0_d0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalDevicesMember_zxFHokipk428" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="NET PURCHASES/CONVERSIONS">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_988_ecustom--NetSalesconversions_pdp0_d0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalDevicesMember_zjwtW2mDCvnb" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="NET SALES/CONVERSIONS">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--DebtAndEquitySecuritiesRealizedGainLoss_pdp0_d0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalDevicesMember_zo8nzbWmHGRl" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="NET REALIZED GAINS/(LOSSES)">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_987_ecustom--NetUnrealizedAppreciationDepreciation_pp0p0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalDevicesMember_fKDEp_z49AU2OgSEf5" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="NET UNREALIZED APPRECIATION (DEPRECIATION)">(12,080,737</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left">)</td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_988_ecustom--TransfersInOutOfLevel3_pdp0_d0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalDevicesMember_z9BkCGlUSgVl" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="TRANSFERS IN (OUT) OF LEVEL 3">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalDevicesMember_zhf134wKg8i8" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="ENDING BALANCE">5,035,984</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt"><b>Total Convertible Notes</b></p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember_zb23F0vnQc86" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="BEGINNING BALANCE">31,585,942</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_988_ecustom--NetPurchasesconversions_pp0p0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember_zauYXn2TpmK6" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="NET PURCHASES/CONVERSIONS">100,000</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_980_ecustom--NetSalesconversions_pdp0_d0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember_zYWoIBPXDXih" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="NET SALES/CONVERSIONS">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--DebtAndEquitySecuritiesRealizedGainLoss_pdp0_d0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember_zzE3zZaTmVti" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="NET REALIZED GAINS/(LOSSES)">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_986_ecustom--NetUnrealizedAppreciationDepreciation_pp0p0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember_fKDEp_zlapj2bYqloj" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="NET UNREALIZED APPRECIATION (DEPRECIATION)">(17,637,589</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left">)</td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_988_ecustom--TransfersInOutOfLevel3_pdp0_d0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember_zafLdgEFOYM1" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="TRANSFERS IN (OUT) OF LEVEL 3">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember_zQAYI29z4Ifb" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="ENDING BALANCE">14,048,353</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Total </p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td> <td id="xdx_982_eus-gaap--Investments_iS_pp0p0_c20230101__20230630_zCgBPYI2fbwi" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right" title="BEGINNING BALANCE">35,929,006</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td> <td id="xdx_98A_ecustom--NetPurchasesconversions_pp0p0_c20230101__20230630_zhTBLSPATbqc" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right" title="NET PURCHASES/CONVERSIONS">100,000</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td> <td id="xdx_983_ecustom--NetSalesconversions_pp0p0_c20230101__20230630_zdG7N6kbRPzj" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right" title="NET SALES/CONVERSIONS">(498,425</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; text-align: left">)</td> <td style="border-bottom: Black 2.5pt double; width: 1%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td> <td id="xdx_98B_eus-gaap--DebtAndEquitySecuritiesRealizedGainLoss_pp0p0_c20230101__20230630_z4WDgP6lcP3g" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right" title="NET REALIZED GAINS/(LOSSES)">(7,864,995</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; text-align: left">)</td> <td style="border-bottom: Black 2.5pt double; width: 1%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td> <td id="xdx_98D_ecustom--NetUnrealizedAppreciationDepreciation_pp0p0_c20230101__20230630_fKDEp_zwnQu1m4G8Jj" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right" title="NET UNREALIZED APPRECIATION (DEPRECIATION)">(11,329,225</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; text-align: left">)</td> <td style="border-bottom: Black 2.5pt double; width: 1%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td> <td id="xdx_982_ecustom--TransfersInOutOfLevel3_pdp0_d0_c20230101__20230630_zL0ZQ5Z9akE3" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right" title="TRANSFERS IN (OUT) OF LEVEL 3">—</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td> <td id="xdx_986_eus-gaap--Investments_iE_pp0p0_c20230101__20230630_z1QFjqXlAive" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right" title="ENDING BALANCE">16,336,361</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; text-align: left"> </td> </tr> </table><p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="width: 18pt; vertical-align: top; text-align: right"> <p style="font: 11pt Times New Roman; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><i id="xdx_F0E_zjvxGOLs8fO3">(1)</i></p> </td> <td style="vertical-align: top; text-align: left"> <p style="font: 11pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"> <i id="xdx_F11_zKkhWfjrZxtj"> The net change in unrealized appreciation (depreciation) from Level 3 instruments held as of June 30, 2023 was $ (18,952,188). </i></p> </td> </tr> </table> 337500 0 0 0 -71409 0 266091 546 0 0 0 -235 0 311 11130 0 0 0 -9250 0 1880 111 0 -7966 -161079 168934 0 0 349287 0 -7966 -161079 88040 0 268282 384067 0 0 0 -79735 0 304332 1049478 0 0 0 -476245 0 573233 865995 0 0 0 -482239 0 383756 737112 0 -490459 -7697238 7450585 0 0 3036652 0 -490459 -7697238 6412366 0 1261321 957125 0 0 -6678 -192042 0 758405 957125 0 0 -6678 -192042 0 758405 100000 0 0 0 0 0 100000 6559791 0 0 0 0 0 6559791 7809430 100000 0 0 -5556852 0 2352578 17116721 0 0 0 -12080737 0 5035984 31585942 100000 0 0 -17637589 0 14048353 35929006 100000 -498425 -7864995 -11329225 0 16336361 <table cellpadding="4" cellspacing="0" id="xdx_893_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_za6glIaXte4" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - FAIR VALUE (Details 2)"> <tr> <td style="vertical-align: top"><span id="xdx_8B7_zOkquNH2MPrk" style="display: none">Schedule of unobservable inputs fair value measurements</span></td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"> </td></tr> <tr> <td style="border-bottom: #000000 1pt solid; vertical-align: bottom; width: 20%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"> </p></td> <td style="border-bottom: #000000 1pt solid; vertical-align: bottom; width: 9%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>FAIR VALUE <br/> AT 6/30/23</b></p></td> <td style="border-bottom: #000000 1pt solid; vertical-align: bottom; width: 20%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>VALUATION TECHNIQUES</b><sup><b>(1)</b></sup></p></td> <td style="border-bottom: #000000 1pt solid; vertical-align: bottom; width: 30%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>UNOBSERVABLE INPUTS</b></p></td> <td style="border-bottom: #000000 1pt solid; vertical-align: bottom; width: 21%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>RANGE <br/> (WEIGHTED AVG.)</b><sup><b>(1)</b></sup></p></td> </tr> <tr style="background-color: Gainsboro"> <td style="vertical-align: top; width: 20%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">Direct venture capital investments: Advanced Materials</p></td> <td style="vertical-align: top; width: 9%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">$<span id="xdx_907_eus-gaap--FairValueHedgeAssetsAtFairValue_iI_pn5n6_c20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancedMaterialsMember_z8dykTXZ0duf" title="FAIR VALUE">0.4</span>M</p></td> <td style="vertical-align: top; width: 20%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Market Comparable Companies </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Option Pricing Model</p></td> <td style="vertical-align: top; width: 30%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">Revenue Multiple<sup>(2)</sup> </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">Years to Maturity<sup>(2)</sup> </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">Volatility<sup>(2)</sup> </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">Risk-Free Rate<sup>(2)</sup> </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">Discount for Lack of </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 4.5pt; margin-bottom: 0pt; margin-top: 0pt">Marketability<sup>(3)</sup></p></td> <td style="vertical-align: top; width: 21%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: right; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">0.7x – 1.0x (0.9x) </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: right; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">5 years (5 years) </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: right; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">50.0% (50.0%) </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: right; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">4.13% (4.13%) </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: right; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">22.7% (22.7%)</p></td> </tr> <tr style="background-color: White"> <td style="vertical-align: top; width: 20%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">Direct venture capital investments: Aerospace</p></td> <td style="vertical-align: top; width: 9%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">$<span id="xdx_90B_eus-gaap--FairValueHedgeAssetsAtFairValue_iI_pn5n6_c20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AerospaceMember_zpyQ4RrWkgyc" title="FAIR VALUE">7.6</span>M</p></td> <td style="vertical-align: top; width: 20%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Market Comparable Companies </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Option Pricing Model</p></td> <td style="vertical-align: top; width: 30%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">EBITDA Multiple<sup>(2)</sup> </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">Years to Maturity<sup>(2)</sup> </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">Volatility<sup>(2)</sup> </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">Risk-Free Rate<sup>(2)</sup></p></td> <td style="vertical-align: top; width: 21%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: right; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">2.1x (2.1x) </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: right; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">5 years (5 years) </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: right; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">60.0% (60.0%) </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: right; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">4.13% (4.13%)</p></td> </tr> <tr style="background-color: Gainsboro"> <td style="vertical-align: top; width: 20%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">Direct venture capital investments: Automotive</p></td> <td style="vertical-align: top; width: 9%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">$<span id="xdx_90A_eus-gaap--FairValueHedgeAssetsAtFairValue_iI_pn5n6_c20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember_zIalS71YFqd5" title="FAIR VALUE">2.9</span>M</p></td> <td style="vertical-align: top; width: 20%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Prior Transaction Analysis </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Option Pricing Model </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Probability-Weighted Expected Return Method</p></td> <td style="vertical-align: top; width: 30%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">Years to Maturity<sup>(2)</sup> </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">Volatility<sup>(2)</sup> </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">Risk-Free Rate<sup>(2)</sup> </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">Discount for Lack of </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 4.5pt; margin-bottom: 0pt; margin-top: 0pt">Marketability<sup>(3)</sup> </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">Going Concern Probability<sup>(2)</sup></p></td> <td style="vertical-align: top; width: 21%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: right; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">5 years (5 years) </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: right; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">50.0% (50.0%) </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: right; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">4.13% (4.13%) </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: right; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">0.0% - 22.7% (0.0%) </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: right; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"> </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: right; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">5% (5%)</p></td> </tr> <tr style="background-color: White"> <td style="vertical-align: top; width: 20%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">Direct venture capital investments: Equipment Leasing</p></td> <td style="vertical-align: top; width: 9%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">$<span id="xdx_90F_eus-gaap--FairValueHedgeAssetsAtFairValue_iI_pn5n6_c20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentLeasingMember_zIY9qSi2y024" title="FAIR VALUE">0.4</span>M</p></td> <td style="vertical-align: top; width: 20%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Market Comparable Companies </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Liquidation Value </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Option Pricing Model</p></td> <td style="vertical-align: top; width: 30%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">EBITDA Multiple<sup>(2)</sup> </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">Years to Maturity<sup>(2)</sup> </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">Volatility<sup>(2)</sup> </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">Risk-Free Rate<sup>(2)</sup></p></td> <td style="vertical-align: top; width: 21%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: right; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">3.0x – 5.1x (4.0x) </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: right; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">5 years (5 years) </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: right; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">50.0% (50.0%) </p><p style="font: 11pt Times New Roman, Times, Serif; text-align: right; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">4.13% (4.13%)</p></td> </tr> <tr style="background-color: Gainsboro"> <td style="vertical-align: top; width: 20%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">Direct venture capital investments: Medical Devices</p></td> <td style="vertical-align: top; width: 9%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">$<span id="xdx_901_eus-gaap--FairValueHedgeAssetsAtFairValue_iI_pn5n6_c20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalDevicesMember_zTFqjLxOoWN9" title="FAIR VALUE">5.0</span>M</p></td> <td style="vertical-align: top; width: 20%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Market Comparable Companies</p></td> <td style="vertical-align: top; width: 30%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">Revenue Multiple<sup>(2)</sup></p></td> <td style="vertical-align: top; width: 21%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: right; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">2.0x – 2.3x (2.1x)</p></td> </tr> </table> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="width: 18pt; vertical-align: top; text-align: right"> <p style="font: 11pt Times New Roman; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><i>(1)</i></p> </td> <td style="vertical-align: top; text-align: left"> <p style="font: 11pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"> <i>Weighted average is calculated by weighting the significant unobservable input by the relative fair value of each investment in the category </i></p> </td> </tr> </table> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="width: 18pt; vertical-align: top; text-align: right"> <p style="font: 11pt Times New Roman; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><i>(2)</i></p> </td> <td style="vertical-align: top; text-align: left"> <p style="font: 11pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"> <i>An increase in the input would result in an increase in the security’s valuation; a decrease in the input would result in a decrease in the security’s valuation. </i></p> </td> </tr> </table> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="width: 18pt; vertical-align: top; text-align: right"> <p style="font: 11pt Times New Roman; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><i>(3)</i></p> </td> <td style="vertical-align: top; text-align: left"> <p style="font: 11pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"> <i>An increase in the input would result in a decrease in the security’s valuation; a decrease in the input would result in an increase in the security’s valuation. </i></p> </td> </tr> </table> <p style="font: 11pt Times New Roman, Times, Serif; text-align: justify; margin-left: 18pt; text-indent: -18pt; margin-bottom: 0pt; margin-top: 0pt"><i> </i></p> 400000 7600000 2900000 400000 5000000.0 <p id="xdx_800_eus-gaap--IncomeTaxDisclosureTextBlock_zFAHS0C0Xkq1" style="font: 14pt Times New Roman, Times, Serif; text-align: left; margin-left: 18pt; text-indent: -18pt; margin-bottom: 0pt; margin-top: 0pt"><b>NOTE 7. <span id="xdx_82F_z6lVoJlAukbk">FEDERAL INCOME TAXES</span> </b></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">Beginning in 2018, we were no longer able to qualify as a RIC under Subchapter M of the Code. The increase in value that resulted from the initial public offerings (IPOs) of Pivotal Systems and Revasum meant that we were no longer able to satisfy the diversification requirements for qualification as a RIC. As a result of this change, we were taxed as a corporation for our fiscal year ended December 31, 2018, and will continue to be taxed in that manner for future fiscal years, paying federal and applicable state corporate taxes on our taxable income, unless and until we are able to once again qualify as a RIC, based on changes in the composition of our portfolio. Consequently, at the close of each fiscal quarter beginning with the quarter ended June 30, 2018, we will record a deferred tax liability for any net realized gains and net ordinary income for the year-to-date period plus net unrealized gains as of the end of the quarter. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">The reorganization described in Note 1 (the formation of FVI as a fully owned subsidiary for investment activities) was structured to avoid any adverse tax consequences for the Company and its shareholders. For the fiscal years which the Company operates as a RIC, we believe Company’s engaging in investment activities through FVI did not, in our view, jeopardize the Company’s ability to continue to qualify as a RIC under the Code at that time when the Company was eligible to be treated as a RIC. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: justify; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">The following information is based upon the U.S. federal income tax cost of portfolio investments as of June 30, 2023. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <table cellpadding="0" cellspacing="0" id="xdx_886_eus-gaap--FederalIncomeTaxNoteTextBlock_zgrxWeLUnBS1" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FEDERAL INCOME TAXES (Details)"> <tr style="vertical-align: bottom"> <td id="xdx_8BC_z1lYsz232Dj8" style="display: none; vertical-align: top">Schedule of federal income tax cost of portfolio investments</td> <td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"> </td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left"> </td></tr> <tr> <td style="vertical-align: top"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: #000000 1pt solid; vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>FEDERAL INCOME <br/> TAX COST:</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Gross unrealized appreciation</p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_988_eus-gaap--TaxBasisOfInvestmentsGrossUnrealizedAppreciation_c20230630_pp0p0" style="width: 12%; text-align: right" title="Gross unrealized appreciation">758,405</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Gross unrealized depreciation</p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_981_eus-gaap--TaxBasisOfInvestmentsGrossUnrealizedDepreciation_iNI_pp0p0_di_c20230630_zaylE2WjyXxd" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Gross unrealized depreciation">(114,566,765</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Net unrealized (depreciation)</p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td> <td id="xdx_980_eus-gaap--TaxBasisOfInvestmentsUnrealizedAppreciationDepreciationNet_c20230630_pp0p0" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Net unrealized (depreciation)">(113,808,360</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Federal income tax cost, Investments</p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td> <td id="xdx_98F_eus-gaap--TaxBasisOfInvestmentsCostForIncomeTaxPurposes_c20230630_pp0p0" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Federal income tax cost, Investments">134,421,317</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; text-align: left"> </td> </tr> </table><p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">The Company did not qualify as a regulated investment company pursuant to Subchapter M of the Internal Revenue Code, therefore it is taxed as a corporation. As a corporation, the Company is obligated to pay federal and state income tax on taxable income. The Company’s net deferred tax asset balance has a full valuation allowance based on management’s estimate of future realization of such assets. The Company is currently using an estimated tax rate of <span id="xdx_90D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_c20230101__20230630_zJfv8Q2fiwX6" title="Statutory tax rate">21</span>% for Federal and <span id="xdx_901_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal_dp_c20230101__20230630_zL1ucnXksT56" title="State tax rate">6.98</span>% for state taxes. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">The Company’s income tax provision consists of the following as of December 31, 2022: </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <table cellpadding="0" cellspacing="0" id="xdx_88D_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zUkXVOJZnqYc" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FEDERAL INCOME TAXES (Details 1)"> <tr> <td id="xdx_8B1_zQSXXp2nHCE1" style="display: none; vertical-align: top">Schedule of income tax provision</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td></tr> <tr> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Deferred tax (expense)/benefit</p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 12%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 22.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Federal</p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_981_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_pp0p0_d0_c20230101__20230630_zcFEk3y0XBK" style="width: 12%; text-align: right" title="Federal">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 22.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">State</p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_988_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_pp0p0_d0_c20230101__20230630_zBfAeaWAZ8rj" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="State">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Total deferred tax (expense)/benefit</p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td> <td id="xdx_988_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefit_pp0p0_d0_c20230101__20230630_zoxjwiopZyB7" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Total deferred tax (expense)/benefit">—</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; text-align: left"> </td> </tr> </table><p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Such temporary differences are principally: (i) taxes on unrealized gains/(losses), which are attributable to the temporary difference between fair market value and tax basis, and (ii) the net tax benefit of accumulated net operating losses and capital loss carryforwards. Deferred tax assets and liabilities are measured using effective tax rates expected to apply to taxable income in the years such temporary differences are realized or otherwise settled. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">Components of the Company’s deferred tax assets and liabilities as of December 31, 2022 are as follows: </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <table cellpadding="0" cellspacing="0" id="xdx_885_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zQ4dECVEfGr9" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FEDERAL INCOME TAXES (Details 2)"> <tr style="vertical-align: bottom"> <td id="xdx_8B5_zUkiusSjZcZ2" style="display: none; vertical-align: top">Schedule of deferred tax assets and liabilities</td> <td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"> </td> <td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"> </td></tr> <tr> <td style="vertical-align: top"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: #000000 1pt solid; vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>AMOUNT</b></p></td> <td style="width: 1%; padding-bottom: 1pt"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Deferred tax assets:</p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 12%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 22.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Net operating loss carryforward</p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_98A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_c20230630_pp0p0" style="width: 12%; text-align: right" title="Net operating loss carryforward">4,616,720</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 22.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Capital loss carryforward</p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--DeferredTaxAssetsCapitalLossCarryforwards_c20230630_pp0p0" style="width: 12%; text-align: right" title="Capital loss carryforward">6,960,412</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 22.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Net unrealized losses (gains) on investment securities</p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_981_ecustom--NetUnrealizedLossesGainsOnInvestmentSecurities_iI_pp0p0_c20230630_zq6JwtH0SPPb" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Net unrealized losses (gains) on investment securities">28,726,530</td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Total deferred tax assets, net</p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--DeferredTaxAssetsGross_c20230630_pp0p0" style="width: 12%; text-align: right" title="Total deferred tax assets">40,303,662</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Valuation allowance</p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_c20230630_zPV2NmvdMTr7" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Valuation allowance">(40,303,662</td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Net</p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td> <td id="xdx_98E_eus-gaap--DeferredTaxAssetsNet_iI_pp0p0_d0_c20230630_z6b28zLVeSV8" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Net">—</td> <td style="white-space: nowrap; width: 1%; padding-bottom: 2.5pt; text-align: left"> </td> </tr> </table><p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">For the year ended December 31, 2022, the Company had an effective tax rate of <span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_c20220101__20221231_zjvyjoyqVIM3" title="Effective tax rate">0</span>% and a statutory tax rate of <span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal_dp_c20230101__20230630_zsZcNKsldxJ8" title="State income tax">21</span>% (<span id="xdx_901_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal_dp_c20220101__20221231_zXhBzn6K0Q0a" title="State income tax">27.98</span>% with state income tax) with the difference being attributable to changes in the components of the deferred tax assets and the valuation allowance account. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">The effective tax rate and statutory federal income tax rate for the three- and six-month periods ended June 30, 2023 and 2022 were as follows: </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <table cellpadding="2" cellspacing="0" id="xdx_889_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zBncYN9E8jKa" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - FEDERAL INCOME TAXES (Details 3)"> <tr> <td style="vertical-align: top"><span id="xdx_8BE_zrLOTKQR1gVj" style="display: none">Schedule of effective tax rate and statutory federal income tax rate</span></td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td></tr> <tr> <td style="vertical-align: bottom; width: 32%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"> </p></td> <td style="border-bottom: #000000 1pt solid; vertical-align: top; width: 17%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>THREE MONTHS ENDED <br/> JUNE 30, 2023</b></p></td> <td style="border-bottom: #000000 1pt solid; vertical-align: top; width: 17%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>THREE MONTHS ENDED <br/> JUNE 30, 2022</b></p></td> <td style="border-bottom: #000000 1pt solid; vertical-align: top; width: 17%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>SIX MONTHS ENDED <br/> JUNE 30, 2023</b></p></td> <td style="border-bottom: #000000 1pt solid; vertical-align: top; width: 17%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>SIX MONTHS ENDED <br/> JUNE, 2023</b></p></td> </tr> <tr style="background-color: Gainsboro"> <td style="vertical-align: top; width: 32%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Effective tax rate</p></td> <td style="vertical-align: bottom; width: 17%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><span id="xdx_900_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_dp_c20230401__20230630_zoPxVkdcHOW3" title="Effective tax rate">0</span>%</p></td> <td style="vertical-align: top; width: 17%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><span id="xdx_90C_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_dp_c20220401__20220630_z4jTd7Exprp3" title="Effective tax rate">0</span>%</p></td> <td style="vertical-align: bottom; width: 17%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><span id="xdx_906_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_dp_c20230101__20230630_zRk27en7izU9" title="Effective tax rate">0</span>%</p></td> <td style="vertical-align: top; width: 17%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_dp_c20220101__20220630_zfs8eretqwf8" title="Effective tax rate">0</span>%</p></td> </tr> <tr style="background-color: White"> <td style="vertical-align: top; width: 32%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Statutory federal income tax rate</p></td> <td style="vertical-align: bottom; width: 17%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><span id="xdx_90D_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_c20230401__20230630_zmtUO7ftoIBg" title="Statutory federal income tax rate">21</span>%</p></td> <td style="vertical-align: bottom; width: 17%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_c20220401__20220630_zYY78Ijkpns2" title="Statutory federal income tax rate">21</span>%</p></td> <td style="vertical-align: bottom; width: 17%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><span id="xdx_90F_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_c20230101__20230630_zH5J4AHvWc68" title="Statutory federal income tax rate">21</span>%</p></td> <td style="vertical-align: bottom; width: 17%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><span id="xdx_90E_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_c20220101__20220630_zSFh1CyPxly1" title="Statutory federal income tax rate">21</span>%</p></td> </tr> </table> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">The variance in the effective tax rate and statutory federal income tax rate for the three-month period ending June 30, 2023, is the result of changes to the deferred tax assets and related valuation allowance account. At June 30, 2023, the Company has established a full valuation allowance on its net deferred tax assets. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">To the extent the Company has a deferred tax asset or if a portion of the deferred tax liability is offset by a tax asset resulting from net operating losses, consideration is given to whether or not a valuation allowance is required against the deferred tax asset amount. A valuation allowance is required if, based on the evaluation criterion provided by Accounting Standard Codification (“ASC”) 740, Income Taxes (ASC 740), it is more-likely-than-not that some portion or all of the deferred tax asset will not be realized. Among the factors considered in assessing the Company’s valuation allowance are: the nature, frequency and severity of current and cumulative losses, forecasts of future profitability, the duration of the statutory carryforward periods, and the associated risks that operating and capital loss carryforwards may expire unused. Based on the Company’s assessment, it has determined that in the future it is more likely than not that the Company will not generate the necessary appropriate character of income within the carryforward periods to realize its deferred tax assets, and as such, has placed a full allowance on the deferred tax assets. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">From time to time, and as new information becomes available, the Company will modify its forecasts, estimates or assumptions regarding its deferred tax liability or asset. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">Modifications of the Company’s estimates or assumptions regarding its deferred tax liability and/or asset balances and any applicable valuation allowance, changes in generally accepted accounting principles or related guidance or interpretations thereof, limitations imposed on net operating losses (if any), and changes in applicable tax law could result in increases or decreases in the Company’s NAV, which could be material. Such changes could have a material impact on the Company’s NAV and results of operations with respect to the Company’s shareholders in the period it is recorded, even though the shareholders at such time might not have held shares in the Company at the time the deferred tax asset or liability had been established. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">The Company’s policy is to classify interest and penalties associated with underpayment of federal and state income taxes, if any, as income tax expense on its Statement of Operations. As of December 31, 2022, the Company did not have any interest or penalties associated with the underpayment of any income taxes. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">The Company files income tax returns in the U.S. federal jurisdiction and California. The Company has reviewed all major jurisdictions and concluded that there is no significant impact on the Company’s net assets and no tax liability resulting from unrecognized tax benefits relating to uncertain tax positions expected to be taken on its tax returns. Furthermore, management of the Company is not aware of any tax positions for which it is reasonably possible that the total amounts of unrecognized tax benefits will significantly change in the next 12 months. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">As of December 31, 2022, the Company had net operating loss carryforwards for federal and state of income tax purposes of $<span id="xdx_904_eus-gaap--OperatingLossCarryforwards_c20221231_pp0p0" title="Net operating loss carryforwards">16,500,072</span>, which may be carried forward indefinitely. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">As of December 31, 2022, the Company had net capital loss carryforwards for federal and state income tax purposes, which may be carried forward for <span id="xdx_909_ecustom--NetCapitalLossCarryforwards_dtY_c20220101__20221231_z9zvvBcoigde" title="Net capital loss carryforwards">5</span> years, as follows: </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--SummaryOfOperatingLossCarryforwardsTextBlock_z0N5yRHNJwUa" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FEDERAL INCOME TAXES (Details 4)"> <tr style="vertical-align: bottom"> <td id="xdx_8BA_z98huL0Lqvub" style="display: none; vertical-align: top">Schedule of net capital loss carryforwards</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: center"> </td> <td style="white-space: nowrap; text-align: left"> </td></tr> <tr> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>EXPIRATION DATE</b></p></td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: #000000 1pt solid; vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>AMOUNT</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 22.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms_c20230101__20230630__us-gaap--TaxCreditCarryforwardAxis__custom--CapitalLossCarryforward1Member" title="EXPIRATION DATE">12/31/24</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_985_eus-gaap--DeferredTaxAssetsCapitalLossCarryforwards_c20230630__us-gaap--TaxCreditCarryforwardAxis__custom--CapitalLossCarryforward1Member_pp0p0" style="width: 12%; text-align: right" title="Capital loss carryforwards">14,230,073</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 22.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms_c20230101__20230630__us-gaap--TaxCreditCarryforwardAxis__custom--CapitalLossCarryforward2Member" title="EXPIRATION DATE">12/31/25</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--DeferredTaxAssetsCapitalLossCarryforwards_c20230630__us-gaap--TaxCreditCarryforwardAxis__custom--CapitalLossCarryforward2Member_pp0p0" style="width: 12%; text-align: right" title="Capital loss carryforwards">7,516,642</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 22.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms_c20230101__20230630__us-gaap--TaxCreditCarryforwardAxis__custom--CapitalLossCarryforward3Member" title="EXPIRATION DATE">12/31/27</span></p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_983_eus-gaap--DeferredTaxAssetsCapitalLossCarryforwards_c20230630__us-gaap--TaxCreditCarryforwardAxis__custom--CapitalLossCarryforward3Member_pp0p0" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Capital loss carryforwards">3,129,665</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Total</p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td> <td id="xdx_981_eus-gaap--DeferredTaxAssetsCapitalLossCarryforwards_iI_pp0p0_c20230630__us-gaap--TaxCreditCarryforwardAxis__custom--CapitalLossCarryforwardsMember_zsDI22GNnI8i" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Capital loss carryforwards">24,876,380</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; text-align: left"> </td> </tr> </table><p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_886_eus-gaap--FederalIncomeTaxNoteTextBlock_zgrxWeLUnBS1" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FEDERAL INCOME TAXES (Details)"> <tr style="vertical-align: bottom"> <td id="xdx_8BC_z1lYsz232Dj8" style="display: none; vertical-align: top">Schedule of federal income tax cost of portfolio investments</td> <td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"> </td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left"> </td></tr> <tr> <td style="vertical-align: top"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: #000000 1pt solid; vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>FEDERAL INCOME <br/> TAX COST:</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Gross unrealized appreciation</p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_988_eus-gaap--TaxBasisOfInvestmentsGrossUnrealizedAppreciation_c20230630_pp0p0" style="width: 12%; text-align: right" title="Gross unrealized appreciation">758,405</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Gross unrealized depreciation</p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_981_eus-gaap--TaxBasisOfInvestmentsGrossUnrealizedDepreciation_iNI_pp0p0_di_c20230630_zaylE2WjyXxd" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Gross unrealized depreciation">(114,566,765</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Net unrealized (depreciation)</p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td> <td id="xdx_980_eus-gaap--TaxBasisOfInvestmentsUnrealizedAppreciationDepreciationNet_c20230630_pp0p0" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Net unrealized (depreciation)">(113,808,360</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Federal income tax cost, Investments</p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td> <td id="xdx_98F_eus-gaap--TaxBasisOfInvestmentsCostForIncomeTaxPurposes_c20230630_pp0p0" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Federal income tax cost, Investments">134,421,317</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; text-align: left"> </td> </tr> </table> 758405 114566765 -113808360 134421317 0.21 0.0698 <table cellpadding="0" cellspacing="0" id="xdx_88D_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zUkXVOJZnqYc" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FEDERAL INCOME TAXES (Details 1)"> <tr> <td id="xdx_8B1_zQSXXp2nHCE1" style="display: none; vertical-align: top">Schedule of income tax provision</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td></tr> <tr> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Deferred tax (expense)/benefit</p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 12%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 22.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Federal</p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_981_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_pp0p0_d0_c20230101__20230630_zcFEk3y0XBK" style="width: 12%; text-align: right" title="Federal">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 22.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">State</p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_988_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_pp0p0_d0_c20230101__20230630_zBfAeaWAZ8rj" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="State">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Total deferred tax (expense)/benefit</p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td> <td id="xdx_988_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefit_pp0p0_d0_c20230101__20230630_zoxjwiopZyB7" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Total deferred tax (expense)/benefit">—</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; text-align: left"> </td> </tr> </table> 0 0 0 <table cellpadding="0" cellspacing="0" id="xdx_885_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zQ4dECVEfGr9" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FEDERAL INCOME TAXES (Details 2)"> <tr style="vertical-align: bottom"> <td id="xdx_8B5_zUkiusSjZcZ2" style="display: none; vertical-align: top">Schedule of deferred tax assets and liabilities</td> <td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"> </td> <td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"> </td></tr> <tr> <td style="vertical-align: top"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: #000000 1pt solid; vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>AMOUNT</b></p></td> <td style="width: 1%; padding-bottom: 1pt"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Deferred tax assets:</p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 12%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 22.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Net operating loss carryforward</p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_98A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_c20230630_pp0p0" style="width: 12%; text-align: right" title="Net operating loss carryforward">4,616,720</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 22.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Capital loss carryforward</p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--DeferredTaxAssetsCapitalLossCarryforwards_c20230630_pp0p0" style="width: 12%; text-align: right" title="Capital loss carryforward">6,960,412</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 22.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Net unrealized losses (gains) on investment securities</p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_981_ecustom--NetUnrealizedLossesGainsOnInvestmentSecurities_iI_pp0p0_c20230630_zq6JwtH0SPPb" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Net unrealized losses (gains) on investment securities">28,726,530</td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Total deferred tax assets, net</p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--DeferredTaxAssetsGross_c20230630_pp0p0" style="width: 12%; text-align: right" title="Total deferred tax assets">40,303,662</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Valuation allowance</p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_c20230630_zPV2NmvdMTr7" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Valuation allowance">(40,303,662</td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Net</p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td> <td id="xdx_98E_eus-gaap--DeferredTaxAssetsNet_iI_pp0p0_d0_c20230630_z6b28zLVeSV8" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Net">—</td> <td style="white-space: nowrap; width: 1%; padding-bottom: 2.5pt; text-align: left"> </td> </tr> </table> 4616720 6960412 28726530 40303662 40303662 0 0 0.21 0.2798 <table cellpadding="2" cellspacing="0" id="xdx_889_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zBncYN9E8jKa" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - FEDERAL INCOME TAXES (Details 3)"> <tr> <td style="vertical-align: top"><span id="xdx_8BE_zrLOTKQR1gVj" style="display: none">Schedule of effective tax rate and statutory federal income tax rate</span></td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td></tr> <tr> <td style="vertical-align: bottom; width: 32%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"> </p></td> <td style="border-bottom: #000000 1pt solid; vertical-align: top; width: 17%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>THREE MONTHS ENDED <br/> JUNE 30, 2023</b></p></td> <td style="border-bottom: #000000 1pt solid; vertical-align: top; width: 17%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>THREE MONTHS ENDED <br/> JUNE 30, 2022</b></p></td> <td style="border-bottom: #000000 1pt solid; vertical-align: top; width: 17%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>SIX MONTHS ENDED <br/> JUNE 30, 2023</b></p></td> <td style="border-bottom: #000000 1pt solid; vertical-align: top; width: 17%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>SIX MONTHS ENDED <br/> JUNE, 2023</b></p></td> </tr> <tr style="background-color: Gainsboro"> <td style="vertical-align: top; width: 32%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Effective tax rate</p></td> <td style="vertical-align: bottom; width: 17%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><span id="xdx_900_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_dp_c20230401__20230630_zoPxVkdcHOW3" title="Effective tax rate">0</span>%</p></td> <td style="vertical-align: top; width: 17%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><span id="xdx_90C_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_dp_c20220401__20220630_z4jTd7Exprp3" title="Effective tax rate">0</span>%</p></td> <td style="vertical-align: bottom; width: 17%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><span id="xdx_906_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_dp_c20230101__20230630_zRk27en7izU9" title="Effective tax rate">0</span>%</p></td> <td style="vertical-align: top; width: 17%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_dp_c20220101__20220630_zfs8eretqwf8" title="Effective tax rate">0</span>%</p></td> </tr> <tr style="background-color: White"> <td style="vertical-align: top; width: 32%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Statutory federal income tax rate</p></td> <td style="vertical-align: bottom; width: 17%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><span id="xdx_90D_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_c20230401__20230630_zmtUO7ftoIBg" title="Statutory federal income tax rate">21</span>%</p></td> <td style="vertical-align: bottom; width: 17%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_c20220401__20220630_zYY78Ijkpns2" title="Statutory federal income tax rate">21</span>%</p></td> <td style="vertical-align: bottom; width: 17%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><span id="xdx_90F_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_c20230101__20230630_zH5J4AHvWc68" title="Statutory federal income tax rate">21</span>%</p></td> <td style="vertical-align: bottom; width: 17%"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><span id="xdx_90E_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_c20220101__20220630_zSFh1CyPxly1" title="Statutory federal income tax rate">21</span>%</p></td> </tr> </table> 0 0 0 0 0.21 0.21 0.21 0.21 16500072 P5Y <table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--SummaryOfOperatingLossCarryforwardsTextBlock_z0N5yRHNJwUa" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FEDERAL INCOME TAXES (Details 4)"> <tr style="vertical-align: bottom"> <td id="xdx_8BA_z98huL0Lqvub" style="display: none; vertical-align: top">Schedule of net capital loss carryforwards</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: center"> </td> <td style="white-space: nowrap; text-align: left"> </td></tr> <tr> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>EXPIRATION DATE</b></p></td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: #000000 1pt solid; vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>AMOUNT</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 22.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms_c20230101__20230630__us-gaap--TaxCreditCarryforwardAxis__custom--CapitalLossCarryforward1Member" title="EXPIRATION DATE">12/31/24</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_985_eus-gaap--DeferredTaxAssetsCapitalLossCarryforwards_c20230630__us-gaap--TaxCreditCarryforwardAxis__custom--CapitalLossCarryforward1Member_pp0p0" style="width: 12%; text-align: right" title="Capital loss carryforwards">14,230,073</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 22.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms_c20230101__20230630__us-gaap--TaxCreditCarryforwardAxis__custom--CapitalLossCarryforward2Member" title="EXPIRATION DATE">12/31/25</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--DeferredTaxAssetsCapitalLossCarryforwards_c20230630__us-gaap--TaxCreditCarryforwardAxis__custom--CapitalLossCarryforward2Member_pp0p0" style="width: 12%; text-align: right" title="Capital loss carryforwards">7,516,642</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 22.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms_c20230101__20230630__us-gaap--TaxCreditCarryforwardAxis__custom--CapitalLossCarryforward3Member" title="EXPIRATION DATE">12/31/27</span></p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_983_eus-gaap--DeferredTaxAssetsCapitalLossCarryforwards_c20230630__us-gaap--TaxCreditCarryforwardAxis__custom--CapitalLossCarryforward3Member_pp0p0" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Capital loss carryforwards">3,129,665</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Total</p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td> <td id="xdx_981_eus-gaap--DeferredTaxAssetsCapitalLossCarryforwards_iI_pp0p0_c20230630__us-gaap--TaxCreditCarryforwardAxis__custom--CapitalLossCarryforwardsMember_zsDI22GNnI8i" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Capital loss carryforwards">24,876,380</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; text-align: left"> </td> </tr> </table> 12/31/24 14230073 12/31/25 7516642 12/31/27 3129665 24876380 <p id="xdx_806_eus-gaap--InvestmentTextBlock_z9yiRa5PtpEa" style="font: 14pt Times New Roman, Times, Serif; text-align: left; margin-left: 18pt; text-indent: -18pt; margin-bottom: 0pt; margin-top: 0pt"><b>NOTE 8. <span><span id="xdx_823_z0l8dLmYFxu5">INVESTMENT TRANSACTIONS</span> </span></b></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">Investment transactions (excluding short-term investments) were as follows for the quarter ended June 30, 2023. </p> <table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--InvestmentTableTextBlock_zecaMynVw6Z5" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INVESTMENT TRANSACTIONS (Details)"> <tr style="vertical-align: bottom"> <td style="vertical-align: top"><span id="xdx_8BF_zjPZCYwenvB8" style="display: none">Schedule of investment transactions</span></td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: center; width: 12%"> </td> <td style="white-space: nowrap; text-align: left; width: 1%"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr> <td style="vertical-align: top"><b>PURCHASES AND SALES</b></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 12%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: top">Purchases of investment securities</td> <td style="width: 1%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td> <td id="xdx_982_eus-gaap--DebtSecuritiesAvailableForSalePurchasedWithCreditDeteriorationAmountAtParValue_c20230401__20230630_pp0p0" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Purchases of investment securities">100,000</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top">Proceeds from sales and maturities of investment securities</td> <td style="width: 1%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td> <td id="xdx_986_eus-gaap--ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_c20230401__20230630_pp0p0" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Proceeds from sales and maturities of investment securities">498,425 </td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; text-align: left"> </td> </tr> </table><p id="xdx_8AB_z399vwiF3gw7" style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--InvestmentTableTextBlock_zecaMynVw6Z5" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INVESTMENT TRANSACTIONS (Details)"> <tr style="vertical-align: bottom"> <td style="vertical-align: top"><span id="xdx_8BF_zjPZCYwenvB8" style="display: none">Schedule of investment transactions</span></td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: center; width: 12%"> </td> <td style="white-space: nowrap; text-align: left; width: 1%"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr> <td style="vertical-align: top"><b>PURCHASES AND SALES</b></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 12%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: top">Purchases of investment securities</td> <td style="width: 1%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td> <td id="xdx_982_eus-gaap--DebtSecuritiesAvailableForSalePurchasedWithCreditDeteriorationAmountAtParValue_c20230401__20230630_pp0p0" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Purchases of investment securities">100,000</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top">Proceeds from sales and maturities of investment securities</td> <td style="width: 1%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td> <td id="xdx_986_eus-gaap--ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_c20230401__20230630_pp0p0" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Proceeds from sales and maturities of investment securities">498,425 </td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; text-align: left"> </td> </tr> </table> 100000 498425 <p id="xdx_80E_eus-gaap--TreasuryStockTextBlock_zpAiF2HCEPzc" style="font: 14pt Times New Roman, Times, Serif; text-align: left; margin-left: 19pt; text-indent: -18pt; margin-bottom: 0pt; margin-top: 0pt"><b>NOTE 9. <span><span id="xdx_82C_zZTdvenOIUTl">SHARE BUYBACKS</span> </span></b></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>SHARE BUYBACKS. </b>On April 26, 2016, the Board of Directors of the Fund approved a discretionary share repurchase plan (the “Plan”). Pursuant to the Plan, the Fund was authorized to purchase in the open market up to $<span id="xdx_903_eus-gaap--ExcessStockSharesAuthorized_iI_pn6n6_c20160426__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z0yr1951ZgEk" title="Common stock value">2</span> million worth of its common stock. The Plan allowed the Fund to acquire its own shares at certain thresholds below its NAV per share, in accordance with the guidelines specified in Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The intent of the Plan was to increase NAV per share and thereby enhance shareholder value. The Fund completed the repurchase plan in September 2016, having repurchased and retired a total of <span id="xdx_903_eus-gaap--StockRepurchasedDuringPeriodShares_c20160401__20160426_pdd" title="Repurchased of shares">272,008</span> shares of stock, at a total cost of approximately $<span id="xdx_90F_eus-gaap--StockRepurchasedDuringPeriodValue_pn6n6_c20160401__20160426_zjjr6aHe6h17" title="Repurchased of shares value">2</span> million. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">On November 10, 2017, the Board of Directors of the Fund approved a discretionary share purchase plan (the “Plan”). Pursuant to the Plan, the Fund was authorized to purchase in the open market up to $<span id="xdx_902_eus-gaap--StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_iI_pn6n6_c20171110_zwqJgMZgyIR9" title="Authorized to purchase">2</span> million worth of its common stock. The Plan allowed the Fund to acquire its own shares in accordance with the guidelines specified in Rule 10b-18 of the Exchange Act. The intent of the Plan was to increase NAV per share and thereby enhance shareholder value. As of December 31, 2017, the Fund had repurchased and retired <span id="xdx_908_eus-gaap--StockRepurchasedAndRetiredDuringPeriodShares_c20171101__20171110_pdd" title="Repurchased and retired shares">128,551</span> shares of stock at a total cost of approximately $<span id="xdx_901_eus-gaap--StockRepurchasedAndRetiredDuringPeriodValue_pn5n6_c20171101__20171110_zxq6qJayQRq" title="Repurchased and retired shares value">1.1</span> million. The Fund had <span id="xdx_906_ecustom--ShareOutstanding_iI_c20171231_zF9SBpF029a9" title="Shares outstanding">7,302,146</span> shares outstanding as of December 31, 2017. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">On August 31, 2018, the Fund announced a plan to repurchase up to $<span id="xdx_90B_eus-gaap--StockRepurchasedDuringPeriodValue_pn6n6_c20180830__20180831__us-gaap--StatementEquityComponentsAxis__custom--SVVCStockMember_zldqBPgWSDkc" title="Repurchased of shares value">2</span> million worth of SVVC stock in the open market by March 31, 2019. The Fund completed this open market repurchase plan on October 24, 2018. Through that date, the Fund repurchased <span id="xdx_90F_eus-gaap--StockRepurchasedDuringPeriodShares_c20180830__20180831_z94XDD3oIeO5" title="Repurchased of shares value">123,376</span> shares at an average price of $<span id="xdx_908_eus-gaap--AcceleratedShareRepurchasesFinalPricePaidPerShare_c20180830__20180831_ziCMqeer3Epd" title="Average price">16.21</span> per share, for total consideration of $<span id="xdx_903_eus-gaap--BusinessCombinationConsiderationTransferred1_pn5n6_c20180830__20180831__us-gaap--StatementEquityComponentsAxis__custom--SVVCStockMember_z2tIaoPJSK29" title="Total consideration amount">2.0</span> million. As of December 31, 2018, the Fund had <span id="xdx_906_ecustom--ShareOutstanding_iI_c20181231_zbxeGc0GByT5" title="Shares outstanding">7,178,770</span> shares outstanding. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>TENDER OFFERS.</b> On December 22, 2014, pursuant to our agreement with a shareholder, the Fund commenced a tender offer to purchase up to $<span id="xdx_90E_eus-gaap--PaymentsOfDividendsCommonStock_pn6n6_c20141201__20141222_zLM6Dl9tgRNl" title="Common shares for cash">20</span> million of its issued and outstanding common shares for cash at a price per share equal to 95% of the Company’s NAV per share determined as of the close of ordinary trading on the NASDAQ Global Market on December 31, 2014 ($<span id="xdx_907_ecustom--TradingPrice_c20141231_pdd" title="Trading price">23.2702</span> per share). The tender offer, which expired on January 22, 2015 at 12:00 midnight, New York City time, was oversubscribed. Because the number of shares tendered exceeded the maximum amount of its offer, the Fund purchased shares from tendering shareholders on a pro-rata basis based on the number of shares properly tendered. <span id="xdx_90A_ecustom--TenderOfferDescription_c20141201__20141222" title="Tender offer description">Of the 5,044,728 shares properly tendered, the Fund purchased 859,468 shares of common stock pursuant to the tender offer</span>. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">On December 16, 2019, the Fund announced the commencement of a “modified Dutch auction” tender offer to purchase up to $<span id="xdx_902_eus-gaap--UnsolicitedTenderOfferCosts_pn6n6_c20191215__20191216__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zd45tDMALAZ2" title="Tender offer">2</span> million of its common stock at a price per share not less than $<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_c20191216__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z4wKWHVpxJ0h" title="Price per share">6.00</span> and not greater than $<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_c20191216__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z84qmGT6oSDa" title="Price per share">8.00</span>, in $<span id="xdx_903_eus-gaap--CommonStockDividendsPerShareDeclared_c20191215__20191216__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zYzh5HWwQ4kd" title="Increment of per share">0.10 </span>increments. The tender offer expired on <span id="xdx_90E_ecustom--TenderOfferExpired_c20191215__20191216__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_za4OXh6p9CE" title="Tender offer expired">February 14, 2020</span>, and resulted in the purchase by the Fund of <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_c20191215__20191216__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjSqcP1KPN92" title="Purchase of shares">285,714</span> shares of common stock at a price of $<span id="xdx_907_ecustom--CommonStockPrice_iI_c20191216__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdjLLf4kDBA8" title="Common stock price">7.00</span> per share. As of March 31, 2020, the Fund had <span id="xdx_90D_ecustom--ShareOutstanding_iI_c20200331_z5nwhxgPUyig" title="Shares outstanding">6,893,056</span> shares outstanding. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> 2000000 272008 2000000 2000000 128551 1100000 7302146 2000000 123376 16.21 2000000.0 7178770 20000000 23.2702 Of the 5,044,728 shares properly tendered, the Fund purchased 859,468 shares of common stock pursuant to the tender offer 2000000 6.00 8.00 0.10 2020-02-14 285714 7.00 6893056 <p id="xdx_80A_eus-gaap--InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock_zxnkY8EqD0S6" style="font: 14pt Times New Roman, Times, Serif; text-align: left; margin-left: 18pt; text-indent: -18pt; margin-bottom: 0pt; margin-top: 0pt"><b>NOTE 10. <span id="xdx_82F_zgAF1Ahlruze">INVESTMENTS IN AFFILIATES AND CONTROLLED INVESTMENTS</span> </b></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: justify; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">Under the 1940 Act, the Company is required to identify investments where it owns greater than 5% (but less than 25%) of the portfolio company’s outstanding voting shares as an affiliate of the Company. Also, under the 1940 Act, the Company is required to identify investments where it owns greater than 25% of the portfolio company’s outstanding voting shares as a controlled investment of the Company. A summary of the Company’s investments in affiliates and controlled investments for the period from December 31, 2022, through June 30, 2023, is noted below: </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfInvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTableTextBlock_zFMbo9NihVUi" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INVESTMENTS IN AFFILIATES AND CONTROLLED INVESTMENTS (Details)"> <tr style="vertical-align: bottom"> <td id="xdx_8BC_zT1SFKJpDSbk" style="display: none; vertical-align: bottom">Schedule of investments in affiliates and controlled investments</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td></tr> <tr> <td style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>AFFILIATE/<br/> CONTROLLED <br/> INVESTMENTS<span style="font-size: 11pt; vertical-align: bottom">*</span></b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>VALUE AT <br/> 12/31/22</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>PURCHASE/ <br/> MERGER</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>INTEREST</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>SALES/ <br/> MATURITY/ <br/> EXPIRATION</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>REALIZED <br/> GAIN (LOSS)</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>CHANGE IN <br/> APPRECIATION/ <br/> DEPRECIATION</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>VALUE <br/> 6/30/23</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>SHARES HELD <br/> AT 6/30/23</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt"><b>Equipment Leasing</b></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">EQX Capital, Inc. Common Stock<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_983_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--EQXCapitalIncCommonStockMember_fKg_____zNU26Eju2qb5" style="width: 8%; text-align: right" title="BEGINNING BALANCE">11,130</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_980_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--EQXCapitalIncCommonStockMember_fKg_____zge2Q3EBi1c" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_987_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--EQXCapitalIncCommonStockMember_fKg_____z8EX75O0whH4" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_984_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--EQXCapitalIncCommonStockMember_fKg_____zYGbn4qPXECf" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_984_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--EQXCapitalIncCommonStockMember_fKg_____znfwsAyjIgX4" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_980_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--EQXCapitalIncCommonStockMember_fKg_____zFWcfYpqsGx3" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(9,250</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_989_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--EQXCapitalIncCommonStockMember_fKg_____zS2uqP5UUdrj" style="width: 8%; text-align: right" title="ENDING BALANCE">1,880</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--EQXCapitalIncCommonStockMember_fKg_____zweiGi7rMuDk" style="width: 8%; text-align: right" title="SHARES HELD">100,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">EQX Capital, Inc. Series A Preferred Stock<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_981_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--EQXCapitalIncSeriesAPreferredStockMember_fKg_____zoKQLW6Eiax4" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="BEGINNING BALANCE">865,995</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_981_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--EQXCapitalIncSeriesAPreferredStockMember_fKg_____zqX66hfnx5Xd" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--EQXCapitalIncSeriesAPreferredStockMember_fKg_____z0vuLE24pMki" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="INTEREST">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--EQXCapitalIncSeriesAPreferredStockMember_fKg_____z83zSsjSmn5j" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--EQXCapitalIncSeriesAPreferredStockMember_fKg_____zlqc2yHdwNZh" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98C_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--EQXCapitalIncSeriesAPreferredStockMember_fKg_____zMRYsqpfyqNc" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(482,239</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left">)</td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--EQXCapitalIncSeriesAPreferredStockMember_fKg_____zMqGTBPSkRy1" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="ENDING BALANCE">383,756</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--EQXCapitalIncSeriesAPreferredStockMember_fKg_____zWKguriRazFe" style="width: 8%; text-align: right" title="SHARES HELD">1,950,000</td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Total Equipment Leasing</p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_984_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentLeasingMember_z9DoIWTAL8F2" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="BEGINNING BALANCE">877,125</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_984_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentLeasingMember_z9L9GyKqnuel" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="INTEREST">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_98C_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentLeasingMember_z6rX1oYmIbLh" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_98B_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentLeasingMember_zbIxTVFKDE1f" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(491,489</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left">)</td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_982_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentLeasingMember_zVCv2KrPfs25" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="ENDING BALANCE">385,636</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt"><b>Aerospace</b></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Hera Systems, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncConvertibleNoteMember_fKg_____z8zEjfsSizk9" style="width: 8%; text-align: right" title="BEGINNING BALANCE">5,359,791</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncConvertibleNoteMember_fKg_____zMra7cSw5AA7" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--InterestIncomeExpenseNet_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncConvertibleNoteMember_fKg_____ztntOnIK9mHf" style="width: 8%; text-align: right" title="INTEREST">269,478</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncConvertibleNoteMember_fKg_____zarDXz61oMLf" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncConvertibleNoteMember_fKg_____zDTbz0dMbAii" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_ecustom--ChangeInAppreciationdepreciation_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncConvertibleNoteMember_fKg_____zgDKjcbkWXBa" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_981_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncConvertibleNoteMember_fKg_____z5Y03WaRzC47" style="width: 8%; text-align: right" title="ENDING BALANCE">5,359,791</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncConvertibleNoteMember_fKg_____zb4vLiD0WmR1" style="width: 8%; text-align: right" title="SHARES HELD">5,359,791</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Hera Systems, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncConvertibleNote1Member_fKg_____zpbYS4cInhpj" style="width: 8%; text-align: right" title="BEGINNING BALANCE">1,200,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncConvertibleNote1Member_fKg_____zyr0JMtf45J4" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--InterestIncomeExpenseNet_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncConvertibleNote1Member_fKg_____zvvmLKwfYHe7" style="width: 8%; text-align: right" title="INTEREST">29,989</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncConvertibleNote1Member_fKg_____zZApdl7YAyga" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_981_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncConvertibleNote1Member_fKg_____z08rWphi3f44" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_ecustom--ChangeInAppreciationdepreciation_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncConvertibleNote1Member_fKg_____zLuQnJGqxCwf" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncConvertibleNote1Member_fKg_____zfRpmAXhWvTi" style="width: 8%; text-align: right" title="ENDING BALANCE">1,200,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncConvertibleNote1Member_fKg_____zH6pqjAutRRj" style="width: 8%; text-align: right" title="SHARES HELD">1,200,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Hera Systems, Inc. Series A Preferred<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesAPreferredMember_fKg_____ztfWby76rJa5" style="width: 8%; text-align: right" title="BEGINNING BALANCE">4,735</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesAPreferredMember_fKg_____z7xvWpPlNXHc" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesAPreferredMember_fKg_____ztEmhvB9yHuh" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesAPreferredMember_fKg_____zTa46yit8kLa" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesAPreferredMember_fKg_____zVUew2tOnEg8" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesAPreferredMember_fKg_____zm342mgSsafd" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(2,169</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesAPreferredMember_fKg_____zev4B0JIbt31" style="width: 8%; text-align: right" title="ENDING BALANCE">2,566</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesAPreferredMember_fKg_____zTRXSTBYdTnf" style="width: 8%; text-align: right" title="SHARES HELD">3,642,324</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Hera Systems, Inc. Series B Preferred<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBPreferredMember_fKg_____zNp5ontjt4Vl" style="width: 8%; text-align: right" title="BEGINNING BALANCE">275,585</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBPreferredMember_fKg_____zedEyzVtqDSb" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBPreferredMember_fKg_____zTE6ZrRpXQw9" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBPreferredMember_fKg_____z4CkSbQYT35k" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBPreferredMember_fKg_____zVSBFBsfN8o2" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98C_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBPreferredMember_fKg_____zYsHnlprVVD5" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(56,352</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBPreferredMember_fKg_____zVHyRMtfJFq" style="width: 8%; text-align: right" title="ENDING BALANCE">219,233</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBPreferredMember_z9G9uGsuVnCe" style="width: 8%; text-align: right" title="SHARES HELD">7,039,203</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Hera Systems, Inc. Series B Warrants<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_981_eus-gaap--Investments_iS_pp0p0_c20221231__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBWarrantsMember_zjYryz5JSTRl" style="width: 8%; text-align: right" title="BEGINNING BALANCE">478,608</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBWarrantsMember_fKg_____zRqUtV9WvYzk" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBWarrantsMember_fKg_____zJJuYRcfxLt5" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBWarrantsMember_fKg_____zClOiQRjIDq7" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBWarrantsMember_fKg_____zt0gLRrLESc5" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBWarrantsMember_fKg_____zD0BYMd04Dv5" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(98,084</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBWarrantsMember_fKg_____zi3DaOfuHlIl" style="width: 8%; text-align: right" title="ENDING BALANCE">380,524</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBWarrantsMember_fKg_____zcEtqNzbFopk" style="width: 8%; text-align: right" title="SHARES HELD">12,250,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Hera Systems, Inc. Series B Warrants<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBWarrants1Member_fKg_____zsfaH0xZ8A2g" style="width: 8%; text-align: right" title="BEGINNING BALANCE">242,817</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBWarrants1Member_fKg_____zPVr1WbPUxng" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBWarrants1Member_fKg_____ze8u6uQbgDol" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBWarrants1Member_fKg_____zuAcggYIoh8k" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBWarrants1Member_fKg_____zFLnBbu66aE2" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBWarrants1Member_fKg_____zKpMNqGSmqV6" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(49,762</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBWarrants1Member_fKg_____zwv3vA7sBGp" style="width: 8%; text-align: right" title="ENDING BALANCE">193,055</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBWarrants1Member_fKg_____zQmbQ1I2jpjj" style="width: 8%; text-align: right" title="SHARES HELD">6,214,922</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Hera Systems, Inc. Series B Warrants<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBWarrants2Member_fKg_____zh6y0PQqiBwb" style="width: 8%; text-align: right" title="BEGINNING BALANCE">205,118</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBWarrants2Member_fKg_____z2zf8YJ99N8l" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_988_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBWarrants2Member_fKg_____zJoCNjFJQao5" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_981_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBWarrants2Member_fKg_____zilRGFoTKd6e" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBWarrants2Member_fKg_____ztKltr5BzD2h" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBWarrants2Member_fKg_____zrWxnth4EnN1" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(42,036</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_981_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBWarrants2Member_fKg_____zIpOzkA0upVg" style="width: 8%; text-align: right" title="ENDING BALANCE">163,082</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_981_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBWarrants2Member_fKg_____zdgvLLtEOPd8" style="width: 8%; text-align: right" title="SHARES HELD">5,250,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Hera Systems, Inc. Series B Warrants<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBWarrants3Member_fKg_____zNYfe6E7YCv7" style="width: 8%; text-align: right" title="BEGINNING BALANCE">27,349</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBWarrants3Member_fKg_____zsaHvtwytEo8" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBWarrants3Member_fKg_____zDGEimR14LHi" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBWarrants3Member_fKg_____zhpUPZKpuvAc" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBWarrants3Member_fKg_____zUf9uFs8EGi7" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBWarrants3Member_fKg_____z5Go0ZzIoGHl" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(5,605</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBWarrants3Member_fKg_____z6JOhiKh68wa" style="width: 8%; text-align: right" title="ENDING BALANCE">21,744</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBWarrants3Member_fKg_____zONm1LtrSuYh" style="width: 8%; text-align: right" title="SHARES HELD">700,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Hera Systems, Inc. Series C Preferred<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesCPreferredMember_fKg_____zLb5j0jqTuCe" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="BEGINNING BALANCE">103,747</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesCPreferredMember_fKg_____zusYFtJNZdng" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesCPreferredMember_fKg_____zV7tVc57gfma" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="INTEREST">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesCPreferredMember_fKg_____zFFcUaM5WRfa" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_988_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesCPreferredMember_fKg_____z01G5ZKaqAcl" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_980_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesCPreferredMember_fKg_____zqxUrItZk1Hf" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(21,214</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left">)</td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesCPreferredMember_fKg_____zT1Lb5lCkage" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="ENDING BALANCE">82,533</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesCPreferredMember_fKg_____zRDAdfUuUUQf" style="width: 8%; text-align: right" title="SHARES HELD">2,650,000</td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Total Aerospace</p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_98D_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AerospaceMember_zbSC04VNiZ1g" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="BEGINNING BALANCE">7,897,750</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_985_eus-gaap--InterestIncomeExpenseNet_pp0p0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AerospaceMember_zMKUuqMjT5Yk" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="INTEREST">299,467</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_985_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AerospaceMember_z7eW189OTP2c" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_981_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AerospaceMember_zW8dO25skQ9b" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(275,222</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left">)</td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_98B_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AerospaceMember_zQPc5EdIyGp9" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="ENDING BALANCE">7,622,528</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt"><b>Medical Devices</b></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">IntraOp Medical Corp. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNoteMember_fKg_____z02beRP5rIG8" style="width: 8%; text-align: right" title="BEGINNING BALANCE">6,746,169</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNoteMember_fKg_____z5PoyQdgyHOc" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNoteMember_fKg_____zvUCOffl0E74" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_981_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNoteMember_fKg_____zwC8H1Vf6cD1" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNoteMember_fKg_____zscceQh9yie7" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98C_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNoteMember_fKg_____z09UFR692uUg" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(4,761,350</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNoteMember_fKg_____z0ev8jYXc8Bf" style="width: 8%; text-align: right" title="ENDING BALANCE">1,984,819</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNoteMember_fKg_____zd2IGsZUqf03" style="width: 8%; text-align: right" title="SHARES HELD">10,961,129</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">IntraOp Medical Corp. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote1Member_fKg_____zE3EUg4BLvre" style="width: 8%; text-align: right" title="BEGINNING BALANCE">800,102</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote1Member_fKg_____zSuiiiwhV3Y" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote1Member_fKg_____zni9ar6MW2yb" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote1Member_fKg_____zOzzw2Zsg7j5" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote1Member_fKg_____zAYwnxpAHcR1" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote1Member_fKg_____zeXjno2DR5xb" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(564,701</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote1Member_fKg_____zKB2J6qoxBLk" style="width: 8%; text-align: right" title="ENDING BALANCE">235,401</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote1Member_fKg_____zETHD5TtxHpg" style="width: 8%; text-align: right" title="SHARES HELD">1,300,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> </table><p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 14pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>Firsthand Technology Value Fund, Inc. </b></p> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr> <td style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>AFFILIATE/<br/> CONTROLLED <br/> INVESTMENTS<span style="font-size: 11pt; vertical-align: bottom">*</span></b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>VALUE AT <br/> 12/31/22</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>PURCHASE/ <br/> MERGER</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>INTEREST</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>SALES/ <br/> MATURITY/ <br/> EXPIRATION</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>REALIZED <br/> GAIN (LOSS)</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>CHANGE IN <br/> APPRECIATION/ <br/> DEPRECIATION</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>VALUE <br/> 6/30/23</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>SHARES HELD <br/> AT 6/30/23</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">IntraOp Medical Corp. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_989_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote2Member_fKg_____zTc9wokB0HCb" style="width: 8%; text-align: right" title="BEGINNING BALANCE">307,731</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_989_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote2Member_fKg_____zddZ4M4l7lQl" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_980_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote2Member_fKg_____zbYEysDtd7Mi" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_985_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote2Member_fKg_____zwT34veQaHrd" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_980_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote2Member_fKg_____zM1sBhiH6bjd" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_983_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote2Member_fKg_____zgUCdMAxPMs" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(217,192</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_982_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote2Member_fKg_____zDLByCTmb9q6" style="width: 8%; text-align: right" title="ENDING BALANCE">90,539</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_981_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote2Member_fKg_____zKAvNWHgf30e" style="width: 8%; text-align: right" title="SHARES HELD">500,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">IntraOp Medical Corp. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_988_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote3Member_fKg_____zUCx250tu4Wb" style="width: 8%; text-align: right" title="BEGINNING BALANCE">307,731</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_988_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote3Member_fKg_____zeof6NOHTgh8" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote3Member_fKg_____zcKGRrFXksAl" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote3Member_fKg_____zBk5d9szXQrk" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote3Member_fKg_____z4hzUlf1Apy5" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote3Member_fKg_____zlkfcBEc18c2" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(217,192</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote3Member_fKg_____zqvGlkOjnDKh" style="width: 8%; text-align: right" title="ENDING BALANCE">90,539</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote3Member_fKg_____zRHi7SCTDvp8" style="width: 8%; text-align: right" title="SHARES HELD">500,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">IntraOp Medical Corp. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote4Member_fKg_____zTgpZ00o265a" style="width: 8%; text-align: right" title="BEGINNING BALANCE">1,846,389</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote4Member_fKg_____zd7HV8r1UGn2" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_981_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote4Member_fKg_____zBoSn1VlNE61" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote4Member_fKg_____z8BUZh02gIcc" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote4Member_fKg_____zKRinEt1IM2" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote4Member_fKg_____zPoYsapbe0gd" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(1,303,155</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote4Member_fKg_____zcDZkl3ebAR1" style="width: 8%; text-align: right" title="ENDING BALANCE">543,234</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_988_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote4Member_fKg_____z6Csmv16TTHi" style="width: 8%; text-align: right" title="SHARES HELD">3,000,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">IntraOp Medical Corp. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote5Member_fKg_____zHkGAEmDPCl9" style="width: 8%; text-align: right" title="BEGINNING BALANCE">615,463</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote5Member_fKg_____z7pbbIgA3r7" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote5Member_fKg_____ze5tTePNx1hd" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote5Member_fKg_____z0INKpqbj9Lf" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote5Member_fKg_____ziQP2MnJXVWc" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote5Member_fKg_____zYVVtA94CGj9" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(434,385</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote5Member_fKg_____zdd5VXTPe5Ld" style="width: 8%; text-align: right" title="ENDING BALANCE">181,078</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote5Member_fKg_____zbNayEk9zOgj" style="width: 8%; text-align: right" title="SHARES HELD">1,000,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">IntraOp Medical Corp. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote6Member_fKg_____zfOJ5StNbx17" style="width: 8%; text-align: right" title="BEGINNING BALANCE">246,185</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote6Member_fKg_____zxRnqRDMlzne" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote6Member_fKg_____zz3LTexLFAHb" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote6Member_fKg_____zK07FgxltvB7" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote6Member_fKg_____zTiMI6oWdyo7" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote6Member_fKg_____z8rSO2cf8rAf" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(173,754</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote6Member_fKg_____z6fec9uqSXv8" style="width: 8%; text-align: right" title="ENDING BALANCE">72,431</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote6Member_fKg_____zxdBwPvQwlva" style="width: 8%; text-align: right" title="SHARES HELD">400,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">IntraOp Medical Corp. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote7Member_fKg_____zAbYlemaCxH4" style="width: 8%; text-align: right" title="BEGINNING BALANCE">307,731</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote7Member_fKg_____ztEh5IKxUdlj" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote7Member_fKg_____zDG7lxqbDdQ" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote7Member_fKg_____zD8QVk0DfFT" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote7Member_fKg_____zdhaRXqmbS98" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote7Member_fKg_____zLs515vGGBJc" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(217,192</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote7Member_fKg_____zGspGJMIHjVl" style="width: 8%; text-align: right" title="ENDING BALANCE">90,539</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote7Member_fKg_____zNGPHBpcSx9i" style="width: 8%; text-align: right" title="SHARES HELD">500,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">IntraOp Medical Corp. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote8Member_fKg_____z6cWS8G08h5d" style="width: 8%; text-align: right" title="BEGINNING BALANCE">461,597</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote8Member_fKg_____zNOT34GPShea" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote8Member_fKg_____zN0GdeA1v2Oi" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote8Member_fKg_____zodpr5GD8Rj6" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote8Member_fKg_____zX1rBkZBBJz7" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_981_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote8Member_fKg_____zPidVAsjREC7" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(325,788</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote8Member_fKg_____z5FdrKUQwNX4" style="width: 8%; text-align: right" title="ENDING BALANCE">135,809</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote8Member_fKg_____zHGwQkAmMLba" style="width: 8%; text-align: right" title="SHARES HELD">750,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">IntraOp Medical Corp. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote9Member_fKg_____z8qlaB4nail7" style="width: 8%; text-align: right" title="BEGINNING BALANCE">307,731</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote9Member_fKg_____z8r0Q2Xk3SC2" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote9Member_fKg_____znLr9qSJGNil" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote9Member_fKg_____zusnpfgwRXTe" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote9Member_fKg_____zUpEsNmR5Fj3" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote9Member_fKg_____zr8n8NgQK0Ea" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(217,192</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote9Member_fKg_____zozegwVqjbVk" style="width: 8%; text-align: right" title="ENDING BALANCE">90,539</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote9Member_fKg_____zMVWQ2ZpGu16" style="width: 8%; text-align: right" title="SHARES HELD">500,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">IntraOp Medical Corp. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_981_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote10Member_fKg_____zx6Fmn5FLAQ8" style="width: 8%; text-align: right" title="BEGINNING BALANCE">307,732</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote10Member_fKg_____zpFdHn6JX1O9" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote10Member_fKg_____zjwaGm0b7Ij7" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote10Member_fKg_____zm0KF8TONHP2" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote10Member_fKg_____zDeVn35rgDG8" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote10Member_fKg_____zudzq94FPnyi" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(217,193</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote10Member_fKg_____zeGTgWnQWAVd" style="width: 8%; text-align: right" title="ENDING BALANCE">90,539</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote10Member_fKg_____znr79tZ7y3Sk" style="width: 8%; text-align: right" title="SHARES HELD">500,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">IntraOp Medical Corp. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote11Member_fKg_____zIFSJrFCLX32" style="width: 8%; text-align: right" title="BEGINNING BALANCE">307,732</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote11Member_fKg_____z40U7Pbaf959" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_981_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote11Member_fKg_____zn9RS2t6K9Wc" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote11Member_fKg_____zjTqJAwO0Fc2" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote11Member_fKg_____zRD0RDopNqYi" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote11Member_fKg_____zBzXoyGQNRM2" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(217,193</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote11Member_fKg_____zfktzEw3J856" style="width: 8%; text-align: right" title="ENDING BALANCE">90,539</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote11Member_fKg_____zAFUbJ7YYj7a" style="width: 8%; text-align: right" title="SHARES HELD">500,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">IntraOp Medical Corp. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_981_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote12Member_fKg_____zsSGwVXLTKMa" style="width: 8%; text-align: right" title="BEGINNING BALANCE">615,463</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote12Member_fKg_____zFf4vn37F6yc" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote12Member_fKg_____zvU81U8nDHfh" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote12Member_fKg_____z2u45pWWqLTh" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_981_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote12Member_fKg_____z1pVZ6HKptg5" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote12Member_fKg_____zl993mKOnMFi" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(434,385</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_988_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote12Member_fKg_____zySO8ejSm9le" style="width: 8%; text-align: right" title="ENDING BALANCE">181,078</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote12Member_fKg_____zfRoZt4apyub" style="width: 8%; text-align: right" title="SHARES HELD">1,000,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">IntraOp Medical Corp. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote13Member_fKg_____zrs0cgstIYwk" style="width: 8%; text-align: right" title="BEGINNING BALANCE">307,732</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote13Member_fKg_____zXK8WdyO9CWg" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote13Member_fKg_____zo26zW99EEB7" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote13Member_fKg_____zA03BOBi4gVf" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote13Member_fKg_____zixPOZYLURF1" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote13Member_fKg_____zjv4WJJYuVV6" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(217,193</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote13Member_fKg_____zAwNma4jFkS5" style="width: 8%; text-align: right" title="ENDING BALANCE">90,539</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote13Member_fKg_____zUyEOA2X2Lvc" style="width: 8%; text-align: right" title="SHARES HELD">500,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">IntraOp Medical Corp. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_988_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote14Member_fKg_____zmmQAhAPPjjg" style="width: 8%; text-align: right" title="BEGINNING BALANCE">615,463</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote14Member_fKg_____zfmvdBpaxFrj" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote14Member_fKg_____z4lHX5swanSb" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote14Member_fKg_____zm073ASrFUCa" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote14Member_fKg_____zznfWux35ufb" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote14Member_fKg_____zOeHEPPF1xhi" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(434,385</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote14Member_fKg_____zkjEwjbn0zh7" style="width: 8%; text-align: right" title="ENDING BALANCE">181,078</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote14Member_fKg_____zbyaByRv7LJ4" style="width: 8%; text-align: right" title="SHARES HELD">1,000,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">IntraOp Medical Corp. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote15Member_fKg_____zsyZGUzL3lV3" style="width: 8%; text-align: right" title="BEGINNING BALANCE">307,732</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote15Member_fKg_____zNHeok9eEhub" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote15Member_fKg_____z56X4FRNT1S9" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote15Member_fKg_____zaLEyfVcZZz3" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote15Member_fKg_____zeXIGWMFi2Ma" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote15Member_fKg_____zWQVPGich7W3" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(217,193</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote15Member_fKg_____zfx52pyVcdZ4" style="width: 8%; text-align: right" title="ENDING BALANCE">90,539</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote15Member_fKg_____zQM4DOf0SG3g" style="width: 8%; text-align: right" title="SHARES HELD">500,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">IntraOp Medical Corp. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote16Member_fKg_____z8IsJWLIH8M3" style="width: 8%; text-align: right" title="BEGINNING BALANCE">307,732</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote16Member_fKg_____zblmOIWiaX2b" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote16Member_fKg_____zMQIcVEPSpz9" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote16Member_fKg_____zdZwEOmEyuR4" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote16Member_fKg_____z4OMSt4ZFc25" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote16Member_fKg_____za3novVhBqf7" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(217,193</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote16Member_fKg_____z13JGX96mDua" style="width: 8%; text-align: right" title="ENDING BALANCE">90,539</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote16Member_fKg_____znEbb9gICZAg" style="width: 8%; text-align: right" title="SHARES HELD">500,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> </table><p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 14pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>Firsthand Technology Value Fund, Inc. </b></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr> <td style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>AFFILIATE/<br/> CONTROLLED <br/> INVESTMENTS<span style="font-size: 11pt; vertical-align: bottom">*</span></b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>VALUE AT <br/> 12/31/22</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>PURCHASE/ <br/> MERGER</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>INTEREST</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>SALES/ <br/> MATURITY/ <br/> EXPIRATION</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>REALIZED <br/> GAIN (LOSS)</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>CHANGE IN <br/> APPRECIATION/ <br/> DEPRECIATION</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>VALUE <br/> 6/30/23</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>SHARES HELD <br/> AT 6/30/23</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">IntraOp Medical Corp. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_985_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote17Member_fKg_____zZueuSquFBz8" style="width: 8%; text-align: right" title="BEGINNING BALANCE">307,732</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_980_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote17Member_fKg_____z0RjSQarINwg" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_984_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote17Member_fKg_____zHqfbAwrYVrc" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_98B_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote17Member_fKg_____z3vmNOGs32fg" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_981_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote17Member_fKg_____z8ODrCEccL14" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_98E_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote17Member_fKg_____zLt3HtJ5rAh3" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(217,193</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_980_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote17Member_fKg_____z4LsCWMLPBuj" style="width: 8%; text-align: right" title="ENDING BALANCE">90,539</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote17Member_fKg_____zJpcrYy4ioZ3" style="width: 8%; text-align: right" title="SHARES HELD">500,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">IntraOp Medical Corp. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote18Member_fKg_____zDPGVuo0MF9e" style="width: 8%; text-align: right" title="BEGINNING BALANCE">123,093</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote18Member_fKg_____z46bwuw9U5Cl" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote18Member_fKg_____zMR0gBJErqy8" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_981_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote18Member_fKg_____zgGqe2cv4a88" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_988_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote18Member_fKg_____zd2pYWMYzsel" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote18Member_fKg_____ztLvk95zYLPf" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(86,877</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote18Member_fKg_____z5P2K009ow99" style="width: 8%; text-align: right" title="ENDING BALANCE">36,216</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote18Member_fKg_____z2vX636ToUi9" style="width: 8%; text-align: right" title="SHARES HELD">200,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">IntraOp Medical Corp. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote19Member_fKg_____zjFopVQMx731" style="width: 8%; text-align: right" title="BEGINNING BALANCE">430,824</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote19Member_fKg_____zkVTvCqYcJUi" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote19Member_fKg_____z4IzsmriIDNc" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote19Member_fKg_____zZ5WTKk5Toyh" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote19Member_fKg_____zJ6dSXGGZUw1" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote19Member_fKg_____zfmib478tlq9" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(304,069</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote19Member_fKg_____zzA0K4mUNVZi" style="width: 8%; text-align: right" title="ENDING BALANCE">126,755</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote19Member_fKg_____zHxBUnb0QqN3" style="width: 8%; text-align: right" title="SHARES HELD">700,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">IntraOp Medical Corp. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote20Member_fKg_____zH6ozDG4TLf2" style="width: 8%; text-align: right" title="BEGINNING BALANCE">92,319</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote20Member_fKg_____zD94AjiZFXVa" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote20Member_fKg_____zcW06mePQXZ4" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote20Member_fKg_____zUhbCmiXJUN7" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote20Member_fKg_____zHQdwkxcTgr5" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_981_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote20Member_fKg_____zj1oOljJNkLl" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(65,157</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote20Member_fKg_____zTvCdaknYZ7h" style="width: 8%; text-align: right" title="ENDING BALANCE">27,162</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote20Member_fKg_____zy80zU6BZSAl" style="width: 8%; text-align: right" title="SHARES HELD">150,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">IntraOp Medical Corp. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote21Member_fKg_____ztlksAXXb9ec" style="width: 8%; text-align: right" title="BEGINNING BALANCE">215,412</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote21Member_fKg_____zvBvYauk64R5" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote21Member_fKg_____zdYARf5YsJxf" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote21Member_fKg_____zsQpnbelvfn5" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote21Member_fKg_____zeCGAkuVi595" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98C_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote21Member_fKg_____z5t0ftoTNne5" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(152,035</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote21Member_fKg_____zJxjAgffQPng" style="width: 8%; text-align: right" title="ENDING BALANCE">63,377</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote21Member_fKg_____zBokYmYDxy4e" style="width: 8%; text-align: right" title="SHARES HELD">350,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">IntraOp Medical Corp. Series C Preferred<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--Investments_iS_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpSeriesCPreferredMember_fKg_____zhx5Uib0INaj" style="width: 8%; text-align: right" title="BEGINNING BALANCE">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpSeriesCPreferredMember_fKg_____zDfaZ5grpkR5" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpSeriesCPreferredMember_fKg_____zq6anjaakRjk" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpSeriesCPreferredMember_fKg_____znS06ztrB1mb" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpSeriesCPreferredMember_fKg_____zVIRiAt1AjH4" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_ecustom--ChangeInAppreciationdepreciation_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpSeriesCPreferredMember_fKg_____zbf3uQdjzEvi" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--Investments_iE_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpSeriesCPreferredMember_fKg_____z7xaeu2MFQI7" style="width: 8%; text-align: right" title="ENDING BALANCE">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpSeriesCPreferredMember_fKg_____zgSuK7ldGdvj" style="width: 8%; text-align: right" title="SHARES HELD">26,856,187</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">IntraOp Medical Corp. Term Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpTermNoteMember_fKg_____ztnMaDx0CvQ9" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="BEGINNING BALANCE">1,230,926</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpTermNoteMember_fKg_____zUOWov0fESW" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpTermNoteMember_fKg_____zvUZEHR4aBWg" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="INTEREST">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpTermNoteMember_fKg_____zpLOYFL8gFJb" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_988_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpTermNoteMember_fKg_____zyDFNpLSIcR" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98A_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpTermNoteMember_fKg_____z1ilkbNE9L5h" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(868,770</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left">)</td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpTermNoteMember_fKg_____zQZkBW5EAyu3" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="ENDING BALANCE">362,156</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpTermNoteMember_fKg_____zCbSB9JQxbvj" style="width: 8%; text-align: right" title="SHARES HELD">2,000,000</td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Total Medical Devices</p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_983_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalDevicesMember_zNpBzaOLRKsg" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="BEGINNING BALANCE">17,116,721</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_983_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalDevicesMember_zQTc3d0yl7Da" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="INTEREST">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_98A_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalDevicesMember_zZpFqc7rMjyh" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_98D_ecustom--ChangeInAppreciationdepreciation_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalDevicesMember_pp0p0" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(12,080,737</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left">)</td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_98D_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalDevicesMember_zIjO7rQz2Av4" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="ENDING BALANCE">5,035,984</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt"><b>Semiconductor Equipment</b></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Revasum, Inc. CDI<span style="font-size: 11pt; vertical-align: bottom">*</span>(1)</p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--RevasumIncCDIMember_fKigxKQ_____zROD2gUBFCP1" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="BEGINNING BALANCE">3,520,496</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_981_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--RevasumIncCDIMember_fKigxKQ_____zta82jp0SII6" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--RevasumIncCDIMember_fKigxKQ_____zQp004RMFmAi" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="INTEREST">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--RevasumIncCDIMember_fKigxKQ_____zvCBUnGY6bGk" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--RevasumIncCDIMember_fKigxKQ_____zIklxUJidWS9" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98E_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--RevasumIncCDIMember_fKigxKQ_____z4ZISoYpbgrh" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">188,950</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--RevasumIncCDIMember_fKigxKQ_____zNkbXTj1UAg9" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="ENDING BALANCE">3,709,446</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_988_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--RevasumIncCDIMember_fKigxKQ_____zjE3yVJ6o2hf" style="width: 8%; text-align: right" title="SHARES HELD">39,774,889</td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Total Semiconductor Equipment</p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_985_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--SemiconductorEquipmentMember_za5zN7A4FtJk" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="BEGINNING BALANCE">3,520,496</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_987_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--SemiconductorEquipmentMember_zGloiybBaSsc" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="INTEREST">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_988_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--SemiconductorEquipmentMember_z9QLngEZP2Of" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_98B_ecustom--ChangeInAppreciationdepreciation_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--SemiconductorEquipmentMember_pp0p0" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">188,950</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_984_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--SemiconductorEquipmentMember_z6R7SGVrTxb9" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="ENDING BALANCE">3,709,446</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt"><b>Intellectual Property</b></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Silicon Genesis Corp. Common Stock<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpCommonStockMember_fKg_____zL3vOx2heRSk" style="width: 8%; text-align: right" title="BEGINNING BALANCE">111</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpCommonStockMember_fKg_____zGWstr6uHRe3" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpCommonStockMember_fKg_____z6O0uVecc4P3" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpCommonStockMember_fKg_____zTtUnQPc8gU2" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">(7,966</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_981_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpCommonStockMember_fKg_____zN0NlyrBu4ph" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">(161,080</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpCommonStockMember_fKg_____zAeBRZJmp8Sd" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">168,935</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--Investments_iE_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpCommonStockMember_fKg_____zP9VCfxA5vb1" style="width: 8%; text-align: right" title="ENDING BALANCE">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--SharesIssued_iI_d0_c20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpCommonStockMember_fKg_____zOTRQteupKVf" style="width: 8%; text-align: right" title="SHARES HELD">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Silicon Genesis Corp. Common Warrants<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpCommonWarrantsMember_fKg_____zt6jA691ZDk1" style="width: 8%; text-align: right" title="BEGINNING BALANCE">1</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpCommonWarrantsMember_fKg_____zOVPQTO5dGLg" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpCommonWarrantsMember_fKg_____zdPxGmPdffS3" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpCommonWarrantsMember_fKg_____ztcOCL0vhGS4" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">(1</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_988_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpCommonWarrantsMember_fKg_____zuWP5erOqYFa" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">(6,677</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpCommonWarrantsMember_fKg_____zLjNA23PvHlg" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">6,677</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_981_eus-gaap--Investments_iE_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpCommonWarrantsMember_fKg_____zmneWoD3gub2" style="width: 8%; text-align: right" title="ENDING BALANCE">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--SharesIssued_iI_d0_c20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpCommonWarrantsMember_fKg_____zj2pnFM0K5kl" style="width: 8%; text-align: right" title="SHARES HELD">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Silicon Genesis Corp. Series 1-G Preferred<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1GPreferredMember_fKg_____zx6Qz5I3uDag" style="width: 8%; text-align: right" title="BEGINNING BALANCE">306,671</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1GPreferredMember_fKg_____zK1vBfHpD1c9" style="width: 8%; text-align: right" title="PURCHASE/MERGER">88</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1GPreferredMember_fKg_____zx5Vxebuduuj" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1GPreferredMember_fKg_____zMTDu5D2spgb" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">(417,972</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1GPreferredMember_fKg_____zkRkyCOnNTng" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">(3,462,620</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1GPreferredMember_fKg_____zoEJLmqskcOg" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">3,573,833</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--Investments_iE_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1GPreferredMember_fKg_____zkB3KrHhMvo4" style="width: 8%; text-align: right" title="ENDING BALANCE">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--SharesIssued_iI_d0_c20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1GPreferredMember_fKg_____zNQn6FUkkZll" style="width: 8%; text-align: right" title="SHARES HELD">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Silicon Genesis Corp. Series 1-H Preferred<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1HPreferredMember_fKg_____zdfJFwLUEn87" style="width: 8%; text-align: right" title="BEGINNING BALANCE">35,529</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1HPreferredMember_fKg_____zp5D4yabxlHe" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1HPreferredMember_fKg_____z501TcOZl6Me" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1HPreferredMember_fKg_____zgjbkxPHoT9a" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">(7,241</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1HPreferredMember_fKg_____zpiDz6S4s4x6" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">(929,654</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1HPreferredMember_fKg_____zzho74jGv6Y4" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">901,366</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--Investments_iE_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1HPreferredMember_fKg_____zWwd0zirF0pc" style="width: 8%; text-align: right" title="ENDING BALANCE">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--SharesIssued_iI_d0_c20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1HPreferredMember_fKg_____zBNbTzFg44Mb" style="width: 8%; text-align: right" title="SHARES HELD">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Silicon Genesis Corp. Series 1-D Preferred<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1DPreferredMember_fKg_____zxZS2cXyXshk" style="width: 8%; text-align: right" title="BEGINNING BALANCE">2,552</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1DPreferredMember_fKg_____zyoKy1j6vmI1" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1DPreferredMember_fKg_____zgEBf0bXZDof" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1DPreferredMember_fKg_____z2thRlZjoHU8" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">(7,351</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--DebtAndEquitySecuritiesGainLoss_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1DPreferredMember_fKg_____zIGU7VCoB59d" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">(424,549</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1DPreferredMember_fKg_____zbEE2lUKhBB" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">429,348</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_981_eus-gaap--Investments_iE_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1DPreferredMember_fKg_____zyMDkhCPMX5f" style="width: 8%; text-align: right" title="ENDING BALANCE">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--SharesIssued_iI_d0_c20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1DPreferredMember_fKg_____zh9E46OF7Ctf" style="width: 8%; text-align: right" title="SHARES HELD">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> </table><p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr> <td style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>AFFILIATE/<br/> CONTROLLED <br/> INVESTMENTS<span style="font-size: 11pt; vertical-align: bottom">*</span></b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>VALUE AT <br/> 12/31/22</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>PURCHASE/ <br/> MERGER</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>INTEREST</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>SALES/ <br/> MATURITY/ <br/> EXPIRATION</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>REALIZED <br/> GAIN (LOSS)</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>CHANGE IN <br/> APPRECIATION/ <br/> DEPRECIATION</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>VALUE <br/> 6/30/23</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>SHARES HELD <br/> AT 6/30/23</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Silicon Genesis Corp. Series 1-E Preferred<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_98F_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1EPreferredMember_fKg_____zJDuxYCFzbui" style="width: 8%; text-align: right" title="BEGINNING BALANCE">320,592</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_984_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1EPreferredMember_fKg_____z1cxmRK5tS5f" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_983_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1EPreferredMember_fKg_____zmdydeosmg09" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_983_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1EPreferredMember_fKg_____zLz48UfVAKWg" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">(49,292</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_980_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1EPreferredMember_fKg_____zH6khQlpqGH6" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">(2,323,111</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_98E_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1EPreferredMember_fKg_____ztDm4rxN9jpe" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">2,051,811</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_988_eus-gaap--Investments_iE_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1EPreferredMember_fKg_____zZxV0TXWSnWh" style="width: 8%; text-align: right" title="ENDING BALANCE">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--SharesIssued_iI_d0_c20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1EPreferredMember_fKg_____zJXvpFLutHS4" style="width: 8%; text-align: right" title="SHARES HELD">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Silicon Genesis Corp. Series 1-F Preferred<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_981_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1FPreferredMember_fKg_____zhrMnLrqTo87" style="width: 8%; text-align: right" title="BEGINNING BALANCE">70,806</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1FPreferredMember_fKg_____zhtl36Vxdv55" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1FPreferredMember_fKg_____zUVkEg2sZPXf" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1FPreferredMember_fKg_____zSG4ETEapr61" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">(7,885</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1FPreferredMember_fKg_____zB2RCdmCXul5" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">(448,504</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1FPreferredMember_fKg_____zEl4wB1w5kk3" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">385,583</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--Investments_iE_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1FPreferredMember_fKg_____zUz5qJ5VuZjk" style="width: 8%; text-align: right" title="ENDING BALANCE">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--SharesIssued_iI_d0_c20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1FPreferredMember_fKg_____z2NB9qcLXC9" style="width: 8%; text-align: right" title="SHARES HELD">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Silicon Genesis Corp. Series 1-C Preferred Stock<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1CPreferredStockMember_fKg_____zc96uZAeCRs" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="BEGINNING BALANCE">962</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_981_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1CPreferredStockMember_fKg_____z1h3WILbBpu2" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1CPreferredStockMember_fKg_____z2ZbiTGosCL" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="INTEREST">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1CPreferredStockMember_fKg_____zDOJn0RNlPQ5" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">(716</td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left">)</td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1CPreferredStockMember_fKg_____zGAytvj8nrf8" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">(108,802</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left">)</td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98A_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1CPreferredStockMember_fKg_____zBfMlJFDBKfi" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">108,556</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--Investments_iE_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1CPreferredStockMember_fKg_____z7GSsN1cVEQe" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="ENDING BALANCE">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--SharesIssued_iI_d0_c20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1CPreferredStockMember_fKg_____zdyMhatB7kA2" style="width: 8%; text-align: right" title="SHARES HELD">—</td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Total Intellectual Property</p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_982_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--IntellectualsPropertyMember_zkl6KasMskcj" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="BEGINNING BALANCE">737,224</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_984_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--IntellectualsPropertyMember_zqPxTJvRfxt4" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="INTEREST">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_981_eus-gaap--DebtAndEquitySecuritiesGainLoss_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--IntellectualsPropertyMember_pp0p0" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">(7,864,997</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left">)</td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_987_ecustom--ChangeInAppreciationdepreciation_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--IntellectualsPropertyMember_pp0p0" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">7,626,109</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_985_eus-gaap--Investments_iE_pp0p0_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--IntellectualsPropertyMember_zUNZRWWbs8r6" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="ENDING BALANCE">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt"><b>Advanced Materials</b></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">UCT Coatings, Inc. Common Stock</p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--UCTCoatingsIncCommonStockMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancedMaterialsMember_zqlWJUlnmm86" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="BEGINNING BALANCE">337,500</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--UCTCoatingsIncCommonStockMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancedMaterialsMember_zFm1scRxZM0j" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--UCTCoatingsIncCommonStockMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancedMaterialsMember_z69hgGZouIBa" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="INTEREST">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--UCTCoatingsIncCommonStockMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancedMaterialsMember_z3YF6dqgBE2g" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--UCTCoatingsIncCommonStockMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancedMaterialsMember_zKqlmmTVHpL8" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_980_ecustom--ChangeInAppreciationdepreciation_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--UCTCoatingsIncCommonStockMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancedMaterialsMember_pp0p0" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(71,409</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left">)</td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--UCTCoatingsIncCommonStockMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancedMaterialsMember_zPbHt6b2BDmi" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="ENDING BALANCE">266,091</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_eus-gaap--SharesIssued_c20230630__us-gaap--InvestmentTypeAxis__custom--UCTCoatingsIncCommonStockMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancedMaterialsMember_pdd" style="width: 8%; text-align: right" title="SHARES HELD">1,500,000</td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Total Advanced Materials</p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_98F_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancedMaterialsMember_zfEAqU8grxDf" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="BEGINNING BALANCE">337,500</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_98F_eus-gaap--InterestIncomeExpenseNet_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancedMaterialsMember_zNxwt83Bby19" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="INTEREST">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_988_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancedMaterialsMember_zxTXlnWR0qP5" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_983_ecustom--ChangeInAppreciationdepreciation_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancedMaterialsMember_pp0p0" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(71,409</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left">)</td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_98D_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancedMaterialsMember_zb0iVkE6ET42" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="ENDING BALANCE">266,091</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt"><b>Automotive</b></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Common Stock<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncCommonStockMember_fKg_____zQZcVmOU52of" style="width: 8%; text-align: right" title="BEGINNING BALANCE">546</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncCommonStockMember_fKg_____zSULLBNukPGj" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncCommonStockMember_fKg_____ze2HHcjazTIk" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncCommonStockMember_fKg_____zhvUMMfVQOUg" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncCommonStockMember_fKg_____zWlaEhWbri1" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncCommonStockMember_fKg_____zKTLzvZHkSDj" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(235</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncCommonStockMember_fKg_____zTCDAWgZq4T4" style="width: 8%; text-align: right" title="ENDING BALANCE">311</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncCommonStockMember_fKg_____z8vI8AHH5KQf" style="width: 8%; text-align: right" title="SHARES HELD">69,102</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNoteMember_fKg_____zm3PpfNcX4yd" style="width: 8%; text-align: right" title="BEGINNING BALANCE">65,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNoteMember_fKg_____zClGphsYrIhj" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNoteMember_fKg_____ztMrRHtj5RO5" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNoteMember_fKg_____zTC3JM7mDJB1" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNoteMember_fKg_____z0wiF3qGap17" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNoteMember_fKg_____zwQmPXyEjcuk" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(45,500</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNoteMember_fKg_____zElzK6TigJI" style="width: 8%; text-align: right" title="ENDING BALANCE">19,500</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNoteMember_fKg_____zc7IwOp5FBuc" style="width: 8%; text-align: right" title="SHARES HELD">200,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote1Member_fKg_____zMHYFBrmBm4" style="width: 8%; text-align: right" title="BEGINNING BALANCE">60,125</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote1Member_fKg_____zSpaxfh0p0h2" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote1Member_fKg_____zZrOILMYgc8a" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote1Member_fKg_____z7vagtx4BXpi" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote1Member_fKg_____zTbGD1t7hxDf" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote1Member_fKg_____zvEujEsp3NBc" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(42,088</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote1Member_fKg_____z4jHZXlOtLae" style="width: 8%; text-align: right" title="ENDING BALANCE">18,037</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote1Member_fKg_____zuYQcBzlPUSk" style="width: 8%; text-align: right" title="SHARES HELD">185,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote2Member_fKg_____zfZbI2cybUOl" style="width: 8%; text-align: right" title="BEGINNING BALANCE">21,125</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote2Member_fKg_____zBQp7DmQrbU" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote2Member_fKg_____zrwyfkGr56Zd" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote2Member_fKg_____zqQ4g0o8Cn8i" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote2Member_fKg_____zX8K5eAJDOa3" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote2Member_fKg_____z9bgHuj3Mowb" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(14,788</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote2Member_fKg_____z4UEgPczMhF7" style="width: 8%; text-align: right" title="ENDING BALANCE">6,337</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote2Member_fKg_____zflmcc0JwwUe" style="width: 8%; text-align: right" title="SHARES HELD">65,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote3Member_fKg_____zzjsYL4lFBV2" style="width: 8%; text-align: right" title="BEGINNING BALANCE">81,250</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote3Member_fKg_____zaBTo4zWtQi4" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_988_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote3Member_fKg_____zOjQ6166PlQl" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote3Member_fKg_____z4jnVtCFYvVl" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote3Member_fKg_____zQPWIaDnrC31" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote3Member_fKg_____z74P0uKsPFu5" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(56,875</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote3Member_fKg_____zd1XEo5uWTyh" style="width: 8%; text-align: right" title="ENDING BALANCE">24,375</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote3Member_fKg_____zWOfA7ZvM6yh" style="width: 8%; text-align: right" title="SHARES HELD">250,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote4Member_fKg_____zbZRhYGzWVj7" style="width: 8%; text-align: right" title="BEGINNING BALANCE">81,250</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote4Member_fKg_____zwp7mi4WnVz6" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote4Member_fKg_____zawafiym4j9" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote4Member_fKg_____z53EAhQ1KBze" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote4Member_fKg_____zABomsohf491" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98C_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote4Member_fKg_____zjaW1c8IUJF6" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(56,875</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote4Member_fKg_____zxaDRdLryuT8" style="width: 8%; text-align: right" title="ENDING BALANCE">24,375</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote4Member_fKg_____zaR3H1NQyGN6" style="width: 8%; text-align: right" title="SHARES HELD">250,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote5Member_fKg_____zvdtMqWK7r3f" style="width: 8%; text-align: right" title="BEGINNING BALANCE">81,250</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote5Member_fKg_____zXSLTysCvQDb" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote5Member_fKg_____zNzAO4Px6Nuj" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote5Member_fKg_____zEpvZzJ97qHk" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote5Member_fKg_____zkQASy32VRtf" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote5Member_fKg_____zJiTeEYfxSVb" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(56,875</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote5Member_fKg_____z8nEgC2vZ1xh" style="width: 8%; text-align: right" title="ENDING BALANCE">24,375</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote5Member_fKg_____zuIVf6XtlVoj" style="width: 8%; text-align: right" title="SHARES HELD">250,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote6Member_fKg_____zW3FiQFCHg34" style="width: 8%; text-align: right" title="BEGINNING BALANCE">227,500</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote6Member_fKg_____zof97qOI9C25" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote6Member_fKg_____zyu8kR7TSCFh" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote6Member_fKg_____zGhyE2lC5hGa" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote6Member_fKg_____zS3Zqm0B10Fk" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_988_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote6Member_fKg_____zvfdnZfWLXFi" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(159,250</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote6Member_fKg_____zhK5kXPJxY81" style="width: 8%; text-align: right" title="ENDING BALANCE">68,250</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote6Member_fKg_____zFRZ9LG6OGLc" style="width: 8%; text-align: right" title="SHARES HELD">700,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote7Member_fKg_____zwoWTaYMaDlf" style="width: 8%; text-align: right" title="BEGINNING BALANCE">81,250</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote7Member_fKg_____zszfatOwfcJ2" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote7Member_fKg_____zWw2lWM18hR2" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote7Member_fKg_____zMAqMffd7cQk" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote7Member_fKg_____zkZUyfK8nw61" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote7Member_fKg_____z3ttL6tk2eEi" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(56,875</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote7Member_fKg_____ztMgrzN3A3le" style="width: 8%; text-align: right" title="ENDING BALANCE">24,375</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote7Member_fKg_____zKGPFDqSlhG1" style="width: 8%; text-align: right" title="SHARES HELD">250,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote8Member_fKg_____zgQsUyZA5s2f" style="width: 8%; text-align: right" title="BEGINNING BALANCE">81,250</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote8Member_fKg_____zGiAOPgl2Dp6" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote8Member_fKg_____z5DwEkpzvByb" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote8Member_fKg_____zGa1y5TviTT9" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote8Member_fKg_____zVvuuRkzTgO8" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote8Member_fKg_____zGziMHHVGlK2" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(56,875</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote8Member_fKg_____zHjGz6m8CeFf" style="width: 8%; text-align: right" title="ENDING BALANCE">24,375</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote8Member_fKg_____z7Ut4XW7jsDd" style="width: 8%; text-align: right" title="SHARES HELD">250,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote9Member_fKg_____zUu30g53F9u3" style="width: 8%; text-align: right" title="BEGINNING BALANCE">81,250</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote9Member_fKg_____zBec1gZryoS2" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote9Member_fKg_____zivs1ExZHNR3" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote9Member_fKg_____znX1jkgQdE91" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote9Member_fKg_____zQsT0EZ7Xkje" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote9Member_fKg_____zMBPUuOrreMk" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(56,875</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote9Member_fKg_____zdtJN2WOLXh4" style="width: 8%; text-align: right" title="ENDING BALANCE">24,375</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote9Member_fKg_____zWVKEzbYT6f" style="width: 8%; text-align: right" title="SHARES HELD">250,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote10Member_fKg_____znCb4f3lX9De" style="width: 8%; text-align: right" title="BEGINNING BALANCE">43,875</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote10Member_fKg_____z142alAgGWJc" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote10Member_fKg_____zg9kf0WlwZLl" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote10Member_fKg_____zbSgzAAeqWla" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote10Member_fKg_____z6SPlekPCoT4" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote10Member_fKg_____zbz6zkYlGCqa" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(30,713</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_988_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote10Member_fKg_____zTMVMSSVOPOd" style="width: 8%; text-align: right" title="ENDING BALANCE">13,162</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote10Member_fKg_____zMkPNziMEQn1" style="width: 8%; text-align: right" title="SHARES HELD">135,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_988_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote11Member_fKg_____zp97H6ziNNTl" style="width: 8%; text-align: right" title="BEGINNING BALANCE">53,625</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote11Member_fKg_____zJ78jaHWnDQc" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote11Member_fKg_____zV0DPF2T7bzf" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote11Member_fKg_____zCz2ikW9egy6" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote11Member_fKg_____zEXNvK2uLcSg" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote11Member_fKg_____z02aqazqFnng" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(37,537</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote11Member_fKg_____zmBHPDOkfkd7" style="width: 8%; text-align: right" title="ENDING BALANCE">16,088</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote11Member_fKg_____z0r5SO5hAB97" style="width: 8%; text-align: right" title="SHARES HELD">165,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> </table><p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr> <td style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>AFFILIATE/<br/> CONTROLLED <br/> INVESTMENTS<span style="font-size: 11pt; vertical-align: bottom">*</span></b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>VALUE AT <br/> 12/31/22</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>PURCHASE/ <br/> MERGER</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>INTEREST</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>SALES/ <br/> MATURITY/ <br/> EXPIRATION</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>REALIZED <br/> GAIN (LOSS)</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>CHANGE IN <br/> APPRECIATION/ <br/> DEPRECIATION</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>VALUE <br/> 6/30/23</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>SHARES HELD <br/> AT 6/30/23</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_986_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote12Member_fKg_____z8yEHWnMNUVj" style="width: 8%; text-align: right" title="BEGINNING BALANCE">40,625</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_988_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote12Member_fKg_____zMuRd8obMT07" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_982_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote12Member_fKg_____zfTQ1GGnQEU1" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_989_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote12Member_fKg_____zN94SF9Fdxka" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_982_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote12Member_fKg_____zHtVx6F5DYwj" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_984_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote12Member_fKg_____zJF7L8WDMJg8" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(28,437</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_98B_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote12Member_fKg_____zAoM4tkwPdY7" style="width: 8%; text-align: right" title="ENDING BALANCE">12,188</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote12Member_fKg_____ztyVBueuNq81" style="width: 8%; text-align: right" title="SHARES HELD">125,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--Investments_iS_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote13Member_fKg_____zWGDD195dPFl" style="width: 8%; text-align: right" title="BEGINNING BALANCE">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_988_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote13Member_fKg_____zEq4w0KyL8P7" style="width: 8%; text-align: right" title="PURCHASE/MERGER">100,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote13Member_fKg_____zxYz6824J8q6" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote13Member_fKg_____zkoB1DTnNJ16" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote13Member_fKg_____zSNHWNzuUCEe" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote13Member_fKg_____zcFZst5tuGSd" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(90,250</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote13Member_fKg_____zd3P1wkHSrBd" style="width: 8%; text-align: right" title="ENDING BALANCE">9,750</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote13Member_fKg_____zADfNmQ5dZvb" style="width: 8%; text-align: right" title="SHARES HELD">100,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote14Member_fKg_____zzXpfnllE6Nd" style="width: 8%; text-align: right" title="BEGINNING BALANCE">81,250</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote14Member_fKg_____zEYQBKHRUrc7" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote14Member_fKg_____zBBcpWa3Qic4" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote14Member_fKg_____zJQNiFQwygwh" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_981_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote14Member_fKg_____zsp39HBqJIcg" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_981_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote14Member_fKg_____z9x4JBF7KQyg" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(56,875</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote14Member_fKg_____zOIMGNV3MjY2" style="width: 8%; text-align: right" title="ENDING BALANCE">24,375</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote14Member_fKg_____zu5gHwZdFfG3" style="width: 8%; text-align: right" title="SHARES HELD">250,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote15Member_fKg_____z3QuzvCXroR3" style="width: 8%; text-align: right" title="BEGINNING BALANCE">325,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote15Member_fKg_____zC0B3qhx81tc" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote15Member_fKg_____zZPZ2oVJmDMg" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote15Member_fKg_____zP2y8n4rYI9i" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote15Member_fKg_____zFfDXJmUWja4" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote15Member_fKg_____z59pkQozfDFg" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(227,500</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote15Member_fKg_____zkYZpxhDEQkl" style="width: 8%; text-align: right" title="ENDING BALANCE">97,500</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote15Member_fKg_____zptq7OCWYsg7" style="width: 8%; text-align: right" title="SHARES HELD">1,000,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote16Member_fKg_____zonnnEldsqSd" style="width: 8%; text-align: right" title="BEGINNING BALANCE">325,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote16Member_fKg_____zs2qpkiQgL4k" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_988_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote16Member_fKg_____z3pm8eJtRh3k" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote16Member_fKg_____zndXPVhF2lY2" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote16Member_fKg_____zjZwnvSH1R6h" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote16Member_fKg_____zP4rFhTN0we" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(227,500</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote16Member_fKg_____zQ1Je9JLIkea" style="width: 8%; text-align: right" title="ENDING BALANCE">97,500</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote16Member_fKg_____zb9eDjcFHhm3" style="width: 8%; text-align: right" title="SHARES HELD">1,000,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote17Member_fKg_____zKCU4KTgV5wk" style="width: 8%; text-align: right" title="BEGINNING BALANCE">325,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_988_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote17Member_fKg_____zoMgduadq9Wl" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote17Member_fKg_____zCSpygoG0gP4" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote17Member_fKg_____z5mPP9Lu5b82" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote17Member_fKg_____zgRFF4ZxPxJ6" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote17Member_fKg_____zOoBTvTYJkke" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(227,500</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote17Member_fKg_____zQn7mnqhdHsg" style="width: 8%; text-align: right" title="ENDING BALANCE">97,500</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote17Member_fKg_____zqw6OXg186l2" style="width: 8%; text-align: right" title="SHARES HELD">1,000,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote18Member_fKg_____zon1pp6H8RT3" style="width: 8%; text-align: right" title="BEGINNING BALANCE">1,601,930</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote18Member_fKg_____zbIcoQQvhhea" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote18Member_fKg_____zWZwHK4RjS99" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote18Member_fKg_____zTQ1U9R1W0Nj" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote18Member_fKg_____zrAutqtuej0d" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98C_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote18Member_fKg_____zKwpnQROYv2i" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(1,121,351</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote18Member_fKg_____zV36ObNN27B4" style="width: 8%; text-align: right" title="ENDING BALANCE">480,579</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote18Member_fKg_____zGv35C29auda" style="width: 8%; text-align: right" title="SHARES HELD">4,929,015</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote19Member_fKg_____zQshFMNpXzl7" style="width: 8%; text-align: right" title="BEGINNING BALANCE">243,750</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote19Member_fKg_____zqmKSfcJXEb4" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote19Member_fKg_____zPm2XMRCaMK7" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote19Member_fKg_____ze2kCX14QSr" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote19Member_fKg_____zRrBWkXjXI74" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote19Member_fKg_____zNRrnu6VcAEd" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(170,625</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote19Member_fKg_____z1pk2hX13TCf" style="width: 8%; text-align: right" title="ENDING BALANCE">73,125</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote19Member_fKg_____z8vk4lwKEZX5" style="width: 8%; text-align: right" title="SHARES HELD">750,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote20Member_fKg_____z6DA2EQIctja" style="width: 8%; text-align: right" title="BEGINNING BALANCE">292,500</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote20Member_fKg_____zeiymRU0kfWl" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote20Member_fKg_____zykIpvSL7eol" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote20Member_fKg_____z7zSik4DMd5f" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote20Member_fKg_____zfCreHiB6THi" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote20Member_fKg_____zdpV1ftmxiui" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(204,750</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote20Member_fKg_____zL4YjSSMXIq1" style="width: 8%; text-align: right" title="ENDING BALANCE">87,750</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_988_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote20Member_fKg_____zrM13GrIVRLh" style="width: 8%; text-align: right" title="SHARES HELD">900,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote21Member_fKg_____zMMHVdauEUC4" style="width: 8%; text-align: right" title="BEGINNING BALANCE">121,875</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_988_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote21Member_fKg_____zlOPyn376co8" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote21Member_fKg_____zPnQTTxm6eKa" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote21Member_fKg_____zoNqVYappMGi" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote21Member_fKg_____zP2mUt6Dm0fb" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote21Member_fKg_____zwRM4kdw2BL3" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(85,313</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote21Member_fKg_____zcW8y4TNBiq5" style="width: 8%; text-align: right" title="ENDING BALANCE">36,562</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote21Member_fKg_____zgXPza1SY6rc" style="width: 8%; text-align: right" title="SHARES HELD">375,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote22Member_fKg_____zG3qAwmQQghl" style="width: 8%; text-align: right" title="BEGINNING BALANCE">130,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote22Member_fKg_____zJwco4LKQYR4" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote22Member_fKg_____zp59qBqWaAKk" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote22Member_fKg_____zCwvLE1NKPVj" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote22Member_fKg_____zRzTsIAdTFJl" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote22Member_fKg_____z3g1VIgTVak9" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(91,000</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote22Member_fKg_____zCUl2uGz0S08" style="width: 8%; text-align: right" title="ENDING BALANCE">39,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote22Member_fKg_____zDKrkNreWV5a" style="width: 8%; text-align: right" title="SHARES HELD">400,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote23Member_fKg_____zL069o5tjNPj" style="width: 8%; text-align: right" title="BEGINNING BALANCE">341,250</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote23Member_fKg_____zhTCMFNQXtA5" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote23Member_fKg_____zYzF8BzHvCT1" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote23Member_fKg_____zyQWxLQBeS19" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote23Member_fKg_____zgMMhhan0MGf" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote23Member_fKg_____zjYrSGIc86y5" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(238,875</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote23Member_fKg_____zUW8ENunvsPd" style="width: 8%; text-align: right" title="ENDING BALANCE">102,375</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote23Member_fKg_____zAQjiIBILa61" style="width: 8%; text-align: right" title="SHARES HELD">1,050,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote24Member_fKg_____z32vsz4GcUD8" style="width: 8%; text-align: right" title="BEGINNING BALANCE">325,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote24Member_fKg_____zZAQZMexT1Tb" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote24Member_fKg_____zZphocxgZIqj" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote24Member_fKg_____zblzGukaUqvh" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote24Member_fKg_____zji8yNYOOoM9" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote24Member_fKg_____zefw7s8vVi58" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(227,500</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote24Member_fKg_____zP5dvfXPrd4i" style="width: 8%; text-align: right" title="ENDING BALANCE">97,500</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote24Member_fKg_____z8yf9nrwJ1M5" style="width: 8%; text-align: right" title="SHARES HELD">1,000,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote25Member_fKg_____zCju34ecavab" style="width: 8%; text-align: right" title="BEGINNING BALANCE">325,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_981_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote25Member_fKg_____zLb0aUZmV8A9" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote25Member_fKg_____zbWRzHRWYZFl" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote25Member_fKg_____zef3oDFkR2C7" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote25Member_fKg_____zgpM8amz27f5" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote25Member_fKg_____zPuqbXHHOCHg" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(227,500</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote25Member_fKg_____zONd9KBt1cNg" style="width: 8%; text-align: right" title="ENDING BALANCE">97,500</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote25Member_fKg_____zpn1CmqRENMi" style="width: 8%; text-align: right" title="SHARES HELD">1,000,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote26Member_fKg_____zJehtCUri3S4" style="width: 8%; text-align: right" title="BEGINNING BALANCE">325,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote26Member_fKg_____zOJMozRED0Jh" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote26Member_fKg_____zD5crtxNpgbf" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_988_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote26Member_fKg_____zsqLR4huH8ve" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote26Member_fKg_____zIMErWtSo9a9" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote26Member_fKg_____zZp6RzFBZV6k" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(227,500</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote26Member_fKg_____zsiwEzMmN5fh" style="width: 8%; text-align: right" title="ENDING BALANCE">97,500</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote26Member_fKg_____zn8LMOIRGis8" style="width: 8%; text-align: right" title="SHARES HELD">1,000,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote27Member_fKg_____zi9yVmlgHmVd" style="width: 8%; text-align: right" title="BEGINNING BALANCE">390,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote27Member_fKg_____zkGWBn0i3Ru5" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote27Member_fKg_____z8JfJXKtMYz3" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote27Member_fKg_____zXDicwQewYF2" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_981_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote27Member_fKg_____zJIth8X2tJO" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote27Member_fKg_____zgIZal7aWuKb" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(273,000</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote27Member_fKg_____zp7TmaaD2Ea4" style="width: 8%; text-align: right" title="ENDING BALANCE">117,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote27Member_fKg_____z9J9DGJVxZsk" style="width: 8%; text-align: right" title="SHARES HELD">1,200,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote28Member_fKg_____z3NQ732bAkCk" style="width: 8%; text-align: right" title="BEGINNING BALANCE">455,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote28Member_fKg_____zaL1T4rFcIp1" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote28Member_fKg_____zM8BPRvzpnT8" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote28Member_fKg_____zkhlNym09RF2" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote28Member_fKg_____zUzsCoe6Dgq2" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote28Member_fKg_____zKbkNtN5yNzg" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(318,500</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote28Member_fKg_____zi4IyCdPR765" style="width: 8%; text-align: right" title="ENDING BALANCE">136,500</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote28Member_fKg_____zGKQcdQuEllc" style="width: 8%; text-align: right" title="SHARES HELD">1,400,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote29Member_fKg_____zVtay282Cj7e" style="width: 8%; text-align: right" title="BEGINNING BALANCE">650,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote29Member_fKg_____zKmvnFLnvQda" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote29Member_fKg_____zTI8Oc0f2eTf" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote29Member_fKg_____zCk0IqjIUttb" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote29Member_fKg_____zl7o494tZk0i" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote29Member_fKg_____zpr9jsDrLct2" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(455,000</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote29Member_fKg_____z8926RZTFYbi" style="width: 8%; text-align: right" title="ENDING BALANCE">195,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote29Member_fKg_____zKpq67v2wiBh" style="width: 8%; text-align: right" title="SHARES HELD">2,000,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote30Member_fKg_____zCVvrMubrjLb" style="width: 8%; text-align: right" title="BEGINNING BALANCE">130,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote30Member_fKg_____z1bgbZmSHqI6" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote30Member_fKg_____zAIaVzGzWvmf" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote30Member_fKg_____z5VCm6VvVFN2" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote30Member_fKg_____zIgpsxw9qsJa" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote30Member_fKg_____zBVraxTaS7q" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(91,000</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote30Member_fKg_____zNVViyae0X4h" style="width: 8%; text-align: right" title="ENDING BALANCE">39,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_981_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote30Member_fKg_____zpPyd1Vlrhc2" style="width: 8%; text-align: right" title="SHARES HELD">400,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote31Member_fKg_____zWjw5n7kXWpe" style="width: 8%; text-align: right" title="BEGINNING BALANCE">97,500</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote31Member_fKg_____zl8aJJN4aMt6" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote31Member_fKg_____zgdHC01PCjqe" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote31Member_fKg_____z7R4kDrgrdQj" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote31Member_fKg_____zRPjgKlESy81" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote31Member_fKg_____zwkWRQNSzpql" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(68,250</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote31Member_fKg_____zjLpclTxZeAl" style="width: 8%; text-align: right" title="ENDING BALANCE">29,250</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote31Member_fKg_____zQJUrvWOb3I6" style="width: 8%; text-align: right" title="SHARES HELD">300,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote32Member_fKg_____zhw8U83ciWM5" style="width: 8%; text-align: right" title="BEGINNING BALANCE">325,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote32Member_fKg_____zrc6T0PFqVfa" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote32Member_fKg_____zOCeuywaA5R2" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote32Member_fKg_____zHUEOUnkhtIk" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote32Member_fKg_____zvqXOHt5kmu" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote32Member_fKg_____zhEq5RKVOZQ" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(227,500</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote32Member_fKg_____zv7zQGFZhOCe" style="width: 8%; text-align: right" title="ENDING BALANCE">97,500</td> <td style="padding-left: -10pt; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote32Member_fKg_____zOn98lo6yGgj" style="width: 8%; text-align: right" title="SHARES HELD">1,000,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> </table><p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr> <td style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>AFFILIATE/<br/> CONTROLLED <br/> INVESTMENTS<span style="font-size: 11pt; vertical-align: bottom">*</span></b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>VALUE AT <br/> 12/31/22</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>PURCHASE/ <br/> MERGER</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>INTEREST</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>SALES/ <br/> MATURITY/ <br/> EXPIRATION</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>REALIZED <br/> GAIN (LOSS)</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>CHANGE IN <br/> APPRECIATION/ <br/> DEPRECIATION</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>VALUE <br/> 6/30/23</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>SHARES HELD <br/> AT 6/30/23</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Series AA Preferred<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_989_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncSeriesAAPreferredMember_fKg_____zF1IAHpOPQac" style="width: 8%; text-align: right" title="BEGINNING BALANCE">1,049,478</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_98F_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncSeriesAAPreferredMember_fKg_____zyp1OO5Ft9g3" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_98D_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncSeriesAAPreferredMember_fKg_____zNAOa7IHSwRc" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_989_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncSeriesAAPreferredMember_fKg_____zs8sy0PBngEk" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_982_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncSeriesAAPreferredMember_fKg_____zbWRZU3CO5C4" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_989_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncSeriesAAPreferredMember_fKg_____z23vpje5KQy6" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(476,245</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_988_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncSeriesAAPreferredMember_fKg_____zVBSTUacFcY1" style="width: 8%; text-align: right" title="ENDING BALANCE">573,233</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncSeriesAAPreferredMember_fKg_____zV6W9RhXvpPi" style="width: 8%; text-align: right" title="SHARES HELD">60,733,693</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Series AA Warrants<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncSeriesAAWarrantsMember_fKg_____zlO53qkGD6n8" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="BEGINNING BALANCE">3,232</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncSeriesAAWarrantsMember_fKg_____zSSPHDGyIJVe" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncSeriesAAWarrantsMember_fKg_____z6Qrac95DRZ2" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="INTEREST">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncSeriesAAWarrantsMember_fKg_____zrQ79SQrgeR8" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncSeriesAAWarrantsMember_fKg_____zILooApMRDbf" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98B_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncSeriesAAWarrantsMember_fKg_____zm3zWPML6eq7" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(3,232</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left">)</td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--Investments_iE_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncSeriesAAWarrantsMember_fKg_____zRUIjInvYC2h" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="ENDING BALANCE">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--SharesIssued_iI_d0_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncSeriesAAWarrantsMember_fKg_____zbuSataAshri" style="width: 8%; text-align: right" title="SHARES HELD">—</td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Total Automotive</p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_98C_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember_zquhqRn2UBLc" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="BEGINNING BALANCE">8,862,686</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_980_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember_zD2KiryuoJN3" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="INTEREST">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_984_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember_zZf5XvmjGmX4" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_98C_ecustom--ChangeInAppreciationdepreciation_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember_pp0p0" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(6,036,564</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left">)</td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_985_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember_ztGfVRD8X2f7" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="ENDING BALANCE">2,926,122</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Total Affiliates and Controlled Investments</p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_984_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--TotalAffiliatesAndControlledInvestmentsMember_zSreAFVmnaEj" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="BEGINNING BALANCE">39,349,502</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_987_eus-gaap--InterestIncomeExpenseNet_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--TotalAffiliatesAndControlledInvestmentsMember_pp0p0" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="INTEREST">299,467</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_98C_eus-gaap--DebtAndEquitySecuritiesGainLoss_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--TotalAffiliatesAndControlledInvestmentsMember_pp0p0" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">(7,864,997</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left">)</td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_984_ecustom--ChangeInAppreciationdepreciation_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--TotalAffiliatesAndControlledInvestmentsMember_pp0p0" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(11,140,362</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left">)</td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_98E_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--TotalAffiliatesAndControlledInvestmentsMember_zcTtCJuiDIe2" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="ENDING BALANCE">19,945,807</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Total Affiliates</p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--AffiliatesMember_z4n2J9MzTcM7" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="BEGINNING BALANCE">337,500</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_983_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--AffiliatesMember_zxbpl5gCwbzc" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="INTEREST">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--AffiliatesMember_zTXHo5GqxNE6" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98E_ecustom--ChangeInAppreciationdepreciation_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--AffiliatesMember_pp0p0" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(71,409</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left">)</td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--AffiliatesMember_zAHyeLWcDMDj" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="ENDING BALANCE">266,091</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Total Controlled Investments</p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td> <td id="xdx_986_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--ControlledInvestmentsMember_zupMH0YRC5l6" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right" title="BEGINNING BALANCE">39,012,002</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; padding-bottom: 2.5pt; text-align: left"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td> <td id="xdx_980_eus-gaap--InterestIncomeExpenseNet_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--ControlledInvestmentsMember_pp0p0" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right" title="INTEREST">299,467</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; padding-bottom: 2.5pt; text-align: left"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td> <td id="xdx_981_eus-gaap--DebtAndEquitySecuritiesGainLoss_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--ControlledInvestmentsMember_pp0p0" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">(7,864,997</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; text-align: left">)</td> <td style="border-bottom: Black 2.5pt double; width: 1%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td> <td id="xdx_98D_ecustom--ChangeInAppreciationdepreciation_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--ControlledInvestmentsMember_pp0p0" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(11,068,953</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; text-align: left">)</td> <td style="border-bottom: Black 2.5pt double; width: 1%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td> <td id="xdx_98E_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--ControlledInvestmentsMember_zwlKHY4tlgx2" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right" title="ENDING BALANCE">19,679,716</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; padding-bottom: 2.5pt; text-align: left"> </td> </tr> </table><p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="width: 18pt; vertical-align: top; text-align: right"> <p style="font: 11pt Times New Roman; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><i><span id="xdx_F0E_ztKPcbqFcw17" style="font-size: 11pt; vertical-align: bottom">*</span> </i> </p> </td> <td style="vertical-align: top; text-align: left"> <p style="font: 11pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><i id="xdx_F17_zXqkD6M2g9K4">Controlled Investments. </i></p> </td> </tr> </table> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="width: 18pt; vertical-align: top; text-align: right"> <p style="font: 11pt Times New Roman; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><i id="xdx_F02_zDXLVb38Bs3">(1)</i></p> </td> <td style="vertical-align: top; text-align: left"> <p style="font: 11pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"> <i id="xdx_F1F_zA7pwRCgtjOe">CDI: CHESS Depositary Interest </i></p> </td> </tr> </table> <p id="xdx_8A2_zG7xa7Har3i3" style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">As of June 30, 2023, Kevin Landis, the Company’s Chairman, President and Chief Executive Officer, represented the Company and sat on the boards of directors of Hera Systems, Inc.; IntraOp Medical Corp.; Revasum, Inc.; and Wrightspeed, Inc. As of June 30,2023, Mr. Landis served as interim CEO at IntraOp Medical Corp. and Wrightspeed, Inc. Serving as a director or officer of portfolio companies may cause conflicts of interest. The Advisor has adopted various procedures to ensure that the Company will not be unfavorably affected by these potential conflicts. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfInvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTableTextBlock_zFMbo9NihVUi" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INVESTMENTS IN AFFILIATES AND CONTROLLED INVESTMENTS (Details)"> <tr style="vertical-align: bottom"> <td id="xdx_8BC_zT1SFKJpDSbk" style="display: none; vertical-align: bottom">Schedule of investments in affiliates and controlled investments</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td></tr> <tr> <td style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>AFFILIATE/<br/> CONTROLLED <br/> INVESTMENTS<span style="font-size: 11pt; vertical-align: bottom">*</span></b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>VALUE AT <br/> 12/31/22</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>PURCHASE/ <br/> MERGER</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>INTEREST</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>SALES/ <br/> MATURITY/ <br/> EXPIRATION</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>REALIZED <br/> GAIN (LOSS)</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>CHANGE IN <br/> APPRECIATION/ <br/> DEPRECIATION</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>VALUE <br/> 6/30/23</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>SHARES HELD <br/> AT 6/30/23</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt"><b>Equipment Leasing</b></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">EQX Capital, Inc. Common Stock<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_983_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--EQXCapitalIncCommonStockMember_fKg_____zNU26Eju2qb5" style="width: 8%; text-align: right" title="BEGINNING BALANCE">11,130</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_980_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--EQXCapitalIncCommonStockMember_fKg_____zge2Q3EBi1c" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_987_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--EQXCapitalIncCommonStockMember_fKg_____z8EX75O0whH4" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_984_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--EQXCapitalIncCommonStockMember_fKg_____zYGbn4qPXECf" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_984_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--EQXCapitalIncCommonStockMember_fKg_____znfwsAyjIgX4" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_980_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--EQXCapitalIncCommonStockMember_fKg_____zFWcfYpqsGx3" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(9,250</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_989_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--EQXCapitalIncCommonStockMember_fKg_____zS2uqP5UUdrj" style="width: 8%; text-align: right" title="ENDING BALANCE">1,880</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--EQXCapitalIncCommonStockMember_fKg_____zweiGi7rMuDk" style="width: 8%; text-align: right" title="SHARES HELD">100,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">EQX Capital, Inc. Series A Preferred Stock<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_981_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--EQXCapitalIncSeriesAPreferredStockMember_fKg_____zoKQLW6Eiax4" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="BEGINNING BALANCE">865,995</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_981_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--EQXCapitalIncSeriesAPreferredStockMember_fKg_____zqX66hfnx5Xd" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--EQXCapitalIncSeriesAPreferredStockMember_fKg_____z0vuLE24pMki" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="INTEREST">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--EQXCapitalIncSeriesAPreferredStockMember_fKg_____z83zSsjSmn5j" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--EQXCapitalIncSeriesAPreferredStockMember_fKg_____zlqc2yHdwNZh" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98C_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--EQXCapitalIncSeriesAPreferredStockMember_fKg_____zMRYsqpfyqNc" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(482,239</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left">)</td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--EQXCapitalIncSeriesAPreferredStockMember_fKg_____zMqGTBPSkRy1" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="ENDING BALANCE">383,756</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--EQXCapitalIncSeriesAPreferredStockMember_fKg_____zWKguriRazFe" style="width: 8%; text-align: right" title="SHARES HELD">1,950,000</td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Total Equipment Leasing</p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_984_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentLeasingMember_z9DoIWTAL8F2" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="BEGINNING BALANCE">877,125</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_984_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentLeasingMember_z9L9GyKqnuel" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="INTEREST">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_98C_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentLeasingMember_z6rX1oYmIbLh" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_98B_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentLeasingMember_zbIxTVFKDE1f" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(491,489</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left">)</td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_982_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentLeasingMember_zVCv2KrPfs25" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="ENDING BALANCE">385,636</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt"><b>Aerospace</b></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Hera Systems, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncConvertibleNoteMember_fKg_____z8zEjfsSizk9" style="width: 8%; text-align: right" title="BEGINNING BALANCE">5,359,791</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncConvertibleNoteMember_fKg_____zMra7cSw5AA7" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--InterestIncomeExpenseNet_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncConvertibleNoteMember_fKg_____ztntOnIK9mHf" style="width: 8%; text-align: right" title="INTEREST">269,478</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncConvertibleNoteMember_fKg_____zarDXz61oMLf" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncConvertibleNoteMember_fKg_____zDTbz0dMbAii" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_ecustom--ChangeInAppreciationdepreciation_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncConvertibleNoteMember_fKg_____zgDKjcbkWXBa" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_981_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncConvertibleNoteMember_fKg_____z5Y03WaRzC47" style="width: 8%; text-align: right" title="ENDING BALANCE">5,359,791</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncConvertibleNoteMember_fKg_____zb4vLiD0WmR1" style="width: 8%; text-align: right" title="SHARES HELD">5,359,791</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Hera Systems, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncConvertibleNote1Member_fKg_____zpbYS4cInhpj" style="width: 8%; text-align: right" title="BEGINNING BALANCE">1,200,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncConvertibleNote1Member_fKg_____zyr0JMtf45J4" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--InterestIncomeExpenseNet_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncConvertibleNote1Member_fKg_____zvvmLKwfYHe7" style="width: 8%; text-align: right" title="INTEREST">29,989</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncConvertibleNote1Member_fKg_____zZApdl7YAyga" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_981_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncConvertibleNote1Member_fKg_____z08rWphi3f44" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_ecustom--ChangeInAppreciationdepreciation_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncConvertibleNote1Member_fKg_____zLuQnJGqxCwf" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncConvertibleNote1Member_fKg_____zfRpmAXhWvTi" style="width: 8%; text-align: right" title="ENDING BALANCE">1,200,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncConvertibleNote1Member_fKg_____zH6pqjAutRRj" style="width: 8%; text-align: right" title="SHARES HELD">1,200,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Hera Systems, Inc. Series A Preferred<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesAPreferredMember_fKg_____ztfWby76rJa5" style="width: 8%; text-align: right" title="BEGINNING BALANCE">4,735</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesAPreferredMember_fKg_____z7xvWpPlNXHc" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesAPreferredMember_fKg_____ztEmhvB9yHuh" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesAPreferredMember_fKg_____zTa46yit8kLa" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesAPreferredMember_fKg_____zVUew2tOnEg8" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesAPreferredMember_fKg_____zm342mgSsafd" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(2,169</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesAPreferredMember_fKg_____zev4B0JIbt31" style="width: 8%; text-align: right" title="ENDING BALANCE">2,566</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesAPreferredMember_fKg_____zTRXSTBYdTnf" style="width: 8%; text-align: right" title="SHARES HELD">3,642,324</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Hera Systems, Inc. Series B Preferred<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBPreferredMember_fKg_____zNp5ontjt4Vl" style="width: 8%; text-align: right" title="BEGINNING BALANCE">275,585</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBPreferredMember_fKg_____zedEyzVtqDSb" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBPreferredMember_fKg_____zTE6ZrRpXQw9" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBPreferredMember_fKg_____z4CkSbQYT35k" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBPreferredMember_fKg_____zVSBFBsfN8o2" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98C_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBPreferredMember_fKg_____zYsHnlprVVD5" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(56,352</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBPreferredMember_fKg_____zVHyRMtfJFq" style="width: 8%; text-align: right" title="ENDING BALANCE">219,233</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBPreferredMember_z9G9uGsuVnCe" style="width: 8%; text-align: right" title="SHARES HELD">7,039,203</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Hera Systems, Inc. Series B Warrants<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_981_eus-gaap--Investments_iS_pp0p0_c20221231__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBWarrantsMember_zjYryz5JSTRl" style="width: 8%; text-align: right" title="BEGINNING BALANCE">478,608</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBWarrantsMember_fKg_____zRqUtV9WvYzk" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBWarrantsMember_fKg_____zJJuYRcfxLt5" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBWarrantsMember_fKg_____zClOiQRjIDq7" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBWarrantsMember_fKg_____zt0gLRrLESc5" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBWarrantsMember_fKg_____zD0BYMd04Dv5" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(98,084</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBWarrantsMember_fKg_____zi3DaOfuHlIl" style="width: 8%; text-align: right" title="ENDING BALANCE">380,524</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBWarrantsMember_fKg_____zcEtqNzbFopk" style="width: 8%; text-align: right" title="SHARES HELD">12,250,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Hera Systems, Inc. Series B Warrants<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBWarrants1Member_fKg_____zsfaH0xZ8A2g" style="width: 8%; text-align: right" title="BEGINNING BALANCE">242,817</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBWarrants1Member_fKg_____zPVr1WbPUxng" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBWarrants1Member_fKg_____ze8u6uQbgDol" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBWarrants1Member_fKg_____zuAcggYIoh8k" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBWarrants1Member_fKg_____zFLnBbu66aE2" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBWarrants1Member_fKg_____zKpMNqGSmqV6" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(49,762</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBWarrants1Member_fKg_____zwv3vA7sBGp" style="width: 8%; text-align: right" title="ENDING BALANCE">193,055</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBWarrants1Member_fKg_____zQmbQ1I2jpjj" style="width: 8%; text-align: right" title="SHARES HELD">6,214,922</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Hera Systems, Inc. Series B Warrants<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBWarrants2Member_fKg_____zh6y0PQqiBwb" style="width: 8%; text-align: right" title="BEGINNING BALANCE">205,118</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBWarrants2Member_fKg_____z2zf8YJ99N8l" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_988_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBWarrants2Member_fKg_____zJoCNjFJQao5" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_981_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBWarrants2Member_fKg_____zilRGFoTKd6e" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBWarrants2Member_fKg_____ztKltr5BzD2h" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBWarrants2Member_fKg_____zrWxnth4EnN1" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(42,036</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_981_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBWarrants2Member_fKg_____zIpOzkA0upVg" style="width: 8%; text-align: right" title="ENDING BALANCE">163,082</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_981_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBWarrants2Member_fKg_____zdgvLLtEOPd8" style="width: 8%; text-align: right" title="SHARES HELD">5,250,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Hera Systems, Inc. Series B Warrants<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBWarrants3Member_fKg_____zNYfe6E7YCv7" style="width: 8%; text-align: right" title="BEGINNING BALANCE">27,349</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBWarrants3Member_fKg_____zsaHvtwytEo8" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBWarrants3Member_fKg_____zDGEimR14LHi" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBWarrants3Member_fKg_____zhpUPZKpuvAc" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBWarrants3Member_fKg_____zUf9uFs8EGi7" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBWarrants3Member_fKg_____z5Go0ZzIoGHl" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(5,605</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBWarrants3Member_fKg_____z6JOhiKh68wa" style="width: 8%; text-align: right" title="ENDING BALANCE">21,744</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesBWarrants3Member_fKg_____zONm1LtrSuYh" style="width: 8%; text-align: right" title="SHARES HELD">700,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Hera Systems, Inc. Series C Preferred<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesCPreferredMember_fKg_____zLb5j0jqTuCe" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="BEGINNING BALANCE">103,747</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesCPreferredMember_fKg_____zusYFtJNZdng" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesCPreferredMember_fKg_____zV7tVc57gfma" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="INTEREST">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesCPreferredMember_fKg_____zFFcUaM5WRfa" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_988_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesCPreferredMember_fKg_____z01G5ZKaqAcl" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_980_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesCPreferredMember_fKg_____zqxUrItZk1Hf" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(21,214</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left">)</td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesCPreferredMember_fKg_____zT1Lb5lCkage" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="ENDING BALANCE">82,533</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--HeraSystemsIncSeriesCPreferredMember_fKg_____zRDAdfUuUUQf" style="width: 8%; text-align: right" title="SHARES HELD">2,650,000</td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Total Aerospace</p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_98D_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AerospaceMember_zbSC04VNiZ1g" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="BEGINNING BALANCE">7,897,750</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_985_eus-gaap--InterestIncomeExpenseNet_pp0p0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AerospaceMember_zMKUuqMjT5Yk" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="INTEREST">299,467</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_985_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AerospaceMember_z7eW189OTP2c" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_981_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AerospaceMember_zW8dO25skQ9b" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(275,222</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left">)</td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_98B_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AerospaceMember_zQPc5EdIyGp9" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="ENDING BALANCE">7,622,528</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt"><b>Medical Devices</b></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">IntraOp Medical Corp. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNoteMember_fKg_____z02beRP5rIG8" style="width: 8%; text-align: right" title="BEGINNING BALANCE">6,746,169</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNoteMember_fKg_____z5PoyQdgyHOc" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNoteMember_fKg_____zvUCOffl0E74" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_981_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNoteMember_fKg_____zwC8H1Vf6cD1" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNoteMember_fKg_____zscceQh9yie7" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98C_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNoteMember_fKg_____z09UFR692uUg" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(4,761,350</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNoteMember_fKg_____z0ev8jYXc8Bf" style="width: 8%; text-align: right" title="ENDING BALANCE">1,984,819</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNoteMember_fKg_____zd2IGsZUqf03" style="width: 8%; text-align: right" title="SHARES HELD">10,961,129</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">IntraOp Medical Corp. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote1Member_fKg_____zE3EUg4BLvre" style="width: 8%; text-align: right" title="BEGINNING BALANCE">800,102</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote1Member_fKg_____zSuiiiwhV3Y" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote1Member_fKg_____zni9ar6MW2yb" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote1Member_fKg_____zOzzw2Zsg7j5" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote1Member_fKg_____zAYwnxpAHcR1" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote1Member_fKg_____zeXjno2DR5xb" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(564,701</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote1Member_fKg_____zKB2J6qoxBLk" style="width: 8%; text-align: right" title="ENDING BALANCE">235,401</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote1Member_fKg_____zETHD5TtxHpg" style="width: 8%; text-align: right" title="SHARES HELD">1,300,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> </table><p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 14pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>Firsthand Technology Value Fund, Inc. </b></p> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr> <td style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>AFFILIATE/<br/> CONTROLLED <br/> INVESTMENTS<span style="font-size: 11pt; vertical-align: bottom">*</span></b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>VALUE AT <br/> 12/31/22</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>PURCHASE/ <br/> MERGER</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>INTEREST</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>SALES/ <br/> MATURITY/ <br/> EXPIRATION</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>REALIZED <br/> GAIN (LOSS)</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>CHANGE IN <br/> APPRECIATION/ <br/> DEPRECIATION</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>VALUE <br/> 6/30/23</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>SHARES HELD <br/> AT 6/30/23</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">IntraOp Medical Corp. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_989_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote2Member_fKg_____zTc9wokB0HCb" style="width: 8%; text-align: right" title="BEGINNING BALANCE">307,731</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_989_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote2Member_fKg_____zddZ4M4l7lQl" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_980_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote2Member_fKg_____zbYEysDtd7Mi" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_985_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote2Member_fKg_____zwT34veQaHrd" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_980_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote2Member_fKg_____zM1sBhiH6bjd" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_983_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote2Member_fKg_____zgUCdMAxPMs" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(217,192</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_982_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote2Member_fKg_____zDLByCTmb9q6" style="width: 8%; text-align: right" title="ENDING BALANCE">90,539</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_981_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote2Member_fKg_____zKAvNWHgf30e" style="width: 8%; text-align: right" title="SHARES HELD">500,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">IntraOp Medical Corp. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_988_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote3Member_fKg_____zUCx250tu4Wb" style="width: 8%; text-align: right" title="BEGINNING BALANCE">307,731</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_988_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote3Member_fKg_____zeof6NOHTgh8" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote3Member_fKg_____zcKGRrFXksAl" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote3Member_fKg_____zBk5d9szXQrk" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote3Member_fKg_____z4hzUlf1Apy5" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote3Member_fKg_____zlkfcBEc18c2" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(217,192</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote3Member_fKg_____zqvGlkOjnDKh" style="width: 8%; text-align: right" title="ENDING BALANCE">90,539</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote3Member_fKg_____zRHi7SCTDvp8" style="width: 8%; text-align: right" title="SHARES HELD">500,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">IntraOp Medical Corp. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote4Member_fKg_____zTgpZ00o265a" style="width: 8%; text-align: right" title="BEGINNING BALANCE">1,846,389</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote4Member_fKg_____zd7HV8r1UGn2" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_981_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote4Member_fKg_____zBoSn1VlNE61" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote4Member_fKg_____z8BUZh02gIcc" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote4Member_fKg_____zKRinEt1IM2" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote4Member_fKg_____zPoYsapbe0gd" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(1,303,155</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote4Member_fKg_____zcDZkl3ebAR1" style="width: 8%; text-align: right" title="ENDING BALANCE">543,234</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_988_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote4Member_fKg_____z6Csmv16TTHi" style="width: 8%; text-align: right" title="SHARES HELD">3,000,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">IntraOp Medical Corp. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote5Member_fKg_____zHkGAEmDPCl9" style="width: 8%; text-align: right" title="BEGINNING BALANCE">615,463</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote5Member_fKg_____z7pbbIgA3r7" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote5Member_fKg_____ze5tTePNx1hd" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote5Member_fKg_____z0INKpqbj9Lf" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote5Member_fKg_____ziQP2MnJXVWc" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote5Member_fKg_____zYVVtA94CGj9" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(434,385</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote5Member_fKg_____zdd5VXTPe5Ld" style="width: 8%; text-align: right" title="ENDING BALANCE">181,078</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote5Member_fKg_____zbNayEk9zOgj" style="width: 8%; text-align: right" title="SHARES HELD">1,000,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">IntraOp Medical Corp. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote6Member_fKg_____zfOJ5StNbx17" style="width: 8%; text-align: right" title="BEGINNING BALANCE">246,185</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote6Member_fKg_____zxRnqRDMlzne" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote6Member_fKg_____zz3LTexLFAHb" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote6Member_fKg_____zK07FgxltvB7" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote6Member_fKg_____zTiMI6oWdyo7" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote6Member_fKg_____z8rSO2cf8rAf" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(173,754</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote6Member_fKg_____z6fec9uqSXv8" style="width: 8%; text-align: right" title="ENDING BALANCE">72,431</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote6Member_fKg_____zxdBwPvQwlva" style="width: 8%; text-align: right" title="SHARES HELD">400,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">IntraOp Medical Corp. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote7Member_fKg_____zAbYlemaCxH4" style="width: 8%; text-align: right" title="BEGINNING BALANCE">307,731</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote7Member_fKg_____ztEh5IKxUdlj" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote7Member_fKg_____zDG7lxqbDdQ" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote7Member_fKg_____zD8QVk0DfFT" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote7Member_fKg_____zdhaRXqmbS98" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote7Member_fKg_____zLs515vGGBJc" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(217,192</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote7Member_fKg_____zGspGJMIHjVl" style="width: 8%; text-align: right" title="ENDING BALANCE">90,539</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote7Member_fKg_____zNGPHBpcSx9i" style="width: 8%; text-align: right" title="SHARES HELD">500,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">IntraOp Medical Corp. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote8Member_fKg_____z6cWS8G08h5d" style="width: 8%; text-align: right" title="BEGINNING BALANCE">461,597</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote8Member_fKg_____zNOT34GPShea" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote8Member_fKg_____zN0GdeA1v2Oi" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote8Member_fKg_____zodpr5GD8Rj6" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote8Member_fKg_____zX1rBkZBBJz7" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_981_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote8Member_fKg_____zPidVAsjREC7" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(325,788</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote8Member_fKg_____z5FdrKUQwNX4" style="width: 8%; text-align: right" title="ENDING BALANCE">135,809</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote8Member_fKg_____zHGwQkAmMLba" style="width: 8%; text-align: right" title="SHARES HELD">750,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">IntraOp Medical Corp. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote9Member_fKg_____z8qlaB4nail7" style="width: 8%; text-align: right" title="BEGINNING BALANCE">307,731</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote9Member_fKg_____z8r0Q2Xk3SC2" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote9Member_fKg_____znLr9qSJGNil" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote9Member_fKg_____zusnpfgwRXTe" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote9Member_fKg_____zUpEsNmR5Fj3" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote9Member_fKg_____zr8n8NgQK0Ea" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(217,192</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote9Member_fKg_____zozegwVqjbVk" style="width: 8%; text-align: right" title="ENDING BALANCE">90,539</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote9Member_fKg_____zMVWQ2ZpGu16" style="width: 8%; text-align: right" title="SHARES HELD">500,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">IntraOp Medical Corp. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_981_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote10Member_fKg_____zx6Fmn5FLAQ8" style="width: 8%; text-align: right" title="BEGINNING BALANCE">307,732</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote10Member_fKg_____zpFdHn6JX1O9" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote10Member_fKg_____zjwaGm0b7Ij7" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote10Member_fKg_____zm0KF8TONHP2" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote10Member_fKg_____zDeVn35rgDG8" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote10Member_fKg_____zudzq94FPnyi" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(217,193</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote10Member_fKg_____zeGTgWnQWAVd" style="width: 8%; text-align: right" title="ENDING BALANCE">90,539</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote10Member_fKg_____znr79tZ7y3Sk" style="width: 8%; text-align: right" title="SHARES HELD">500,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">IntraOp Medical Corp. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote11Member_fKg_____zIFSJrFCLX32" style="width: 8%; text-align: right" title="BEGINNING BALANCE">307,732</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote11Member_fKg_____z40U7Pbaf959" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_981_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote11Member_fKg_____zn9RS2t6K9Wc" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote11Member_fKg_____zjTqJAwO0Fc2" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote11Member_fKg_____zRD0RDopNqYi" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote11Member_fKg_____zBzXoyGQNRM2" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(217,193</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote11Member_fKg_____zfktzEw3J856" style="width: 8%; text-align: right" title="ENDING BALANCE">90,539</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote11Member_fKg_____zAFUbJ7YYj7a" style="width: 8%; text-align: right" title="SHARES HELD">500,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">IntraOp Medical Corp. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_981_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote12Member_fKg_____zsSGwVXLTKMa" style="width: 8%; text-align: right" title="BEGINNING BALANCE">615,463</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote12Member_fKg_____zFf4vn37F6yc" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote12Member_fKg_____zvU81U8nDHfh" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote12Member_fKg_____z2u45pWWqLTh" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_981_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote12Member_fKg_____z1pVZ6HKptg5" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote12Member_fKg_____zl993mKOnMFi" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(434,385</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_988_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote12Member_fKg_____zySO8ejSm9le" style="width: 8%; text-align: right" title="ENDING BALANCE">181,078</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote12Member_fKg_____zfRoZt4apyub" style="width: 8%; text-align: right" title="SHARES HELD">1,000,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">IntraOp Medical Corp. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote13Member_fKg_____zrs0cgstIYwk" style="width: 8%; text-align: right" title="BEGINNING BALANCE">307,732</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote13Member_fKg_____zXK8WdyO9CWg" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote13Member_fKg_____zo26zW99EEB7" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote13Member_fKg_____zA03BOBi4gVf" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote13Member_fKg_____zixPOZYLURF1" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote13Member_fKg_____zjv4WJJYuVV6" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(217,193</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote13Member_fKg_____zAwNma4jFkS5" style="width: 8%; text-align: right" title="ENDING BALANCE">90,539</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote13Member_fKg_____zUyEOA2X2Lvc" style="width: 8%; text-align: right" title="SHARES HELD">500,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">IntraOp Medical Corp. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_988_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote14Member_fKg_____zmmQAhAPPjjg" style="width: 8%; text-align: right" title="BEGINNING BALANCE">615,463</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote14Member_fKg_____zfmvdBpaxFrj" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote14Member_fKg_____z4lHX5swanSb" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote14Member_fKg_____zm073ASrFUCa" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote14Member_fKg_____zznfWux35ufb" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote14Member_fKg_____zOeHEPPF1xhi" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(434,385</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote14Member_fKg_____zkjEwjbn0zh7" style="width: 8%; text-align: right" title="ENDING BALANCE">181,078</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote14Member_fKg_____zbyaByRv7LJ4" style="width: 8%; text-align: right" title="SHARES HELD">1,000,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">IntraOp Medical Corp. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote15Member_fKg_____zsyZGUzL3lV3" style="width: 8%; text-align: right" title="BEGINNING BALANCE">307,732</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote15Member_fKg_____zNHeok9eEhub" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote15Member_fKg_____z56X4FRNT1S9" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote15Member_fKg_____zaLEyfVcZZz3" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote15Member_fKg_____zeXIGWMFi2Ma" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote15Member_fKg_____zWQVPGich7W3" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(217,193</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote15Member_fKg_____zfx52pyVcdZ4" style="width: 8%; text-align: right" title="ENDING BALANCE">90,539</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote15Member_fKg_____zQM4DOf0SG3g" style="width: 8%; text-align: right" title="SHARES HELD">500,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">IntraOp Medical Corp. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote16Member_fKg_____z8IsJWLIH8M3" style="width: 8%; text-align: right" title="BEGINNING BALANCE">307,732</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote16Member_fKg_____zblmOIWiaX2b" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote16Member_fKg_____zMQIcVEPSpz9" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote16Member_fKg_____zdZwEOmEyuR4" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote16Member_fKg_____z4OMSt4ZFc25" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote16Member_fKg_____za3novVhBqf7" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(217,193</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote16Member_fKg_____z13JGX96mDua" style="width: 8%; text-align: right" title="ENDING BALANCE">90,539</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote16Member_fKg_____znEbb9gICZAg" style="width: 8%; text-align: right" title="SHARES HELD">500,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> </table><p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 14pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>Firsthand Technology Value Fund, Inc. </b></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr> <td style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>AFFILIATE/<br/> CONTROLLED <br/> INVESTMENTS<span style="font-size: 11pt; vertical-align: bottom">*</span></b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>VALUE AT <br/> 12/31/22</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>PURCHASE/ <br/> MERGER</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>INTEREST</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>SALES/ <br/> MATURITY/ <br/> EXPIRATION</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>REALIZED <br/> GAIN (LOSS)</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>CHANGE IN <br/> APPRECIATION/ <br/> DEPRECIATION</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>VALUE <br/> 6/30/23</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>SHARES HELD <br/> AT 6/30/23</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">IntraOp Medical Corp. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_985_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote17Member_fKg_____zZueuSquFBz8" style="width: 8%; text-align: right" title="BEGINNING BALANCE">307,732</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_980_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote17Member_fKg_____z0RjSQarINwg" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_984_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote17Member_fKg_____zHqfbAwrYVrc" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_98B_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote17Member_fKg_____z3vmNOGs32fg" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_981_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote17Member_fKg_____z8ODrCEccL14" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_98E_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote17Member_fKg_____zLt3HtJ5rAh3" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(217,193</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_980_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote17Member_fKg_____z4LsCWMLPBuj" style="width: 8%; text-align: right" title="ENDING BALANCE">90,539</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote17Member_fKg_____zJpcrYy4ioZ3" style="width: 8%; text-align: right" title="SHARES HELD">500,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">IntraOp Medical Corp. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote18Member_fKg_____zDPGVuo0MF9e" style="width: 8%; text-align: right" title="BEGINNING BALANCE">123,093</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote18Member_fKg_____z46bwuw9U5Cl" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote18Member_fKg_____zMR0gBJErqy8" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_981_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote18Member_fKg_____zgGqe2cv4a88" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_988_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote18Member_fKg_____zd2pYWMYzsel" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote18Member_fKg_____ztLvk95zYLPf" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(86,877</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote18Member_fKg_____z5P2K009ow99" style="width: 8%; text-align: right" title="ENDING BALANCE">36,216</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote18Member_fKg_____z2vX636ToUi9" style="width: 8%; text-align: right" title="SHARES HELD">200,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">IntraOp Medical Corp. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote19Member_fKg_____zjFopVQMx731" style="width: 8%; text-align: right" title="BEGINNING BALANCE">430,824</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote19Member_fKg_____zkVTvCqYcJUi" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote19Member_fKg_____z4IzsmriIDNc" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote19Member_fKg_____zZ5WTKk5Toyh" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote19Member_fKg_____zJ6dSXGGZUw1" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote19Member_fKg_____zfmib478tlq9" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(304,069</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote19Member_fKg_____zzA0K4mUNVZi" style="width: 8%; text-align: right" title="ENDING BALANCE">126,755</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote19Member_fKg_____zHxBUnb0QqN3" style="width: 8%; text-align: right" title="SHARES HELD">700,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">IntraOp Medical Corp. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote20Member_fKg_____zH6ozDG4TLf2" style="width: 8%; text-align: right" title="BEGINNING BALANCE">92,319</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote20Member_fKg_____zD94AjiZFXVa" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote20Member_fKg_____zcW06mePQXZ4" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote20Member_fKg_____zUhbCmiXJUN7" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote20Member_fKg_____zHQdwkxcTgr5" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_981_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote20Member_fKg_____zj1oOljJNkLl" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(65,157</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote20Member_fKg_____zTvCdaknYZ7h" style="width: 8%; text-align: right" title="ENDING BALANCE">27,162</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote20Member_fKg_____zy80zU6BZSAl" style="width: 8%; text-align: right" title="SHARES HELD">150,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">IntraOp Medical Corp. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote21Member_fKg_____ztlksAXXb9ec" style="width: 8%; text-align: right" title="BEGINNING BALANCE">215,412</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote21Member_fKg_____zvBvYauk64R5" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote21Member_fKg_____zdYARf5YsJxf" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote21Member_fKg_____zsQpnbelvfn5" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote21Member_fKg_____zeCGAkuVi595" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98C_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote21Member_fKg_____z5t0ftoTNne5" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(152,035</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote21Member_fKg_____zJxjAgffQPng" style="width: 8%; text-align: right" title="ENDING BALANCE">63,377</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpConvertibleNote21Member_fKg_____zBokYmYDxy4e" style="width: 8%; text-align: right" title="SHARES HELD">350,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">IntraOp Medical Corp. Series C Preferred<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--Investments_iS_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpSeriesCPreferredMember_fKg_____zhx5Uib0INaj" style="width: 8%; text-align: right" title="BEGINNING BALANCE">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpSeriesCPreferredMember_fKg_____zDfaZ5grpkR5" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpSeriesCPreferredMember_fKg_____zq6anjaakRjk" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpSeriesCPreferredMember_fKg_____znS06ztrB1mb" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpSeriesCPreferredMember_fKg_____zVIRiAt1AjH4" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_ecustom--ChangeInAppreciationdepreciation_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpSeriesCPreferredMember_fKg_____zbf3uQdjzEvi" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--Investments_iE_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpSeriesCPreferredMember_fKg_____z7xaeu2MFQI7" style="width: 8%; text-align: right" title="ENDING BALANCE">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpSeriesCPreferredMember_fKg_____zgSuK7ldGdvj" style="width: 8%; text-align: right" title="SHARES HELD">26,856,187</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">IntraOp Medical Corp. Term Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpTermNoteMember_fKg_____ztnMaDx0CvQ9" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="BEGINNING BALANCE">1,230,926</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpTermNoteMember_fKg_____zUOWov0fESW" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpTermNoteMember_fKg_____zvUZEHR4aBWg" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="INTEREST">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpTermNoteMember_fKg_____zpLOYFL8gFJb" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_988_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpTermNoteMember_fKg_____zyDFNpLSIcR" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98A_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpTermNoteMember_fKg_____z1ilkbNE9L5h" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(868,770</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left">)</td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpTermNoteMember_fKg_____zQZkBW5EAyu3" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="ENDING BALANCE">362,156</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--IntraOpMedicalCorpTermNoteMember_fKg_____zCbSB9JQxbvj" style="width: 8%; text-align: right" title="SHARES HELD">2,000,000</td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Total Medical Devices</p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_983_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalDevicesMember_zNpBzaOLRKsg" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="BEGINNING BALANCE">17,116,721</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_983_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalDevicesMember_zQTc3d0yl7Da" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="INTEREST">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_98A_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalDevicesMember_zZpFqc7rMjyh" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_98D_ecustom--ChangeInAppreciationdepreciation_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalDevicesMember_pp0p0" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(12,080,737</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left">)</td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_98D_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalDevicesMember_zIjO7rQz2Av4" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="ENDING BALANCE">5,035,984</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt"><b>Semiconductor Equipment</b></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Revasum, Inc. CDI<span style="font-size: 11pt; vertical-align: bottom">*</span>(1)</p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--RevasumIncCDIMember_fKigxKQ_____zROD2gUBFCP1" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="BEGINNING BALANCE">3,520,496</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_981_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--RevasumIncCDIMember_fKigxKQ_____zta82jp0SII6" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--RevasumIncCDIMember_fKigxKQ_____zQp004RMFmAi" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="INTEREST">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--RevasumIncCDIMember_fKigxKQ_____zvCBUnGY6bGk" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--RevasumIncCDIMember_fKigxKQ_____zIklxUJidWS9" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98E_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--RevasumIncCDIMember_fKigxKQ_____z4ZISoYpbgrh" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">188,950</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--RevasumIncCDIMember_fKigxKQ_____zNkbXTj1UAg9" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="ENDING BALANCE">3,709,446</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_988_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--RevasumIncCDIMember_fKigxKQ_____zjE3yVJ6o2hf" style="width: 8%; text-align: right" title="SHARES HELD">39,774,889</td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Total Semiconductor Equipment</p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_985_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--SemiconductorEquipmentMember_za5zN7A4FtJk" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="BEGINNING BALANCE">3,520,496</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_987_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--SemiconductorEquipmentMember_zGloiybBaSsc" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="INTEREST">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_988_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--SemiconductorEquipmentMember_z9QLngEZP2Of" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_98B_ecustom--ChangeInAppreciationdepreciation_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--SemiconductorEquipmentMember_pp0p0" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">188,950</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_984_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--SemiconductorEquipmentMember_z6R7SGVrTxb9" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="ENDING BALANCE">3,709,446</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt"><b>Intellectual Property</b></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Silicon Genesis Corp. Common Stock<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpCommonStockMember_fKg_____zL3vOx2heRSk" style="width: 8%; text-align: right" title="BEGINNING BALANCE">111</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpCommonStockMember_fKg_____zGWstr6uHRe3" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpCommonStockMember_fKg_____z6O0uVecc4P3" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpCommonStockMember_fKg_____zTtUnQPc8gU2" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">(7,966</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_981_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpCommonStockMember_fKg_____zN0NlyrBu4ph" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">(161,080</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpCommonStockMember_fKg_____zAeBRZJmp8Sd" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">168,935</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--Investments_iE_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpCommonStockMember_fKg_____zP9VCfxA5vb1" style="width: 8%; text-align: right" title="ENDING BALANCE">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--SharesIssued_iI_d0_c20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpCommonStockMember_fKg_____zOTRQteupKVf" style="width: 8%; text-align: right" title="SHARES HELD">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Silicon Genesis Corp. Common Warrants<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpCommonWarrantsMember_fKg_____zt6jA691ZDk1" style="width: 8%; text-align: right" title="BEGINNING BALANCE">1</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpCommonWarrantsMember_fKg_____zOVPQTO5dGLg" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpCommonWarrantsMember_fKg_____zdPxGmPdffS3" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpCommonWarrantsMember_fKg_____ztcOCL0vhGS4" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">(1</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_988_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpCommonWarrantsMember_fKg_____zuWP5erOqYFa" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">(6,677</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpCommonWarrantsMember_fKg_____zLjNA23PvHlg" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">6,677</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_981_eus-gaap--Investments_iE_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpCommonWarrantsMember_fKg_____zmneWoD3gub2" style="width: 8%; text-align: right" title="ENDING BALANCE">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--SharesIssued_iI_d0_c20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpCommonWarrantsMember_fKg_____zj2pnFM0K5kl" style="width: 8%; text-align: right" title="SHARES HELD">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Silicon Genesis Corp. Series 1-G Preferred<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1GPreferredMember_fKg_____zx6Qz5I3uDag" style="width: 8%; text-align: right" title="BEGINNING BALANCE">306,671</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1GPreferredMember_fKg_____zK1vBfHpD1c9" style="width: 8%; text-align: right" title="PURCHASE/MERGER">88</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1GPreferredMember_fKg_____zx5Vxebuduuj" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1GPreferredMember_fKg_____zMTDu5D2spgb" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">(417,972</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1GPreferredMember_fKg_____zkRkyCOnNTng" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">(3,462,620</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1GPreferredMember_fKg_____zoEJLmqskcOg" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">3,573,833</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--Investments_iE_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1GPreferredMember_fKg_____zkB3KrHhMvo4" style="width: 8%; text-align: right" title="ENDING BALANCE">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--SharesIssued_iI_d0_c20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1GPreferredMember_fKg_____zNQn6FUkkZll" style="width: 8%; text-align: right" title="SHARES HELD">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Silicon Genesis Corp. Series 1-H Preferred<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1HPreferredMember_fKg_____zdfJFwLUEn87" style="width: 8%; text-align: right" title="BEGINNING BALANCE">35,529</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1HPreferredMember_fKg_____zp5D4yabxlHe" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1HPreferredMember_fKg_____z501TcOZl6Me" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1HPreferredMember_fKg_____zgjbkxPHoT9a" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">(7,241</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1HPreferredMember_fKg_____zpiDz6S4s4x6" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">(929,654</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1HPreferredMember_fKg_____zzho74jGv6Y4" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">901,366</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--Investments_iE_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1HPreferredMember_fKg_____zWwd0zirF0pc" style="width: 8%; text-align: right" title="ENDING BALANCE">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--SharesIssued_iI_d0_c20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1HPreferredMember_fKg_____zBNbTzFg44Mb" style="width: 8%; text-align: right" title="SHARES HELD">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Silicon Genesis Corp. Series 1-D Preferred<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1DPreferredMember_fKg_____zxZS2cXyXshk" style="width: 8%; text-align: right" title="BEGINNING BALANCE">2,552</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1DPreferredMember_fKg_____zyoKy1j6vmI1" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1DPreferredMember_fKg_____zgEBf0bXZDof" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1DPreferredMember_fKg_____z2thRlZjoHU8" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">(7,351</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--DebtAndEquitySecuritiesGainLoss_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1DPreferredMember_fKg_____zIGU7VCoB59d" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">(424,549</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1DPreferredMember_fKg_____zbEE2lUKhBB" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">429,348</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_981_eus-gaap--Investments_iE_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1DPreferredMember_fKg_____zyMDkhCPMX5f" style="width: 8%; text-align: right" title="ENDING BALANCE">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--SharesIssued_iI_d0_c20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1DPreferredMember_fKg_____zh9E46OF7Ctf" style="width: 8%; text-align: right" title="SHARES HELD">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> </table><p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr> <td style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>AFFILIATE/<br/> CONTROLLED <br/> INVESTMENTS<span style="font-size: 11pt; vertical-align: bottom">*</span></b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>VALUE AT <br/> 12/31/22</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>PURCHASE/ <br/> MERGER</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>INTEREST</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>SALES/ <br/> MATURITY/ <br/> EXPIRATION</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>REALIZED <br/> GAIN (LOSS)</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>CHANGE IN <br/> APPRECIATION/ <br/> DEPRECIATION</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>VALUE <br/> 6/30/23</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>SHARES HELD <br/> AT 6/30/23</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Silicon Genesis Corp. Series 1-E Preferred<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_98F_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1EPreferredMember_fKg_____zJDuxYCFzbui" style="width: 8%; text-align: right" title="BEGINNING BALANCE">320,592</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_984_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1EPreferredMember_fKg_____z1cxmRK5tS5f" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_983_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1EPreferredMember_fKg_____zmdydeosmg09" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_983_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1EPreferredMember_fKg_____zLz48UfVAKWg" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">(49,292</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_980_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1EPreferredMember_fKg_____zH6khQlpqGH6" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">(2,323,111</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_98E_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1EPreferredMember_fKg_____ztDm4rxN9jpe" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">2,051,811</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_988_eus-gaap--Investments_iE_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1EPreferredMember_fKg_____zZxV0TXWSnWh" style="width: 8%; text-align: right" title="ENDING BALANCE">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--SharesIssued_iI_d0_c20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1EPreferredMember_fKg_____zJXvpFLutHS4" style="width: 8%; text-align: right" title="SHARES HELD">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Silicon Genesis Corp. Series 1-F Preferred<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_981_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1FPreferredMember_fKg_____zhrMnLrqTo87" style="width: 8%; text-align: right" title="BEGINNING BALANCE">70,806</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1FPreferredMember_fKg_____zhtl36Vxdv55" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1FPreferredMember_fKg_____zUVkEg2sZPXf" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1FPreferredMember_fKg_____zSG4ETEapr61" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">(7,885</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1FPreferredMember_fKg_____zB2RCdmCXul5" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">(448,504</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1FPreferredMember_fKg_____zEl4wB1w5kk3" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">385,583</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--Investments_iE_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1FPreferredMember_fKg_____zUz5qJ5VuZjk" style="width: 8%; text-align: right" title="ENDING BALANCE">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--SharesIssued_iI_d0_c20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1FPreferredMember_fKg_____z2NB9qcLXC9" style="width: 8%; text-align: right" title="SHARES HELD">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Silicon Genesis Corp. Series 1-C Preferred Stock<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1CPreferredStockMember_fKg_____zc96uZAeCRs" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="BEGINNING BALANCE">962</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_981_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1CPreferredStockMember_fKg_____z1h3WILbBpu2" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1CPreferredStockMember_fKg_____z2ZbiTGosCL" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="INTEREST">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1CPreferredStockMember_fKg_____zDOJn0RNlPQ5" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">(716</td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left">)</td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1CPreferredStockMember_fKg_____zGAytvj8nrf8" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">(108,802</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left">)</td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98A_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1CPreferredStockMember_fKg_____zBfMlJFDBKfi" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">108,556</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--Investments_iE_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1CPreferredStockMember_fKg_____z7GSsN1cVEQe" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="ENDING BALANCE">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--SharesIssued_iI_d0_c20230630__us-gaap--InvestmentTypeAxis__custom--SiliconGenesisCorpSeries1CPreferredStockMember_fKg_____zdyMhatB7kA2" style="width: 8%; text-align: right" title="SHARES HELD">—</td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Total Intellectual Property</p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_982_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--IntellectualsPropertyMember_zkl6KasMskcj" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="BEGINNING BALANCE">737,224</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_984_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--IntellectualsPropertyMember_zqPxTJvRfxt4" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="INTEREST">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_981_eus-gaap--DebtAndEquitySecuritiesGainLoss_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--IntellectualsPropertyMember_pp0p0" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">(7,864,997</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left">)</td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_987_ecustom--ChangeInAppreciationdepreciation_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--IntellectualsPropertyMember_pp0p0" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">7,626,109</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_985_eus-gaap--Investments_iE_pp0p0_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--IntellectualsPropertyMember_zUNZRWWbs8r6" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="ENDING BALANCE">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt"><b>Advanced Materials</b></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">UCT Coatings, Inc. Common Stock</p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--UCTCoatingsIncCommonStockMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancedMaterialsMember_zqlWJUlnmm86" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="BEGINNING BALANCE">337,500</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--UCTCoatingsIncCommonStockMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancedMaterialsMember_zFm1scRxZM0j" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--UCTCoatingsIncCommonStockMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancedMaterialsMember_z69hgGZouIBa" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="INTEREST">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--UCTCoatingsIncCommonStockMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancedMaterialsMember_z3YF6dqgBE2g" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--UCTCoatingsIncCommonStockMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancedMaterialsMember_zKqlmmTVHpL8" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_980_ecustom--ChangeInAppreciationdepreciation_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--UCTCoatingsIncCommonStockMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancedMaterialsMember_pp0p0" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(71,409</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left">)</td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--UCTCoatingsIncCommonStockMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancedMaterialsMember_zPbHt6b2BDmi" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="ENDING BALANCE">266,091</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_eus-gaap--SharesIssued_c20230630__us-gaap--InvestmentTypeAxis__custom--UCTCoatingsIncCommonStockMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancedMaterialsMember_pdd" style="width: 8%; text-align: right" title="SHARES HELD">1,500,000</td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Total Advanced Materials</p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_98F_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancedMaterialsMember_zfEAqU8grxDf" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="BEGINNING BALANCE">337,500</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_98F_eus-gaap--InterestIncomeExpenseNet_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancedMaterialsMember_zNxwt83Bby19" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="INTEREST">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_988_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancedMaterialsMember_zxTXlnWR0qP5" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_983_ecustom--ChangeInAppreciationdepreciation_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancedMaterialsMember_pp0p0" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(71,409</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left">)</td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_98D_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancedMaterialsMember_zb0iVkE6ET42" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="ENDING BALANCE">266,091</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt"><b>Automotive</b></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Common Stock<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncCommonStockMember_fKg_____zQZcVmOU52of" style="width: 8%; text-align: right" title="BEGINNING BALANCE">546</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncCommonStockMember_fKg_____zSULLBNukPGj" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncCommonStockMember_fKg_____ze2HHcjazTIk" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncCommonStockMember_fKg_____zhvUMMfVQOUg" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncCommonStockMember_fKg_____zWlaEhWbri1" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncCommonStockMember_fKg_____zKTLzvZHkSDj" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(235</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncCommonStockMember_fKg_____zTCDAWgZq4T4" style="width: 8%; text-align: right" title="ENDING BALANCE">311</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncCommonStockMember_fKg_____z8vI8AHH5KQf" style="width: 8%; text-align: right" title="SHARES HELD">69,102</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNoteMember_fKg_____zm3PpfNcX4yd" style="width: 8%; text-align: right" title="BEGINNING BALANCE">65,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNoteMember_fKg_____zClGphsYrIhj" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNoteMember_fKg_____ztMrRHtj5RO5" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNoteMember_fKg_____zTC3JM7mDJB1" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNoteMember_fKg_____z0wiF3qGap17" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNoteMember_fKg_____zwQmPXyEjcuk" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(45,500</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNoteMember_fKg_____zElzK6TigJI" style="width: 8%; text-align: right" title="ENDING BALANCE">19,500</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNoteMember_fKg_____zc7IwOp5FBuc" style="width: 8%; text-align: right" title="SHARES HELD">200,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote1Member_fKg_____zMHYFBrmBm4" style="width: 8%; text-align: right" title="BEGINNING BALANCE">60,125</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote1Member_fKg_____zSpaxfh0p0h2" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote1Member_fKg_____zZrOILMYgc8a" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote1Member_fKg_____z7vagtx4BXpi" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote1Member_fKg_____zTbGD1t7hxDf" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote1Member_fKg_____zvEujEsp3NBc" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(42,088</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote1Member_fKg_____z4jHZXlOtLae" style="width: 8%; text-align: right" title="ENDING BALANCE">18,037</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote1Member_fKg_____zuYQcBzlPUSk" style="width: 8%; text-align: right" title="SHARES HELD">185,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote2Member_fKg_____zfZbI2cybUOl" style="width: 8%; text-align: right" title="BEGINNING BALANCE">21,125</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote2Member_fKg_____zBQp7DmQrbU" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote2Member_fKg_____zrwyfkGr56Zd" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote2Member_fKg_____zqQ4g0o8Cn8i" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote2Member_fKg_____zX8K5eAJDOa3" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote2Member_fKg_____z9bgHuj3Mowb" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(14,788</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote2Member_fKg_____z4UEgPczMhF7" style="width: 8%; text-align: right" title="ENDING BALANCE">6,337</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote2Member_fKg_____zflmcc0JwwUe" style="width: 8%; text-align: right" title="SHARES HELD">65,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote3Member_fKg_____zzjsYL4lFBV2" style="width: 8%; text-align: right" title="BEGINNING BALANCE">81,250</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote3Member_fKg_____zaBTo4zWtQi4" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_988_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote3Member_fKg_____zOjQ6166PlQl" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote3Member_fKg_____z4jnVtCFYvVl" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote3Member_fKg_____zQPWIaDnrC31" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote3Member_fKg_____z74P0uKsPFu5" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(56,875</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote3Member_fKg_____zd1XEo5uWTyh" style="width: 8%; text-align: right" title="ENDING BALANCE">24,375</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote3Member_fKg_____zWOfA7ZvM6yh" style="width: 8%; text-align: right" title="SHARES HELD">250,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote4Member_fKg_____zbZRhYGzWVj7" style="width: 8%; text-align: right" title="BEGINNING BALANCE">81,250</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote4Member_fKg_____zwp7mi4WnVz6" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote4Member_fKg_____zawafiym4j9" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote4Member_fKg_____z53EAhQ1KBze" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote4Member_fKg_____zABomsohf491" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98C_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote4Member_fKg_____zjaW1c8IUJF6" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(56,875</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote4Member_fKg_____zxaDRdLryuT8" style="width: 8%; text-align: right" title="ENDING BALANCE">24,375</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote4Member_fKg_____zaR3H1NQyGN6" style="width: 8%; text-align: right" title="SHARES HELD">250,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote5Member_fKg_____zvdtMqWK7r3f" style="width: 8%; text-align: right" title="BEGINNING BALANCE">81,250</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote5Member_fKg_____zXSLTysCvQDb" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote5Member_fKg_____zNzAO4Px6Nuj" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote5Member_fKg_____zEpvZzJ97qHk" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote5Member_fKg_____zkQASy32VRtf" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote5Member_fKg_____zJiTeEYfxSVb" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(56,875</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote5Member_fKg_____z8nEgC2vZ1xh" style="width: 8%; text-align: right" title="ENDING BALANCE">24,375</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote5Member_fKg_____zuIVf6XtlVoj" style="width: 8%; text-align: right" title="SHARES HELD">250,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote6Member_fKg_____zW3FiQFCHg34" style="width: 8%; text-align: right" title="BEGINNING BALANCE">227,500</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote6Member_fKg_____zof97qOI9C25" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote6Member_fKg_____zyu8kR7TSCFh" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote6Member_fKg_____zGhyE2lC5hGa" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote6Member_fKg_____zS3Zqm0B10Fk" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_988_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote6Member_fKg_____zvfdnZfWLXFi" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(159,250</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote6Member_fKg_____zhK5kXPJxY81" style="width: 8%; text-align: right" title="ENDING BALANCE">68,250</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote6Member_fKg_____zFRZ9LG6OGLc" style="width: 8%; text-align: right" title="SHARES HELD">700,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote7Member_fKg_____zwoWTaYMaDlf" style="width: 8%; text-align: right" title="BEGINNING BALANCE">81,250</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote7Member_fKg_____zszfatOwfcJ2" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote7Member_fKg_____zWw2lWM18hR2" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote7Member_fKg_____zMAqMffd7cQk" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote7Member_fKg_____zkZUyfK8nw61" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote7Member_fKg_____z3ttL6tk2eEi" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(56,875</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote7Member_fKg_____ztMgrzN3A3le" style="width: 8%; text-align: right" title="ENDING BALANCE">24,375</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote7Member_fKg_____zKGPFDqSlhG1" style="width: 8%; text-align: right" title="SHARES HELD">250,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote8Member_fKg_____zgQsUyZA5s2f" style="width: 8%; text-align: right" title="BEGINNING BALANCE">81,250</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote8Member_fKg_____zGiAOPgl2Dp6" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote8Member_fKg_____z5DwEkpzvByb" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote8Member_fKg_____zGa1y5TviTT9" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote8Member_fKg_____zVvuuRkzTgO8" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote8Member_fKg_____zGziMHHVGlK2" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(56,875</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote8Member_fKg_____zHjGz6m8CeFf" style="width: 8%; text-align: right" title="ENDING BALANCE">24,375</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote8Member_fKg_____z7Ut4XW7jsDd" style="width: 8%; text-align: right" title="SHARES HELD">250,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote9Member_fKg_____zUu30g53F9u3" style="width: 8%; text-align: right" title="BEGINNING BALANCE">81,250</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote9Member_fKg_____zBec1gZryoS2" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote9Member_fKg_____zivs1ExZHNR3" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote9Member_fKg_____znX1jkgQdE91" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote9Member_fKg_____zQsT0EZ7Xkje" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote9Member_fKg_____zMBPUuOrreMk" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(56,875</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote9Member_fKg_____zdtJN2WOLXh4" style="width: 8%; text-align: right" title="ENDING BALANCE">24,375</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote9Member_fKg_____zWVKEzbYT6f" style="width: 8%; text-align: right" title="SHARES HELD">250,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote10Member_fKg_____znCb4f3lX9De" style="width: 8%; text-align: right" title="BEGINNING BALANCE">43,875</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote10Member_fKg_____z142alAgGWJc" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote10Member_fKg_____zg9kf0WlwZLl" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote10Member_fKg_____zbSgzAAeqWla" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote10Member_fKg_____z6SPlekPCoT4" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote10Member_fKg_____zbz6zkYlGCqa" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(30,713</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_988_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote10Member_fKg_____zTMVMSSVOPOd" style="width: 8%; text-align: right" title="ENDING BALANCE">13,162</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote10Member_fKg_____zMkPNziMEQn1" style="width: 8%; text-align: right" title="SHARES HELD">135,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_988_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote11Member_fKg_____zp97H6ziNNTl" style="width: 8%; text-align: right" title="BEGINNING BALANCE">53,625</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote11Member_fKg_____zJ78jaHWnDQc" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote11Member_fKg_____zV0DPF2T7bzf" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote11Member_fKg_____zCz2ikW9egy6" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote11Member_fKg_____zEXNvK2uLcSg" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote11Member_fKg_____z02aqazqFnng" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(37,537</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote11Member_fKg_____zmBHPDOkfkd7" style="width: 8%; text-align: right" title="ENDING BALANCE">16,088</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote11Member_fKg_____z0r5SO5hAB97" style="width: 8%; text-align: right" title="SHARES HELD">165,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> </table><p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr> <td style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>AFFILIATE/<br/> CONTROLLED <br/> INVESTMENTS<span style="font-size: 11pt; vertical-align: bottom">*</span></b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>VALUE AT <br/> 12/31/22</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>PURCHASE/ <br/> MERGER</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>INTEREST</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>SALES/ <br/> MATURITY/ <br/> EXPIRATION</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>REALIZED <br/> GAIN (LOSS)</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>CHANGE IN <br/> APPRECIATION/ <br/> DEPRECIATION</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>VALUE <br/> 6/30/23</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>SHARES HELD <br/> AT 6/30/23</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_986_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote12Member_fKg_____z8yEHWnMNUVj" style="width: 8%; text-align: right" title="BEGINNING BALANCE">40,625</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_988_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote12Member_fKg_____zMuRd8obMT07" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_982_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote12Member_fKg_____zfTQ1GGnQEU1" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_989_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote12Member_fKg_____zN94SF9Fdxka" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_982_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote12Member_fKg_____zHtVx6F5DYwj" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_984_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote12Member_fKg_____zJF7L8WDMJg8" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(28,437</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_98B_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote12Member_fKg_____zAoM4tkwPdY7" style="width: 8%; text-align: right" title="ENDING BALANCE">12,188</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote12Member_fKg_____ztyVBueuNq81" style="width: 8%; text-align: right" title="SHARES HELD">125,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--Investments_iS_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote13Member_fKg_____zWGDD195dPFl" style="width: 8%; text-align: right" title="BEGINNING BALANCE">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_988_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote13Member_fKg_____zEq4w0KyL8P7" style="width: 8%; text-align: right" title="PURCHASE/MERGER">100,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote13Member_fKg_____zxYz6824J8q6" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote13Member_fKg_____zkoB1DTnNJ16" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote13Member_fKg_____zSNHWNzuUCEe" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote13Member_fKg_____zcFZst5tuGSd" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(90,250</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote13Member_fKg_____zd3P1wkHSrBd" style="width: 8%; text-align: right" title="ENDING BALANCE">9,750</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote13Member_fKg_____zADfNmQ5dZvb" style="width: 8%; text-align: right" title="SHARES HELD">100,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote14Member_fKg_____zzXpfnllE6Nd" style="width: 8%; text-align: right" title="BEGINNING BALANCE">81,250</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote14Member_fKg_____zEYQBKHRUrc7" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote14Member_fKg_____zBBcpWa3Qic4" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote14Member_fKg_____zJQNiFQwygwh" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_981_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote14Member_fKg_____zsp39HBqJIcg" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_981_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote14Member_fKg_____z9x4JBF7KQyg" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(56,875</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote14Member_fKg_____zOIMGNV3MjY2" style="width: 8%; text-align: right" title="ENDING BALANCE">24,375</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote14Member_fKg_____zu5gHwZdFfG3" style="width: 8%; text-align: right" title="SHARES HELD">250,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote15Member_fKg_____z3QuzvCXroR3" style="width: 8%; text-align: right" title="BEGINNING BALANCE">325,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote15Member_fKg_____zC0B3qhx81tc" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote15Member_fKg_____zZPZ2oVJmDMg" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote15Member_fKg_____zP2y8n4rYI9i" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote15Member_fKg_____zFfDXJmUWja4" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote15Member_fKg_____z59pkQozfDFg" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(227,500</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote15Member_fKg_____zkYZpxhDEQkl" style="width: 8%; text-align: right" title="ENDING BALANCE">97,500</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote15Member_fKg_____zptq7OCWYsg7" style="width: 8%; text-align: right" title="SHARES HELD">1,000,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote16Member_fKg_____zonnnEldsqSd" style="width: 8%; text-align: right" title="BEGINNING BALANCE">325,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote16Member_fKg_____zs2qpkiQgL4k" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_988_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote16Member_fKg_____z3pm8eJtRh3k" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote16Member_fKg_____zndXPVhF2lY2" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote16Member_fKg_____zjZwnvSH1R6h" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote16Member_fKg_____zP4rFhTN0we" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(227,500</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote16Member_fKg_____zQ1Je9JLIkea" style="width: 8%; text-align: right" title="ENDING BALANCE">97,500</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote16Member_fKg_____zb9eDjcFHhm3" style="width: 8%; text-align: right" title="SHARES HELD">1,000,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote17Member_fKg_____zKCU4KTgV5wk" style="width: 8%; text-align: right" title="BEGINNING BALANCE">325,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_988_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote17Member_fKg_____zoMgduadq9Wl" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote17Member_fKg_____zCSpygoG0gP4" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote17Member_fKg_____z5mPP9Lu5b82" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote17Member_fKg_____zgRFF4ZxPxJ6" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote17Member_fKg_____zOoBTvTYJkke" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(227,500</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote17Member_fKg_____zQn7mnqhdHsg" style="width: 8%; text-align: right" title="ENDING BALANCE">97,500</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote17Member_fKg_____zqw6OXg186l2" style="width: 8%; text-align: right" title="SHARES HELD">1,000,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote18Member_fKg_____zon1pp6H8RT3" style="width: 8%; text-align: right" title="BEGINNING BALANCE">1,601,930</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote18Member_fKg_____zbIcoQQvhhea" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote18Member_fKg_____zWZwHK4RjS99" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote18Member_fKg_____zTQ1U9R1W0Nj" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote18Member_fKg_____zrAutqtuej0d" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98C_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote18Member_fKg_____zKwpnQROYv2i" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(1,121,351</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote18Member_fKg_____zV36ObNN27B4" style="width: 8%; text-align: right" title="ENDING BALANCE">480,579</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote18Member_fKg_____zGv35C29auda" style="width: 8%; text-align: right" title="SHARES HELD">4,929,015</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote19Member_fKg_____zQshFMNpXzl7" style="width: 8%; text-align: right" title="BEGINNING BALANCE">243,750</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote19Member_fKg_____zqmKSfcJXEb4" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote19Member_fKg_____zPm2XMRCaMK7" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote19Member_fKg_____ze2kCX14QSr" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote19Member_fKg_____zRrBWkXjXI74" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote19Member_fKg_____zNRrnu6VcAEd" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(170,625</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote19Member_fKg_____z1pk2hX13TCf" style="width: 8%; text-align: right" title="ENDING BALANCE">73,125</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote19Member_fKg_____z8vk4lwKEZX5" style="width: 8%; text-align: right" title="SHARES HELD">750,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote20Member_fKg_____z6DA2EQIctja" style="width: 8%; text-align: right" title="BEGINNING BALANCE">292,500</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote20Member_fKg_____zeiymRU0kfWl" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote20Member_fKg_____zykIpvSL7eol" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote20Member_fKg_____z7zSik4DMd5f" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote20Member_fKg_____zfCreHiB6THi" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote20Member_fKg_____zdpV1ftmxiui" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(204,750</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote20Member_fKg_____zL4YjSSMXIq1" style="width: 8%; text-align: right" title="ENDING BALANCE">87,750</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_988_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote20Member_fKg_____zrM13GrIVRLh" style="width: 8%; text-align: right" title="SHARES HELD">900,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote21Member_fKg_____zMMHVdauEUC4" style="width: 8%; text-align: right" title="BEGINNING BALANCE">121,875</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_988_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote21Member_fKg_____zlOPyn376co8" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote21Member_fKg_____zPnQTTxm6eKa" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote21Member_fKg_____zoNqVYappMGi" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote21Member_fKg_____zP2mUt6Dm0fb" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote21Member_fKg_____zwRM4kdw2BL3" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(85,313</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote21Member_fKg_____zcW8y4TNBiq5" style="width: 8%; text-align: right" title="ENDING BALANCE">36,562</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote21Member_fKg_____zgXPza1SY6rc" style="width: 8%; text-align: right" title="SHARES HELD">375,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote22Member_fKg_____zG3qAwmQQghl" style="width: 8%; text-align: right" title="BEGINNING BALANCE">130,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote22Member_fKg_____zJwco4LKQYR4" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote22Member_fKg_____zp59qBqWaAKk" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote22Member_fKg_____zCwvLE1NKPVj" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote22Member_fKg_____zRzTsIAdTFJl" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote22Member_fKg_____z3g1VIgTVak9" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(91,000</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote22Member_fKg_____zCUl2uGz0S08" style="width: 8%; text-align: right" title="ENDING BALANCE">39,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote22Member_fKg_____zDKrkNreWV5a" style="width: 8%; text-align: right" title="SHARES HELD">400,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote23Member_fKg_____zL069o5tjNPj" style="width: 8%; text-align: right" title="BEGINNING BALANCE">341,250</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote23Member_fKg_____zhTCMFNQXtA5" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote23Member_fKg_____zYzF8BzHvCT1" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote23Member_fKg_____zyQWxLQBeS19" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote23Member_fKg_____zgMMhhan0MGf" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote23Member_fKg_____zjYrSGIc86y5" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(238,875</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote23Member_fKg_____zUW8ENunvsPd" style="width: 8%; text-align: right" title="ENDING BALANCE">102,375</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote23Member_fKg_____zAQjiIBILa61" style="width: 8%; text-align: right" title="SHARES HELD">1,050,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote24Member_fKg_____z32vsz4GcUD8" style="width: 8%; text-align: right" title="BEGINNING BALANCE">325,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote24Member_fKg_____zZAQZMexT1Tb" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote24Member_fKg_____zZphocxgZIqj" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote24Member_fKg_____zblzGukaUqvh" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote24Member_fKg_____zji8yNYOOoM9" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote24Member_fKg_____zefw7s8vVi58" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(227,500</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote24Member_fKg_____zP5dvfXPrd4i" style="width: 8%; text-align: right" title="ENDING BALANCE">97,500</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote24Member_fKg_____z8yf9nrwJ1M5" style="width: 8%; text-align: right" title="SHARES HELD">1,000,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote25Member_fKg_____zCju34ecavab" style="width: 8%; text-align: right" title="BEGINNING BALANCE">325,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_981_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote25Member_fKg_____zLb0aUZmV8A9" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote25Member_fKg_____zbWRzHRWYZFl" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote25Member_fKg_____zef3oDFkR2C7" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote25Member_fKg_____zgpM8amz27f5" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote25Member_fKg_____zPuqbXHHOCHg" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(227,500</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote25Member_fKg_____zONd9KBt1cNg" style="width: 8%; text-align: right" title="ENDING BALANCE">97,500</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote25Member_fKg_____zpn1CmqRENMi" style="width: 8%; text-align: right" title="SHARES HELD">1,000,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote26Member_fKg_____zJehtCUri3S4" style="width: 8%; text-align: right" title="BEGINNING BALANCE">325,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote26Member_fKg_____zOJMozRED0Jh" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote26Member_fKg_____zD5crtxNpgbf" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_988_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote26Member_fKg_____zsqLR4huH8ve" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote26Member_fKg_____zIMErWtSo9a9" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote26Member_fKg_____zZp6RzFBZV6k" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(227,500</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote26Member_fKg_____zsiwEzMmN5fh" style="width: 8%; text-align: right" title="ENDING BALANCE">97,500</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote26Member_fKg_____zn8LMOIRGis8" style="width: 8%; text-align: right" title="SHARES HELD">1,000,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote27Member_fKg_____zi9yVmlgHmVd" style="width: 8%; text-align: right" title="BEGINNING BALANCE">390,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote27Member_fKg_____zkGWBn0i3Ru5" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote27Member_fKg_____z8JfJXKtMYz3" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote27Member_fKg_____zXDicwQewYF2" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_981_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote27Member_fKg_____zJIth8X2tJO" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote27Member_fKg_____zgIZal7aWuKb" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(273,000</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote27Member_fKg_____zp7TmaaD2Ea4" style="width: 8%; text-align: right" title="ENDING BALANCE">117,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote27Member_fKg_____z9J9DGJVxZsk" style="width: 8%; text-align: right" title="SHARES HELD">1,200,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote28Member_fKg_____z3NQ732bAkCk" style="width: 8%; text-align: right" title="BEGINNING BALANCE">455,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote28Member_fKg_____zaL1T4rFcIp1" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote28Member_fKg_____zM8BPRvzpnT8" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote28Member_fKg_____zkhlNym09RF2" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote28Member_fKg_____zUzsCoe6Dgq2" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote28Member_fKg_____zKbkNtN5yNzg" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(318,500</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote28Member_fKg_____zi4IyCdPR765" style="width: 8%; text-align: right" title="ENDING BALANCE">136,500</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote28Member_fKg_____zGKQcdQuEllc" style="width: 8%; text-align: right" title="SHARES HELD">1,400,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote29Member_fKg_____zVtay282Cj7e" style="width: 8%; text-align: right" title="BEGINNING BALANCE">650,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote29Member_fKg_____zKmvnFLnvQda" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote29Member_fKg_____zTI8Oc0f2eTf" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote29Member_fKg_____zCk0IqjIUttb" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote29Member_fKg_____zl7o494tZk0i" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote29Member_fKg_____zpr9jsDrLct2" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(455,000</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote29Member_fKg_____z8926RZTFYbi" style="width: 8%; text-align: right" title="ENDING BALANCE">195,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote29Member_fKg_____zKpq67v2wiBh" style="width: 8%; text-align: right" title="SHARES HELD">2,000,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote30Member_fKg_____zCVvrMubrjLb" style="width: 8%; text-align: right" title="BEGINNING BALANCE">130,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote30Member_fKg_____z1bgbZmSHqI6" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote30Member_fKg_____zAIaVzGzWvmf" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote30Member_fKg_____z5VCm6VvVFN2" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote30Member_fKg_____zIgpsxw9qsJa" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote30Member_fKg_____zBVraxTaS7q" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(91,000</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote30Member_fKg_____zNVViyae0X4h" style="width: 8%; text-align: right" title="ENDING BALANCE">39,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_981_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote30Member_fKg_____zpPyd1Vlrhc2" style="width: 8%; text-align: right" title="SHARES HELD">400,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote31Member_fKg_____zWjw5n7kXWpe" style="width: 8%; text-align: right" title="BEGINNING BALANCE">97,500</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote31Member_fKg_____zl8aJJN4aMt6" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote31Member_fKg_____zgdHC01PCjqe" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote31Member_fKg_____z7R4kDrgrdQj" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote31Member_fKg_____zRPjgKlESy81" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote31Member_fKg_____zwkWRQNSzpql" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(68,250</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote31Member_fKg_____zjLpclTxZeAl" style="width: 8%; text-align: right" title="ENDING BALANCE">29,250</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote31Member_fKg_____zQJUrvWOb3I6" style="width: 8%; text-align: right" title="SHARES HELD">300,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Convertible Note<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote32Member_fKg_____zhw8U83ciWM5" style="width: 8%; text-align: right" title="BEGINNING BALANCE">325,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote32Member_fKg_____zrc6T0PFqVfa" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote32Member_fKg_____zOCeuywaA5R2" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote32Member_fKg_____zHUEOUnkhtIk" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote32Member_fKg_____zvqXOHt5kmu" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_980_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote32Member_fKg_____zhEq5RKVOZQ" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(227,500</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote32Member_fKg_____zv7zQGFZhOCe" style="width: 8%; text-align: right" title="ENDING BALANCE">97,500</td> <td style="padding-left: -10pt; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncConvertibleNote32Member_fKg_____zOn98lo6yGgj" style="width: 8%; text-align: right" title="SHARES HELD">1,000,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> </table><p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr> <td style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 4.5pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>AFFILIATE/<br/> CONTROLLED <br/> INVESTMENTS<span style="font-size: 11pt; vertical-align: bottom">*</span></b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>VALUE AT <br/> 12/31/22</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>PURCHASE/ <br/> MERGER</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>INTEREST</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>SALES/ <br/> MATURITY/ <br/> EXPIRATION</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>REALIZED <br/> GAIN (LOSS)</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>CHANGE IN <br/> APPRECIATION/ <br/> DEPRECIATION</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>VALUE <br/> 6/30/23</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt"><b>SHARES HELD <br/> AT 6/30/23</b></p></td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Series AA Preferred<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_989_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncSeriesAAPreferredMember_fKg_____zF1IAHpOPQac" style="width: 8%; text-align: right" title="BEGINNING BALANCE">1,049,478</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_98F_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncSeriesAAPreferredMember_fKg_____zyp1OO5Ft9g3" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_98D_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncSeriesAAPreferredMember_fKg_____zNAOa7IHSwRc" style="width: 8%; text-align: right" title="INTEREST">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_989_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncSeriesAAPreferredMember_fKg_____zs8sy0PBngEk" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_982_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncSeriesAAPreferredMember_fKg_____zbWRZU3CO5C4" style="width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_989_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncSeriesAAPreferredMember_fKg_____z23vpje5KQy6" style="width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(476,245</td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_988_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncSeriesAAPreferredMember_fKg_____zVBSTUacFcY1" style="width: 8%; text-align: right" title="ENDING BALANCE">573,233</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--SharesIssued_iI_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncSeriesAAPreferredMember_fKg_____zV6W9RhXvpPi" style="width: 8%; text-align: right" title="SHARES HELD">60,733,693</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Wrightspeed, Inc. Series AA Warrants<span style="font-size: 11pt; vertical-align: bottom">*</span></p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncSeriesAAWarrantsMember_fKg_____zlO53qkGD6n8" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="BEGINNING BALANCE">3,232</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--PaymentsForMergerRelatedCosts_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncSeriesAAWarrantsMember_fKg_____zSSPHDGyIJVe" style="width: 8%; text-align: right" title="PURCHASE/MERGER">—</td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncSeriesAAWarrantsMember_fKg_____z6Qrac95DRZ2" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="INTEREST">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_982_eus-gaap--GainLossOnSaleOfInvestments_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncSeriesAAWarrantsMember_fKg_____zrQ79SQrgeR8" style="width: 8%; text-align: right" title="SALES/MATURITY/EXPIRATION">—</td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncSeriesAAWarrantsMember_fKg_____zILooApMRDbf" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98B_ecustom--ChangeInAppreciationdepreciation_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncSeriesAAWarrantsMember_fKg_____zm3zWPML6eq7" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(3,232</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left">)</td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--Investments_iE_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncSeriesAAWarrantsMember_fKg_____zRUIjInvYC2h" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="ENDING BALANCE">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--SharesIssued_iI_d0_c20230630__us-gaap--InvestmentTypeAxis__custom--WrightspeedIncSeriesAAWarrantsMember_fKg_____zbuSataAshri" style="width: 8%; text-align: right" title="SHARES HELD">—</td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Total Automotive</p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_98C_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember_zquhqRn2UBLc" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="BEGINNING BALANCE">8,862,686</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_980_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember_zD2KiryuoJN3" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="INTEREST">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_984_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember_zZf5XvmjGmX4" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_98C_ecustom--ChangeInAppreciationdepreciation_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember_pp0p0" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(6,036,564</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left">)</td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_985_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AutomotiveMember_ztGfVRD8X2f7" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="ENDING BALANCE">2,926,122</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Total Affiliates and Controlled Investments</p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_984_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--TotalAffiliatesAndControlledInvestmentsMember_zSreAFVmnaEj" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="BEGINNING BALANCE">39,349,502</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_987_eus-gaap--InterestIncomeExpenseNet_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--TotalAffiliatesAndControlledInvestmentsMember_pp0p0" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="INTEREST">299,467</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_98C_eus-gaap--DebtAndEquitySecuritiesGainLoss_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--TotalAffiliatesAndControlledInvestmentsMember_pp0p0" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">(7,864,997</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left">)</td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_984_ecustom--ChangeInAppreciationdepreciation_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--TotalAffiliatesAndControlledInvestmentsMember_pp0p0" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(11,140,362</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left">)</td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_98E_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--TotalAffiliatesAndControlledInvestmentsMember_zcTtCJuiDIe2" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="ENDING BALANCE">19,945,807</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: Gainsboro"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Total Affiliates</p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--AffiliatesMember_z4n2J9MzTcM7" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="BEGINNING BALANCE">337,500</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_983_eus-gaap--InterestIncomeExpenseNet_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--AffiliatesMember_zxbpl5gCwbzc" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="INTEREST">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--DebtAndEquitySecuritiesGainLoss_pp0p0_d0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--AffiliatesMember_zTXHo5GqxNE6" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">—</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98E_ecustom--ChangeInAppreciationdepreciation_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--AffiliatesMember_pp0p0" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(71,409</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left">)</td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98C_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--AffiliatesMember_zAHyeLWcDMDj" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="ENDING BALANCE">266,091</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom"><p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 13.5pt; text-indent: -9pt; margin-bottom: 0pt; margin-top: 0pt">Total Controlled Investments</p></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td> <td id="xdx_986_eus-gaap--Investments_iS_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--ControlledInvestmentsMember_zupMH0YRC5l6" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right" title="BEGINNING BALANCE">39,012,002</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; padding-bottom: 2.5pt; text-align: left"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td> <td id="xdx_980_eus-gaap--InterestIncomeExpenseNet_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--ControlledInvestmentsMember_pp0p0" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right" title="INTEREST">299,467</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; padding-bottom: 2.5pt; text-align: left"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td> <td id="xdx_981_eus-gaap--DebtAndEquitySecuritiesGainLoss_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--ControlledInvestmentsMember_pp0p0" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right" title="REALIZED GAIN (LOSS)">(7,864,997</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; text-align: left">)</td> <td style="border-bottom: Black 2.5pt double; width: 1%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td> <td id="xdx_98D_ecustom--ChangeInAppreciationdepreciation_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--ControlledInvestmentsMember_pp0p0" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right" title="CHANGE IN APPRECIATION/(DEPRECIATION)">(11,068,953</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; text-align: left">)</td> <td style="border-bottom: Black 2.5pt double; width: 1%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td> <td id="xdx_98E_eus-gaap--Investments_iE_pp0p0_c20230101__20230630__us-gaap--InvestmentTypeAxis__custom--ControlledInvestmentsMember_zwlKHY4tlgx2" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right" title="ENDING BALANCE">19,679,716</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right"> </td> <td style="white-space: nowrap; width: 1%; padding-bottom: 2.5pt; text-align: left"> </td> </tr> </table><p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="width: 18pt; vertical-align: top; text-align: right"> <p style="font: 11pt Times New Roman; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><i><span id="xdx_F0E_ztKPcbqFcw17" style="font-size: 11pt; vertical-align: bottom">*</span> </i> </p> </td> <td style="vertical-align: top; text-align: left"> <p style="font: 11pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><i id="xdx_F17_zXqkD6M2g9K4">Controlled Investments. </i></p> </td> </tr> </table> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="width: 18pt; vertical-align: top; text-align: right"> <p style="font: 11pt Times New Roman; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><i id="xdx_F02_zDXLVb38Bs3">(1)</i></p> </td> <td style="vertical-align: top; text-align: left"> <p style="font: 11pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"> <i id="xdx_F1F_zA7pwRCgtjOe">CDI: CHESS Depositary Interest </i></p> </td> </tr> </table> 11130 0 0 0 0 -9250 1880 100000 865995 0 0 0 0 -482239 383756 1950000 877125 0 0 -491489 385636 5359791 0 269478 0 0 0 5359791 5359791 1200000 0 29989 0 0 0 1200000 1200000 4735 0 0 0 0 -2169 2566 3642324 275585 0 0 0 0 -56352 219233 7039203 478608 0 0 0 0 -98084 380524 12250000 242817 0 0 0 0 -49762 193055 6214922 205118 0 0 0 0 -42036 163082 5250000 27349 0 0 0 0 -5605 21744 700000 103747 0 0 0 0 -21214 82533 2650000 7897750 299467 0 -275222 7622528 6746169 0 0 0 0 -4761350 1984819 10961129 800102 0 0 0 0 -564701 235401 1300000 307731 0 0 0 0 -217192 90539 500000 307731 0 0 0 0 -217192 90539 500000 1846389 0 0 0 0 -1303155 543234 3000000 615463 0 0 0 0 -434385 181078 1000000 246185 0 0 0 0 -173754 72431 400000 307731 0 0 0 0 -217192 90539 500000 461597 0 0 0 0 -325788 135809 750000 307731 0 0 0 0 -217192 90539 500000 307732 0 0 0 0 -217193 90539 500000 307732 0 0 0 0 -217193 90539 500000 615463 0 0 0 0 -434385 181078 1000000 307732 0 0 0 0 -217193 90539 500000 615463 0 0 0 0 -434385 181078 1000000 307732 0 0 0 0 -217193 90539 500000 307732 0 0 0 0 -217193 90539 500000 307732 0 0 0 0 -217193 90539 500000 123093 0 0 0 0 -86877 36216 200000 430824 0 0 0 0 -304069 126755 700000 92319 0 0 0 0 -65157 27162 150000 215412 0 0 0 0 -152035 63377 350000 0 0 0 0 0 0 0 26856187 1230926 0 0 0 0 -868770 362156 2000000 17116721 0 0 -12080737 5035984 3520496 0 0 0 0 188950 3709446 39774889 3520496 0 0 188950 3709446 111 0 0 -7966 -161080 168935 0 0 1 0 0 -1 -6677 6677 0 0 306671 88 0 -417972 -3462620 3573833 0 0 35529 0 0 -7241 -929654 901366 0 0 2552 0 0 -7351 -424549 429348 0 0 320592 0 0 -49292 -2323111 2051811 0 0 70806 0 0 -7885 -448504 385583 0 0 962 0 0 -716 -108802 108556 0 0 737224 0 -7864997 7626109 0 337500 0 0 0 0 -71409 266091 1500000 337500 0 0 -71409 266091 546 0 0 0 0 -235 311 69102 65000 0 0 0 0 -45500 19500 200000 60125 0 0 0 0 -42088 18037 185000 21125 0 0 0 0 -14788 6337 65000 81250 0 0 0 0 -56875 24375 250000 81250 0 0 0 0 -56875 24375 250000 81250 0 0 0 0 -56875 24375 250000 227500 0 0 0 0 -159250 68250 700000 81250 0 0 0 0 -56875 24375 250000 81250 0 0 0 0 -56875 24375 250000 81250 0 0 0 0 -56875 24375 250000 43875 0 0 0 0 -30713 13162 135000 53625 0 0 0 0 -37537 16088 165000 40625 0 0 0 0 -28437 12188 125000 0 100000 0 0 0 -90250 9750 100000 81250 0 0 0 0 -56875 24375 250000 325000 0 0 0 0 -227500 97500 1000000 325000 0 0 0 0 -227500 97500 1000000 325000 0 0 0 0 -227500 97500 1000000 1601930 0 0 0 0 -1121351 480579 4929015 243750 0 0 0 0 -170625 73125 750000 292500 0 0 0 0 -204750 87750 900000 121875 0 0 0 0 -85313 36562 375000 130000 0 0 0 0 -91000 39000 400000 341250 0 0 0 0 -238875 102375 1050000 325000 0 0 0 0 -227500 97500 1000000 325000 0 0 0 0 -227500 97500 1000000 325000 0 0 0 0 -227500 97500 1000000 390000 0 0 0 0 -273000 117000 1200000 455000 0 0 0 0 -318500 136500 1400000 650000 0 0 0 0 -455000 195000 2000000 130000 0 0 0 0 -91000 39000 400000 97500 0 0 0 0 -68250 29250 300000 325000 0 0 0 0 -227500 97500 1000000 1049478 0 0 0 0 -476245 573233 60733693 3232 0 0 0 0 -3232 0 0 8862686 0 0 -6036564 2926122 39349502 299467 -7864997 -11140362 19945807 337500 0 0 -71409 266091 39012002 299467 -7864997 -11068953 19679716 <p id="xdx_805_ecustom--MarketDisruptionGeopoliticalRisksTextBlock_zvNwNm82Bmf4" style="font: 14pt Times New Roman, Times, Serif; text-align: left; margin-left: 18pt; text-indent: -18pt; margin-bottom: 0pt; margin-top: 0pt"><b>NOTE 11. <span><span id="xdx_822_z4fuFzbKxjQj">MARKET DISRUPTION AND GEOPOLITICAL RISKS</span> </span></b></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">Certain local, regional or global events such as war, acts of terrorism, the spread of infectious illness or other public health issues, or other events could have a significant impact on a security or instrument. Since 2020, the novel strain of coronavirus (COVID-19) has negatively affected the worldwide economy, as well as the economies of individual countries, the financial health of individual companies and the market in general in significant and unforeseen ways. Following Russia’s large-scale invasion of Ukraine, the President of the United States signed an Executive Order in February 2022 prohibiting U.S. persons from entering transactions with the Central Bank of Russia and Executive Orders in March 2022 prohibiting U.S. persons from importing oil and gas from Russia as well as other popular Russian exports, such as diamonds, seafood and vodka. The duration of the coronavirus outbreak and the Russian-Ukraine conflict could adversely affect the Company’s performance. The ultimate impact of COVID-19 and Russia invasion on the financial performance of the Company’s investments is not reasonably estimable at this time. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p id="xdx_809_eus-gaap--SubsequentEventsTextBlock_zVS8MUh9H8ak" style="font: 14pt Times New Roman, Times, Serif; text-align: left; margin-left: 18pt; text-indent: -18pt; margin-bottom: 0pt; margin-top: 0pt"><b>NOTE 12. <span id="xdx_82B_zAgOLNwPBFue">SUBSEQUENT EVENTS</span> </b></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-left: 0pt; text-indent: 0pt; margin-bottom: 0pt; margin-top: 0pt">Management has evaluated the impact of all subsequent events on the Company through the date the financial statements were issued and has determined that there were no subsequent events requiring recognition or disclosure in the financial statements. </p> Includes Fidelity Investment Money Market Treasury Portfolio - Class I, which invests primarily in U.S. Treasury securities. The yields as of 06/30/23 and 12/31/22 were 4.98% and 4.13%, respectively. Please see https://fundresearch.fidelity.com/mutual-funds/summary/316175504 for additional information. Includes warrants whose primary risk exposure is equity contracts. Primary exposure is equity risk. Per share results are calculated based on weighted average shares outstanding for each period. Calculated using average shares outstanding. Amount includes the incentive fee. For the years ended December 31, 2019 and December 31, 2018, the ratio of the incentive fee to average net assets was (5.64)% and 3.98%, respectively. Deferred tax expense estimate is derived from net investment income (loss), and realized and unrealized gains (losses). The deferred tax expense and tax benefit are based on average net assets. As restated to reflect the removal of parenthetical notation to appropriately present ratio as deferred tax expense. Deferred tax benefit estimate for the ratio calculation is derived from net investment income (loss) only. Not Annualized. Less than 1% Annualized. Restricted security. Fair Value is determined by or under the direction of the Company's Board of Directors (see Note 3). At June 30, 2023, we held $16,336,361 (or 147.2% of net assets) in restricted securities (see Note 2). Controlled investments. Fair Value Level 3 security (147.2% of net assets). Security whose interest accrues until maturity however, based on June 30, 2023 valuation no such interest accrued during period ended June 30, 2023. Affiliated issuer. The Fidelity Investments Money Market Treasury Portfolio invests primarily in U.S. Treasury securities. Non-income producing security. Restricted security. Fair Value is determined by or under the direction of the Company's Board of Directors (See note 3). At December 31, 2022, we held $35,929,006 (or 117.3% of net assets) in restricted securities (see Note 2). Controlled investments. Fair Value Level 3 security. Affiliated issuer. Security whose interest accrues over the life of the Note and is not payable until maturity. An interest adjustment was made during the year ending December 31, 2022 of approximately $21,400,000. The Fidelity Investments Money Market Treasury Portfolio invests primarily in U.S. Treasury securities. Asset derivatives include warrants. The net change in unrealized appreciation (depreciation) from Level 3 instruments held as of June 30, 2023 was $ (18,952,188). Controlled Investments. CDI: CHESS Depositary Interest EXCEL 58 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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
)S6*IH5!'.4A)@PI-6!(; P+ M#&6JP)!2 X;$UF=)H4Q[8DBI 4-B TETP)!2)PPI-6!(;!9+#64Z"D-*$H8T M&^&Z5&%("3"DI,:0DH AN5G*K"I3P)!2)PPI"1B2%^],51A2 @PI:3$D6\>0 MR/I+"P@PI+0:AI2&8$@),*34 T-* H;DO" XL&GL+((RU8M(21"1RL"J,@4, M*2DPI-2 (;'U65(HTYX84FK D-A $ATPI-0)0TH-&!*;Q5)#F8["D)*$(5F7 MA:>,5!I2 @TIJ36D)&A(9K*EXA,I-9A(; P+#'6J,)%2@XG$UF=) MH4Y[FDBIP41B TET,)%2)Q,I-9A(;!9+#74ZRD1*S282B\ .!NI4;2*E1A.) M36*9H4X[F4BIV41B$UEVJ%.MB63K)A)9?VD%@8F45C.1TA 3*8&)E'J82*G5 M1&+3V%D$=:HWD5*#B<3&L,!0IPH3*3682&Q]EA3JM*>)E!I,)#:01 <3*74R MD5*#B<1FL=10IZ-,I-1L(K$([&"@3M4F4FHTD=@DEAGJM).)E)I-)#:198WJ>Y@41BZ[.D,R3MV*>Y@41B TET()%R)Q(I-Y!(;!9+#7TZBD3*$HDD M/M!E$=C!0)^J2:0LD$AF%D.K^A1,I-S)1,J"B63%YWO91)8=^E2+(KDZBD36 M7]I!@"+EU5"D/ 1%RH BY1XH4A90)/&=IVP:.XN@3_4H4FY D=@8%ACZ5($B MY084B:W/DD*?]D21<@.*Q :2Z( BY4XH4FY D=@LEAKZ=!2*E"4427KG*4O MC@7J5&TB9<%$DMYYRB:QS-"FG4RD+)A(\LVIRD3*8")EK8GDZB8267]I 8&) ME%PD@B[5DTBY@41B8UA@Z%(%B90;2"2V M/DL*7=J31,H-)!(;2*(#B90[D4BY@41BLUAJZ-)1)%*62*28RS>$LP3L6*!+ MU212%DBD6ZVTR*SJ4B"1YLWSR/]__[347*0U2D#"I2[J$B94%%,I.??:0J5&"1LIY%R@TL M$AO# D.A*EBDW, BL?594BC4GBQ2;F"1V$ 2'5BDW(E%R@TL$IO%4D.ACF*1 MLL0B^12MOR\,L0CL8*!0U2Q2%EBDD)QU]YEA-HJ%AD;MQ")E@46*4W(NSF5X M5:6"BY0_TT6"2OWKZ6YW>M-3U48=XB)E<)'R:BY2'N(B97"1<@\7*8LNDKMO M5K-9[!R".M6K2+E!16)C6&"H4X6*E!M4)+8^2PIUVE-%R@TJ$AM(HH.*E#NI M2+E!16*S6&JHTU$J4I94).FR5)E(.4*91G69QK),RV^]JD?!0\J=/*0L>$AE M:E6!@H24B83TP^7UZ3FVS.-] 3VYO+C>79Z?WY;JH9ZJ13I$1,H@(N751*0\ M1$3*("+E'B)2ED2DV?DY3(>K]EX$:$6B#E5+1E"-[#S[F([-A7(CAE#[OEL6 MW4G:GX;S?#0%%!?A@!3[:%EB)\88/[EX[%\%<*%,P)^&35%@AO(IJNT%]F:57$!! ^0[F66$WJ!- BX\%FH5 /6V[@> ".?>[YVKO M!8"2(+Y/=2^X^UJYSNZ-A-V\SN2T;P-WZS2-APV8J#;+K_^[A7^_+>TO__E8 M*-B2B5S3-F6@T2QX4U)=FW^S5]_[+=@_ M.6,B[Q=__)O]CR=/GW^Q>?+ML]>O-T^W[R^OSJY/=__<_Z7K[?["N9:NEH=7 M/V^WUT]/KT\???ENN_MI^V1[?GZU>7/YX>+ZYML*O[O9;7_S MBZO-^?;'?<3ICS<]=?MDY:=?7%^^_^K!_I+Y^^7U]>6[V__\>7OZ=KN[^0O[ M/__Q\O+ZTR]N!OQZN?O'[;?AT?\'4$L#!!0 ( +J+#U>E/1RO4P, ,X5 M - >&PO^[Q^9RX]$N]%.QNQICV M%IF0Y8#,M"Z^^'XYF;&,EE=YP:1!TEQE5)NNFOIEH1A-2G#*A-]NM2(_HUR2 M85_.LYM,E]XDGTL](+W&Y-G;]V1 @N@S\2S=*$_8@#QSSZ= MG;4>+J]W[1<5<$E\)VGG -*K%LYK,(PZ.HQZ+S=*WMTF7XT_-V2-\SGFW#M( MV1Y=&''L4+66A.GIMIR3V9@*YA@^1 MB@$94<''BH-72C,NEM;3(N;EK^*%O=LH5?EM$AQS>T3U/QO\SQEDBDJ-D6;VC_F++]9<=A]+\G5 M4V57L%-C?20X=I&=4Q 9';_(,#Y^C?7![-A%]DY!Y"DL=_?=GNRO$1DB=A,\5P#XLX;>,2Q>[6Q.."!K0)6.Q#?'0=JRNT3AK"J MF#9L!^-('&,(U**[1J,(R4X$'_?Z8+LD#./8C0#F5A"&& *[$4@_NO(_\U7O*7_^".WP&4$L#!!0 ( +J+#U>7BKL

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

IG 0!X;"]W;W)K8F]O M:RYX;6Q02P$"% ,4 " "ZBP]7*5V(H),! #B& &@ M@ '6:P$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " "Z MBP]7B(RI-Z4! O&0 $P @ &A;0$ 6T-O;G1E;G1?5'EP =97-=+GAM;%!+!08 ,0 Q $X- !W;P$ ! end XML 59 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 60 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 61 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 742 225 1 true 196 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://firsthandtvf.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Consolidated Statements of Assets and Liabilities (UNAUDITED) Sheet http://firsthandtvf.com/role/StatementsOfAssetsAndLiabilities Consolidated Statements of Assets and Liabilities (UNAUDITED) Statements 2 false false R3.htm 00000003 - Statement - Consolidated Statements of Assets and Liabilities (UNAUDITED) (Parenthetical) Sheet http://firsthandtvf.com/role/StatementsOfAssetsAndLiabilitiesParenthetical Consolidated Statements of Assets and Liabilities (UNAUDITED) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statements of Operations (Unaudited) Sheet http://firsthandtvf.com/role/StatementsOfOperations Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Consolidated Statements of Cash Flows (Unaudited) Sheet http://firsthandtvf.com/role/StatementsOfCashFlows Consolidated Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Consolidated Statements of Changes in Net Assets (Unaudited) Sheet http://firsthandtvf.com/role/StatementsOfChangesInNetAssets Consolidated Statements of Changes in Net Assets (Unaudited) Statements 6 false false R7.htm 00000007 - Statement - Consolidated Financial Highlights Sheet http://firsthandtvf.com/role/FinancialHighlights Consolidated Financial Highlights Statements 7 false false R8.htm 00000008 - Statement - Consolidated Schedule of Investments Sheet http://firsthandtvf.com/role/ScheduleOfInvestments Consolidated Schedule of Investments Statements 8 false false R9.htm 00000009 - Disclosure - THE COMPANY Sheet http://firsthandtvf.com/role/Company THE COMPANY Notes 9 false false R10.htm 00000010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://firsthandtvf.com/role/SummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 10 false false R11.htm 00000011 - Disclosure - BUSINESS RISKS AND UNCERTAINTIES Sheet http://firsthandtvf.com/role/BusinessRisksAndUncertainties BUSINESS RISKS AND UNCERTAINTIES Notes 11 false false R12.htm 00000012 - Disclosure - INVESTMENT MANAGEMENT FEE Sheet http://firsthandtvf.com/role/InvestmentManagementFee INVESTMENT MANAGEMENT FEE Notes 12 false false R13.htm 00000013 - Disclosure - DEBT Sheet http://firsthandtvf.com/role/Debt DEBT Notes 13 false false R14.htm 00000014 - Disclosure - FAIR VALUE Sheet http://firsthandtvf.com/role/FairValue FAIR VALUE Notes 14 false false R15.htm 00000015 - Disclosure - FEDERAL INCOME TAXES Sheet http://firsthandtvf.com/role/FederalIncomeTaxes FEDERAL INCOME TAXES Notes 15 false false R16.htm 00000016 - Disclosure - INVESTMENT TRANSACTIONS Sheet http://firsthandtvf.com/role/InvestmentTransactions INVESTMENT TRANSACTIONS Notes 16 false false R17.htm 00000017 - Disclosure - SHARE BUYBACKS Sheet http://firsthandtvf.com/role/ShareBuybacks SHARE BUYBACKS Notes 17 false false R18.htm 00000018 - Disclosure - INVESTMENTS IN AFFILIATES AND CONTROLLED INVESTMENTS Sheet http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestments INVESTMENTS IN AFFILIATES AND CONTROLLED INVESTMENTS Notes 18 false false R19.htm 00000019 - Disclosure - MARKET DISRUPTION AND GEOPOLITICAL RISKS Sheet http://firsthandtvf.com/role/MarketDisruptionAndGeopoliticalRisks MARKET DISRUPTION AND GEOPOLITICAL RISKS Notes 19 false false R20.htm 00000020 - Disclosure - SUBSEQUENT EVENTS Sheet http://firsthandtvf.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 20 false false R21.htm 00000021 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://firsthandtvf.com/role/SummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 21 false false R22.htm 00000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://firsthandtvf.com/role/SummaryOfSignificantAccountingPoliciesTables SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://firsthandtvf.com/role/SummaryOfSignificantAccountingPolicies 22 false false R23.htm 00000023 - Disclosure - FAIR VALUE (Tables) Sheet http://firsthandtvf.com/role/FairValueTables FAIR VALUE (Tables) Tables http://firsthandtvf.com/role/FairValue 23 false false R24.htm 00000024 - Disclosure - FEDERAL INCOME TAXES (Tables) Sheet http://firsthandtvf.com/role/FederalIncomeTaxesTables FEDERAL INCOME TAXES (Tables) Tables http://firsthandtvf.com/role/FederalIncomeTaxes 24 false false R25.htm 00000025 - Disclosure - INVESTMENT TRANSACTIONS (Tables) Sheet http://firsthandtvf.com/role/InvestmentTransactionsTables INVESTMENT TRANSACTIONS (Tables) Tables http://firsthandtvf.com/role/InvestmentTransactions 25 false false R26.htm 00000026 - Disclosure - INVESTMENTS IN AFFILIATES AND CONTROLLED INVESTMENTS (Tables) Sheet http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsTables INVESTMENTS IN AFFILIATES AND CONTROLLED INVESTMENTS (Tables) Tables http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestments 26 false false R27.htm 00000027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) Sheet http://firsthandtvf.com/role/SummaryOfSignificantAccountingPoliciesDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) Details http://firsthandtvf.com/role/SummaryOfSignificantAccountingPoliciesTables 27 false false R28.htm 00000028 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://firsthandtvf.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://firsthandtvf.com/role/SummaryOfSignificantAccountingPoliciesTables 28 false false R29.htm 00000029 - Disclosure - INVESTMENT MANAGEMENT FEE (Details Narrative) Sheet http://firsthandtvf.com/role/InvestmentManagementFeeDetailsNarrative INVESTMENT MANAGEMENT FEE (Details Narrative) Details http://firsthandtvf.com/role/InvestmentManagementFee 29 false false R30.htm 00000030 - Disclosure - FAIR VALUE (Details) Sheet http://firsthandtvf.com/role/FairValueDetails FAIR VALUE (Details) Details http://firsthandtvf.com/role/FairValueTables 30 false false R31.htm 00000031 - Disclosure - FAIR VALUE (Details 1) Sheet http://firsthandtvf.com/role/FairValueDetails1 FAIR VALUE (Details 1) Details http://firsthandtvf.com/role/FairValueTables 31 false false R32.htm 00000032 - Disclosure - FAIR VALUE (Details 2) Sheet http://firsthandtvf.com/role/FairValueDetails2 FAIR VALUE (Details 2) Details http://firsthandtvf.com/role/FairValueTables 32 false false R33.htm 00000033 - Disclosure - FEDERAL INCOME TAXES (Details) Sheet http://firsthandtvf.com/role/FederalIncomeTaxesDetails FEDERAL INCOME TAXES (Details) Details http://firsthandtvf.com/role/FederalIncomeTaxesTables 33 false false R34.htm 00000034 - Disclosure - FEDERAL INCOME TAXES (Details 1) Sheet http://firsthandtvf.com/role/FederalIncomeTaxesDetails1 FEDERAL INCOME TAXES (Details 1) Details http://firsthandtvf.com/role/FederalIncomeTaxesTables 34 false false R35.htm 00000035 - Disclosure - FEDERAL INCOME TAXES (Details 2) Sheet http://firsthandtvf.com/role/FederalIncomeTaxesDetails2 FEDERAL INCOME TAXES (Details 2) Details http://firsthandtvf.com/role/FederalIncomeTaxesTables 35 false false R36.htm 00000036 - Disclosure - FEDERAL INCOME TAXES (Details 3) Sheet http://firsthandtvf.com/role/FederalIncomeTaxesDetails3 FEDERAL INCOME TAXES (Details 3) Details http://firsthandtvf.com/role/FederalIncomeTaxesTables 36 false false R37.htm 00000037 - Disclosure - FEDERAL INCOME TAXES (Details 4) Sheet http://firsthandtvf.com/role/FederalIncomeTaxesDetails4 FEDERAL INCOME TAXES (Details 4) Details http://firsthandtvf.com/role/FederalIncomeTaxesTables 37 false false R38.htm 00000038 - Disclosure - FEDERAL INCOME TAXES (Details Narrative) Sheet http://firsthandtvf.com/role/FederalIncomeTaxesDetailsNarrative FEDERAL INCOME TAXES (Details Narrative) Details http://firsthandtvf.com/role/FederalIncomeTaxesTables 38 false false R39.htm 00000039 - Disclosure - INVESTMENT TRANSACTIONS (Details) Sheet http://firsthandtvf.com/role/InvestmentTransactionsDetails INVESTMENT TRANSACTIONS (Details) Details http://firsthandtvf.com/role/InvestmentTransactionsTables 39 false false R40.htm 00000040 - Disclosure - SHARE BUYBACKS (Details Narrative) Sheet http://firsthandtvf.com/role/ShareBuybacksDetailsNarrative SHARE BUYBACKS (Details Narrative) Details http://firsthandtvf.com/role/ShareBuybacks 40 false false R41.htm 00000041 - Disclosure - INVESTMENTS IN AFFILIATES AND CONTROLLED INVESTMENTS (Details) Sheet http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails INVESTMENTS IN AFFILIATES AND CONTROLLED INVESTMENTS (Details) Details http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsTables 41 false false All Reports Book All Reports fp0084654-3_10qaixbrl.htm fp0084654-3_ex311.htm fp0084654-3_ex312.htm fp0084654-3_ex32.htm svvc-20230630.xsd svvc-20230630_cal.xml svvc-20230630_def.xml svvc-20230630_lab.xml svvc-20230630_pre.xml fp0084654-2_46.jpg fp0084654-2_57.jpg http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 64 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "fp0084654-3_10qaixbrl.htm": { "axisCustom": 0, "axisStandard": 9, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 1634, "http://xbrl.sec.gov/dei/2023": 27 }, "contextCount": 742, "dts": { "calculationLink": { "local": [ "svvc-20230630_cal.xml" ] }, "definitionLink": { "local": [ "svvc-20230630_def.xml" ] }, "inline": { "local": [ "fp0084654-3_10qaixbrl.htm" ] }, "labelLink": { "local": [ "svvc-20230630_lab.xml" ] }, "presentationLink": { "local": [ "svvc-20230630_pre.xml" ] }, "schema": { "local": [ "svvc-20230630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 519, "entityCount": 1, "hidden": { "http://firsthandtvf.com/20230630": 23, "http://xbrl.sec.gov/dei/2023": 7, "total": 30 }, "keyCustom": 72, "keyStandard": 153, "memberCustom": 187, "memberStandard": 8, "nsprefix": "SVVC", "nsuri": "http://firsthandtvf.com/20230630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentQuarterlyReport", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://firsthandtvf.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentQuarterlyReport", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "menuCat": "Notes", "order": "10", "role": "http://firsthandtvf.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "SVVC:BusinessRisksAndUncertaintiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - BUSINESS RISKS AND UNCERTAINTIES", "menuCat": "Notes", "order": "11", "role": "http://firsthandtvf.com/role/BusinessRisksAndUncertainties", "shortName": "BUSINESS RISKS AND UNCERTAINTIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "SVVC:BusinessRisksAndUncertaintiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "SVVC:InvestmentManagementFeeTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - INVESTMENT MANAGEMENT FEE", "menuCat": "Notes", "order": "12", "role": "http://firsthandtvf.com/role/InvestmentManagementFee", "shortName": "INVESTMENT MANAGEMENT FEE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "SVVC:InvestmentManagementFeeTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - DEBT", "menuCat": "Notes", "order": "13", "role": "http://firsthandtvf.com/role/Debt", "shortName": "DEBT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - FAIR VALUE", "menuCat": "Notes", "order": "14", "role": "http://firsthandtvf.com/role/FairValue", "shortName": "FAIR VALUE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - FEDERAL INCOME TAXES", "menuCat": "Notes", "order": "15", "role": "http://firsthandtvf.com/role/FederalIncomeTaxes", "shortName": "FEDERAL INCOME TAXES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - INVESTMENT TRANSACTIONS", "menuCat": "Notes", "order": "16", "role": "http://firsthandtvf.com/role/InvestmentTransactions", "shortName": "INVESTMENT TRANSACTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:TreasuryStockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - SHARE BUYBACKS", "menuCat": "Notes", "order": "17", "role": "http://firsthandtvf.com/role/ShareBuybacks", "shortName": "SHARE BUYBACKS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:TreasuryStockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - INVESTMENTS IN AFFILIATES AND CONTROLLED INVESTMENTS", "menuCat": "Notes", "order": "18", "role": "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestments", "shortName": "INVESTMENTS IN AFFILIATES AND CONTROLLED INVESTMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "SVVC:MarketDisruptionGeopoliticalRisksTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - MARKET DISRUPTION AND GEOPOLITICAL RISKS", "menuCat": "Notes", "order": "19", "role": "http://firsthandtvf.com/role/MarketDisruptionAndGeopoliticalRisks", "shortName": "MARKET DISRUPTION AND GEOPOLITICAL RISKS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "SVVC:MarketDisruptionGeopoliticalRisksTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "SVVC:UnaffiliatedInvestmentsAtAcquisitionCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - Consolidated Statements of Assets and Liabilities (UNAUDITED)", "menuCat": "Statements", "order": "2", "role": "http://firsthandtvf.com/role/StatementsOfAssetsAndLiabilities", "shortName": "Consolidated Statements of Assets and Liabilities (UNAUDITED)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "SVVC:UnaffiliatedInvestmentsAtAcquisitionCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - SUBSEQUENT EVENTS", "menuCat": "Notes", "order": "20", "role": "http://firsthandtvf.com/role/SubsequentEvents", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "menuCat": "Policies", "order": "21", "role": "http://firsthandtvf.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:AvailableForSaleSecuritiesPurchasedOptionsPricePolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "menuCat": "Tables", "order": "22", "role": "http://firsthandtvf.com/role/SummaryOfSignificantAccountingPoliciesTables", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AvailableForSaleSecuritiesPurchasedOptionsPricePolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - FAIR VALUE (Tables)", "menuCat": "Tables", "order": "23", "role": "http://firsthandtvf.com/role/FairValueTables", "shortName": "FAIR VALUE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FederalIncomeTaxNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - FEDERAL INCOME TAXES (Tables)", "menuCat": "Tables", "order": "24", "role": "http://firsthandtvf.com/role/FederalIncomeTaxesTables", "shortName": "FEDERAL INCOME TAXES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FederalIncomeTaxNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:InvestmentTextBlock", "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - INVESTMENT TRANSACTIONS (Tables)", "menuCat": "Tables", "order": "25", "role": "http://firsthandtvf.com/role/InvestmentTransactionsTables", "shortName": "INVESTMENT TRANSACTIONS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InvestmentTextBlock", "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock", "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - INVESTMENTS IN AFFILIATES AND CONTROLLED INVESTMENTS (Tables)", "menuCat": "Tables", "order": "26", "role": "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsTables", "shortName": "INVESTMENTS IN AFFILIATES AND CONTROLLED INVESTMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock", "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "us-gaap:AvailableForSaleSecuritiesPurchasedOptionsPricePolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "SVVC:PurchasedOptionsContracts", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)", "menuCat": "Details", "order": "27", "role": "http://firsthandtvf.com/role/SummaryOfSignificantAccountingPoliciesDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "us-gaap:AvailableForSaleSecuritiesPurchasedOptionsPricePolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "SVVC:PurchasedOptionsContracts", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:InvestmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:VentureCapitalGainsLossesNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "menuCat": "Details", "order": "28", "role": "http://firsthandtvf.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:InvestmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:VentureCapitalGainsLossesNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "p", "SVVC:InvestmentManagementFeeTextBlock", "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "AsOf2023-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentInterestRateEffectivePercentage", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - INVESTMENT MANAGEMENT FEE (Details Narrative)", "menuCat": "Details", "order": "29", "role": "http://firsthandtvf.com/role/InvestmentManagementFeeDetailsNarrative", "shortName": "INVESTMENT MANAGEMENT FEE (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "SVVC:InvestmentManagementFeeTextBlock", "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "AsOf2023-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentInterestRateEffectivePercentage", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "SVVC:ForeignCurrencyCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - Consolidated Statements of Assets and Liabilities (UNAUDITED) (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://firsthandtvf.com/role/StatementsOfAssetsAndLiabilitiesParenthetical", "shortName": "Consolidated Statements of Assets and Liabilities (UNAUDITED) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "SVVC:ForeignCurrencyCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Assets", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - FAIR VALUE (Details)", "menuCat": "Details", "order": "30", "role": "http://firsthandtvf.com/role/FairValueDetails", "shortName": "FAIR VALUE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "AsOf2023-06-30_us-gaap_FairValueInputsLevel1Member", "decimals": "0", "lang": null, "name": "us-gaap:Assets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Investments", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - FAIR VALUE (Details 1)", "menuCat": "Details", "order": "31", "role": "http://firsthandtvf.com/role/FairValueDetails1", "shortName": "FAIR VALUE (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "0", "lang": null, "name": "SVVC:NetPurchasesconversions", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "AsOf2023-06-30_custom_AdvancedMaterialsMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:FairValueHedgeAssetsAtFairValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - FAIR VALUE (Details 2)", "menuCat": "Details", "order": "32", "role": "http://firsthandtvf.com/role/FairValueDetails2", "shortName": "FAIR VALUE (Details 2)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "AsOf2023-06-30_custom_AdvancedMaterialsMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:FairValueHedgeAssetsAtFairValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FederalIncomeTaxNoteTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:TaxBasisOfInvestmentsGrossUnrealizedAppreciation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - FEDERAL INCOME TAXES (Details)", "menuCat": "Details", "order": "33", "role": "http://firsthandtvf.com/role/FederalIncomeTaxesDetails", "shortName": "FEDERAL INCOME TAXES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FederalIncomeTaxNoteTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:TaxBasisOfInvestmentsGrossUnrealizedAppreciation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredFederalIncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - FEDERAL INCOME TAXES (Details 1)", "menuCat": "Details", "order": "34", "role": "http://firsthandtvf.com/role/FederalIncomeTaxesDetails1", "shortName": "FEDERAL INCOME TAXES (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredFederalIncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000035 - Disclosure - FEDERAL INCOME TAXES (Details 2)", "menuCat": "Details", "order": "35", "role": "http://firsthandtvf.com/role/FederalIncomeTaxesDetails2", "shortName": "FEDERAL INCOME TAXES (Details 2)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "From2023-04-012023-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000036 - Disclosure - FEDERAL INCOME TAXES (Details 3)", "menuCat": "Details", "order": "36", "role": "http://firsthandtvf.com/role/FederalIncomeTaxesDetails3", "shortName": "FEDERAL INCOME TAXES (Details 3)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "From2023-04-012023-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsCapitalLossCarryforwards", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000037 - Disclosure - FEDERAL INCOME TAXES (Details 4)", "menuCat": "Details", "order": "37", "role": "http://firsthandtvf.com/role/FederalIncomeTaxesDetails4", "shortName": "FEDERAL INCOME TAXES (Details 4)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "From2023-01-012023-06-30_custom_CapitalLossCarryforward1Member", "decimals": null, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000038 - Disclosure - FEDERAL INCOME TAXES (Details Narrative)", "menuCat": "Details", "order": "38", "role": "http://firsthandtvf.com/role/FederalIncomeTaxesDetailsNarrative", "shortName": "FEDERAL INCOME TAXES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:InvestmentTableTextBlock", "us-gaap:InvestmentTextBlock", "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "From2023-04-012023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtSecuritiesAvailableForSalePurchasedWithCreditDeteriorationAmountAtParValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000039 - Disclosure - INVESTMENT TRANSACTIONS (Details)", "menuCat": "Details", "order": "39", "role": "http://firsthandtvf.com/role/InvestmentTransactionsDetails", "shortName": "INVESTMENT TRANSACTIONS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:InvestmentTableTextBlock", "us-gaap:InvestmentTextBlock", "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "From2023-04-012023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtSecuritiesAvailableForSalePurchasedWithCreditDeteriorationAmountAtParValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "From2023-04-012023-06-30", "decimals": "0", "first": true, "lang": null, "name": "SVVC:UnaffiliatedInterest", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - Consolidated Statements of Operations (Unaudited)", "menuCat": "Statements", "order": "4", "role": "http://firsthandtvf.com/role/StatementsOfOperations", "shortName": "Consolidated Statements of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "From2023-04-012023-06-30", "decimals": "0", "first": true, "lang": null, "name": "SVVC:UnaffiliatedInterest", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:TreasuryStockTextBlock", "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "From2018-08-302018-08-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockRepurchasedDuringPeriodShares", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000040 - Disclosure - SHARE BUYBACKS (Details Narrative)", "menuCat": "Details", "order": "40", "role": "http://firsthandtvf.com/role/ShareBuybacksDetailsNarrative", "shortName": "SHARE BUYBACKS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:TreasuryStockTextBlock", "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "From2018-08-302018-08-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockRepurchasedDuringPeriodShares", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Investments", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000041 - Disclosure - INVESTMENTS IN AFFILIATES AND CONTROLLED INVESTMENTS (Details)", "menuCat": "Details", "order": "41", "role": "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails", "shortName": "INVESTMENTS IN AFFILIATES AND CONTROLLED INVESTMENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfInvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTableTextBlock", "us-gaap:InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock", "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "From2023-01-012023-06-30_custom_EquipmentLeasingMember351324812", "decimals": "0", "lang": null, "name": "us-gaap:InterestIncomeExpenseNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "From2023-04-012023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - Consolidated Statements of Cash Flows (Unaudited)", "menuCat": "Statements", "order": "5", "role": "http://firsthandtvf.com/role/StatementsOfCashFlows", "shortName": "Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "From2023-04-012023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "From2023-04-012023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetInvestmentIncome", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - Consolidated Statements of Changes in Net Assets (Unaudited)", "menuCat": "Statements", "order": "6", "role": "http://firsthandtvf.com/role/StatementsOfChangesInNetAssets", "shortName": "Consolidated Statements of Changes in Net Assets (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "From2023-04-012023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetInvestmentIncome", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NetAssetValuePerShare", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000007 - Statement - Consolidated Financial Highlights", "menuCat": "Statements", "order": "7", "role": "http://firsthandtvf.com/role/FinancialHighlights", "shortName": "Consolidated Financial Highlights", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "AsOf2017-12-31", "decimals": "INF", "lang": null, "name": "us-gaap:NetAssetValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Investments", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000008 - Statement - Consolidated Schedule of Investments", "menuCat": "Statements", "order": "8", "role": "http://firsthandtvf.com/role/ScheduleOfInvestments", "shortName": "Consolidated Schedule of Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "td", "tr", "table", "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "lang": null, "name": "SVVC:Investment", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentCompanyFinancialHighlightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - THE COMPANY", "menuCat": "Notes", "order": "9", "role": "http://firsthandtvf.com/role/Company", "shortName": "THE COMPANY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "fp0084654-3_10qaixbrl.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentCompanyFinancialHighlightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 196, "tag": { "SVVC_AcquisitionDates": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ACQUISITION DATE" } } }, "localname": "AcquisitionDates", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "stringItemType" }, "SVVC_AdministrationFees": { "auth_ref": [], "calculation": { "http://firsthandtvf.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Administration fees" } } }, "localname": "AdministrationFees", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "SVVC_AdvancedMaterialsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Advanced Materials [Member]" } } }, "localname": "AdvancedMaterialsMember", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/FairValueDetails", "http://firsthandtvf.com/role/FairValueDetails1", "http://firsthandtvf.com/role/FairValueDetails2", "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_AerospaceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Aerospace [Member]" } } }, "localname": "AerospaceMember", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/FairValueDetails", "http://firsthandtvf.com/role/FairValueDetails1", "http://firsthandtvf.com/role/FairValueDetails2", "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_AffiliatedInvestmentsAtAcquisitionCost": { "auth_ref": [], "calculation": { "http://firsthandtvf.com/role/StatementsOfAssetsAndLiabilities": { "order": 2.0, "parentTag": "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Affiliated investments at acquisition cost" } } }, "localname": "AffiliatedInvestmentsAtAcquisitionCost", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/StatementsOfAssetsAndLiabilities" ], "xbrltype": "monetaryItemType" }, "SVVC_AffiliatedInvestmentsAtMarketValue": { "auth_ref": [], "calculation": { "http://firsthandtvf.com/role/StatementsOfAssetsAndLiabilities": { "order": 2.0, "parentTag": "us-gaap_EquityMethodInvestmentQuotedMarketValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Affiliated investments at market value" } } }, "localname": "AffiliatedInvestmentsAtMarketValue", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/StatementsOfAssetsAndLiabilities" ], "xbrltype": "monetaryItemType" }, "SVVC_Affiliatedcontrolled": { "auth_ref": [], "calculation": { "http://firsthandtvf.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_DebtSecuritiesRealizedGainLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Affiliated/controlled" } } }, "localname": "Affiliatedcontrolled", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "SVVC_AffiliatedcontrolledInterest": { "auth_ref": [], "calculation": { "http://firsthandtvf.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_InvestmentCompanyGainLossOnInKindRedemption", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Affiliated/controlled interest" } } }, "localname": "AffiliatedcontrolledInterest", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "SVVC_AffiliatedcontrolledWarrantsInvestments1": { "auth_ref": [], "calculation": { "http://firsthandtvf.com/role/StatementsOfOperations": { "order": 3.0, "parentTag": "SVVC_NetChangeInUnrealizedDepreciation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Affiliated/controlled warrants investments" } } }, "localname": "AffiliatedcontrolledWarrantsInvestments1", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "SVVC_AffiliatesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Affiliates [Member]" } } }, "localname": "AffiliatesMember", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_AntidilutiveEffectFromCapitalShareTransactions": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Anti-dilutive effect from capital share transactions" } } }, "localname": "AntidilutiveEffectFromCapitalShareTransactions", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/FinancialHighlights" ], "xbrltype": "perShareItemType" }, "SVVC_AssetDerivativesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Asset Derivatives [Member]" } } }, "localname": "AssetDerivativesMember", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/FairValueDetails", "http://firsthandtvf.com/role/FairValueDetails1" ], "xbrltype": "domainItemType" }, "SVVC_AssetNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NET ASSETS:" } } }, "localname": "AssetNetAbstract", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/StatementsOfChangesInNetAssets" ], "xbrltype": "stringItemType" }, "SVVC_AutomotiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Automotive [Member]" } } }, "localname": "AutomotiveMember", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/FairValueDetails", "http://firsthandtvf.com/role/FairValueDetails1", "http://firsthandtvf.com/role/FairValueDetails2", "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_BasedOnMarketValue": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "BasedOnMarketValue", "negatedLabel": "Based on Market Value" } } }, "localname": "BasedOnMarketValue", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/FinancialHighlights" ], "xbrltype": "percentItemType" }, "SVVC_BasedOnNetAssetValue": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Based on Net Asset Value" } } }, "localname": "BasedOnNetAssetValue", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/FinancialHighlights" ], "xbrltype": "percentItemType" }, "SVVC_BeforeTaxBenefit": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Before tax benefit" } } }, "localname": "BeforeTaxBenefit", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/FinancialHighlights" ], "xbrltype": "percentItemType" }, "SVVC_BeforeTaxBenefitexpense": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Before tax (benefit)/expense" } } }, "localname": "BeforeTaxBenefitexpense", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/FinancialHighlights" ], "xbrltype": "percentItemType" }, "SVVC_BusinessRisksAndUncertaintiesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "BUSINESS RISKS AND UNCERTAINTIES" } } }, "localname": "BusinessRisksAndUncertaintiesTextBlock", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/BusinessRisksAndUncertainties" ], "xbrltype": "textBlockItemType" }, "SVVC_CapitalLossCarryforward1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Capital Loss Carryforward 1 [Member]" } } }, "localname": "CapitalLossCarryforward1Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/FederalIncomeTaxesDetails4" ], "xbrltype": "domainItemType" }, "SVVC_CapitalLossCarryforward2Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Capital Loss Carryforward 2 [Member]" } } }, "localname": "CapitalLossCarryforward2Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/FederalIncomeTaxesDetails4" ], "xbrltype": "domainItemType" }, "SVVC_CapitalLossCarryforward3Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Capital Loss Carryforward 3 [Member]" } } }, "localname": "CapitalLossCarryforward3Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/FederalIncomeTaxesDetails4" ], "xbrltype": "domainItemType" }, "SVVC_CapitalLossCarryforwardsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Capital Loss Carryforwards [Member]" } } }, "localname": "CapitalLossCarryforwardsMember", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/FederalIncomeTaxesDetails4" ], "xbrltype": "domainItemType" }, "SVVC_ChangeInAppreciationdepreciation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "CHANGE IN APPRECIATION/(DEPRECIATION)" } } }, "localname": "ChangeInAppreciationdepreciation", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "SVVC_CommonStockActivityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "COMMON STOCK ACTIVITY:" } } }, "localname": "CommonStockActivityAbstract", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/StatementsOfChangesInNetAssets" ], "xbrltype": "stringItemType" }, "SVVC_CommonStockPrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock price" } } }, "localname": "CommonStockPrice", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ShareBuybacksDetailsNarrative" ], "xbrltype": "perShareItemType" }, "SVVC_ComplianceFees": { "auth_ref": [], "calculation": { "http://firsthandtvf.com/role/StatementsOfOperations": { "order": 9.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Compliance fees" } } }, "localname": "ComplianceFees", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "SVVC_ConsultingFeePayable": { "auth_ref": [], "calculation": { "http://firsthandtvf.com/role/StatementsOfAssetsAndLiabilities": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Consulting fee payable" } } }, "localname": "ConsultingFeePayable", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/StatementsOfAssetsAndLiabilities" ], "xbrltype": "monetaryItemType" }, "SVVC_ControlledInvestmentsAtAcquisitionCost": { "auth_ref": [], "calculation": { "http://firsthandtvf.com/role/StatementsOfAssetsAndLiabilities": { "order": 3.0, "parentTag": "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Controlled investments at acquisition cost" } } }, "localname": "ControlledInvestmentsAtAcquisitionCost", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/StatementsOfAssetsAndLiabilities" ], "xbrltype": "monetaryItemType" }, "SVVC_ControlledInvestmentsAtMarketValue": { "auth_ref": [], "calculation": { "http://firsthandtvf.com/role/StatementsOfAssetsAndLiabilities": { "order": 3.0, "parentTag": "us-gaap_EquityMethodInvestmentQuotedMarketValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Controlled investments at market value" } } }, "localname": "ControlledInvestmentsAtMarketValue", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/StatementsOfAssetsAndLiabilities" ], "xbrltype": "monetaryItemType" }, "SVVC_ControlledInvestmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Controlled Investments [Member]" } } }, "localname": "ControlledInvestmentsMember", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_ConvertibleNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Notes [Member]" } } }, "localname": "ConvertibleNotesMember", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/FairValueDetails", "http://firsthandtvf.com/role/FairValueDetails1" ], "xbrltype": "domainItemType" }, "SVVC_DeferredTaxBenefit": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred tax benefit" } } }, "localname": "DeferredTaxBenefit", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/FinancialHighlights" ], "xbrltype": "perShareItemType" }, "SVVC_DeferredTaxBenefitexpense": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred tax (benefit)/expense" } } }, "localname": "DeferredTaxBenefitexpense", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/FinancialHighlights" ], "xbrltype": "percentItemType" }, "SVVC_DeferredTaxBenefits": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DeferredTaxBenefits", "verboseLabel": "Deferred tax benefit" } } }, "localname": "DeferredTaxBenefits", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/FinancialHighlights" ], "xbrltype": "percentItemType" }, "SVVC_DeferredTaxExpense": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred tax expense" } } }, "localname": "DeferredTaxExpense", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/FinancialHighlights" ], "xbrltype": "perShareItemType" }, "SVVC_DisclosureBusinessRisksAndUncertaintiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Risks And Uncertainties" } } }, "localname": "DisclosureBusinessRisksAndUncertaintiesAbstract", "nsuri": "http://firsthandtvf.com/20230630", "xbrltype": "stringItemType" }, "SVVC_DisclosureInvestmentManagementFeeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment Management Fee" } } }, "localname": "DisclosureInvestmentManagementFeeAbstract", "nsuri": "http://firsthandtvf.com/20230630", "xbrltype": "stringItemType" }, "SVVC_DisclosureMarketDisruptionAndGeopoliticalRisksAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Market Disruption And Geopolitical Risks" } } }, "localname": "DisclosureMarketDisruptionAndGeopoliticalRisksAbstract", "nsuri": "http://firsthandtvf.com/20230630", "xbrltype": "stringItemType" }, "SVVC_EQXCapitalIncCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "E Q X Capital Inc Common Stock [Member]" } } }, "localname": "EQXCapitalIncCommonStockMember", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_EQXCapitalIncSeriesAPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "E Q X Capital Inc Series A Preferred Stock [Member]" } } }, "localname": "EQXCapitalIncSeriesAPreferredStockMember", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_EquipmentLeasingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equipment Leasing [Member]" } } }, "localname": "EquipmentLeasingMember", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/FairValueDetails", "http://firsthandtvf.com/role/FairValueDetails1", "http://firsthandtvf.com/role/FairValueDetails2", "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails", "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_EquityContractsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity Contracts [Member]" } } }, "localname": "EquityContractsMember", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/FairValueDetails", "http://firsthandtvf.com/role/FairValueDetails1" ], "xbrltype": "domainItemType" }, "SVVC_EqxCapitalInc1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Eqx Capital Inc 1 [Member]" } } }, "localname": "EqxCapitalInc1Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_EqxCapitalIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Eqx Capital Inc [Member]" } } }, "localname": "EqxCapitalIncMember", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_ForeignCurrencyAtValue": { "auth_ref": [], "calculation": { "http://firsthandtvf.com/role/StatementsOfAssetsAndLiabilities": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Foreign currency at value (cost $2,629 and $3,235)" } } }, "localname": "ForeignCurrencyAtValue", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/StatementsOfAssetsAndLiabilities" ], "xbrltype": "monetaryItemType" }, "SVVC_ForeignCurrencyCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Foreign currency cost" } } }, "localname": "ForeignCurrencyCost", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/StatementsOfAssetsAndLiabilitiesParenthetical" ], "xbrltype": "monetaryItemType" }, "SVVC_FromOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "FROM OPERATIONS:" } } }, "localname": "FromOperationsAbstract", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/StatementsOfChangesInNetAssets" ], "xbrltype": "stringItemType" }, "SVVC_HeraSystemsInc1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Hera Systems Inc 1 [Member]" } } }, "localname": "HeraSystemsInc1Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_HeraSystemsInc2Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Hera Systems Inc 2 [Member]" } } }, "localname": "HeraSystemsInc2Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_HeraSystemsInc3Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Hera Systems Inc 3 [Member]" } } }, "localname": "HeraSystemsInc3Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_HeraSystemsInc4Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Hera Systems Inc 4 [Member]" } } }, "localname": "HeraSystemsInc4Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_HeraSystemsInc5Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Hera Systems Inc 5 [Member]" } } }, "localname": "HeraSystemsInc5Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_HeraSystemsInc6Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Hera Systems Inc 6 [Member]" } } }, "localname": "HeraSystemsInc6Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_HeraSystemsInc7Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Hera Systems Inc 7 [Member]" } } }, "localname": "HeraSystemsInc7Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_HeraSystemsInc8Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Hera Systems Inc 8 [Member]" } } }, "localname": "HeraSystemsInc8Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_HeraSystemsInc9Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Hera Systems Inc 9 [Member]" } } }, "localname": "HeraSystemsInc9Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_HeraSystemsIncConvertibleNote1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Hera Systems Inc Convertible Note 1 [Member]" } } }, "localname": "HeraSystemsIncConvertibleNote1Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_HeraSystemsIncConvertibleNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Hera Systems Inc Convertible Note [Member]" } } }, "localname": "HeraSystemsIncConvertibleNoteMember", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_HeraSystemsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Hera Systems Inc [Member]" } } }, "localname": "HeraSystemsIncMember", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_HeraSystemsIncSeriesAPreferredMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Hera Systems Inc Series A Preferred [Member]" } } }, "localname": "HeraSystemsIncSeriesAPreferredMember", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_HeraSystemsIncSeriesBPreferredMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Hera Systems Inc Series B Preferred [Member]" } } }, "localname": "HeraSystemsIncSeriesBPreferredMember", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_HeraSystemsIncSeriesBWarrants1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Hera Systems Inc Series B Warrants 1 [Member]" } } }, "localname": "HeraSystemsIncSeriesBWarrants1Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_HeraSystemsIncSeriesBWarrants2Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Hera Systems Inc Series B Warrants 2 [Member]" } } }, "localname": "HeraSystemsIncSeriesBWarrants2Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_HeraSystemsIncSeriesBWarrants3Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Hera Systems Inc Series B Warrants 3 [Member]" } } }, "localname": "HeraSystemsIncSeriesBWarrants3Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_HeraSystemsIncSeriesBWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Hera Systems Inc Series B Warrants [Member]" } } }, "localname": "HeraSystemsIncSeriesBWarrantsMember", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_HeraSystemsIncSeriesCPreferredMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Hera Systems Inc Series C Preferred [Member]" } } }, "localname": "HeraSystemsIncSeriesCPreferredMember", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_IncomeFromInvestmentOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income from investment operations:" } } }, "localname": "IncomeFromInvestmentOperationsAbstract", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/FinancialHighlights" ], "xbrltype": "stringItemType" }, "SVVC_IncreaseDecreaseInNotePayableRelatedParties": { "auth_ref": [], "calculation": { "http://firsthandtvf.com/role/StatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Increase (decrease) in payable to affiliates" } } }, "localname": "IncreaseDecreaseInNotePayableRelatedParties", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "SVVC_IncreaseDecreaseInProceedsFromDispositionOfInvestments": { "auth_ref": [], "calculation": { "http://firsthandtvf.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Proceeds from disposition of investments" } } }, "localname": "IncreaseDecreaseInProceedsFromDispositionOfInvestments", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "SVVC_IncreaseDecreaseInReceivableInInvestmentSold": { "auth_ref": [], "calculation": { "http://firsthandtvf.com/role/StatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Increase (decrease) in receivable in investment sold" } } }, "localname": "IncreaseDecreaseInReceivableInInvestmentSold", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "SVVC_IntellectualsPropertyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intellectuals Property [Member]" } } }, "localname": "IntellectualsPropertyMember", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_IntraOpMedicalCorpConvertibleNote10Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intra Op Medical Corp Convertible Note 10 [Member]" } } }, "localname": "IntraOpMedicalCorpConvertibleNote10Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_IntraOpMedicalCorpConvertibleNote11Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intra Op Medical Corp Convertible Note 11 [Member]" } } }, "localname": "IntraOpMedicalCorpConvertibleNote11Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_IntraOpMedicalCorpConvertibleNote12Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intra Op Medical Corp Convertible Note 12 [Member]" } } }, "localname": "IntraOpMedicalCorpConvertibleNote12Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_IntraOpMedicalCorpConvertibleNote13Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intra Op Medical Corp Convertible Note 13 [Member]" } } }, "localname": "IntraOpMedicalCorpConvertibleNote13Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_IntraOpMedicalCorpConvertibleNote14Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intra Op Medical Corp Convertible Note 14 [Member]" } } }, "localname": "IntraOpMedicalCorpConvertibleNote14Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_IntraOpMedicalCorpConvertibleNote15Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intra Op Medical Corp Convertible Note 15 [Member]" } } }, "localname": "IntraOpMedicalCorpConvertibleNote15Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_IntraOpMedicalCorpConvertibleNote16Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intra Op Medical Corp Convertible Note 16 [Member]" } } }, "localname": "IntraOpMedicalCorpConvertibleNote16Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_IntraOpMedicalCorpConvertibleNote17Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intra Op Medical Corp Convertible Note 17 [Member]" } } }, "localname": "IntraOpMedicalCorpConvertibleNote17Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_IntraOpMedicalCorpConvertibleNote18Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intra Op Medical Corp Convertible Note 18 [Member]" } } }, "localname": "IntraOpMedicalCorpConvertibleNote18Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_IntraOpMedicalCorpConvertibleNote19Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intra Op Medical Corp Convertible Note 19 [Member]" } } }, "localname": "IntraOpMedicalCorpConvertibleNote19Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_IntraOpMedicalCorpConvertibleNote1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intra Op Medical Corp Convertible Note 1 [Member]" } } }, "localname": "IntraOpMedicalCorpConvertibleNote1Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_IntraOpMedicalCorpConvertibleNote20Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intra Op Medical Corp Convertible Note 20 [Member]" } } }, "localname": "IntraOpMedicalCorpConvertibleNote20Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_IntraOpMedicalCorpConvertibleNote21Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intra Op Medical Corp Convertible Note 21 [Member]" } } }, "localname": "IntraOpMedicalCorpConvertibleNote21Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_IntraOpMedicalCorpConvertibleNote2Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intra Op Medical Corp Convertible Note 2 [Member]" } } }, "localname": "IntraOpMedicalCorpConvertibleNote2Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_IntraOpMedicalCorpConvertibleNote3Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intra Op Medical Corp Convertible Note 3 [Member]" } } }, "localname": "IntraOpMedicalCorpConvertibleNote3Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_IntraOpMedicalCorpConvertibleNote4Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intra Op Medical Corp Convertible Note 4 [Member]" } } }, "localname": "IntraOpMedicalCorpConvertibleNote4Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_IntraOpMedicalCorpConvertibleNote5Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intra Op Medical Corp Convertible Note 5 [Member]" } } }, "localname": "IntraOpMedicalCorpConvertibleNote5Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_IntraOpMedicalCorpConvertibleNote6Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intra Op Medical Corp Convertible Note 6 [Member]" } } }, "localname": "IntraOpMedicalCorpConvertibleNote6Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_IntraOpMedicalCorpConvertibleNote7Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intra Op Medical Corp Convertible Note 7 [Member]" } } }, "localname": "IntraOpMedicalCorpConvertibleNote7Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_IntraOpMedicalCorpConvertibleNote8Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intra Op Medical Corp Convertible Note 8 [Member]" } } }, "localname": "IntraOpMedicalCorpConvertibleNote8Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_IntraOpMedicalCorpConvertibleNote9Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intra Op Medical Corp Convertible Note 9 [Member]" } } }, "localname": "IntraOpMedicalCorpConvertibleNote9Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_IntraOpMedicalCorpConvertibleNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intra Op Medical Corp Convertible Note [Member]" } } }, "localname": "IntraOpMedicalCorpConvertibleNoteMember", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_IntraOpMedicalCorpSeriesCPreferredMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intra Op Medical Corp Series C Preferred [Member]" } } }, "localname": "IntraOpMedicalCorpSeriesCPreferredMember", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_IntraOpMedicalCorpTermNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intra Op Medical Corp Term Note [Member]" } } }, "localname": "IntraOpMedicalCorpTermNoteMember", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_IntraopMedicalCorp10Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intraop Medical Corp 10 [Member]" } } }, "localname": "IntraopMedicalCorp10Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_IntraopMedicalCorp11Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intraop Medical Corp 11 [Member]" } } }, "localname": "IntraopMedicalCorp11Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_IntraopMedicalCorp12Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intraop Medical Corp 12 [Member]" } } }, "localname": "IntraopMedicalCorp12Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_IntraopMedicalCorp13Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intraop Medical Corp 13 [Member]" } } }, "localname": "IntraopMedicalCorp13Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_IntraopMedicalCorp14Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intraop Medical Corp 14 [Member]" } } }, "localname": "IntraopMedicalCorp14Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_IntraopMedicalCorp15Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intraop Medical Corp 15 [Member]" } } }, "localname": "IntraopMedicalCorp15Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_IntraopMedicalCorp16Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intraop Medical Corp 16 [Member]" } } }, "localname": "IntraopMedicalCorp16Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_IntraopMedicalCorp17Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intraop Medical Corp 17 [Member]" } } }, "localname": "IntraopMedicalCorp17Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_IntraopMedicalCorp18Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intraop Medical Corp 18 [Member]" } } }, "localname": "IntraopMedicalCorp18Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_IntraopMedicalCorp19Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intraop Medical Corp 19 [Member]" } } }, "localname": "IntraopMedicalCorp19Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_IntraopMedicalCorp1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intraop Medical Corp 1 [Member]" } } }, "localname": "IntraopMedicalCorp1Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_IntraopMedicalCorp20Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intraop Medical Corp 20 [Member]" } } }, "localname": "IntraopMedicalCorp20Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_IntraopMedicalCorp21Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intraop Medical Corp 21 [Member]" } } }, "localname": "IntraopMedicalCorp21Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_IntraopMedicalCorp22Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intraop Medical Corp 22 [Member]" } } }, "localname": "IntraopMedicalCorp22Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_IntraopMedicalCorp23Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intraop Medical Corp 23 [Member]" } } }, "localname": "IntraopMedicalCorp23Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_IntraopMedicalCorp24Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intraop Medical Corp 24 [Member]" } } }, "localname": "IntraopMedicalCorp24Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_IntraopMedicalCorp2Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intraop Medical Corp 2 [Member]" } } }, "localname": "IntraopMedicalCorp2Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_IntraopMedicalCorp3Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intraop Medical Corp 3 [Member]" } } }, "localname": "IntraopMedicalCorp3Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_IntraopMedicalCorp4Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intraop Medical Corp 4 [Member]" } } }, "localname": "IntraopMedicalCorp4Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_IntraopMedicalCorp5Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intraop Medical Corp 5 [Member]" } } }, "localname": "IntraopMedicalCorp5Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_IntraopMedicalCorp6Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intraop Medical Corp 6 [Member]" } } }, "localname": "IntraopMedicalCorp6Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_IntraopMedicalCorp7Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intraop Medical Corp 7 [Member]" } } }, "localname": "IntraopMedicalCorp7Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_IntraopMedicalCorp8Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intraop Medical Corp 8 [Member]" } } }, "localname": "IntraopMedicalCorp8Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_IntraopMedicalCorp9Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intraop Medical Corp 9 [Member]" } } }, "localname": "IntraopMedicalCorp9Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_IntraopMedicalCorpMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intraop Medical Corp [Member]" } } }, "localname": "IntraopMedicalCorpMember", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_Investment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "TOTAL INVESTMENTS" } } }, "localname": "Investment", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "monetaryItemType" }, "SVVC_InvestmentCompanyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment Company [Member]" } } }, "localname": "InvestmentCompanyMember", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_InvestmentManagementFeeTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "INVESTMENT MANAGEMENT FEE" } } }, "localname": "InvestmentManagementFeeTextBlock", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentManagementFee" ], "xbrltype": "textBlockItemType" }, "SVVC_KymaIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Kyma Inc [Member]" } } }, "localname": "KymaIncMember", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_LiabilitiesInExcessOfOtherAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "LIABILITIES IN EXCESS OF OTHER ASSETS" } } }, "localname": "LiabilitiesInExcessOfOtherAssets", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "monetaryItemType" }, "SVVC_LynceanTechnologiesIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lyncean Technologies Inc [Member]" } } }, "localname": "LynceanTechnologiesIncMember", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_MarketDisruptionGeopoliticalRisksTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "MARKET DISRUPTION AND GEOPOLITICAL RISKS" } } }, "localname": "MarketDisruptionGeopoliticalRisksTextBlock", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/MarketDisruptionAndGeopoliticalRisks" ], "xbrltype": "textBlockItemType" }, "SVVC_MedicalDevicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Medical Devices [Member]" } } }, "localname": "MedicalDevicesMember", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/FairValueDetails", "http://firsthandtvf.com/role/FairValueDetails1", "http://firsthandtvf.com/role/FairValueDetails2", "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_MiscellaneousFees": { "auth_ref": [], "calculation": { "http://firsthandtvf.com/role/StatementsOfOperations": { "order": 10.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Miscellaneous fees" } } }, "localname": "MiscellaneousFees", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "SVVC_MutualFundsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Mutual Funds [Member]" } } }, "localname": "MutualFundsMember", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/FairValueDetails" ], "xbrltype": "domainItemType" }, "SVVC_NetAssetsAtEndOfPeriod": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Net assets at end of period (millions)" } } }, "localname": "NetAssetsAtEndOfPeriod", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/FinancialHighlights" ], "xbrltype": "monetaryItemType" }, "SVVC_NetAssetsConsistOfAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Assets consist of:" } } }, "localname": "NetAssetsConsistOfAbstract", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/StatementsOfAssetsAndLiabilities" ], "xbrltype": "stringItemType" }, "SVVC_NetCapitalLossCarryforwards": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net capital loss carryforwards" } } }, "localname": "NetCapitalLossCarryforwards", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/FederalIncomeTaxesDetailsNarrative" ], "xbrltype": "durationItemType" }, "SVVC_NetChangeInUnrealizedAppreciationDepreciationOnInvestmentsOtherAssetsAndWarrantsTransactions": { "auth_ref": [], "calculation": { "http://firsthandtvf.com/role/StatementsOfChangesInNetAssets": { "order": 3.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Net change in unrealized (depreciation) on investments, other assets, and warrants transactions" } } }, "localname": "NetChangeInUnrealizedAppreciationDepreciationOnInvestmentsOtherAssetsAndWarrantsTransactions", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/StatementsOfChangesInNetAssets" ], "xbrltype": "monetaryItemType" }, "SVVC_NetChangeInUnrealizedDepreciation": { "auth_ref": [], "calculation": { "http://firsthandtvf.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "SVVC_NetRealizedAndUnrealizedLossOnInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "NetChangeInUnrealizedDepreciation", "totalLabel": "Net change in unrealized (depreciation)" } } }, "localname": "NetChangeInUnrealizedDepreciation", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "SVVC_NetIncreaseDecreaseInNetAssetsPerShareResultingFromOperations": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Decrease In Net Assets Per Share Resulting From Operations" } } }, "localname": "NetIncreaseDecreaseInNetAssetsPerShareResultingFromOperations", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/StatementsOfOperations" ], "xbrltype": "perShareItemType" }, "SVVC_NetInvestmentGainLosses": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net investment gain (losses)" } } }, "localname": "NetInvestmentGainLosses", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/FinancialHighlights" ], "xbrltype": "perShareItemType" }, "SVVC_NetInvestmentIncomeLoss": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NetInvestmentIncomeLoss", "verboseLabel": "Net investment income (loss)" } } }, "localname": "NetInvestmentIncomeLoss", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/FinancialHighlights" ], "xbrltype": "percentItemType" }, "SVVC_NetInvestmentIncomeLossBeforeDeferredTaxes": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net investment income (loss), before deferred taxes" } } }, "localname": "NetInvestmentIncomeLossBeforeDeferredTaxes", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/FinancialHighlights" ], "xbrltype": "perShareItemType" }, "SVVC_NetPurchasesconversions": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "NET PURCHASES/CONVERSIONS" } } }, "localname": "NetPurchasesconversions", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/FairValueDetails1" ], "xbrltype": "monetaryItemType" }, "SVVC_NetRealizedAndUnrealizedGainsLossesOnInvestmentsAfterDeferredTaxes": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net realized and unrealized gains (losses) on investments, after deferred taxes" } } }, "localname": "NetRealizedAndUnrealizedGainsLossesOnInvestmentsAfterDeferredTaxes", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/FinancialHighlights" ], "xbrltype": "perShareItemType" }, "SVVC_NetRealizedAndUnrealizedGainsLossesOnInvestmentsBeforeDeferredTaxes": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net realized and unrealized gains (losses) on investments, before deferred taxes" } } }, "localname": "NetRealizedAndUnrealizedGainsLossesOnInvestmentsBeforeDeferredTaxes", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/FinancialHighlights" ], "xbrltype": "perShareItemType" }, "SVVC_NetRealizedAndUnrealizedLossOnInvestments": { "auth_ref": [], "calculation": { "http://firsthandtvf.com/role/StatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "NetRealizedAndUnrealizedLossOnInvestments", "totalLabel": "Net Realized and Unrealized (Loss) on Investments" } } }, "localname": "NetRealizedAndUnrealizedLossOnInvestments", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "SVVC_NetRealizedGainLossFromSecurityTransactionsAndForeignCurrency": { "auth_ref": [], "calculation": { "http://firsthandtvf.com/role/StatementsOfChangesInNetAssets": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Net realized gain (loss) from security transactions and foreign currency" } } }, "localname": "NetRealizedGainLossFromSecurityTransactionsAndForeignCurrency", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/StatementsOfChangesInNetAssets" ], "xbrltype": "monetaryItemType" }, "SVVC_NetSalesconversions": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "NET SALES/CONVERSIONS" } } }, "localname": "NetSalesconversions", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/FairValueDetails1" ], "xbrltype": "monetaryItemType" }, "SVVC_NetUnrealizedAppreciationDepreciation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "NET UNREALIZED APPRECIATION (DEPRECIATION)" } } }, "localname": "NetUnrealizedAppreciationDepreciation", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/FairValueDetails1" ], "xbrltype": "monetaryItemType" }, "SVVC_NetUnrealizedAppreciationDepreciationFromInvestmentsOtherAssetsAndWarrantsTransactions": { "auth_ref": [], "calculation": { "http://firsthandtvf.com/role/StatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Net unrealized appreciation (depreciation) from investments, other assets, and warrants transactions" } } }, "localname": "NetUnrealizedAppreciationDepreciationFromInvestmentsOtherAssetsAndWarrantsTransactions", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "SVVC_NetUnrealizedLossesGainsOnInvestmentSecurities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Net unrealized losses (gains) on investment securities" } } }, "localname": "NetUnrealizedLossesGainsOnInvestmentSecurities", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/FederalIncomeTaxesDetails2" ], "xbrltype": "monetaryItemType" }, "SVVC_NonaffiliatedInvestments": { "auth_ref": [], "calculation": { "http://firsthandtvf.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "SVVC_NetChangeInUnrealizedDepreciation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Non-affiliated investments" } } }, "localname": "NonaffiliatedInvestments", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "SVVC_PayableToAffiliatesCurrent": { "auth_ref": [], "calculation": { "http://firsthandtvf.com/role/StatementsOfAssetsAndLiabilities": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Payable to affiliates (Note 4)" } } }, "localname": "PayableToAffiliatesCurrent", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/StatementsOfAssetsAndLiabilities" ], "xbrltype": "monetaryItemType" }, "SVVC_PortfolioTurnoverRate": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Portfolio turnover rate" } } }, "localname": "PortfolioTurnoverRate", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/FinancialHighlights" ], "xbrltype": "percentItemType" }, "SVVC_PrintingFees": { "auth_ref": [], "calculation": { "http://firsthandtvf.com/role/StatementsOfOperations": { "order": 7.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Printing fees" } } }, "localname": "PrintingFees", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "SVVC_PurchasedOptionsContracts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "PURCHASED OPTIONS (CONTRACTS)" } } }, "localname": "PurchasedOptionsContracts", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "SVVC_PurchasesOfInvestments": { "auth_ref": [], "calculation": { "http://firsthandtvf.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "PurchasesOfInvestments", "negatedLabel": "Purchases of investments" } } }, "localname": "PurchasesOfInvestments", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "SVVC_RatioOfNetInvestmentIncomeLossToAverageNetAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ratio of net investment income (loss) to average net assets:" } } }, "localname": "RatioOfNetInvestmentIncomeLossToAverageNetAssetsAbstract", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/FinancialHighlights" ], "xbrltype": "percentItemType" }, "SVVC_RatioOfTotalExpensesToAverageNetAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ratio of total expenses to average net assets:" } } }, "localname": "RatioOfTotalExpensesToAverageNetAssetsAbstract", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/FinancialHighlights" ], "xbrltype": "stringItemType" }, "SVVC_RealizedCapitalGains": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Realized capital gains" } } }, "localname": "RealizedCapitalGains", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/FinancialHighlights" ], "xbrltype": "perShareItemType" }, "SVVC_RealizedGainLossUnrealizedAppreciationDepreciationPortfolioInvestmentsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "REALIZED GAIN OR LOSS AND UNREALIZED APPRECIATION OR DEPRECIATION OF PORTFOLIO INVESTMENTS" } } }, "localname": "RealizedGainLossUnrealizedAppreciationDepreciationPortfolioInvestmentsPolicyTextBlock", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "SVVC_RestrictedSecuritiesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "RESTRICTED SECURITIES" } } }, "localname": "RestrictedSecuritiesPolicyTextBlock", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "SVVC_RevasumIncCDIMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revasum Inc C D I [Member]" } } }, "localname": "RevasumIncCDIMember", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_RevasumIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revasum Inc [Member]" } } }, "localname": "RevasumIncMember", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_SVVCStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "S V V C Stock [Member]" } } }, "localname": "SVVCStockMember", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ShareBuybacksDetailsNarrative" ], "xbrltype": "domainItemType" }, "SVVC_SemiconductorEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Semiconductor Equipment [Member]" } } }, "localname": "SemiconductorEquipmentMember", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/FairValueDetails", "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_ShareOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares outstanding" } } }, "localname": "ShareOutstanding", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ShareBuybacksDetailsNarrative" ], "xbrltype": "sharesItemType" }, "SVVC_ShareValuationPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SHARE VALUATION" } } }, "localname": "ShareValuationPolicyTextBlock", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "SVVC_SiliconGenesisCorp1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Silicon Genesis Corp 1 [Member]" } } }, "localname": "SiliconGenesisCorp1Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_SiliconGenesisCorp2Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Silicon Genesis Corp 2 [Member]" } } }, "localname": "SiliconGenesisCorp2Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_SiliconGenesisCorp3Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Silicon Genesis Corp 3 [Member]" } } }, "localname": "SiliconGenesisCorp3Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_SiliconGenesisCorp4Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Silicon Genesis Corp 4 [Member]" } } }, "localname": "SiliconGenesisCorp4Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_SiliconGenesisCorp5Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Silicon Genesis Corp 5 [Member]" } } }, "localname": "SiliconGenesisCorp5Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_SiliconGenesisCorp6Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Silicon Genesis Corp 6 [Member]" } } }, "localname": "SiliconGenesisCorp6Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_SiliconGenesisCorp7Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Silicon Genesis Corp 7 [Member]" } } }, "localname": "SiliconGenesisCorp7Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_SiliconGenesisCorp8Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Silicon Genesis Corp 8 [Member]" } } }, "localname": "SiliconGenesisCorp8Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_SiliconGenesisCorpCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Silicon Genesis Corp Common Stock [Member]" } } }, "localname": "SiliconGenesisCorpCommonStockMember", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_SiliconGenesisCorpCommonWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Silicon Genesis Corp Common Warrants [Member]" } } }, "localname": "SiliconGenesisCorpCommonWarrantsMember", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_SiliconGenesisCorpMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Silicon Genesis Corp [Member]" } } }, "localname": "SiliconGenesisCorpMember", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_SiliconGenesisCorpSeries1CPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Silicon Genesis Corp Series 1 C Preferred Stock [Member]" } } }, "localname": "SiliconGenesisCorpSeries1CPreferredStockMember", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_SiliconGenesisCorpSeries1DPreferredMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Silicon Genesis Corp Series 1 D Preferred [Member]" } } }, "localname": "SiliconGenesisCorpSeries1DPreferredMember", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_SiliconGenesisCorpSeries1EPreferredMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Silicon Genesis Corp Series 1 E Preferred [Member]" } } }, "localname": "SiliconGenesisCorpSeries1EPreferredMember", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_SiliconGenesisCorpSeries1FPreferredMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Silicon Genesis Corp Series 1 F Preferred [Member]" } } }, "localname": "SiliconGenesisCorpSeries1FPreferredMember", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_SiliconGenesisCorpSeries1GPreferredMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Silicon Genesis Corp Series 1 G Preferred [Member]" } } }, "localname": "SiliconGenesisCorpSeries1GPreferredMember", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_SiliconGenesisCorpSeries1HPreferredMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Silicon Genesis Corp Series 1 H Preferred [Member]" } } }, "localname": "SiliconGenesisCorpSeries1HPreferredMember", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_StatementConsolidatedStatementsOfAssetsAndLiabilitiesUnauditedParentheticalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consolidated Statements Of Assets And Liabilities Unaudited" } } }, "localname": "StatementConsolidatedStatementsOfAssetsAndLiabilitiesUnauditedParentheticalAbstract", "nsuri": "http://firsthandtvf.com/20230630", "xbrltype": "stringItemType" }, "SVVC_StatementConsolidatedStatementsOfChangesInNetAssetsUnauditedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consolidated Statements Of Changes In Net Assets" } } }, "localname": "StatementConsolidatedStatementsOfChangesInNetAssetsUnauditedAbstract", "nsuri": "http://firsthandtvf.com/20230630", "xbrltype": "stringItemType" }, "SVVC_TenderOfferDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Tender offer description" } } }, "localname": "TenderOfferDescription", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ShareBuybacksDetailsNarrative" ], "xbrltype": "stringItemType" }, "SVVC_TenderOfferExpired": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Tender offer expired" } } }, "localname": "TenderOfferExpired", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ShareBuybacksDetailsNarrative" ], "xbrltype": "dateItemType" }, "SVVC_TotalAffiliatesAndControlledInvestmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Total Affiliates And Controlled Investments [Member]" } } }, "localname": "TotalAffiliatesAndControlledInvestmentsMember", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_TotalExpenses": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Total expenses" } } }, "localname": "TotalExpenses", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/FinancialHighlights" ], "xbrltype": "percentItemType" }, "SVVC_TotalExpensesExcludingIncentiveFeesAndDeferredTaxExpense": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Total expenses, excluding incentive fees and deferred tax expense" } } }, "localname": "TotalExpensesExcludingIncentiveFeesAndDeferredTaxExpense", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/FinancialHighlights" ], "xbrltype": "percentItemType" }, "SVVC_TotalFromInvestmentOperations": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Total from investment operations" } } }, "localname": "TotalFromInvestmentOperations", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/FinancialHighlights" ], "xbrltype": "perShareItemType" }, "SVVC_TradingPrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Trading price" } } }, "localname": "TradingPrice", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ShareBuybacksDetailsNarrative" ], "xbrltype": "perShareItemType" }, "SVVC_TransfersInOutOfLevel3": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "TRANSFERS IN (OUT) OF LEVEL 3" } } }, "localname": "TransfersInOutOfLevel3", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/FairValueDetails1" ], "xbrltype": "monetaryItemType" }, "SVVC_UCTCoatingsIncCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "U C T Coatings Inc Common Stock [Member]" } } }, "localname": "UCTCoatingsIncCommonStockMember", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_UctCoatingsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Uct Coatings Inc [Member]" } } }, "localname": "UctCoatingsIncMember", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_UnaffiliatedInterest": { "auth_ref": [], "calculation": { "http://firsthandtvf.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_InvestmentCompanyGainLossOnInKindRedemption", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Unaffiliated interest" } } }, "localname": "UnaffiliatedInterest", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "SVVC_UnaffiliatedInvestmentsAtAcquisitionCost": { "auth_ref": [], "calculation": { "http://firsthandtvf.com/role/StatementsOfAssetsAndLiabilities": { "order": 1.0, "parentTag": "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Unaffiliated investments at acquisition cost" } } }, "localname": "UnaffiliatedInvestmentsAtAcquisitionCost", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/StatementsOfAssetsAndLiabilities" ], "xbrltype": "monetaryItemType" }, "SVVC_UnaffiliatedInvestmentsAtMarketValue": { "auth_ref": [], "calculation": { "http://firsthandtvf.com/role/StatementsOfAssetsAndLiabilities": { "order": 1.0, "parentTag": "us-gaap_EquityMethodInvestmentQuotedMarketValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Unaffiliated investments at market value" } } }, "localname": "UnaffiliatedInvestmentsAtMarketValue", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/StatementsOfAssetsAndLiabilities" ], "xbrltype": "monetaryItemType" }, "SVVC_WrightSpeedInc10Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wright Speed Inc 10 [Member]" } } }, "localname": "WrightSpeedInc10Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_WrightSpeedInc11Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wright Speed Inc 11 [Member]" } } }, "localname": "WrightSpeedInc11Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_WrightSpeedInc12Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wright Speed Inc 12 [Member]" } } }, "localname": "WrightSpeedInc12Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_WrightSpeedInc13Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wright Speed Inc 13 [Member]" } } }, "localname": "WrightSpeedInc13Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_WrightSpeedInc14Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wright Speed Inc 14 [Member]" } } }, "localname": "WrightSpeedInc14Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_WrightSpeedInc15Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wright Speed Inc 15 [Member]" } } }, "localname": "WrightSpeedInc15Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_WrightSpeedInc16Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wright Speed Inc 16 [Member]" } } }, "localname": "WrightSpeedInc16Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_WrightSpeedInc17Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wright Speed Inc 17 [Member]" } } }, "localname": "WrightSpeedInc17Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_WrightSpeedInc18Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wright Speed Inc 18 [Member]" } } }, "localname": "WrightSpeedInc18Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_WrightSpeedInc19Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wright Speed Inc 19 [Member]" } } }, "localname": "WrightSpeedInc19Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_WrightSpeedInc1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wright Speed Inc 1 [Member]" } } }, "localname": "WrightSpeedInc1Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_WrightSpeedInc20Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wright Speed Inc 20 [Member]" } } }, "localname": "WrightSpeedInc20Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_WrightSpeedInc21Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wright Speed Inc 21 [Member]" } } }, "localname": "WrightSpeedInc21Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_WrightSpeedInc22Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wright Speed Inc 22 [Member]" } } }, "localname": "WrightSpeedInc22Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_WrightSpeedInc23Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wright Speed Inc 23 [Member]" } } }, "localname": "WrightSpeedInc23Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_WrightSpeedInc24Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wright Speed Inc 24 [Member]" } } }, "localname": "WrightSpeedInc24Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_WrightSpeedInc25Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wright Speed Inc 25 [Member]" } } }, "localname": "WrightSpeedInc25Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_WrightSpeedInc26Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wright Speed Inc 26 [Member]" } } }, "localname": "WrightSpeedInc26Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_WrightSpeedInc27Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wright Speed Inc 27 [Member]" } } }, "localname": "WrightSpeedInc27Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_WrightSpeedInc28Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wright Speed Inc 28 [Member]" } } }, "localname": "WrightSpeedInc28Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_WrightSpeedInc29Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wright Speed Inc 29 [Member]" } } }, "localname": "WrightSpeedInc29Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_WrightSpeedInc2Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wright Speed Inc 2 [Member]" } } }, "localname": "WrightSpeedInc2Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_WrightSpeedInc30Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wright Speed Inc 30 [Member]" } } }, "localname": "WrightSpeedInc30Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_WrightSpeedInc31Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wright Speed Inc 31 [Member]" } } }, "localname": "WrightSpeedInc31Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_WrightSpeedInc32Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wright Speed Inc 32 [Member]" } } }, "localname": "WrightSpeedInc32Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_WrightSpeedInc33Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wright Speed Inc 33 [Member]" } } }, "localname": "WrightSpeedInc33Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_WrightSpeedInc34Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wright Speed Inc 34 [Member]" } } }, "localname": "WrightSpeedInc34Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_WrightSpeedInc36Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wright Speed Inc 36 [Member]" } } }, "localname": "WrightSpeedInc36Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_WrightSpeedInc3Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wright Speed Inc 3 [Member]" } } }, "localname": "WrightSpeedInc3Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_WrightSpeedInc4Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wright Speed Inc 4 [Member]" } } }, "localname": "WrightSpeedInc4Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_WrightSpeedInc5Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wright Speed Inc 5 [Member]" } } }, "localname": "WrightSpeedInc5Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_WrightSpeedInc6Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wright Speed Inc 6 [Member]" } } }, "localname": "WrightSpeedInc6Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_WrightSpeedInc7Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wright Speed Inc 7 [Member]" } } }, "localname": "WrightSpeedInc7Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_WrightSpeedInc8Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wright Speed Inc 8 [Member]" } } }, "localname": "WrightSpeedInc8Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_WrightSpeedInc9Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wright Speed Inc 9 [Member]" } } }, "localname": "WrightSpeedInc9Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_WrightSpeedIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wright Speed Inc [Member]" } } }, "localname": "WrightSpeedIncMember", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "SVVC_WrightspeedIncCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wrightspeed Inc Common Stock [Member]" } } }, "localname": "WrightspeedIncCommonStockMember", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_WrightspeedIncConvertibleNote10Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wrightspeed Inc Convertible Note 10 [Member]" } } }, "localname": "WrightspeedIncConvertibleNote10Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_WrightspeedIncConvertibleNote11Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wrightspeed Inc Convertible Note 11 [Member]" } } }, "localname": "WrightspeedIncConvertibleNote11Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_WrightspeedIncConvertibleNote12Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wrightspeed Inc Convertible Note 12 [Member]" } } }, "localname": "WrightspeedIncConvertibleNote12Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_WrightspeedIncConvertibleNote13Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wrightspeed Inc Convertible Note 13 [Member]" } } }, "localname": "WrightspeedIncConvertibleNote13Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_WrightspeedIncConvertibleNote14Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wrightspeed Inc Convertible Note 14 [Member]" } } }, "localname": "WrightspeedIncConvertibleNote14Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_WrightspeedIncConvertibleNote15Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wrightspeed Inc Convertible Note 15 [Member]" } } }, "localname": "WrightspeedIncConvertibleNote15Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_WrightspeedIncConvertibleNote16Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wrightspeed Inc Convertible Note 16 [Member]" } } }, "localname": "WrightspeedIncConvertibleNote16Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_WrightspeedIncConvertibleNote17Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wrightspeed Inc Convertible Note 17 [Member]" } } }, "localname": "WrightspeedIncConvertibleNote17Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_WrightspeedIncConvertibleNote18Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wrightspeed Inc Convertible Note 18 [Member]" } } }, "localname": "WrightspeedIncConvertibleNote18Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_WrightspeedIncConvertibleNote19Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wrightspeed Inc Convertible Note 19 [Member]" } } }, "localname": "WrightspeedIncConvertibleNote19Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_WrightspeedIncConvertibleNote1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wrightspeed Inc Convertible Note 1 [Member]" } } }, "localname": "WrightspeedIncConvertibleNote1Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_WrightspeedIncConvertibleNote20Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wrightspeed Inc Convertible Note 20 [Member]" } } }, "localname": "WrightspeedIncConvertibleNote20Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_WrightspeedIncConvertibleNote21Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wrightspeed Inc Convertible Note 21 [Member]" } } }, "localname": "WrightspeedIncConvertibleNote21Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_WrightspeedIncConvertibleNote22Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wrightspeed Inc Convertible Note 22 [Member]" } } }, "localname": "WrightspeedIncConvertibleNote22Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_WrightspeedIncConvertibleNote23Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wrightspeed Inc Convertible Note 23 [Member]" } } }, "localname": "WrightspeedIncConvertibleNote23Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_WrightspeedIncConvertibleNote24Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wrightspeed Inc Convertible Note 24 [Member]" } } }, "localname": "WrightspeedIncConvertibleNote24Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_WrightspeedIncConvertibleNote25Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wrightspeed Inc Convertible Note 25 [Member]" } } }, "localname": "WrightspeedIncConvertibleNote25Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_WrightspeedIncConvertibleNote26Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wrightspeed Inc Convertible Note 26 [Member]" } } }, "localname": "WrightspeedIncConvertibleNote26Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_WrightspeedIncConvertibleNote27Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wrightspeed Inc Convertible Note 27 [Member]" } } }, "localname": "WrightspeedIncConvertibleNote27Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_WrightspeedIncConvertibleNote28Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wrightspeed Inc Convertible Note 28 [Member]" } } }, "localname": "WrightspeedIncConvertibleNote28Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_WrightspeedIncConvertibleNote29Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wrightspeed Inc Convertible Note 29 [Member]" } } }, "localname": "WrightspeedIncConvertibleNote29Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_WrightspeedIncConvertibleNote2Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wrightspeed Inc Convertible Note 2 [Member]" } } }, "localname": "WrightspeedIncConvertibleNote2Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_WrightspeedIncConvertibleNote30Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wrightspeed Inc Convertible Note 30 [Member]" } } }, "localname": "WrightspeedIncConvertibleNote30Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_WrightspeedIncConvertibleNote31Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wrightspeed Inc Convertible Note 31 [Member]" } } }, "localname": "WrightspeedIncConvertibleNote31Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_WrightspeedIncConvertibleNote32Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wrightspeed Inc Convertible Note 32 [Member]" } } }, "localname": "WrightspeedIncConvertibleNote32Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_WrightspeedIncConvertibleNote3Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wrightspeed Inc Convertible Note 3 [Member]" } } }, "localname": "WrightspeedIncConvertibleNote3Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_WrightspeedIncConvertibleNote4Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wrightspeed Inc Convertible Note 4 [Member]" } } }, "localname": "WrightspeedIncConvertibleNote4Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_WrightspeedIncConvertibleNote5Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wrightspeed Inc Convertible Note 5 [Member]" } } }, "localname": "WrightspeedIncConvertibleNote5Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_WrightspeedIncConvertibleNote6Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wrightspeed Inc Convertible Note 6 [Member]" } } }, "localname": "WrightspeedIncConvertibleNote6Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_WrightspeedIncConvertibleNote7Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wrightspeed Inc Convertible Note 7 [Member]" } } }, "localname": "WrightspeedIncConvertibleNote7Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_WrightspeedIncConvertibleNote8Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wrightspeed Inc Convertible Note 8 [Member]" } } }, "localname": "WrightspeedIncConvertibleNote8Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_WrightspeedIncConvertibleNote9Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wrightspeed Inc Convertible Note 9 [Member]" } } }, "localname": "WrightspeedIncConvertibleNote9Member", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_WrightspeedIncConvertibleNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wrightspeed Inc Convertible Note [Member]" } } }, "localname": "WrightspeedIncConvertibleNoteMember", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_WrightspeedIncSeriesAAPreferredMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wrightspeed Inc Series A A Preferred [Member]" } } }, "localname": "WrightspeedIncSeriesAAPreferredMember", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_WrightspeedIncSeriesAAWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wrightspeed Inc Series A A Warrants [Member]" } } }, "localname": "WrightspeedIncSeriesAAWarrantsMember", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "SVVC_WrittenOptionsContracts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "WRITTEN OPTIONS (CONTRACTS)" } } }, "localname": "WrittenOptionsContracts", "nsuri": "http://firsthandtvf.com/20230630", "presentation": [ "http://firsthandtvf.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://firsthandtvf.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://firsthandtvf.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r476" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://firsthandtvf.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r476" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://firsthandtvf.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://firsthandtvf.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://firsthandtvf.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://firsthandtvf.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r475" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://firsthandtvf.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r473", "r475", "r476" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://firsthandtvf.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://firsthandtvf.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://firsthandtvf.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://firsthandtvf.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://firsthandtvf.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r474" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://firsthandtvf.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r462" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://firsthandtvf.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r475" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://firsthandtvf.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r475" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://firsthandtvf.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r477" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://firsthandtvf.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://firsthandtvf.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r465" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://firsthandtvf.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://firsthandtvf.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://firsthandtvf.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://firsthandtvf.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://firsthandtvf.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://firsthandtvf.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://firsthandtvf.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://firsthandtvf.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r468" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://firsthandtvf.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r464" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://firsthandtvf.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://firsthandtvf.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://firsthandtvf.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r464" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://firsthandtvf.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r481" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://firsthandtvf.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://firsthandtvf.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r464" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://firsthandtvf.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://firsthandtvf.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r478" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://firsthandtvf.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r476" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://firsthandtvf.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://firsthandtvf.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r464" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://firsthandtvf.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r464" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://firsthandtvf.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r464" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://firsthandtvf.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r464" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://firsthandtvf.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://firsthandtvf.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r479" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://firsthandtvf.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://firsthandtvf.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://firsthandtvf.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://firsthandtvf.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r475" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://firsthandtvf.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r469" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://firsthandtvf.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r470" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://firsthandtvf.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r463" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://firsthandtvf.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r467" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://firsthandtvf.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r466" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://firsthandtvf.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r471" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://firsthandtvf.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r472" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://firsthandtvf.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://firsthandtvf.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r480" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://firsthandtvf.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_MaximumMember": { "auth_ref": [ "r143", "r144", "r145", "r146", "r191", "r253", "r269", "r302", "r303", "r344", "r365", "r370", "r371", "r406", "r430", "r431", "r437", "r443", "r447", "r451", "r500", "r515", "r516", "r517", "r518", "r519", "r520" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://firsthandtvf.com/role/ShareBuybacksDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r143", "r144", "r145", "r146", "r191", "r253", "r269", "r302", "r303", "r344", "r365", "r370", "r371", "r406", "r430", "r431", "r437", "r443", "r447", "r451", "r500", "r515", "r516", "r517", "r518", "r519", "r520" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://firsthandtvf.com/role/ShareBuybacksDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r143", "r144", "r145", "r146", "r184", "r191", "r192", "r193", "r194", "r251", "r253", "r269", "r302", "r303", "r344", "r365", "r370", "r371", "r406", "r430", "r431", "r437", "r443", "r447", "r451", "r454", "r497", "r500", "r516", "r517", "r518", "r519", "r520" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://firsthandtvf.com/role/ShareBuybacksDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r143", "r144", "r145", "r146", "r184", "r191", "r192", "r193", "r194", "r251", "r253", "r269", "r302", "r303", "r344", "r365", "r370", "r371", "r406", "r430", "r431", "r437", "r443", "r447", "r451", "r454", "r497", "r500", "r516", "r517", "r518", "r519", "r520" ], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://firsthandtvf.com/role/ShareBuybacksDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare": { "auth_ref": [ "r72" ], "lang": { "en-us": { "role": { "documentation": "Final price paid per share for the purchase of the targeted number of shares, determined by an average market price over a fixed period of time.", "label": "Average price" } } }, "localname": "AcceleratedShareRepurchasesFinalPricePaidPerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/ShareBuybacksDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://firsthandtvf.com/role/StatementsOfAssetsAndLiabilities": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.", "label": "Accrued expenses and other payables" } } }, "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/StatementsOfAssetsAndLiabilities" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedInvestmentIncomeReceivable": { "auth_ref": [ "r79", "r262", "r484" ], "calculation": { "http://firsthandtvf.com/role/StatementsOfAssetsAndLiabilities": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest, dividends, rents, ancillary and other revenues earned but not yet received by the entity on its investments.", "label": "Receivable from dividends and interest" } } }, "localname": "AccruedInvestmentIncomeReceivable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/StatementsOfAssetsAndLiabilities" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [ "r101", "r102", "r238", "r239", "r240", "r241", "r242", "r243" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/ShareBuybacksDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r101", "r102", "r238", "r239", "r240", "r241", "r242", "r243" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/ShareBuybacksDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AcquisitionCosts": { "auth_ref": [ "r77", "r78" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The capitalized costs incurred during the period (excluded from amortization) to purchase, lease or otherwise acquire an unproved property, including costs of lease bonuses and options to purchase or lease properties, the portion of costs applicable to minerals when land including mineral rights is purchased in fee, brokers' fees, recording fees, legal costs, and other costs incurred in acquiring properties.", "label": "COST BASIS" } } }, "localname": "AcquisitionCosts", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r56", "r450", "r523" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Paid-in-capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/StatementsOfAssetsAndLiabilities" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net increase (decrease) in Net Assets derived from operations to net cash provided by (used in) operating activities" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_Assets": { "auth_ref": [ "r80", "r97", "r111", "r128", "r130", "r132", "r135", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r218", "r222", "r236", "r259", "r316", "r450", "r461", "r498", "r499", "r513" ], "calculation": { "http://firsthandtvf.com/role/StatementsOfAssetsAndLiabilities": { "order": 1.0, "parentTag": "us-gaap_AssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total Assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/FairValueDetails", "http://firsthandtvf.com/role/StatementsOfAssetsAndLiabilities" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/StatementsOfAssetsAndLiabilities" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsNet": { "auth_ref": [ "r9" ], "calculation": { "http://firsthandtvf.com/role/StatementsOfAssetsAndLiabilities": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of net assets (liabilities).", "label": "Net assets", "periodEndLabel": "End of period", "periodStartLabel": "Beginning of period", "totalLabel": "NET ASSETS" } } }, "localname": "AssetsNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments", "http://firsthandtvf.com/role/StatementsOfAssetsAndLiabilities", "http://firsthandtvf.com/role/StatementsOfChangesInNetAssets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AuctionMarketPreferredSecuritiesStockSeriesParValuePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The par value of the auction market preferred security.", "label": "Auction Market Preferred Securities, Stock Series, Par Value Per Share", "periodEndLabel": "Market value at end of period" } } }, "localname": "AuctionMarketPreferredSecuritiesStockSeriesParValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/FinancialHighlights" ], "xbrltype": "perShareItemType" }, "us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy": { "auth_ref": [ "r47" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for premium paid to acquire option for investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "OPTIONS" } } }, "localname": "AvailableForSaleSecuritiesPurchasedOptionsPricePolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "BASIS OF PRESENTATION" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": { "auth_ref": [], "calculation": { "http://firsthandtvf.com/role/StatementsOfAssetsAndLiabilities": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.", "label": "Business Acquisition, Transaction Costs", "totalLabel": "Total acquisition cost" } } }, "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/StatementsOfAssetsAndLiabilities" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r0", "r1", "r10" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Total consideration amount" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/ShareBuybacksDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "CASH AND CASH EQUIVALENTS" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r24", "r64", "r108" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash and foreign currency - end of period", "periodStartLabel": "Cash and foreign currency - beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r4", "r64" ], "calculation": { "http://firsthandtvf.com/role/StatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r70" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Increment of per share" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/ShareBuybacksDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r492", "r493", "r509", "r522", "r529" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/FairValueDetails", "http://firsthandtvf.com/role/FairValueDetails1", "http://firsthandtvf.com/role/ShareBuybacksDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockOtherSharesOutstanding": { "auth_ref": [], "calculation": { "http://firsthandtvf.com/role/StatementsOfAssetsAndLiabilities": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized.", "label": "Common Stock, Other Shares, Outstanding", "totalLabel": "Total Shares of Common Stock outstanding" } } }, "localname": "CommonStockOtherSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/StatementsOfAssetsAndLiabilities" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r55" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/StatementsOfAssetsAndLiabilitiesParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r55", "r306" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/StatementsOfAssetsAndLiabilitiesParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r55", "r260", "r450" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, par value $0.001 per share 100,000,000 shares authorized" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/StatementsOfAssetsAndLiabilities" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockValueOutstanding": { "auth_ref": [ "r55", "r306" ], "calculation": { "http://firsthandtvf.com/role/StatementsOfAssetsAndLiabilities": { "order": 1.0, "parentTag": "us-gaap_CommonStockOtherSharesOutstanding", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.", "label": "Shares of Common Stock outstanding" } } }, "localname": "CommonStockValueOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/StatementsOfAssetsAndLiabilities" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r51", "r90" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "CONCENTRATION OF CREDIT RISK" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CustodyFees": { "auth_ref": [ "r61" ], "calculation": { "http://firsthandtvf.com/role/StatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Those fees charged for services related to holding, advising, and managing customer investment assets. These account fees usually charged annually or semi-annually, on a per security basis, for the costs of services.", "label": "Custody fees" } } }, "localname": "CustodyFees", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtAndEquitySecuritiesGainLoss": { "auth_ref": [ "r59", "r60" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized and realized gain (loss) on investment in debt and equity securities.", "label": "REALIZED GAIN (LOSS)" } } }, "localname": "DebtAndEquitySecuritiesGainLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtAndEquitySecuritiesRealizedGainLoss": { "auth_ref": [ "r328", "r329", "r410", "r411", "r412", "r486", "r487" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain (loss) on investment in debt and equity securities.", "label": "NET REALIZED GAINS/(LOSSES)" } } }, "localname": "DebtAndEquitySecuritiesRealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/FairValueDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r69", "r110", "r156", "r162", "r163", "r164", "r165", "r166", "r167", "r172", "r179", "r180", "r181" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "DEBT" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/Debt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r18", "r52", "r53", "r81", "r82", "r113", "r157", "r158", "r159", "r160", "r161", "r163", "r168", "r169", "r170", "r171", "r173", "r174", "r175", "r176", "r177", "r178", "r244", "r438", "r439", "r440", "r441", "r442", "r490" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/FairValueDetails", "http://firsthandtvf.com/role/FairValueDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r20", "r50", "r182", "r244" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Annual rate" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/InvestmentManagementFeeDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r21", "r113", "r157", "r158", "r159", "r160", "r161", "r163", "r168", "r169", "r170", "r171", "r173", "r174", "r175", "r176", "r177", "r178", "r244", "r438", "r439", "r440", "r441", "r442", "r490" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/FairValueDetails", "http://firsthandtvf.com/role/FairValueDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_DebtSecuritiesAvailableForSalePurchasedWithCreditDeteriorationAmountAtParValue": { "auth_ref": [ "r138" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount at par value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), purchased with credit deterioration.", "label": "Purchases of investment securities" } } }, "localname": "DebtSecuritiesAvailableForSalePurchasedWithCreditDeteriorationAmountAtParValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/InvestmentTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesRealizedGainLoss": { "auth_ref": [ "r268", "r486", "r487" ], "calculation": { "http://firsthandtvf.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "SVVC_NetRealizedAndUnrealizedLossOnInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading).", "label": "Debt Securities, Realized Gain (Loss)", "totalLabel": "Net realized gains (losses)" } } }, "localname": "DebtSecuritiesRealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesRealizedGainLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net realized gains (losses) from security transactions on:" } } }, "localname": "DebtSecuritiesRealizedGainLossAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesTradingRestricted": { "auth_ref": [ "r252", "r428", "r429" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of restricted investment in debt security measured at fair value with change in fair value recognized in net income (trading).", "label": "Restricted securities" } } }, "localname": "DebtSecuritiesTradingRestricted", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r491", "r506", "r507" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Federal" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/FederalIncomeTaxesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r502" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Total deferred tax (expense)/benefit" } } }, "localname": "DeferredFederalStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/FederalIncomeTaxesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r491", "r506", "r507" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "State" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/FederalIncomeTaxesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsCapitalLossCarryforwards": { "auth_ref": [ "r35", "r505" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.", "label": "Capital loss carryforward", "verboseLabel": "Capital loss carryforwards" } } }, "localname": "DeferredTaxAssetsCapitalLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/FederalIncomeTaxesDetails2", "http://firsthandtvf.com/role/FederalIncomeTaxesDetails4" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r205" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/FederalIncomeTaxesDetails2" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r504" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Net" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/FederalIncomeTaxesDetails2" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r35", "r505" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Net operating loss carryforward" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/FederalIncomeTaxesDetails2" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r206" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/FederalIncomeTaxesDetails2" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [ "r300", "r303", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r317", "r318", "r319", "r320", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r391", "r392", "r393", "r394", "r452", "r454" ], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/FairValueDetails", "http://firsthandtvf.com/role/FairValueDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r40", "r42", "r43", "r44", "r300", "r303", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r317", "r318", "r319", "r320", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r391", "r392", "r393", "r394", "r433", "r452", "r454" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/FairValueDetails", "http://firsthandtvf.com/role/FairValueDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r201" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "verboseLabel": "Effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/FederalIncomeTaxesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r112", "r201", "r213" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Statutory tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/FederalIncomeTaxesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "auth_ref": [ "r503", "r508" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/FederalIncomeTaxesDetails3" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r503", "r508" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "Statutory federal income tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/FederalIncomeTaxesDetails3" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal": { "auth_ref": [ "r503", "r508" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax contingency.", "label": "State tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/FederalIncomeTaxesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal": { "auth_ref": [ "r503", "r508" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax settlement.", "label": "State income tax" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/FederalIncomeTaxesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r12", "r94", "r101", "r102", "r103", "r114", "r115", "r116", "r118", "r123", "r125", "r127", "r136", "r137", "r183", "r195", "r196", "r197", "r210", "r211", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r238", "r239", "r240", "r241", "r242", "r243", "r245", "r270", "r271", "r272", "r289", "r340" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/FairValueDetails", "http://firsthandtvf.com/role/FairValueDetails1", "http://firsthandtvf.com/role/ShareBuybacksDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentAdditionalInformation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This serves as a place to record data that is not required by accounting literature but is useful for readers of the financial statements as it relates to the details of an equity method investment in common stock. Such information may include the amount of change for a change in ownership (equity) percentage in a given period and the amount and type of the consideration given or received in relation to the change in ownership.", "label": "TYPE OF INVESTMENT" } } }, "localname": "EquityMethodInvestmentAdditionalInformation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "stringItemType" }, "us-gaap_EquityMethodInvestmentQuotedMarketValue": { "auth_ref": [ "r134" ], "calculation": { "http://firsthandtvf.com/role/StatementsOfAssetsAndLiabilities": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the aggregate value of each identified investment accounted for under the equity method of accounting based on the quoted market price for those investments in common stock for which a quoted market price is available.", "label": "Equity Method Investment, Quoted Market Value", "totalLabel": "Total Market value (Note 6)" } } }, "localname": "EquityMethodInvestmentQuotedMarketValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/StatementsOfAssetsAndLiabilities" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": { "auth_ref": [], "localname": "EquityMethodInvestmentsAndJointVenturesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": { "auth_ref": [ "r268", "r496" ], "calculation": { "http://firsthandtvf.com/role/StatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Realized Gain (Loss)", "negatedLabel": "Net realized gain (loss) from investments" } } }, "localname": "EquitySecuritiesFvNiRealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ExcessStockSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum number of excess stock shares permitted to be issued.", "label": "Common stock value" } } }, "localname": "ExcessStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/ShareBuybacksDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [ "r233", "r234", "r235" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/FairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r233", "r234", "r235" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/FairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r48", "r76" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of fair value of net asset" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/FairValueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r14", "r49" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.", "label": "Schedule of unobservable inputs fair value measurements" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/FairValueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r170", "r185", "r186", "r187", "r188", "r189", "r190", "r234", "r248", "r249", "r250", "r439", "r440", "r444", "r445", "r446" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/FairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r232" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "FAIR VALUE" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/FairValue" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueHedgeAssetsAtFairValue": { "auth_ref": [ "r42" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of all derivative assets designated as fair value hedging instruments.", "label": "Fair Value Hedge Assets", "verboseLabel": "FAIR VALUE" } } }, "localname": "FairValueHedgeAssetsAtFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/FairValueDetails2" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r170", "r185", "r190", "r234", "r248", "r444", "r445", "r446" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/FairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r170", "r185", "r190", "r234", "r249", "r439", "r440", "r444", "r445", "r446" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/FairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r170", "r185", "r186", "r187", "r188", "r189", "r190", "r234", "r250", "r439", "r440", "r444", "r445", "r446" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/FairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r170", "r185", "r186", "r187", "r188", "r189", "r190", "r248", "r249", "r250", "r439", "r440", "r444", "r445", "r446" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/FairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/FairValueDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r14", "r15" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/FairValueDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_FederalIncomeTaxNoteTextBlock": { "auth_ref": [ "r521" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the federal tax basis of investment holdings. This item captures the aggregate cost of securities, aggregate gross unrealized appreciation for all securities in which there is an excess of value over tax cost, aggregate gross unrealized depreciation for all securities in which there is an excess of tax cost over value, net unrealized appreciation (depreciation), and an explanation of the differences between tax and book.", "label": "Schedule of federal income tax cost of portfolio investments" } } }, "localname": "FederalIncomeTaxNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/FederalIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r139", "r140", "r141", "r142", "r254", "r255" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/FairValueDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r29", "r30" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/FairValueDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossRealized": { "auth_ref": [ "r322", "r459", "r510", "r511", "r527" ], "calculation": { "http://firsthandtvf.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_DebtSecuritiesRealizedGainLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of realized gain (loss) from foreign currency transaction.", "label": "Foreign currency" } } }, "localname": "ForeignCurrencyTransactionGainLossRealized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r237" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "FOREIGN CURRENCY TRANSLATION" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GainLossOnSaleOfInvestments": { "auth_ref": [ "r7" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.", "label": "SALES/MATURITY/EXPIRATION" } } }, "localname": "GainLossOnSaleOfInvestments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r112", "r198", "r202", "r203", "r208", "r212", "r214", "r215", "r216", "r286" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "FEDERAL INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/FederalIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r100", "r199", "r200", "r203", "r204", "r207", "r209", "r279" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "INCOME TAXES" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInDueToRelatedParties": { "auth_ref": [ "r6" ], "calculation": { "http://firsthandtvf.com/role/StatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.", "label": "Increase (decrease) in due to Custodian" } } }, "localname": "IncreaseDecreaseInDueToRelatedParties", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInterestAndDividendsReceivable": { "auth_ref": [ "r6" ], "calculation": { "http://firsthandtvf.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount due to the entity in the form of unpaid interest and dividends.", "label": "Increase (Decrease) in Interest and Dividends Receivable", "negatedLabel": "Increase (decrease) in dividends, interest, and reclaims receivable" } } }, "localname": "IncreaseDecreaseInInterestAndDividendsReceivable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r6" ], "calculation": { "http://firsthandtvf.com/role/StatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.", "label": "Increase (decrease) in accrued expenses and other payables" } } }, "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "auth_ref": [ "r489" ], "calculation": { "http://firsthandtvf.com/role/StatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in current assets classified as other.", "label": "Increase (Decrease) in Other Current Assets", "negatedLabel": "Increase (decrease) in other assets" } } }, "localname": "IncreaseDecreaseInOtherCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "auth_ref": [ "r6" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.", "label": "TOTAL DECREASE IN NET ASSETS" } } }, "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/StatementsOfChangesInNetAssets" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntellectualPropertyMember": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Intangible asset arising from original creative thought. Include, but is not limited to, trademarks, patents, and copyrights.", "label": "Intellectual Property [Member]" } } }, "localname": "IntellectualPropertyMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/FairValueDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_InterestIncomeExpenseNet": { "auth_ref": [ "r84" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of operating interest income (expense).", "label": "INTEREST" } } }, "localname": "InterestIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeShortTermInvestmentIncreaseDecrease": { "auth_ref": [ "r93" ], "calculation": { "http://firsthandtvf.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in interest income on short-term investment.", "label": "Interest Income, Short-Term Investment, Increase (Decrease)", "negatedLabel": "Net purchases/sales from short-term investments" } } }, "localname": "InterestIncomeShortTermInvestmentIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentCompanyAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment Company [Abstract]" } } }, "localname": "InvestmentCompanyAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_InvestmentCompanyFinancialHighlightsTextBlock": { "auth_ref": [ "r287", "r290", "r291", "r293" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of financial highlights reported by investment company.", "label": "THE COMPANY" } } }, "localname": "InvestmentCompanyFinancialHighlightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/Company" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentCompanyGainLossOnInKindRedemption": { "auth_ref": [ "r325" ], "calculation": { "http://firsthandtvf.com/role/StatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on redemption of investment company shares or units by payment in portfolio securities.", "label": "Investment Company, Gain (Loss) on in-kind Redemption", "totalLabel": "TOTAL INVESTMENT INCOME" } } }, "localname": "InvestmentCompanyGainLossOnInKindRedemption", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentCompanyRealizedAndUnrealizedGainLossOnInvestmentAndForeignCurrency": { "auth_ref": [ "r323", "r427", "r459", "r528" ], "calculation": { "http://firsthandtvf.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "SVVC_NetChangeInUnrealizedDepreciation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of realized and unrealized gain (loss) on investment and derivative, classified as operating, and foreign currency transaction. Investment includes, but is not limited to, debt and equity securities, security sold short, real estate, and commodity.", "label": "Affiliated/controlled investments and foreign currency" } } }, "localname": "InvestmentCompanyRealizedAndUnrealizedGainLossOnInvestmentAndForeignCurrency", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentCompanyRealizedAndUnrealizedGainLossOnInvestmentAndForeignCurrencyAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Realized and Unrealized Gain (Loss) on Investments:" } } }, "localname": "InvestmentCompanyRealizedAndUnrealizedGainLossOnInvestmentAndForeignCurrencyAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentCompanyRegistrationExpense": { "auth_ref": [ "r525" ], "calculation": { "http://firsthandtvf.com/role/StatementsOfOperations": { "order": 5.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of registration fee expense for issuance of shares or units.", "label": "Registration and filing fees" } } }, "localname": "InvestmentCompanyRegistrationExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeNet": { "auth_ref": [ "r62", "r63" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.", "label": "NET INVESTMENT INCOME/(LOSS)" } } }, "localname": "InvestmentIncomeNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "INVESTMENT INCOME" } } }, "localname": "InvestmentIncomeNetAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentOwnedUnrealizedAppreciationDepreciationNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net change in unrealized appreciation (depreciation) on:" } } }, "localname": "InvestmentOwnedUnrealizedAppreciationDepreciationNetAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentPolicyTextBlock": { "auth_ref": [ "r267", "r275", "r276", "r277", "r278", "r361", "r363" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment in financial asset.", "label": "PORTFOLIO INVESTMENT VALUATIONS" } } }, "localname": "InvestmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentTableTextBlock": { "auth_ref": [ "r482", "r483", "r494" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of investment.", "label": "Schedule of investment transactions" } } }, "localname": "InvestmentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/InvestmentTransactionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentTextBlock": { "auth_ref": [ "r482", "r483", "r494" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investment.", "label": "INVESTMENT TRANSACTIONS" } } }, "localname": "InvestmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/InvestmentTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r296", "r297", "r298", "r299", "r301", "r341", "r350", "r366", "r374", "r387", "r395", "r396", "r417", "r421", "r422", "r423", "r424", "r454" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails", "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r296", "r297", "r298", "r299", "r301", "r341", "r350", "r366", "r374", "r387", "r395", "r396", "r417", "r421", "r422", "r423", "r424", "r454" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value." } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails", "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "us-gaap_Investments": { "auth_ref": [ "r257" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.", "label": "VALUE", "periodEndLabel": "ENDING BALANCE", "periodStartLabel": "BEGINNING BALANCE" } } }, "localname": "Investments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/FairValueDetails1", "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails", "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsAllOtherInvestmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, All Other Investments [Abstract]" } } }, "localname": "InvestmentsAllOtherInvestmentsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment securities:" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/StatementsOfAssetsAndLiabilities" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentsInAndAdvancesToAffiliatesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments in and Advances to Affiliates [Abstract]" } } }, "localname": "InvestmentsInAndAdvancesToAffiliatesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Investments in and Advances to Affiliates [Line Items]" } } }, "localname": "InvestmentsInAndAdvancesToAffiliatesLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock": { "auth_ref": [ "r86", "r405", "r413", "r414" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the information summarizing investments in and advances to majority-owned subsidiaries, other controlled companies, and other affiliates. It reflects specified information about ownership, financial results from, and financial position in such entities.", "label": "INVESTMENTS IN AFFILIATES AND CONTROLLED INVESTMENTS" } } }, "localname": "InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestments" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r19", "r111", "r135", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r219", "r222", "r223", "r236", "r305", "r435", "r461", "r498", "r513", "r514" ], "calculation": { "http://firsthandtvf.com/role/StatementsOfAssetsAndLiabilities": { "order": 2.0, "parentTag": "us-gaap_AssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total Liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/StatementsOfAssetsAndLiabilities" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/StatementsOfAssetsAndLiabilities" ], "xbrltype": "stringItemType" }, "us-gaap_ManagementFeePayable": { "auth_ref": [ "r304" ], "calculation": { "http://firsthandtvf.com/role/StatementsOfAssetsAndLiabilities": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of fee payable for management of fund or trust.", "label": "Trustees\u2019 fees payable" } } }, "localname": "ManagementFeePayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/StatementsOfAssetsAndLiabilities" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetAssetValuePerShare": { "auth_ref": [ "r2", "r3", "r16", "r292", "r294", "r295", "r308", "r321", "r425", "r461" ], "lang": { "en-us": { "role": { "documentation": "Net asset value per share or per unit of investments in certain entities that calculate net asset value per share. Includes, but is not limited to, by unit, membership interest, or other ownership interest. Investment includes, but is not limited to, investment in certain hedge funds, venture capital funds, private equity funds, real estate partnerships or funds. Excludes fair value disclosure.", "label": "Net asset value per share (Note 2)", "periodEndLabel": "Net asset value at end of period", "periodStartLabel": "Net asset value at beginning of period" } } }, "localname": "NetAssetValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/FinancialHighlights", "http://firsthandtvf.com/role/StatementsOfAssetsAndLiabilities" ], "xbrltype": "perShareItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r107" ], "calculation": { "http://firsthandtvf.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r64", "r65", "r66" ], "calculation": { "http://firsthandtvf.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash (used in) operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r58", "r66", "r83", "r95", "r98", "r99", "r103", "r111", "r117", "r119", "r120", "r121", "r122", "r124", "r125", "r126", "r128", "r129", "r131", "r133", "r135", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r231", "r236", "r264", "r324", "r338", "r339", "r436", "r459", "r498" ], "calculation": { "http://firsthandtvf.com/role/StatementsOfChangesInNetAssets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Decrease In Net Assets Resulting From Operations", "totalLabel": "Net decrease in net assets from operations" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/StatementsOfChangesInNetAssets", "http://firsthandtvf.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetInvestmentIncome": { "auth_ref": [ "r87", "r265", "r266", "r327", "r459" ], "calculation": { "http://firsthandtvf.com/role/StatementsOfChangesInNetAssets": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after investment expense, of income earned from investments in securities and real estate. Includes, but is not limited to, real estate investment, policy loans, dividends, and interest. Excludes realized gain (loss) on investments.", "label": "Net investment income (loss)" } } }, "localname": "NetInvestmentIncome", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/StatementsOfChangesInNetAssets" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoninterestExpenseInvestmentAdvisoryFees": { "auth_ref": [ "r85" ], "calculation": { "http://firsthandtvf.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This represents the company's cost incurred during an accounting period for managing the money in a fund, which will be billed back to the client and is a component of noninterest expenses.", "label": "Investment advisory fees (Note 4)" } } }, "localname": "NoninterestExpenseInvestmentAdvisoryFees", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoninterestExpenseTransferAgentAndCustodianFees": { "auth_ref": [ "r85" ], "calculation": { "http://firsthandtvf.com/role/StatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fees paid to an agent employed by a corporation or mutual fund to maintain shareholder records, including purchases, sales, and account balances. Also includes custodian fees incurred during an accounting period from an agent, bank, trust company, or other organization that holds and safeguards an individual's, mutual fund's, or investment company's assets for them. These fees will be billed back to the client and are a component of noninterest expense.", "label": "Transfer agent fees" } } }, "localname": "NoninterestExpenseTransferAgentAndCustodianFees", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://firsthandtvf.com/role/StatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "TOTAL GROSS EXPENSES" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "EXPENSES" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r34" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Net operating loss carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/FederalIncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssets": { "auth_ref": [ "r79", "r96", "r258", "r461" ], "calculation": { "http://firsthandtvf.com/role/StatementsOfAssetsAndLiabilities": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets classified as other.", "label": "Other assets" } } }, "localname": "OtherAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/StatementsOfAssetsAndLiabilities" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentForIncentiveFee": { "auth_ref": [ "r488", "r512" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount paid for incentive rights held by the managing member or general partner, of limited liability company (LLC) or limited partnership (LP).", "label": "Incentive fee adjustments" } } }, "localname": "PaymentForIncentiveFee", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/InvestmentManagementFeeDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForMergerRelatedCosts": { "auth_ref": [ "r5" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the reporting period for charges associated with the mergers.", "label": "PURCHASE/MERGER" } } }, "localname": "PaymentsForMergerRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfWarrants": { "auth_ref": [ "r23" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt.", "label": "WARRANTS (NOTIONAL VALUE)" } } }, "localname": "PaymentsForRepurchaseOfWarrants", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividendsCommonStock": { "auth_ref": [ "r23" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.", "label": "Common shares for cash" } } }, "localname": "PaymentsOfDividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/ShareBuybacksDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [ "r452", "r453", "r455", "r456", "r457", "r458", "r522", "r529" ], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/FairValueDetails", "http://firsthandtvf.com/role/FairValueDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": { "auth_ref": [ "r104", "r105", "r495" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from sales and maturities of investment securities" } } }, "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/InvestmentTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfessionalFees": { "auth_ref": [ "r459", "r524", "r526" ], "calculation": { "http://firsthandtvf.com/role/StatementsOfOperations": { "order": 6.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.", "label": "Professional fees" } } }, "localname": "ProfessionalFees", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r95", "r98", "r99", "r106", "r111", "r117", "r124", "r125", "r128", "r129", "r131", "r133", "r135", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r217", "r220", "r221", "r231", "r236", "r256", "r263", "r288", "r324", "r338", "r339", "r436", "r448", "r449", "r460", "r485", "r498" ], "calculation": { "http://firsthandtvf.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net increase (decrease) in Net Assets resulting from operations" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/FairValueDetails", "http://firsthandtvf.com/role/FairValueDetails1", "http://firsthandtvf.com/role/FairValueDetails2", "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/FairValueDetails2" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r68" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/FairValueDetails", "http://firsthandtvf.com/role/FairValueDetails1", "http://firsthandtvf.com/role/FairValueDetails2", "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r57", "r70", "r261", "r273", "r274", "r285", "r307", "r450" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated undistributed earnings (deficit).", "label": "Total distributable earnings (loss)" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/StatementsOfAssetsAndLiabilities" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r326", "r432", "r434" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "INCOME RECOGNITION" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r75" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of income tax provision" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/FederalIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r74" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of deferred tax assets and liabilities" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/FederalIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": { "auth_ref": [ "r13", "r36", "r37", "r38", "r39", "r41", "r43", "r45", "r46" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Schedule of derivatives" } } }, "localname": "ScheduleOfDerivativeInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock": { "auth_ref": [ "r501" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the effect of fair value measurements using significant unobservable inputs (Level 3) on changes in plan assets of pension plans and/or other employee benefit plans for the period.", "label": "Schedule of unobservable inputs of fair value" } } }, "localname": "ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/FairValueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r73" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of effective tax rate and statutory federal income tax rate" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/FederalIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A tabular presentation of the information summarizing investments in and advances to majority-owned subsidiaries, other controlled companies, and other affiliates, as prescribed by the SEC. It reflects specified information about ownership, financial results from, and financial position in such entities. Includes the tabular presentations that disaggregate investments in and advances to majority-owned subsidiaries, other controlled companies, and other affiliates.", "label": "Schedule of investments in affiliates and controlled investments" } } }, "localname": "ScheduleOfInvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInvestmentsLineItems": { "auth_ref": [ "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r362", "r364", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r415", "r416", "r417", "r418", "r419", "r420" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule of Investments [Line Items]" } } }, "localname": "ScheduleOfInvestmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfInvestmentsTable": { "auth_ref": [ "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r362", "r364", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r397", "r398", "r399", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r415", "r416", "r417", "r418", "r419", "r420" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investments owned by investment company.", "label": "Schedule of Investments [Table]" } } }, "localname": "ScheduleOfInvestmentsTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails", "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/FairValueDetails2" ], "xbrltype": "stringItemType" }, "us-gaap_SecuritiesBorrowedAndLoanedPolicy": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for securities borrowed or loaned by the entity. Disclosure may include a description of the business purposes for the transactions, how the transactions are recognized in the financial statements, the types of securities involved in the transactions, the method for monitoring the market value of the securities, the entity's practice and policies associated with cash deposits and collateral for the transactions, and the classification of fees and interest associated with the transactions.", "label": "SECURITIES TRANSACTIONS" } } }, "localname": "SecuritiesBorrowedAndLoanedPolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms": { "auth_ref": [ "r32" ], "lang": { "en-us": { "role": { "documentation": "Description of modification of award under share-based payment arrangement. Includes, but is not limited to, terms for expiration date, vesting rights and exercise price.", "label": "EXPIRATION DATE" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/FederalIncomeTaxesDetails4" ], "xbrltype": "stringItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "SHARES/PAR VALUE", "verboseLabel": "SHARES HELD" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/InvestmentsInAffiliatesAndControlledInvestmentsDetails", "http://firsthandtvf.com/role/ScheduleOfInvestments" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Price per share" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/ShareBuybacksDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Shares outstanding, end of period", "periodStartLabel": "Shares outstanding, beginning of period" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/StatementsOfChangesInNetAssets" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r67", "r109" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r12", "r22", "r94", "r101", "r102", "r103", "r114", "r115", "r116", "r118", "r123", "r125", "r127", "r136", "r137", "r183", "r195", "r196", "r197", "r210", "r211", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r238", "r239", "r240", "r241", "r242", "r243", "r245", "r270", "r271", "r272", "r289", "r340" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/FairValueDetails", "http://firsthandtvf.com/role/FairValueDetails1", "http://firsthandtvf.com/role/ShareBuybacksDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.", "label": "Purchase of shares" } } }, "localname": "StockIssuedDuringPeriodSharesPurchaseOfAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/ShareBuybacksDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount remaining of a stock repurchase plan authorized.", "label": "Authorized to purchase" } } }, "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/ShareBuybacksDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": { "auth_ref": [ "r12", "r54", "r55", "r70" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased and retired during the period.", "label": "Repurchased and retired shares" } } }, "localname": "StockRepurchasedAndRetiredDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/ShareBuybacksDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": { "auth_ref": [ "r12", "r54", "r55", "r70" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).", "label": "Repurchased and retired shares value" } } }, "localname": "StockRepurchasedAndRetiredDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/ShareBuybacksDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedDuringPeriodShares": { "auth_ref": [ "r12", "r54", "r55", "r70", "r284", "r340", "r426" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Repurchased of shares value" } } }, "localname": "StockRepurchasedDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/ShareBuybacksDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedDuringPeriodValue": { "auth_ref": [ "r12", "r54", "r55", "r70", "r289", "r340", "r426", "r460" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Value", "verboseLabel": "Repurchased of shares value" } } }, "localname": "StockRepurchasedDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/ShareBuybacksDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r246", "r247" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock": { "auth_ref": [ "r33" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.", "label": "Schedule of net capital loss carryforwards" } } }, "localname": "SummaryOfOperatingLossCarryforwardsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/FederalIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes": { "auth_ref": [ "r283" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost of investment for federal income tax purpose.", "label": "Federal income tax cost, Investments" } } }, "localname": "TaxBasisOfInvestmentsCostForIncomeTaxPurposes", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/FederalIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxBasisOfInvestmentsGrossUnrealizedAppreciation": { "auth_ref": [ "r280" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cumulative increase in investment from unrealized gain when value exceeds cost for federal income tax purpose.", "label": "Gross unrealized appreciation" } } }, "localname": "TaxBasisOfInvestmentsGrossUnrealizedAppreciation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/FederalIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxBasisOfInvestmentsGrossUnrealizedDepreciation": { "auth_ref": [ "r281" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cumulative decrease in investment from unrealized loss when cost for federal income tax purpose exceeds value.", "label": "Investment, Tax Basis, Unrealized Loss", "negatedLabel": "Gross unrealized depreciation" } } }, "localname": "TaxBasisOfInvestmentsGrossUnrealizedDepreciation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/FederalIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxBasisOfInvestmentsUnrealizedAppreciationDepreciationNet": { "auth_ref": [ "r282" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cumulative increase (decrease) in investment from unrealized gain (loss) when value exceeds (is less than) cost for federal income tax purpose.", "label": "Net unrealized (depreciation)" } } }, "localname": "TaxBasisOfInvestmentsUnrealizedAppreciationDepreciationNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/FederalIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxCreditCarryforwardAxis": { "auth_ref": [ "r33" ], "lang": { "en-us": { "role": { "documentation": "Information by specific tax credit related to an unused tax credit.", "label": "Tax Credit Carryforward [Axis]" } } }, "localname": "TaxCreditCarryforwardAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/FederalIncomeTaxesDetails4" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Tax Credit Carryforward [Line Items]" } } }, "localname": "TaxCreditCarryforwardLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/FederalIncomeTaxesDetails4" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardNameDomain": { "auth_ref": [ "r33" ], "lang": { "en-us": { "role": { "documentation": "The name of the tax credit carryforward." } } }, "localname": "TaxCreditCarryforwardNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/FederalIncomeTaxesDetails4" ], "xbrltype": "domainItemType" }, "us-gaap_TaxCreditCarryforwardTable": { "auth_ref": [ "r33" ], "lang": { "en-us": { "role": { "documentation": "A listing of tax credit carryforwards available to reduce future taxable income including descriptions, amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances.", "label": "Tax Credit Carryforward [Table]" } } }, "localname": "TaxCreditCarryforwardTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/FederalIncomeTaxesDetails4" ], "xbrltype": "stringItemType" }, "us-gaap_TreasuryStockCommonShares": { "auth_ref": [ "r31" ], "calculation": { "http://firsthandtvf.com/role/StatementsOfAssetsAndLiabilities": { "order": 2.0, "parentTag": "us-gaap_CommonStockOtherSharesOutstanding", "weight": -1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common, Shares", "negatedLabel": "Shares of Treasury Stock outstanding" } } }, "localname": "TreasuryStockCommonShares", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/StatementsOfAssetsAndLiabilities" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockTextBlock": { "auth_ref": [ "r71" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.", "label": "SHARE BUYBACKS" } } }, "localname": "TreasuryStockTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/ShareBuybacks" ], "xbrltype": "textBlockItemType" }, "us-gaap_TrusteeFees": { "auth_ref": [ "r61" ], "calculation": { "http://firsthandtvf.com/role/StatementsOfOperations": { "order": 8.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fees charged annually for the professional services of a trustee, usually quoted as a percentage of the funds being managed. The fee for appointing an offshore Trustee is included in the trust price.", "label": "Trustees fees" } } }, "localname": "TrusteeFees", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnsolicitedTenderOfferCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Costs incurred in connection with an unsolicited tender offer (one where the Entity being sought has not requested the offer). These would include costs relating to evaluation and dissemination of information regarding an unsolicited tender offer. A tender offer is a broad solicitation by an Entity or a third party to purchase a substantial percentage of another entity's shares or units for a limited period of time. The offer is at a fixed price, usually at a premium over the current market price, and is contingent on shareholders' tendering a fixed number of their shares or units.", "label": "Tender offer" } } }, "localname": "UnsolicitedTenderOfferCosts", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/ShareBuybacksDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r26", "r27", "r28", "r88", "r89", "r91", "r92" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "USE OF ESTIMATES" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VentureCapitalGainsLossesNet": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on venture capital activities. Includes venture capital revenue, fair value adjustments, interest and dividends, investment gain (loss) and fee or other income from venture capital activities.", "label": "Venture capital investments" } } }, "localname": "VentureCapitalGainsLossesNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://firsthandtvf.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-7", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "44", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-44", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org//740/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "54B", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482134/820-10-35-54B", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(i)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iii)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iv)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(i)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "https://asc.fasb.org//830/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org//855/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)(i)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(h))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(16))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(2)(d))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(b))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(d)(1))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(f)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(f)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(f)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(h)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(h)(2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(h)(2)(ii))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(h)(2)(iii))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(h)(2)(iv))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(h)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(c)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(c)(2)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "59", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482134/820-10-35-59", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(4)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(14))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(16)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(17))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(19))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(a)(2)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(1)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column B)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column B))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 10))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(i)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(2)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(3)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 10))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 12))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 13))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column B))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column C)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column C)(Footnote 6)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column C))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 5)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column F))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "36", "Publisher": "FASB", "Section": "45", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480228/946-830-45-36", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147480602/954-210-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r462": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r463": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r464": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r465": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r466": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r467": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r468": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r469": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-9", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r471": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r472": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r473": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r474": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r475": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r476": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r477": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r478": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r479": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r481": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r482": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "321", "URI": "https://asc.fasb.org//321/tableOfContent", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r483": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "325", "URI": "https://asc.fasb.org//325/tableOfContent", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(7)(c))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(9)(a))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r494": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org//320/tableOfContent", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "321", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(h)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(18))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(k)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(m)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(7)(c))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(9)(a))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org//235/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org//470/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org//505-30/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481138/505-30-25-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-10(c)(3)(ii)(A))", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147479664/932-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-10(c)(7)(ii))", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147479664/932-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.10)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.14)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "https://asc.fasb.org//946-320/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147479910/205-30-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r93": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" } }, "version": "2.2" } ZIP 65 0001398344-23-014977-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001398344-23-014977-xbrl.zip M4$L#!!0 ( +J+#U

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�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

    G,EN M&6=RBW%FZU,\N[^_-#X;O1W$F7X"B7EV)W F%P'.M+4//TJ2W#H=MAJ"O%V< MN9KN8>Z$Y0#0Y)*4 \W BG?[FXU&H!F$WF$V$PON8$@%$1?8FFJ8&9@.7DQ, M'U2][E5LO4V0&9R^83J5 +:E$&)&4 &QL&5XF5H,+_LW;#5Y)[V=I?([""_] M- WSW$[ 2S8">&G+%Y8^!"ES)C]F^5JTH5Y7!N&>G@9F'2AO]EHA)>! M2!;&XVA*2#4,%]B::G@9F)1=3$R?"05>TB!3&))=N3RWX%!*D/#R9"2 5?U; MV7:,81!^89+>![Z GE&Z$^>90_BL#3/ZH@PA1K Y_98L,X(HZH.AH$T4K0>Z M#RR7 .\R7443-%$15-!HL(0B;W"(NA2^#4Q1?K=A2TR)V^FU)'C(?XZ.F(HB MJ]+?3$/HR?\P1T?PV9+R;CW=W4#>YRUX9(*AW^5.-_AWEJLC#@B2! ^>>?X0 M-.NH8\C"ZU%'!H,1C U!_1 FIK?O5FX:>9S3#_9#77UQ CN#],6L'=+;)K!4 M%,,<]05-8MJRV-? 7K$W8>X$=2PS%;![3 ,+[K9Z)'X$GW=!'8[IJXJ$ACU M$M,2^[(T!OL>O9%)N FT$NVOY M*QCXDZK")1!,XF@QA;\/!;"?);^OW8R.;DBR 4,JJC TP>QA_?0/\Z%(HSZX M2S+Y"T=9#.^"3+YJ==RI*HBO#'PD\JO%S'?Z3-NH-]N5^E6USOS;,9@3\)K% M^G6C4'NT?S_\!>,JM7+;_J30:I7;K=_.[[424ZV5;EOMYN-BYMRV^BP,5#$? M;?KN>_M :N"&\'C$?P^X@Y_8=[,QE ![;M_C_AC8B8-80Q9MH)C#OY:<^]KW M?D!HPXY+[/LZ[+Y&;AU4-T=# ;+!!@>Q!GT (4ZG615TH-7&[61R4U:G\L\9 M8YO*M=ZP4WIQ/JQ1&ET4V8KZ>*'L8#XL[9#[,C>V2C\6O)Z7OKDE5" MN5Y"<>C),LLII[>EY/3VX=1H3GI?)\NL-^)F7BGHQ%EZI<09FSQA4YMDSM8S M4/B&SX2384NODV%;S<2A9-O6DVE?5 HNN1FG9RL^\=?V#M2F5TW);>080:;G MUG.3I53TG^,KZ5!R>/[.$>"$L5$^+S!'2*79!/=]NM@:;D WGCG'\?MU':98YG5 M #"+"\!03QU+AP-L,Q13Q]83_*%D%#@U$POJV'I67W8 -AZF#Z?P MB[^MMTD="\RN;"I4N])_^#6Y98S)+\:8IZ:5:>A%RR8S.;A=C\JMB3"X=!XR9#0=C\A1CS/4DV/TQ9BJ;B0/0 M2$6!,?E88,SUK+XL[!4/TP),0.S*\NQB5PVM-(Y=,3R^% MSG8Q9FY5C,EM1!2-:BEBP\&8.8HQ9BX C,G!Y2@.4",3!L8+-#?6@(X%T(R"D&E[WK0K9259*0@7;UL6?79, M_I7L,Q<'J!F2'HEM.!JQIF/"C< F%P^\$8DFB6-OJM'FFI9?"C=C:/X Q>_\ M[;U5];O ;)O*[W!,<]MY[2,YD?226P22T$V S$HEE M6V.Y_5*JGTVOA5JONV6PN9K(@LQT1H M.4 ]WIB8OQ(.V*10:CDPVZ:X'8]N;ONP.;M$:OD^F>H]WI5S8G<7*QJQ/EK+ MH,=W G!&4=+(]KRI*74O'ZK%TWZ;WS+@7$UMF3_A8A'=S(4$.&F66V:#T%N. M#>(H1@(XXR&YO*;E?P+@#(>ON<#>6P6<@=F67L"Y"]'-)<++[&U2*=A@AC%\ F'P78M*673;[R62HJF>3YEHL;L:MI+V=/.#X.8#,DUB9+ ML_@R&X3Z LQK6OXG@,UP#J$OL/=6P69@MJ47;$84W>2W#3B7 M*!L5'K0W.7U3'BNONP@X?:2-N"3MTD;Q.21D>]ZT5^MVN?Q#X57;-G=S-;IML+E$'&@X%">U>D-.=W8RE>ZC#L0E=T,=J!(%V+3E@1Z5 M1O_R\S37J^:W##97TP?*QR25SH4$-FG6!W),N$GQ]GA@#3X2J!D/A: U[;X, MCL3#^.&<25]@[:T"S< LF\\F,J'CS).1 !;W;RG!8RR#< R3]#[P!?2,TITX MSQS"9VVH-B_*$&D$J3??^=.2948017TP%+2)HO5 ]X$U$P!?IJMH@B8J@@H: M#=91Y VPOSI_*'T;6-;PNPU;8DK<3J\EP4/^ZP;^S7!UQ0 E>/#,\X>@64<=0Q9>CSHR&(M@ M; CJAS QO7VWM=O/1\HQY$+.M/@L#5:GT=S$QYB-IS"5IES2V8WMDJ_%K M\2QO7[)*--=[LBG\K)DM>)R^&YJ?J>ONF2Y^G36S7HF;>:? ,V@KJA\G3S*; M9-#6LU#XED^%E&E;2R5Y-1N'DW4+0C(YNUGB92L^\9>O.V0C2,V2NJMX0A['ME2AULBT#QXS5R? M=^3';/H<*]JWQ2OMIV2985-9J3 /'@4B6 M#@G>TBS2S :ATAP;VGHR$L0:#Z'F-2W_$TXM9,(!H?2)-0=G6WI/+41T3#:] M;<2Y1*Z9O5'*]YUL*YN5=A%Q^N@U<\G=T&M.1H$X;<%F]K1_K7Y^CAO5WI81 MYXJ*S6Q,Y/0R(2%.FB6;V2 TFV,#.=A($&<\1)O7M/Q/0)Q\.(B3/MGFX&Q+ M+^*,(+ZY]9+32X2;KZ879_5KEA?J_"ZB31_E9BZY&\K-IU&@35NZ^:[0'/+3 MEZ'T^;IEM+F:=C.4TXN%R D?$MJD6;V9#4:^.29P@XL$;<9#OWE-R_\$M)D- M!VW2I^ +U_.[@IK32MT=1)R=-R_ZY[I56-9#ZS7<3)K2;AS)'P)DT^[+N'[Q,'XXBGH+K+U-L!F<97E:L68$D; /6_Z)#_4[OKB%6]L6=^$6TV].74",^GTX\R0Q/0XFM6; MN4#4FW.AKD@!\JLCP)GQT&Y>T^[+PIKQ,'XX0GH+K+U5G!F89?ED@N4R%.+, MB&*:Q6UCS27"S;6*>M?[O.^;TBYR-CD_X69V-X2;(XEIVL+-;STU-8;F MEK/HW&K"S>D3-AT'K!F2EAY'LW S%X1P<[C!CS#.@(4'->.AVKRFV;<6^ HC M71$@TJ1/LCDXPW(LI4AS![B:W!+%YDQ#*3=>KY],.;.+*--/L9G=#<5F+@J4 M:2LVY^KB;?%)UY(OZI91YFJ*S9D3=!J=>I09DH >1[-B,Q>$8C.7B47R-!+Y M/"X>>LUKVGT9&HF'\<,1SUM@[:WBS, LFV,3P+@4XLR((IJE;6/-)6+-N=?^ MDZ(II\);9Q>QII]8,[L;8LV18$U;K+G,91LE>7BK#?I;QIJKB35G3C@^#E@S M)/T\VW!48LT@Q)IC C*-0.S++58,X*8 M9F';.'.)3O-#5GT=3!YO+YYV,J;II]/,[H9.,Q\%SK1UFBN&FI=5*2N?=;>, M,U?3:>9C$M,,J7J\;3@J<680.LTQ@1J1E(-WK$TWS@Q,S364E'46#,(=:*8P(U("KES*TL/ M;1=K!J! M+Z!GE.[$>>80/FM#)7I1AD@C2"WZSI^6+#."*.J#H:!-%*T'N@^LF0#W,EU% M$S11$530:+".(F^ _=7Y0^G;P(K9WVW8$E/B=GHM"1[RGZ,CIJ+(JO0WTQ!Z M\C_,T1%\MJ2\6T]W-Y#W>0L>F6#H=[G3#?Z=Y>J( P(HP8-GGC\$S3KJ&++P M>M21P5@$8T-0/X2)Z>V[E9M&'N?T@_U05U^H8YFI@%UD D!Y\9C9U,G7]"7ZN@EL>DQ=520PZB6F M)?9E:0RV/WJ7<:T+S!%:&!0-H+YM=]CF.]@-.ZQ4+I:O3\M-)L4F&+S1B+(_ MT H&_J2J< D$DSA:2^'O0P%L:\GO:S>CHQN2;,#0BBH,33![6#\Y"M#)Y"\< M;3&\"S+YJM5QIZH@OC+PD,K]3*;?N30JM5;K=^.[_72DRU5KIMM9N/EF?,@YAM]5D8 MJ&(^ZO3=]_;!U, -@9]K_SW@#GYBW\U&4@+LN7V/^V-@)Q9B#5FT@6(.__J] M[_VP>]^)3.S[.NR^1FX=5#='PPFRP08'L09] .&^63T[;[<:Y7()[!]J1??^ M@;;6*K#!AS9N)Y.;LL ;5C$&/ALMYR.+]GW22,WKAFYK[-FUBMQ,^\4> 9M-0GD M[(9$K?4L%+[E0]*NX]922E[-QN%DW8)03=XP\;(5G_CKRS/+X27F5I95WL@Q M DW2!2;#^W-\)1Q5O 7.$>"$L5E.+S!'V"RGMX8?T,TBV_K)V"7*S)6VV;HO MRV*EN9,UI?V4F=G=4&9.1@&(;67FP>O=8SM;3_9.^2W3R%939LZ=0&UF^FED MV9# +1)<.!G_2),@=G66I/*T1T,G;; M6GFI)9K,+'_>;U7O2T^IU YBS92?)C.[&YK,N0BPINUYT\MFOWG=Y*OO]R_; MQ9JIU32980V671;+2]$LRIP*0I293<5"Q2(2L;Q4/$29U[3[,K&\>!@_'+&\ M!=;>)M@,SK+I5"*7W5$)DVU3 %)+1)D-O?U^)]P6KS*[2 %(^8DR<[LARAP) MT+1%F7O2RTLCS37S9G[+0',U46:6W6VEO!3-JLRI0%29XR&7%HE47BH>JLQK MVGT9T(R'\"JU\B**:O+;!IM+5)EO5?[QQ6E:%9E M3@6ARLQRL8 ;D>CEI>(AR[RFW9=AS7@8/QR]O 76WBK6#,RRZ22E6#."H":[ M;9SIZ#(KO<_+5F\"_DU>WCS#?Z:?5^W;M'Z9?>_T=Q%I^BDS#G5WYI&I3&7L'E@VBR H^!_E./1D#3U4C3K-Z>" MT&_FDXEL*I7@\RG:44DDLGJI>$@XKVGZ99 TFTAE,HE<+DN[_<-1UEM@\*VB MTN",FTBF\XET-D M!:?W@F$(N!Q;+%%J(0J4:FL^-TH30S]52RV#VS),74WS&<)4T -YRN%I2%)\ MMMVHA*=!2#[SR7PBF^%IQR:12/$YUJ8;FP8F##P?*&4HLWLX*GP+#+U53!J8 M45,)+L51B$?#"90&Z7:+#;^P>$/T8V/?R&\V\M^.?7'GC^]D4UDPV2A5/%%L M.NO8(GE);<3J_.OU7::SQN33"77^"4Z9*9'CN02?\\,4G?T\%-/1LV]DW!NY M%YOX:6(3W%YL8B\VL1>;V(M-[,4F]F(3>[&)O=A$+/MN+S:Q%YO8I=[?BTWL MQ2:6A))H%YMPECC&0@;_BUJUB.Q7GTI7TRTW:@IL: [O 27=&HC@DM%D6057.[9_EWKFCQAK@7C509] M9\B".38F3$,W1ETP5^A@>UA4!=-DJLQA9ONR$EPHG)9%OCB=2NGQ1UMX?$UN M55=BH7,L9;C<"8:BC\T?(BL1&!%FD;'ITY58:/9-:#%9+I'FOIU&IU0L($#F MS$+WH%A98C-'69+RC*.W &STU\),>% '%%?SDO7FCH#3X%MPBI6SX''6FHAA MAG3?R)UJ9%1G*T+8%&^V_>K\:=?;A2O7!K'%',+UE/F+37.);#Z9 )C@-_-_ M_G<.3/;_,&R*/69_K;6'CJ5#[!NY+6+>8B22<7:RSDKMQ\B;I@MO9ZGWZWRY ME79"(;-^_BV"'=HX.D]?ABH"*73 *90\(.=730A1^'SF M$60T:S:K)$^?IP^O+Y./S*?Z\O"RPELN@17+7PZ89;-Z2-!F_T/\;A5DX3># M>-^>+3U/W^]JW8?<>VW8ZVU($)QUYJ^ZX_/OKJZ/X,E+S-LCOT#N7B9WP'P. MU+]5 3J?K!W=ME 'UG0-# E1'\C,T-"E,71.Q@3;< ,,<7R&#?JUZ]9_O!WF MG3.A]^^X_Z>>IW(W6]/%_M7E2R9D_S]D?[OFSH!\&(S@S[S^SMT4Y/(M1Y$/ MYWU\^'] +S3!%&PH(CQFZ+AN15 ,ECL"Q$CTC MD4\N&(E%T#)#5U7@R'X(;^^[Z_CNV>,3=]-2\D(S;!AUF K!=S//T\OKKJCK MO3MM0-$RPK,+G+?0[2JJ@DZK*Y E;>S]=GV_+3Y/U8?*D*N]*/)K-VR_38?@ MM]GG:3>9.V_*U=IXH%+DM]P"OW4AG2OY75:9E .#]AZ\M@>#+5SYJ7QUT96O M:UPG; _.A.#!E>G%GAP>Z6XDL_Q, PR3+!W54!K%'4" MT?3M<>O8N=@!U/O!L/Y@2#Y/:XU^51GV[B\X(>S!P(>SFSWK/8XN+Y+UZ3U% M$1D^O6 PM,CU("^T)N419R2^T+ MN>T+N2US=IP^0&M%DDNGN'2&99-YEDWG8"^B',&^UMMJU UKEO 4?:O84T8K ML"DC]E7>+FYK92:51.MHBCF\K15N2]5VN?0[VG[YLAY "I_W'>GX9_XH!5"N M;(K"$/(R !29K08Q=^33-O\YP)8JQ)=F&SSD5-7%5T\%D!S F7XG8U>XS_.T M;CP,,X6*D+J9R[9L/BPVQ0]@9-3;988]9EQS#7QC#N#22U8XXZ_?&_=]]>!/ M^[QL57XA4\]NCY35)MY#B%0A68Q+_D.\)8%^9?]A7']"W[ ^)Y^-S=E/]+%A M?P0?3#[^D,F'OQ,07@MP/SI1X06B;@QU ]4W05\ !@8O*QN:H )$#/H+K'V@ MI6"<'8&5439,I:O #T05('OI"(!KLE7*DO9Z1922^F((X@ MMF?S:3!#P?N#OTK@4>Z.AG^$%UIW!+MM)VT&T./;6(%T#P5LS!4-;+W!_#^T MM^S@YJX'[7&D'6C)VC*5+"R<5_Z@ #NA;21/!?#OP$?!1L=W9W0 MP\V<>0K<^<#.4F78H>"#PM .R8V ^=GEO6^&K@0=(<(+QS*V.ZFZSNY4=_Z MUBWJ8PU2HU1&5 QQ/ "H&7P5M,O5).9#L9DV##"U*@O@AUP2)0EA_^$D(>18 MN=UC. 9^9\JP>\'PLGL&&UV!S_CH*V)_EG]#G =M*^UKL8^!"X"#.DW(X": MIBH&Z+)W68-;SRY8&0A/ +9-DTY@*A68X%T!;P9>9M2'+>K#7:M=^&77.XD@D=J\")K[.&KCIFJ_TV H R8>:XJ(C9N F=H/W7@%.Z$$ MION #Q(,'OR:"5=//#8-'7S)/(:T=17V,>APO!>'NR5-@GED2>ZBX8!]VWYK MX*@C>&E/UH!/P8G#D'O@>CR^\2O"C5A/UR74Z4Z'2S*D_V/+@A="LX !;O.! M]O[P?J"[!#3+@):#<0A>2(;]HX'?&7F@F"9R87@)& @C&;\9\)6QB%Z" ?V& M\M4P@ \V9!-,$F"1T/C, (I])0@4XJ?N\-DN*^39[&'@=M93@Y#S8Z8.'NG,1XH[>@AOK"-7Z3(R*FZ%GDQ^1(,$W!P,%-<4!H>)XYS(,RS3 MNAIZ*)C8 :!9._J[C&=-%.!QXITN'Q TL&_J .^39? "K-5\]("_6/MU&%F M+B2HP-6MB=0U4T Z%.[_=TA8 V,7OCDLSH5Z&74?_ JZSLM_0!3L[#^FU:], M1S!ESWQH7V&B\CYH!*J*2292%)8JM$J%&^9,U3O@!B2.ZZP_YF30T55K'H#G M9XZM.<"9S8OD\=?V2HG7?FN2@S/X$$Q1L-H4>*573?_0X,AI*7?0X<[ C.T MT((%!XK7UG.\4U%!>E=,W7#6>SC4X)N9LQTKP"OA:WB7&(C9=A.ON==)B)(T M/SP#[0F&G:I_F"C*!,.38&K#DP[R3#C1C<'V$X)FV/@3S23[-[[#E4/'46JM^52T54%VY>H5IW9ZV MJJ5JH5DMMXX1#;NN@1$X87((X60PBO'A1WGG$!PC?H<0<=P!H4>"4Y9XX.Q-T'PM__IY]&MR/2JZIXP[TQ-BP<"ZB M;UEN ?^9@7]@D@$-QDPQ M\$(:PH."W6%HT'B;C;H5-]Z.]X.O@[O@&7P$UA>3L/[G(/#%&+2"M5[QEDS7 M8%";8-LOPA[%'##:[IXRP>/>\9H)6@XQ)/(+O & U[H=PO& M!&KU[@[/DI.2Z2KP$ 7*S)@,WI?-9&98'@TE\$,VX:SN>!0*MEO-CUNO;Y(= M$C:/#-$.<"L(&5<9LK-H9W;0'C-E %G<0_P#[6.+P@1T+%,UX=;:G-M;X_>? M3T$@J#9[0XB^\8*"/1J-%2LJ N8Z M&./@KP/=\((YE% C;V_%)BRH[=W"N[H1QN6!%WE>W[UAQ]$%IHFW9' QP[L> MRT3 /. %7H!5X:R!4N%=64)3 ^%YCX3/8S2=S#0# 3(=[!O0EQ"D@V\(YY*Y M'M[AX=A>?]U3E3<(:1R.,70@/+*(TWL&#[BJ!KZ+1C6'!G4.3MIPY^2ZT=RL M;<\$7)9\*4HC*9]_RY]H-^X.['*IS/.4?[WMR#EU_*3E-TR_AY'P=**L*%]M MO<225RH]3[L7U\GV^692T_F6G5 M3+N69%"=!A>>IXVK:UVY>\Q//QU"RM9RJT[+^.>I5IFY4PW/4B-*WWJC+%ZKM=?W6L-GZRWWJ=7AIK*NK>GZT:'WRVN@5:@N) VL@)$S6 M.XL @RU*4_/N,O KW>!Y.KDP'Z:YU&OA88X_24U^FIO/3Z>>ISFQVRI(K/IA M<@=_6K?7UX7F(PH.5<]JU4JU6*BUF4*Q6+^MM:NU,Z91OZH6J^56/-/7_OS! M37<*.-B)3KS#C9XY'@S@QA(F01WW<8="A\2!R#?102J\\33P#F_^H*(=AO?= M'I,<&;F/8I)]\=\1;PX"'KVG< =?[\X,O G^[X+1F^9U&SQ/S;L746T- MW\I:FKJY?F;(\F#(7J3;8&1>\]>9[L$?I! !VRC66Z5:VT4W26C\Q@.3A0* M]+ ]?5T(!?HZ, ^%G1 [$_R>@0/U*)+B=F(#>)T"MJ;NC!;XNSP<.0Y]JZ$T M+4(+:/]<0.XAV#':LT*A88?RAV/#',.Q0A(NAHQ8!B0$I#$5W1@P;/+H\I@I MM(HPHI]@X-D8!Y60I"FI+#1'?0!C#A)][:>3N[BBQ !]%B #';X6N#N;1!^Q MB O=E'MC%0_.UM$#RH["5NI#12,#=N!*7\'XJ,.^]J3K462<)%(-F&1$P3^4 M?Y43[F2^)L/:9@4F#=O\IL=3B;\P_+R/H! ZM#CH>#)#(WJ%$ZC$F;$) M QH,L\\Z)!7@?+:@X5]\,FPP,:!9]!1P ^MS[&$P* 7\QUR<<;"Y!8@LHLE= M9<2,S6.$]<&0D\E7$#<(!L!FPL^YN22'LT,P8?31',K($ZTX*GHY>#B'9,,7 M_1V,<<@*T%7/R>*YL!NP!_)>32?]Y5EF838%7:,Z51K!? '>WGT92IC8#"PG M48)9"!U!Q<0&9Y38E HTM[D,J&N1#ISP0?.M*=>[90"4!ECDR;.\LJ[EU7OA M\_2LFC/OJ^/BN$K?EFEV&04['[5?&I\7\^_MC AF@!;2?2NWVM7K0MO&M\X* M.@/-%L P: "83$!'>P)=,,E::+K)A&#X#H17,'XL&V""H@D0Z! [,^)]"=TN M2A7T7?D280";A9Y \H\S0P:2>%#E#)@26K;&.-/C_*U)-@+1:SZ'L@;I;*[3 M1PX= "]0QW#F'6,*TE@=P=CW&,P%D@)>P, S)XZKVR_\PX:> UB6@]RB+Y-Z M#M<^73]FSOJ7ZMOM=R(KT0[(RO/T4R^)>O'AJ:N"K:@CINU2S81J1PC@>L>G M^S0I7&V1=TK0@PG.>X=11)OUZZ0MR:"S%GV+@4;2J: W$??3Z:S[IEODB M%!1"8D,56J]T,*NB&H]#+:/QJ-)CRE:+2R7Y5/)Y>O,^TI3KGLQ-1$?0:W'; MOE)X6]8,7[4WW_EII5*/1QF[UB,_6^N1Y8_]*E*C\>H0--L>'S,M*LDRTZ", M/WB\/E/I:24'/&9NA^!7$[29C"LO+3-A?\^B2\.9!*Q"E@. \:(BNL1 F$"* M-5Z5X#*,%J8/^!7%WF*!+UB+E(1?UKI>E,FRUI%MRB[$I^"U3*OL%$_HP38G MQ!F,9$X09\)"LY5X?LZ:6!3,?D&3X/]!*5K0"_ E5P\"K?1]L%;>5#J]24:> M"@KU:V7F>9JKG[:4^_>G7CM]\*=8:)TSA5J)03^4;VZK8*&$DCUS*-:]9X,Q M!I/0#2P0*.&ZE\#+,7H%.R'M->$9A6#^'Z"*#611Z>*#&(@I)!LC,.LP9A_ MNB,X1,$-.W"S!4EE9!!C,O?(S:Q&+ EPTU'?A'M;S.E&YQA$8#7$S"9F\^-3 M Q2)QYR-/!&O'#W(609@&Y31V V+$7^(+((B#+0H&KE^H_F>._C3 M!#"W62VVRR6F52[>-I' A6<(%T:S6,#6YN'BQ4[7-3#QXN[^&=, M95;O$WYF4Q;U'C[SM7PN.W4YS)??!7-#WAB?:ULRTRP7ZV>UZEQ*JJ3 "#7:(*, $=J.PGVR(V%@XXEBS_#<+UK\K=::!%@@PTZM WYV#-\*B8T6 M 'MX>@O *+C?$&7P2 D>-Y0U#*1Z/7[J*!QNFOVE@[H*=@>U8?NAEGQ,G;VO4MLN6NIJ9DV6W,-5 MOW1=?V@,[[]CGBU05S\*ABD-7NK3FD@3=15TI9([OS(?1Q]9/A,PHO'4&I%1]DZHP1 M%74U_SS57]BT\79_DVQ'/3I61D3YBH*D[3@N:P[*X2]?%.1=P(D2[\&*V1RTYN*U.9RFX*"\/<38&P9 MK?)@6&ZR'[)\\*=U7FB6G?2?O=.$;@/CFK;6 @'3%L&K5KASV&60*=(G_"MT MYGR,:VF*@BK"!!_.)B <;P7>S?' NMJ#TEU ' 4'2!8"3_8HSH?V!+ ,"MHE MX/!J@@%@'<8 5=63:C]T"H#820,;:E;$I#"']2D&C MHB0[/]LEAEWYX^6#+>V.1H;PN.>I-!2S$ZE9N\S-G0FA;I "'/"8':O-L5&K MMC@8ORQ<59_*)>:L4*TQ]29S56^U4%[BMF;_K=!H-,O%*BE"T&1*9??O%<8O M[]_RC/>"DXKKP6P#S!@ UA!!++K_H";9F^!"B@1HYAV[1=229=4"[*/Q[KR M=%9E%M^"*3"BC\\8V^60G%/PA#N#GH:K 2$>C<65@=,5V*"+LBR9]D8?YQ'- ML=AW?_&8:;K?EO!T4%H7EWYR)B]T!AIQZ[I@0,%@Q,@I@H&:"@_ZVYTGN/P4 M=J+D\M4U.F8^A.'N"/+"KMZ",Q9\1^>J'S(+.20>&-YH"Y_+YY*2A\/C_Y7G M:?&]5>4+O>KEW1S0IFX^ (LV*Z;.SS_UOMI7["!@N_#@PZ>S E(V6Q7R51!7 M Q>0(>?9K2/RLNMD.ZY9!_-E0P-*>22 /XH"K&*%BVRY2VL)/H?L6^..V!>& ML*A'T2&72MZZ1\Y<8GJ#9& U%M01KDSF:I2U3O\P9Z[@4@7%L0%'_J3M8LH6 M- G]2JA17ZZ#G=16:VRU%@@UC1Y1$Q! [[ZI[;HSIA=JS>NH%LT>#0@"5_M BD M-B7'.\PD7<;5[!6P5X>7HMP\*6#FBL C/B@D"5E%&*$U3#7=R&; M"%REJ^^RS9\ 37A%M2VM70'D,@!\C\L>HH;^[?.2).6&:QJ"Z8C,CZAX'YBA M[(4>;TG@(30DM0"K(\+ 2 +^#?@:] W1:@,Y-8 Y"IBWY*(3DTZ!12+!=T5# MEL ,#+\Y#P5FB@FZ>A8;F(QX6,P(TJOG79)L7UQ>"+"/YB;UPSR%TS8W))EA MC!!48J!X)\XV"88&.GIVD/VPR=Q)%9_JA@$/'H+Y]DH7P/R!9]J92=O-FC&:EUVD M7^^)$<.>KTD1(??4-YJIQ.4J,H0)11#W.*Q$]]R@P )0(]FP9F!OG2'F4#F6 MCQ/PYA)^UN\?YJ]%78-/QO-]$TPK133#P)^6>.J2;SU/W][J-_SU0Z9ULXIN MV79]-/T\S2;K@[)T63.K+P>P@%\1[(:;]EZYV"R7JFVF66U=S@$(&U^K ERP MX+$O<2%9;1E73D UF,&+NV:1$.KXL$X#0@O? M>=B]5?S6_< ^,E,JW8SN;\J%3>LS11)72I^.&_QG1JJ^]0_^U!OS1SYF*I&Z M#@V0.KX(J&$L0C"&5;E8'QNXMALZQ(E($",/14-']T(,$%Q7>8*G83P)Z^1H M%:0^C& ,1 ?#00+X2T#QF=$LM+%Q"&J8=0K2;CR\N[T4#,5?[(,,#N!,Y MG38/;-&6'&R\P+62(OHU'='Q$0O$M_&$O.)>M0C)!!U@Q5@0,D40\H8H8<>@+(/[D"'8;RCPP(0F?\J&J%C<*JOVX(SM;)(7^)+@BH^: MWM@N\5X/Y7KF+(4[%&EYC!5U)%XU%!2T5<4C BU7J)(KZ"Y;,MM(#A\J9YGP0#P6!G M!>L)N(8= HZ6&1*S+0";,&<4V%%H>S?LQJ(H7J:BHA&6VBB<$\BN# DQ6APT MM$WMR^3\NF/IOMNF@B=B/R,I@:=4G-.R9P=@7QAN<&TVK>VE ,-Y7>$=@ @D MW8@WP78A%3@%>A'UQ/TZ\'-K!L=/HJ*28O9Y>LYJT[-LWGCJ;9H!HH..!J5V M\Z98+]X*W?---X;!T]'X-4O)Z:F:T!O?<%WC.X?0+Y_E"^/3 M]-IT- _?HE9-ZF]3[:&=[OC>*"BB&MCV7(VUCWJI,:F]O01)5/-P=Z;E_,<5 M]S 1]L#$,Q#IAEKQOIGE&\EXPW M^M*>@7'8P"0TK*?2']I5Y[3^G7#41KU/92D]X1V#;708%&S:WG5U/%@H6N-H M]7C*BIC*IW6:%-?/]YR90Q#8*KUG1EDB+Y0B>2VQ+TMC5:YW2W9O5)WSMNY\ MK*-Q[M8T]VB>I]7*U;A\J:IG;U"5'M="1'?\&YW- < ? MGN\_8E:O-RK^[ZP1^KQZ#SNAQU)2_K7&^?].HG\8:":TC"V0J+=LE/_E/D] R0X!S/B-VV;Q MO- JEQ@2BF3^[1C,"7CWPV(=!N2+[99K]M^17KDO-)M@Q(+A6:O#7BER19K7=+M?6\1)[!-I=(XBO/439A=.4;OS-H$(NH,?T@S5':0C11#9U MG)DO1IQ?N9-6VF7X^\SLZ^('S3F%?3X[5W#(NK.ID2+48A'$D?D\'":'R6O1<,0P ?^YH= M^81M;Y]I#D]O\;"UA1._Z(B ZT,ML3R;X#)<@D_EOVG[+\=]Q1GW]SC"N^:H M9]/W_K(8G:*?R9S8['_@FC>QAO^ $A'QN MY91("4)^"N2_WFJ$!CA:HE&0\_3Z\_)H,*^YFY>)H[JTB-1$%J7J*@ M\CR]G8H9O?[!UC+3>;$+"7-YH(*2 BOCRK@J1,&EO6#A<2.F7M2H\^4Y5=< M]N&="%.: YBBQ/+.X$F(M^;6?T9YY ^8TE45^9UH3T(R$9JN0/,!+OX8]<%; MC&3\/BC12XK@ZD/X=F#. 6-:G"7>+GQH JXG?48%/8@/'J!&VK7=10%3169N M]\6;>*6:/4+LJ!@X^1YF[N$$K6(Q+2"I M*A,:L/=$A? ;?!<3!29HU0-2#[ MM2/#/PDC196M0F+P!A85&%N9D")&T"8P1XRDL?'I(A/9RR9R=&0WDT8DZP.I MR&N3B[$>O.T2JO"!F5N(8>WW1$>(F\@IFO:)#;V;0(EO^5. ,G>X>*?0[8(; M8%X J4/GW,)5!-UA#K\[ZM;P!I9JHX)5(8GR(RY9,B,_CCK4:Q!;W17ZI(Q= M3!60;>S2RQ)PRCZIHF^)T>NP&@RP%U2AG7BXZH1R/!E"( .?C,N7PX-BA+X_ M-/2N,B(==\R\X'MBF8!YZ56G$C-J*^(W(2%UG#?'!VQF7GZV M_B76L^\A4H-A9]K1Z3I$65!,9U1@94U81)KIG+\F R M-Z*Y"&DJV/= :XVM4C[;[[9-=MA]K2G(GA:$3=#8KDJR@"V 'O JO9A_6L'%\3?!JK'KY\E\5JK;+(^!2W6 W MA!17!J EUK%@T*X!*@)HGP;!9:<_^CI:ON$X).4%K->"$SBX'DST5I%Q;\8* MT;;0J5=4%%597/:;S?N5_9XO(PX[U7F7!F1Q26.#,%:]A%BW[(57*>!E+/7< MK#JG[Q85.U TGU%.ZO-[3^+8?#)W2>4/J_ Q8J5;Y\=FC-C%!#=IXG:BF7;( MGXJ)*BL78$TSA]#J^(>G'!EIMITVAV]6=RW.IF70FCQR9LE#L*]%/_V&-Q@O M.CGM.55V;#E T:]1.BZLYK-V+\'@N"OAU(Y5$A AF(C#D*G/PH [/%VU[7$* M&8>RU@-(3<(% !6D]']7);H*F '%'5YBIK(U0:D*!J2-= *R%JYNJM').C&JZV.87"85.L(>R:(V=/Z -$ M#E_#M]%8 OQM+!AP]1QKB*PJH5K[LX7[X9O !JAX7G/:;(D+X0XP10""G8F$ MZ X9\$T-?,OE+Z^8KF(*8#2ZWPLU!#\&MPE<["K8CG9SNHIKMYM#6/$:KDQ= MW?"05OUK&'QQD--96*B@C>:?IQ>3Z;@H9XS&ITI=0/([M-'T\[15'^35YO#J M:4@?;32[SKOPS]./XGW_7,U7WRM\#&BCW/-4+,BET?M$$UOJ!K11\.9LI5GJ MEBYU_<9?R3LHVBAX5&F8KQ8RD^&]W@^'-II[GIYWU)?>R[NFOTB1T$;!(Z^R MVIGQ>M9\U.9* &Z=J1BB:/?P&]\92= MFV>W;HRH:*-@J-T.LY^=\<5C_6:.RKQ%177QO%FIW%UI]S7IY])&P>1\/YZ\ M=*JYV]?SR!G5=*'^^QED[JGO80M@#6;DKTQ['S\O@H6^)&L8U?I_49+!())P ME%YWR8\X*#+A LI]JUC1.SH -8 (]0AL7HA@$Y $IWKT\S](, M7!\B JF0'*_;\DA&P_#V90_;W_UA9Z94X,;,/6K6)*P_9Y0WV;!^] M\3K+Q3MR#Y[K1-M8=+EO9L>52^C(.).CD" U$=7QZG[9^S2?^)Z5*5J\R_S' M'D>^/ 3D_/L1]C-'&!>O$;8@ANV-5*.T$AF&8,3@NHM0S$'^,*W3P%C.V)C, MAM17&U(XU2C8V:'%8\NJH? JF[.A%D^P*N$-JR2\%<:<>\*8[@!,#)+@$>1< MO=%+&_L/O&@_&^SL;)"*UVP ZRZXEEPPUO$$,)#ED2W]@C]R%/\\X\ET!M1Z MB^H*@\DB]!BR6TK&''?0+>P2!%].9_!1,%735;Z80V#Y(4E>DNKS1HZI&.=A MTPN=8M/7-GNE(LN+B(6G#K'PJV\^3V_Z]8YPS?<^DR%(<@1$*4S/4PHSS]/; M9N-,[;V4TI(@1P"88(N%9BN M+!.2DTY*^/NWS4Y#H3G1'%D5\S_P%D378/B T)4%A$/@6LRS?3\_R]:N7?E&VN?P%Y^FK""RN_/0 !"VKM8K-H#_B M7!3ZQM@ C>6.D\E%LHN_K'1TSX!\/PS4\@-\Z" [>Z9#]/<\S<[^DE2&&5$U+'IL4]X(] M";8*AAV40!KWW,P-_1*^7SP $D!D-,?,/N(?+*5'WL]5IMQ=@PQ.4W &PWHD MB@DG.1$77#/LTSF>0^V+WNB8.9WO7M-^P!!>;R&289X@@3-W><&P9DB3<0QT!8W#;0!%S$'((N'T/A>1]>QI=#SWF M^]NHTBLBK0U@:62X>&E, ?B8RK 9F%Y@6Y ;,[*+K.ESJI:H[)K'\. &A&M#XANC.==P M^P6RCY]F\/SLA@:DQ>!"JCTZB9+"4G ?,JK_;?48J5X!-TCP: .&6KC$*H.U M"3Q%\H+N6J^!\1KR=6$-BT&.-GRS2[K/F4QPUZK5LV!?81W*T_T/Y0VFKS6N M]_YF/CF:R56/81RUT2]UD_U;\*UC<$>F+,+U_ /6Z)>U%0_#:?H2?>H%+Q6M M8&KXE7$AMG(J@BS:D.9GL*#/-YZG];PY?!$?,CUA3MJ,FHUH9GXCFGZ>9MCL M*#M6'ENMS,&?4OFTO=]SSNPY"?!1\>X34L]5 57=A>1T528X$4YKMI0$.EZ# MX)6+^NS61T-BRGH'M)W$C0YU4K@2W)K4"2:'=Z F&U9VP8IL8&1'6V9]"0GC MM-OG*_W"VS"_:94L.CA_W/.TF)?YS^GYZ5OE.^45P^7\Y=8D,+UUSG)F4[V^ MUJ(F,'V'\\<^3]^?;G-GQMO]X]EL2<1U2'*0GZ)7'Y]>'G.6F\3!7EF_K-+.P M.']%T-,?'Z,/Z;'X>IFEA58&QL43)\AFJE0N57>7\Y=ZGG:,U]/15?JE]/X= M\:U0C ,&9^?JXS5_VWK-\M^1 8X)YP\X88.3BF?#N_YM(_*A$8',G* 8: 9Q MX/W"VA=NK9>EWWN>EL^EP\.DP2#AKCZ@F6&)J9P+%.G9Q;JA5:I<)- M$W"8$,GZA$ MX56B@ MB@8&B1\K!J,*)B2=0LX;: (JM8]+U3NA/G@S')6&9^MQ= \U#_3THVZ\D@:6 M+=DWNW&/K;+=M$.\B0&;IO3?R233.+X^9LK@V;*A(3O])J(!=FE\Q72J3I#0 MER1,/.4_)G98R^K!$5).&>CHG41$UE-(>8H=CB;/NRH1^.$(2X49 MA%Z<8#KC$>K]Y?XZ(L4=0&^['.?0)3,Q^S=BU#F2<\*ZF=MTEA/;)H0^Z;0( M"V$03@794N_N%QD#%A9F!..,C#%"D>9B]&% MSRBXZR#,5@_PTJ-N//(> =]AOJNB\/LJ^6:6O$J[J M.J2^@3,G)CR&GC=M LM9>8\IP\RW^Z@RM +,[3A?[X'GRBHL5F1GMF4HIH>S MQG;^RCD4XR,B3+P5.H:MGF.?,W$>L,/&1O0BPG?$E$0BB 6Z%J>"4,$ 39IC M)Q/QM24LR1WNUK93'006-.AI-B=T5J_7D%T%D^RI=K;SR52MR?"@B6 HZ."_ M=3@+)X$M_(*F,E>M@([L)$P_L&(=1+=.@AZ65-%5R2GD8MT/VQ4VK#M&A;E$ MQ1#' UR=P22">!J!8:8.J^.@Q[DF:*CSK5ID6N5=D<:>:EJ6P"RLPP:^BR<; M@100SG?.E,JM\O-ZVH-B@HX>^EC MYJQ0:&#%5%R.QYQ9J1TE,6_U&EL.SRIP)V@8,Z!Z59!4 -T8JK;!NCAN84*X M%D/],Z1#YI$%MG3L",9 O!VHV*@Y]*,!<"#@8;C^'"0V',J?"I$D_XU*%F*% MNP1Z,;P'];X3=CDO4X[..4\B2I\/ALWRZV*F< M93?8*H#IJB7D+>GGU']R;T': MCF)UG D'79F"-?4<7O_^FVG/#T,X(9E6&5QGVPZ<7WZ'5 \W,.S)L/(D"6*1 M^[C6753925??T48.S@NP3Y#&*1Q^AGLM@ZJE9"%'*LX5=]E:G\D"##NH+HK: M2OZ$#O^#ZXETE26H"^.PB+CG/!3<_]J^&,-5L S#6<3 =>5(75Q+"=>Y-RZG MBPB8]MU(+2Y4^8L04#\P5\_9]*'[XB^Z2,NNVP*T "<8@#X-<@Z+5*BUR@@B M17@R+^)E"U;S-)T5@4Q*;AQS"#FJ"HE&05.^P>,>Y(/?=!S1VD]<^XEK>6NK M>/EW)JXJF;AF@!B>#!SD,8+\";"?DZW*@/#EK(VDM<,\]-3'%@6SSW11V5HT MSO'"_QO!>:N,KK7G)1L93'\^A 7T4$A9^HWG _$0*LGJ;;\4G*1C'R[@-K_G;F][PMBR4Y]01MLT[^Q:5#KR2 M]/C*WGYRN3N%MC?B\FN^2K-2>+D?]D>#ZGE7M"^D(; MWD7#I ./O-4JA5[JH7O_.3<.MD[>"HM)EWR>/IP-%+EWTSK/S9W-WA99*_,\ M3;\_J[7N:?R+YV6Y#?K5%X@"R J;.P,BG0O^871T+.S(RG\. M=$E6S01)BY!,-M0@@:+!.MB_'ET#5 OC;&!3/E8%YE# S!#I"'Z"O_\;Q\Z8 MCJ+I WQ@%7P*+U6%T0A&)O%EELH-!-;&4$WU(K[X:)[Y/ =5!0R32=F M-I !;I7L&Y,DN!V E7TJ1%M!NWT0;;\7I6TO6D#QYU.TF7,VI 6R(?6+3J/- M)4I_>4+&MEB*S4@A@3!RRA1R_UP!,3AB<%0+?!/?Q!)N@#&CT02I,LF&24=0 MA[(<$ 2#=F:2N2X76K=-5(<&YR>K_AP>R,Y G]AJ&PY<*>#SPG"&;L%S;X(A MF4Y].-=\Y@H#X&BJY'"I">,(YA,3'N((N6:^(!-QC)EZ^0+35V1#,,0^D=X! MBX<.F3%3<@=%&XY'R(=\%Z7E4S(.9SA/Z$&A=70-%$^#_#?RN(GG 5;( YW/ M'VMV<09">B3Q942?[>_>TH=.D?J[9*[\#J M'83O@/L(]A],_[E/-[KR/;CS2 -2'O-&>W*1KA'6=H\7T/N@2Q43I5K[AHQ/ MDJHV/\KET(Y;"::E&+4OO+O.BL]Q4#3\RS4_D\/:XI2L^F!&ML;PD>NT12PP MP/_@$R6NQQU]R+#7_B:GF_]AT(?H NNS@S^WPEM3E@T2 M7/C!@N,V52AD#1,2M*X&V)]01G9E#LXFF$ M^P;PJ7LF2;B_:BH#!7*+G"^9Y%OD.ZA5,]^W-/A0/3=4OT<>XO(N,/$L2^ C MT9 E983T3,%O$P7)JXV-=WBY)'>%L6I_&XE&D6: V4C83S_[Z<>9?E([,_W< M^FP\ELT?9/\!V@@'GLW$F;^)I;SA.HQFD[2M6G>S9L;\2W@3X!TL6NYBF%L-IFI*H'"313H*]RDLUSCG U"Y_!W6 MGD=A"_MX*6)3DY^)C"G6""9"@7"6@EM<0Y'QG0G!*$%6(U3QNCO+RAI-AD3W M$-\:!GIELI3*W@.PH,/@5,"CA,N3IK8 M%V"!+]#Q4);>=#-HR9"Q6@ 66<\80BNXLY]W$S1PQ!VOAMZ0 *I^Y^IP6'W0 M.Y)=KX'?8$XRTK7WM=E>2,79XGD=H]@2.FBH3JR;P*J%'C*8_"D;(A+5533/ M*2;7_6VQ<1.KO+H7?L@[Z>D&(CO;P":UXP$,8N_9<)@[F@? &:3JX:*!#CWP MZ_@&.D& DCA0W]W$0\F)!5I<;),X/K('\2??< GA%CJT;?^8(R$6@BMAW!"N M H8,1ZFW!*=G;B;A,ZL)PS$9+?"0SGQ,;,%C9QY(14VO_/-TE*DD;^YO'LY> MOI.WIX^(!+4O]9Z@JH6A$BH3J?P\O)!&:T8?+]K? JG:N/WQG^83&1 M>JU:1>(+8J=+7X&UJ)A(E>?IC7(IMH7/Y*7RG7J+H1CG]'GZ9-3JUP^O;Y># M396?*68BE9ZGW493*:4FXS;_G??<)A4)I@F4[B0<> MPY__/WILVIZIM;<.? MGW_!NYYSJM9ZBJQ%(XU[[[.K;!,3H\8FW9<4*BH1P0"VO_Z=8U.C,HQU1#R-J%QNCB_J[;BG98=((]Z=O,MX>!Z[9BZY#\ MVTH]-+W49J<0*WI]]6[3JVQZ_-!'(,6@CP8#>'-=]CU;L\>M""0'"@/&3"QR M8I$5OE8Z^YS^Q""KMZ'8$_W1M++;9:4*%Q/F J5A<79[03>3QUR6/$LFG8JZ M>7S=Q[Q'M^[(7+FN]?O;9.@F66IM(?KFO[!5X3B@2VTA&#^SHB%(LO[K",%L MH@3OFQ: CC#4@:6R^&F-:-W#H9K2 EXFM/I=306','RAJOV%O?0DV+ED'_4( M5GF]KER:_)AGJE]/[197&@?<\8:R,(/DGP+>6VOUQ#8L+[/.!8!_+4&\ MY+\6#*@KH;O-?FY][B\N"_._?F*5EEN\D'5T= M0(JA]/SOQRK-PE(8B^?^+X'^ Y_'D/VW[0GQ:\6"( F*N>=<$2.Q?YH:]@=, M^JE1!O815JD6,KD="[FQ""B$V+X$RX5V1^@IK_@FVT)AY?I=KKKQ. M [Y8]62L^*_[2=I!^=\D/:\_[!L*;A"HX*J.[5'_>YW:\(3P<$QO/$1M/'7, M&7W2 .*)A7MB)\BG]XN$_[)I1H(<+YNI]AA&\K:Q1P%Z5P59#T8^_V/[_+*= M%6^O06X:U+#UI-7!BK UH/S8OM6F9\L?[Q;.,N3=3$TEW>F! B(9T$?(1]1J MS/:IB@;+ !FSBBPH1DIIY[Y&TA!R@^E9?384S7%M8=>C:N&SL$9'=3;L6[W)OLKD8WL>N MI3/7XL-M*1:OV)K@>@?/N:BI;4'O>>SW9763=6CZ%5X]YXS\](603X48^=V, M?'O?X>;-?!B!3\7 ]P/XW#;P P,['5ZP(TD/(\QI7V'NVJ%Y!]8IEL6))'D& MK$?X3G:RW3<"?U1A!/B9[F,K#9",J-&W7#$_SSSYC:LKGW-Y\) ,HS;8M/8V MUR ^[3P WN'(BX2M%PC@7U6"IX;W=W2+#B/@-ZV\&/!' )Z*D(T7!,@C8]P= MB>YCK#J:#+E%%V46;PEQK"@*L'KEV8VZ7#2-NN4?K77S\Z2K%.=W#4ZO#0:M M,.J"#=/.927B\\X#^/EH&GA!@K^8+?2%SG0L:\TP@I^*P1_@=3ZLQEZ @(^* MR7<:TH\Q_$BJ"O:,JN)$PW!M M29>?/)?"\+H!(; ;=RY4D/=)G".2>"+!>E M>Y?3MW/VG'%\!PI?-II&:N"" M./]\5S+MXB3;'_2C*(^4__(8F$$;"Z(S.WH603S1> Y>$(M5DNB*X]?JA(JB M(-*Q($:=AZ7)TPSQNFH(,K86[WQV)I:^J)%]A3=H,ES&;"1((8>;WH6,S1/. MH]E7CM2K";4T2(01EU1(SI)( )*\*$MYA5J1#EXK4BR/4SP5)248NGANDN%NSH0WBI$=>,08/, MWZ?3M^Q#E@GC<;P9J+NQ"HM'G>86FXDKT!.AN;>$ O09;OZ>5A(]H$S#"/K- M8-T8]$>!GHE.!$= 0 _]+>MDA!_%2A$)G*;C^]>U)F)=*FSQ\HE8SJ?=B*BQ M>J*9>,Z',F;1:RY6?-Q%A9L.!^R'S!O9+KW.^;X41MA[S=%V42S[_TK*!BDB*:D^];0+_SR9A[>;L;/F5J M#^_=* 8D'9;A=<'S,PX+=/901\$L#5@$[R=4L_A<>J!ZKO4QPBR"A^69Q2(8 MNLC:V(QA:+RVZAN:'P=(-P4$:"2[H4BDHQX?G.L.RR3WTZR_M.O44:O]T#,OP MY0EU:2Z:@W5O MS_'_;%W7KSYJ-)Y8U"86X3N+'VX"8P:[E1I0>QY_6PE1YO)*7Q663>FKDM[? M9C/@B6M-?.MH#N.=J/.048;/TX%KE[=*$B8T,V5[DTZ]5$!]Y M\$:"H!(),N8KSR>/#H&;$9)'GR^#ECQ.DL8C^?G Z)GKDT=O]\DU>:1C>3R? M/.YJ9Q1R8?3Y.FP)XU!_9[BG/#>M79\P>KM8KPDC<_I%FV-X/$$P(9#(B%[# M_7$L;%W&H]!%PYNZ02^SS2Q*QOBC06:?M%J^F20OQ<4M0OB<5]%G:YN+V>,S MW$[/(Q'!F,./S>)7MZ_<*V]L]"3B"'LW&4N$MQ3NL(M#, :IT>7ZI8E(/9:X MZ(G#X18G0Y[3XOS&U._I+;(5--2F+&(EU1#C,BSQQ$(YL8C>^J+2)MO?>BQ9 ML6FL3O+U4]RF<9#".=ZRC@?D9;A,,C9D M(X[]@%IMS^GGK^K;:W>4[EWZ2G<$]KUUT8ZQOS.$.)QX#ZC;]D4CZXX'NK<^ MVCY$WA$$3A!Q@YTKK<*WRZ48VI//YQ)^\UJ^IBJE5.FYTXF>(MA=F2\^Z4X, M9[DTUGVNW#WSX7[+L2:VX7L(^QXEB< M89(XEXSS)ZZQT-X1%<_'1]LW-N"VT MTYVR*M[) S9]!79 FQC+L#_@-7 )6!I-+%5(MMGRY^/#=>4HD@*PGGMJ5@& M(B@#"[-MGG_\S+WR'?FV+%^5##@:=I&5@8@R5:=Z?!%3Y:^5AT:$M=41N"3L MV8+_>*W"%'A/A\-M->=I7K!1P^E660*G.!9GDD>W6=E8DV"/)1>MSA1S (;"FOB-R/=ZEST=BA1RF_C%9+$[3X/]9+YD) M9X"K9?O\,03PNJ.L%-.N0#8%1JQ_X2>P+:7.;/6=0_!=<(;PR["6*,M#H=V6 ME"Y:*/AO.)'%OP\>R6+:!/'?+7/'R2;ZL=OJ0W:;HUG$._6# !]WQ"5X@X=5 MW6'M[9["/]*_9M^*A7#G"?)C/GI\NQ_.7Y\27&)M(0_L:"']^W_,3=O&YM[I MFVA#LU\.C4Q]S)L)YCE!B;7I5#YBCQW@Y7FAIG]U5-505$,TBWI9_X"%O9)@ MF:8#^2]9@. 3E9MVM69>T;6L2(BDM>=06L8F@:8)BZ+_AXDC_(FE>O/[? M]45;ES$D 2?>!C9G;K&__/9UP/R=I_L F.YB+N;H3?U4 C=H36K]:]M'/@7V M\2%;*(YZW:_VB;OH<+,AMN;ALJL.L]A0-?Y?NTX97,K C)Z(B4H;4SN8*+1Z M&#PGE+:@85\C03-$#0=/*4(7%>;#Q#$XAP18O@P^ADXBC,($\+CY,XT)Z%Q# MOY(EH2G)DB&!CX-C"FOU )@18L&?OD926S)FN(5?H&.QYL@ )X8!_C@ 9T@; M2/!?X#@1P3=IF( U-;4/?I!TH%9E&7[>4#%Q*K9&0'P$3K-/OZ5>\>HV$/PLG& MJ#;&]?_=W&!Y293;?V$5($Q_8SE3+>K\6<6&==1,0#.94U[>>E]3@N= MT&V&61L5G.P9<%Q#-EV !WI>4@2E)8%#:UDC6,=NT&$L*2.Q??CFPY M56SDL)]9T1 D6/!=KO%+?!J< M:832GJ6Z[?=,>F73M"5]* LS2$,JXH]_%^L,!<,)]N#7*X@O&:<%S>3*AWO@ MWRV&.9V[+91*A=(MEDX54Z5,[H?3.XZI[[Q_##X,OY2K8Y5&-7.7JN5J?S+E MTG.N6BN42[7H3:.6*D9]"M5 MR8T:7/A:X;94R!1 ;B4# M*TMD\1O;<1YOT.4VR+2MXDT)U:8L3:S%OIA6X^K0,*W'>(LNMT4V.WAY^MCM MX>5>K=G%:,?TT1"^Y2=I;2#Z=[R-9]_&E=F_V"R[^;_XG66@Q;(61A./8/_0 MQ!\JB-WYQFF<8-DSZF"@*ACJ9*B[KV[ W=3X*^T2%\\KGE<\KWA>(9_7-TUL M.U=S2>?4"GO;]((R%G4#Q4]\2+6U3M$D07Y\.*1<^-+CZ_ FSZ:]8._P/']\ M>&F^?A:?.G/IQWZ?VFZ$[T[.L"V38X8&=4-2-S2YI_?7,H%C:RZGIVW0-(0M5==# G?3.!+?Q(K3RIR=>WATKFG?[A MW7UZ#&)KS\^9OUS6[<>.: F'?N6G@?@;%'!RQB^YAM\:F&ZTL4N\I[+/M5OQ MGF5^>/.9GX+;S?6*,7L.S*9M)@$L3&$!SIC5 )8UE&50%<%[YF(;4@]%58\@ MD(N_B[T?AT1.G&(X>%S,&.7G0'EJ33,W%,W:A=1PJ(&50.&567'U M<[3,XY!(%?"4)=$Q2] P[;@E(>&>6.F4P>);6N MO74*]X_U)V.\N@5ZB[=?A_=Y:LI\=E:5 M>EU"ZH(D+/P%XU%=DU@6)\+>_O+2?K8(M\!TE=@@6,;-5F6^B&J^]T(VYT:N MUDN&C%[XK^[6HSOIQ*@@5AI0W+U6?X4J,^PL8@S4(X":.(9#C IZN3&3Z^6)>[W3 MB3AW&&/["&P3EV<.@X"U11GFN:=NNC-FQ-O.]5"&!^#K.;7=C"R*AQ0?F2Q?MJ[_TU6EQAK+1/-$@"YPP#@>MKYW7&#-]:QG,O3&3A M&>D'F@PY0QCE,,0EHK&B*.B2TCT[29@[(TFX_*,U65]9_23Y0*;F+5GMA8LJ M=)ET@!)+DCA)1RL.<0= ,Q?A#(.$:D8C,N2\(,\%(3+,X6DH_MY64/;L_&&0 MZ'WGOFH<^ 61;X>>1HQ1>SQJCPI(C!:4WY37:;WPE=!KS6A3BC'.3[JC7IA8 M#!#B%KU8D NI*5MJ]&:?5T,O'HYY.\F8H'TD&9,XY:E9:=AI1OH2-&.0"EZB M\EV#>>&2I6Z4R,98G1^/X=09*<<@H5MX>Q1%]9EO$%*(B,<+D!DXSY^#R_C& M(8H%L.NR++907_>% (2NM3M]&E&9EP"LQ*(T%MM@OH+2E9JR:-9J3L\>A4]5 MR\B"OBF8]J59K(R?4O[T\E(Q4I\O=W7! VOI<6D#9347HKYC90*E-H_NB??= M&F*G_>)-PRDY8OMN^IYE!LR+= ")&H0$^4"R^B=4D6VP'0F9(CPPN5$4IFF_ MUDSF4NFO6]XCIWN:(.VA"HXD?<]]-+FE)^))]N@6V2=)E -;$&)A8H\EF*,H M89]3MC-MCS)T5SB(:@Y$SH+AHD,B?B1+X@3G)3WXNPM@)@CF.Y3B9]'@E>TM&E)%[',-1%2>Y.3; ]G4G](V+Y>+J^"2#&(L M+E&/=O:AYGA=-009\Z_R>%"ZPM6-Z,W;<((T-U-,OG9R.F>QXF$EQ"^V-A93TT# M"5K11*#+-+$=]UZ,YQ7/*YY7/*]O.:^(N@%/+HD.#&VT:&F2+ M61[MZE^:"6OF;#'%ME(J\51-?X:KT-'FA!>&K-,T?/ ,\@F<8+UX!D.L?=PR M"\Y6&3T@C";Z8H,?J+>CSPC51C\:OM\[X9H_?W7T@% [E02^+F:8T6A]9\.*H:!05A[K97&O'OO=DX$>V*1C&^0^19"P.T+1^=)CZQE0=:UIK4 MU50R.@SK=O<<[VM;Q23.746U=.XBU=(#TNB?_&=)&Y32#^JASKB+EC"*]??I M]DG@%=,#@FRM\MG.SOA:K2>&J'31F>D)(H'3M!=7VS=VI<6]%<_5V$K0A?EK/SH% MTT^ \/>V@-@H=EMTQNVK,&T6I/97\D$(/Z$8X_4XO#(A812# G%"IZM/XFO^ MJQ%U2C%&N!_61$1;+^XB%4?48T_44O$PM-M9Q:2?#1@3'(M3B6N@ M%?V*S \%\N>,4GVY,U(CL=F.%*\8*_'CT)N-5BM&9]#.1L8;_\+7QI6]E4[. MR2R>EZU@.!JG:#K13R;<0D2_K9M#'!4^ :[:5:3]B)268O,1DI33_3 MJGKW.3,UAI&*> Q*KU^U-B>CV*W1)7N(*RC""TN\I]LAXB8OPG+0/(USC)=: M@''PX]$L9=RU\3P%UYVE/3=D>O..\$4V^8A5:?90=CT8K<#1'$Z28:@^%(F" M6?P5]6]T"3\NYK*#P=O=2S%Q/96B?1&ON!1=D)+E)<(THB+%D72O=S_F&JQX M!=6JSWA4N9$$20)/,'%)WXM5M0ZMI)5N]=0+_3X9SMEKKYE]>3'D<#;)X13M M)4'GNPMBXDJ[.NYBR_5B@Q9FN;=[N?5M*G>R2FA['0QA MJF/^O84FHB'4OG5Z]+74>5!*X\1B#J>)=6/*37*/]ZD)%S%'0D"^0YR@69QE M8C_!N2O'GECTITE.F=R TNJ?UT/F7_'!% EL9[W$90>)ZO%[?Y";LLKG^S7P MZ3%9'A)<'Q6R'3C8Y>F=W!YSE?E7Y]HI[9BO#HTL,)?L!;F+5.;9AU?JJ]=4 MLO2W(97W,\8)'SI"LGB"I'#Z0MV"(V@'46=N"NF2@C.5J'1A4FN,>E=%Z\96 M_L4CW4X) C\-U,]O.2DQ*I7I-ATE5C6H0I@42^(T188 NA$.[?:!/44.!RP+ MOFXLP,HB<8_(>%[QO.)YQ?/Z9O.*J /1CQI,Q@S+@/% $T0/G<_PQ,2FU M4'1#&\&'JY+>WTY9A!:MM0A^EU1@DGGC?2RH@ZCD,-F2&K>7)5C3.,EP.$G% M,6X>Q2/MEU M:]9H8O9Y%O]IT&6J8HD)J\0<788__#*4)ZE1<7S?E;KRM?IESVK8N3AM69SU MU 'HNSML\T$X;$,@9Y;;5[A7;N\YJC'-2)=S^UZ@,M>AH?T(PNE*-,?L/!DGQ^)TNT+U6&XR'/]L="$6F@"*C86"C$:ML7)'9/_[(M73O:? MR;R+V?Y3*9)+L?W!"II%]QOSB6Y4%#JM-K\-W7^4Y-GY?M;/#L$QWW]$2>@S M\/T!GW.3CE)*YJEWV2;-Y5 MRQ?.*YQ7/*Y[7=YM7A-W>IZ:SI=IC06F);>P1 M&'Z:!,R6,QV /KJRF\;*YEVW=VTG/#K@M^S=@_KT+=9JN51+9O0S=\M-.&+2 M;WIP9)_14>TR_X7AZSP?'ZHU$ 1.$,2U](),^.=*OCA4&U)72B3:#]DZ>8 C M^;*.8A]0_+U;4^?]<>5>'+QR\J[*YLM?:K/KT9%[.4=M#-H307M4*Y,2, @_O#3HY^VGQNQS*A2SJ4-K45[4.QCK\1,AG#G5 M?W=QY!9%213+\BBE=?9Y[\[HG;MZ"B.B_K>3B4>@+="BG9UO/+&ISADE=;%$ M2Y[QY7G\)"D6X97-TJ2QS6ZC5RLDKH@9C/;U#3T>$$MQ$*OTII^^?A1+=8:-# M!4:99?C.$8@C\$<59EZU?AH2"JH5P,TQ8C M^/Q2O\WDA#0OLL$Q@FU>3:I;X) RZX+,XS7BJ<^%+!Y#R< M>%3HP2TU?M?.-W*UO/'^<&BE\3#S@['2#J[FQ^6PVGVM4S,NFYPQT2$(?;_# M43C-4#CCJ5Q;'"9X%#OX*+;A,+&L.)9:8OBZ;;JVB \;A6@MI+6."S'F.R3S MFFRE]6(G6B6X=XNZTV1]H&PXG"19G M%%_I(%+4B(QC7Z"PHT_R=VI>&_01U M/9TV3Y6AN"!CL4ES.)"70&SZRQ#*J_, MFR^#N]OJ.;MLAH[]C07L*NMM7U2V+)8YD4PUJ'*WENLPWZ;4]C'"9F>B*5\[ M:U(XP1,X1W-QL>TS%MN^[+F63/!@PT,@&1&.[O6MK::_Q;;/KAX"H_/G38K. M$V/EJ16U+IC.$SI=./_D::_WS@3I]=H)U_I1Z*U#)>:+0:4:>%/7AEIG B02/ MTPP= LA&-&KY5-;3I#S]93=1(#765D< ,'OVX#^'E2/9Q6W.,]UT!8A7ISF1 MCJ4G'4<>)$/I P?)X$DJB1,$>ZP0;4PZ6-7O@HUS(RQU"@\Y[]73Q5HE56]^ MM4ZE$D]'W+%LHJ&N-/W%&3,6"] 3;K'T=GT6P3Y6E$#A*W_+W_-)N/JO4TIFT=O78V MC:']9--(G 96*!7K7^]7G!,8M7F1>']BWI-"/T?[08KY9(4>SHNY*]?SY90T%H^BL,YWQ?;O;L/B- W^GSTZF]9?>%E4U1]# *\[ MBE0R:2!$ 6'$^A=^ JTD=6:K[QR"[X(SA%^&M419'@KMMJ1TT4+!?\.)+/Y] M\$@6TR:(_VZQ4TX4UH_=)!VBV1Q)+!Z^S^'CCL #;_"PJCO(N=U3^$=:BF&> MR'W,/\?3VW)1YSME&I@#)#C*I'_-A=_&U]XIF(CQ-H-=9*,%!(]3PNQS(LF/ M^4._]]+YU-ZGQJP";@E__!?I(\GF0HG.3Y7[\Q).J+,?^[O2/K0HA$Q%(. M)?!UFM2"@KE8$3[%?\P-.6&4]:SZI;2/$)0UD=V2SE-UP/H+X7:)TY8\:HOV M65 T^S%7OEKC_IR5\IEC9F$'6 MLBJAM\-G$%IGM CGG"%ZX"XM@7=LD=DR) M^Y@_&:7B3,P\-9^:89L231TR%R!V'7IR/R&S]',]>2K(G*9FQ\G&J#;&]?_= MW&!Y"4C<7UA%Z()3[^8&#KTMC6T#3GS,A]-[Z:XZ:.9Z['+ ]F5@'=:*1;MM MGSD0+UG/EZ3WA_=ZS?$]JUUPWJMU!8VF!\:Z/>3DQUS2]6)ZILM$:24"0S#' MFR;03_V;I@@,#G"R"_)$F.GKF^IM-D#,Y($R>BGW^K529V,ZUA#M^V -U+;D M?^":PR7W"IWTQWSVGAF\O;2H]JR["9W$R7ZJ$^4Z+VFZ 0Z"-E876SU%E=7N M#'L6Y)&(Y4=*&\<*2NLW=KCT P"^/;S.7\2[6?^Y=V:)<1U5"FQ&)3M];7R- M)\5^Z#8#.8&!X0$S)9#W53# D9R7%$$!A[",U0SP"_/(O4&&N:2,Q/;AFT-] MS._K[83V)K!DA0O+YH #H]UL97LOK7'[GC[QP/!_<^X;I=S*LOG9**4:V4(] ME_UUZ.K3'W/U;FS,WNK=9G-+(P2]^CX;KZ%^9MYY)'1%< MJX=@9, ,%W]L7.'S8+Y(BZ=T733T1W/.[;)2A52]!FZ5:4&7](9MV0IPU<"? M5:!K9-/DKX-AI&6UU0<"L+JFVJ^E:]?6Q(^579ZD;22(SZ/YF ML5RX(KX8( MOE(?#<"*S]#W_H5E5R@!9W:J4,6>4\5&#ON9%0U!DG6,^G7J9=HB(EJJ+ M# M'=@CBY^L*[27>!6PALIJL=) ]97[7Z/2'?58T5;G$H#\4!9FD,M0P-MKK9[8 M'H%= /^B26Z21M9T4 M\=_30X=\OYG85?<>#NSP*2?#.&-HAJXD]9^FAOT!TT[5,?8/3?RA:/R]R5"D^-7 VM@SX:PK\C,@LN"_IW,(M#AW5Q&J5RNI:K/J?2 MQ1Q6*%4:]5J0&"%#N@S55.EV)2\_7W*%V[LZ=*X^W_[^Y0DL6[&9)V6?^RM5 M#A9\PB$DT_N*925-;!E@MQ4#F@? >))@B*:T\G;\A:7:8W#7 I>N1W#3TL"= MRZ7<[*[9AU+'_F?=Y$@2G)-]=B>VNY:1EC*6O_V0"A]#A5%8RW&U'JY]6!5I M:WV7R[NL0MN>]>NO[T1[M*I"NSH4]GFL]DS 2RRVR\@\.KENF*67B]WTR(0UE$1T&/ZE?YBD0W)Z<-NHW M4= 0!0;D$,:4S:(Q[&=5!G=4.3+CK4IZ_R:OB2)6!?HN&F.&5WM@F1@FL0.] M_VKGK$.U?G> .A2:-DS0OW99ZSMUOA\6*/+ ^VA1$+^Y*8:B@\B_,?(W,<5^ M$K^3TU\^P;HUIC M[[K6<+^=$N/B:TT(!GW-UYIQ6,N M6Y;Z[52LZMIL66 /JAJ&BI[6NQQV/3]N*F;5C'?"V$?5C7]U:%*C&C*BU1@RIR MJ7NN\N83E7M%3.#[Y5\"RWB#63Q^F%?3%K$9LI$Q$(BQ^\/UUKB\^F!%4="! M-KW6RV/^(I?'Y1^MU5U>(=^27S6)FA%4XC)72.>!T0Q)4R3#4G'0US5[1XH2 MV/TV2BFQ,AU#.]38D1.R0<>WW8O?=J_D.D/#B*E%^!2#O#H)\*NPVKCQ[2OV MZIS?/K?Z0F)68\AKM<[)BUCGSNU%Z_FOS^*TK+Z4DI>QS4_H!;K+(&=^.]50 M_D8&^;78C;OS&J[$.J#LU@'UFU[$?#B<%LM"67&]N@C6JXMH5;K_ T:^=' * M8)"P*I*D@U-<;HUD5+:F.<,FZ!/PYFKTQ#WU.N#GX:CU';U45-&; @:8TM)$01<78#)Q.%%' M =3NLJ$W+J];?[.DZ&V62]J5ZG2Y,=<^WQ*3/IEYFO" MAJO V>EE3P,<7 95JM5-8,V@.:".-*<22#CXW[8TEMHC099G.'C3;%'F%D)P MW:1H >D5P"O!C_"/YD5I!4\;$?';Y)'.4@XL9$N?!6MEJ):D]T1-1,:;M70& MVHNV""8QD)2%G;>^RK9E!'\58+%N3%$-K >L1J!.@(IH2_(,V)"")*.=')A7 M6/0"W.&%>_8*[7E''K4,H%Q$LV;Q$"R3VH;S,'_ZC:7 X0A5CPF3X[ZD+74Z MHF8W:\$\T/?!I]&KK"F;VA'-N"F*"C;21?C/MC7_V6+.XE32H>D,XZ7TT9K! MJV.P1J?M:P=6G0JW[[3- #T&;\OP&?!YJ]CS;RP_TL#'--S\LO-!?$?14+E[ M]YRI-*A^XCJJ(!,?\V1UH'?F&M$8'U,'-= IT?2!59#%6JLK9!ZE5I6)0!7D MS,>\DNDK>;'5+)2Y$ZH@IS[F]YPZ'K7NYDRZ%6@9Y-S'O"%,4OW/H43W/H,I M@\Q\S+_ZR<;]4W4Z)+MG*8,,1+OU.BS>/2?JJ0H9NLJ[ 99!9CGEKI?B.H4R M'Y9*NP#.12W_]5X:O[QEM\J97WPSSE4&F0-BH%:JS'MYD"YWPK(YX,30JN^- MWIO\\%H,V2W!YS+(_%TFT6>T\FWIF/X )ZU^N*SL-3M/$[&NJ(@:LNWT4?,3 MNDF!-,AB%X ?ZB@56FWPMFV .R8T8W5,5>"_!5@<5C/_/I' W1N^3!9U'9-1 MT!,T#15L.&K*4@N\W-"$-I L?=F^[S=66+-]40,/302/:B*RGV4K=@J:[D-5 M,SI /-4-7E: ]BNLH0=&(MMBK>#HP 7- ")KD@7("MVPG]%@T2B7!BTLTCSI M2$506P 'F#H&?X+/RE)G>1?:O/NT!'"'07_IPH $M-6JKH,OWKYGM"$X MP4?U]=< -#5%ZS8#Q[7<=%LWFLV7:V)'-G.II!5 !%,"8"5I$6%(T"&FQ/99 M,;%)_/A?TQN8(.I K O358WKNK@JT&UCF@ABK0.9^V,?\WSJKD9DB-?^5P!& MV:G<&C %RO4+O/LKN^ [*H>T"/Z-J!D@,11!\C@V$<'_@7-! >I! 0?#$S'?A8J9?T7?'-%&JLP"*@VTX&%9W(>57$LZ*,! M+&EN:@ECQPQTH STCNE)!+<6V#09'BWH_+'.,5/[0(K%G.[BSXM)_\92.B)F M$)>-I@L=FTBOKA;/$*9BVWP&G$'@*#1? E\+N3E$\]W(6H"C!/^PR%.H(G"PW>CXA:\8@1')<+8"ZK=@ MKB[,-,,$J)2WH()C34$W5?W&$01>/51U=#PMF-NEY? ;F?A@7Y#BQC&+MX)J M:N7UM:8+OE&#$&PN$3V1#-,F6/S)7&E;0X<%W.$BF\8"\F X"%[1IB"0\[* MF4,+# T+V!IMXP"""P)_#9X'EQ!M9BT8>@1^/]P)(',WR#"RR,:A/-+10UO' MF=DH#3XGPJ.X8Y_"-S9CZLCYKVI=09'FIC2UP7&H24U3&."M$".QGXBL1=%@ M%J+RSP43AIT1M)C5B0)MVE%3E]H2W"RX2S8+%<9^C9&U^PN9M["-70O*%3)P MA;$*S&2( Z$-U0>2&"B@)DI;HK[<]84E"M$A 96B]X"L]%09R"$PI//6I^S" MZF#&PG@] 5YW5X(T09U0)&"=;5'0HM(5NI8R=YP2>+>FCKH]M"AM,!-%-:!3 M!(G=6!(G./8IJD,! 'DN.K+<"W$ :V%72RY'P^(H,"47_A> "YBFJ&Q=(\"4 MNI*E2*"2 U)A+%0H5+L10GXP37" 1I35B;F[*X"#L\?4K*.A:49CC=^UWTMU M;VDB$Z0Z.J^<[F6Z4WO&LRYY #UNS"58VK=00=@-8C,68FDSKK7EW?GLQ[RK M35_$8D-)U\CMZ(G-Z(I=#6@NK/[U'K]&)GQ6*X@&O)B[[A]M+QXUER>3LZ54)$'"E76 M-ID/J50PQ>FC+=DD;"[,Y!SU\CE[G;;=!TSN;\M(/RE[_"2L&18FUU!*XP>W;&^?PC M]HFJ\W%B!S28KNM)N',I=@NH\]1\E%%/,_-;6J''Z7\_;K;%EL9Y@L=IUBG[ M\!@H7$1RHWS$YIVOHS"DQW8%#97PYO<);P9,(*]J2_JB,M*&JB[JKO+J91%\ M%-LCI-9M2@$?JW0"3U D3I/33T0ZVTAXKHQBQ PD$!@K'(*H9D-@H(UU"4)0Q7D707;Y_E M*;3]!E]CO<&#:A,L"AH<##Z'D>DV-YWIF[.))"1XUUQRIH=UDZ*'7J4U)Y8 M\^R!VI9A!T,4&6,Z0U;A$9@ N67TYZ6?#NRCT$7NT)5_03>#-Q"-9SH;S;-T MZ6Q!D>+H^_2UP:'DSV4$Q@@6U8))0(L7FN/4K%=OUC_(VO1=KM,1H3M#7&H" M6 )FO1-XRK#T&8P$'!FJ-EO[\$=[:"E"DB _/E97C?O.F'^B.M+DE5UJQN4K MEB/LL /:XXKNI@6%;$C&75XI.QRC=D5\ EO_I@W^J_/ MY?MWY>NM%9SC#",#=YUM^<;(C_E3[?5U2"EWF1QYM&_,";L>_%_>_5L'^*\" M]D^%\"J8M1M-/T43R;_^-$TL!^.>V/>0RPWJH$T[#\]^:?J.HGPA L[IA;); M3POP;88>K"O4!45..!M*K7RN3\^(U_3#YM7>'_>3MT$>9RO-14UM"WK/X]4< MG??4W['O*2AY0.9OZ'Q,O(/(K!GJQPE.NI,2A9?4.Z]]KM\P_/(F>9,K+S,) MF73Y[TNZFA/I5'NDCH+=V\%8)<%0TT[B::,ZEM@^5#[5Z>=$4H?OLS2WE$\O MRW,VTOJ@R49!A*^.M]Z1@YT5RA/^E:N\#.03$VK#454B]S%77K*MAL&UA-%6 M O>EIT0G#DR15QM,)U\A6_7F5A):"*M*Y#_FB<^Q4!!Z]^.IJI9V-*S%]^,UV#'9+RF&;F#=:X99O=$T^, M$%>58#_F=%EK-?CRJ&.TSKWZX7*>+.G.%>N\RJ%'7A+H289FM8B\9Z;S1!Q M;[8V6Z;FPYRWIFA,1'%11 7&962E2K764J8)L+\ M#_CDT KN0 _ =RY>A2JCF0E[*Z+<^O!OK :=S\X#A&FJ0PT\)0UAW8R_L)_2 MKU6RZV8.YI^?9D&!7[B5DH>R7 U#DYHC8Y'M"L?E]&7+Q4 EX^SEZLSI@"$W M87B+F>#[4X(#L:VU=7%!J]9JC096\ +*+T7)@'"!K'H'\ 6+Q@CP5^;:@_69 M"%H;+$AV*PI@>P_@U :BH*,,1],Q+RZZY?W4 MK\;'N< YN&A;/27 S7NU''O]FXRC?_.@MW[,GQ+M7.8YU[G5D@'Z-JG0I04R MT*TKC?3:YWOKG3K:]>D!UE'-!'0D3QR2[^+TO[-S*ZG'M%3#CZ'Y9E=7HRQ"(:8L9O'.Y-7=DS-7T^Z MAX$&&^*>P%F2Q3G*2P+*-_;EG2HO&;=KVIF4Y$I%"C:.I?;\ MG/GKL/D&*[ 4#XXT%F=H/XZUPZ]JT3[K HA;,6\$.*0QSW[@,;L./)2Q[WJZ MNX_ :8+&638^RP(3@.?MO+K0'50[I6(Y@=1B_*[U.2K/5&DP M;C_6M55DEL/\SU25P\-,(B1>'@^>N/@&,A]#%@J9VR5@L'C&TN!KK]E\;)/B MY\5GL?;,VVV^LTFIJCU/';4 MJ4QQ\!H[Y7*G]R8,FSFX(["7%B6F*OHB,YA:Q@4#U,"&4Y_CV:2X[&"G@3A&[E*FYQ+]1%(W-.E/$K!K0_K_FE6\40[P>FZZTXISAZ=H MUY ;'@4[>4O0UM];I0==;D_O^8T$[56@AD\IVFYC"T_._$\?DN3W[<"6(+SV MTG.%?2">""%4.Q"0;%#DZA-;[SJ1AY'6Q7']X MJI+=YT_G6)CUL)=C)<)2=?N;CB_"=MPN/R'XO-? EL7MU=I%FOIO(%?1A,-- MU+N:LT?_[KEH>@N<6:&6\V&^0031U.^JN1SV6"[5[VI8KI3-99=UM-<"MSW7 MTOYF"T-]NX6I%5YCO!RX+,YKLD7YG43M!:Y;3Z7YMN_VS@#9XAN=W2$^8=T=<[NCM_ MX@TS$5 9&X#)^ 08:@D8R@1,XK/>YG+3H38,!6"H)6"H, $FDDJ&]4W);'"" MU3[%B0HGS1O),& F,"KP^ZF9_1R^5S5#KJN9CLZ+FFA\33I\&"!CYR[/#A@/ MAIW'$(G0&W6U_63'U:K?0VL;.U>($MUMO8'1*',=0RVDNPY%C5T6W \1LC&14"640C6%5' MW&(/--&L%;(K_@!+&9M?MQ[+A;I\ "1(>@_V-'%O% (S30RW;B/Z[W/ZU\.& M'G.;P,,P!V=S>06GYBRPI$T'_ E5P#%;J6SM]*(2@MDYIM-!35UFX*'5:TS( M0$AU@&9Q+!J#F[T0VE9$&WQ7%X!:@>":]$1X+X:C@7UT!,=]EV"-H*^1!(@+F]+Y(Z^*KS#%J\U1,M#5QS-?@3JHD/8SS M%,FH.'$@*Y5 MVH+6AMUYI XX%-%C/V%L*47\G:IET$_DW[\P+D&@JFI0/I$ZQGZ"/\-?_\*M M7CX#51-O9*DORK,;6)SM!JX$ZEVOPZ>6&Z3!F;A' X%S&/P9/MM<%;L!*P'$ MOVMVH :6=7TY6Z@.DSH61T5X7$J_>(HV+ J'RH@),"&/#C8>;"HHM*:F>I) M!(8"Q Q4(V8#'K-LD%E9"*JS!2Y@@;^68#7)L-K[@!7O2(:%.U-5M$<6Y^WZ7GQ]3LS38^JO,@?4*^\7$725+R\D\'X'ZJ^3'_/EU3#?X M9TDMK8I^'EZP-/TQ5]3&NYB;MCH3YT*NJVTXK?XJ6.1*\E6CWX:O.6XE [[6 M7X6%)U^$]TKUJ=5O<&>IOPJV@J@_3GCF.47DMN3@XB4_@ZJ_"NZ=W8J4ZV?5 MTKC:"TN)3S"J\:Q<&;U1E2&UI6];6Y6*KZ?^:N)C_J 6JHG..)_-G+WZ;;BNB9#\P0QI8%83!?^[ MM.D4,!I),2D@:&DW16@U IMV+$@R9&GP;6MT .\^,V0N+@UY?-E@4T<7%ET? M#88HCPFV104&)[2[MPS,U3W3?$;\SED+C[8KI6M)SM-6&6SZG\5*+[JTFH0. MW%Q8;!5\/PS6=[C^X?9,%?,R(H.;B]!JB4.H/X75+=DJ?RN;HUQP1=T1T+3H ME@"+ZH+=&&JB8-'=$TVG!RPS\].;ZX19=U93PSB3%&"95SB$>9Q-6+C81@!^8\EWZBTZ!(9) M"_%O,$=,!HN(="Z<"U@T!)>AJ BR581W27@@M "3$HB7,$.5>2#%LJ/7,YRB M*4@X/!!LE++5X69!OR[-(OC&59XJZCWM5 )X_>18=,PV)4.Q304@PWTF\!6; MLS&?7HT_1@Y:X8XDBVO[!]3K2%.6PMKX7?N]1,+G2)/TMF3ZG" L,F" X#17 M)&&]FS:D>S1Q+(D3J./AZ2]\@AVS/V]5!U<59/VTEQR6AHA71<5T,'5TM('] MVZT)H9ZWN1D4=>, VV"=87&JE@I>/K=TC5727#_ M$?IGS&-DH94%756 !IS!#^D2.K$6#*"!*@+92MN[SQ:99;95!N\SSZ/%WBL M7AA)8<@E])T%QI.N@L?3ML6QP1*CC@);>G6CL^ZBNP#X]7\V/=()FT=Z3^U0 M,_/ZH-JA^C[7\H%50 _+J=Y1AX-D<88@<()S*EN#7,8+4POR\$V3MI;,9@R( MN8:;WI' .T5Y%B/9&Y)W>#N<<>P XCW; M^S"?'D6HE"UXJ?;>/-N=1 MIUNJU&V+:[AWG\X2]3ORGW<7"KC1Q=9?[9$&JY+\V"@ZZ%H2]%]FJYZ+B66S M105^1:T0S"SJ<*#&SZEWI?M(0 FQZD A=TX,4 M$ .^-RH2Q:_QJ.F/]) MSU8?J9C7\Q34)A594.QD9A:<)YJ$>,J4TJZ#BY3N&)C[L?SJNC#-:&);,NR' M06HJZ1\?"WO"Y2@F'Y$YM,KI61JKS[N.U>*\8'553WF)+Q7M%U\KTK@8,%!_RYUFHJZ.J7.KTZI"ZI3MUOCH$:I<^5NT&TF[EG&J9]DLMTSA))7&693RH MY;VK]CTM85\:LX2L3#YYE'0[-$OR0\QU2\SG>K9 4;1EY?P1^@N6^H??OO&M_ON"5LVV["Z?51 NOU;RR>'3 M'_/D3*H*3,48Y@3_X\1)?EN%F;_S'"I>KN=J]<=O]0H$F %L3%VP M(HA^FK'3,)1![ZF:<0/SYVS]Y?1?FV6UE\G.7R-!@SEO#C6Y5^$!@8+_B(+7 MA*W@=9)VEI*-8M9B2WB<*<\3]IW9Z>!T0>'2QQD2#^$!DL++SL M>_/?2J.:N4O5GJE%?DI>U6K *%Q,J_TB&3W3),^**)??#%-.H3#*E%$1-)1VYUC!;/W* MO7^ESFB,^SEW7\NB[?(XP3 _(EPF>:#W\(JFMD01QM3!X&1=D*WDF@&LEX"V M+@I"9[?9%S."((%02RGM1W,RLW)G$X>V#L,>I.OXM3J;V!TY^W/)5R+)XPEJ MF^3"PGGG79ISJ?3'G$XFQQ,I3W,J^WCW?OI5[KQ&38 M<%2$R((I/>6;E6&BJ5>Z89L2S1Y8W4)E->$M^?D\O$U&H"($6/PW9J*EL^]Z M(L,<7!$BP+H/23"R!Z8X[#S?)0NKI?2A[L,9JCLD/N83-5,R#+J6E.70%10( MJKH#]S$?5MYOV4$R*?&)L!00(#[F_>%3O\92SXEMG7GQS3A7=0>@FS2BWZSF MQYG)_;EUTZX:.J47^IEGR4$I>TP-G8A4=P#JK/+$UCOET:OQMD4=![WZP5/K M=9@:.-)F-4-M]=W8=7M-4^<'@ ))27GJ+I.KS ,053+I"\&>="/8@8R]U]MC M42D7&G7YQ[^UNU0UAZ4;;^E4YB'FU3=:.JTM#EA2L!QE!4L--4G&*!;*',F: MZ6%I%69LP?0Q21/-XH!6+BL\K\R:$GMM(H[>1Y;@K+XB$10%$K>FKY=N3'55B%A7=3L(T) MBK7Y<9>'0NYK!&YWF6435M.7N_P<^,, 5MP%7[#PWQ(SC4PRY'LWUU_Y;]'' M $# YU MC?V%?MU'[N1@)5EXG013L)[_V!J8Q^OE#;N\7[*V^Z4YAA__NN9H M8@-)EN$T)JIF]-!5W8#%+U;S-M/(X8Z;-43$]FKCP3X*+52/$SVF3I1%80G! MP);)VCWP"UB80L>:(G@!^B@LE3$4-?/C."KVT8*5+5!AD67% %AJ1)0E!;P0 MELV0.I)9\[(*O0,DT01*:@'XU;4= WM@)DVG6BBWFTS2"92Y!W8*^9;L0+=_ M> 5X.&58V&"5'(X6 (=S'E1=&1]%HNRE9K8G&&BTD-3L57E, %DOANM'FP1 M+(N&M:";T@BF68,565!6J"GR/6$,'6NK3[:MQI^FVZA;+=H[/]>)\+%E!!(N"QD MY9!*U]N"P%$X0;CV@5[ %TX*#A>'0%ZL:TO5S;H54*U.4?D>>;:MR/(>U]KD MK]=TV=J"SS\_-5:X$]D>R>U>>6^J:>]8?%U^%X5DAGGLTT;?.!T1@4UR?ASV83KJ*7<)J6AJ5Q,&57$ C@X S]7QN?J,Z0 \7E@($Y'O3<#4G>D%[9XI.DQ^^S_/3#V7[(!GNX M.E936$@0FB

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�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

    ?HN%K4I2 ,!*9!^K?2F)>S))RA/+%6*YXM$X#02FH/QPS$X$0'EBN>+A. T$IJ#\<,Q>6P'EB>6* MA^,T$)B"\L,Q>Y$%E-HCBBW!PA)\#Q M)Q%;$5/+#_3!7Z$=D/0Q>/:L%>J>944.IN^GGWG^/ *>0]^R%8%&]$Y=[RV; MF,_("ATTGJU,Q#>VBX;T;8A9/K=&!I&< WJ7AZQG$LMP9,45Z9X8>+:R8JJX MGV$[6-VHZQ&:/!L^PD.,0V3!S\BZE"HLP*:#0UE=)*QUEKZ'@[SG82F:E52, M#,!\B)!.782L08*Y6!-2C(9-RR$&NF75NPM+W*JX--=JR)TGDJ]AM(U',FT+ MH@L(!Z\FPG@\&P?/R.]AC'+[+M4K4E/)]9Q8($).:QOR(^M&*.]!B ?+6$05 M/@"[(=^?K2#]=I1!1'[C1_Q=SE>I-M%K@%QK-7U).6!F^SAX-EPK>)E],KWY M481^N?"4V&8'5.7X_9^+UF'KRL:FX^'01^0_IM\&K?[X]JXW^G/-Y!+,FH3S MN>&_C6<3^\FU9[9ID.FZ:7JA2Z]CO/-(AF:O9LLIJ]O'6:LG#[>WO?L_6^/K MUF3X=32\'O9[HVFKU^^/'T;3X>AKZVY\,^P/!Y-R05V&F'08C.]M_ /W7.O! M-9$?D,X7@%C:62R7#Y/A:#"9M.Z'D]\GK=[HJO4PZ@_NI[TA@5(V@E7?OS5< MXPG1OZX1RK==R]H^''T?3*:W ^+[V]ZH]W40_7D]&)1K]!5Z#/(M[&0MO!I< M3LLUYMJP_>^&$P(^ZV8MNNX-[UO?>S#@ M:G#?NR'DDH%AT)KV_JBN$TY]P\6&21L&S#UE],'I?6\TZ?6GP_&H9(NCS.LR M?'LTS!^ H6<;@]:WWOV /.Y_7O;ZOU?F43)UZ,UF9!I!,W4R1/4]-R B#K)R M$H$T@G/8U1/R=ZMW?3V\&?:F@_=1JS\>3>_'-S>#JW7!&OX/%! C_7 1 MS19 V(B$)*+\/IJVKX>3^X8YVH0C4U\&8AI(I"3 W M[R-TV6'R$:._0D+*X 5D1LL)B)>3P3\?Z$,P^%Z^V_F".3.H:QN!D#^HM_X6 M-_WW)N"<&H\.A'(C9(J@?&^X9(Q)_&+!V(BKJRA6E9D;X8QE[V;4S0EJ%5F> M']U8UF^$9"#&50Z *YBPD#&B-W](J0@VW\-_AG4J\^%#NC%[ #.AZH$E SJK:W8VIA#K(WK2 M]6JI'R4 WJLM9)Q9JX3=(H,:;(W=>V2&OD\Z*1$8>:X?_^>E@>W-0LYF#4KR MS]13:Y,!(AI-R_73\B>DEOD,QR%&DV^MX+-) A%Y5 9.]!A_.<#H:;T2OU'\ M*Z6+96J%TJG)65H]7GF /,C(^G(0^&&.HRONC)=OR9_?;#)M\\WGMQOT@IS> MJ\WS1!;H2^U&S\0AOAD^HD/R*7+QVH:*4KI-FE*@RW YL$%+[8FU2R=$$\%- M"%=199ZC _ U(W?5(&;_T$I9"7<"/I( AD4X/..K^5=Q*YX@XQ=!=A@"/(\&&7+/!-);V>Y<#M'DR SGQ4S1VU MU^R%#\DP0*YNEMXK[M9A@>0UBCWX? T#9G(V9;_86X<%QM':V+OS/3+O#-[N M'%IP<2VZH75!H5^^T:W-[(DRE_+>SI(%7->@C9"@U=3FHND2EW(]TV$1-CAY MW/1(DV; 91/9Y-ENJ627,\&%]NE;+X9K(NO6")!O&PYF'H4!I&N:JXH\.!X7 M"-FC)>3T,/#F'JV!L[V=$=-KNF=I6S_GF0_V:\DN3FR\(8&61%.FH_.%]9J. M.&[I;@8(R.FGDIT^07-ZP,P*3:*1V,,^7,=0T6NZZ6=+ @JA0#1D._A MA6$6C"YI*;VN-TYL.[KDF0]FIR>277R+++JQZ@J]V"9BQ\P\4;VN2P2V=#:, M ?)X5ZOM9,\D((&=8GH_'$DW@GLN3:;9R62!VMZFD5SN:M#!K8R919D&(%Y/ MDLCGZ[PCO@#>)B6$,HAI>.PD\\T=1^71#M*8,D/UL>,4V M-VYTNR/-()^,Z%P\Y$G7-I$3(0,V')["U<;)%?+MEVC+VM#%@1_2,8!NJ6?/ M)]A:>SN=X'&6O$/($KF--O$:)E?YDJU5S]R"R_$05S#X)LTPY)/5Y/F&9$(K M+2O'L>#="':"G"NKU_62**YGPN.R'GR 9-^K'0WE*\,+:OBYPGJGIJNL1/W- M,A_NW;6M;],SNJO'MVC&L"F[Q_,$R#'R[M20S-[(F',$&TBCKED!Z&86'YM0 MFS4/D$5+L^/_CM15&O')Z/V"_, F3_S("PIB4+ZP7M>KV@K[OL=G.NAKV2^/ MN0V#T'"N0]:]P_*Q\9XF+.V7FW?(L(+N"^V' M+IG?QA])_!6V69?-L<3=U\W;;O^Q^_IC]_7'[NN/W==-W'TMNUK^L?MZHU]+ M=O''[FN>W=>R^_7'MM^-/2.RZVZ[;OM5R]DP!K 6M_5&ZX]MOXU(:[;<#5P; MZQ^[@1N:H'SL!N8D[V,W<.-W ]=X6/YC-S PLZN-DVOJ.71#@K$U= /#?:)+ MP>^K8)=OM\;_>7[?,7#!K$.HD5]M#K*%AQNT@Y]A_%,IAG;H.Q6_[D&9?2\?$ M!9%W4>/^W7T\^U-M//\X$O1Q)$@=LIH<4G_M(T&J'%%A6 \[NXE'@FK;CBWG M2% Y6[(_C@15/GWX."GT<5*H;EJ:/2WXY4X*U;0[1,9)(=:>D,[6FT(DE"DV MWH.95Y=8O5:^]E,MU>\GWX /\2CYD2%([T+??#8PPF;4K?#ZJV$SSPP@_4L1 M5N@'<&5).G,3P^%D+2OY*S*6[X/&KVEG9-P9NN,P&,_>7Y\!D)HO_,NQR'(#1Y)>]W%@+;$R=1QXXW75 M><>!M9J. X.;>3>($CCYO9%K/A@G&GB05ZUSTPP0X&#=M%.F2CDI_U>PW9#W%EZH%R:?P M/*A L7%GW8O23QX\'$MCE5=_$+' <(8N^01-C5>$E[6<_"I09Z,*-+@:W/=N M6L-1?WP[:$U[?PPF23WH[VNXJK0=N-&N*V0\O=NN'O.!"MR)F/E:7>9W\LT_ M%3._4Y?YW7SSS\3,[]94"25(^CX)'T'?\/VWF>?_-'R+HPI:I%=/=,FUJJ#F MR=)I3)63CZ9,B"GV1N-KFKD0V)5,ADIM]4L.)CBH:VB=,M=6GGV"A8KUU">+ M?<_!5;/W=)9%69,KD9)IK7:_I[&P \.A6S;6K6FS]WTRE6JJ1/(^+)X(CHJ* MD8 AVC8L:/46TN31H-504@-,Z6Q#1*?>BH\\(CIEUGW$B"C8C\Y4JJN0(X^( M=2 0$?7M49\\&SZZ-,C,GEXL0V*K\>Y6WW"?T/O"W$KDSGB+CD-06+3"=>M9 M]LPVEWO,L.G;BTC;M:;(9Z6+9?ZJ7M/[.+;*R4IW!$?-L.IMON\7$Q%WO5F8=*& MV>7MBRR2X>C[8#*]'8RFK>E];S3I]:?#\:BR"O?[T!&^/1KF#SXRNL=9")-O MO?M!Z_+AS\M>__=\&NIY49!IAO/0,0)DC8-GY-/QTT?/-#ND9_EI'Z1/#D?M M4KREFEZ-Q&=G07U3K)7&5#RWI3O[;J4M?-CXJNB>W=.[%4=2[MRM;1;^<>=N M0RNC'W?N^5C)RIR& D:!RCX.].S8X%J@X^N;ZR\LWK:*X M*M&=C8R9_"ZO,AH6>/V6N&P>SEE^3XGH[:JWRP.]U6/9!\:XK7?$;^=LB>KOJ!;YBYV[:!SIWZX6[W>?AKR;". K,45$+]\+@V?/I07?&;!Q6TMLU MK2M)JF,40FMF#[NXWIK%;VK MP8(5(K^T*=SX(@B,^HY%?@W*.*+#M M_;M0U8YVLG$8X,!P+6('5+;+B"E+!PP&N[R$$^A1I9O.H]^-IVZ=L] M;!/=&;9%^DXDP%SD%6M*67YW PSU@;.Z^L!EB E2C(D;'HG=U/5]C_B"[JR) M;O5>7@Y&QA'&9$ND%=69%\<*D7Y>VX4P[_OZ\'AV9;\0PUT+KRWLP#2S]50G ME@<=1.6%]&L,:=R(!A$@8*Z+*.OY?"!@S4'RJ98IW=[FCV?D85W;S0KY.U=8 M;<\S(,'U[KH&K0<7>XYMV@3QFN%]#[,N.V+15IY0?(\BN[.N05P/# MX'5AYS.4"05+067)8,$!_5[;2X>BWO(^"FR6YN)7'XQG[P]?7P9MB;#B:MWNBJU1^/IO?CFYO!54IP M=2ZG[A<&#>DQON6%FWCJK;RSP3WSE4(\S=1]._F:N=SWD6_J-.:DRE8D@I>1 M0\YI_*&4M>-S;T6WC>?)-N!R<=#WT"NL&GQ[>-K(/NF$3W35.2J1%K\ZO5BW MGK,G#->S.&+!;]+IDW)):^0>6_G$5OM*YG_^L3RV369K/(=/H@MRF4HU'4,1 M>&(\$2BR1T8>(B8D(2'SRCM_><1>D!*&>EU7,4M@IP@5^,A(9NH;\HW)&Z:S MH:C/I%[QR22)0U._4(D?7D#@LE>5U+!O&^-1K7XW?'GLI"#!I?Y2"$)2"!!<,*B"HO_T,(:NJ=Y3*4/DA M@03)SD^';N ;X\7RI3I]SU^(Y*BHE,J& MQ6"!9%6>$5_L1M9%C*JF7;@ED96"!9*U]:M MDZ*CW?,BH]C7/M5PDCC OFJ MOHBQ:Q4CSO?/]JR,D<(%\756>1VCO6,A(];7S_:KDI'&!?)5>2FCO6,M(];7 MS_:KF)'&!?)5>36CO6,Y(];7S_>KGI'&!?%U7GE!H[UC12/6U\_WJZ21Q@7R M57E-H[UC42/6U\_WJZJ1Q@7R57E9H[UC72/6UR_VJ["1Q@7Q=5%Y9:.]8VDC MUM) H,IDQV9@1:]FU'RK+Z!)E2J9$H,)@R MV/E$JX^*# Y)R M(CO5RMK#?]B40Y.@42J]XH<$$R0[L6+:Q%Z]X%$E>)1*IP0PP1S)SJ281K%W M9/*HZNU3I?(G 4P@1Z>R4R>F4>Q=F#RJ!(]2"9, )I@CV;D2TRCVSDL>58)' MJ0Q) !/,D>SDB&D4>[/E,J$1+ !')T)CO]81K%WF')HTKP*+4Z*( ) MYDCVI9%4 $\Q1V1FKP"%1'E5Z^^#><)3&!')T+GM5EVD4 M>_%1O2 MH&":*JTV%!P Y=+5VQ?[4V_(@ )INJBTX%!P[I-+ER#:GY)#!A1,4Z4UAX+C MGERZ!-'^5!TRH&":*BT[%)SRY-+5M>/]*3QD0$$TD6\KI6F'TD-R %([WI_: M0P843%.EQ8>",YU32I3?L[P]-:5 @3>U*2Q % M)SBY= FB_2E"9$#!-%5:A2@XN,FE2Q#M3Q4B PJFJ=(J1,%Y32Y=@FA_JA 9 M4#!-U>YYV&730_+N"FU_JA 94"!-6J55"&V'*D2L2Q#M3Q4B PJFJ=(JA+9# M%2+6)8CVIPJ1 0735&D50MNA"J$E"7MG?ZH0&5 @39U*JQ#:#E4(+4G8._M3 MAW9\J1 843%.E58C.#E6(3I*P=_>G"I$!!=-4:16BLT,5HK-Z M=^;^5"$RH&":*JU"=':H0G22A/UD?ZH0&5 @32?E5B&6+\OF?'4!\ MX5 K8YALLH3:T+53I7+=;<"!])W*SGE7AC$9RHH1.Y7*9 '[83_+3EK%'PIF M+SE3*D$MA@(2<;9U6DH!XQCQS,"/$>PECB/*T!%R AQ_$G$6\;7\0+_SO069 MK+S=.61X)8_MX*_07E#3+]\H^-ZKC7.H6VIS*4LE\)DTZYOA(SHDGR(7DU9 M&B?F,[)"!XUG:X1,#3(MR](G @9H" ?$Z^E7TI M&IK3&[^LT"0:B>%,Y[-4B/TU)31;DL !!B:CA/?R(#*]-X/0<' ,B,D%0T-O M=VM*\+>DHA@+R$17>CYOO1BNB:Q;DIKY-K&'/>SG2]=WL]RVXS\3!^S]LVU3 M$\C[8>#-O.@2 M+I:=&D^]5?7JQG;1,$!S:,J_"03BI+YP^IXK,M02Z$/7].9H\+H@Z2X:H8#UD.5KJ$U> :K&U<2^$K_< M>!B/W8F1*0#"U#&4U&:O&!B81=9%X!5ZC"-U\#9!9N@3-R,<(X%)+%!4FT@^ M'-7KS)5R2:2=VF7DW1$F3S M1B:]).7$]]<_@-])H &0$H'VWF[-3")U0Y\F/L27[D;CS__Q[6%/GF@4^V'P ME^]&OWOW':'!)MSZP=U?OON\>C-93>?S[TB<>,'6VXS(-=^&_DVGN@/Y*/-*"1EX31OY$OWO[ /PDO M_#V-R#1\>-S3A+(OLA_^D?SA=Z/W'GGSQJ#=+S38AM'GY;QL]SY)'N,?W[[] M^O7K[X+PR?L:1K_%O]N$#V8-KA(O.<1E:^^^O>\'O_W(_W7KQ92P MYQ7$/WZ+_;]\QW\W_]FO9[\+H[NWXW?O1F__=G6YVMS3!^^-'_#GMJ'?%5J\ M%9G>Z/W[]V_3;PM10?+;;;0O?N/L;0&G;)E]ZROD:TAB_\SCZ*W7/]M0.^\A&[Y#[WG/S3Z@?_0O^0?7WJW=/\=X9*,'Z!= M[QMMY4IO;8.]H9$?;F=!/]1M;4?PV;L3)4<84->W;L(Z3+Q]+_!U3>NPKVF_ M)U[IV7_2;)RG_9YT37,0V(D(N?/CE3_7/?_PDOVI 9%^2]@$1K<%2-Z$8@1. M?R&=&/*VR];#3:/=/1_-PTBTG<^,:9L[+[Y-&S[$;^X\[Y']P/CL+=TG$*5U*_[V[+%[$&R'P6@-\0B&H>':$,[ M]6,=O_8!YM >]DR4K\9H\.;SZKM_KP0)ER2_<-G_]^>W5:-]F!(_/6W2[G_W MP]F[E *K+U^FO\[^\6WJ/?ILM)L'FROZ<$NC%GY8S$;WZT#RSH=DG'>]!EB[ MXYDDR44)DR6_9-+#=?W!?^0TNZ1>S+8#JMZ72UHD@ IJC0,R,2PT4& 3F9 + MDUQZ>"[42#HR' =&;@>"D%@@ )9FP%'OR^&P]^;Y<'?S#EP1\<\^ /1CSX UX>_*$;#_Y@EP<_F/+@ M!\<\^,&(!S_@Y<$/W7CP@UT>_-&4!W]TS(,_&O'@CWAY\,=N//BC71[\R90' M?W+,@S\9\>!/>'GPIVX\^)-='KPWY<%[QSQX;\2#]WAY\+X;#]X/S8-YD$1> M^'A%M_[&VT_#Z!&F BQKC0TZN"4A($$R0 M&I"S$93$2@ZUTU'*CL$=CR)*A?-1(>R0'Y 3$I3$R@^U,U+*C\$=DB)*A5-2 M(>R0'Y!S$I3$R@^UDU+*C\$=E2)*A;-2(>R0'Y#3$I3$R@^U\U+*C\$=F")* MA1-3(>R0'Y S$Y3$R@^U4U/*C\$=FR)*A7-3(>R0'Y"3$Y3$R@^ULU/*C\$= MGB)*A=-3(>R0'Y#S$Y3$R@^U$U3*C\$=H2)*A3-4(>R0'Y!3%)3$R@^UR0'Y"S%)3$R@^UTU3*#P>.T]&[3@ZR=P@8TH:L=7*HC##[5-F052Y![54<]W*HC!W[542?'Z@B#9[4-6<42Y+[540_G MZLB!=W74R;TZPN!?;4-6L02YAW74P\4Z%G;D%4L0>YG'?5P MM(X<>%I'G5RM(PR^UC9D%4N0>UM'/=RM(P?^UE$GA^L(@\>U#5G%$N0^UU$/ MI^O(@==UU,GM.L+@=VU#5K$$N>=UU,/U.G+@>QUW\KU6TBZSS\Q]KX4H5I:T M\)DEH#GPO8X[^5['&'RO;<@JEB#WO8Y[^%['+O)8NR6R8O"]MB&K6(+<]SKN MD\SJP/?WI^\)1%FUH"UK@@!59V?^-;'#TN@]3N9"YCHR#3Y3-[N%ZPIIO[ M(-R'=SY55^92RUOKST<^?-\DT]!(_N%,/"'(Y:_VM@EGVN4P(1[\KD+7[ MGHF20M8& 7Z._+O[9/5(Z59) +F<-0*H8)8$D GA(( "69L F2A)9>T30.&# M @0=40#R/$FE,)) [6\26#"XJZF)3N%E @0=\0#R+4FE,/) [5$2>#"X,ZF) M3N%' @0=\0#R'DFE,/) [3,2>#"XNZB)3N$I @0=\0#R#TFE,/) [142>#"X M0ZB)3I&'!P@ZX@&4?2>5PL@#=G,"#P5/FFN@4V7* H",>0#ER4BF, M/%!GQ@D\&#PIKHE.D0\'"#KB 90%)Y7"R -U[IO @\'3WEK>#47*&R3IRI,$ MI;K)Q3!R07.\6'0F#9[>UL)G[E9T[E MQ'5D6(E-SP;+'D;5,6%(TA4;S)R,N(X&*['IV6#9SZ@Z#@Q)NF*#F:L1UQ%@ M)38]&RQ[&U7'?B%)5VPPC98]D6JCM]"DJZRF(Z6JO$IF>#[3Q'\T1'U[Y(\!BM7 PE&[HF.UKV1:J.S4*2KMA@ MYHO$=516B4W/!LN^2-7Q6$C2%1O,?)&XCL0JL>G98-D7.3;V18Y=^R+;4"$V M(/9%CCOZ(L>6?9%C8U_DV+4OL@T58@-B7^2XHR]R;-D7.3;V18Y=^R+;4"$V M(/9%CCOZ(L>6?9%C8U_DV+4OL@T58@-B7^2XHR]R;-D7.3;V18Y=^R+;4"$V M(/9%CCOZ(L>6?9%GQK[(,]>^R#94Z$@=8E_D64=?Y)EE7^29L2_RS+4OL@T5 M8@-B7^191U_DF65?Y)FQ+_+,M2^R#15B V)?Y%E'7^29[9/7YD>O7?LBVU A M-B#V19YU/7YMV1=Y9NR+/'/MBVQ#A=B V!=YUM$7>6;9%WEF['TZ<^U]:D.% MV(#8^W36T?MT9N%2BR<:)P\T2*;APZ,7/,-T $4M%O%4@JU5\)3*X6"$&IQ8 MN[.0)KGXT(Q8^7N?=<1'&M#8CWFM4)@2L*PU3NC@EJ2 !'&P0H.N38MT\04FLY%#O/Z7L&'P+*J)4[$(5P@[Y >U%04FL_%#O M2*7\&'Q3*J)4[$L5P@[Y >U.04FL_%#O4:7\&'R;*J)4[%05P@[Y >U704FL M_%#O6J7\&'SC*J)4Y-$HA!WR \JF 26Q\D.=4R/EQ^!I-2)*A6]#(>R0'Y"' M Y3$R@^UGT/*C\%='2)*1:Z-0M@A/Z",&U 2*S_4>3=2?@R>>B.B5&3?*(0= M\@/*P0$EL?)#G8DCY>'WWQ]@?ZX;G\XR>?1NS9WC]?TB=&AV]^W'H2795MT*R?09QV MW32=T[ 7W#8MN09)54BI0[Q@2ZXG7\@O7!$1->?!XR&)4Y/D;CPC#2*XZ,;B!'FV&N2*;TFJ=H)_7M'D^PF"A]IE#S?,.C))-C._G'P'WD,X\/S MFOVL8O STK1)N@ZFU,EGH(:&A.98A2NEPN#NS:7_1+=DS3[W;_>43.*8)B<: M[8"%VF3[Y+&.VUYY"8U\;Q_#RS10U-HB30.V7*(!(:F M5<(P<7)SEB?//*8:!NROL6)0TNC8'(Z,X-<'(J6"P-"G)PU9C0_!Y' MW\M!"2-"(85G<7'#FJ%11+?ZC8Y%]4:O89)$)^#J;5/)H6&4 LLVN2H54.L.Z? N_ M4)!$WB91.'P!06N3D!)H.15)I9Q30@L-=,'EPH,O/WALH6*?RN\/2-I;C"BA M5FL2J1@.)BBQ"2N4-.Q3D\8TY]PFU3BEG&E$0;OS"P2T.:NTI9S310M-G$%N M$VMS!QN>GFB4\.CD=9BH1@U(TMJHH89:CAIR,>% M[/4\!+#J]K8$DCX'8 D=GLJ15!#/&N'"#_R$IJDL\R#)U]VT: ML9DZF7I1]+P+HZ]>M%4,A@IYF[S2PJ[3"A1&PRH=PC:IF#S)%$A=8^#=EO?H M)][^,HSC^H\J2D7H-.SMOHR@5[LPI;ASUIAC%'9EF1+A6DWF#%Y# L"K*"2A MTW#-'JBDA%H<-7O4J5$P>P:O, '@5929T&FX9@]4<$(MCIH]ZIPGF#V#YSP! M>%7^0HV&:_: _D.E.&KV:/R)$'L&=RSQ?\&9$'(1>_E2QP$D(,2 M$J'(%_;_J94\ASA*:ILE]K=JH\3^\NN2X9*=;6M]9Z/7I7!X=S>^<-[/,C1" M!R=>XL=)ZB2^HEY\B.@)0T:].OK*#_R'PX/T39=\;ZO#I;"*3F]\B:+C98@$ M9W$FX_:]OO*^J;N[^;VU[I;!*KN[_B6.[I8@$KH[DQEZKI[]]6_Y0F$>;'2G MM8PT[*47&4&O\HR4XLYY88Y1R#PB?R5_(\5RCY=*'N26R-LB$#)5N"]#O$XV\U7.48Y 9 M2HZUE?!R#$!JRK$/CCGVLQ=%7J ZHV*DYI9ACCX9;82DRN] (9U7(F)%'.R%"OA*](NS/1PD Q*P3!1>@$D4Z=C&)!L M\+P,)7Q%=H:9'@Z209D:)DHO@&3JK T#D@V>OB&#/^VYX!?UG)(,,D-)LK82 M7I(!2$U)-K6WX)_S@\Z+Q_S0$B\[;NQ]-5:U>)MB)V-JMRL:Z>'@6S>PDK1\ MQKG%(RF.J:65YFV[9+4V*#8#YKIX> =M"DP57PCSU)L#0^H-OD'0FJ'8))CK MXB$?M%DP57PAY%-O&@S)-_C&06N&8O-@KHN'?- FPE3QA9!/O9DP)-_@&PJM M&8KK"]]7_*]?U'D>W\*\KUW3K[1NV.\S._PT:]M4 <_\[L71< 6W+Z> MYG?N*7A4H -CI*-_J..%Q3I.$^QP'^T8'1/N&"&,=[0-ZD#!EQ7Q&)TDY#%R M'_,8'1/T&"&,>K0-ZD#!EQ7W&)TD\#%R'_D8'1/Z&"&,?;0-ZD#!EQ7]&)TD M_#%R'_\8'1, &2&,@+0-ZD#!EQ4#&9TD"#)R'P49'1,&&2&,@[0-ZD#!EQ4) M&9TD%#)R'PL9'1,,&2&,AK0-ZD#!EQ4/&9TD(#)R'Q$9'1,2&2&,B;0-ZD#! MEQ45&9TD+#)R'Q<9'1,8&2&,C+0-ZD#!EQ4;&9TD.#)R'QT9'Q,=J93Q4+!M M4(=$Z)<5'6G![9L*[3XZ,CXF.C)&&!UI&]2!@B\K.C(^271D[" Z8G[,TES7 M(0$-CUN:*F*E7Z=CEW+V83A[N:;10W6$S\STMHY#LLGA*TC65,!*+BE*,U)Q M52LG*I?TR8L/#[QTVOD*E^ M?^^S9_^1!C3VXVPZ-J@!;*1FKZ2_N1%5F7^]#@[RF ,5JL5GFB17+59*]DH# M0]#U5<%,-9U33%,;S$P--]&,*H2IN&:K1IAH0+8P&WTT6))W4'9(.HU!"MX! MFEBIIX9KQ+Y\53XB'^VMRT%#/AU#05'9/04A@_04;&LBIR MQL%/R&@X/DQ M%!25W5,0,DA/P;8F<@H"<+M1\!P!!6?'4%!4=D]!R" ]!=N:R"D(P.U&P1D" M"EX<0T%1V3T%(8/T%&QK(J<@ +<;!2\04+#R-7?VLJA;<$]&I6EZ1DK5D=-2 MA;D;-Z>V[\Z9!PG=[^DF.7C[^"8*'VF4/"L#"+"XS=B!#G0]; #)XF"5'J D M6%!ID$)E:*9\GJZGH9?XP5UL>DV<5L4:8PS!EZS1R.-@CAG(-GL^LT%F30I% MZW?%_1SY=_=)_$CIUI1&6A5K-#($7])((X^#1F8@VS2J:3GGD*2 K8FA4C5G M7%(8 ?))HH.34S!0/:]::3TNN:7(*#/3P\$N*(_,1.D%\$N=/:8EV.!I8TKP MBO/T9GHX* :=HC=1>@$44Y^=UU)L\$/S2O"*\_)F>C@H!IV2-U%Z 113GXW7 M4FSP0_%*\(KS\&9Z."@&G8(W47H!%%.??==2;/!#[TKPBO/N9GHX* :=@$44Y]MUU)L\$/M2O"*\^QF>C@H!IUB-U%Z 113GUW74FSP0^M*\(KSZF9Z M."@&G5(W47H!%%.?3==2;/!#Z4KPBO/H9GHX* :=0C=1>@$44Y\]UU)L\$/G M2O"*\^9F>C@H!ITR-U%Z 113GRW74FSP0^5JIY[B0+FA(@Z2@65VC;1> ,TT MY77U_M?!CXZKX?=V\F/S\O=S\[\@/_^QCGZWGGY5Z5Q#121$Z^7LQU4NMPO4 M[D1SZ^]7%<@U5$1"M%XN?UQ%<;M [4XTMUY_51E<0T4D1.OE^,=5^K8+U.Y$ M<^O[5Q6[-51$0K1>[G]5I#121$ZQ40P%62M@O4[D1S&Q-0 M%:$U5$1"M%YA 5R%9[M [4XTMY$!5:E90T4<1 -+S!IIO0"B:4K+ZM-FW48& M5 5E#161$*U79 !7$=DN4+L3S?$9@-Z' )!%!MJ&&!+MY40&QL<>!' ;&1CW MC0R,D44&VH88$NWE1 ;&1T8&QFXC ^.^D8$QLLA VQ!#HKV::Y_LE$"3/+C*Y^4I#,ULU/ZS#Q]I/=SM_[7L* !ULVI";, MXCTWYXG&R0-5DJUC ]98U\NPDGZ=M''PL _D-B'3-DC5"&&MD*H94FMG:&)6 M(&#NB3+6Z 7!*QG4%L!!$@!5FP1!/VXT7V4&'A X';$ MS)#4B)AN?G<7/KW=4O\M9P__0TJCE$+L+PP_VP%,;N,D\C9)RT#)]S9( L+B MK!"^=$X#")'8[TR&_%)(V>[H\W!SX$Q;LQ8E%C2_MM7-,E!%+]>_0]')$D#M M/BY$")>QW,$3]L-;_N,7>^]. K_UO:TNEL(J^KCQ)8I.EB$2YO="AG A5]U\ M3N--Y#\F?ABH[&B(6>]T"4BA[VLRN"@@ H.94)-U-+ OZ9W/IQ8.896PU2?_ M4#&, ?*VAWXE[/9<(!5&01H3A.!L45 M'R09'G(16]R P!6<:'^/@@L J#8',C'"Y4@FZ*3GBRA!D%Q[#[(10BYFEP%R MD$T6-&40,4$*#&!#)4NXL!-&3-G(%'G[>;"EWWZBSZ!=@IQ=3@ PFZ1H"2%B MA1P90(M@_5)9N^Q2P&UR2B*(B$DP.H _N>3KX@^$ZY!% M@(4TXPZFCMV39FQ*FC%JTHS[D&;]-41"FK,.IIZY)\V9*6G.4)/FK!=I6,<[ M'6NF[(^+:!U^E25G@Y).*"-"E1*F$L-'%P&;CBQ<@:]GN(I+FJ0+JT5T$X5/ M?K"!E\R0N!/" *"EK&G)XJ..'*"./^6"N-!S.M9DBW+M2U*(N1EEFB#E0TPF M@X\D36#:P263=DF)FS!.O/U_^H_*C;A#:ERA(($,D'@'.O">9D.UNYAR-J >,",VO MK76R!%39Q[7O<'2Q"$CHX?2]9C(N7N3+D.=(W8NI&$GE''GCOR4TB.7#=^T[:S-[&TXYD1=?H.C=-AIAFBZ^M]R;/T=^ MPGYY&CX\'((\RB/+&P3D;/6R$F;1XU(A%+VO0B8I-<9E25/8,BU6X=[?^(D? MW%VQS6?D>S*K9$*V" $#+-@@2J"@ @BKS8-*D!22EDEP$U%.0LHZ(CT$2(,M MC1:[G72V5PG;(H4><$$.6!(%2;3PVF1A"F\V-0V2J9!4QRUMYG%\H%$G\DA4 M'%$(! \029#'2"<(I)94F:)+;JWHYL#FQ^?1^';M)WO9YE(4L38G >#*&:GU M/0IN *"$>I/\.Q+NR&C\ZO9[4FA9[O[K%@&DL(JN;WR)HM-EB(27O]'7 MCH;\V;?-/0-%@0,)OB0$(U9=WI%P%W MSA8!=YI%P!W&1<"=Z2+@SMDBH/C9K$0(&Y<6MWO_S@.*$RJE;9-" ;G-#XDH M*JK ^, QHU0AE8[MBI9IB;-YL NCA_3W+]@?)%8"1P< M,@,IT"E3*VH9EHI5J4O;KO0L >-GNM__%(1?@Q7UXC"@V\R7(HL4J>7M9LQH M8#>39@!A%'0R00BDSG"E-[]Q+5*HY9XP)TSZ$NX/0>)%Z5GR2#8R 7)VF0/ M;#*F)82(*7)D $-*89))NSF@G56/*!=9?,"3EH!1BUL^KJT$W3JU+95%Q!DE M0.@,=U[SHUH;9UJ.CE@FE-\7X3_1B@DQ$"EDG M7%@]>/O]AT/L!S2&)Z*6E%TN2"$VN= 00<0%&2Z "ZDH*62=<&'V0*,[-KU] MC,*OR7U>GQ6T#9"VRPTEY"9'I**(N*+"!W"F4"&93E%2UPUYOE4%Q;,JB["E M$E'+M '!MC@CR&$B# 1.8,N>;KB_Y3I,R#HDGV-*DGM*TG36+?N\5@D^:\?5 M32.;#3\0D:W*@ZT7R2BD$K9^ZP@(6+A[1)!$020M//@>DE*#%"J66;-@'([J M^[@4Q#RA#^!I![V*+0:9@B]XI)-'P29#D&U.I6K-S76J2+BFRVI&]>+V\!*O M(61Y92P!V%H8UR10< 2$!2V+ZW<%N*F==[C=^YN+?>C!7I:&C.6*>2*\5K&\ M2@ 1 T144(F\5)"DDD[Z_X,7_!8='I/-\TT4;BCE659Q.5KI_&^&VG8YT\FD M)IN,5!'QK M>@(%5$Z36QNO:C.72F<>3QGDUMW#SV^K>8P]P<4AB/H,R8+ 7 M7*ED.;Q@8$ KR*#00$0] YA0P"'5)*GJ:Y(IDYJVH_U97%4!I-L/STNZHQ$_ M=["FWY(/[(=^4^PP#'1M[]Z,S6EOYK2**$C8%2VTU8M)O0%RRW/$\B;(+[P1 MDK9RVOO+=UY\F]IYB-_<>=YCQDRZ3^+BDXJB^0>_EMDCBUV94G(39HX-X$;[ M;JHV"-K'&,[/+GK.Z=D#K)"P6*CR5-;N?O?3YYUY!/DLF&HJ:8USW4PI&6>FAH-OG; *,ZQKKDW#(&'V[;MS MS533&M>ZF5)RS4P-!][/M2PRT3+];I0 MQ2R]"@Y>&>,T7PM:X!2PLM!PRD3+]?I/Q2F]"@Y.&>,T7_.=DE-'K_[#FH5_/83L98 IV%G;YGJNHTGU]9NA*J[U6C?0\O7958V3Y-4U4R4_?#_0 M@'<11M2_"[+\@\WS!![D($EK YL::CF8R<5P#&!*;&TRY,)DDTOSX2KG!%^U MDW\=O_YA_)YXP9;\Z]GK\=D?CN;(\8&JS28ZU$=G'OA]H$NZH?Z3=RL4\>F@ M9S6<96I&(\*E4W).P:Y(VX2L! A_7F3K/_E;&FSCE(,^/Z!($7A-TFS@++ ' M/("&A$UB2:#5*53[&@U91$SR[&LO%7'>^ M^1RT#DM/02S/H=9*6UNZZB&7RU=8U#D9S/ )]:4S!9*$I'07QOFVYO?NEZQ7 M7N#=I7E@%Y3F6(&70"YJ6I#W$":7Q__V7/XU'?_PW MLF-_)H^9RG >P/BPYTGY(!\4\N%^7=?ZK>/\56 MEQ]?C7/PDV";K92SO55MOI3/3?V;L;P1[F5D:U_;I]_:W MT#58XBZ:?8FK^]NPA+L59FMRFKQR8!W#?CK#P.=//\T8D6^3M=+6UC1ZR.7* M!A9U/GV8X1/X0)/N[W[U[-R*/;#41\U.>9/3NW>MWV3_9)VS!<4CNP\C_ M;WK: BN]9ICM-LT[\_8WGK^=!U/OT4^$:P>UTE9G'S7DQEPD%T7#-34^T7'C M;]_XP9M-)N6<.TN:>'Y MS,O"OCY>;:P/CP<]CQ3Z)SN^"V*@-DFBC8996Y( MG5QZ+30\,X8J7Q)OV>P7^;>')/4;TKP1\FH?QK%[AV%[P(:K)1AIN)PH@3H) M!N)HJ*;'*)S[S2;%<-?(B>4V2YA2EJX"$HY&W22PN[ M3BY0V ZUWF?4"N@='Y54.SD=4)A?A29"AM5>F]2II2O\TD'/T8"F-@,8UN1* MN#P)IG#E<^D+&.V*O7(Z?M_D!@(/ Y"UR3DEW#K/I()H)DX5.IES(LWOR3>= MU6XS"^..A\I.+6MT<#=*N/>W?+"N[OA9[/+Z#4'='?\Y\++K@6X\[I:_IXF_ M\?8J[]<@/V/-;3;@0RK];0/\AO,W86##9'',X@=J]U21Q:YP_+$?J8<#2/DS M=G*_H1/.4C%76=_2L\L2&1SL@H%ID[U1'$"NK3T8U1=12MNMR41MI.EHJ:@S M!5@L0FK.J=8=*^!=CEO>94S\RQ:RD]*5K7\&HH8COD'0 9ZUQ3'R"\"HYA6^ M<$1V\*&LOL]7Z:G:])O/KZ>)J9J4D1G9>2K9NE,LY M*GG1A F4N,B$G%- ATQ3PN(T)]BT]2HVM7/L, G4\@YJ5,"P)=4I1&$D>+NI%Q) GYP&<;Q(I@'/_G!=DFW].&1!_ZU Z9!"VXF M)V/3Y).55AV7S[\[<,'[OUA/+LG)Y[7C#^<^TLCCR?RS/!U:LTY2R%L]N*N# MW3C&"PD['P%-$0JW"OSM9G:].OY$W_&QHC HQMT<>O6J3+9/?AQ&SQ<4#)2; MJUN-*'4TJA%D,M1%0[V.@!65C[U<.CL5=JH#A=#B;?O@!SPOR>.#KH1BH)2] MA1H(L5J>"2+.>:'&)2S%&H)ISSL?DZ:'. FWJF&G(6'5"2E":S@=JZ^=\P#& M)#@5,PDI91-H"%C/]SB M*>9,AWA<"0=OA1W&DMZ5XVINJ^GF1*KJ=)NH,$:Y/Y3HH>%B![!BX:9*,CU^ MROT9V7EJ]TR\B<(=C>/T6()BB!3%;#(, EEG4UL, 8,)YCYK82:@!U6^) M_" _^2]=1#>_MU>C10*KJLI2^])YOT*(Q [-1'"\YWDM#\4KWI"PF[@N0&NF MJI=?.^][&!-4.V7(5YG/1'NV^-G(NE4J8;% B@Q:K31*_6OGW0ICDJ14Y$)# M=NR5'V_HGOTP#0\QU+<2(6O="P(L>UB0P-')$*QV/S?D<(S@@M?8U+OLV%=O MY*/'%0""X,G#/!^7B]6*H''22_(OS#,UG&>_&&:].!]-]-AD-4>$B.#;5Y>, M/.Z/U4JVM]Z>)PE.@NWG(,K_4H^#EE-NNJVV:>W7*GW+L\#C9P](X2([^ M'80OSLF-DQV@*EI/'3!5^X3_ 'G%?^)[$@:D=K.%^_(O_';2ZE+29>N1:%XS M4V6;+TXW@^JO@IDF&G)W@BNC:\G/.Z:3%U^@C*)IY??\TMEGDE3WCL6,O4-= M02M+VI+&$:5R3E/EQ!BL1,@Y;73(C%+BG ]7K4&Y=BE>0?SB10#>FBX-V!RV MNAM6'[K,M9WSL#=DW7DZY]Q4#\B]1G%,4V?W*1/7AML(:X=YTCG?JG7DXFM M:PO:R>-C1#=^&@P\I]6?NYQ9Z=.DF_U1?^/E^Z#N[:$94T]@A.P%V-RS3RAA MFYA#M:GQ:DV25]M:H]\/N$R\#N67F49/R=>#W?8J/_L16SY MGL2UH6%DNOV4ZSK=T*O,46[R98K.B=H'K1D#O^8-G'*$AVN=3]-5R#RH7JKZ M2D8Z;>F5;%8^-S.@7@!=K8%C>]4)J_'JLKF@'(Y4TL&Z/5#+5Y?FRC9)ULV@ M.MG,-'&1KA/F+B$;:;3&^>J5(6< M;GBY5\HH06J7.2QI<7G5!0^W1,@S9'M^,-KX]X_5MSSMV3F="!Z*S!K-CL<)0_>H0L:P00GWML@ 4+VK,E$BJA:D<%%_P,F W4<@O2-]^ M>/X<<\]8F=0WV23^D\G5Q7T:LCRG]S2T-?%W; 4-?WM#%]*Z)ZM/Y.)R\?.* M7"P75V1Q,UM.UO/KCV0R7<^_G.0^Y9,%836/M@5O8M&MX( MD&0SK9]/WWR_F_WI>[X1KDVZ43G5IFDY(9ZI=K+]KT.^,5J'2\K[T-_3QF)Z M'9YFD!SFI^Q>,373W7ZWT'S2@UHG%B%HOPI?JUY5/P8"8S>VBV-_">Z M;;^SO"G>P(:O:1YSD.3VF;PZQ*E'__M"F+WO7HEUJ%.:K&_N&?AXL=/XNB!) M>R@A"L<["V&^$![>R2YN)MF+M*%T&_-MWKD?/X9Q>KN< MEC!]6[)&J.-,+0G7KQGG ^KQV"4GRU/5;,3;5LHG9NX)$@"R8A]Y9>+[,$K6 M-'IH'+%I/!8P[-NY';NA_)YF-N/U'1O!,M(>:X!LJ?Y8C,5O8V]/D)&\_6H73V(2;,]]ONP(MC%;05'_B=_ "#Z^KLU8+I/>R\A6_?1.;> C M>"_\DL+KL@7MMFC@=5D*]W4:*&/+X;WG/_#=:=$R0LZ?'RC?)J27DMYX$5]) M&S]&J:Y;=BO,45-:HNA\!=('K2EK#Y3OL\JR7=86R]5K-J]%GU?A7GJ0J9N^ MPX6QWBS%J Q*PI:YSD)5-OO&<.0SD2=E=WR$BM M40I"@KI8^:@#;$C'QZP)/C*6J=D8%ZKI!:A9/FP>QS:>.62J;J=LV!CUC"WJ MX5]X@I@-"1IR_>P.4K2\G&PVX8%M\/+WD:VQV2?1@=9OCNSVP,Q:1,#B+J8; MD-ND.>TN-JW M..M0.V8.Y4(.\DLVDR0'?%3U[,D!?L;YB#^\;;)7R_!4;?ME>]U8,V6>N?)( M3KULB_,YPSR'ZN@D+*S9<<=EQ>$X==$;M_38#\^!&#;O82C>7OB!%VQ.D.6I M; @!CPT,->"SHA7G _[1T'59GA?SZ\GU%%F6I[FU1S\NK#P^CK\OD+>ZH;B> MCK8KU#$-QMQ._@_?QSQY>[X"6K*E4.1OV,:'?S'AER;6/ZA)WM#(#[?MC?SL MVV9_V*8U>+-3J$NVB9KM=A0/ OZ T]^0MG]?UY3!F^2KPH&>PM@I9T?'J455@A;\@MO?.#@,^4X8YD M&%4OR?\<;HP=L&,6*!V@IS&H"SLH=]^;\.((WVAY6'(:!G&X][?<#UQ^&"]V M66&.N'8R^'/@L6F!B0&[UA.V:\WO>:QR^!E01!.7BNCO/O $$*:(*PPPR0B7:SH>GWI#E MESB>SZ;+V60U(_-KPF_JFZQ6L_71T6"H3C-_*> ;'P 9>W67 7A5?>66@',R MJ%#)[F',>E>YV1WP' 5++]TXJ;5.O%%>.WG^P&-V]WP.9_A+X-I/ M>6;!?3T-'Q["8)6$F]_R7 7H;D^]N,V;QW6@Z]>00[(XAC0]0,'CN[BZ6ER3 MU7HQ_:E(:_J[>Z]>6ILT7AR2.&$K$G7$?FX,@7A VV>H#$+W9IJVBQ.T,&4>ET" S7GKWYW MK)*#KCR$USJZ5//2#791H!ATY'[%#Y2'5L[ICD81W:Z];_)*&%VT[=Y_T,FD MYF4'1JHX.-<9;Y=(,E]\\G;(-F^()+RE@8A80_N!!G3G2PL_U-1&T-/$4HV&&?JHFX&%1&L? 2IY'"P0 U.,S948?D3 M7.K<\:8QCC7.P#8"F^;3U/'-.K^=K,=#T-Y;UJ%--!0^D2'*'!0>LJZ%NYLW MF@OA;D?SY"PK?Z(9[TLI%_-D"Z)LGLQ%<- +Q*6<)_,Z-$@&QET;!&J6-@)=L54KC M(*()1"'?@^LHO!X#D:9X8?)\E/15D9DDE[-&$17,DADR(1R$4"!K\Z 0)9M, M-AM@ALKX"1)_Z^\/B?^4G_+EK,U1INY@77YNUQ;L90OU,JW*)>JDCH-EO3 + MUQBQ1MX4K1":-I,-2P4AX_1"3QS)J\?$9! FV*B!&D1D<$5D)X>4'U=>]!M- M;J)\$535$TPS2%8,*XUOO$C:C>T,I&-:M'I[V_&F-]+"^C>'C^7'&]-^$[*F M!GH-@+GS@Q?3[2)HO+*R45DN9VT>5,$L9SN9$(XY38%,R/#DHGP#5AXY["<1VS]=$L!2A5<,#.S\?"H;L^?*\^R1A(]UBEY72 3P2 M4DF;WB(%U+H'2"*&8P108@.71+$P#9!7#_Y^SY>K0X5LEGRGOMBE._G<91JO MP\D3V\+?T97G&7S_ M=MA BI@$H2"%0MAAP@E$#% 2!S5T\)31-5OT: QZH(>[$K ;*F@#:X8&BF]Q M=+<,DMSU7\P--KJT+/,X9X\[X)Z^"TKY@7BSD'K_MMP0I8>Y]+N_<$ YR M'XD>7*L'BDQ@MRMWD[6FP[6Z=I&.@S< *L6R?-CL7W%)*%US2<4<+L#%]9=$ MQFJ/L_?R-HPIZ$V$\6')_1:+\;1<87)1UP=*9 Y%F1PJ-J@Q(B@T>!-&R2[< M^^'Z$ 4A,X<78Y=9 @A:8X42:,D)J12.&4$%K4V$4I8DN3")F+3S8/MJ.%8/2CNGDC%$X6Q]KL 7GS45\DNJI#SR M[(Y:EWY YPE]@"Y)T"DYIYA@@)9FI09NJK5A&M.-*Y)4TSWGLKM'KVARSV\I M*4!.MEN?YXYX^WG 5N*B=VP[#&*:YS?N.];+T@RMC+:P7@59FK+0'G'%"A$K)/ MIW_]/%_->=%W;37@(^/T0-^'>W_C: K8J!;M[3QWPYBX4DD;# M+"U$P7-5*I!" ]/XM_+O G_G;[P@$4W3#7RFRE9]7YT,:GC%C#31,+$37,&3 M]OGJ:K+\.U\VK^8?K^<7\^GD>DTFT^GB\_5Z?OV1W"PNYU.VQAXJMZDLXOSA M$/L!6_LO_?BW.*W/LZ%1XOE! @]S_9JPEQ/5S[@J7ZJ;OG-*'@%:2*[+=4FJ M3)@V::@/E5"I@@P-@YTT[25?=C*E2LDT4L-!M4Y8!89]7LVON>8%WE]YQ?4&IV5"G578PR!D:)!G>-)HXV-85 MKF(#7*D1IC>XT[J!4CF*Z74<.+C5\"5N;[D"#A89HA3(4SK'R=7D>O)QEO[Q M8N8^]GE.;Y/JU=#L1R%AFSL#->#Z3D NZ9Q'1O#$C/7;I'9E"J:]9],.W683 ME';'(>5V$A!%RB+=.'0^^W!T8M4@-SGI:*/1<7V7DY)"2@4T1#)!*5SG-)EC MR>')3GBLO6_&DYE2P_+MR3KHK>N2(7$T9-)C!.X%8BI(ISF)2?J(DDK%,<4T M\2)8'C/)M /6['RV3)-5IHNK&5E/_G:\I^"4J6:3_3Y-G:A_9!H=5RL[2E S M, C(75-H(F)@![BP0R%^39@Z2?6;1S8P#7\%+/,XNO-HN6%,'./0!F%3>!;6 MR\GUBM^^O+AV/ZAE1T(T@U=;R/XQ'=5@U)1 PPTI+.&F]E0(TP"RCJC'INCG MM/RO;@R!A&T21 VX3A2Y)!K"*.%)#V>0#Y___F$R_?!)-A.MD\> MZSE>_F6W\_<^/VQDOD(R:,+1.LG8.&"UI-5'P\8>H!4K)^(':36JHA5>P*=J M!]/X9V*W_&BY\7JK?\/86&_V(+J^"^I67]0;8F0*O%9,<^XG%Q?SR_ED/&1GP]C!G^DX6/(CQ1LO'V6'& 45._6 MDH,(>Q]3)>'V+LTX)_7QV(';(*HVTO2B>BM9UM% S&U;(,!71NB[:%MC:'>3 M2E::J^)@8F>\ OLFRY]F:W(^7RT_WZ0'V?G8^7&VX)F6Z_ETGD_=9@PSU+7) MMD[FU)EGI(B&A5W0"F6,)JM/F4N-_X$MP.:,C@,ZTY;L?8G\35*_95/-+W,U MBW> &QM1NQ)!6E9+[/QS$#/YEAF;$9]'-,J.:=<5Z1BG"#-CEO.IHN/U_-3+-6!@2LM M%LB3CCT]A4P4K U61L#+84HI[9PMQA#EJ0+E2FNPRHH@&#'OD!;&WX2\;+Q&0 M_G6?OGN&.^@CVK-ZJ.Q8LQL'SOHVAH;!QUH@G/M8+&?SC]>$;:"6L^OIW[-< MZ4L<;NAJ2_@AC*+P*YMO@NUEZ 5TFUD'18/T>E9C;:9F-&)N.B4TE#1%*JR2 MRUT[K@3]:9C>Z1FEKQ%/?9A&=.LG_$^02TRE8=4%J8?><#S"XFC8I<S+:OU$8\QMU$ZL4]#:$A\#/HVO10'=VG&AG%A#>-FG-3:Z&BDM/R&81MHB-L3N(K .]8D>>)M%C=AIT7AG9.Y M>D=GNQW=)(M=K2[JYR"\C6GTQ&>6>?!X2.+I/3.0WS=PPRS-GDYZEZ+Y:'RJ MGW$S:I_V(0X8@7?:Y?_-;,(XX5\]EC>+5Q?- MNZ=A-2_R.S;"@(/BATIS^V??'FD0TP\TH#L_Z;C(ZM&BF_54;]/E2Z?.S:&A M__$VJ%Z.VDOQ&(5/?LR&=T0OP#G=T8A-4,S0;,;B#O[J=K..Y._8FBOW3P^3 M(6]0AZ80$KX/?K6O*&LOI7MV]5I:J6)?M8F(^]FF*/6,Y>_ZTDMH:R769XO= MK4F7V^D^QJNVSEW:0_@^]#9"]5+0HM'TK8A8@^D[$2=>*1\B!=<,%#WOPNBK%VT-CL1V:<+N*=GNQC4/SIKKXV%Z M=] J9G-?ZL9[]!-&WCUKB/VEUI)S_M8*"IJ,XK"XHT*.VM$7DD7#-PU ];JY MO'HDJ65".2>5M A1QY)%W=84)_L=-PN-$S\F^>KC1#^"YL49RC*S-RZK,%=5 ME./+%=;G"8.]9XO[$[IR@/,/[=2)*?]Q-@)(KSM7"%L[AZ %7)XE "6=<\\( MGG 0^?-R^FFRFIV3/'F%O$IKJDVFZ]7WS@?K&^\YI>E%&"WI8V[:8O<<9/+[#:.H]D&C$4_ M1WZ2T,!D) )%K8U#&K#E* 3(.:>& 3B!#\OY>CV[1CG^?&'T/D1TFNV1^!FK MF&^X:'Q-H9ID:A6;(X\)^/JPHY)W3JP.(-L$RU7*G2ZF2!:_":O*.%U'WI;M MZ:N#]\!#T&K9OI?,P(3V_60*%31D,\,I'),L!4A<*J-@6I5!.@\2RIY6PMVC MI=/TAD8\G]^[HXKGT:$-VRSL;%Z;D\8-H&)H5]1MODZ"X,"&110NZWQ)R5:4 M\_1L"<-_02$Z0L(.EO< 8,FJOB6)ADE*>)*+SS(1LJ.4>-O_.F"94%OY6\UX MJ"2;BPES_+!CVG>8$7C\8U'D O9O',W+<&J+A*.]/+\O_8'7 MI&PD==/5FR&_I&VX+Z1[BL=QZ0=TGM 'R&ESXM]X:2^7\'A._8*5/_!/]9*U MK5*]:),JGZ7V0Z3X)1(&JGV3)4-7@ M>@SVRYQYN5XD7)9=&V5SPFNS#[./\ M^GI^_9%\F%Q.KJ>S@:*RC"Y%JD+,'OT3C?C!"FE4%A2U%I75@"VCLH"<\Z'" M %R;!]>S-2ER0U9OIXOK+[/EZA3%36 ^\.HK!EP0Q6SR )9YT!;!DW_ \!D M?;^:7)ZVWT\2P)H$V^R2Z"HJURZ J@B4&&G;#EIU,*D=KC)0=4Z]?GAEC&Q4 MGUV]?<6+S\Z.SQ&!QR-]*5W@-3-1M#EFF1M2'\7T6L[)U1FJC%=0[>)7]>:U=8J9[+$\&0-8;*[NYFR'F5'R(QMJ7>^+5LWE+L;-:[9^#C5,JT?U7GO?N3@E)SIV&<)]3G5UL=HD>V+(,V8QW;<$YOG7E:1D,- MX":Q!K6P9)97UWQ-:DTZIV]12*Y=2K19/!&,[9@IVPVM=3&H&5DST41#T4YP M 6ZBH=\J8:NH](JJ35\2FC7A@HI=C),1TD0?'2T[@!9JVR083B2VWJ^&/3T' M2%T;#L=),_,4PZ6Z 73T[():"!"&O)I HV3J*YHI?O_V-E-%0]^R0BQ<.5#S MJ(Q:<$'=#J;)B&N@CHZVYIAENZBP4!*+/N+C:U[IHS=;87VG7-69I60JI(R7 MIQK$PCV14%%2&]E>63V9M+3,(J@V:572FC8+R: %-_E?QJ;)$\&TZLX)V!^S MQMVT3YLAK^YX0]_S,PRU J>HRKRTWKS47VSZFN;"3D?&!F#E,)A*.J><$3R# MM:.'XS2L8 8/!Z=.ULE^'W[EM4M-'X!,TRFU8%.4/!/5L,66S"$+Q=$*0>(5 MDO@H"(>'Y*).20:$=&1R>,+X+/Q']P.]BX/=2TB#.-F2\./Y=>I_O MA^=*)"^_.>%F\ 3_JW";WO.=Y4?%F\A/JZFSX7Y-(Y"QP_ZDU3-*%AY>XUS3 M@+^'YEVS8*2PVO[;S7R9':@]GZR5IP9>?OC%;M47@T,>W:$;1V+<>RI-ULB3 MI!;A3U>_#>$C5M_:EK'MH0P?1=>ME*99-&/?Z6R!-U9H=E)F]Z!^XU>S^&SH M9Q_2N+&=/.(A:MK%]EH8/8:N+X6RT1?U2IA8(DW(V4_),_ \Z M6>=D,00HHPKB6^>;E[Y-GCQ_SV,8%V'$RV>6]^O^["?WF0OZG":\^E6VY)@\ MA(<@F20WGK+8R:E_Q-V%?Z=Z0/#]@,?^@O/W9%"SA#I!18W?YI7@F')4;Z)P M0^DVOF"TXI:S9*7?5I"LU;)>8'CM#360]:DC_D]F&PVAX?#GB=WIKE+/"@3T7L:Q.5*G\^IJ@R( M;DW89'P?XQJ7&7701\/M'J"%2Y&J)DC:!FDT0K)6R"O>SO=H\BL,#;_49%QT M;P8AI04C>]#Z$EV>1D_@1]+[$E$^Q^S;AL;Q*@DWOZ51\GAR2.[#B!\/@MPV M*@VKKC4]](;;#!9'PT<]1B&4'3X\A &)N0IYXDMHYY1*X2_I8['T/S_P2W%N MLNM<4JN@3 X#1:OI.L:&-))NM%IHZ&8,5;P-OM3A*]$XE7T!]%-Y+PSTL) / M]#%HE;!%O4P!OV "LLW<7>0]+.F#YP?\QM=R2*]D,C?(R.PA=6K0(65[&*[@ M]/7:'%( MXH3], ,KBTB*,M8BNQ"\,IS;%G#."A4J(5\DZ]^P$G0^-$TV&[KG60BUQ8$[)MEG=' MR2.7=\[=#X?8#V@<3\.'6V8%C_%.PR#VMWGV8G%;&1M:H>U.MR9L,K:/<76R M=M%'P],>H.6%@39U+>*E&QWG?,T/A,6+W;G_Q- %VSASJ:8K"BC:JU&R&H0W M,J 1:U=JH.&=$4S('9Y-ZKLP(ALOOA_NGDN^7D@':MD*I/F]S3LM!5CUFRS+ M+YUW-81(&#\RD=-,<5!G,H+1:+%C(UGM(*@4,"!IKX.54*NNEHHAZ705-J'[ M4V$2%J!O&K%" WEU+#YK1A +T^9RC$G1/*'*.* M6,[)E&U$YW%\H-ML[:_>W2GDK=[ MK%R'RH5OWH;U@$I7\X20BFD#S@EY#&KHY$:5I3'0\%0;1L$-N2AC;6B"X)4# M4UO .0M4J)19B#@+J39SNV,;-H>D7N;5 MAZ1.#3@GXS&HQ553V0;Q@S386S3#LVJJAG!E:A?^T(LPNJ+1'8V6-,TX5[D; M-#HN_-1*^#(WM50!#2%-4 ISXN?E]--D-7M[-5M^G"V=,VL>))0]ER0[II!? M$P:7IX?%[0Z :M#-L4XNBX9%&H#""':]GBUGJ[5SYO ;:/BAED7 SS4V+I0% M+%5JV.2/ ?0ZA13B:%BDQR@DOTPN9ZNW5Y/UY^5\_?>W55U+Y\SBQ\K9_#[[ MQ\%/GJL#LX6)P!/0:MDN*6!@0KM&@$(%#=/,< HI=K/)Y?P_9^?DXV1^35Y= M+E:KH^\XAW:#][SZ*ULBUFYDK]^M+MWK:'7L[18-X5>[1XV"<^9T02GL+C]- MKC_."./,Y.9F.9O.TR'J[:OS6?4W)9$LA3]T$0]\I72EZ(1)XM.$+3;(I]GE MN:.'7*0@339LP(G]+ 4I3A:[](.(;F=!P@:B-!/)VQ1?2T?8GDU9[CJ3?*R^ M%K2[MVB/U!I\36KJ)-5WU/79%'-%D_MP6ZUG_GH(V1[KRHM^HPF8QVZHBJAK MNR(62D"F^B1K@%0MO"99&R1KA'S1);,/V*&7OG?K[\%",+6O$76,#%7[X==D M'#W:=42]^! ]I^[:W',+'DL"A1$]=CU&,5,LTR"IRFN2*;TF*VWHP4X8.ZT. MD8$!3E08*R'J)W.L0. @[ZVL=D:FS?YF=B3#BI.=U_/P@N=JAST/?O+Y&:,M M?1"R[WJH(^K,/JAA%SO)&WE->#-%"93TIN$WO['&2-6:HTXNJX+F;C=U==-" M"%&'P=C:W5)*DD+4V=4E]:*!R_P^:IUG!-9 U!N&0-M=P]5(I?>:%)KU]\9R M;Y6E4/-M>W7_^+G*%Z'50-!;'8%*JKVJ-1WU5$&:2;!M7A9?OR5>6H_73!-1 MSW4$+.E!LQ9<]&19[A0,2RC$L/21!AU8XK4A[FSA5X_'K>[#*.'W@57 TLQ+ MAO:<9O_51QT-&D'0<\=C%Y>"64MY$3R^%6.-O>&M-3P418/D5=&D*Y=NV[1Y M4-C 1HHR17=)-]1_@@I]=FT#5=?WA"[-3F[V*,^W*0G!$V_*]DC5()INSTI" M'J*(WQ@(YG::Z*'N7@5/\=TR\A:;&$G_.H8T(ULKHVH M4WN EEU#P=L@12/D]IF\XNVP]_1[4CD JK9<.4492OX/)^.3M^>+O26;%2)_ MP[/GV!=I"9_Z!S7)+!&]/93-OFWVAVWJ"-FDNS-^GU!VRY#4PVH5 2*>.3)< MO(4UOG^=L;76/A^$BI\FF8B7N@D;'S8U,DRR)>1K4B(C!33"L9$,W$LD_\FY M_.O9/P#I51B;O!H7AMC/Y) F/V01\YLHOW.Z6C-E M1;K9P$/CXO(:99VJ_LTAFCE.8858TS3+,LES$\I6&^O3M&&2MR_*NO#\;"#]1+=W-/.M3)+R M4]E.,/F+:MPU$G=@;.IPU M\IJP1DG:ZFM2M4(U,3DC&Z=?=H?A?A]^Y<='Y7D+6C5$7=D%+31II5V7 M:;\FI3XI&W#E&+9UKSR>WNP!&KY4/K_#BG=NZC]IWM.=^F V5%W0<\@M\C"W MI>#I2W.LXH7H?.M4+V^>Z>9>L]=@-GC]HTOV)_9Q\1'[URUKBGWR_P%02P,$ M% @ NHL/5Q!%9PL8.P X.T# !4 !S=G9C+3(P,C,P-C,P7W!R92YX M;6SM?5USXSBRY?M&W/^@K7V9^U!=)=GUU;=G;\B27*UMV_)820Q]:/P MKV^Z/[U_TR&A&WE^>/_7-[?3M_WI8#Q^TZ&)$WI.$(7DKV_"Z,U__]__^%\= M]L\O__OMV\ZY3P+OY\XP&?.Q]^ZGYQ.F_? MK]1D(OBF]OQKMV'Y)D27]^]^[' MCQ\_A=&C\R.*O].?W&@!:W":.,F*[EI[__1^\\^Z^B^!'W[_F?_GSJ&DP_ * MZ<]/U/_K&_[=S6=_G/P4Q??O>N_?=]_]_?)BZCZ0A?/6#SEN+GFSK<5;*:O7 M_?+ER[OTM]NBA9)/=W&P_<;)NVUW=BVSW_J2\IF>4/]GFG;O(G*=)*5=^9F. ML 3_V]MML;?\1V^[O;J/=F"WZ*8!P%Y(;,._S_C+W=5^=^3),'-KR2 MQSDG[1TO\&X0L4')>IM6?8C)_*]OZ..CR[[0.WG_\>0];___'!1*GI=L<%*? MCZTWG79]2DM!^Z%WXSIT?^(E/J*I;T/KM]?C:B=DO'TCB MNTY0M_NEC9F19;+D2P@;HUJ8%VN9Z=W H0_G0?1#JW.%2H;ZQGY[3^@XO"+) MFD2M3@IK-]?;N.9WP6;TN'A1K$)O58N'$SY/YU+\/_3E; ,*D[[K1*DS8AN$Z"GP7 MLCYJM=)<[\]6U \)I3<^_<[7M%NF$./$\4/(H@ZJW%Q?]\/HT@F=^W1BGA.B MZJ6B6G/]&Y*[1-69;)D&UPW'C].MFG*UR!=LL _$8RHF&+.=\H+,G"?U\!'7 M,#%F9K$34L<%:4YYK0;7C@>V;SA;/=\Y[G?U$E%6V 123,?UYW.VLV'*CT_K M010FK$A /(W5OV)SS:7T ZR6D+MIZK"M"A4;;GH%#PO:204-3,-<8DBQ73LS-\$?E1JU>J\;W MW+KB:#9C8(4$#B91>7,]ZNIVJ6N^3SW=/O7:T"50"E456^BCFE1ES19ZJ:99 M6;.%7IY4[N5)B[T\K=S+TQ9["5ZPX2V8WIL!9SVHLB'+75NY0RJC[22U :_2 MJDRZ94PHJY(>5URP'QQ4(4\)"3WB;1OB$NJ$4>X@;GO>FIX$4N+^=!\]OO.(_XYCQO^0@I<"Q_[R M1_JA_AU-8C90MRT%SAT)TO;_8&5R1=ZUT*LM$C/68GFG#DOD^Y0EKA^[G2AF MBPC#>MN6$[L'=!6/3CQ]%"A,X&B4C0T2Q0[!/MH-EG MW_?2C6[@W)?#F2L"Q+.+ 6BI-%B(#@EU8S]UR2F /2@)Q+>'BF^);"W#O)T[ M-^3>Y_WE7=F=A,K7!4$5(/ GF"N%5%HD!OIAN'*"&[*,8@7PAR6!>)]BXETF M&Q+,?ULY<4+BX!F"=*$P$.P/F& +)$3".]VA^QP?".#%TD#$/Z)N/ 0R(D$^ M?2!!L(F!@(!>5AX(^R=,V,5R6@!\>CPW9*H%CGVF"A#^S[; 7Y 6B8%K$ON1 MQU1Z#,"^4!B(^A=,U 42HN(]"CTHVKNB8/L''^R<>$A0G_O4=8)UC\[9SZ@< M[I+B4,A1;$ZEF*BP_X,X,1CT3&$HY"AFJ$+$E@$?K.+XH#/2545<&@HYB@&J M$K)ES$=AXB?//"OE:K6XVSM.#[$NEH)BC&)TBH1"P7;K:0@3GFPCPS=?$HHQ MBJTI$PX%YP&3)SW#\LC3;^19!G2A*!1I%!M3*AX*U->QS\-5IKZK7C2*9:%@ MHUB6<@%1T)XY3V./297&!7&0U* +JT"Q1S$K0>*B4, /QN-EE'$7#WAL5OP\ MB#SIDJZH"*4#Q=[4$!V%E+[G,;CHYG\7?DBZ,BI*BX//B/ (D(AI">P]/=A[ M<-A1[%"EF); ?J('^PD<=A1;5"DF)NP#]L=)/(M^"$Z@A86AD*/8H@H1,0%/ M-'8HYHN,H$;=O!N.:=.RU$H42Y(E!\46S54G':AI0S'!-'/'P/ M2T !13% RX1I&<^+B)]]/$2AU!];+ 7%%<62% G5]L++@XFI<.IG?@V.8$-9 M5O-BM SC[[&?L!X,HL5B%6Y\-()3,4%1*+PHYI]4O):AGJ:9?SP'\)+M$&-_ M?]O0(YTA[HHM>\_=WMV,9\P(5IE"*2C6*":?2*B6 ML;V*9K'#;Y.. M.)-,6@&<9X.)N$34MO/WTI0??L]PO$C[<<[^4 Z[H"@4<)P429EX;4.]\OR$ M>.LN[>X(W=]G*D!=60M* $X.)5!H%/?^[R0(?@NC'^&4.#0*B;?>ZLL\_,(J M4!80SQ 5XJ)0\"T*5@RE. T$C05S0% 4"CGBV:% /)S8RW50\T[WK"^4ER$N MJ@$%'O$042XL4GQ:0GB?_4:X@%&W$4-A2T5! GBZ<(-A>0BT#.5<0"C)BS&NI:"@@CQ8DOF>+VM2)S=/Z6=&3.[31;TH*X%90'%7(4*C:-;,YG\ M4M5Z4 Z*-Z)A6B883L[4ZB[PW?,@#)1Y'Y/+\>DDU62OJ_'^B=U M&DCK0:G!3.($"(ZT"Z+[1"_BG3W?D#F)>9C"C#PE9^Q#W^6;(D!U*#^H-PJ! M82BAZ9=W!;DNV ^,WG8*?FGOX"+47N=M9UUSH_2]H)YIWUHUV MV'<[F68[?[F]ZM\.Q[/1\#_KWZ Z=^A=RNF*OKUWG.5ZJ)(@H=N?[,?LY@=_ M['HYF>]\_]?1VJR07+6ZJ0ZK77_^59%L0Z-2AGPYK/M9M2 ]G'@"20PLA%6( M.+C/^"YA$VOTKQ7?4ZZ/6MDT4).DTP;:A;!R&J+* C7#8\F-VM^^#?ZX#9WM M-=39FZ?[S,QE'5J/NT%$R[CA]>'5T>Z1!=&B)XM11OIU^(!61KM<%LR&'@R& MN"B]E1W*!;0RVL6S8"[T8$#7.-LC@%S_V-:._R FWMJ,R+QYP']==ABR:;%R M@VC7W.KHHIIP9>AFXK&-/JMQL890*$0J01(E3I"6;$FEK5\F/'C*$ZK.#JJB M7:5;7Y650-"N&E-S *F(=JMN7?75'OZ"-5N-/Z0BVK6Z=566 ?QKJZOUSO^2 M) ]1IK-_6T5L\,CIVK0 ;@#M7EX==:0)AW7JYSR*B7\?KCW$[G-?.ME$A?%N M]07/,+F\*8)VI!,8 G:WT6'9+W:S:/_BGO@HF]>05<"[3ABLF=7RHJ]!!R\:;_HK'NWEI?&N&]89 M[C))S9E^=!7P, 4IN!LSJ:0HWMW".O:=4$;TT;T)$:2;?O5#;[T/6&_',@N@ M>!G:[^ T6\*[FUAS9UH)(71J2X("I-H9\W;BBEKY!>REUB)?$>6Y?UH$[_IB M_8UN1B;K/!^L;^M.\L793T\0Q!M97D-6 >]RXQJ1&"JA+%G$,@%T"M=BL23> M[\M/],$L?WQN' 6?I)Z35EV\5 5 'OIN0& ICD**"S=,.? M8P^)-W+BD$<#L]W*:K$*^"'/D,SY36QBPB!U\:Y:KL\='!MT&O.K@#QL6K!T M5(F9-G!G<_-KHNE8ZBJ,S6+BT%7\G/9RT^$T\%O,EZ0*WFW/]=E2(J&_*?RR MWA2&Y)Y/5M1M>V8LIN8@)*VA.(Q%5?%NH6YTELJ1.6*C;;MQ3I>AZXV,8L8% MQ?&NQJ[/LA2!(TF5N$XQ>B")[V:V;@=Y$R=-YDUT_G+PQ6IY% *#=M>7; ]5 M -R&SOI*I8-^*2QA(U\R&-4@"7LM+8F556$,VZ+=+T$(?0.541],GDF<2N\! M%UI09;2LBY88UL'"/M+7VX7^*GF(8O_?^_5>2G:Q$EH.!QK)(N L5,:3)8ES MU^P?:-U3N-;=-\4T[19!I S%=STMW7'^!Y/(]^MI!)RAJ*" M$&&BFU#\5C+;$L)0@F6Q;8MB)Q("@18+8!3>?8"[FPFUEL(LKX*=(*@!-T1V M=/6_GWF;BUN^.GYX$5$Z"3D5J6HH*8B=+ZBCV81RHL^1P8HFD:>8 M!@>%L+,$]49ZB7SHF!=G7YH%S#1?_YY+%'KK7ON.:$X(I[&B(>P,P[JK% @G M='X+>R#^"NIV]F\DT=@;X'*1IC\L@IX0J*'DRX1#'\NSF*V0A,B'\4$A] Q O1%<(J"Q M_(_%,F"JQA6AN4Z@."R$GNVG,8#+!32$YJ5/71($3DBB%94 6E(./2%/ U.A MF.@K0\%\UW!96)"O5]-7\0)\3R5G %I''Q:D^M4^]+!F-I5L<)V 'VTR(^4V MC#=_R?I"=^Z6T,O?^:!QD-7DU]#S$VO;%(U!CCZ>^/65^ULK;W+"J$<(M#YZ M7J,>YWJPM'A&IW$V9T'N8LU#.6MF26X69^[2VPZ)[1 1SQ2=-M!3&O5FBSX\ MZ(S*)WC5]C)KN4BQ92=3WT-$V= M%14*@XUW=I3._/RL%VI$>'WT_$L]0O5@.>(=+I-UC8S<<,D50\^SU(S0*!/2 MW*+(OL4SM:,XS^JT"67+!D=.(_!9F* S M<.C#>1#]$.3G?(#GY_"6.FE3^/DYF73GG8!:+X>5U$);!WE?KN/HT??XLW6W ME)M'NQ.YOIOXC\#[6:NT9<_+8T(BBXMJ1<3034P>3^0G"M8O>!:7ZF M-]5&B*@P=D*2#E4R.:J:&,U=[2-@J;A/VSR63/FN;.C3Y>;B$PB+51O#3D;2 M9;D>:.AK^#;1<;.C?XCB9$;BQ4',RX%\,@^L=E/8V4L55M_*@!WU75[%4;[% MH1]Z0Y^KF="CD.=8]%O"3KBJ-$BJP?7"QLAP1?@.);TW\MJ)Y==L ZMCIX$U M,AHDP!C:@17[L!]]XXP+=!H%HJ BO2:P4[[JZW$U0*UQ=14EVV<1E-.I7!A) M"]@I7?694L)CP38KW^?TXL?->PBJ-YQ@M=%SP!I9&L6XO##EN'TB(_=R1O'1 M#.UQ 6L4/<>MN>&B@R+Z4K!^$7,?97?^>.7# PYAM=&3Z2IPJX.+A7_4&FY#6)??Z6^N%.>/3D!BLOS31VT]C% M&P;D:#XGLA6@[7Z@9WI6&%XX7!VQBJH%F*&Q:D'":=M#K_9(6J9CEW4[3E[' M4Z[D'ST+LFG;'E%^LW+T(J+Y.!MH$65&AX7^CB:RN'GW9;?C))FM1>*H85RFERA16B@ MKZIK&:33*E,$+;#2\*PIH'#T'C$=7C4\5/'Z;/&0Y^Z0417,21 M2%X+S5.0#E7@:]>"XLB7,T#H*/H$Q')C+[3B/)9H00ZC+\$'-]#*V%=""U=0'1);J-H"?,ZQ)3#25TOWD3/AM<=VK# M?AM;SJOJGT2NTJ%VZ<3?27*]%6"?PYV>YTQ95PF]=F(@_[4:1<]\KS!&&D#1 MRG//,X<2;Q(>3 '!TEU>%#T=77>!EDEL2'-N/KD>/ "(#PJBYWM7!+A$6CNO MA-B$7R9L@DWFZVQ L>556A@]X[J".261VM0>G>,QF:=FPO:MW5G4?V0FPCW9 M]TA^Y*#;"'JVM/;&OA)*IA:NU">U=_<2J9M(6!H]IUA["9/+W=I9@AQO27GT M5-KZ1POM8'XPSV1^&OWWS:WQ%93*V :>NR3Z<>@RL9A%S)^YY]>K0CW/U9M# M?X^U%DL5D#.KM04'KE7U=X7FT)]IK:C)*R/7DDX'*G,+WD"MJ\5;5]\BA5): M$OT]T_HJNWXB%)L2=Q$E9@R]LFD("26H\@B;-=:X0FX+F;J.XF0>!7XT6\5A MQ+[#K]X1\"0HB_ZNJ"Y+4IEM>5G-?2#>*B#ECV09V4[K_T5^F'QC?X$%XFHWA!0N7T;B3/X4W&;)I)$K)5]>Q@4#TN(61EQ,K:=U@IU=M^S=A7^D^^ M]);P8MDC):9,E$R MPU<#)@>NH]B_]\IEI=D<4=B*#?E=>W@2CSBI!R5B[3/ MKVAR#C*+N[DPAMR!;E"G')NWE!'.J']PJD MRPMCAZ=7!5LFNC&\,PQWX>.ZJXFU,8.E@8'=;07I7TGL3)\I5_*J%:2\*';@ MP-H$UQK#N:8#=T]:--J/=0T#[1 /M$UVTC7G#FT#[ M! 'M4PVT3W71-N9V;0+M4P2T/VB@_4$7;:MUY <$M#]JH/U1%VVKM>1'!+0_ M::#]21-M+[K!(,H7DH!%Q='/VJLAKE*_M9@E]N5DO)0X(T%E38%?#L&9O&[2CRUBO8=@S2XG?E1JFD/!1YZS5L.\9I\;MR U52'HJ\]1JV'4.U^%VY ML2HI#[TJRGH-VX[16ORNW'"5E(^KBG;U;5E3ZW7M'D,V@-?UYKMZIJS'ZQ7MGD,V@-?UZ#M MZEJT'ZS7MWD,V@-?UZ;MZAJU'^Q7N%A6;5?7K.WJVK4?[%>X6(9M5]>R[>J: MMA_L5[A8MFU7U[CMZEJW'^U7N%CF;5?7ONWJ&K@?[5>X6!9N3]?"W5> @F^] MPLUCT![XNA9N3]?"_6B]PLUCT![XVH>UNA;N1^L5;AZ#]L#7M7![NA;N)^L5 M;AZ#]L#7M7![NA;N)^L5;AX#0^#_]KQP5#DUN3)0B"V+."N5U!"J%\^A2YQP M1MR', JB>Y\H$Y?D5:"86Q:=#<'!$ 4WY-&AJX4*]F(Q*-26A6:+Y#4$[ZV; M#"*'OVZM'-GE1<%I8G;!+)/;$-2_Q_R%PNF2$$\%=7E1*-26!63+Y&X%:KGQ M(R@+!=LR[2B5O!6TY=:.H"P4;"LE"T+5.-4LE;05MNSPC* M M'^8IF&E$K>"MKR(SI!62C:5BO)=@[F#K\I/Y,3E(6B;;66;.W^*+GP M[2"N8V5J1WUV;;M#2BY\.XCK6)K:H9Y=V^Z1D@O?#N(ZUJ9V?&?7MKNDY,*W M@[B.Q:D=U-FU[3XIN?#M'/+HV)S:D9Q=V^Z4D@O?#N(Z-J=V^&;7MGNEY,*W M@[C62::VS=FS6G.V%+"9^ZB.S:D=J-GM6:TY6XK2S'U4Q^;4CL[LGEBM.5L* MS)W9H3P^;L MZ=BMLUY:K?FQ+ Y3W1LSA-MF_/4:LV9%[X=Q'5L MSA-MF_/4:LV9%[X=Q'5LSA-MF_/4:LV9%[X=Q+4B:+5MSE.K-6=>^'80U[$Y M3[1MS@]6:\Z\\.T@KF,!G6A;0!_LUIQM7;2R[>H@6BR=\%D*N; T&'/K$E^E MXAL"?>H'OAN%7TE(J$^5+P&(BT.O1;?MIF(5 *WA+M\I2LJ#D;?L@@DE!*U! M+]\R2LJ#H;?L>@DE!*U!+]\[2LI#H;?MKF(E!*U!+]]$2LJ#H;=,PRHA: UZ M^0F&I#P8>NNU;#OG&,7ORC?RDO)@Z*U7L^ULYXO?E9]I2,J#H;=>S;9SLE'\ MKOQP0U(>"KUMMQ0K(:@+/1>.,NE2R>8.O4O%V_3Y'>?D'0D2NOU)RE+*T.8' MZ2/U"3/RDH?(V\O8]SR?2\;?%)]'\2(5LX2V32M:C0"Y-$7DU'T@WBH@D_F^ MI_3"#\F8OWV7)[&*@$8G5=]E7:'I9X=L$%+!7"H6 R=T6(%[N0R6S)GI Q.8 MCBE=$4\\*0Y+05Z,X7OC.'=MY)>GU=J,GEU Z MF4^2!Q+W*26EHY774U>#WN-J#^90*- 7DW5WKDC9T-\NA/LBT$L![2"BV'\A MZ+^\*\C#FOV^_6WI+P]:(T\)";V]OCZ0>N['-'EP0B]YG/_D1HMWJ<2;DYY= MK_R$5WF__N=+YVUGZ%,WB.@J)NPOLU]'G<'D\KI_]8\WR&IGT_'^'4UBQY6, M'$D5;-6YZ="Y'SJAZSO!K_[]0\#//>F,47G&/O]=0RYY,\BFEY(XH>+5 ,F2 M.35=+19._#R93_W[T)_[KL/L1=>-5B&_J_(Z"GS7SY@TV2G7?9^?1I;,I;T>OG1"YY[P/YT34CZ+>OE9-+[Z M-IK.+D=,85WVK_I?1^D?STR8)D NRGT$ M4SX.3_#P8CLYF.-LSWLE]5]1;,U%YG&W986\ ^S!A!>2-EYR& MW*9+(;4EP__<\>-O3K 2Z(+3_!PX[X]O.M_Z%[?5%O_:8VG7WWVO *:*O!;. MK"CK$V!N**HASQ (/;EY L+!EME"&'K\L)C]A,R<)Y$A\J$P;4;#T4W_@FVE M!I/+46?6_SN6I;_KNXX^D5;"\K\5N@1RM\EJH7O7E-04_&MJ$"R9.IGPF]@) M*9.)-2R8/A\E%LCLIG\U[0]FX\D5V@S:G1?T@R ]B"]_G7_LVHD6;,.P%+/ MCGPYG%DPBXG#P'N>)FP$ ":"J#SR7"@'/3?FY;):,NPS4W@<]N=S/_!Y1%D_ M] 91F+ B ?'*PCP.)L9GL5Z9LC]W^N?GXXMQ?S9:NXH'DZO9S>3B8C3,%D17 M.DS^T.M[CT[HLIURE %#1_4 6L%60.(^EA[>:^FKZFW;H][ T$<#E4384L6 MATLG_DZXLR5>+5,:0N\KB981CYIQG2!UU9>O"(78B,O^S6^C66_Q"R0)6QT[DTB9. M"Q9#:3$W;.C$OIL0;TK<59PFA:B)X55!-;&3N^"<@$6R9$[=$+9!79$;XD9L M!\CQ!,\G0%7L1#+MN02&P]3%!OP0A0<=.# JTIL Y'6P$\OTY@X( &.+F!/X M_R;>5\A M- @X^M*ZBX'0V$Z*:@!Y-7:3;(7=I%QX=';.HYCX]^%@%3/Q60LJ-@=^^LL:;FOA=E0G"S,NI>!< MH9#MI7.NL&[X]52ACG[P_LI'Q2,8AZ],*&M0";^'83A9TL;%D4NXR M&F3SKI!=ML^L09Y7+S#%9GUORV4:Y\A6]?"&+_4Q&XCIV95.U@VXI2-.Q-%$ M"WT#M%\F1O,Y<9,#;7@;1G>4Q(]\1HW#Y2JA S9A[_EE2M>!$ZYE3>>;UE+; MU)>P3Q4KC!-3<*./(^ $*(C(W=BAFP9.,M::6TW@'\(^!36WVNB";43ZIM.CIR4)*3DC(9G[B;X2K] HMK[69[H!#"T:!T,R)S'3$ZSG:\7!O:?[ M&S+UQX!F@]B:M@[_E;"SB/OU=C/U 6Q N'$2DML05-S)Z[6*';Q49Q141Q%_ M*&R]G9,EX2[Y\)X?9P^<.'Z>1_$/)_9@X>\ZK6#'1%6@N@)*EFR;RR\)D&V= M"S=M"*X*0-\]_TGN# NO^(:Z#OI9FX/@"Z@1Y!++9M^DILZX!G5]LS-%YY: M79K4JYD"K+V_:NQ3]JP,51.OC>%OR<(".XT>DL3Q \&"4KR[1.,X>M/RG_D\ M6A!SFX]H2!=Z]A710QJ2\D=SB*R0PQ*;YMIY3B?V>13?D.6FNY/Y[VR[[DB? MY5%6Q'95:1_W Z$P%);^>^PG;,4#3A!A:6P'D=[\4 A]C'KEB@\7[M\H5S"% M.X J*)C.[AM_9E536XIO;(PP#@;.TD^<@&ME(6[D83O #2V,![IVP"- M3+!]8.,X3 @;" GWR^^\]= >MEYAD.X1Z_4!YMV6R".CD(EJR<^X@FB;?BI'"M53:(%]<;\6*C> \/ MK4OBQEB!JRB,#X-6N=L,')!7YQ.JJ5D8Y4;V-?4#\NI@D,VZ.]XQ??'7WT2,]0?GB_((PGZ3SYD%"GJ_\F& MAP*-S!X'F?:-T&O?9:'+PVC!K'H ^[!F+!L$H"$O8A@F\=X,0>9YG<^02M>] M)(L[$@-8+:N$[?6H-')%)(I103>WROK8J\)<3Y,Y\XD6#3/7.P+F3JHP=Z+) MG+&035/,G5C&W'4<+4F_8\8Y^5[X1 E2W3@(:V02 H M,LN-96SS/JIV/J#*=K"M,:JA/&:%K+G%$;C--T%%WJ63D-AW BI<0'EQ86GL MW8K&&,L>;2ND-Q1%T%\ET2+B/DTYV(5BV''F55$6R&L(WEVO+M@*RY91*TD\_L;*D#SZ+I%KR/*BT(7;F&51$6:9X.A6Q)3A MEYI(ZQ?L]IFK$VURV5E2 H;@>7H'&:XT<@$+:; MDW5H$87I(Y J1TM)46PC03JH"I152E#SSCHT-U%TY"X#2$-6P@T;Q8)3RD17$C(I@4_V1 MQ(G/1@B_FTR^=(D*0Y MT] !5R@GNCI8KY_B%63[>ULN%&XRHC9_(_\!%)9F G1W_3M(!2B\SUN2"M#I MOB8#-"7)57:+EPZ<[7A\KGJ7+#!'P-B7[=@1U$D=, :-11D%SG?.OCCK/G2^>?43P('*K05%J-V+&H8?GR=)!"#XB6]';?5TBP M@79#E@P2_V)8'WQL<(& ^Y>8X7MC15N6[.\AA"WHD=>0XC? MG!@[=;(GA+C)E]9D9DZFD"U!KRT$?0G?$BP+B%UNG5T7:_R$XJYE95V/O&GB MQ$E:OMEIQK#9/K-$W70 4OZ8C&">"4MCNWTQN)8"8G2WQ[XZ=0(@8<62UMR# MV#Y9(MC05U>N*#9'N25]2!Y9;W7O++&GL86A\;)\\/@+=CAMJF0YP47$3]?2]C#PHJCD>!P85NN ME.ZPA28Y7+QF++T<,E\SCUXSCUXSCZS-/#*:J6', W<4B1JFL[ILN]/W!6=U MV99 AY+5U5;BD3>$O,.]H_XD.\^^WU.,GNIP [6%01^?03;D*)KE*0(U+9 MC?-(XKN($AN<.(0QX 3CD/V$S)PG0J7O!9\4G#FCX>BF?]$97PTFEZ/.K/_W MT13[Y>"=,/N>JGTZTDHX\Y)U)O5 3N89)^)7MOV@Y0Y^L7#Z+2'/7 "%N2E; M%2STU1?2<<6IF 8$E<[(C-DY9FA6''0!E^HOZP4R)/?,FLK[VRT8(NI#OBLB M6>_JM(EMNC4T;+00M'.=&$0T.8_B'2#7JWC)-A82=Z)F,]AV9$-4JW"RY:I& MT6Y,<&?CJ=9V#.WVQI>R(1MN%$>>IM'3DH24G)&0S'V)2-#Z1[?YT@,&?2D= M[A*MF6KG%\&RKU1G$];*\6VUJJ!D#;6;D7C0]^HS5=7,\6V(*N%DNY841*!\ MT-.26+$H+TU+LDZM/6>3):,K\<-['E@Z<.+X>1[%/YS8DX;R:C1RM/I2 R)K M5M9=GP?.TD^U$TGX=X>VL=]"PY?=!LY(@58 M13Q;IV#J^-*8;YORQV?4RR6WCQA^3+2&,PBB'SPH0X.ELLK8A\P-4";&Y*B= MLP4YI6[7\M+8I]H-L"MWE5IE)NQS*0[,A(]Z9L+)JYE0[^K+^9RXZ\M;-GV[ M87/Y,+EBDCR0N._]2D,Z7.YMD!QKU6CT^.Z,)%&U? MH4_+5^A/>BOTZ>L*7??$<<)E?;N0ITC MI*IG!UOJ,0@AZ\*F;*#2'LIS@"157A)-EF3XE/8-91B&;K] MJMQ_VI7?@J6HA+W? XZM@SNQ0#@8\B8+/MZK0D+/EN24YDCH89)P4H6$$ULR M*9HCX023!,6E?(I*V"]"-4>";4DMTPQ[HM< M.\_IU8]<$)XL# MPO7(@M?&J.0!W(1]D-"#QSQ]0:'HFELI6!F;(#PM'1D MK#N^8GW?1/>57U$K1:.\C2.*MJH@G1'U;\. * SM*4F8VD\/:9M=*,0-8[M> MC"T3*BS1%XDJ4= -!#U;%!%F/LA9'!*K89!M D1KVU\V1&LI9;$J'F ??)O> M@B'%E[RI-+[Z-IK.+D=7L\[LIG\U[0]FX\F5!7=2[')1^T&0ANAD M?P0PEV#U\6YNW\=+]Q\9T/SL[SR*^67SV]/.;J:O(XCEQ"/GC.PN"!,CU\RLY!)^3R9 MYZ64YC%L6JS<(+Y%56-TU(31$H6P]@ROGN\<]SO,=W;Z/J\0IK_V;T:=L]M_ MG/4'OUGD-5N_P*!>^?/E<*9EWW57BU7 H^W3DI;L7+ M[8IJ+X92A9SHH6FY;JD"T@3%[: +-!3SSJ!R@;!?0V<=6O"H^\C]KGH$O:0H M]D93.JAR! @E->2ZX?^1XYJ6R)?"?G &!&EISTV:831.,J.9_6T_DME?_KCA M(1D"/D[@[:7R4/4(UIM8H=NF!D\%6"U;I'HAZRSB1_74P#R5K##/0PM M'1#HCH1O3?4@;00[Q*15MAL]@!;YD?B(FJP2FCBAQ[XL]M@H&W+Z&S]4*RI])K!4CZ9\M)KP(=.M^;]#XZ MF0_]1];5T*.9\P1)"(^B'I#3+Y9S"H/'D()D X:KAG2Q$"C'PR)@WX2MJ!=% M,@LP#WZ*)W,V*3.IK"*H!86AH%OK$9()9\DJ=1O2*/!=GXF8Z2E_049BS$DK MX1TU-+M 9!!9V]M.HXI71%OO?-1;ATE5?!.,QHVQ%2HH/.6T70[[;?MY)"X M ?N?Y#P$5AO*INU.%!VLS&NST=/2+RU)LCDJ-:7$SVW(I ^SK\@3 M&LK*'CU/>U'0$Q4..S5@8^6>G^JG6*I"Y"%U[>!*/.*D')6+9.86W='?_K[) M_F>;+DB> J^EJH0=EP8?7=GM) P*0SOY@X]/F47!5.EUO'MB58L1:77L0)$& MN ' 8XBE7TGL3)\IUVCI&&&RQ(G/UMZK*!''ZO.JH)KH9R;5R-% !8,7^8W@ ML*KHCEX#S+1S0_AA%_)35X,:455TOU(3U,AQ:9&:L^K4%*M"J3%V\MX<-2)< MVJ3F=WXE!=OMZS.3KPD--#=X16!CQ)2C@L&+CJ(1584R8_#VL,:9P5,TNR[( M'Z2 58528RPVS U[3Q0(>V"_)D*6%5H[H-E%J<.+BU2,ZB^!RA6A5)CF<&I M@XLA:L9A$CN3Y27Q?-<)!E&\U#$XP;7!#@&["-)$!XLC^9X 7AW*DF4&J"X^ M6#3)]P?PZE":+#-&=?'!HDF^5X!7A])DF6&JBP\63:?U:#K5I.F#96:J+CY8 M-'VH1],'79HLLUEU\<&BZ6,]FC[JTF29_:J+#Q9-G^K1]$F3IH^6V;*Z^ M]+D>39]U:;+,KM7%!XNF+_5H^J)+D[% 5T,T?;&#IN[[FO;M>TVB/AV;&R*/ M$!I3=3T1NJZ(3T?GBK#$%]&MZ8SHZGHC/AV;-R*/$!I3-?T175V'Q*=C(32F:KHGNKK^B2_'YI_((X3&5$T/15?71?'E MV%P4>830SG9K^BCV]>'Q^4=&51XB-*IJ.BEZV@'[[X_-2Y&'J#6JM&+#X-7! M1%GOI+ D2&Q&XD6%Z+!\-3 OUKLDR@$QQ,<->73H:L&S;89C*06E)<$7N%EF MM$K$-@3TU ]\-PJ_DI!0GZX72ECV*J@F^$XVRRP=#5A:)@:4O0*M#*;',O-& M#YS6&%JKKNY7F'+7J _FR3+C1ANBMJGZM295Q?KP%-=Z0#@,D?%[[-\_)'1) M^.V08#*4M<"7ZEIF,0'A:(D,>/XEJ":8%,O,(PU8,(B1GR+ JL*OE3DB:MHY M.Y!V01[<"*L*YL8R^T<'& QNY.&,L*I@;BPS>'2 P>!&'L (JPKFQC(+1P<8 M#&[D(8NPJN ;V2TS9'2 P>!&'J0(JPKFQK)3.1U@,+B1AR7"JH*YL7^ (2L2+F))8\V!-8%LW-,CH&6 M4B'E?:CC&]!V#GPY*N> !=X!1>XCL"Z8GF/R#[24]"CO0PT/@7:R8_?+,;D( M6LITE/>AAI- .\.Q^^68O 0MI3?*^U##3Z"=ULCZ=DST6. I4.0S NN"Z3DF M7T%+B8SR/M3P%F@G,/;>'Y.[H*7L17D?:C@,M+,6>^9>,#=!CP4N T6Z(K N MF)YC T5>(K N_-6-8Z+' J]!KTY0 M@?;[#KUC\AKDH4&AIX;7H*?K->CUCLEKD(<&A9X:7H.>KM>@USLFKT$>&A1Z M:G@->MI>@Y-C\AKDH4&AIX;7H*?M-3@Y)J]!'AH4>FIX#7K:7H.38_(:Y*%! MH:>&UZ"G[34X/2:O01X:%'IJ> UZVEZ#TV/R&N2A08G7K>$U.-'V&IP>D]<@ M#PT*/36\!B<57H0\)GHL\!J0 8^#@VL"Z;' M:J^! II6Z0'=XP*K"B;':I^!'!A#W,RBQ GZ\[D?^*S3M!]Z; HG3/" ]VDK ME)PDS3:@;'VTS$:M!)4AVO;=D#)3+ 8&WS(+5"2P(7SU)T$C0_Z3989E"P.< MBT>9?*ELI0)N>OV.,_..! G=_B3E*N5I\X,_KN-HR;84?/GKFH_2>?EE"VJ0VJK&*O (01!J?N _%6 9G,,US,'+;3RC.G(]LN M3L4Z^G@?A]'"\<,*]&4KVT&?QC"%\I@55WPE1* 6$^,0VC 7B&@)W(G2&B.76^WJQ!D+8[W6GV;R)O&GBQ$E: M'LU00"+V08A8\%$9"LPDW4I.GJ?$7<5^XA.Z[;J8/65%((,M!,!49Q"(CBG/_H,3WA/6^27# MSO53Y#RR_[/(O:^L!J2FA4.M"M3 1+1D>NEN*?_H@=EIX?2^D5TE%ZF1?>4H M]%!WE=,'AAX=4[HBGIC,PU+8#N4FN"R3NS*5CR2^BRC)$?G+NP(ZK%??V6\W MO^'_N7,H83_Y'U!+ 0(4 Q0 ( +J+#U

    "F(P $@ @ $>:P 9G P,#@T-C4T+3)?-3HD &9P,# X-#8U-"TS7S$P<6%I>&)R;"YH=&U02P$"% ,4 " "ZBP]7 M;?21RH,' !,0 %0 @ '#M@( 9G P,#@T-C4T+3-?97@S M,3$N:'1M4$L! A0#% @ NHL/5^XDM..+!P S$ !4 M ( !>;X" &9P,# X-#8U-"TS7V5X,S$R+FAT;5!+ 0(4 Q0 ( +J+#U>5 M2K=J700 .\3 4 " 3?& @!F<# P.#0V-30M,U]E>#,R M+FAT;5!+ 0(4 Q0 ( +J+#U?R/L!A Q4 $8N 0 1 " M <;* @!S=G9C+3(P,C,P-C,P+GAS9%!+ 0(4 Q0 ( +J+#U=?6,T/Y0T M '&@ 5 " ?C? @!S=G9C+3(P,C,P-C,P7V-A;"YX;6Q0 M2P$"% ,4 " "ZBP]7)MLED:\D #.30( %0 @ $0[@( M&UL4$L! A0#% @ NHL/5\,T689N4@ M=OP$ !4 ( !\A(# '-V=F,M,C R,S V,S!?;&%B+GAM;%!+ M 0(4 Q0 ( +J+#U<016<+&#L .#M P 5 " 9-E P!S J=G9C+3(P,C,P-C,P7W!R92YX;6Q02P4& L "P#: @ WJ # end